{"PMC5121417": [["Introduction of glycan probes onto epitopes on MERS-CoV RBD ::: ResultsTo evaluate the neutralizing immunogenicity of a specific epitope on viral RBD vaccines, we can either delete or mask the epitope and then measure the corresponding changes in the vaccine's capacity to elicit neutralizing immune responses.", [["epitopes", "PROTEIN", 35, 43], ["MERS", "PROTEIN", 47, 51], ["CoV RBD", "PROTEIN", 52, 59], ["Introduction of glycan probes", "TREATMENT", 0, 29], ["viral RBD vaccines", "TREATMENT", 140, 158], ["the epitope", "TREATMENT", 189, 200]]], ["Alanine scanning of vaccine-surface residues likely leads to changes in the vaccine's overall immunogenicity that are too subtle to be measurable using currently available experimental methods, while deletion of a whole epitope may disturb the tertiary structure of the viral RBD.", [["Alanine", "CHEMICAL", 0, 7], ["RBD", "DISEASE", 276, 279], ["Alanine", "CHEMICAL", 0, 7], ["Alanine", "AMINO_ACID", 0, 7], ["viral RBD", "PROTEIN", 270, 279], ["Alanine scanning of vaccine", "TREATMENT", 0, 27], ["surface residues", "PROBLEM", 28, 44], ["experimental methods", "TREATMENT", 172, 192], ["a whole epitope", "TREATMENT", 212, 227], ["the viral RBD", "PROBLEM", 266, 279], ["viral RBD", "OBSERVATION", 270, 279]]], ["Instead, in this study we chose to mask the epitope of interest using a host-cell-derived glycan probe.", [["cell", "ANATOMY", 77, 81], ["cell", "CELL", 77, 81], ["this study", "TEST", 12, 22], ["a host-cell-derived glycan probe", "TREATMENT", 70, 102]]], ["This approach is effective and convenient because the glycan probe can impose steric interference for the access of antibodies and immune cells to the epitope, and also because the glycan probe is unlikely to interfere with the folding and solubility of the RBD.", [["immune cells", "ANATOMY", 131, 143], ["RBD", "DISEASE", 258, 261], ["immune cells", "CELL", 131, 143], ["antibodies", "PROTEIN", 116, 126], ["immune cells", "CELL_TYPE", 131, 143], ["RBD", "PROTEIN", 258, 261], ["the glycan probe", "TREATMENT", 50, 66], ["steric interference", "PROBLEM", 78, 97], ["the access of antibodies", "TREATMENT", 102, 126], ["immune cells", "PROBLEM", 131, 143], ["the glycan probe", "TREATMENT", 177, 193], ["the folding and solubility of the RBD", "PROBLEM", 224, 261], ["RBD", "OBSERVATION", 258, 261]]], ["To place the glycan probe on an epitope, we introduced the N-linked glycosylation motif, asparagine-X-threonine (where X is any amino acid other than proline)33, onto different epitopes on viral RBD vaccines using site-directed mutagenesis.Introduction of glycan probes onto epitopes on MERS-CoV RBD ::: ResultsAs proof-of-concept, we chose to study several epitopes on the MERS-CoV RBD vaccine.", [["asparagine-X-threonine", "CHEMICAL", 89, 111], ["amino acid", "CHEMICAL", 128, 138], ["proline", "CHEMICAL", 150, 157], ["N", "CHEMICAL", 59, 60], ["asparagine", "CHEMICAL", 89, 99], ["threonine", "CHEMICAL", 102, 111], ["amino acid", "CHEMICAL", 128, 138], ["proline", "CHEMICAL", 150, 157], ["asparagine-X-threonine", "SIMPLE_CHEMICAL", 89, 111], ["amino acid", "AMINO_ACID", 128, 138], ["proline", "AMINO_ACID", 150, 157], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 374, 382], ["N-linked glycosylation motif", "PROTEIN", 59, 87], ["epitopes", "PROTEIN", 177, 185], ["epitopes", "PROTEIN", 275, 283], ["MERS", "PROTEIN", 287, 291], ["CoV RBD", "PROTEIN", 292, 299], ["epitopes", "PROTEIN", 358, 366], ["MERS-CoV", "SPECIES", 374, 382], ["an epitope", "TREATMENT", 29, 39], ["the N-linked glycosylation motif", "TREATMENT", 55, 87], ["asparagine-X-threonine", "TREATMENT", 89, 111], ["any amino acid other than proline)", "TREATMENT", 124, 158], ["viral RBD vaccines", "TREATMENT", 189, 207], ["Introduction of glycan probes", "TREATMENT", 240, 269], ["CoV RBD vaccine", "TREATMENT", 379, 394]]], ["The Fc-tagged RBD fragment containing residues from 377 to 588 was selected in this study because we previously showed that this fragment is a stable and effective vaccine candidate34.", [["Fc", "GENE_OR_GENE_PRODUCT", 4, 6], ["fragment", "CELLULAR_COMPONENT", 129, 137], ["Fc", "PROTEIN", 4, 6], ["RBD fragment", "PROTEIN", 14, 26], ["The Fc-tagged RBD fragment containing residues", "PROBLEM", 0, 46], ["this study", "TEST", 79, 89], ["this fragment", "PROBLEM", 124, 137], ["effective vaccine candidate34", "TREATMENT", 154, 183], ["Fc", "OBSERVATION_MODIFIER", 4, 6], ["RBD fragment", "OBSERVATION", 14, 26], ["fragment", "OBSERVATION", 129, 137], ["stable", "OBSERVATION_MODIFIER", 143, 149]]], ["Four distinct epitopes on this MERS-CoV RBD fragment were selected based on their location on the RBD surface and their possible functional role in receptor binding: (i) Arg511 (located on a protruding loop and in the receptor-binding motif (RBM) region); (ii) Ala562 (located on a \u03b2-strand and in the RBM region); (iii) Val403 (located on a \u03b2-strand and in the core region); (iv) Thr579 (located on a protruding loop and in the core region) (Fig. 1a,b).", [["surface", "ANATOMY", 102, 109], ["Thr", "CHEMICAL", 381, 384], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 31, 39], ["Arg511", "GENE_OR_GENE_PRODUCT", 170, 176], ["Val403", "GENE_OR_GENE_PRODUCT", 321, 327], ["Thr579", "AMINO_ACID", 381, 387], ["epitopes", "PROTEIN", 14, 22], ["MERS-CoV RBD fragment", "DNA", 31, 52], ["RBD", "PROTEIN", 98, 101], ["Arg511", "PROTEIN", 170, 176], ["protruding loop", "PROTEIN", 191, 206], ["receptor-binding motif (RBM) region", "PROTEIN", 218, 253], ["Ala562", "PROTEIN", 261, 267], ["\u03b2-strand", "PROTEIN", 282, 290], ["RBM region", "PROTEIN", 302, 312], ["Val403", "PROTEIN", 321, 327], ["\u03b2-strand", "DNA", 342, 350], ["Thr579", "PROTEIN", 381, 387], ["protruding loop", "PROTEIN", 402, 417], ["core region", "PROTEIN", 429, 440], ["MERS-CoV", "SPECIES", 31, 39], ["Four distinct epitopes", "PROBLEM", 0, 22], ["CoV RBD fragment", "PROBLEM", 36, 52], ["a protruding loop", "TREATMENT", 189, 206], ["the receptor-binding motif (RBM", "TREATMENT", 214, 245], ["a \u03b2-strand", "TREATMENT", 280, 290], ["a \u03b2-strand and in the core region", "TREATMENT", 340, 373], ["a protruding loop", "TREATMENT", 400, 417], ["distinct", "OBSERVATION_MODIFIER", 5, 13], ["epitopes", "OBSERVATION", 14, 22], ["RBD fragment", "OBSERVATION", 40, 52], ["protruding", "OBSERVATION", 191, 201], ["RBM", "ANATOMY", 302, 305], ["region", "ANATOMY_MODIFIER", 306, 312]]], ["On the basis of three-dimensional protrusion index map (Supplementary Fig. 2)35, the epitopes containing Arg511 and Thr579 both have a high protrusion index, whereas the epitopes containing Ala562 and Val403 both have a low protrusion index.Introduction of glycan probes onto epitopes on MERS-CoV RBD ::: ResultsWe introduced a glycan probe onto each of the above four epitopes on MERS-CoV RBD.", [["Arg511", "CHEMICAL", 105, 111], ["Thr", "CHEMICAL", 116, 119], ["Arg511", "GENE_OR_GENE_PRODUCT", 105, 111], ["Thr579", "AMINO_ACID", 116, 122], ["Ala562", "GENE_OR_GENE_PRODUCT", 190, 196], ["Val403", "GENE_OR_GENE_PRODUCT", 201, 207], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 381, 389], ["epitopes", "PROTEIN", 85, 93], ["Arg511", "PROTEIN", 105, 111], ["Thr579", "PROTEIN", 116, 122], ["epitopes", "PROTEIN", 170, 178], ["Ala562", "PROTEIN", 190, 196], ["Val403", "PROTEIN", 201, 207], ["epitopes", "PROTEIN", 276, 284], ["MERS", "PROTEIN", 288, 292], ["CoV RBD", "PROTEIN", 293, 300], ["epitopes", "PROTEIN", 369, 377], ["MERS-CoV RBD", "PROTEIN", 381, 393], ["MERS-CoV", "SPECIES", 381, 389], ["the epitopes", "TEST", 81, 93], ["Thr", "TEST", 116, 119], ["a high protrusion index", "PROBLEM", 133, 156], ["the epitopes", "TEST", 166, 178], ["Ala562", "TEST", 190, 196], ["Val403", "TEST", 201, 207], ["a low protrusion index", "PROBLEM", 218, 240], ["Introduction of glycan probes", "TREATMENT", 241, 270], ["a glycan probe", "TREATMENT", 326, 340], ["CoV RBD", "PROBLEM", 386, 393], ["high", "OBSERVATION_MODIFIER", 135, 139], ["protrusion index", "OBSERVATION", 140, 156], ["low protrusion", "OBSERVATION", 220, 234], ["index", "OBSERVATION", 235, 240]]], ["To this end, we introduced single mutations V403N, T579N and A562N to pair with the already existent Thr405, Thr581 and Thr564, respectively, to generate three N-linked glycosylation sites.", [["Thr", "CHEMICAL", 101, 104], ["Thr581", "CHEMICAL", 109, 115], ["Thr", "CHEMICAL", 120, 123], ["N", "CHEMICAL", 160, 161], ["Thr405", "AMINO_ACID", 101, 107], ["Thr564", "AMINO_ACID", 120, 126], ["N-linked glycosylation sites", "PROTEIN", 160, 188]]], ["We also introduced double mutations R511N/E513T to generate the fourth N-linked glycosylation site.", [["N", "CHEMICAL", 71, 72], ["fourth N-linked glycosylation site", "DNA", 64, 98], ["double mutations R511N", "TREATMENT", 19, 41], ["E513T", "TREATMENT", 42, 47], ["the fourth N-linked glycosylation site", "TREATMENT", 60, 98]]], ["Each of these glycosylation sites was located in an individual MERS-CoV RBD fragment.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 63, 71], ["MERS-CoV RBD fragment", "DNA", 63, 84], ["MERS-CoV", "SPECIES", 63, 71], ["these glycosylation sites", "PROBLEM", 8, 33], ["CoV RBD fragment", "PROBLEM", 68, 84], ["glycosylation sites", "OBSERVATION", 14, 33], ["individual", "OBSERVATION_MODIFIER", 52, 62], ["MERS", "OBSERVATION", 63, 67], ["CoV RBD fragment", "OBSERVATION", 68, 84]]], ["We expressed and purified each of the four mutant RBDs in mammalian cells (Supplementary Fig. 3A).Characterization of RBDs containing engineered glycan probes ::: ResultsTo test whether each of the above four epitopes on MERS-CoV RBD was actually glycosylated, we performed both SDS gel electrophoresis and mass spectrometry.", [["cells", "ANATOMY", 68, 73], ["RBDs", "GENE_OR_GENE_PRODUCT", 50, 54], ["mammalian cells", "CELL", 58, 73], ["RBDs", "SIMPLE_CHEMICAL", 118, 122], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 221, 229], ["mutant RBDs", "PROTEIN", 43, 54], ["mammalian cells", "CELL_TYPE", 58, 73], ["RBDs", "DNA", 118, 122], ["epitopes", "PROTEIN", 209, 217], ["MERS-CoV RBD", "PROTEIN", 221, 233], ["MERS-CoV", "SPECIES", 221, 229], ["CoV RBD", "PROBLEM", 226, 233], ["both SDS gel electrophoresis", "TREATMENT", 274, 302], ["mass spectrometry", "PROBLEM", 307, 324], ["mammalian cells", "OBSERVATION", 58, 73], ["mass spectrometry", "OBSERVATION", 307, 324]]], ["Compared with the wild type RBD, each of the mutant RBDs exhibited a slower electrophoretic mobility on the gel, consistent with additional glycosylation (Supplementary Fig. 3A).", [["RBDs", "GENE_OR_GENE_PRODUCT", 52, 56], ["wild type RBD", "PROTEIN", 18, 31], ["mutant RBDs", "PROTEIN", 45, 56], ["the wild type RBD", "PROBLEM", 14, 31], ["the mutant RBDs", "PROBLEM", 41, 56], ["a slower electrophoretic mobility on the gel", "PROBLEM", 67, 111], ["additional glycosylation", "TREATMENT", 129, 153], ["slower", "OBSERVATION_MODIFIER", 69, 75], ["electrophoretic mobility", "OBSERVATION", 76, 100], ["consistent with", "UNCERTAINTY", 113, 128]]], ["Mass spectrometry revealed that the molecular weights of the mutant RBDs were \u223c1\u20132 kDa larger than that of the wild type RBD, which was also consistent with an introduced glycan probe in each of the mutant RBDs (Supplementary Fig. 3B\u2013F).", [["RBDs", "GENE_OR_GENE_PRODUCT", 68, 72], ["RBD", "GENE_OR_GENE_PRODUCT", 121, 124], ["mutant RBDs", "PROTEIN", 61, 72], ["wild type RBD", "PROTEIN", 111, 124], ["mutant RBDs", "PROTEIN", 199, 210], ["Mass spectrometry", "TEST", 0, 17], ["1\u20132 kDa", "PROBLEM", 79, 86], ["the wild type RBD", "PROBLEM", 107, 124], ["an introduced glycan probe", "TREATMENT", 157, 183], ["RBD", "OBSERVATION", 121, 124], ["consistent with", "UNCERTAINTY", 141, 156]]], ["For each of the purified mutant RBD samples, there was no visible presence of unglycosylated RBD on the SDS gel or the mass spectrometry spectrum (Supplementary Fig. 3).", [["samples", "ANATOMY", 36, 43], ["RBD", "PROTEIN", 32, 35], ["unglycosylated RBD", "PROTEIN", 78, 96], ["the purified mutant RBD samples", "PROBLEM", 12, 43], ["unglycosylated RBD", "PROBLEM", 78, 96], ["the SDS gel", "TREATMENT", 100, 111], ["the mass spectrometry spectrum", "PROBLEM", 115, 145], ["no visible", "UNCERTAINTY", 55, 65], ["unglycosylated RBD", "OBSERVATION", 78, 96], ["mass", "OBSERVATION", 119, 123]]], ["Thus, each of the four epitopes on MERS-CoV RBD had been successfully glycosylated.Characterization of RBDs containing engineered glycan probes ::: ResultsTo understand the correlation between the epitopes' role in receptor binding and their potential to be recognized by immune responses, we examined whether these engineered glycan probes on MERS-CoV RBD interfered with receptor binding.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 35, 43], ["RBDs", "SIMPLE_CHEMICAL", 103, 107], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 344, 352], ["epitopes", "PROTEIN", 23, 31], ["MERS-CoV RBD", "PROTEIN", 35, 47], ["RBDs", "DNA", 103, 107], ["epitopes", "PROTEIN", 197, 205], ["MERS-CoV RBD", "PROTEIN", 344, 356], ["MERS-CoV", "SPECIES", 35, 43], ["MERS-CoV", "SPECIES", 344, 352], ["CoV RBD", "PROBLEM", 40, 47], ["CoV RBD", "PROBLEM", 349, 356], ["receptor binding", "TREATMENT", 373, 389]]], ["To this end, we used two alternative approaches.", [["alternative approaches", "TREATMENT", 25, 47]]], ["One approach was an AlphaScreen assay, which analysed the interaction between recombinant RBDs and recombinant human DPP4 in solution (Fig. 1c), and the other approach was fluorescence-activated cell sorting (FACS), which examined the interaction between recombinant RBDs and human DPP4 expressed on the Huh-7 cell-surface (Fig. 1d).", [["cell", "ANATOMY", 195, 199], ["Huh-7 cell-surface", "ANATOMY", 304, 322], ["RBDs", "GENE_OR_GENE_PRODUCT", 90, 94], ["human", "ORGANISM", 111, 116], ["DPP4", "GENE_OR_GENE_PRODUCT", 117, 121], ["cell", "CELL", 195, 199], ["RBDs", "GENE_OR_GENE_PRODUCT", 267, 271], ["human", "ORGANISM", 276, 281], ["DPP4", "GENE_OR_GENE_PRODUCT", 282, 286], ["Huh-7 cell", "CELL", 304, 314], ["recombinant RBDs", "PROTEIN", 78, 94], ["recombinant human DPP4", "PROTEIN", 99, 121], ["recombinant RBDs", "PROTEIN", 255, 271], ["human DPP4", "PROTEIN", 276, 286], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 276, 281], ["an AlphaScreen assay", "TEST", 17, 37], ["recombinant RBDs", "TREATMENT", 78, 94], ["recombinant human DPP4 in solution", "TREATMENT", 99, 133], ["recombinant RBDs", "TREATMENT", 255, 271], ["human DPP4", "TREATMENT", 276, 286], ["the Huh", "TEST", 300, 307]]], ["The results from both assays revealed that the glycan probe located at residue 562 reduced the binding of the RBD to DPP4, the glycan probe located at residue 511 reduced the binding of the RBD to DPP4 even more, and the ones located at residues 403 and 579 had no impact on DPP4 binding.", [["residue 562", "AMINO_ACID", 71, 82], ["DPP4", "GENE_OR_GENE_PRODUCT", 117, 121], ["residue 511", "AMINO_ACID", 151, 162], ["DPP4", "GENE_OR_GENE_PRODUCT", 197, 201], ["DPP4", "GENE_OR_GENE_PRODUCT", 275, 279], ["RBD", "PROTEIN", 110, 113], ["DPP4", "PROTEIN", 117, 121], ["RBD", "PROTEIN", 190, 193], ["DPP4", "PROTEIN", 197, 201], ["DPP4", "PROTEIN", 275, 279], ["both assays", "TEST", 17, 28], ["the glycan probe", "TREATMENT", 43, 59], ["DPP4", "TREATMENT", 117, 121], ["the glycan probe", "TREATMENT", 123, 139], ["DPP4", "TEST", 197, 201], ["DPP4 binding", "TREATMENT", 275, 287]]], ["Structural analysis of the RBD/DPP4 interactions suggests that a glycan probe located at residue 511 would have serious steric clash with DPP4 binding, whereas a glycan probe located at residue 562 would have partial steric interference with DPP4 binding (Fig. 1b).", [["RBD", "GENE_OR_GENE_PRODUCT", 27, 30], ["DPP4", "GENE_OR_GENE_PRODUCT", 31, 35], ["DPP4", "GENE_OR_GENE_PRODUCT", 138, 142], ["DPP4", "GENE_OR_GENE_PRODUCT", 242, 246], ["RBD", "PROTEIN", 27, 30], ["DPP4", "PROTEIN", 31, 35], ["DPP4", "PROTEIN", 138, 142], ["DPP4", "PROTEIN", 242, 246], ["Structural analysis", "TEST", 0, 19], ["the RBD/DPP4 interactions", "PROBLEM", 23, 48], ["a glycan probe", "TREATMENT", 63, 77], ["serious steric clash with DPP4 binding", "PROBLEM", 112, 150], ["a glycan probe", "TREATMENT", 160, 174], ["partial steric interference", "PROBLEM", 209, 236], ["DPP4 binding", "TREATMENT", 242, 254], ["serious", "OBSERVATION_MODIFIER", 112, 119], ["steric clash", "OBSERVATION", 120, 132], ["steric interference", "OBSERVATION", 217, 236]]], ["Glycan probes located at residues 403 and 579 would be too far away from the receptor-binding region to have any impact on DPP4 binding.", [["Glycan", "GENE_OR_GENE_PRODUCT", 0, 6], ["DPP4", "GENE_OR_GENE_PRODUCT", 123, 127], ["receptor-binding region", "PROTEIN", 77, 100], ["DPP4", "PROTEIN", 123, 127], ["Glycan probes", "TREATMENT", 0, 13], ["DPP4 binding", "TREATMENT", 123, 135]]], ["Hence, both the biochemical and structural analyses similarly elucidated the role of each of the glycan probes in the binding of the RBD to DPP4.Characterization of RBDs containing engineered glycan probes ::: ResultsTo understand the epitopes' potential to interact with neutralizing monoclonal antibodies (mAbs), we analysed how the engineered glycan probes interfered with the binding of the RBD to different neutralizing mAbs.", [["DPP4", "GENE_OR_GENE_PRODUCT", 140, 144], ["RBDs", "SIMPLE_CHEMICAL", 165, 169], ["RBD", "PROTEIN", 133, 136], ["DPP4", "PROTEIN", 140, 144], ["RBDs", "DNA", 165, 169], ["epitopes", "PROTEIN", 235, 243], ["neutralizing monoclonal antibodies", "PROTEIN", 272, 306], ["mAbs", "PROTEIN", 308, 312], ["RBD", "PROTEIN", 395, 398], ["neutralizing mAbs", "PROTEIN", 412, 429], ["the glycan probes", "TREATMENT", 93, 110], ["DPP4", "TEST", 140, 144], ["neutralizing monoclonal antibodies", "TREATMENT", 272, 306], ["the engineered glycan probes", "TREATMENT", 331, 359], ["the RBD", "PROBLEM", 391, 398], ["neutralizing mAbs", "OBSERVATION", 412, 429]]], ["We had access to four humanized mAbs (hMS-1, m336-Fab, m337-Fab, and m338-Fab).", [["hMS-1", "GENE_OR_GENE_PRODUCT", 38, 43], ["m336-Fab", "GENE_OR_GENE_PRODUCT", 45, 53], ["m337-Fab", "GENE_OR_GENE_PRODUCT", 55, 63], ["m338-Fab", "GENE_OR_GENE_PRODUCT", 69, 77], ["humanized mAbs", "PROTEIN", 22, 36], ["hMS", "PROTEIN", 38, 41], ["m336", "PROTEIN", 45, 49], ["Fab", "PROTEIN", 50, 53], ["Fab", "PROTEIN", 60, 63], ["m338", "PROTEIN", 69, 73], ["Fab", "PROTEIN", 74, 77], ["hMS", "TEST", 38, 41], ["Fab", "TEST", 50, 53], ["Fab", "TEST", 60, 63], ["m338", "TEST", 69, 73]]], ["All of these mAbs were previously shown to be highly potent in neutralizing MERS-CoV infection of human cells36373839.", [["cells", "ANATOMY", 104, 109], ["infection", "DISEASE", 85, 94], ["mAbs", "GENE_OR_GENE_PRODUCT", 13, 17], ["MERS-CoV", "ORGANISM", 76, 84], ["human", "ORGANISM", 98, 103], ["cells36373839", "CELL", 104, 117], ["mAbs", "PROTEIN", 13, 17], ["human", "SPECIES", 98, 103], ["MERS-CoV", "SPECIES", 76, 84], ["human", "SPECIES", 98, 103], ["neutralizing MERS", "PROBLEM", 63, 80], ["CoV infection of human cells", "PROBLEM", 81, 109], ["potent", "OBSERVATION_MODIFIER", 53, 59], ["neutralizing MERS", "OBSERVATION", 63, 80]]], ["ELISA between each of the RBDs and each of the mAbs demonstrated that the glycan probe located at residue 511 abolished the binding of the RBD to hMS-1 (Fig. 2a), reduced the binding of the RBD to m336-Fab and m337-Fab (Fig. 2b,c), and had no significant impact on the binding of the RBD to m338-Fab (Fig. 2d).", [["RBDs", "CANCER", 26, 30], ["hMS-1", "GENE_OR_GENE_PRODUCT", 146, 151], ["m336-Fab", "GENE_OR_GENE_PRODUCT", 197, 205], ["m337-Fab", "GENE_OR_GENE_PRODUCT", 210, 218], ["m338-Fab", "GENE_OR_GENE_PRODUCT", 291, 299], ["RBDs", "PROTEIN", 26, 30], ["mAbs", "PROTEIN", 47, 51], ["RBD", "PROTEIN", 139, 142], ["hMS", "PROTEIN", 146, 149], ["RBD", "PROTEIN", 190, 193], ["m336", "PROTEIN", 197, 201], ["Fab", "PROTEIN", 202, 205], ["m337", "PROTEIN", 210, 214], ["Fab", "PROTEIN", 215, 218], ["Fig. 2b,c)", "PROTEIN", 220, 230], ["RBD", "PROTEIN", 284, 287], ["m338", "PROTEIN", 291, 295], ["Fab", "PROTEIN", 296, 299], ["Fig. 2d", "PROTEIN", 301, 308], ["the mAbs", "TREATMENT", 43, 51], ["the glycan probe", "TREATMENT", 70, 86], ["Fab", "TEST", 202, 205], ["m337", "TEST", 210, 214], ["Fab", "TEST", 215, 218]]], ["In contrast, the glycan probes located at the other three residues, 403, 562 and 579, did not interfere with the binding of the RBD to any of the mAbs.", [["mAbs", "GENE_OR_GENE_PRODUCT", 146, 150], ["RBD", "PROTEIN", 128, 131], ["mAbs", "PROTEIN", 146, 150], ["the glycan probes", "TREATMENT", 13, 30], ["the RBD", "PROBLEM", 124, 131]]], ["The binding sites on the RBD for each of the mAbs were previously characterized through mutagenesis and/or structural studies36373839.", [["mAbs", "GENE_OR_GENE_PRODUCT", 45, 49], ["binding sites", "DNA", 4, 17], ["RBD", "PROTEIN", 25, 28], ["mAbs", "PROTEIN", 45, 49], ["The binding sites on the RBD", "PROBLEM", 0, 28], ["the mAbs", "TREATMENT", 41, 49], ["structural studies", "TEST", 107, 125], ["binding sites", "OBSERVATION", 4, 17], ["RBD", "OBSERVATION", 25, 28]]], ["Three of the four mAbs, hMS-1, m336-Fab and m337-Fab, bind at or near the epitope containing Arg511, whereas all of the mAbs bind away from the epitopes containing Ala562, Val403, and Thr579 (Fig. 2e).", [["Ala562", "CHEMICAL", 164, 170], ["Val", "CHEMICAL", 172, 175], ["Thr", "CHEMICAL", 184, 187], ["hMS-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["m336-Fab", "GENE_OR_GENE_PRODUCT", 31, 39], ["m337-Fab", "GENE_OR_GENE_PRODUCT", 44, 52], ["Arg511", "GENE_OR_GENE_PRODUCT", 93, 99], ["mAbs", "GENE_OR_GENE_PRODUCT", 120, 124], ["Ala562", "GENE_OR_GENE_PRODUCT", 164, 170], ["Thr579", "AMINO_ACID", 184, 190], ["mAbs", "PROTEIN", 18, 22], ["hMS", "PROTEIN", 24, 27], ["m336", "PROTEIN", 31, 35], ["Fab", "PROTEIN", 36, 39], ["m337", "PROTEIN", 44, 48], ["Fab", "PROTEIN", 49, 52], ["epitope", "PROTEIN", 74, 81], ["Arg511", "PROTEIN", 93, 99], ["mAbs", "PROTEIN", 120, 124], ["epitopes", "PROTEIN", 144, 152], ["Ala562", "PROTEIN", 164, 170], ["Val403", "PROTEIN", 172, 178], ["the four mAbs", "TEST", 9, 22], ["hMS", "TEST", 24, 27], ["m336", "TEST", 31, 35], ["Fab", "TEST", 36, 39], ["m337", "TEST", 44, 48], ["Fab", "TEST", 49, 52], ["the epitopes", "TEST", 140, 152], ["Ala562", "TEST", 164, 170], ["Val", "TEST", 172, 175], ["Thr", "TEST", 184, 187]]], ["Overall, among the four selected epitopes, the epitope containing Arg511 played the most important role in the binding of neutralizing mAbs, and consequently the glycan probe covering this epitope interfered most with the binding of neutralizing mAbs.Characterization of RBDs containing engineered glycan probes ::: ResultsThis study thus far has characterized the structural features, receptor binding, and neutralizing mAb binding for four selected RBD epitopes using a glycan probe strategy.", [["Arg511", "CHEMICAL", 66, 72], ["Arg", "CHEMICAL", 66, 69], ["Arg511", "AMINO_ACID", 66, 72], ["RBDs", "SIMPLE_CHEMICAL", 271, 275], ["epitopes", "PROTEIN", 33, 41], ["epitope", "PROTEIN", 47, 54], ["Arg511", "PROTEIN", 66, 72], ["neutralizing mAbs", "PROTEIN", 122, 139], ["neutralizing mAbs", "PROTEIN", 233, 250], ["RBDs", "DNA", 271, 275], ["neutralizing mAb", "PROTEIN", 408, 424], ["RBD epitopes", "PROTEIN", 451, 463], ["neutralizing mAbs", "TREATMENT", 122, 139], ["the glycan probe", "TREATMENT", 158, 174], ["this epitope", "TREATMENT", 184, 196], ["neutralizing mAbs", "TREATMENT", 233, 250], ["This study", "TEST", 323, 333], ["the structural features", "PROBLEM", 361, 384], ["receptor binding", "PROBLEM", 386, 402], ["neutralizing mAb binding", "TREATMENT", 408, 432], ["a glycan probe strategy", "TREATMENT", 470, 493]]], ["Each of the glycan probes introduced to one of the RBD epitopes only interfered with the binding of DPP4 or mAbs that interact with this specific epitope, but had no impact on the binding of DPP4 or mAbs to distant epitopes.", [["DPP4", "GENE_OR_GENE_PRODUCT", 100, 104], ["mAbs", "GENE_OR_GENE_PRODUCT", 108, 112], ["DPP4", "GENE_OR_GENE_PRODUCT", 191, 195], ["mAbs", "GENE_OR_GENE_PRODUCT", 199, 203], ["RBD epitopes", "PROTEIN", 51, 63], ["DPP4", "PROTEIN", 100, 104], ["mAbs", "PROTEIN", 108, 112], ["DPP4", "PROTEIN", 191, 195], ["mAbs", "PROTEIN", 199, 203], ["the glycan probes", "TREATMENT", 8, 25], ["the RBD epitopes", "PROBLEM", 47, 63], ["DPP4 or mAbs", "TREATMENT", 100, 112], ["DPP4", "TREATMENT", 191, 195]]], ["This observation suggests that each of the glycan probes only shielded the epitope where the glycan probe was attached to, but did not affect the structures of other antigenic sites.", [["This observation", "TEST", 0, 16], ["the glycan probes", "TREATMENT", 39, 56], ["the epitope", "TREATMENT", 71, 82], ["the glycan probe", "TREATMENT", 89, 105], ["antigenic sites", "OBSERVATION", 166, 181]]], ["It is consistent with findings obtained in studies on another viral spike protein, respiratory syncytial (RSV) virus F protein40.Measurement of neutralizing immunogenicity of RBD epitopes ::: ResultsTo evaluate how the glycan probes altered the neutralizing immunogenicity (that is, the capacity to induce neutralizing immune responses) of MERS-CoV RBDs, we immunized BALB/c mice with each of the four RBDs containing one of the glycan probes.", [["respiratory syncytial (RSV) virus F protein40", "GENE_OR_GENE_PRODUCT", 83, 128], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 340, 348], ["BALB/c mice", "ORGANISM", 368, 379], ["viral spike protein", "PROTEIN", 62, 81], ["respiratory syncytial (RSV) virus F protein40", "PROTEIN", 83, 128], ["RBD epitopes", "PROTEIN", 175, 187], ["RBDs", "DNA", 402, 406], ["mice", "SPECIES", 375, 379], ["RSV", "SPECIES", 106, 109], ["MERS-CoV", "SPECIES", 340, 348], ["mice", "SPECIES", 375, 379], ["another viral spike protein", "TEST", 54, 81], ["respiratory syncytial (RSV)", "PROBLEM", 83, 110], ["the neutralizing immunogenicity", "PROBLEM", 241, 272], ["the capacity", "PROBLEM", 283, 295], ["CoV RBDs", "TREATMENT", 345, 353], ["the four RBDs", "TREATMENT", 393, 406], ["the glycan probes", "TREATMENT", 425, 442], ["consistent with", "UNCERTAINTY", 6, 21], ["respiratory syncytial", "ANATOMY", 83, 104], ["neutralizing", "OBSERVATION_MODIFIER", 144, 156]]], ["The immunization schedule is shown in Supplementary Fig. 4A.", [["The immunization schedule", "TREATMENT", 0, 25]]], ["Sera were collected from mice immunized with each of the RBDs, and tested for MERS-CoV-neutralizing antibodies.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mice", "ORGANISM", 25, 29], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 78, 86], ["MERS-CoV-neutralizing antibodies", "PROTEIN", 78, 110], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["MERS-CoV", "SPECIES", 78, 86], ["Sera", "TEST", 0, 4], ["the RBDs", "TEST", 53, 61], ["MERS", "TEST", 78, 82], ["CoV", "TEST", 83, 86], ["neutralizing antibodies", "PROBLEM", 87, 110]]], ["Compared to the wild type RBD vaccine, the RBDs containing a glycan probe at residues 579 and 511 induced significantly higher and lower neutralizing antibody titres, respectively, in mouse sera, whereas the RBDs containing a glycan probe at residues 403 and 562 failed to induce significant changes in neutralizing antibody titres in mouse sera (Fig. 3a; Supplementary Table 1).", [["sera", "ANATOMY", 190, 194], ["sera", "ANATOMY", 341, 345], ["residues 403 and 562", "CHEMICAL", 242, 262], ["RBD", "GENE_OR_GENE_PRODUCT", 26, 29], ["RBDs", "CANCER", 43, 47], ["mouse", "ORGANISM", 184, 189], ["sera", "ORGANISM_SUBSTANCE", 190, 194], ["RBDs", "GENE_OR_GENE_PRODUCT", 208, 212], ["mouse", "ORGANISM", 335, 340], ["sera", "ORGANISM_SUBSTANCE", 341, 345], ["RBDs", "DNA", 43, 47], ["RBDs", "PROTEIN", 208, 212], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 335, 340], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 335, 340], ["the RBDs", "TEST", 39, 47], ["a glycan probe", "TREATMENT", 59, 73], ["lower neutralizing antibody titres", "PROBLEM", 131, 165], ["a glycan probe", "TREATMENT", 224, 238], ["significant changes", "PROBLEM", 280, 299], ["neutralizing antibody titres", "TREATMENT", 303, 331], ["lower", "OBSERVATION_MODIFIER", 131, 136], ["neutralizing antibody titres", "OBSERVATION", 137, 165], ["neutralizing antibody", "OBSERVATION", 303, 324]]], ["Thus, masking the epitope containing Arg511 led to reduced neutralizing antibody titres in the immunized mice, demonstrating that this epitope made a positive contribution to the vaccine's overall neutralizing immunogenicity.", [["Arg511", "CHEMICAL", 37, 43], ["Arg511", "CHEMICAL", 37, 43], ["Arg511", "SIMPLE_CHEMICAL", 37, 43], ["mice", "ORGANISM", 105, 109], ["Arg511", "PROTEIN", 37, 43], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["the epitope containing Arg", "TREATMENT", 14, 40], ["reduced neutralizing antibody titres", "TREATMENT", 51, 87], ["the vaccine", "TREATMENT", 175, 186], ["neutralizing antibody titres", "OBSERVATION", 59, 87]]], ["Based on the same rationale, the epitope containing Thr579 made a negative contribution and the epitopes containing Val403 and Ala562 made insignificant contributions to the vaccine's overall neutralizing immunogenicity.", [["Thr579", "CHEMICAL", 52, 58], ["Thr", "CHEMICAL", 52, 55], ["Thr579", "AMINO_ACID", 52, 58], ["Val403", "GENE_OR_GENE_PRODUCT", 116, 122], ["Ala562", "GENE_OR_GENE_PRODUCT", 127, 133], ["Thr579", "PROTEIN", 52, 58], ["epitopes", "PROTEIN", 96, 104], ["Val403", "PROTEIN", 116, 122], ["Ala562", "PROTEIN", 127, 133], ["the vaccine", "TREATMENT", 170, 181], ["neutralizing immunogenicity", "OBSERVATION", 192, 219]]], ["These results provided a qualitative evaluation of the neutralizing immunogenicity for each of these epitopes.Measurement of neutralizing immunogenicity of RBD epitopes ::: ResultsHow can we quantitatively evaluate the epitopes' neutralizing immunogenicity?", [["epitopes", "PROTEIN", 101, 109], ["RBD epitopes", "PROTEIN", 156, 168], ["epitopes", "PROTEIN", 219, 227], ["a qualitative evaluation", "TEST", 23, 47], ["the neutralizing immunogenicity", "TREATMENT", 51, 82], ["these epitopes", "PROBLEM", 95, 109], ["the epitopes' neutralizing immunogenicity", "PROBLEM", 215, 256], ["neutralizing", "OBSERVATION_MODIFIER", 125, 137]]], ["Here we introduce a novel concept NII to describe an epitope's neutralizing immunogenicity.", [["a novel concept NII", "TREATMENT", 18, 37], ["an epitope's neutralizing immunogenicity", "PROBLEM", 50, 90]]], ["NII is defined as the contribution of an epitope to the vaccine's overall neutralizing immunogenicity.", [["an epitope", "PROBLEM", 38, 48]]], ["It can be determined by masking the epitope with a glycan probe and then measuring the relative change of the vaccine's overall capacity to elicit neutralizing antibody titres (Fig. 3b).", [["a glycan probe", "TREATMENT", 49, 63], ["the vaccine", "TREATMENT", 106, 117], ["neutralizing antibody titres", "TEST", 147, 175]]], ["Based on this definition, we calculated the NII for each of the four epitopes on the RBD (Fig. 3c; Supplementary Table 1).", [["NII", "DNA", 44, 47], ["epitopes", "PROTEIN", 69, 77], ["RBD", "PROTEIN", 85, 88], ["the NII", "TREATMENT", 40, 47]]], ["The epitope containing Thr579 had an NII of \u22123.0.", [["Thr", "CHEMICAL", 23, 26], ["Thr579", "AMINO_ACID", 23, 29], ["Thr579", "PROTEIN", 23, 29], ["The epitope containing Thr", "TREATMENT", 0, 26], ["an NII", "TEST", 34, 40]]], ["The negative sign of the NII suggests a negative contribution from this epitope to the vaccine's overall neutralizing immunogenicity, and the value of the NII implicates that masking this epitope using a glycan probe increased the vaccine's overall neutralizing immunogenicity by three fold.", [["this epitope", "PROBLEM", 67, 79], ["this epitope", "TREATMENT", 183, 195], ["a glycan probe", "TREATMENT", 202, 216], ["the vaccine", "TREATMENT", 227, 238], ["negative", "OBSERVATION", 4, 12], ["negative", "OBSERVATION", 40, 48]]], ["Conversely, the epitope containing Arg511 had an NII of 0.6, suggesting that this epitope made a positive contribution to the vaccine's overall neutralizing immunogenicity and that masking this epitope using a glycan probe reduced the vaccine's overall neutralizing immunogenicity to 60% of that of the wild type vaccine.", [["Arg511", "CHEMICAL", 35, 41], ["Arg", "CHEMICAL", 35, 38], ["Arg511", "AMINO_ACID", 35, 41], ["Arg511", "PROTEIN", 35, 41], ["an NII", "TEST", 46, 52], ["the vaccine", "TREATMENT", 122, 133], ["this epitope", "TREATMENT", 189, 201], ["a glycan probe", "TREATMENT", 208, 222], ["the vaccine", "TREATMENT", 231, 242], ["the wild type vaccine", "TREATMENT", 299, 320]]], ["Therefore, the NII can serve as an effective tool to quantitatively evaluate the neutralizing immunogenicity of any epitope on the MERS-CoV RBD vaccine.Measurement of neutralizing immunogenicity of RBD epitopes ::: ResultsTo investigate why masking a negative epitope led to enhanced neutralizing immunogenicity of the MERS-CoV RBD vaccine, we performed a competition assay between neutralizing mAbs and mutant-RBD-induced mouse serum for the binding of wild type MERS-CoV RBD.", [["serum", "ANATOMY", 429, 434], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 131, 139], ["MERS-CoV", "ORGANISM", 319, 327], ["mAbs", "GENE_OR_GENE_PRODUCT", 395, 399], ["RBD", "GENE_OR_GENE_PRODUCT", 411, 414], ["mouse", "ORGANISM", 423, 428], ["serum", "ORGANISM_SUBSTANCE", 429, 434], ["MERS-CoV RBD", "ORGANISM", 464, 476], ["RBD epitopes", "PROTEIN", 198, 210], ["mAbs", "PROTEIN", 395, 399], ["RBD", "PROTEIN", 411, 414], ["wild type MERS-CoV RBD", "PROTEIN", 454, 476], ["mouse", "SPECIES", 423, 428], ["MERS-CoV", "SPECIES", 131, 139], ["MERS-CoV", "SPECIES", 319, 327], ["mouse", "SPECIES", 423, 428], ["MERS-CoV", "SPECIES", 464, 472], ["CoV RBD vaccine", "TREATMENT", 136, 151], ["CoV RBD vaccine", "TREATMENT", 324, 339], ["a competition assay", "TEST", 354, 373], ["neutralizing mAbs", "TREATMENT", 382, 399], ["RBD", "PROBLEM", 411, 414], ["CoV RBD", "PROBLEM", 469, 476], ["neutralizing", "OBSERVATION_MODIFIER", 167, 179]]], ["More specifically, ELISA was carried out between a neutralizing mAb and MERS-CoV RBD in the presence of mouse serum induced by the 579-glycosylated MERS-CoV RBD (Fig. 4a,b).", [["serum", "ANATOMY", 110, 115], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["mouse", "ORGANISM", 104, 109], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 148, 156], ["neutralizing mAb", "PROTEIN", 51, 67], ["MERS-CoV RBD", "PROTEIN", 72, 84], ["579-glycosylated MERS-CoV RBD", "PROTEIN", 131, 160], ["Fig. 4a,b)", "PROTEIN", 162, 172], ["mouse", "SPECIES", 104, 109], ["MERS-CoV", "SPECIES", 72, 80], ["mouse", "SPECIES", 104, 109], ["MERS-CoV", "SPECIES", 148, 156], ["ELISA", "TEST", 19, 24], ["a neutralizing mAb", "TREATMENT", 49, 67], ["CoV RBD", "PROBLEM", 77, 84], ["glycosylated MERS", "TEST", 135, 152], ["CoV RBD", "TEST", 153, 160]]], ["As a comparison, the mouse serum induced by the wild type MERS-CoV RBD was also included.", [["serum", "ANATOMY", 27, 32], ["mouse", "ORGANISM", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["MERS-CoV", "ORGANISM", 58, 66], ["wild type MERS-CoV RBD", "PROTEIN", 48, 70], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 21, 26], ["MERS-CoV", "SPECIES", 58, 66], ["the mouse serum", "TEST", 17, 32], ["CoV RBD", "PROBLEM", 63, 70]]], ["Two different mAbs were used in the competition binding assay: hMs-1, which binds to the RBM epitope containing Arg511 (refs 36, 39), and m336-Fab, which binds to the RBM epitope surrounding Glu536-Asp539 (refs 37, 38).", [["Glu536-Asp539", "CHEMICAL", 191, 204], ["hMs-1", "GENE_OR_GENE_PRODUCT", 63, 68], ["Arg511", "GENE_OR_GENE_PRODUCT", 112, 118], ["m336-Fab", "GENE_OR_GENE_PRODUCT", 138, 146], ["Glu536-Asp539", "GENE_OR_GENE_PRODUCT", 191, 204], ["mAbs", "PROTEIN", 14, 18], ["hMs", "PROTEIN", 63, 66], ["RBM epitope", "PROTEIN", 89, 100], ["Arg511", "PROTEIN", 112, 118], ["m336", "PROTEIN", 138, 142], ["Fab", "PROTEIN", 143, 146], ["RBM epitope", "PROTEIN", 167, 178], ["Two different mAbs", "TREATMENT", 0, 18], ["the RBM epitope surrounding Glu536", "TEST", 163, 197], ["mAbs", "OBSERVATION", 14, 18]]], ["The result showed that the serum induced by the 579-glycosylated RBD inhibited the mAb-RBD binding significantly better than the serum induced by the wild type RBD, revealing enhanced neutralizing capability of the mouse serum due to the glycosylation at the 579 position.", [["serum", "ANATOMY", 27, 32], ["serum", "ANATOMY", 129, 134], ["serum", "ANATOMY", 221, 226], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["RBD", "GENE_OR_GENE_PRODUCT", 65, 68], ["mAb-RBD", "GENE_OR_GENE_PRODUCT", 83, 90], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["RBD", "GENE_OR_GENE_PRODUCT", 160, 163], ["mouse", "ORGANISM", 215, 220], ["serum", "ORGANISM_SUBSTANCE", 221, 226], ["579-glycosylated RBD", "PROTEIN", 48, 68], ["mAb", "PROTEIN", 83, 86], ["RBD", "PROTEIN", 87, 90], ["wild type RBD", "PROTEIN", 150, 163], ["mouse", "SPECIES", 215, 220], ["mouse", "SPECIES", 215, 220], ["the serum", "TEST", 23, 32], ["glycosylated RBD", "PROBLEM", 52, 68], ["the mAb", "TEST", 79, 86], ["RBD binding", "PROBLEM", 87, 98], ["the wild type RBD", "PROBLEM", 146, 163], ["enhanced neutralizing capability of the mouse serum", "PROBLEM", 175, 226], ["the glycosylation", "TREATMENT", 234, 251], ["neutralizing capability", "OBSERVATION", 184, 207]]], ["Moreover, the mouse serum induced by the 579-glycosylated RBD demonstrated enhanced binding for at least two separate neutralizing epitopes on the RBM, one surrounding Arg511 and the other Glu536-Asp539.", [["serum", "ANATOMY", 20, 25], ["Glu536-Asp539", "CHEMICAL", 189, 202], ["Arg511", "CHEMICAL", 168, 174], ["Asp", "CHEMICAL", 196, 199], ["mouse", "ORGANISM", 14, 19], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["RBD", "GENE_OR_GENE_PRODUCT", 58, 61], ["RBM", "CANCER", 147, 150], ["Arg511", "GENE_OR_GENE_PRODUCT", 168, 174], ["Glu536-Asp539", "GENE_OR_GENE_PRODUCT", 189, 202], ["579-glycosylated RBD", "PROTEIN", 41, 61], ["neutralizing epitopes", "PROTEIN", 118, 139], ["RBM", "PROTEIN", 147, 150], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["the mouse serum", "TEST", 10, 25], ["enhanced binding", "PROBLEM", 75, 91], ["the other Glu536", "TEST", 179, 195], ["Asp", "TEST", 196, 199], ["neutralizing", "OBSERVATION_MODIFIER", 118, 130], ["epitopes", "OBSERVATION", 131, 139]]], ["Thus, masking an epitope on the RBD core structure with a high negative NII refocuses the host immune response on neutralizing epitopes on the RBM, leading to enhanced neutralizing immunogenicity of the RBD vaccine.Rational design of RBD vaccine with enhanced efficacy ::: ResultsTo prove that highly effective MERS-CoV RBD vaccines can be rationally designed based on epitopes' neutralizing immunogenicity, we investigated the efficacy of two engineered MERS-CoV RBD vaccines using virus challenge studies.", [["MERS-CoV", "ORGANISM", 311, 319], ["MERS-CoV", "ORGANISM", 455, 463], ["RBD", "PROTEIN", 32, 35], ["high negative NII", "PROTEIN", 58, 75], ["neutralizing epitopes", "PROTEIN", 114, 135], ["epitopes", "PROTEIN", 369, 377], ["MERS-CoV", "SPECIES", 311, 319], ["MERS-CoV", "SPECIES", 455, 463], ["an epitope on the RBD core structure", "PROBLEM", 14, 50], ["neutralizing epitopes on the RBM", "PROBLEM", 114, 146], ["RBD vaccine", "TREATMENT", 234, 245], ["CoV RBD vaccines", "TREATMENT", 316, 332], ["epitopes' neutralizing immunogenicity", "TREATMENT", 369, 406], ["CoV RBD vaccines", "TREATMENT", 460, 476], ["virus challenge studies", "TEST", 483, 506], ["epitope", "OBSERVATION", 17, 24], ["host immune response", "OBSERVATION", 90, 110]]], ["These engineered RBD vaccines have a negative epitope (that is, the epitope containing Thr579 and with an NII of \u22123.0) and a positive epitope (that is, the epitope containing Arg511 and with an NII of 0.6) masked, respectively, by a glycan probe.", [["Thr", "CHEMICAL", 87, 90], ["epitope", "PROTEIN", 68, 75], ["Thr579", "PROTEIN", 87, 93], ["NII", "PROTEIN", 106, 109], ["positive epitope", "PROTEIN", 125, 141], ["epitope", "PROTEIN", 156, 163], ["Arg511", "PROTEIN", 175, 181], ["an NII", "TEST", 103, 109], ["a positive epitope", "PROBLEM", 123, 141], ["an NII", "TREATMENT", 191, 197], ["a glycan probe", "TREATMENT", 231, 245], ["positive epitope", "OBSERVATION", 125, 141]]], ["We chose to mask the epitopes rather than deleting them or mutating all of their residues to alanines because introducing a glycan is more convenient in practice and less disruptive to the immunogen's tertiary structure.", [["alanines", "CHEMICAL", 93, 101], ["epitopes", "PROTEIN", 21, 29]]], ["The wild type RBD vaccine was used as a control.", [["The wild type RBD vaccine", "TREATMENT", 0, 25]]], ["The animal model for vaccine testing was the lethal transgenic mouse model expressing human DPP4 (hDPP4-Tg mice)4142.", [["mouse", "ORGANISM", 63, 68], ["human", "ORGANISM", 86, 91], ["DPP4", "GENE_OR_GENE_PRODUCT", 92, 96], ["hDPP4", "GENE_OR_GENE_PRODUCT", 98, 103], ["human DPP4", "PROTEIN", 86, 96], ["hDPP4", "PROTEIN", 98, 103], ["mouse", "SPECIES", 63, 68], ["human", "SPECIES", 86, 91], ["mice", "SPECIES", 107, 111], ["mouse", "SPECIES", 63, 68], ["human", "SPECIES", 86, 91], ["vaccine testing", "TEST", 21, 36]]], ["These mice were chosen for analysis because they are very susceptible to MERS-CoV and also because preventing disease in these mice is a stringent test of efficacy.", [["mice", "ORGANISM", 6, 10], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 73, 81], ["mice", "ORGANISM", 127, 131], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 6, 10], ["MERS-CoV", "SPECIES", 73, 81], ["mice", "SPECIES", 127, 131], ["analysis", "TEST", 27, 35], ["disease", "PROBLEM", 110, 117]]], ["The immunization schedule is shown in Supplementary Fig. 4B.", [["4B", "GENE_OR_GENE_PRODUCT", 57, 59], ["The immunization schedule", "TREATMENT", 0, 25]]], ["Briefly, hDPP4-Tg mice were immunized with each of the RBD vaccines and challenged with MERS-CoV, and the survival rate and weight changes of the mice were recorded.Rational design of RBD vaccine with enhanced efficacy ::: ResultsThe efficacies of the RBD vaccines were evaluated based on the morbidity and mortality of the immunized and challenged mice.", [["hDPP4", "GENE_OR_GENE_PRODUCT", 9, 14], ["mice", "ORGANISM", 18, 22], ["MERS-CoV", "ORGANISM", 88, 96], ["mice", "ORGANISM", 146, 150], ["mice", "ORGANISM", 349, 353], ["hDPP4", "PROTEIN", 9, 14], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 349, 353], ["mice", "SPECIES", 18, 22], ["MERS-CoV", "SPECIES", 88, 96], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 349, 353], ["hDPP4-Tg mice", "TREATMENT", 9, 22], ["the RBD vaccines", "TREATMENT", 51, 67], ["the survival rate", "TEST", 102, 119], ["RBD vaccine", "TREATMENT", 184, 195], ["the RBD vaccines", "TREATMENT", 248, 264], ["RBD", "ANATOMY", 252, 255]]], ["First, hDPP4-Tg mice immunized with the negative-epitope-masked RBD vaccine (that is, RBD containing T579N mutation) all survived MERS-CoV challenge (100% survival rate), whereas hDPP4-Tg mice immunized with the wild type RBD vaccine and with the positive-epitope-masked RBD vaccine (that is, RBD containing R511N/E513T mutations) demonstrated survival rates of 67 and 17%, respectively, after MERS-CoV challenge (Fig. 5a).", [["hDPP4", "GENE_OR_GENE_PRODUCT", 7, 12], ["mice", "ORGANISM", 16, 20], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 130, 138], ["hDPP4-Tg mice", "ORGANISM", 179, 192], ["hDPP4", "PROTEIN", 7, 12], ["RBD", "PROTEIN", 64, 67], ["RBD", "PROTEIN", 86, 89], ["hDPP4", "PROTEIN", 179, 184], ["RBD", "PROTEIN", 271, 274], ["RBD", "PROTEIN", 293, 296], ["R511N", "PROTEIN", 308, 313], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 188, 192], ["mice", "SPECIES", 16, 20], ["MERS-CoV", "SPECIES", 130, 138], ["mice", "SPECIES", 188, 192], ["MERS-CoV", "SPECIES", 394, 402], ["hDPP4", "TEST", 7, 12], ["masked RBD vaccine", "TREATMENT", 57, 75], ["CoV challenge", "TREATMENT", 135, 148], ["survival rate", "TEST", 155, 168], ["hDPP4", "TEST", 179, 184], ["the wild type RBD vaccine", "TREATMENT", 208, 233], ["masked RBD vaccine", "TREATMENT", 264, 282], ["RBD", "TEST", 293, 296], ["survival rates", "TEST", 344, 358]]], ["Second, MERS-CoV challenge did not cause any weight loss in hDPP4-Tg mice immunized with the negative-epitope-masked RBD vaccine, but led to significant weight loss in hDPP4-Tg mice immunized with either the wild type RBD vaccine or the positive-epitope-masked RBD vaccine (Fig. 5b).", [["weight loss", "DISEASE", 45, 56], ["weight loss", "DISEASE", 153, 164], ["MERS-CoV", "ORGANISM", 8, 16], ["hDPP4", "GENE_OR_GENE_PRODUCT", 60, 65], ["mice", "ORGANISM", 69, 73], ["hDPP4-Tg mice", "ORGANISM", 168, 181], ["hDPP4", "PROTEIN", 60, 65], ["RBD", "PROTEIN", 117, 120], ["hDPP4", "PROTEIN", 168, 173], ["epitope", "PROTEIN", 246, 253], ["RBD", "PROTEIN", 261, 264], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 177, 181], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 177, 181], ["CoV challenge", "TREATMENT", 13, 26], ["weight loss", "PROBLEM", 45, 56], ["hDPP4", "TEST", 60, 65], ["masked RBD vaccine", "TREATMENT", 110, 128], ["significant weight loss", "PROBLEM", 141, 164], ["hDPP4", "TEST", 168, 173], ["Tg mice immunized", "TREATMENT", 174, 191], ["the wild type RBD vaccine", "TREATMENT", 204, 229], ["masked RBD vaccine", "TREATMENT", 254, 272]]], ["These results revealed the enhanced efficacy of the negative-epitope-masked RBD vaccine and reduced efficacy of the positive-epitope-masked RBD vaccine, and demonstrated the utility of NII in developing a vaccine with increased immunogenicity in a stringent model of severe MERS.DiscussionCurrent vaccine design lacks an effective approach to evaluate the neutralizing immunogenicity of epitopes on viral subunit vaccines.", [["NII", "CHEMICAL", 185, 188], ["MERS", "DISEASE", 274, 278], ["NII", "SIMPLE_CHEMICAL", 185, 188], ["epitopes", "PROTEIN", 387, 395], ["masked RBD vaccine", "PROBLEM", 69, 87], ["the positive-epitope", "PROBLEM", 112, 132], ["masked RBD vaccine", "PROBLEM", 133, 151], ["a vaccine", "TREATMENT", 203, 212], ["increased immunogenicity", "PROBLEM", 218, 242], ["severe MERS", "PROBLEM", 267, 278], ["DiscussionCurrent vaccine", "TREATMENT", 279, 304], ["an effective approach", "TREATMENT", 318, 339], ["epitopes", "PROBLEM", 387, 395], ["viral subunit vaccines", "TREATMENT", 399, 421], ["increased", "OBSERVATION_MODIFIER", 218, 227], ["immunogenicity", "OBSERVATION", 228, 242], ["stringent model", "OBSERVATION_MODIFIER", 248, 263], ["severe", "OBSERVATION_MODIFIER", 267, 273], ["MERS", "OBSERVATION", 274, 278]]], ["In this study, we have developed a novel approach to measure vaccine epitopes' neutralizing immunogenicity.", [["this study", "TEST", 3, 13], ["a novel approach", "TREATMENT", 33, 49], ["vaccine epitopes", "TREATMENT", 61, 77]]], ["Using the MERS-CoV RBD as a model, we singly mask selected epitopes using host-derived glycan probes, and then measure the corresponding changes in the vaccine's overall neutralizing immunogenicity.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 10, 18], ["MERS-CoV RBD", "PROTEIN", 10, 22], ["epitopes", "PROTEIN", 59, 67], ["MERS-CoV", "SPECIES", 10, 18], ["host-derived glycan probes", "TREATMENT", 74, 100], ["the vaccine", "TREATMENT", 148, 159]]], ["We have also developed a method for calculating the NII for the selected epitopes.", [["NII", "PROTEIN", 52, 55], ["epitopes", "PROTEIN", 73, 81], ["a method", "TREATMENT", 23, 31], ["calculating the NII", "TREATMENT", 36, 55]]], ["An epitope's neutralizing immunogenicity contains two parts: the neutralization capacity and immunogenicity.", [["An epitope's neutralizing immunogenicity", "TREATMENT", 0, 40], ["the neutralization capacity", "PROBLEM", 61, 88], ["neutralizing immunogenicity", "OBSERVATION", 13, 40], ["neutralization capacity", "OBSERVATION", 65, 88]]], ["On the one hand, an epitope's neutralizing capacity is determined by the physical overlap of the epitope with the receptor-binding region and the potential role of the epitope in receptor binding.", [["receptor-binding region", "PROTEIN", 114, 137], ["an epitope's neutralizing capacity", "PROBLEM", 17, 51], ["the epitope in receptor binding", "TREATMENT", 164, 195]]], ["On the other hand, an epitope's immunogenicity is determined by its immune selfness (that is, how similar or dissimilar the viral epitope is to a host-originated epitope), protrusion, and other physical and chemical properties of the epitope.", [["viral epitope", "PROTEIN", 124, 137], ["an epitope's immunogenicity", "TEST", 19, 46], ["dissimilar the viral epitope", "PROBLEM", 109, 137], ["protrusion", "PROBLEM", 172, 182], ["protrusion", "OBSERVATION", 172, 182]]], ["Logically, an epitope's NII is correlated with a combination of factors such as immune selfness, protrusion, potential overlap with receptor-binding region, and more.", [["NII", "PROTEIN", 24, 27], ["receptor-binding region", "PROTEIN", 132, 155], ["an epitope's NII", "TREATMENT", 11, 27], ["immune selfness", "PROBLEM", 80, 95], ["protrusion", "PROBLEM", 97, 107], ["receptor-binding region", "TREATMENT", 132, 155], ["protrusion", "OBSERVATION", 97, 107]]], ["Because of the complex nature of NII, it is unlikely that the NII can be reliably predicted by software; instead, this study demonstrates that NII can be experimentally measured using the glycan probe approach.DiscussionAs proof-of-concept, we measured the NII for four distinct epitopes on the MERS-CoV RBD vaccine, and also characterized the protrusion index, receptor binding, and monoclonal antibody binding of the RBDs each with an epitope masked by a glycan probe.", [["NII", "SIMPLE_CHEMICAL", 143, 146], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 295, 303], ["NII", "DNA", 62, 65], ["NII", "PROTEIN", 143, 146], ["NII", "DNA", 257, 260], ["epitopes", "PROTEIN", 279, 287], ["monoclonal antibody", "PROTEIN", 384, 403], ["RBDs", "PROTEIN", 419, 423], ["MERS-CoV", "SPECIES", 295, 303], ["this study", "TEST", 114, 124], ["the glycan probe approach", "TREATMENT", 184, 209], ["CoV RBD vaccine", "TREATMENT", 300, 315], ["the protrusion index", "PROBLEM", 340, 360], ["receptor binding", "PROBLEM", 362, 378], ["monoclonal antibody binding", "PROBLEM", 384, 411], ["an epitope", "TREATMENT", 434, 444], ["a glycan probe", "TREATMENT", 455, 469], ["protrusion index", "OBSERVATION", 344, 360], ["monoclonal antibody", "OBSERVATION", 384, 403]]], ["The results revealed that the epitopes with a high and low protrusion index tend to have an NII with a high and low absolute value, respectively.", [["epitopes", "PROTEIN", 30, 38], ["the epitopes", "PROBLEM", 26, 38], ["a high and low protrusion index", "PROBLEM", 44, 75], ["a high and low absolute value", "PROBLEM", 101, 130], ["low protrusion", "OBSERVATION", 55, 69], ["high", "OBSERVATION_MODIFIER", 103, 107]]], ["In addition, epitopes within the receptor-binding region tend to have a positive NII, and the epitopes located outside the receptor-binding region tend to have a negative NII.", [["NII", "GENE_OR_GENE_PRODUCT", 81, 84], ["epitopes", "PROTEIN", 13, 21], ["receptor-binding region", "PROTEIN", 33, 56], ["NII", "PROTEIN", 81, 84], ["epitopes", "PROTEIN", 94, 102], ["receptor-binding region", "PROTEIN", 123, 146], ["negative NII", "PROTEIN", 162, 174], ["a positive NII", "PROBLEM", 70, 84], ["positive", "OBSERVATION", 72, 80], ["negative", "OBSERVATION", 162, 170]]], ["We cannot correlate the immune selfness of epitopes with NII because there is no good method to evaluate the immune selfness of conformational epitopes.", [["epitopes", "PROTEIN", 43, 51], ["conformational epitopes", "PROTEIN", 128, 151], ["conformational epitopes", "PROBLEM", 128, 151]]], ["Overall, in rational design of viral subunit vaccines, the epitopes with a high positive NII should be preserved and exposed, while those with a high negative NII should be eliminated via deletion or masking.", [["NII", "GENE_OR_GENE_PRODUCT", 159, 162], ["epitopes", "PROTEIN", 59, 67], ["viral subunit vaccines", "TREATMENT", 31, 53], ["the epitopes", "PROBLEM", 55, 67], ["a high positive NII", "PROBLEM", 73, 92], ["a high negative NII", "PROBLEM", 143, 162]]], ["Indeed, our study has identified an epitope containing Thr579 as one with a high negative NII on MERS-CoV RBD.", [["Thr", "CHEMICAL", 55, 58], ["Thr579", "AMINO_ACID", 55, 61], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["Thr579", "PROTEIN", 55, 61], ["high negative NII", "PROTEIN", 76, 93], ["MERS-CoV RBD", "PROTEIN", 97, 109], ["MERS-CoV", "SPECIES", 97, 105], ["our study", "TEST", 8, 17], ["an epitope containing Thr", "PROBLEM", 33, 58], ["CoV RBD", "PROBLEM", 102, 109]]], ["Thr579 is located on a protruding loop and away from the receptor-binding region, both of which contribute to its high negative NII.", [["Thr579", "GENE_OR_GENE_PRODUCT", 0, 6], ["Thr579", "PROTEIN", 0, 6], ["receptor-binding region", "PROTEIN", 57, 80], ["NII", "PROTEIN", 128, 131], ["a protruding loop", "TREATMENT", 21, 38], ["protruding", "OBSERVATION", 23, 33], ["binding", "ANATOMY_MODIFIER", 66, 73], ["region", "ANATOMY_MODIFIER", 74, 80]]], ["Importantly, Thr579 is buried inside the full-length coronavirus spike proteins, and only becomes exposed on the surface of the recombinant MERS-CoV RBD vaccine as an outcome of subunit vaccine design (Supplementary Fig. 1).", [["surface", "ANATOMY", 113, 120], ["Thr579", "GENE_OR_GENE_PRODUCT", 13, 19], ["coronavirus", "ORGANISM", 53, 64], ["MERS-CoV", "ORGANISM", 140, 148], ["Thr579", "PROTEIN", 13, 19], ["full-length coronavirus spike proteins", "PROTEIN", 41, 79], ["MERS", "PROTEIN", 140, 144], ["MERS-CoV", "SPECIES", 140, 148], ["coronavirus spike proteins", "PROBLEM", 53, 79], ["the recombinant MERS", "TREATMENT", 124, 144], ["CoV RBD vaccine", "TREATMENT", 145, 160], ["subunit vaccine design", "TREATMENT", 178, 200], ["Supplementary Fig", "TREATMENT", 202, 219], ["full-length", "OBSERVATION_MODIFIER", 41, 52]]], ["To overcome this limitation of subunit vaccine design, the newly exposed epitopes with a high negative NII need to be masked or deleted.DiscussionTo apply the NII strategy to vaccine design, we successfully enhanced the efficacy of the MERS-CoV RBD vaccine in virus challenge studies by masking its strong negative epitope (that is, the epitope containing Thr579, with an NII of \u22123.0) with a glycan probe.", [["Thr", "CHEMICAL", 356, 359], ["MERS-CoV", "ORGANISM", 236, 244], ["NII", "PROTEIN", 103, 106], ["strong negative epitope", "PROTEIN", 299, 322], ["epitope", "PROTEIN", 337, 344], ["Thr579", "PROTEIN", 356, 362], ["MERS-CoV", "SPECIES", 236, 244], ["subunit vaccine design", "TREATMENT", 31, 53], ["the newly exposed epitopes", "PROBLEM", 55, 81], ["the NII strategy", "TREATMENT", 155, 171], ["the MERS", "PROBLEM", 232, 240], ["CoV RBD vaccine", "TREATMENT", 241, 256], ["virus challenge studies", "TEST", 260, 283], ["the epitope containing Thr", "TREATMENT", 333, 359], ["an NII", "TEST", 369, 375], ["a glycan probe", "TREATMENT", 390, 404]]], ["This engineered vaccine effectively protected hDPP4-transgenic mice from a lethal MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 82, 100], ["hDPP4", "GENE_OR_GENE_PRODUCT", 46, 51], ["mice", "ORGANISM", 63, 67], ["MERS-CoV", "ORGANISM", 82, 90], ["hDPP4", "PROTEIN", 46, 51], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["MERS-CoV", "SPECIES", 82, 90], ["This engineered vaccine", "TREATMENT", 0, 23], ["a lethal MERS", "PROBLEM", 73, 86], ["CoV infection", "PROBLEM", 87, 100], ["CoV", "OBSERVATION_MODIFIER", 87, 90], ["infection", "OBSERVATION", 91, 100]]], ["Compared with the wild type RBD vaccine, mice immunized with the engineered RBD vaccine showed increased neutralizing antibody responses in their sera; when challenged by MERS-CoV, they also demonstrated higher survival rate and less weight loss.", [["sera", "ANATOMY", 146, 150], ["weight loss", "DISEASE", 234, 245], ["RBD", "GENE_OR_GENE_PRODUCT", 28, 31], ["mice", "ORGANISM", 41, 45], ["sera", "ORGANISM_SUBSTANCE", 146, 150], ["MERS-CoV", "ORGANISM", 171, 179], ["RBD", "PROTEIN", 76, 79], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["MERS-CoV", "SPECIES", 171, 179], ["the wild type RBD vaccine", "TREATMENT", 14, 39], ["mice immunized", "TREATMENT", 41, 55], ["the engineered RBD vaccine", "TREATMENT", 61, 87], ["increased neutralizing antibody responses", "PROBLEM", 95, 136], ["higher survival rate", "PROBLEM", 204, 224], ["less weight loss", "PROBLEM", 229, 245], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["neutralizing antibody", "OBSERVATION", 105, 126], ["less", "OBSERVATION_MODIFIER", 229, 233], ["weight loss", "OBSERVATION", 234, 245]]], ["In contrast, another engineered vaccine with a positive epitope masked (that is, the epitope containing Arg511, with an NII of 0.6) showed reduced efficacy in virus challenge studies, confirming that positive epitopes should be preserved and exposed in vaccine design.", [["Arg511", "GENE_OR_GENE_PRODUCT", 104, 110], ["epitope", "PROTEIN", 85, 92], ["Arg511", "PROTEIN", 104, 110], ["another engineered vaccine", "TREATMENT", 13, 39], ["a positive epitope masked", "PROBLEM", 45, 70], ["an NII", "TEST", 117, 123], ["reduced efficacy in virus challenge studies", "PROBLEM", 139, 182], ["positive epitopes", "PROBLEM", 200, 217]]], ["Taken altogether, we validated both the significance and feasibility of the NII strategy in vaccine design by successfully engineering a variant form of the MERS-CoV RBD vaccine with significantly enhanced efficacy.DiscussionOverall, our study contributes to viral subunit vaccine design in the following ways.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 157, 165], ["MERS-CoV", "SPECIES", 157, 165], ["the NII strategy", "TREATMENT", 72, 88], ["CoV RBD vaccine", "TREATMENT", 162, 177], ["our study", "TEST", 234, 243], ["viral subunit vaccine", "TREATMENT", 259, 280]]], ["First, our study introduces a new concept NII for the evaluation of how individual epitopes contribute to the overall neutralizing immunogenicity of subunit vaccines.", [["our study", "TEST", 7, 16], ["the evaluation", "TEST", 50, 64], ["how individual epitopes", "PROBLEM", 68, 91], ["subunit vaccines", "TREATMENT", 149, 165]]], ["Previous studies could not evaluate the neutralizing immunogenicity of conformational B-cell epitopes that dominate coronavirus RBD vaccines.", [["B-cell", "ANATOMY", 86, 92], ["coronavirus RBD", "DISEASE", 116, 131], ["B-cell", "CELL", 86, 92], ["coronavirus", "ORGANISM", 116, 127], ["conformational B-cell epitopes", "PROTEIN", 71, 101], ["Previous studies", "TEST", 0, 16], ["conformational B-cell epitopes", "PROBLEM", 71, 101], ["coronavirus RBD vaccines", "TREATMENT", 116, 140]]], ["Second, using the NII strategy our study identified an immunodominant non-neutralizing epitope on the surface of the MERS-CoV RBD core structure.", [["surface", "ANATOMY", 102, 109], ["surface", "CELLULAR_COMPONENT", 102, 109], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 117, 125], ["immunodominant non-neutralizing epitope", "PROTEIN", 55, 94], ["MERS-CoV RBD core structure", "PROTEIN", 117, 144], ["MERS-CoV", "SPECIES", 117, 125], ["our study", "TEST", 31, 40], ["an immunodominant non-neutralizing epitope", "PROBLEM", 52, 94], ["immunodominant", "OBSERVATION_MODIFIER", 55, 69], ["non-neutralizing epitope", "OBSERVATION", 70, 94], ["CoV RBD", "OBSERVATION", 122, 129]]], ["This result shows that exposure of previously buried epitopes on viral subunit vaccines poses a challenge for subunit vaccine design.", [["previously buried epitopes", "PROBLEM", 35, 61], ["viral subunit vaccines", "TREATMENT", 65, 87], ["subunit vaccine design", "TREATMENT", 110, 132]]], ["This concept, although needing further investigations, may be critical for the development of many viral RBD-based vaccines.", [["RBD", "PROTEIN", 105, 108], ["further investigations", "TEST", 31, 53], ["many viral RBD", "PROBLEM", 94, 108], ["based vaccines", "TREATMENT", 109, 123]]], ["Third, our study demonstrates that masking an immunodominant non-neutralizing epitope with a negative NII value on the surface of the MERS-CoV RBD core structure can shift host immune responses towards the neutralizing epitopes in the RBM region, providing means to overcome the limitation of viral subunit vaccines from vaccine design.", [["surface", "ANATOMY", 119, 126], ["surface", "CELLULAR_COMPONENT", 119, 126], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 134, 142], ["immunodominant non-neutralizing epitope", "PROTEIN", 46, 85], ["NII", "PROTEIN", 102, 105], ["neutralizing epitopes", "PROTEIN", 206, 227], ["RBM region", "DNA", 235, 245], ["MERS-CoV", "SPECIES", 134, 142], ["our study", "TEST", 7, 16], ["an immunodominant non-neutralizing epitope", "PROBLEM", 43, 85], ["CoV RBD core structure", "PROBLEM", 139, 161], ["the neutralizing epitopes in the RBM region", "PROBLEM", 202, 245], ["viral subunit vaccines", "TREATMENT", 293, 315], ["immunodominant", "OBSERVATION_MODIFIER", 46, 60], ["non-neutralizing epitope", "OBSERVATION", 61, 85], ["host immune", "OBSERVATION", 172, 183]]], ["Previous studies showed that hypervariable regions on HIV gp120 divert host immune responses and that masking these regions can shift host immune responses towards conserved neutralizing epitopes1112, providing means to overcome the limitation of viral subunit vaccines from viral evolution.", [["HIV gp120", "ORGANISM", 54, 63], ["HIV gp120", "PROTEIN", 54, 63], ["epitopes1112", "PROTEIN", 187, 199], ["HIV", "SPECIES", 54, 57], ["HIV", "SPECIES", 54, 57], ["Previous studies", "TEST", 0, 16], ["hypervariable regions", "PROBLEM", 29, 50], ["HIV gp120", "TREATMENT", 54, 63], ["neutralizing epitopes", "TREATMENT", 174, 195], ["viral subunit vaccines", "TREATMENT", 247, 269], ["hypervariable", "OBSERVATION_MODIFIER", 29, 42], ["viral evolution", "OBSERVATION", 275, 290]]], ["Fourth, although the NII strategy was used in the current study to improve the efficacy of viral subunit vaccines, it can also be potentially helpful in other epitope-based vaccine research.", [["the NII strategy", "TREATMENT", 17, 33], ["the current study", "TEST", 46, 63], ["viral subunit vaccines", "TREATMENT", 91, 113], ["other epitope-based vaccine research", "TREATMENT", 153, 189]]], ["For example, previous studies masked or resurfaced non-neutralizing epitopes on viral immunogens, and used the engineered immunogens as baits to screen from neutralizing sera for monoclonal antibodies that bind to conserved neutralizing epitopes43444546.", [["sera", "ANATOMY", 170, 174], ["sera", "ORGANISM_SUBSTANCE", 170, 174], ["non-neutralizing epitopes", "PROTEIN", 51, 76], ["monoclonal antibodies", "PROTEIN", 179, 200], ["conserved neutralizing epitopes43444546", "PROTEIN", 214, 253], ["previous studies", "TEST", 13, 29], ["resurfaced non-neutralizing epitopes", "PROBLEM", 40, 76], ["viral immunogens", "TREATMENT", 80, 96], ["the engineered immunogens", "TREATMENT", 107, 132], ["neutralizing sera", "TREATMENT", 157, 174], ["monoclonal antibodies", "TREATMENT", 179, 200], ["neutralizing epitopes", "TEST", 224, 245]]], ["It is conceivable that the NII strategy can help identify immunodominant non-neutralizing epitopes on immunogens, allowing more targeted epitope modifications for efficient antibody screening.", [["immunodominant non-neutralizing epitopes", "PROTEIN", 58, 98], ["the NII strategy", "TREATMENT", 23, 39], ["immunodominant non-neutralizing epitopes", "PROBLEM", 58, 98], ["immunogens", "TREATMENT", 102, 112], ["targeted epitope modifications", "TREATMENT", 128, 158], ["efficient antibody screening", "TEST", 163, 191]]], ["Finally, our study suggests that a three-dimensional \u2018neutralizing immunogenicity map' (NIM) can be drawn to describe the distribution of epitopes with different neutralizing immunogenicity on the surface of viral subunit vaccines.", [["surface", "ANATOMY", 197, 204], ["epitopes", "PROTEIN", 138, 146], ["our study", "TEST", 9, 18], ["a three-dimensional \u2018neutralizing immunogenicity map", "TREATMENT", 33, 85], ["epitopes", "PROBLEM", 138, 146], ["different neutralizing immunogenicity", "PROBLEM", 152, 189], ["viral subunit vaccines", "TREATMENT", 208, 230], ["neutralizing immunogenicity", "OBSERVATION", 162, 189]]], ["Such an NIM can guide targeted masking of multiple strong negative epitopes, further enhancing the efficacy of viral subunit vaccines.", [["multiple strong negative epitopes", "PROTEIN", 42, 75], ["multiple strong negative epitopes", "PROBLEM", 42, 75], ["viral subunit vaccines", "TREATMENT", 111, 133]]], ["We believe that our approach can facilitate the rational subunit vaccine design not only for coronaviruses such as MERS-CoV and SARS-CoV, but also for other life-threatening viruses such as HIV, influenza virus, and Ebola virus.Animals ::: MethodsFemale BALB/c mice of 6\u20138 week age mice and female human-DPP4-transgenic mice of 4-month age were used in the study.", [["SARS", "DISEASE", 128, 132], ["HIV, influenza virus", "DISEASE", 190, 210], ["Ebola virus", "DISEASE", 216, 227], ["coronaviruses", "ORGANISM", 93, 106], ["MERS-CoV", "ORGANISM", 115, 123], ["SARS-CoV", "ORGANISM", 128, 136], ["HIV", "ORGANISM", 190, 193], ["influenza virus", "ORGANISM", 195, 210], ["Ebola virus", "ORGANISM", 216, 227], ["BALB/c mice", "ORGANISM", 254, 265], ["mice", "ORGANISM", 282, 286], ["human-DPP4", "GENE_OR_GENE_PRODUCT", 298, 308], ["mice", "ORGANISM", 320, 324], ["HIV", "SPECIES", 190, 193], ["influenza virus", "SPECIES", 195, 210], ["Ebola virus", "SPECIES", 216, 227], ["mice", "SPECIES", 261, 265], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 320, 324], ["MERS-CoV", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 128, 136], ["HIV", "SPECIES", 190, 193], ["influenza virus", "SPECIES", 195, 210], ["Ebola virus", "SPECIES", 216, 227], ["mice", "SPECIES", 261, 265], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 320, 324], ["the rational subunit vaccine", "TREATMENT", 44, 72], ["coronaviruses", "PROBLEM", 93, 106], ["CoV", "PROBLEM", 120, 123], ["SARS", "PROBLEM", 128, 132], ["CoV", "PROBLEM", 133, 136], ["other life-threatening viruses", "PROBLEM", 151, 181], ["HIV", "PROBLEM", 190, 193], ["influenza virus", "PROBLEM", 195, 210], ["Ebola virus", "PROBLEM", 216, 227], ["the study", "TEST", 353, 362]]], ["The animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.", [["The animal studies", "TEST", 0, 18]]], ["The animal protocols were approved by the Committee on the Ethics of Animal Experiments of the New York Blood Center (Permit Number: 194.17) and Beijing Institute of Microbiology and Epidemiology (Permit Number: PMB15-0012).Cell lines ::: MethodsHEK293T (human embryonic kidney) and Vero E6 (monkey kidney) cells were obtained from American Type Culture Collection.", [["Cell lines", "ANATOMY", 224, 234], ["embryonic kidney", "ANATOMY", 261, 277], ["kidney) cells", "ANATOMY", 299, 312], ["Cell lines", "CELL", 224, 234], ["human", "ORGANISM", 255, 260], ["embryonic kidney", "ORGAN", 261, 277], ["Vero E6", "CELL", 283, 290], ["monkey kidney) cells", "CELL", 292, 312], ["MethodsHEK293T", "CELL_LINE", 239, 253], ["Vero E6 (monkey kidney) cells", "CELL_LINE", 283, 312], ["human", "SPECIES", 255, 260], ["Vero", "SPECIES", 283, 287], ["monkey", "SPECIES", 292, 298], ["human", "SPECIES", 255, 260], ["Vero E6", "SPECIES", 283, 290], ["The animal protocols", "TREATMENT", 0, 20], ["MethodsHEK293T (human embryonic kidney)", "TREATMENT", 239, 278], ["Vero E6 (monkey kidney) cells", "TEST", 283, 312], ["kidney", "ANATOMY", 271, 277], ["kidney", "ANATOMY", 299, 305]]], ["Huh-7 (human hepatoma) cells were kindly provided by Dr Charles M. Rice at Rockefeller University.", [["Huh-7", "ANATOMY", 0, 5], ["hepatoma) cells", "ANATOMY", 13, 28], ["Huh-7", "CELL", 0, 5], ["human", "ORGANISM", 7, 12], ["hepatoma) cells", "CELL", 13, 28], ["Dr Charles M. Rice", "ORGANISM", 53, 71], ["Huh-7 (human hepatoma) cells", "CELL_LINE", 0, 28], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["Huh", "TEST", 0, 3], ["hepatoma", "ANATOMY", 13, 21]]], ["These cell lines were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units ml\u22121 penicillin, and 100 \u03bcg ml\u22121 streptomycin (Life Technologies Inc.).", [["cell lines", "ANATOMY", 6, 16], ["fetal bovine serum", "ANATOMY", 96, 114], ["FBS", "ANATOMY", 116, 119], ["L-glutamine", "CHEMICAL", 127, 138], ["penicillin", "CHEMICAL", 155, 165], ["streptomycin", "CHEMICAL", 183, 195], ["L-glutamine", "CHEMICAL", 127, 138], ["penicillin", "CHEMICAL", 155, 165], ["streptomycin", "CHEMICAL", 183, 195], ["cell lines", "CELL", 6, 16], ["bovine", "ORGANISM", 102, 108], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["FBS", "ORGANISM_SUBSTANCE", 116, 119], ["L-glutamine", "SIMPLE_CHEMICAL", 127, 138], ["penicillin", "SIMPLE_CHEMICAL", 155, 165], ["streptomycin", "SIMPLE_CHEMICAL", 183, 195], ["cell lines", "CELL_LINE", 6, 16], ["bovine", "SPECIES", 102, 108], ["10% fetal bovine serum (FBS", "TREATMENT", 92, 119], ["2 mM L-glutamine", "TREATMENT", 122, 138], ["penicillin", "TREATMENT", 155, 165], ["1 streptomycin", "TREATMENT", 181, 195], ["cell lines", "OBSERVATION", 6, 16]]], ["Sf9 insect cells were purchased from Life Technologies Inc., and cultured in Sf-900 III SFM medium supplemented with 100 units ml\u22121 penicillin and 100 \u03bcg ml\u22121 streptomycin (Life Technologies Inc.)Expression and purification of recombinant proteins ::: MethodsThe expression and purification of recombinant MERS-CoV RBD was carried out as previously described34.", [["cells", "ANATOMY", 11, 16], ["Sf-900 III", "CHEMICAL", 77, 87], ["penicillin", "CHEMICAL", 132, 142], ["streptomycin", "CHEMICAL", 159, 171], ["penicillin", "CHEMICAL", 132, 142], ["streptomycin", "CHEMICAL", 159, 171], ["Sf9 insect cells", "CELL", 0, 16], ["penicillin", "SIMPLE_CHEMICAL", 132, 142], ["streptomycin", "SIMPLE_CHEMICAL", 159, 171], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 306, 314], ["Sf9 insect cells", "CELL_LINE", 0, 16], ["recombinant proteins", "PROTEIN", 227, 247], ["recombinant MERS-CoV RBD", "PROTEIN", 294, 318], ["Sf9", "SPECIES", 0, 3], ["MERS-CoV", "SPECIES", 306, 314], ["Sf9 insect cells", "PROBLEM", 0, 16], ["penicillin", "TREATMENT", 132, 142], ["Methods", "TREATMENT", 252, 259], ["recombinant MERS", "PROBLEM", 294, 310], ["CoV RBD", "PROBLEM", 311, 318]]], ["Briefly, wild type (WT) RBD (residues 377\u2013588; GenBank accession number: AFS88936.1) containing a C-terminal human IgG1 Fc tag was expressed in HEK293T cells, secreted into the cell culture supernatant, and purified by protein A affinity chromatography (GE Healthcare).", [["HEK293T cells", "ANATOMY", 144, 157], ["cell culture supernatant", "ANATOMY", 177, 201], ["C", "CHEMICAL", 98, 99], ["wild type (WT) RBD", "ORGANISM", 9, 27], ["human", "ORGANISM", 109, 114], ["IgG1 Fc", "GENE_OR_GENE_PRODUCT", 115, 122], ["HEK293T cells", "CELL", 144, 157], ["cell", "CELL", 177, 181], ["wild type (WT) RBD", "PROTEIN", 9, 27], ["C-terminal human IgG1 Fc tag", "PROTEIN", 98, 126], ["HEK293T cells", "CELL_LINE", 144, 157], ["protein A", "PROTEIN", 219, 228], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["wild type (WT) RBD (residues", "PROBLEM", 9, 37], ["a C-terminal human IgG1 Fc tag", "TREATMENT", 96, 126], ["the cell culture", "TEST", 173, 189]]], ["Mutant RBD fragments containing engineered glycan probes were constructed via site-directed mutagenesis, and expressed and purified in the same way as the wild type RBD.Expression and purification of recombinant proteins ::: MethodsThe expression and purification of recombinant human DPP4 was carried out as previously described47.", [["RBD", "DISEASE", 165, 168], ["human", "ORGANISM", 279, 284], ["DPP4", "GENE_OR_GENE_PRODUCT", 285, 289], ["Mutant RBD fragments", "DNA", 0, 20], ["wild type RBD", "PROTEIN", 155, 168], ["recombinant proteins", "PROTEIN", 200, 220], ["recombinant human DPP4", "PROTEIN", 267, 289], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 279, 284], ["Mutant RBD fragments", "PROBLEM", 0, 20], ["engineered glycan probes", "TREATMENT", 32, 56], ["the wild type RBD", "PROBLEM", 151, 168], ["Methods", "TREATMENT", 225, 232], ["recombinant human DPP4", "TREATMENT", 267, 289], ["RBD fragments", "OBSERVATION", 7, 20], ["glycan probes", "OBSERVATION", 43, 56], ["RBD", "OBSERVATION", 165, 168]]], ["Briefly, human DPP4 ectodomain (residues 39-766; GenBank accession no. NP_001926.2) containing an N-terminal human CD5 signal peptide and a C-terminal His6 tag was expressed in insect sf9 cells using the Bac-to-Bac expression system (Life Technologies Inc.), secreted to cell culture medium, and purified sequentially on HiTrap nickel chelating HP column and Superdex 200 gel filtration column (GE Healthcare).SDS gel electrophoresis ::: Methods5 \u03bcg wild type or mutant MERS-CoV RBDs were subjected to SDS gel electrophoresis under denatured condition.", [["sf9 cells", "ANATOMY", 184, 193], ["cell", "ANATOMY", 271, 275], ["residues 39-766", "CHEMICAL", 32, 47], ["NP_001926.2", "CHEMICAL", 71, 82], ["nickel", "CHEMICAL", 328, 334], ["N", "CHEMICAL", 98, 99], ["nickel", "CHEMICAL", 328, 334], ["human", "ORGANISM", 9, 14], ["DPP4", "GENE_OR_GENE_PRODUCT", 15, 19], ["human", "ORGANISM", 109, 114], ["CD5", "GENE_OR_GENE_PRODUCT", 115, 118], ["sf9 cells", "CELL", 184, 193], ["cell", "CELL", 271, 275], ["MERS-CoV RBDs", "ORGANISM", 470, 483], ["human DPP4 ectodomain", "PROTEIN", 9, 30], ["CD5", "PROTEIN", 115, 118], ["C-terminal His6 tag", "PROTEIN", 140, 159], ["insect sf9 cells", "CELL_LINE", 177, 193], ["mutant MERS-CoV RBDs", "DNA", 463, 483], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 109, 114], ["MERS-CoV", "SPECIES", 470, 478], ["human DPP4 ectodomain (residues", "TREATMENT", 9, 40], ["an N-terminal human CD5 signal peptide", "TREATMENT", 95, 133], ["a C-terminal His6 tag", "PROBLEM", 138, 159], ["the Bac", "TEST", 200, 207], ["HiTrap nickel chelating HP column", "TREATMENT", 321, 354], ["Superdex 200 gel filtration column (GE Healthcare", "TREATMENT", 359, 408], ["Methods5", "TREATMENT", 438, 446], ["mutant MERS", "PROBLEM", 463, 474], ["CoV RBDs", "TREATMENT", 475, 483], ["SDS gel electrophoresis under denatured condition", "PROBLEM", 502, 551]]], ["Protein bands were stained using Coomassie Brilliant Blue R (Sigma-Aldrich), and image captured using myECL Imager (Life Technologies Inc.).Mass spectrometry ::: MethodsWild type or mutant MERS-CoV RBDs at 100 \u03bcM concentration in 20 mM Tris-Cl, pH 7.4, 200 mM NaCl was ultrafiltrated with deionized water five times using an Amicon Ultra Centrifugal filter with a 10 kDa molecular weight cutoff.", [["Tris-Cl", "CHEMICAL", 236, 243], ["NaCl", "CHEMICAL", 260, 264], ["Brilliant Blue", "CHEMICAL", 43, 57], ["Tris-Cl", "CHEMICAL", 236, 243], ["NaCl", "CHEMICAL", 260, 264], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 189, 197], ["Tris-Cl", "SIMPLE_CHEMICAL", 236, 243], ["mutant MERS-CoV RBDs", "PROTEIN", 182, 202], ["Coomassie Brilliant Blue R", "SPECIES", 33, 59], ["MERS-CoV", "SPECIES", 189, 197], ["Protein bands", "TEST", 0, 13], ["Coomassie", "TEST", 33, 42], ["image", "TEST", 81, 86], ["myECL Imager", "TREATMENT", 102, 114], ["mutant MERS", "PROBLEM", 182, 193], ["CoV RBDs", "TREATMENT", 194, 202], ["Tris", "TEST", 236, 240], ["pH", "TEST", 245, 247], ["200 mM NaCl", "TREATMENT", 253, 264], ["deionized water", "TREATMENT", 289, 304], ["an Amicon Ultra Centrifugal filter", "TREATMENT", 322, 356], ["Centrifugal filter", "OBSERVATION", 338, 356]]], ["The desalted protein samples were subjected to MALDI-TOF Mass Spectrometry at Tufts University Core Facility.", [["samples", "ANATOMY", 21, 28], ["The desalted protein samples", "TEST", 0, 28], ["MALDI", "TEST", 47, 52]]], ["Mass spectrometry was performed in linear mode for molecular weight screening.AlphaScreen protein-protein binding assay ::: MethodsBinding between recombinant MERS-CoV RBDs and recombinant human DPP4 was measured using an AlphaScreen assay as previously described3436.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 159, 167], ["human", "ORGANISM", 189, 194], ["DPP4", "GENE_OR_GENE_PRODUCT", 195, 199], ["AlphaScreen protein", "PROTEIN", 78, 97], ["recombinant MERS-CoV RBDs", "PROTEIN", 147, 172], ["recombinant human DPP4", "PROTEIN", 177, 199], ["human", "SPECIES", 189, 194], ["MERS-CoV", "SPECIES", 159, 167], ["human", "SPECIES", 189, 194], ["Mass spectrometry", "TEST", 0, 17], ["molecular weight screening", "TEST", 51, 77], ["AlphaScreen protein", "TEST", 78, 97], ["MethodsBinding", "TREATMENT", 124, 138], ["CoV RBDs", "TREATMENT", 164, 172], ["recombinant human DPP4", "TREATMENT", 177, 199], ["an AlphaScreen assay", "TEST", 219, 239]]], ["Briefly, 3 nM wild type or mutant MERS-CoV RBD with a C-terminal Fc tag was incubated with 300 nM human DPP4 with a C-terminal His6 tag at room temperature for 1 h.", [["C", "CHEMICAL", 54, 55], ["C", "CHEMICAL", 116, 117], ["mutant MERS-CoV", "ORGANISM", 27, 42], ["human", "ORGANISM", 98, 103], ["DPP4", "GENE_OR_GENE_PRODUCT", 104, 108], ["mutant MERS-CoV RBD", "PROTEIN", 27, 46], ["C-terminal Fc tag", "PROTEIN", 54, 71], ["human DPP4", "PROTEIN", 98, 108], ["C-terminal His6 tag", "PROTEIN", 116, 135], ["human", "SPECIES", 98, 103], ["MERS-CoV", "SPECIES", 34, 42], ["human", "SPECIES", 98, 103], ["mutant MERS", "PROBLEM", 27, 38], ["CoV RBD", "PROBLEM", 39, 46], ["a C-terminal Fc tag", "TREATMENT", 52, 71]]], ["AlphaScreen protein A acceptor beads and nickel chelate donor beads (PerkinElmer Life Sciences) were added to the mixture at a final concentration of 5 \u03bcg ml\u22121 each.", [["nickel", "CHEMICAL", 41, 47], ["nickel", "CHEMICAL", 41, 47], ["nickel chelate", "SIMPLE_CHEMICAL", 41, 55], ["AlphaScreen protein A acceptor beads and nickel chelate donor beads (PerkinElmer Life Sciences", "TREATMENT", 0, 94]]], ["After incubation at room temperature for 1 h, the AlphaScreen signal was measured using an EnSpire plate reader (PerkinElmer Life Sciences), reflecting the binding affinity between the two proteins.FACS ::: MethodsThe binding between recombinant MERS-CoV RBDs and human DPP4 expressed on the Huh-7 cell-surface was measured using fluorescence-activated cell sorting (FACS) as previously described2836.", [["Huh-7 cell-surface", "ANATOMY", 292, 310], ["cell", "ANATOMY", 353, 357], ["MERS-CoV RBDs", "GENE_OR_GENE_PRODUCT", 246, 259], ["human", "ORGANISM", 264, 269], ["DPP4", "GENE_OR_GENE_PRODUCT", 270, 274], ["Huh-7 cell", "CELL", 292, 302], ["cell", "CELL", 353, 357], ["recombinant MERS-CoV RBDs", "PROTEIN", 234, 259], ["human DPP4", "PROTEIN", 264, 274], ["human", "SPECIES", 264, 269], ["MERS-CoV", "SPECIES", 246, 254], ["human", "SPECIES", 264, 269], ["the AlphaScreen signal", "TEST", 46, 68], ["an EnSpire plate", "TREATMENT", 88, 104], ["the binding affinity", "PROBLEM", 152, 172], ["CoV RBDs", "TREATMENT", 251, 259], ["human DPP4", "TREATMENT", 264, 274], ["the Huh", "TEST", 288, 295]]], ["Briefly, Huh-7 cells were incubated with wild type or mutant MERS-CoV RBD (1.25 \u03bcg ml\u22121) at room temperature for 30 min, followed by addition of FITC-conjugated anti-human-IgG-Fc polyclonal antibody (1:50 dilution) (Sigma-Aldrich) for 30 min.", [["Huh-7 cells", "ANATOMY", 9, 20], ["FITC", "CHEMICAL", 145, 149], ["Huh-7 cells", "CELL", 9, 20], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 61, 69], ["FITC", "SIMPLE_CHEMICAL", 145, 149], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 216, 229], ["Huh-7 cells", "CELL_LINE", 9, 20], ["mutant MERS-CoV RBD", "PROTEIN", 54, 73], ["IgG", "PROTEIN", 172, 175], ["Fc polyclonal antibody", "PROTEIN", 176, 198], ["MERS-CoV", "SPECIES", 61, 69], ["Huh", "TEST", 9, 12], ["mutant MERS", "PROBLEM", 54, 65], ["CoV RBD", "PROBLEM", 66, 73], ["FITC", "TEST", 145, 149], ["conjugated anti-human", "TREATMENT", 150, 171], ["IgG", "TEST", 172, 175], ["polyclonal antibody", "TEST", 179, 198]]], ["The amounts of RBD-bound Huh-7 cells were measured using flow cytometry, and the binding affinity between RBD and cell-surface DPP4 was characterized as median fluorescence intensity.Animal immunization and sample collection ::: MethodsAnimal immunization and sample collection were carried out as previously described34.", [["Huh-7 cells", "ANATOMY", 25, 36], ["cell", "ANATOMY", 114, 118], ["surface", "ANATOMY", 119, 126], ["sample", "ANATOMY", 207, 213], ["RBD", "GENE_OR_GENE_PRODUCT", 15, 18], ["Huh-7 cells", "CELL", 25, 36], ["RBD", "GENE_OR_GENE_PRODUCT", 106, 109], ["cell", "CELL", 114, 118], ["DPP4", "GENE_OR_GENE_PRODUCT", 127, 131], ["RBD", "PROTEIN", 15, 18], ["Huh-7 cells", "CELL_LINE", 25, 36], ["RBD", "PROTEIN", 106, 109], ["cell-surface DPP4", "PROTEIN", 114, 131], ["RBD", "TEST", 15, 18], ["flow cytometry", "TEST", 57, 71], ["the binding affinity", "TEST", 77, 97], ["RBD", "TEST", 106, 109], ["cell-surface DPP4", "TEST", 114, 131], ["median fluorescence intensity", "PROBLEM", 153, 182], ["Animal immunization", "TREATMENT", 183, 202], ["MethodsAnimal immunization", "TREATMENT", 229, 255], ["sample collection", "TEST", 260, 277], ["amounts", "OBSERVATION_MODIFIER", 4, 11], ["RBD", "OBSERVATION", 15, 18], ["median fluorescence", "OBSERVATION", 153, 172]]], ["Briefly, BALB/c mice were subcutaneously immunized with wild type or mutant MERS-CoV RBD (10 \u03bcg per mouse) in the presence of Montanide ISA51 adjuvant3448.", [["Montanide ISA51", "CHEMICAL", 126, 141], ["BALB/c mice", "ORGANISM", 9, 20], ["MERS-CoV RBD", "ORGANISM", 76, 88], ["mouse", "ORGANISM", 100, 105], ["mutant MERS-CoV RBD", "PROTEIN", 69, 88], ["mice", "SPECIES", 16, 20], ["mouse", "SPECIES", 100, 105], ["mice", "SPECIES", 16, 20], ["MERS-CoV", "SPECIES", 76, 84], ["mouse", "SPECIES", 100, 105], ["BALB/c mice", "TREATMENT", 9, 20], ["mutant MERS", "PROBLEM", 69, 80], ["CoV RBD", "PROBLEM", 81, 88], ["Montanide ISA51 adjuvant", "TREATMENT", 126, 150]]], ["PBS plus Montanide ISA51 was included as a negative control.", [["Montanide", "CHEMICAL", 9, 18], ["PBS", "SIMPLE_CHEMICAL", 0, 3], ["Montanide ISA51", "SIMPLE_CHEMICAL", 9, 24], ["PBS", "TEST", 0, 3], ["Montanide ISA51", "TREATMENT", 9, 24], ["negative", "OBSERVATION", 43, 51]]], ["Immunized mice were boosted twice with the same immunogen and adjuvant at a 3-week interval, and sera were collected 10 days after the last immunization for detection of neutralizing antibodies.ELISA ::: MethodsThe binding between recombinant MERS-CoV RBD and neutralizing mAbs was measured using ELISA as previously described36.", [["sera", "ANATOMY", 97, 101], ["mice", "ORGANISM", 10, 14], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 243, 251], ["neutralizing antibodies", "PROTEIN", 170, 193], ["recombinant MERS-CoV RBD", "PROTEIN", 231, 255], ["neutralizing mAbs", "PROTEIN", 260, 277], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["MERS-CoV", "SPECIES", 243, 251], ["Immunized mice", "TREATMENT", 0, 14], ["the same immunogen", "TREATMENT", 39, 57], ["adjuvant", "TREATMENT", 62, 70], ["the last immunization", "TREATMENT", 131, 152], ["neutralizing antibodies", "PROBLEM", 170, 193], ["MethodsThe binding between recombinant MERS", "PROBLEM", 204, 247], ["CoV RBD", "PROBLEM", 248, 255], ["neutralizing mAbs", "TREATMENT", 260, 277], ["ELISA", "TEST", 297, 302]]], ["Briefly, ELISA plates were pre-coated with the same amount of wild type or mutant RBD (1 \u03bcg ml\u22121) overnight at 4 \u00b0C. After blocking with 2% non-fat milk at 37 \u00b0C for 2 h, serially diluted mAbs were added to the plates and incubated at 37 \u00b0C for 1 h.", [["fat milk", "ANATOMY", 144, 152], ["RBD", "DISEASE", 82, 85], ["fat milk", "ORGANISM_SUBSTANCE", 144, 152], ["mutant RBD", "PROTEIN", 75, 85], ["mAbs", "PROTEIN", 188, 192], ["ELISA plates", "TEST", 9, 21], ["mutant RBD", "PROBLEM", 75, 85], ["2% non-fat milk", "TREATMENT", 137, 152], ["serially diluted mAbs", "TREATMENT", 171, 192], ["the plates", "TREATMENT", 207, 217]]], ["After washes, the plates were incubated at 37 \u00b0C for 1 h with horseradish-peroxidase-conjugated anti-human-IgG-Fab polyclonal antibody (1:5,000 dilution) (Sigma-Aldrich).", [["horseradish-peroxidase", "SIMPLE_CHEMICAL", 62, 84], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 155, 168], ["horseradish-peroxidase", "PROTEIN", 62, 84], ["IgG", "PROTEIN", 107, 110], ["Fab polyclonal antibody", "PROTEIN", 111, 134], ["horseradish", "SPECIES", 62, 73], ["the plates", "TEST", 14, 24], ["horseradish", "TEST", 62, 73], ["peroxidase", "TEST", 74, 84], ["conjugated anti-human", "TEST", 85, 106], ["IgG", "TEST", 107, 110], ["Fab polyclonal antibody", "TEST", 111, 134]]], ["Enzymatic reaction was carried out using substrate 3,3\u2032,5,5\u2032-tetramethylbenzidine (Life Technologies Inc.) and stopped with 1 N H2SO4.", [["3,3\u2032,5,5\u2032-tetramethylbenzidine", "CHEMICAL", 51, 81], ["3,3\u2032,5,5\u2032-tetramethylbenzidine", "CHEMICAL", 51, 81], ["H2SO4", "CHEMICAL", 128, 133], ["substrate 3,3\u2032,5,5\u2032-tetramethylbenzidine", "SIMPLE_CHEMICAL", 41, 81], ["1 N H2SO4", "SIMPLE_CHEMICAL", 124, 133], ["Enzymatic reaction", "PROBLEM", 0, 18], ["substrate", "TEST", 41, 50], ["tetramethylbenzidine", "TREATMENT", 61, 81], ["1 N H2SO4", "TREATMENT", 124, 133]]], ["Absorbance at 450 nm (A450) was measured using ELISA Plate Reader (Tecan Group Ltd.).ELISA ::: MethodsThe competition between neutralizing mAbs and mutant-RBD-induced mouse serum for the binding of wild type MERS-CoV RBD was carried out using ELISA as described above, except that the binding between wild type RBD and the neutralizing mAb (hMS-1 or m336-Fab at 5 \u03bcg ml\u22121 concentration) was performed in the presence of serially diluted mouse serum (T579N-RBD-induced, wild-type-RBD-induced, or PBS-induced).", [["serum", "ANATOMY", 173, 178], ["serum", "ANATOMY", 443, 448], ["mAbs", "GENE_OR_GENE_PRODUCT", 139, 143], ["RBD", "GENE_OR_GENE_PRODUCT", 155, 158], ["mouse", "ORGANISM", 167, 172], ["serum", "ORGANISM_SUBSTANCE", 173, 178], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 208, 216], ["RBD", "GENE_OR_GENE_PRODUCT", 311, 314], ["hMS-1", "GENE_OR_GENE_PRODUCT", 341, 346], ["m336-Fab", "GENE_OR_GENE_PRODUCT", 350, 358], ["mouse", "ORGANISM", 437, 442], ["serum", "ORGANISM_SUBSTANCE", 443, 448], ["neutralizing mAbs", "PROTEIN", 126, 143], ["RBD", "PROTEIN", 155, 158], ["wild type MERS-CoV RBD", "PROTEIN", 198, 220], ["wild type RBD", "PROTEIN", 301, 314], ["neutralizing mAb", "PROTEIN", 323, 339], ["hMS", "PROTEIN", 341, 344], ["m336", "PROTEIN", 350, 354], ["Fab", "PROTEIN", 355, 358], ["RBD", "PROTEIN", 456, 459], ["RBD", "PROTEIN", 479, 482], ["mouse", "SPECIES", 167, 172], ["mouse", "SPECIES", 437, 442], ["mouse", "SPECIES", 167, 172], ["MERS-CoV", "SPECIES", 208, 216], ["mouse", "SPECIES", 437, 442], ["neutralizing mAbs", "TREATMENT", 126, 143], ["mutant-RBD", "PROBLEM", 148, 158], ["induced mouse serum", "PROBLEM", 159, 178], ["wild type MERS", "PROBLEM", 198, 212], ["CoV RBD", "PROBLEM", 213, 220], ["ELISA", "TEST", 243, 248], ["wild type RBD", "PROBLEM", 301, 314], ["the neutralizing mAb", "TEST", 319, 339], ["hMS", "TEST", 341, 344], ["serially diluted mouse serum", "PROBLEM", 420, 448], ["RBD", "PROBLEM", 456, 459], ["RBD", "PROBLEM", 479, 482], ["PBS", "PROBLEM", 495, 498]]], ["The RBD-mAb binding was detected by addition of horseradish-peroxidase-conjugated anti-human-IgG-Fab polyclonal antibody (1:5,000 dilution) and subsequent enzymatic reaction.Live MERS-CoV neutralization assay ::: MethodsA micro-neutralization assay was carried out to test neutralizing antibodies against live MERS-CoV as previously described36.", [["RBD-mAb", "GENE_OR_GENE_PRODUCT", 4, 11], ["horseradish-peroxidase", "SIMPLE_CHEMICAL", 48, 70], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 310, 318], ["RBD", "PROTEIN", 4, 7], ["mAb", "PROTEIN", 8, 11], ["horseradish-peroxidase", "PROTEIN", 48, 70], ["IgG", "PROTEIN", 93, 96], ["Fab polyclonal antibody", "PROTEIN", 97, 120], ["neutralizing antibodies", "PROTEIN", 273, 296], ["live MERS-CoV", "PROTEIN", 305, 318], ["horseradish", "SPECIES", 48, 59], ["MERS-CoV", "SPECIES", 310, 318], ["The RBD-mAb binding", "TEST", 0, 19], ["horseradish", "TEST", 48, 59], ["peroxidase", "TEST", 60, 70], ["conjugated anti-human", "TEST", 71, 92], ["IgG", "TEST", 93, 96], ["Fab polyclonal antibody", "TEST", 97, 120], ["subsequent enzymatic reaction", "PROBLEM", 144, 173], ["MethodsA micro-neutralization assay", "TEST", 213, 248], ["test neutralizing antibodies", "TEST", 268, 296], ["mAb", "OBSERVATION", 8, 11], ["enzymatic reaction", "OBSERVATION", 155, 173]]], ["Briefly, serially diluted mouse sera were incubated at room temperature for 1 h with \u223c100 infectious MERS-CoV virions (EMC-2012 strain), and were then incubated with Vero E6 cells at 37 \u00b0C for 72 h.", [["sera", "ANATOMY", 32, 36], ["cells", "ANATOMY", 174, 179], ["mouse", "ORGANISM", 26, 31], ["sera", "ORGANISM_SUBSTANCE", 32, 36], ["MERS-CoV virions", "ORGANISM", 101, 117], ["EMC-2012 strain", "CELL", 119, 134], ["Vero E6 cells", "CELL", 166, 179], ["Vero E6 cells", "CELL_LINE", 166, 179], ["mouse", "SPECIES", 26, 31], ["mouse", "SPECIES", 26, 31], ["MERS-CoV", "SPECIES", 101, 109], ["Vero E6", "SPECIES", 166, 173], ["CoV virions", "PROBLEM", 106, 117], ["Vero E6 cells", "TREATMENT", 166, 179]]], ["The neutralizing capability of the mouse sera was measured by determining the presence or absence of virus-induced cytopathic effect (CPE).", [["sera", "ANATOMY", 41, 45], ["mouse", "ORGANISM", 35, 40], ["sera", "ORGANISM_SUBSTANCE", 41, 45], ["mouse", "SPECIES", 35, 40], ["mouse", "SPECIES", 35, 40], ["the mouse sera", "TEST", 31, 45], ["virus", "PROBLEM", 101, 106], ["induced cytopathic effect", "PROBLEM", 107, 132], ["neutralizing", "OBSERVATION_MODIFIER", 4, 16], ["cytopathic", "OBSERVATION_MODIFIER", 115, 125]]], ["Neutralizing antibody titres were expressed as the reciprocal of the highest dilution of sera that completely inhibited virus-induced CPE in at least 50% of the wells (NT50).MERS-CoV challenge studies ::: MethodsMERS-CoV challenge studies were carried out using human-DPP4-transgenic mice as previously described41.", [["sera", "ANATOMY", 89, 93], ["CPE", "CHEMICAL", 134, 137], ["sera", "ORGANISM_SUBSTANCE", 89, 93], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 174, 182], ["DPP4", "GENE_OR_GENE_PRODUCT", 268, 272], ["mice", "ORGANISM", 284, 288], ["DPP4", "PROTEIN", 268, 272], ["mice", "SPECIES", 284, 288], ["mice", "SPECIES", 284, 288], ["Neutralizing antibody titres", "TEST", 0, 28], ["virus", "PROBLEM", 120, 125], ["CPE", "PROBLEM", 134, 137], ["MethodsMERS", "TEST", 205, 216], ["CoV challenge studies", "TEST", 217, 238], ["human-DPP4", "TREATMENT", 262, 272]]], ["Briefly, mice were intramuscularly immunized with wild type or mutant MERS-CoV RBD (5 \u03bcg per mouse) in the presence of aluminium adjuvant49, and boosted once 4 weeks after the initial immunization.", [["aluminium adjuvant49", "CHEMICAL", 119, 139], ["aluminium adjuvant49", "CHEMICAL", 119, 139], ["mice", "ORGANISM", 9, 13], ["MERS-CoV RBD", "ORGANISM", 70, 82], ["mouse", "ORGANISM", 93, 98], ["aluminium adjuvant49", "SIMPLE_CHEMICAL", 119, 139], ["mutant MERS-CoV RBD", "PROTEIN", 63, 82], ["mice", "SPECIES", 9, 13], ["mouse", "SPECIES", 93, 98], ["mice", "SPECIES", 9, 13], ["MERS-CoV", "SPECIES", 70, 78], ["mouse", "SPECIES", 93, 98], ["CoV RBD", "TREATMENT", 75, 82], ["aluminium adjuvant49", "TREATMENT", 119, 139], ["the initial immunization", "TREATMENT", 172, 196]]], ["12 weeks after the second immunization, mice were challenged with MERS-CoV (EMC-2012 strain, 104 TCID50), and observed for 21 days for detection of survival rate and weight changes.Statistical analyses ::: MethodsIn Fig. 1c\u2013d, comparisons between WT RBD and each of the mutant RBDs in their binding to recombinant DPP4 by AlphaScreen (Fig. 1c) or to cell-surface DPP4 by FACS (Fig. 1d) were done using two-tailed t-test (, P<0.001; 12 different dilutions of each mAb, 4 measurements at each dilution for each mAb).Statistical analyses ::: MethodsIn Fig. 3a, comparisons between WT RBD and each of the mutant RBDs in their capacity to induce neutralizing serum in mice were done using two-tailed t-test (**, P<0.001; 4 different dilutions of each serum, 4 measurements at each dilution for each serum).Statistical analyses ::: MethodsAll statistical analyses were performed using GraphPad Prism 6 software.Data availability ::: MethodsAll relevant data are available from the authors.Additional informationHow to cite this article: Du, L. et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.", [["cell", "ANATOMY", 350, 354], ["surface", "ANATOMY", 355, 362], ["serum", "ANATOMY", 654, 659], ["serum", "ANATOMY", 746, 751], ["serum", "ANATOMY", 794, 799], ["mice", "ORGANISM", 40, 44], ["MERS-CoV", "ORGANISM", 66, 74], ["EMC-2012", "CELL", 76, 84], ["RBDs", "GENE_OR_GENE_PRODUCT", 277, 281], ["DPP4", "GENE_OR_GENE_PRODUCT", 314, 318], ["cell", "CELL", 350, 354], ["DPP4", "GENE_OR_GENE_PRODUCT", 363, 367], ["RBDs", "GENE_OR_GENE_PRODUCT", 608, 612], ["serum", "ORGANISM_SUBSTANCE", 654, 659], ["mice", "ORGANISM", 663, 667], ["serum", "ORGANISM_SUBSTANCE", 746, 751], ["serum", "ORGANISM_SUBSTANCE", 794, 799], ["MERS coronavirus", "ORGANISM", 1121, 1137], ["WT RBD", "PROTEIN", 247, 253], ["mutant RBDs", "PROTEIN", 270, 281], ["recombinant DPP4", "PROTEIN", 302, 318], ["AlphaScreen", "PROTEIN", 322, 333], ["DPP4", "PROTEIN", 363, 367], ["mAb", "PROTEIN", 463, 466], ["mAb", "PROTEIN", 509, 512], ["WT RBD", "PROTEIN", 578, 584], ["mutant RBDs", "PROTEIN", 601, 612], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 663, 667], ["mice", "SPECIES", 40, 44], ["MERS-CoV", "SPECIES", 66, 74], ["mice", "SPECIES", 663, 667], ["MERS coronavirus", "SPECIES", 1121, 1137], ["the second immunization", "TREATMENT", 15, 38], ["survival rate", "TEST", 148, 161], ["weight changes", "PROBLEM", 166, 180], ["MethodsIn Fig.", "TREATMENT", 206, 220], ["WT RBD", "PROBLEM", 247, 253], ["the mutant RBDs", "PROBLEM", 266, 281], ["AlphaScreen", "TEST", 322, 333], ["P", "TEST", 423, 424], ["each mAb", "TREATMENT", 458, 466], ["WT RBD", "PROBLEM", 578, 584], ["the mutant RBDs", "PROBLEM", 597, 612], ["neutralizing serum", "TEST", 641, 659], ["each serum", "TEST", 741, 751], ["Methods", "TREATMENT", 826, 833], ["All statistical analyses", "TEST", 833, 857], ["Methods", "TREATMENT", 927, 934], ["neutralizing immunogenicity index", "TREATMENT", 1061, 1094], ["MERS coronavirus subunit vaccines", "TREATMENT", 1121, 1154]]]], "82c21763f8d4e442f2a164a78ba7297cc0b60ae9": [["camels in particular, Haagmans et al., 2014) in MERS-CoV transmission rapidly led to a number of experimental and field studies that aimed to improve our understanding of the epidemiology of this virus in animal hosts (Adney et al., 2014; Alagaili et al., 2014; Hemida et al., 2013; Meyer et al., 2015; Reusken et al., 2013) .", [["MERS-CoV", "ORGANISM", 48, 56], ["MERS-CoV", "SPECIES", 48, 56], ["experimental and field studies", "TEST", 97, 127]]], ["These studies have led to the consensus that dromedary camels are the natural reservoir.", [["camels", "ORGANISM", 55, 61], ["These studies", "TEST", 0, 13], ["natural reservoir", "OBSERVATION", 70, 87]]], ["They have furthermore provided some insight about the host and geographical range of the virus and have suggested some epidemiological characteristics, including the clinical picture and age distribution in dromedary camels (Wernery, Lau, & Woo, 2017) .", [["the virus", "PROBLEM", 85, 94]]], ["The evidence base that builds from these experimental and field studies provides the foundation for more complex epidemiological analyses, including statistical and mathematical modelling, risk assessments and meta-analyses.", [["these experimental and field studies", "TEST", 35, 71], ["risk assessments", "TEST", 189, 205], ["meta-analyses", "TEST", 210, 223], ["base", "ANATOMY_MODIFIER", 13, 17]]], ["Rigorous, detailed epidemiological data based on pragmatic research questions are crucial to these analyses and ultimately for sound policy and health interventions.", [["detailed epidemiological data", "TEST", 10, 39], ["these analyses", "TEST", 93, 107], ["health interventions", "TREATMENT", 144, 164]]]], "3ef709d285cbdc7196f2e315894c0f9a526f7f14": [["[Background] Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children and classified into two major histological subgroups, embryonal and alveolar types that are presented with different clinical pictures and prognosis.", [["Rhabdomyosarcoma", "ANATOMY", 13, 29], ["RMS", "ANATOMY", 31, 34], ["soft-tissue sarcoma", "ANATOMY", 55, 74], ["embryonal", "ANATOMY", 141, 150], ["alveolar", "ANATOMY", 155, 163], ["Rhabdomyosarcoma", "DISEASE", 13, 29], ["RMS", "DISEASE", 31, 34], ["soft-tissue sarcoma", "DISEASE", 55, 74], ["Background] Rhabdomyosarcoma", "CANCER", 1, 29], ["RMS", "CANCER", 31, 34], ["soft-tissue sarcoma", "CANCER", 55, 74], ["children", "ORGANISM", 78, 86], ["embryonal", "CANCER", 141, 150], ["alveolar", "ORGAN", 155, 163], ["children", "SPECIES", 78, 86], ["Background] Rhabdomyosarcoma (RMS", "PROBLEM", 1, 34], ["soft-tissue sarcoma", "PROBLEM", 55, 74], ["Rhabdomyosarcoma", "OBSERVATION", 13, 29], ["most common", "OBSERVATION_MODIFIER", 43, 54], ["soft-tissue", "OBSERVATION_MODIFIER", 55, 66], ["sarcoma", "OBSERVATION", 67, 74], ["alveolar types", "OBSERVATION", 155, 169]]], ["Although distinct genetic mechanisms are implicated in their pathogenesis, little has been known about those genetic changes that characterize these distinctive histology types, except for common PAX3 and PAX7 rearrangements in alveolar types.", [["alveolar", "ANATOMY", 228, 236], ["PAX3", "GENE_OR_GENE_PRODUCT", 196, 200], ["PAX7", "GENE_OR_GENE_PRODUCT", 205, 209], ["alveolar", "MULTI-TISSUE_STRUCTURE", 228, 236], ["PAX3 and PAX7 rearrangements", "DNA", 196, 224], ["common PAX3", "PROBLEM", 189, 200], ["PAX7 rearrangements", "OBSERVATION", 205, 224], ["alveolar types", "OBSERVATION", 228, 242]]], ["[Methods] In order to investigate the genetic changes that underlie the pathogenesis of both alveolar and embryonal RMSs, we performed comprehensive analysis of copy number alterations in RMS genomes obtained from a total of 30 RMS samples including RMSderived cell lines using high-density SNP-genotyping microarrays (Affymetirx GeneChip 100K/500K arrays).", [["alveolar", "ANATOMY", 93, 101], ["embryonal RMSs", "ANATOMY", 106, 120], ["RMS samples", "ANATOMY", 228, 239], ["cell lines", "ANATOMY", 261, 271], ["SNP", "CHEMICAL", 291, 294], ["alveolar", "MULTI-TISSUE_STRUCTURE", 93, 101], ["embryonal RMSs", "CANCER", 106, 120], ["RMSderived cell lines", "CELL", 250, 271], ["RMS genomes", "DNA", 188, 199], ["RMSderived cell lines", "CELL_LINE", 250, 271], ["the genetic changes", "PROBLEM", 34, 53], ["both alveolar and embryonal RMSs", "PROBLEM", 88, 120], ["comprehensive analysis", "TEST", 135, 157], ["copy number alterations in RMS genomes", "PROBLEM", 161, 199], ["RMSderived cell lines", "TREATMENT", 250, 271], ["high-density SNP-genotyping microarrays", "TREATMENT", 278, 317], ["Affymetirx GeneChip 100K/500K arrays", "TREATMENT", 319, 355], ["both", "ANATOMY_MODIFIER", 88, 92], ["alveolar", "ANATOMY", 93, 101], ["embryonal RMSs", "OBSERVATION", 106, 120], ["cell lines", "OBSERVATION", 261, 271]]]], "PMC3835827": [["IntroductionOn 31 March 2013, three died urban residents from eastern China were reported to be infected with a novel avian-origin influenza A virus [1].", [["influenza A virus", "DISEASE", 131, 148], ["avian-origin influenza A virus", "ORGANISM", 118, 148], ["avian-origin influenza A virus", "SPECIES", 118, 148], ["A virus", "SPECIES", 141, 148]]], ["Sequencing analyses revealed that hemagglutinin (HA) and neuraminidase (NA) genes of this emerging reassortant virus belonged to H7 and N9 subtypes of influenza A virus respectively, while six internal genes were closely related to those of avian H9N2 viruses [1].", [["influenza A virus", "DISEASE", 151, 168], ["avian H9N2 viruses", "DISEASE", 241, 259], ["hemagglutinin (HA)", "GENE_OR_GENE_PRODUCT", 34, 52], ["neuraminidase (NA)", "GENE_OR_GENE_PRODUCT", 57, 75], ["reassortant virus", "ORGANISM", 99, 116], ["N9 subtypes", "ORGANISM", 136, 147], ["influenza A virus", "ORGANISM", 151, 168], ["avian H9N2 viruses", "ORGANISM", 241, 259], ["hemagglutinin (HA) and neuraminidase (NA) genes", "DNA", 34, 81], ["influenza A virus", "SPECIES", 151, 168], ["avian H9N2 viruses", "SPECIES", 241, 259], ["influenza A virus", "SPECIES", 151, 168], ["Sequencing analyses", "TEST", 0, 19], ["hemagglutinin (HA)", "TREATMENT", 34, 52], ["neuraminidase (NA) genes", "TREATMENT", 57, 81], ["this emerging reassortant virus", "PROBLEM", 85, 116], ["H7", "PROBLEM", 129, 131], ["influenza A virus", "PROBLEM", 151, 168]]], ["An increasing number of patients infected with H7N9 virus subsequently occurred in many provinces of China.", [["patients", "ORGANISM", 24, 32], ["H7N9 virus", "ORGANISM", 47, 57], ["patients", "SPECIES", 24, 32], ["H7N9 virus", "SPECIES", 47, 57], ["H7N9 virus", "PROBLEM", 47, 57], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["infected", "OBSERVATION_MODIFIER", 33, 41], ["H7N9 virus", "OBSERVATION", 47, 57]]], ["As of 30 May 2013, a total of 132 laboratory-confirmed cases of human infection with avian influenza A (H7N9) virus have been reported, 37 of whom have died [2].", [["infection", "DISEASE", 70, 79], ["avian influenza A (H7N9) virus", "DISEASE", 85, 115], ["human", "ORGANISM", 64, 69], ["avian influenza A (H7N9) virus", "ORGANISM", 85, 115], ["human", "SPECIES", 64, 69], ["avian influenza A (H7N9) virus", "SPECIES", 85, 115], ["human", "SPECIES", 64, 69], ["avian influenza A (H7N9) virus", "SPECIES", 85, 115], ["human infection", "PROBLEM", 64, 79], ["avian influenza A (H7N9) virus", "PROBLEM", 85, 115], ["infection", "OBSERVATION", 70, 79]]], ["The novel virus infection is associated with severe clinical symptoms characterized by rapidly progressive pneumonia, acute respiratory distress syndrome (ARDS) and multiorgan failure [1], [3], [4].", [["respiratory", "ANATOMY", 124, 135], ["multiorgan", "ANATOMY", 165, 175], ["infection", "DISEASE", 16, 25], ["pneumonia", "DISEASE", 107, 116], ["acute respiratory distress syndrome", "DISEASE", 118, 153], ["ARDS", "DISEASE", 155, 159], ["multiorgan failure", "DISEASE", 165, 183], ["The novel virus infection", "PROBLEM", 0, 25], ["severe clinical symptoms", "PROBLEM", 45, 69], ["rapidly progressive pneumonia", "PROBLEM", 87, 116], ["acute respiratory distress syndrome", "PROBLEM", 118, 153], ["ARDS)", "PROBLEM", 155, 160], ["multiorgan failure", "PROBLEM", 165, 183], ["virus infection", "OBSERVATION", 10, 25], ["associated with", "UNCERTAINTY", 29, 44], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["rapidly", "OBSERVATION_MODIFIER", 87, 94], ["progressive", "OBSERVATION_MODIFIER", 95, 106], ["pneumonia", "OBSERVATION", 107, 116], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory distress syndrome", "OBSERVATION", 124, 153], ["multiorgan failure", "OBSERVATION", 165, 183]]], ["Since H7N9 virus has not been detected previously in human beings or animals, the possible source of infections and the reservoirs of this virus remain unclear.", [["infections", "DISEASE", 101, 111], ["H7N9 virus", "ORGANISM", 6, 16], ["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["H7N9 virus", "SPECIES", 6, 16], ["human", "SPECIES", 53, 58], ["H7N9 virus", "PROBLEM", 6, 16], ["infections", "PROBLEM", 101, 111], ["this virus", "PROBLEM", 134, 144], ["infections", "OBSERVATION", 101, 111]]], ["Moreover, sporadic human infections with H7N9 virus to date raise more important questions that whether this virus will persistently evolve for better adaption to humans, and whether limit or even sustained human-to-human transmissions will occur.", [["infections", "DISEASE", 25, 35], ["human", "ORGANISM", 19, 24], ["H7N9 virus", "ORGANISM", 41, 51], ["humans", "ORGANISM", 163, 169], ["human", "ORGANISM", 207, 212], ["human", "ORGANISM", 216, 221], ["human", "SPECIES", 19, 24], ["humans", "SPECIES", 163, 169], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 19, 24], ["H7N9 virus", "SPECIES", 41, 51], ["humans", "SPECIES", 163, 169], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 216, 221], ["sporadic human infections", "PROBLEM", 10, 35], ["H7N9 virus", "PROBLEM", 41, 51], ["this virus", "PROBLEM", 104, 114], ["infections", "OBSERVATION", 25, 35]]], ["Such questions induce global public health concerns.IntroductionFor more effective prevention and control of H7N9 virus infection in humans, development of a rapid, sensitive and specific molecular diagnostic assay is urgently needed in many laboratories.", [["infection", "DISEASE", 120, 129], ["H7N9 virus", "ORGANISM", 109, 119], ["humans", "ORGANISM", 133, 139], ["humans", "SPECIES", 133, 139], ["H7N9 virus", "SPECIES", 109, 119], ["humans", "SPECIES", 133, 139], ["Introduction", "TREATMENT", 52, 64], ["H7N9 virus infection", "PROBLEM", 109, 129], ["a rapid, sensitive and specific molecular diagnostic assay", "PROBLEM", 156, 214]]], ["Conventional virus isolation from cell lines is time-consuming and thus delays the detection efficiency.", [["cell lines", "ANATOMY", 34, 44], ["cell lines", "CELL", 34, 44], ["cell lines", "CELL_LINE", 34, 44], ["Conventional virus isolation", "TREATMENT", 0, 28], ["cell lines", "TREATMENT", 34, 44], ["virus", "OBSERVATION", 13, 18], ["cell lines", "OBSERVATION", 34, 44]]], ["Because specific antibodies in response to virus infection are generally produced at about 3\u223c4 weeks in the bodies of infected patients, monoclonal antibody-based ELISA is not well suitable as an early diagnostic tool in the initial stage of the disease.", [["infection", "DISEASE", 49, 58], ["patients", "ORGANISM", 127, 135], ["monoclonal antibody", "PROTEIN", 137, 156], ["patients", "SPECIES", 127, 135], ["specific antibodies", "PROBLEM", 8, 27], ["virus infection", "PROBLEM", 43, 58], ["monoclonal antibody-based ELISA", "TEST", 137, 168], ["the disease", "PROBLEM", 242, 253], ["virus infection", "OBSERVATION", 43, 58], ["infected", "OBSERVATION_MODIFIER", 118, 126], ["disease", "OBSERVATION", 246, 253]]], ["In contrast, viral DNA or RNA from different clinical samples is an appropriate detection target during the acute phase of an infection or even before the onset of illness.", [["samples", "ANATOMY", 54, 61], ["infection", "DISEASE", 126, 135], ["illness", "DISEASE", 164, 171], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["viral DNA", "DNA", 13, 22], ["viral DNA", "PROBLEM", 13, 22], ["RNA", "PROBLEM", 26, 29], ["an infection", "PROBLEM", 123, 135], ["illness", "PROBLEM", 164, 171], ["viral DNA", "OBSERVATION", 13, 22], ["infection", "OBSERVATION", 126, 135]]], ["Various detection methods targeting viral nucleic acids have been developed for the rapid identification of viral diseases, including conventional RT-PCR [5], real time RT-PCR [6], microarray examination [7], electrospray ionization mass spectrometry [8] and loop-mediated isothermal amplification (LAMP) [9], of which real-time RT-PCR has become the most popular molecular diagnostic approach in clinical laboratories owing to its simplicity, high sensitivity and specificity.", [["nucleic acids", "CHEMICAL", 42, 55], ["viral diseases", "DISEASE", 108, 122], ["Various detection methods", "TEST", 0, 25], ["viral nucleic acids", "TEST", 36, 55], ["viral diseases", "PROBLEM", 108, 122], ["conventional RT-PCR", "TEST", 134, 153], ["real time RT-PCR", "TEST", 159, 175], ["microarray examination", "TEST", 181, 203], ["electrospray ionization mass spectrometry", "TEST", 209, 250], ["loop-mediated isothermal amplification", "TREATMENT", 259, 297], ["RT-PCR", "TEST", 329, 335], ["viral diseases", "OBSERVATION", 108, 122]]], ["Real-time RT-PCR assays are usually carried out with the use of hydrolysis probe (Taqman) or SYBR green fluorescence dye.", [["SYBR green fluorescence dye", "SIMPLE_CHEMICAL", 93, 120], ["time RT-PCR assays", "TEST", 5, 23], ["hydrolysis probe", "TREATMENT", 64, 80], ["SYBR green fluorescence dye", "PROBLEM", 93, 120]]], ["Compared to the Taqman probe, SYBR green-based real time RT-PCR assay can achieve the same detection efficiency with lower costs and thus has been also widely applied in the detection of a variety of viruses [10], [11], [12], [13], [14].IntroductionIn present study, we developed a rapid, sensitive and specific SYBR green-based one-step real time RT-PCR assay for the molecular diagnosis of H7N9 virus.", [["SYBR green", "CHEMICAL", 30, 40], ["[11], [12], [13]", "SIMPLE_CHEMICAL", 214, 230], ["[14]", "SIMPLE_CHEMICAL", 232, 236], ["H7N9 virus", "ORGANISM", 392, 402], ["Taqman probe", "DNA", 16, 28], ["H7N9 virus", "SPECIES", 392, 402], ["the Taqman probe", "TEST", 12, 28], ["SYBR green", "TEST", 30, 40], ["RT-PCR assay", "TEST", 57, 69], ["a variety of viruses", "PROBLEM", 187, 207], ["IntroductionIn present study", "TEST", 237, 265], ["H7N9 virus", "PROBLEM", 392, 402], ["lower", "OBSERVATION_MODIFIER", 117, 122], ["costs", "OBSERVATION", 123, 128], ["variety", "OBSERVATION_MODIFIER", 189, 196], ["viruses", "OBSERVATION", 200, 207], ["H7N9 virus", "OBSERVATION", 392, 402]]], ["Compared with cell culture strategy and immunological assays, this nucleic acid-targeting diagnostic procedure has great advantages in virus detection during the early stage of infection, which could facilitate enhanced epidemiological surveillance of suspected human infection with the emerging influenza virus as well as dynamic monitoring of viral gene sequence evolution.", [["cell", "ANATOMY", 14, 18], ["infection", "DISEASE", 177, 186], ["infection", "DISEASE", 268, 277], ["influenza virus", "DISEASE", 296, 311], ["cell", "CELL", 14, 18], ["human", "ORGANISM", 262, 267], ["influenza virus", "ORGANISM", 296, 311], ["viral gene sequence", "DNA", 345, 364], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 262, 267], ["influenza virus", "SPECIES", 296, 311], ["cell culture strategy", "TEST", 14, 35], ["immunological assays", "TEST", 40, 60], ["this nucleic acid-", "TEST", 62, 80], ["diagnostic procedure", "TREATMENT", 90, 110], ["virus detection", "TREATMENT", 135, 150], ["infection", "PROBLEM", 177, 186], ["human infection", "PROBLEM", 262, 277], ["the emerging influenza virus", "PROBLEM", 283, 311], ["dynamic monitoring", "TEST", 323, 341], ["viral gene sequence evolution", "PROBLEM", 345, 374], ["early stage", "OBSERVATION_MODIFIER", 162, 173], ["infection", "OBSERVATION", 177, 186], ["infection", "OBSERVATION", 268, 277], ["viral gene", "OBSERVATION", 345, 355]]], ["Since the original natural reservoirs of H7N9 virus have not been definitely determined, the established detection assay could also provide a simple and economic approach for H7N9 virus screening in large scale specimens from various animals, including chickens, ducks, geese, pigeons, quails and wild birds.Ethics Statement ::: Materials and MethodsThis study was approved by the Ethics Committee of Jiangsu Provincial Center for Disease Control and Prevention.", [["specimens", "ANATOMY", 211, 220], ["H7N9 virus", "ORGANISM", 41, 51], ["H7N9 virus", "ORGANISM", 175, 185], ["chickens", "ORGANISM", 253, 261], ["ducks", "ORGANISM", 263, 268], ["geese", "ORGANISM", 270, 275], ["pigeons", "ORGANISM", 277, 284], ["quails", "ORGANISM", 286, 292], ["birds", "ORGANISM", 302, 307], ["chickens", "SPECIES", 253, 261], ["ducks", "SPECIES", 263, 268], ["pigeons", "SPECIES", 277, 284], ["quails", "SPECIES", 286, 292], ["H7N9 virus", "SPECIES", 41, 51], ["H7N9 virus", "SPECIES", 175, 185], ["chickens", "SPECIES", 253, 261], ["H7N9 virus", "PROBLEM", 41, 51], ["the established detection assay", "TEST", 89, 120], ["a simple and economic approach", "TREATMENT", 140, 170], ["H7N9 virus screening", "TEST", 175, 195], ["large scale specimens", "TEST", 199, 220], ["This study", "TEST", 350, 360], ["Disease Control", "TREATMENT", 431, 446], ["reservoirs", "OBSERVATION_MODIFIER", 27, 37]]], ["Written informed consent for the use of the clinical samples was obtained from all of the patients involved in this study.Clinical Samples and Virus Isolation ::: Materials and MethodsThe respiratory specimens obtained from patients with influenza-like illnesses were maintained in the viral transportation medium (Yocon Biotech, Beijing, China) and then detected for H7N9 virus infection according to the protocol provided by World Health Organization (WHO) [15].", [["samples", "ANATOMY", 53, 60], ["respiratory specimens", "ANATOMY", 188, 209], ["influenza-like illnesses", "DISEASE", 238, 262], ["infection", "DISEASE", 379, 388], ["patients", "ORGANISM", 90, 98], ["respiratory specimens", "CANCER", 188, 209], ["patients", "ORGANISM", 224, 232], ["H7N9 virus", "ORGANISM", 368, 378], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 224, 232], ["H7N9 virus", "SPECIES", 368, 378], ["the clinical samples", "TEST", 40, 60], ["this study", "TEST", 111, 121], ["Methods", "TREATMENT", 177, 184], ["The respiratory specimens", "TEST", 184, 209], ["influenza", "PROBLEM", 238, 247], ["illnesses", "PROBLEM", 253, 262], ["H7N9 virus infection", "PROBLEM", 368, 388], ["Virus Isolation", "OBSERVATION", 143, 158], ["respiratory", "ANATOMY", 188, 199]]], ["A total of 7 clinical samples (5 throat-swabs, 1 sputum and 1 tracheal aspirate) from H7N9-infected patients were collected and stored at \u221270\u00b0C until further analysis.", [["samples", "ANATOMY", 22, 29], ["throat-swabs", "ANATOMY", 33, 45], ["sputum", "ANATOMY", 49, 55], ["tracheal aspirate", "ANATOMY", 62, 79], ["samples", "CANCER", 22, 29], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 62, 79], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["H7N9", "SPECIES", 86, 90], ["clinical samples", "TEST", 13, 29], ["throat-swabs", "TEST", 33, 45], ["sputum", "TEST", 49, 55], ["1 tracheal aspirate", "TEST", 60, 79], ["H7N9", "PROBLEM", 86, 90], ["further analysis", "TEST", 150, 166], ["tracheal", "ANATOMY", 62, 70]]], ["Virus isolation was performed in Madin-Darby canine kidney cells for 7 to 14 days.", [["kidney cells", "ANATOMY", 52, 64], ["Virus", "ORGANISM", 0, 5], ["Madin-Darby canine kidney cells", "CELL", 33, 64], ["Madin-Darby canine kidney cells", "CELL_LINE", 33, 64], ["canine", "SPECIES", 45, 51], ["Virus isolation", "TREATMENT", 0, 15], ["Madin", "TREATMENT", 33, 38], ["Darby canine kidney cells", "TREATMENT", 39, 64], ["kidney", "ANATOMY", 52, 58]]], ["The positive cell culture supernatant was harvested and stored at \u221270\u00b0C. A H7N9 virus isolate (A/Nanjing/1/2013) was used as the reference virus.RNA Extraction ::: Materials and MethodsViral RNA was extracted from 200 \u00b5l of cell culture supernatants or respiratory specimens using QIAsymphony Virus/Bacteria Mini Kit combined with the QIAsymphony SP instrument (Qiagen, Germany), following the manufacturer\u2019s instructions.", [["cell", "ANATOMY", 13, 17], ["supernatant", "ANATOMY", 26, 37], ["cell", "ANATOMY", 224, 228], ["supernatants", "ANATOMY", 237, 249], ["respiratory specimens", "ANATOMY", 253, 274], ["cell", "CELL", 13, 17], ["H7N9 virus", "ORGANISM", 75, 85], ["cell", "CELL", 224, 228], ["MethodsViral RNA", "RNA", 178, 194], ["A H7N9 virus", "SPECIES", 73, 85], ["A/Nanjing/1/2013", "SPECIES", 95, 111], ["The positive cell culture", "TEST", 0, 25], ["A H7N9 virus isolate", "PROBLEM", 73, 93], ["A/Nanjing/1/2013)", "TREATMENT", 95, 112], ["MethodsViral RNA", "TREATMENT", 178, 194], ["cell culture supernatants", "TEST", 224, 249], ["respiratory specimens", "TEST", 253, 274], ["QIAsymphony Virus", "PROBLEM", 281, 298], ["Bacteria", "PROBLEM", 299, 307], ["the QIAsymphony SP instrument", "TREATMENT", 331, 360], ["positive cell", "OBSERVATION", 4, 17], ["culture", "OBSERVATION_MODIFIER", 18, 25], ["supernatant", "OBSERVATION_MODIFIER", 26, 37]]], ["The extracted RNA was eluted in 60 \u00b5l of nuclease-free water and stored at \u221270\u00b0C until use.Sequence Analysis and Primer Design ::: Materials and MethodsThe primers of HA and NA genes were designed based on the first three genomic sequences of the emerging H7N9 virus (A/Anhui/1/2013, A/Shanghai/1/2013 and A/Shanghai/2/2013) deposited in the GISAID EpiFlu database, using the software Primer3 version 4.0.", [["HA", "GENE_OR_GENE_PRODUCT", 167, 169], ["H7N9 virus", "ORGANISM", 256, 266], ["nuclease", "PROTEIN", 41, 49], ["HA and NA genes", "DNA", 167, 182], ["GISAID EpiFlu database", "DNA", 342, 364], ["H7N9 virus", "SPECIES", 256, 266], ["A/Anhui/1/2013, A/Shanghai/1/2013 and A/Shanghai/2/2013", "SPECIES", 268, 323], ["The extracted RNA", "TREATMENT", 0, 17], ["Sequence Analysis", "TEST", 91, 108], ["Methods", "TREATMENT", 145, 152], ["HA and NA genes", "PROBLEM", 167, 182], ["the software Primer3 version", "TEST", 372, 400]]], ["To increase the wide spectrum compatibility of the primers for other strains of H7 or N9 subtype influenza A virus, the mixed base was introduced into each primer.", [["influenza A", "DISEASE", 97, 108], ["H7 or N9 subtype influenza A virus", "ORGANISM", 80, 114], ["influenza A virus", "SPECIES", 97, 114], ["N9 subtype influenza A virus", "SPECIES", 86, 114], ["the wide spectrum compatibility", "TREATMENT", 12, 43], ["the primers", "TREATMENT", 47, 58], ["other strains", "PROBLEM", 63, 76], ["H7", "PROBLEM", 80, 82], ["N9 subtype influenza A virus", "PROBLEM", 86, 114], ["the mixed base", "TREATMENT", 116, 130]]], ["In detail, all of the H7 or N9 gene sequences of the known circulating virus strains from Asian origin were downloaded from the NCBI\u2019s influenza virus resource database [16] and subsequently aligned with the primers by BLAST.", [["H7 or N9 gene sequences", "DNA", 22, 45], ["influenza virus", "SPECIES", 135, 150], ["NCBI\u2019s influenza virus", "SPECIES", 128, 150], ["N9 gene sequences", "TREATMENT", 28, 45], ["the known circulating virus strains", "PROBLEM", 49, 84]]], ["If a base close to the 3\u2032 end of each primer was different from that of other H7 or N9 subtype viral gene sequences, the original base would be substituted by a mixed base to ensure full complementation of several bases close to the 3\u2032 end of each primer with the templates as possible.", [["3\u2032 end", "DNA", 23, 29], ["H7 or N9 subtype viral gene sequences", "DNA", 78, 115], ["3\u2032 end", "DNA", 233, 239], ["N9 subtype viral gene sequences", "PROBLEM", 84, 115], ["a mixed base", "TREATMENT", 159, 171], ["the templates", "TREATMENT", 260, 273], ["full complementation", "OBSERVATION", 182, 202]]], ["Additionally, the number of mixed base sites within each primer was not allowed more than three positions as a general rule.SYBR Green-based Real Time RT-PCR Assay ::: Materials and MethodsThe one-step real time quantitative RT-PCR assays were performed to amplify the HA and NA genes of H7N9 virus respectively using SuperScript III Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen, CA, USA).", [["H7N9 virus", "ORGANISM", 288, 298], ["HA and NA genes", "DNA", 269, 284], ["H7N9 virus", "SPECIES", 288, 298], ["mixed base sites", "PROBLEM", 28, 44], ["Methods", "TREATMENT", 182, 189], ["PCR assays", "TEST", 228, 238], ["the HA", "PROBLEM", 265, 271], ["H7N9 virus", "PROBLEM", 288, 298], ["SuperScript III Platinum", "TREATMENT", 318, 342], ["qRT", "TEST", 363, 366], ["PCR kit", "TEST", 367, 374], ["number", "OBSERVATION_MODIFIER", 18, 24], ["mixed", "OBSERVATION_MODIFIER", 28, 33], ["base", "OBSERVATION_MODIFIER", 34, 38], ["sites", "OBSERVATION_MODIFIER", 39, 44]]], ["The assay was carried out in a 10 \u00b5l reaction mixture containing 5 \u00b5l of 2\u00d7 SYBR Green Reaction Mix, 0.8 \u00b5M of each primer, 0.2 \u00b5l of ROX Reference Dye, 0.2 \u00b5l of SuperScript III RT/Platinum Taq Mix and 1 \u00b5l of purified RNA.", [["ROX", "CHEMICAL", 134, 137], ["purified RNA", "RNA", 211, 223], ["The assay", "TEST", 0, 9], ["a 10 \u00b5l reaction mixture", "TREATMENT", 29, 53], ["ROX Reference Dye", "TREATMENT", 134, 151], ["SuperScript III RT/Platinum Taq Mix", "TREATMENT", 163, 198], ["purified RNA", "TREATMENT", 211, 223]]], ["The optimized thermal cycling conditions were as follows: a reverse transcription step at 50\u00b0C for 10 min, an initial denaturation step at 95\u00b0C for 5 min, 40 cycles of PCR amplification at 95\u00b0C for 15 sec, 60\u00b0C for 20 sec, and 72\u00b0C for 30 sec, followed by a melting curve analysis program according to the instrument documentation.", [["an initial denaturation step", "PROBLEM", 107, 135], ["PCR amplification", "TEST", 168, 185], ["a melting curve analysis", "TEST", 256, 280], ["the instrument documentation", "TEST", 302, 330]]], ["All real time RT-PCR reactions were conducted in triplicate on the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, CA, USA).", [["PCR reactions", "TEST", 17, 30]]], ["The RT-PCR amplicons were subjected to capillary electrophoresis analysis on the QIAxcel System (Qiagen, Germany) to confirm their specificity.In-vitro Transcription of Viral RNA ::: Materials and MethodsThe viral HA and NA genes were amplified from a H7N9 virus isolate A/Nanjing/1/2013 using the following primers containing T7 promoter sequence in the reverse sites: HA-For: 5\u2032-CCTGGTATTCGCTCTGATTGC-3\u2032, HA-Rev: 5\u2032- ACTCGTTAATACGACTCACTATAGGGAGGCACCGCATGTTTCCATTCT-3\u2032; NA-For: 5\u2032-TCTATGCACTTCAGCCACTG-3\u2032, NA-Rev: 5\u2032- ACTCGTTAATACGACTCACTATAGGGAGCCATCAGGCCAGTTCCATTG-3\u2032.", [["capillary", "TISSUE", 39, 48], ["Viral", "ORGANISM", 169, 174], ["RT-PCR amplicons", "DNA", 4, 20], ["Viral RNA", "RNA", 169, 178], ["viral HA and NA genes", "DNA", 208, 229], ["T7 promoter sequence", "DNA", 327, 347], ["reverse sites", "DNA", 355, 368], ["H7N9 virus isolate A/Nanjing/1/2013", "SPECIES", 252, 287], ["The RT-PCR amplicons", "TREATMENT", 0, 20], ["capillary electrophoresis analysis", "TEST", 39, 73], ["the QIAxcel System", "TREATMENT", 77, 95], ["Materials", "TREATMENT", 183, 192], ["Methods", "TREATMENT", 197, 204], ["The viral HA and NA genes", "PROBLEM", 204, 229], ["the following primers", "TREATMENT", 294, 315], ["T7 promoter sequence", "TREATMENT", 327, 347], ["CCTGGTATTCGCTCTGATTGC", "TEST", 381, 402], ["HA", "TEST", 407, 409], ["ACTCGTTAATACGACTCACTATAGGGAGGCACCGCATGTTTCCATTCT", "TEST", 419, 467], ["NA", "TEST", 472, 474], ["TCTATGCACTTCAGCCACTG", "TEST", 483, 503], ["NA", "TEST", 508, 510], ["ACTCGTTAATACGACTCACTATAGGGAGCCATCAGGCCAGTTCCATTG", "TEST", 520, 568], ["Viral RNA", "OBSERVATION", 169, 178]]], ["The amplified HA and NA gene segments were then in-vitro transcribed with T7 RNA polymerase (TaKaRa, Dalian, China) according to the manufacturer\u2019s instructions.", [["HA", "GENE_OR_GENE_PRODUCT", 14, 16], ["amplified HA and NA gene segments", "DNA", 4, 37], ["T7 RNA polymerase", "PROTEIN", 74, 91], ["The amplified HA and NA gene segments", "TREATMENT", 0, 37], ["T7 RNA polymerase", "TREATMENT", 74, 91]]], ["Finally, the synthesized RNA transcripts were purified, quantified and mixed with equal-molar amounts.Detection Limit and Standard Curve ::: Materials and MethodsThe detection limit of the SYBR green real time RT-PCR assay was determined by testing serial ten-fold dilutions of the in-vitro transcribed viral RNA ranging from 106 to 100 copies/\u00b5l.", [["synthesized RNA transcripts", "RNA", 13, 40], ["viral RNA", "RNA", 303, 312], ["the synthesized RNA transcripts", "TREATMENT", 9, 40], ["Methods", "TREATMENT", 155, 162], ["the SYBR", "TEST", 185, 193], ["PCR assay", "TEST", 213, 222], ["viral RNA", "TEST", 303, 312], ["RNA transcripts", "OBSERVATION", 25, 40], ["mixed", "OBSERVATION_MODIFIER", 71, 76], ["viral RNA", "OBSERVATION", 303, 312]]], ["Then the obtained cycle-threshold (Ct) values were plotted against the amount of RNA copy number to construct standard curve.Specificity of the Assay ::: Materials and MethodsThe specificity of the assay developed to detect H7N9 virus was evaluated on viral RNA from known genetically and clinically related influenza A viruses including seasonal H1N1 (A/Nanjing/4/2009), H1N1 pdm09 (A/Jiangsu/S61/2009), H3N2 (A/Nanjing/1/2009), H5N1 (A/Jiangsu/1/2007) and H9N2 (A/swine/Jiangxi/wx2/2004), as well as other human respiratory viruses including influenza B virus, parainfluenza viruses (types 1, 2, 3 and 4), coronaviruses (HKU1, OC43, 229E and NL63), rhinovirus (China/JS/YC29/2011), respiratory syncytial viruses (types A and B) and enterovirus 71 (Nanjing08-1).Sequence Analysis and Primer Design ::: ResultsWe designed specific forward and reverse primers for the detection of HA and NA genes of H7N9 virus based on the viral genomic sequences from the first three infected patients published in the GISAID EpiFlu database.", [["influenza A viruses", "DISEASE", 308, 327], ["respiratory viruses", "DISEASE", 514, 533], ["influenza B", "DISEASE", 544, 555], ["parainfluenza viruses", "DISEASE", 563, 584], ["respiratory syncytial viruses", "DISEASE", 684, 713], ["H7N9 virus", "ORGANISM", 224, 234], ["influenza A viruses", "ORGANISM", 308, 327], ["H1N1 pdm09", "ORGANISM", 372, 382], ["H3N2", "ORGANISM", 405, 409], ["Nanjing/1/2009", "ORGANISM", 413, 427], ["H5N1", "ORGANISM", 430, 434], ["Jiangsu/1/2007", "ORGANISM", 438, 452], ["H9N2 (A/swine", "ORGANISM", 458, 471], ["human", "ORGANISM", 508, 513], ["respiratory viruses", "ORGANISM", 514, 533], ["influenza B virus", "ORGANISM", 544, 561], ["parainfluenza viruses", "ORGANISM", 563, 584], ["3", "GENE_OR_GENE_PRODUCT", 598, 599], ["4", "GENE_OR_GENE_PRODUCT", 604, 605], ["coronaviruses", "ORGANISM", 608, 621], ["HKU1", "GENE_OR_GENE_PRODUCT", 623, 627], ["OC43", "GENE_OR_GENE_PRODUCT", 629, 633], ["NL63", "GENE_OR_GENE_PRODUCT", 644, 648], ["rhinovirus", "ORGANISM", 651, 661], ["respiratory syncytial viruses", "ORGANISM", 684, 713], ["enterovirus 71", "ORGANISM", 734, 748], ["Nanjing08-1", "GENE_OR_GENE_PRODUCT", 750, 761], ["HA", "GENE_OR_GENE_PRODUCT", 880, 882], ["H7N9 virus", "ORGANISM", 899, 909], ["patients", "ORGANISM", 977, 985], ["viral RNA", "RNA", 252, 261], ["HA and NA genes", "DNA", 880, 895], ["viral genomic sequences", "DNA", 923, 946], ["GISAID EpiFlu database", "DNA", 1003, 1025], ["seasonal H1N1", "SPECIES", 338, 351], ["H3N2", "SPECIES", 405, 409], ["H5N1", "SPECIES", 430, 434], ["H9N2", "SPECIES", 458, 462], ["swine", "SPECIES", 466, 471], ["human", "SPECIES", 508, 513], ["influenza B virus", "SPECIES", 544, 561], ["parainfluenza viruses", "SPECIES", 563, 584], ["patients", "SPECIES", 977, 985], ["H7N9 virus", "SPECIES", 224, 234], ["seasonal H1N1 (A/Nanjing/4/2009)", "SPECIES", 338, 370], ["H1N1 pdm09 (A/Jiangsu/S61/2009)", "SPECIES", 372, 403], ["A/Nanjing/1/2009)", "SPECIES", 411, 428], ["A/Jiangsu/1/2007)", "SPECIES", 436, 453], ["A/swine/Jiangxi/wx2/2004)", "SPECIES", 464, 489], ["human respiratory viruses", "SPECIES", 508, 533], ["influenza B virus", "SPECIES", 544, 561], ["China/JS/YC29/2011)", "SPECIES", 663, 682], ["respiratory syncytial viruses", "SPECIES", 684, 713], ["H7N9 virus", "SPECIES", 899, 909], ["Ct) values", "TEST", 35, 45], ["Methods", "TREATMENT", 168, 175], ["the assay", "TEST", 194, 203], ["H7N9 virus", "PROBLEM", 224, 234], ["viral RNA", "PROBLEM", 252, 261], ["influenza A viruses", "PROBLEM", 308, 327], ["seasonal H1N1", "PROBLEM", 338, 351], ["H1N1", "PROBLEM", 372, 376], ["H3N2", "PROBLEM", 405, 409], ["H5N1", "PROBLEM", 430, 434], ["H9N2", "PROBLEM", 458, 462], ["Jiangxi", "TEST", 472, 479], ["other human respiratory viruses", "PROBLEM", 502, 533], ["influenza B virus", "PROBLEM", 544, 561], ["parainfluenza viruses", "PROBLEM", 563, 584], ["coronaviruses", "TEST", 608, 621], ["HKU1", "TEST", 623, 627], ["OC43", "TEST", 629, 633], ["NL63", "TEST", 644, 648], ["rhinovirus", "TEST", 651, 661], ["respiratory syncytial viruses", "PROBLEM", 684, 713], ["enterovirus", "PROBLEM", 734, 745], ["Sequence Analysis", "TEST", 763, 780], ["reverse primers", "TREATMENT", 843, 858], ["HA", "PROBLEM", 880, 882], ["NA genes", "PROBLEM", 887, 895], ["H7N9 virus", "PROBLEM", 899, 909], ["the viral genomic sequences", "TEST", 919, 946], ["respiratory", "ANATOMY", 514, 525], ["viruses", "OBSERVATION", 526, 533], ["parainfluenza viruses", "OBSERVATION", 563, 584], ["respiratory", "ANATOMY", 684, 695], ["syncytial viruses", "OBSERVATION", 696, 713]]], ["The regions targeted by primer pairs were nucleotide 1047 to 1149 for HA sequence and nucleotide 490 to 654 for NA sequence respectively, as shown in Figure 1.", [["nucleotide", "CHEMICAL", 42, 52], ["nucleotide", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 42, 52], ["nucleotide", "CHEMICAL", 86, 96], ["primer pairs", "DNA", 24, 36], ["nucleotide 1047 to 1149 for HA sequence", "DNA", 42, 81], ["nucleotide 490 to 654 for NA sequence", "DNA", 86, 123], ["nucleotide", "TEST", 42, 52], ["HA sequence", "TEST", 70, 81], ["nucleotide", "TEST", 86, 96], ["NA sequence", "TEST", 112, 123], ["regions", "ANATOMY_MODIFIER", 4, 11]]], ["In order to increase the detection scope of the primers for known H7 or N9 subtype avian influenza viruses, 135 H7 and 36 N9 subtype full-length viral gene sequences from Asian lineage were downloaded from NCBI\u2019s influenza virus resource database and then aligned with the primers by BLAST.", [["influenza viruses", "DISEASE", 89, 106], ["H7 or N9 subtype avian influenza viruses", "ORGANISM", 66, 106], ["135 H7", "ORGANISM", 108, 114], ["135 H7 and 36 N9 subtype full-length viral gene sequences", "DNA", 108, 165], ["avian influenza viruses", "SPECIES", 83, 106], ["influenza virus", "SPECIES", 213, 228], ["N9 subtype avian influenza viruses", "SPECIES", 72, 106], ["NCBI\u2019s influenza virus", "SPECIES", 206, 228], ["the primers", "TREATMENT", 44, 55], ["H7", "PROBLEM", 66, 68], ["N9 subtype avian influenza viruses", "PROBLEM", 72, 106], ["N9 subtype full-length viral gene sequences", "TREATMENT", 122, 165]]], ["A mixed base was used close to the 3\u2032 end of each primer when a different nucleotide was found between the primers and the downloaded viral gene sequences (Figure 1).", [["nucleotide", "CHEMICAL", 74, 84], ["nucleotide", "CHEMICAL", 74, 84], ["3\u2032 end", "DNA", 35, 41], ["downloaded viral gene sequences", "DNA", 123, 154], ["A mixed base", "TREATMENT", 0, 12], ["a different nucleotide", "PROBLEM", 62, 84], ["the primers", "TEST", 103, 114], ["the downloaded viral gene sequences", "TEST", 119, 154], ["mixed", "OBSERVATION_MODIFIER", 2, 7], ["base", "OBSERVATION_MODIFIER", 8, 12]]], ["Detailed primer sequences were listed in Table 1.Validation of SYBR Green-based Real Time RT-PCR Assays ::: ResultsWe employed the genomic RNA as the template purified from a H7N9 virus isolate (A/Nanjing/1/2013) for the initial validation experiments.", [["SYBR Green", "GENE_OR_GENE_PRODUCT", 63, 73], ["H7N9 virus", "ORGANISM", 175, 185], ["primer sequences", "DNA", 9, 25], ["genomic RNA", "RNA", 131, 142], ["H7N9 virus", "SPECIES", 175, 185], ["A/Nanjing/1/2013", "SPECIES", 195, 211], ["Detailed primer sequences", "TEST", 0, 25], ["a H7N9 virus isolate", "TREATMENT", 173, 193], ["genomic RNA", "OBSERVATION", 131, 142]]], ["The optimal annealing temperature was set at 60\u00b0C, while optimal primer concentrations were 0.8 \u00b5M in a 10 \u00b5l of reaction mixture.", [["The optimal annealing temperature", "TEST", 0, 33], ["reaction mixture", "TREATMENT", 113, 129]]], ["After 40 amplification cycles, the melting curve analysis revealed that the mean melting temperatures (Tm) of the specific amplicons were 80.77\u00b10.06\u00b0C for H7 and 81.20\u00b10.17\u00b0C for N9, quite different from those of primer-dimers (Figure 2A and 2B).", [["primer-dimers", "PROTEIN", 213, 226], ["40 amplification cycles", "TREATMENT", 6, 29], ["the melting curve analysis", "TEST", 31, 57], ["the mean melting temperatures", "TEST", 72, 101], ["the specific amplicons", "TEST", 110, 132], ["H7", "TEST", 155, 157], ["N9", "PROBLEM", 179, 181]]], ["The RT-PCR amplification segments were then confirmed with a length of 103 bp for H7 and 165bp for N9 by capillary electrophoresis analysis (Figure 2C).Detection Limit and Standard Curve ::: ResultsUsing serial ten-fold diluted in-vitro transcribed viral RNA, we observed that real time RT-PCR assays with 106 to 101 RNA copies as the reaction templates could generate positive amplification signals for both H7 and N9 examinations, but not with 100 RNA copy (Figure 3A and 3D).", [["capillary", "TISSUE", 105, 114], ["RT-PCR amplification segments", "DNA", 4, 33], ["H7", "DNA", 82, 84], ["viral RNA", "RNA", 249, 258], ["The RT-PCR amplification segments", "TREATMENT", 0, 33], ["a length", "TEST", 59, 67], ["bp", "TEST", 75, 77], ["bp", "TEST", 92, 94], ["capillary electrophoresis analysis", "TEST", 105, 139], ["serial ten-fold diluted", "TREATMENT", 204, 227], ["real time RT-PCR assays", "TEST", 277, 300], ["RNA copies", "TEST", 317, 327], ["the reaction templates", "PROBLEM", 331, 353], ["positive amplification signals", "PROBLEM", 369, 399], ["N9 examinations", "TEST", 416, 431], ["viral RNA", "OBSERVATION", 249, 258]]], ["The Ct values corresponding to 101 RNA copies per reaction were 31.70\u00b10.14 (H7) and 32.80\u00b10.76 (N9) respectively (Figure 3B and 3E).", [["The Ct values", "TEST", 0, 13], ["RNA copies", "TEST", 35, 45]]], ["The standard curves showed a dynamic linear range across at least 6 log units of RNA copy number.", [["The standard curves", "TEST", 0, 19]]], ["Linear regression analysis revealed that the correlation coefficients (R2) were 0.991 with a slope value of 3.144 for H7 assay and 0.997 with a slope value of 3.573 for N9 assay (Figure 3C and 3F).Specificity of the Assay ::: ResultsThe specificity of SYBR green real time RT-PCR assay was tested on genomic RNA from a panel of viral positive isolates.", [["H7", "PROTEIN", 118, 120], ["genomic RNA", "RNA", 300, 311], ["Linear regression analysis", "TEST", 0, 26], ["a slope value", "TEST", 91, 104], ["H7 assay", "TEST", 118, 126], ["a slope value", "TEST", 142, 155], ["N9 assay", "TEST", 169, 177], ["SYBR green real time RT-PCR assay", "TEST", 252, 285], ["genomic RNA", "PROBLEM", 300, 311], ["a panel", "TEST", 317, 324], ["viral positive isolates", "PROBLEM", 328, 351]]], ["Negative amplification signals were obtained in both assays for several known subtypes of human influenza A virus, including seasonal H1N1, H1N1 pdm09, H3N2, H5N1 and H9N2 viruses (Table 2).", [["influenza A virus", "DISEASE", 96, 113], ["H1N1 pdm09, H3N2, H5N1 and H9N2 viruses", "DISEASE", 140, 179], ["human influenza A virus", "ORGANISM", 90, 113], ["seasonal H1N1", "ORGANISM", 125, 138], ["H1N1 pdm09", "ORGANISM", 140, 150], ["H3N2, H5N1", "ORGANISM", 152, 162], ["H9N2 viruses", "ORGANISM", 167, 179], ["human", "SPECIES", 90, 95], ["influenza A virus", "SPECIES", 96, 113], ["seasonal H1N1", "SPECIES", 125, 138], ["H1N1", "SPECIES", 140, 144], ["H3N2", "SPECIES", 152, 156], ["H5N1 and H9N2", "SPECIES", 158, 171], ["human influenza A virus", "SPECIES", 90, 113], ["H9N2 viruses", "SPECIES", 167, 179], ["amplification signals", "TEST", 9, 30], ["human influenza A virus", "PROBLEM", 90, 113], ["seasonal H1N1", "PROBLEM", 125, 138], ["H1N1 pdm09", "PROBLEM", 140, 150], ["H3N2", "PROBLEM", 152, 156], ["H5N1", "PROBLEM", 158, 162], ["H9N2 viruses", "PROBLEM", 167, 179]]], ["And there were also no positive amplification signals produced when the H7 and N9 assays were applied in the detection of other human respiratory viruses (Table 2).Evaluation of the SYBR Green Real Time RT-PCR Assays in Clinical Samples ::: ResultsTo evaluate the ability of the developed assays to detect the clinical samples, the respiratory specimens from seven previously confirmed patients infected with H7N9 virus were used for analysis.", [["samples", "ANATOMY", 319, 326], ["respiratory specimens", "ANATOMY", 332, 353], ["respiratory viruses", "DISEASE", 134, 153], ["human", "ORGANISM", 128, 133], ["patients", "ORGANISM", 386, 394], ["H7N9 virus", "ORGANISM", 409, 419], ["human", "SPECIES", 128, 133], ["patients", "SPECIES", 386, 394], ["human respiratory viruses", "SPECIES", 128, 153], ["H7N9 virus", "SPECIES", 409, 419], ["positive amplification signals", "PROBLEM", 23, 53], ["the H7 and N9 assays", "TEST", 68, 88], ["other human respiratory viruses", "PROBLEM", 122, 153], ["Evaluation", "TEST", 164, 174], ["the SYBR", "TEST", 178, 186], ["assays", "TEST", 289, 295], ["the clinical samples", "TEST", 306, 326], ["the respiratory specimens", "TEST", 328, 353], ["H7N9 virus", "PROBLEM", 409, 419], ["analysis", "TEST", 434, 442], ["no", "UNCERTAINTY", 20, 22], ["positive", "OBSERVATION_MODIFIER", 23, 31], ["amplification", "OBSERVATION", 32, 45], ["respiratory viruses", "OBSERVATION", 134, 153]]], ["Real time RT-PCR results showed that positive signals were produced in all of the samples for both H7 and N9 examinations.", [["samples", "ANATOMY", 82, 89], ["Real time RT-PCR", "TEST", 0, 16], ["positive signals", "PROBLEM", 37, 53], ["both H7 and N9 examinations", "TEST", 94, 121]]], ["Moreover, the Ct value obtained from H7 assay was well comparable with that obtained from N9 assay for each individual infected patient (Figure 4).DiscussionInfluenza A virus, a negative-sense RNA virus, belongs to the family Orthomyxoviridae.", [["Influenza A virus", "DISEASE", 157, 174], ["patient", "ORGANISM", 128, 135], ["Influenza A virus", "ORGANISM", 157, 174], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 226, 242], ["H7", "PROTEIN", 37, 39], ["patient", "SPECIES", 128, 135], ["Influenza A virus", "SPECIES", 157, 174], ["Influenza A virus", "SPECIES", 157, 174], ["the Ct value", "TEST", 10, 22], ["H7 assay", "TEST", 37, 45], ["N9 assay", "TEST", 90, 98], ["Influenza A virus", "PROBLEM", 157, 174], ["sense RNA virus", "PROBLEM", 187, 202]]], ["It is subtyped on the basis of HA and NA glycoproteins on the surface of the virus particle, which are antigenically classified into 16 (H1 to H16) and 9 (N1 to N9) subtypes, respectively.", [["surface", "ANATOMY", 62, 69], ["HA", "GENE_OR_GENE_PRODUCT", 31, 33], ["NA glycoproteins", "GENE_OR_GENE_PRODUCT", 38, 54], ["surface", "CELLULAR_COMPONENT", 62, 69], ["HA and NA glycoproteins", "PROTEIN", 31, 54], ["HA", "PROBLEM", 31, 33], ["NA glycoproteins", "PROBLEM", 38, 54], ["the virus particle", "TREATMENT", 73, 91], ["NA glycoproteins", "OBSERVATION_MODIFIER", 38, 54], ["virus particle", "OBSERVATION", 77, 91]]], ["Human infections with influenza A virus are generally confined to 3 HA subtypes (H1, H2 and H3) and 2 NA subtypes (N1 and N2), whereas domestic poultry and wild birds usually serve as the natural reservoirs for the other subtypes [17].", [["infections", "DISEASE", 6, 16], ["influenza A virus", "DISEASE", 22, 39], ["Human", "ORGANISM", 0, 5], ["influenza A virus", "ORGANISM", 22, 39], ["H3", "GENE_OR_GENE_PRODUCT", 92, 94], ["birds", "ORGANISM", 161, 166], ["Human", "SPECIES", 0, 5], ["influenza A virus", "SPECIES", 22, 39], ["Human", "SPECIES", 0, 5], ["influenza A virus", "SPECIES", 22, 39], ["Human infections", "PROBLEM", 0, 16], ["influenza A virus", "PROBLEM", 22, 39], ["3 HA subtypes (H1, H2 and H3)", "PROBLEM", 66, 95], ["2 NA subtypes (N1 and N2)", "PROBLEM", 100, 125], ["infections", "OBSERVATION", 6, 16], ["influenza", "OBSERVATION", 22, 31]]], ["Cross-species transmissions of avian influenza viruses from poultry to humans have been reported before and only focused on H5N1 [18], H7N2 [19], H7N3 [20] and H7N7 [21] subtypes, among which highly pathogenic H5N1 virus has caused 634 infections and 371 deaths as of 12 March 2013 [22], and H7N7 virus infection was associated with a fatal case in Netherland [21].DiscussionMost recently, a newly identified avian-origin reassortant influenza A (H7N9) virus emerged in China and has led to an increasing number of human infection and fatal cases.", [["avian influenza viruses", "DISEASE", 31, 54], ["H5N1 virus", "DISEASE", 210, 220], ["infections", "DISEASE", 236, 246], ["deaths", "DISEASE", 255, 261], ["infection", "DISEASE", 303, 312], ["influenza A (H7N9) virus", "DISEASE", 434, 458], ["infection", "DISEASE", 521, 530], ["avian influenza viruses", "ORGANISM", 31, 54], ["humans", "ORGANISM", 71, 77], ["H5N1 [18]", "ORGANISM", 124, 133], ["H7N2 [19]", "ORGANISM", 135, 144], ["H7N3", "ORGANISM", 146, 150], ["H5N1 virus", "ORGANISM", 210, 220], ["H7N7 virus", "ORGANISM", 292, 302], ["avian-origin reassortant", "ORGANISM", 409, 433], ["influenza A (H7N9) virus", "ORGANISM", 434, 458], ["human", "ORGANISM", 515, 520], ["avian influenza viruses", "SPECIES", 31, 54], ["humans", "SPECIES", 71, 77], ["H5N1 virus", "SPECIES", 210, 220], ["reassortant influenza A (H7N9", "SPECIES", 422, 451], ["human", "SPECIES", 515, 520], ["humans", "SPECIES", 71, 77], ["H7N2", "SPECIES", 135, 139], ["H7N3", "SPECIES", 146, 150], ["H5N1 virus", "SPECIES", 210, 220], ["H7N7 virus", "SPECIES", 292, 302], ["A (H7N9) virus", "SPECIES", 444, 458], ["human", "SPECIES", 515, 520], ["avian influenza viruses", "PROBLEM", 31, 54], ["H7N3", "TEST", 146, 150], ["H7N7", "PROBLEM", 160, 164], ["subtypes", "TEST", 170, 178], ["highly pathogenic H5N1 virus", "PROBLEM", 192, 220], ["H7N7 virus infection", "PROBLEM", 292, 312], ["reassortant influenza A (H7N9) virus", "PROBLEM", 422, 458], ["human infection and fatal cases", "PROBLEM", 515, 546], ["H5N1 virus", "OBSERVATION", 210, 220], ["infection", "OBSERVATION", 303, 312], ["influenza", "OBSERVATION", 434, 443], ["increasing", "OBSERVATION_MODIFIER", 494, 504], ["number", "OBSERVATION_MODIFIER", 505, 511], ["human infection", "OBSERVATION", 515, 530]]], ["Although at this moment there is no potent evidence of sustained human-to-human transmission, genetic analysis suggests that several amino acid changes in viral HA and PB2 RNA polymerase genes improve the ability to bind human-type receptors and facilitate the efficient replication in mammals [22], highlighting the great threat to human beings.", [["amino acid", "CHEMICAL", 133, 143], ["amino acid", "CHEMICAL", 133, 143], ["human", "ORGANISM", 65, 70], ["human", "ORGANISM", 74, 79], ["amino acid", "AMINO_ACID", 133, 143], ["human", "ORGANISM", 221, 226], ["human", "ORGANISM", 333, 338], ["viral HA and PB2 RNA polymerase genes", "DNA", 155, 192], ["human-type receptors", "PROTEIN", 221, 241], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 333, 338], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 333, 338], ["genetic analysis", "TEST", 94, 110], ["several amino acid changes", "PROBLEM", 125, 151], ["viral HA", "PROBLEM", 155, 163], ["PB2 RNA polymerase genes", "PROBLEM", 168, 192], ["no potent evidence of", "UNCERTAINTY", 33, 54], ["amino acid", "OBSERVATION", 133, 143]]], ["Furthermore, the real sources of infection and the reservoirs of this novel virus are still uncertain despite the fact that one virus isolate has been acquired from a chicken [3].", [["infection", "DISEASE", 33, 42], ["chicken", "ORGANISM", 167, 174], ["chicken", "SPECIES", 167, 174], ["chicken", "SPECIES", 167, 174], ["infection", "PROBLEM", 33, 42], ["this novel virus", "PROBLEM", 65, 81], ["one virus isolate", "PROBLEM", 124, 141], ["infection", "OBSERVATION", 33, 42]]], ["Many other questions, such as modes of transmission, viral incubation period, the optimal clinical specimens for laboratory confirmation and the spectrum of clinical illness, remain to be further determined [23].", [["specimens", "ANATOMY", 99, 108], ["laboratory confirmation", "TEST", 113, 136], ["clinical illness", "PROBLEM", 157, 173]]], ["Therefore, a lot of measures must be taken to effectively prevent and control the outbreak of H7N9 virus infection, of which development of a rapid molecular diagnostic assay is the top priority in public health laboratories.DiscussionHere we developed a SYBR green-based real time RT-PCR assay for rapid identification of this novel H7N9 virus.", [["infection", "DISEASE", 105, 114], ["SYBR green", "CHEMICAL", 255, 265], ["H7N9 virus", "ORGANISM", 94, 104], ["H7N9 virus", "ORGANISM", 334, 344], ["H7N9 virus", "SPECIES", 94, 104], ["H7N9 virus", "SPECIES", 334, 344], ["a lot of measures", "TREATMENT", 11, 28], ["H7N9 virus infection", "PROBLEM", 94, 114], ["a rapid molecular diagnostic assay", "PROBLEM", 140, 174], ["a SYBR green", "TEST", 253, 265], ["PCR assay", "TEST", 285, 294], ["this novel H7N9 virus", "PROBLEM", 323, 344], ["rapid", "OBSERVATION_MODIFIER", 142, 147]]], ["Although the primers were designed based on the sequences from the initial three isolates, the H7 and N9 primer pairs used in this study are suitable for the detection of all of the new reassortant H7N9 virus stains available in the GISAID EpiFlu database by sequence alignment.", [["H7N9 virus", "ORGANISM", 198, 208], ["H7 and N9 primer pairs", "DNA", 95, 117], ["GISAID EpiFlu database", "DNA", 233, 255], ["reassortant H7N9 virus", "SPECIES", 186, 208], ["reassortant H7N9 virus", "SPECIES", 186, 208], ["the H7 and N9 primer pairs", "PROBLEM", 91, 117], ["this study", "TEST", 126, 136], ["the new reassortant H7N9 virus stains", "PROBLEM", 178, 215]]], ["Moreover, the introduction of mixed bases into primers could make it possible to detect other known circulating H7Nx and HxN9 influenza viruses.", [["influenza", "DISEASE", 126, 135], ["H7Nx", "GENE_OR_GENE_PRODUCT", 112, 116], ["HxN9 influenza viruses", "ORGANISM", 121, 143], ["HxN9 influenza viruses", "SPECIES", 121, 143], ["mixed bases into primers", "TREATMENT", 30, 54], ["known circulating H7Nx", "PROBLEM", 94, 116], ["HxN9 influenza viruses", "PROBLEM", 121, 143], ["influenza viruses", "OBSERVATION", 126, 143]]], ["Since SYBR green dye can intercalate into non-specific DNA such as primer dimers [10], the results are usually analyzed in terms of amplification plots combined with melting curves to discriminate non-specific amplification.", [["SYBR green dye", "CHEMICAL", 6, 20], ["SYBR green", "CHEMICAL", 6, 16], ["SYBR", "GENE_OR_GENE_PRODUCT", 6, 10], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["SYBR green dye", "PROBLEM", 6, 20], ["non-specific DNA", "PROBLEM", 42, 58], ["primer dimers", "PROBLEM", 67, 80], ["amplification plots", "PROBLEM", 132, 151], ["melting curves", "TEST", 166, 180], ["non-specific amplification", "PROBLEM", 197, 223], ["non-specific DNA", "OBSERVATION_MODIFIER", 42, 58]]], ["H7- and N9-specific amplicons in this assay had unique Tm values, significantly different from those of primer dimers to avoid false positive results.", [["H7", "ORGANISM", 0, 2], ["N9", "CELL", 8, 10], ["H7- and N9-specific amplicons", "DNA", 0, 29], ["H7", "PROBLEM", 0, 2], ["this assay", "TEST", 33, 43], ["unique Tm values", "TEST", 48, 64], ["false positive results", "PROBLEM", 127, 149]]], ["In-vitro transcribed viral RNA is very useful for eliminating the need for handling contagious virus isolates and has been preferentially applied in testing sensitivity of various virus diagnostic assays [11], [12], [14].", [["[12]", "SIMPLE_CHEMICAL", 210, 214], ["viral RNA", "RNA", 21, 30], ["handling contagious virus isolates", "TREATMENT", 75, 109], ["testing sensitivity", "TEST", 149, 168], ["various virus diagnostic assays", "TEST", 172, 203]]], ["With the use of in-vitro RNA transcripts of HA and NA genes of H7N9 virus, the assay was found to detect H7 and N9 genes with a detection limit of 10 copies per reaction, similar to the Taqman probe-based assay presented by Corman et al [24].", [["HA", "GENE_OR_GENE_PRODUCT", 44, 46], ["H7N9 virus", "ORGANISM", 63, 73], ["in-vitro RNA transcripts", "RNA", 16, 40], ["HA and NA genes", "DNA", 44, 59], ["H7 and N9 genes", "DNA", 105, 120], ["Taqman probe", "DNA", 186, 198], ["H7N9 virus", "SPECIES", 63, 73], ["HA", "PROBLEM", 44, 46], ["H7N9 virus", "PROBLEM", 63, 73], ["the assay", "TEST", 75, 84], ["H7", "PROBLEM", 105, 107], ["the Taqman probe", "TEST", 182, 198]]], ["The specificity of the assay was subsequently established through testing a panel of previously known influenza A virus subtypes as well as other human respiratory viruses.", [["respiratory viruses", "DISEASE", 152, 171], ["influenza A virus", "ORGANISM", 102, 119], ["human", "ORGANISM", 146, 151], ["influenza A virus", "SPECIES", 102, 119], ["human", "SPECIES", 146, 151], ["influenza A virus", "SPECIES", 102, 119], ["human", "SPECIES", 146, 151], ["the assay", "TEST", 19, 28], ["a panel", "TEST", 74, 81], ["previously known influenza A virus subtypes", "PROBLEM", 85, 128], ["other human respiratory viruses", "PROBLEM", 140, 171], ["influenza", "OBSERVATION", 102, 111], ["respiratory viruses", "OBSERVATION", 152, 171]]], ["No specific amplification signals were observed in all of the reactions with the viruses above as the templates, indicating the high specificity of the assay.", [["specific amplification signals", "PROBLEM", 3, 33], ["the reactions", "PROBLEM", 58, 71], ["the viruses", "PROBLEM", 77, 88]]], ["To evaluate the practical use of the SYBR green-based real time RT-PCR assay, we collected clinical samples from seven H7N9 infected patients during the acute stage of the disease.", [["samples", "ANATOMY", 100, 107], ["SYBR green", "CHEMICAL", 37, 47], ["H7N9 infected", "DISEASE", 119, 132], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["H7N9", "SPECIES", 119, 123], ["the SYBR green", "TEST", 33, 47], ["clinical samples", "TEST", 91, 107], ["the disease", "PROBLEM", 168, 179], ["acute stage", "OBSERVATION_MODIFIER", 153, 164], ["disease", "OBSERVATION", 172, 179]]], ["All of the samples were readily amplified in H7 and N9 examinations by this method, suggesting its effectiveness in clinical practice.", [["samples", "ANATOMY", 11, 18], ["samples", "CANCER", 11, 18], ["H7", "CELL", 45, 47], ["the samples", "TEST", 7, 18], ["N9 examinations", "TEST", 52, 67], ["this method", "TEST", 71, 82]]], ["Besides the diagnosis of clinically suspected samples, this developed real time RT-PCR assay has the potential in dynamic monitoring of viral replication based on series specimens from individual patient with H7N9 virus infection, thus guiding the therapeutic strategy in clinic.", [["samples", "ANATOMY", 46, 53], ["specimens", "ANATOMY", 170, 179], ["H7N9 virus infection", "DISEASE", 209, 229], ["samples", "CANCER", 46, 53], ["patient", "ORGANISM", 196, 203], ["H7N9 virus", "ORGANISM", 209, 219], ["patient", "SPECIES", 196, 203], ["H7N9 virus", "SPECIES", 209, 219], ["clinically suspected samples", "PROBLEM", 25, 53], ["PCR assay", "TEST", 83, 92], ["viral replication", "TREATMENT", 136, 153], ["series specimens", "TEST", 163, 179], ["H7N9 virus infection", "PROBLEM", 209, 229], ["viral replication", "OBSERVATION", 136, 153]]], ["Large scale specimens need to be collected to further evaluate the diagnostic robustness of the assay.DiscussionConsidering the high variation frequency in sequences of influenza viruses, we didn\u2019t develop a Taqman probe-based assay for the detection of the emerging H7N9 virus.", [["specimens", "ANATOMY", 12, 21], ["influenza viruses", "DISEASE", 169, 186], ["influenza viruses", "ORGANISM", 169, 186], ["H7N9 virus", "ORGANISM", 267, 277], ["Taqman probe", "DNA", 208, 220], ["H7N9 virus", "SPECIES", 267, 277], ["Large scale specimens", "PROBLEM", 0, 21], ["the assay", "TEST", 92, 101], ["the high variation frequency", "PROBLEM", 124, 152], ["influenza viruses", "PROBLEM", 169, 186], ["a Taqman probe", "TEST", 206, 220], ["the detection", "TEST", 237, 250], ["the emerging H7N9 virus", "PROBLEM", 254, 277]]], ["Reduced sensitivity and elevated false negative results have been often encountered in probe-based assays designed to detect highly variable viral genomes due to the fact that the presence of mutations within the probe target region can prevent annealing of the probe and subsequent hydrolysis [25], [26], [27], [28].", [["[27]", "SIMPLE_CHEMICAL", 306, 310], ["viral genomes", "DNA", 141, 154], ["probe target region", "DNA", 213, 232], ["Reduced sensitivity", "PROBLEM", 0, 19], ["elevated false negative results", "PROBLEM", 24, 55], ["based assays", "TEST", 93, 105], ["highly variable viral genomes", "PROBLEM", 125, 154], ["mutations within the probe target region", "PROBLEM", 192, 232]]], ["However, SYBR green-based RT-PCR assays are less influenced by mismatches because of probe independency.", [["SYBR green", "CHEMICAL", 9, 19], ["SYBR", "GENE_OR_GENE_PRODUCT", 9, 13], ["SYBR green", "TEST", 9, 19], ["based RT-PCR assays", "TEST", 20, 39]]], ["We also took other advantages of SYBR green quantification into account including the comparable amplification performance with Taqman probes but the relative simplicity and lower running costs, which might be more appropriate for use in first line clinical laboratories.DiscussionIn summary, the present SYBR green-based real time RT-PCR assay proved to be a powerful tool for rapid, sensitive and specific detection of the emerging H7N9 virus.", [["SYBR green", "CHEMICAL", 33, 43], ["SYBR green", "CHEMICAL", 305, 315], ["H7N9 virus", "ORGANISM", 434, 444], ["H7N9 virus", "SPECIES", 434, 444], ["Taqman probes", "TEST", 128, 141], ["lower running costs", "PROBLEM", 174, 193], ["RT-PCR assay", "TEST", 332, 344], ["the emerging H7N9 virus", "PROBLEM", 421, 444], ["lower", "OBSERVATION_MODIFIER", 174, 179]]], ["It could provide a simple and economic alternative approach for high throughput screening of suspected samples from humans, animals and environments, thus allowing better pandemic preparedness.", [["samples", "ANATOMY", 103, 110], ["humans", "ORGANISM", 116, 122], ["humans", "SPECIES", 116, 122], ["humans", "SPECIES", 116, 122], ["a simple and economic alternative approach", "TREATMENT", 17, 59]]]], "4562513d3f2f9c259d9ce5a0eae9233dbf8b8f87": [["IntroductIonCoronaviruses (CoVs), a genus in the coronaviridae family, are pleomorphic, enveloped viruses [1] , and include alpha-, beta-, and gammacoronavirus, as well as a tentative new genus, deltacoronavirus [2] .", [["IntroductIonCoronaviruses", "CHEMICAL", 0, 25], ["IntroductIonCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["coronaviridae", "GENE_OR_GENE_PRODUCT", 49, 62], ["alpha-", "GENE_OR_GENE_PRODUCT", 124, 130], ["beta-", "GENE_OR_GENE_PRODUCT", 132, 137], ["gammacoronavirus", "GENE_OR_GENE_PRODUCT", 143, 159], ["alpha-", "TEST", 124, 130], ["gammacoronavirus", "TREATMENT", 143, 159]]], ["Transmissible gastroenteritis virus (TGEV), a coronavirus in the alphacoronavirus genus, causes clinical watery diarrhea, dehydration and vomiting in piglets less than 2 weeks old [3] , and persists in lung or intestine up to 104 days [4] , but does not cause obvious apoptosis in intestinal epithelial cells [5] .", [["lung", "ANATOMY", 202, 206], ["intestine", "ANATOMY", 210, 219], ["intestinal epithelial cells", "ANATOMY", 281, 308], ["Transmissible gastroenteritis", "DISEASE", 0, 29], ["coronavirus", "DISEASE", 46, 57], ["watery diarrhea", "DISEASE", 105, 120], ["dehydration", "DISEASE", 122, 133], ["vomiting", "DISEASE", 138, 146], ["Transmissible gastroenteritis virus", "ORGANISM", 0, 35], ["TGEV", "ORGANISM", 37, 41], ["piglets", "ORGANISM", 150, 157], ["lung", "ORGAN", 202, 206], ["intestine", "ORGAN", 210, 219], ["intestinal epithelial cells", "CELL", 281, 308], ["intestinal epithelial cells", "CELL_TYPE", 281, 308], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["TGEV", "SPECIES", 37, 41], ["coronavirus", "SPECIES", 46, 57], ["piglets", "SPECIES", 150, 157], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["TGEV", "SPECIES", 37, 41], ["Transmissible gastroenteritis virus", "PROBLEM", 0, 35], ["a coronavirus in the alphacoronavirus genus", "PROBLEM", 44, 87], ["clinical watery diarrhea", "PROBLEM", 96, 120], ["dehydration", "PROBLEM", 122, 133], ["vomiting", "PROBLEM", 138, 146], ["obvious apoptosis in intestinal epithelial cells", "PROBLEM", 260, 308], ["gastroenteritis", "OBSERVATION", 14, 29], ["lung", "ANATOMY", 202, 206], ["intestine", "ANATOMY", 210, 219], ["not cause", "UNCERTAINTY", 250, 259], ["obvious", "OBSERVATION_MODIFIER", 260, 267], ["apoptosis", "OBSERVATION", 268, 277], ["intestinal epithelial cells", "OBSERVATION", 281, 308]]], ["Although intestinal epithelial cells are the targets for TGEV, little is known about TGEV infection or the mechanisms underlying intestinal injury, diarrhea, dehydration and long periods carry of virus.IntroductIonIntestinal epithelial cells play an important role in the nutrition absorption and immune response against pathogens.", [["intestinal epithelial cells", "ANATOMY", 9, 36], ["intestinal", "ANATOMY", 129, 139], ["IonIntestinal epithelial cells", "ANATOMY", 211, 241], ["infection", "DISEASE", 90, 99], ["intestinal injury", "DISEASE", 129, 146], ["diarrhea", "DISEASE", 148, 156], ["dehydration", "DISEASE", 158, 169], ["intestinal epithelial cells", "CELL", 9, 36], ["TGEV", "ORGANISM", 57, 61], ["TGEV", "ORGANISM", 85, 89], ["intestinal", "ORGAN", 129, 139], ["IonIntestinal epithelial cells", "CELL", 211, 241], ["intestinal epithelial cells", "CELL_TYPE", 9, 36], ["IonIntestinal epithelial cells", "CELL_LINE", 211, 241], ["TGEV", "SPECIES", 57, 61], ["TGEV", "SPECIES", 85, 89], ["intestinal epithelial cells", "PROBLEM", 9, 36], ["TGEV", "PROBLEM", 57, 61], ["TGEV infection", "PROBLEM", 85, 99], ["intestinal injury", "PROBLEM", 129, 146], ["diarrhea", "PROBLEM", 148, 156], ["dehydration", "PROBLEM", 158, 169], ["long periods carry of virus", "PROBLEM", 174, 201], ["IntroductIonIntestinal epithelial cells", "TREATMENT", 202, 241], ["the nutrition absorption", "TREATMENT", 268, 292], ["pathogens", "PROBLEM", 321, 330], ["intestinal", "ANATOMY", 9, 19], ["epithelial cells", "OBSERVATION", 20, 36], ["infection", "OBSERVATION", 90, 99], ["intestinal", "ANATOMY", 129, 139], ["injury", "OBSERVATION", 140, 146], ["diarrhea", "OBSERVATION", 148, 156], ["virus", "OBSERVATION", 196, 201], ["epithelial cells", "OBSERVATION", 225, 241]]], ["The absorption and barrier functions are heavily dependent on mitochondrial function [6] [7] [8] .", [["mitochondrial", "ANATOMY", 62, 75], ["mitochondrial", "CELLULAR_COMPONENT", 62, 75], ["The absorption and barrier functions", "TREATMENT", 0, 36], ["heavily dependent", "PROBLEM", 41, 58], ["mitochondrial function", "TEST", 62, 84]]], ["Because mitochondria also play important roles as energy sources, platforms for inflammatory and immune response signaling, and regulators of apoptosis, the mitochondrial mass, function and integrity are strictly regulated in order to respond to varying energy requirements and environmental conditions [9] .", [["mitochondria", "ANATOMY", 8, 20], ["mitochondrial", "ANATOMY", 157, 170], ["mitochondria", "CELLULAR_COMPONENT", 8, 20], ["mitochondrial", "CELLULAR_COMPONENT", 157, 170], ["inflammatory and immune response signaling", "PROBLEM", 80, 122], ["apoptosis", "PROBLEM", 142, 151], ["the mitochondrial mass", "PROBLEM", 153, 175], ["varying energy requirements", "PROBLEM", 246, 273], ["mass", "OBSERVATION", 171, 175]]], ["Dysfunctional or damaged mitochondria trigger a destructive cycle of mitochondrial damage and reactive oxygen species (ROS) generation, which is detrimental to cell survival [10] .", [["mitochondria", "ANATOMY", 25, 37], ["mitochondrial", "ANATOMY", 69, 82], ["cell", "ANATOMY", 160, 164], ["mitochondrial damage", "DISEASE", 69, 89], ["oxygen", "CHEMICAL", 103, 109], ["ROS", "CHEMICAL", 119, 122], ["oxygen", "CHEMICAL", 103, 109], ["mitochondria", "CELLULAR_COMPONENT", 25, 37], ["mitochondrial", "CELLULAR_COMPONENT", 69, 82], ["reactive oxygen species", "SIMPLE_CHEMICAL", 94, 117], ["ROS", "SIMPLE_CHEMICAL", 119, 122], ["cell", "CELL", 160, 164], ["Dysfunctional or damaged mitochondria", "PROBLEM", 0, 37], ["mitochondrial damage", "PROBLEM", 69, 89], ["reactive oxygen species", "PROBLEM", 94, 117], ["destructive", "OBSERVATION_MODIFIER", 48, 59], ["mitochondrial damage", "OBSERVATION", 69, 89], ["reactive", "OBSERVATION_MODIFIER", 94, 102], ["oxygen species", "OBSERVATION", 103, 117]]], ["Therefore, cells maintain a balance between mitochondrial biogenesis [11] and the removal of damaged mitochondria [12] .", [["cells", "ANATOMY", 11, 16], ["mitochondrial", "ANATOMY", 44, 57], ["mitochondria", "ANATOMY", 101, 113], ["cells", "CELL", 11, 16], ["mitochondrial", "CELLULAR_COMPONENT", 44, 57], ["mitochondria", "CELLULAR_COMPONENT", 101, 113], ["mitochondrial biogenesis", "TREATMENT", 44, 68], ["the removal of damaged mitochondria", "TREATMENT", 78, 113]]], ["Evidence suggests that mitophagy may counteract apoptosis [13] [14] [15] .", [["mitophagy", "PROBLEM", 23, 32], ["apoptosis", "TEST", 48, 57]]], ["Several viruses such as Hepatitis B Virus (HBV) [16] and Hepatitis C Virus (HCV) [17] stimulate mitophagy and attenuate apoptosis, presumably to enhance viral replication.", [["Hepatitis B", "DISEASE", 24, 35], ["Hepatitis C", "DISEASE", 57, 68], ["Hepatitis B Virus (HBV) [16]", "ORGANISM", 24, 52], ["Hepatitis C Virus", "ORGANISM", 57, 74], ["HCV", "ORGANISM", 76, 79], ["Hepatitis B Virus", "SPECIES", 24, 41], ["Hepatitis C Virus", "SPECIES", 57, 74], ["Hepatitis B Virus", "SPECIES", 24, 41], ["HBV", "SPECIES", 43, 46], ["Hepatitis C Virus", "SPECIES", 57, 74], ["HCV", "SPECIES", 76, 79], ["Several viruses", "PROBLEM", 0, 15], ["Hepatitis B Virus (HBV)", "TEST", 24, 47], ["Hepatitis C Virus (HCV)", "PROBLEM", 57, 80], ["stimulate mitophagy", "PROBLEM", 86, 105], ["attenuate apoptosis", "PROBLEM", 110, 129], ["viruses", "OBSERVATION", 8, 15], ["Hepatitis", "OBSERVATION", 24, 33], ["apoptosis", "OBSERVATION", 120, 129]]], ["Although TGEV induces apoptosis in some cell lines, but not in intestinal epithelial cells [5] , the potential role played by mitophagy in this system has not yet been explored.", [["cell lines", "ANATOMY", 40, 50], ["intestinal epithelial cells", "ANATOMY", 63, 90], ["TGEV", "ORGANISM", 9, 13], ["cell lines", "CELL", 40, 50], ["intestinal epithelial cells", "CELL", 63, 90], ["cell lines", "CELL_LINE", 40, 50], ["intestinal epithelial cells", "CELL_TYPE", 63, 90], ["TGEV", "SPECIES", 9, 13], ["TGEV", "PROBLEM", 9, 13], ["apoptosis", "PROBLEM", 22, 31], ["some cell lines", "PROBLEM", 35, 50], ["intestinal epithelial cells", "PROBLEM", 63, 90], ["apoptosis", "OBSERVATION_MODIFIER", 22, 31], ["some cell lines", "OBSERVATION", 35, 50], ["intestinal epithelial", "ANATOMY", 63, 84]]], ["Here, we present experiments that examine the effect of TGEV infection on mitochondrial function and mitophagy in the nontransformed porcine intestinal epithelial cell line IPEC-J2.", [["mitochondrial", "ANATOMY", 74, 87], ["intestinal epithelial cell line IPEC-J2", "ANATOMY", 141, 180], ["infection", "DISEASE", 61, 70], ["TGEV", "ORGANISM", 56, 60], ["mitochondrial", "CELLULAR_COMPONENT", 74, 87], ["porcine", "ORGANISM", 133, 140], ["intestinal epithelial cell line IPEC-J2", "CELL", 141, 180], ["nontransformed porcine intestinal epithelial cell line", "CELL_LINE", 118, 172], ["IPEC-J2", "CELL_LINE", 173, 180], ["porcine", "SPECIES", 133, 140], ["TGEV", "SPECIES", 56, 60], ["TGEV infection", "PROBLEM", 56, 70], ["mitochondrial function", "TEST", 74, 96], ["mitophagy", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 61, 70], ["porcine", "ANATOMY_MODIFIER", 133, 140], ["intestinal", "ANATOMY", 141, 151], ["epithelial cell line", "OBSERVATION", 152, 172], ["J2", "ANATOMY", 178, 180]]], ["IPEC-J2 cell is originally isolated from jejunal epithelia of a neonatal unsuckled piglet, models in vivo function of the small intestine more closely than colon tumorigenic cell lines [18] [19] [20] [21] .", [["IPEC-J2 cell", "ANATOMY", 0, 12], ["jejunal epithelia", "ANATOMY", 41, 58], ["piglet", "ANATOMY", 83, 89], ["small intestine", "ANATOMY", 122, 137], ["colon tumorigenic cell lines", "ANATOMY", 156, 184], ["IPEC-J2 cell", "CELL", 0, 12], ["jejunal epithelia", "TISSUE", 41, 58], ["piglet", "ORGAN", 83, 89], ["small intestine", "ORGAN", 122, 137], ["colon tumorigenic cell lines", "CELL", 156, 184], ["IPEC-J2 cell", "CELL_LINE", 0, 12], ["colon tumorigenic cell lines", "CELL_LINE", 156, 184], ["piglet", "SPECIES", 83, 89], ["IPEC", "TEST", 0, 4], ["J2 cell", "PROBLEM", 5, 12], ["a neonatal unsuckled piglet", "TREATMENT", 62, 89], ["the small intestine", "PROBLEM", 118, 137], ["J2 cell", "OBSERVATION", 5, 12], ["jejunal", "ANATOMY", 41, 48], ["epithelia", "ANATOMY_MODIFIER", 49, 58], ["small intestine", "ANATOMY", 122, 137], ["tumorigenic cell lines", "OBSERVATION", 162, 184]]], ["Our data reveal that TGEV infection promotes selective autophagic degradation of damaged mitochondria via mitophagy, which attenuates apoptosis and enhances viral infection.results tGeV infection induces mitochondrial damage, reduction and the formation of mitophagosomelike vesiclesPrevious study suggested that the infection of TGEV induces huge damage of mitochondrial in ST cells [22] , we investigated TGEV-infected IPEC-J2 to learn if they respond similarly.", [["autophagic", "ANATOMY", 55, 65], ["mitochondria", "ANATOMY", 89, 101], ["mitochondrial", "ANATOMY", 204, 217], ["mitophagosomelike vesicles", "ANATOMY", 257, 283], ["mitochondrial", "ANATOMY", 358, 371], ["ST cells", "ANATOMY", 375, 383], ["TGEV infection", "DISEASE", 21, 35], ["viral infection", "DISEASE", 157, 172], ["tGeV", "CHEMICAL", 181, 185], ["infection", "DISEASE", 186, 195], ["mitochondrial damage", "DISEASE", 204, 224], ["infection", "DISEASE", 317, 326], ["TGEV", "DISEASE", 330, 334], ["TGEV", "ORGANISM", 21, 25], ["mitochondria", "CELLULAR_COMPONENT", 89, 101], ["tGeV", "GENE_OR_GENE_PRODUCT", 181, 185], ["mitochondrial", "CELLULAR_COMPONENT", 204, 217], ["mitophagosomelike vesicles", "CELLULAR_COMPONENT", 257, 283], ["TGEV", "ORGANISM", 330, 334], ["mitochondrial", "CELLULAR_COMPONENT", 358, 371], ["ST cells", "CELL", 375, 383], ["TGEV", "ORGANISM", 407, 411], ["IPEC-J2", "CELL", 421, 428], ["ST cells", "CELL_TYPE", 375, 383], ["TGEV", "SPECIES", 21, 25], ["TGEV", "SPECIES", 330, 334], ["TGEV", "SPECIES", 407, 411], ["Our data", "TEST", 0, 8], ["TGEV infection", "PROBLEM", 21, 35], ["damaged mitochondria via mitophagy", "PROBLEM", 81, 115], ["apoptosis", "PROBLEM", 134, 143], ["enhances viral infection", "PROBLEM", 148, 172], ["tGeV infection", "PROBLEM", 181, 195], ["mitochondrial damage", "PROBLEM", 204, 224], ["mitophagosomelike vesicles", "PROBLEM", 257, 283], ["Previous study", "TEST", 283, 297], ["the infection of TGEV", "PROBLEM", 313, 334], ["huge damage of mitochondrial in ST cells", "PROBLEM", 343, 383], ["TGEV", "PROBLEM", 407, 411], ["TGEV", "OBSERVATION_MODIFIER", 21, 25], ["infection", "OBSERVATION", 26, 35], ["selective", "OBSERVATION_MODIFIER", 45, 54], ["autophagic degradation", "OBSERVATION", 55, 77], ["apoptosis", "OBSERVATION_MODIFIER", 134, 143], ["enhances", "OBSERVATION_MODIFIER", 148, 156], ["viral", "OBSERVATION_MODIFIER", 157, 162], ["infection", "OBSERVATION", 163, 172], ["infection", "OBSERVATION", 186, 195], ["mitochondrial damage", "OBSERVATION", 204, 224], ["reduction", "OBSERVATION_MODIFIER", 226, 235], ["mitophagosomelike vesicles", "OBSERVATION", 257, 283], ["infection", "OBSERVATION", 317, 326]]], ["As shown as in Figure 1A and 1B, the level of membrane electric potential (\u0394\u03c8), decrease at 12 hours after TGEV infection, reaches a minimum at 24 hours, despite treated with ciclosporin A (CsA) or not.", [["membrane", "ANATOMY", 46, 54], ["TGEV infection", "DISEASE", 107, 121], ["ciclosporin A", "CHEMICAL", 175, 188], ["CsA", "CHEMICAL", 190, 193], ["ciclosporin A", "CHEMICAL", 175, 188], ["CsA", "CHEMICAL", 190, 193], ["membrane", "CELLULAR_COMPONENT", 46, 54], ["ciclosporin A", "SIMPLE_CHEMICAL", 175, 188], ["CsA", "SIMPLE_CHEMICAL", 190, 193], ["TGEV", "SPECIES", 107, 111], ["TGEV infection", "PROBLEM", 107, 121], ["ciclosporin A (CsA)", "TREATMENT", 175, 194], ["infection", "OBSERVATION", 112, 121]]], ["The decrease of \u0394\u03c8 could be partial suppressed by CsA (a strong stabilizer of \u0394\u03c8) treatment.", [["CsA", "CHEMICAL", 50, 53], ["CsA", "CHEMICAL", 50, 53], ["\u0394\u03c8", "GENE_OR_GENE_PRODUCT", 16, 18], ["CsA", "SIMPLE_CHEMICAL", 50, 53], ["\u0394\u03c8", "PROTEIN", 16, 18], ["The decrease of \u0394\u03c8", "PROBLEM", 0, 18], ["a strong stabilizer of \u0394\u03c8) treatment", "TREATMENT", 55, 91], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["could be", "UNCERTAINTY", 19, 27], ["partial", "OBSERVATION_MODIFIER", 28, 35], ["suppressed", "OBSERVATION_MODIFIER", 36, 46]]], ["The reduction of membrane potential is often associated with cell apoptosis.", [["membrane", "ANATOMY", 17, 25], ["cell", "ANATOMY", 61, 65], ["membrane", "CELLULAR_COMPONENT", 17, 25], ["cell", "CELL", 61, 65], ["cell apoptosis", "PROBLEM", 61, 75], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["membrane potential", "OBSERVATION", 17, 35], ["often associated with", "UNCERTAINTY", 39, 60], ["cell apoptosis", "OBSERVATION", 61, 75]]], ["However, the expected apoptosis does not occur after TGEV infection ( Figure 1C ).", [["infection", "DISEASE", 58, 67], ["TGEV", "ORGANISM", 53, 57], ["TGEV", "SPECIES", 53, 57], ["the expected apoptosis", "PROBLEM", 9, 31], ["TGEV infection", "PROBLEM", 53, 67], ["apoptosis", "OBSERVATION", 22, 31], ["does not occur", "UNCERTAINTY", 32, 46], ["infection", "OBSERVATION", 58, 67]]], ["The total mitochondrial mass is another important factor to contribute \u0394\u03c8.", [["mitochondrial", "ANATOMY", 10, 23], ["mitochondrial", "CELLULAR_COMPONENT", 10, 23], ["The total mitochondrial mass", "PROBLEM", 0, 28], ["total", "OBSERVATION_MODIFIER", 4, 9], ["mitochondrial", "OBSERVATION_MODIFIER", 10, 23], ["mass", "OBSERVATION", 24, 28]]], ["Using MitoTracker Green FM (total mitochondria) and MitoTracker Red CMXRos (functional mitochondria), we found that the tendency of total mitochondrial mass is similar with that of \u0394\u03c8 after TGEV infection ( Figure 1E ) and the ratio of dysfunctional mitochondria does not change significantly ( Figure 1D ).", [["mitochondria", "ANATOMY", 34, 46], ["mitochondria", "ANATOMY", 87, 99], ["mitochondrial", "ANATOMY", 138, 151], ["mitochondria", "ANATOMY", 250, 262], ["infection", "DISEASE", 195, 204], ["MitoTracker", "SIMPLE_CHEMICAL", 6, 17], ["mitochondria", "CELLULAR_COMPONENT", 34, 46], ["MitoTracker Red CMXRos", "GENE_OR_GENE_PRODUCT", 52, 74], ["mitochondria", "CELLULAR_COMPONENT", 87, 99], ["mitochondrial", "CELLULAR_COMPONENT", 138, 151], ["TGEV", "ORGANISM", 190, 194], ["mitochondria", "CELLULAR_COMPONENT", 250, 262], ["MitoTracker Red CMXRos", "PROTEIN", 52, 74], ["TGEV", "SPECIES", 190, 194], ["MitoTracker Green FM (total mitochondria", "TREATMENT", 6, 46], ["MitoTracker Red CMXRos", "TEST", 52, 74], ["total mitochondrial mass", "PROBLEM", 132, 156], ["TGEV infection", "PROBLEM", 190, 204], ["dysfunctional mitochondria", "PROBLEM", 236, 262], ["total", "OBSERVATION_MODIFIER", 132, 137], ["mitochondrial", "OBSERVATION_MODIFIER", 138, 151], ["mass", "OBSERVATION", 152, 156], ["infection", "OBSERVATION", 195, 204]]], ["The decrease of total mitochondrial mass indicated mitochondria degradation, which usually performed by autophagy.results tGeV infection induces mitochondrial damage, reduction and the formation of mitophagosomelike vesiclesTo confirm whether mitochondria were damaged and degraded by autophagy after TGEV infection, the ultrastructure of mock-or TGEV-infected IPEC-J2 cells was observed by transmission electron microscope (TEM).", [["mitochondrial", "ANATOMY", 22, 35], ["mitochondria", "ANATOMY", 51, 63], ["mitochondrial", "ANATOMY", 145, 158], ["mitophagosomelike vesicles", "ANATOMY", 198, 224], ["mitochondria", "ANATOMY", 243, 255], ["IPEC-J2 cells", "ANATOMY", 361, 374], ["tGeV", "CHEMICAL", 122, 126], ["infection", "DISEASE", 127, 136], ["mitochondrial damage", "DISEASE", 145, 165], ["TGEV infection", "DISEASE", 301, 315], ["mitochondrial", "CELLULAR_COMPONENT", 22, 35], ["mitochondria", "CELLULAR_COMPONENT", 51, 63], ["tGeV", "GENE_OR_GENE_PRODUCT", 122, 126], ["mitochondrial", "CELLULAR_COMPONENT", 145, 158], ["mitophagosomelike vesicles", "CELLULAR_COMPONENT", 198, 224], ["mitochondria", "CELLULAR_COMPONENT", 243, 255], ["TGEV", "ORGANISM", 301, 305], ["TGEV", "ORGANISM", 347, 351], ["IPEC-J2 cells", "CELL", 361, 374], ["mock-or TGEV-infected IPEC-J2 cells", "CELL_LINE", 339, 374], ["TGEV", "SPECIES", 301, 305], ["TGEV", "SPECIES", 347, 351], ["total mitochondrial mass", "PROBLEM", 16, 40], ["mitochondria degradation", "PROBLEM", 51, 75], ["tGeV infection", "PROBLEM", 122, 136], ["mitochondrial damage", "PROBLEM", 145, 165], ["mitophagosomelike vesicles", "PROBLEM", 198, 224], ["TGEV infection", "PROBLEM", 301, 315], ["mock", "TEST", 339, 343], ["TGEV", "PROBLEM", 347, 351], ["J2 cells", "PROBLEM", 366, 374], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["total", "OBSERVATION_MODIFIER", 16, 21], ["mitochondrial", "OBSERVATION_MODIFIER", 22, 35], ["mass", "OBSERVATION", 36, 40], ["mitochondria degradation", "OBSERVATION", 51, 75], ["infection", "OBSERVATION", 127, 136], ["mitochondrial damage", "OBSERVATION", 145, 165], ["reduction", "OBSERVATION_MODIFIER", 167, 176], ["mitophagosomelike vesicles", "OBSERVATION", 198, 224], ["J2 cells", "OBSERVATION", 366, 374]]], ["As shown as in Figure 1F , swollen mitochondria and mitochondria lacking cristae were observed after TGEV infection, indicative of injured mitochondria.", [["swollen mitochondria", "ANATOMY", 27, 47], ["mitochondria", "ANATOMY", 52, 64], ["cristae", "ANATOMY", 73, 80], ["mitochondria", "ANATOMY", 139, 151], ["infection", "DISEASE", 106, 115], ["Figure 1F", "GENE_OR_GENE_PRODUCT", 15, 24], ["swollen mitochondria", "CELLULAR_COMPONENT", 27, 47], ["mitochondria", "CELLULAR_COMPONENT", 52, 64], ["cristae", "CELLULAR_COMPONENT", 73, 80], ["mitochondria", "CELLULAR_COMPONENT", 139, 151], ["TGEV", "SPECIES", 101, 105], ["swollen mitochondria", "PROBLEM", 27, 47], ["mitochondria lacking cristae", "PROBLEM", 52, 80], ["TGEV infection", "PROBLEM", 101, 115], ["injured mitochondria", "PROBLEM", 131, 151], ["infection", "OBSERVATION", 106, 115], ["indicative of", "UNCERTAINTY", 117, 130], ["injured mitochondria", "OBSERVATION", 131, 151]]], ["We also observed double membrane vesicles surrounding mitochondria in TGEV-infected IPEC-J2 cells ( Figure 1F ).", [["membrane vesicles", "ANATOMY", 24, 41], ["mitochondria", "ANATOMY", 54, 66], ["IPEC-J2 cells", "ANATOMY", 84, 97], ["membrane vesicles", "CELLULAR_COMPONENT", 24, 41], ["mitochondria", "CELLULAR_COMPONENT", 54, 66], ["TGEV", "ORGANISM", 70, 74], ["IPEC-J2 cells", "CELL", 84, 97], ["Figure 1F", "CELL", 100, 109], ["TGEV-infected IPEC-J2 cells", "CELL_LINE", 70, 97], ["TGEV", "SPECIES", 70, 74], ["double membrane vesicles", "PROBLEM", 17, 41], ["J2 cells", "PROBLEM", 89, 97], ["double membrane vesicles", "OBSERVATION", 17, 41], ["infected", "OBSERVATION_MODIFIER", 75, 83], ["J2 cells", "OBSERVATION", 89, 97]]], ["We suggest that these are autophagosome-like or mitophagosome-like vesicles.", [["autophagosome", "ANATOMY", 26, 39], ["mitophagosome-like vesicles", "ANATOMY", 48, 75], ["autophagosome", "CELLULAR_COMPONENT", 26, 39], ["vesicles", "CELLULAR_COMPONENT", 67, 75], ["mitophagosome-like vesicles", "PROBLEM", 48, 75], ["autophagosome", "OBSERVATION", 26, 39], ["vesicles", "ANATOMY", 67, 75]]], ["The mitophagosomelike vesicles were rarely observed in mock-infected cells ( Figure 1G ).", [["mitophagosomelike vesicles", "ANATOMY", 4, 30], ["cells", "ANATOMY", 69, 74], ["mitophagosomelike vesicles", "CELLULAR_COMPONENT", 4, 30], ["cells", "CELL", 69, 74], ["Figure 1G", "CELL", 77, 86], ["mock-infected cells", "CELL_TYPE", 55, 74], ["The mitophagosomelike vesicles", "PROBLEM", 0, 30], ["infected cells", "OBSERVATION", 60, 74]]], ["The microscopy data are summarized quantitatively in Figure 1F , which shows the numbers of dysfunctional mitochondria observed in mock and infected cells.results tGeV infection induces mitochondrial damage, reduction and the formation of mitophagosomelike vesiclesTogether, these data suggest that TGEV infection induce mitochondrial damage and may induce selected elimination of damaged mitochondria by autophagy.tGeV infection induces the accumulation of autophagosomes and preserves autophagic fluxTo determine if autophagy is triggered by TGEV infection, we examined the levels of the autophagy marker (LC3 conversion) in TGEV-infected cells (Figure 2A and 2B).", [["mitochondria", "ANATOMY", 106, 118], ["cells", "ANATOMY", 149, 154], ["mitochondrial", "ANATOMY", 186, 199], ["mitophagosomelike vesicles", "ANATOMY", 239, 265], ["mitochondrial", "ANATOMY", 321, 334], ["mitochondria", "ANATOMY", 389, 401], ["autophagosomes", "ANATOMY", 458, 472], ["cells", "ANATOMY", 641, 646], ["tGeV", "CHEMICAL", 163, 167], ["infection", "DISEASE", 168, 177], ["mitochondrial damage", "DISEASE", 186, 206], ["TGEV infection", "DISEASE", 299, 313], ["mitochondrial damage", "DISEASE", 321, 341], ["infection", "DISEASE", 420, 429], ["TGEV infection", "DISEASE", 544, 558], ["mitochondria", "CELLULAR_COMPONENT", 106, 118], ["cells", "CELL", 149, 154], ["tGeV", "GENE_OR_GENE_PRODUCT", 163, 167], ["mitochondrial", "CELLULAR_COMPONENT", 186, 199], ["mitophagosomelike vesicles", "CELLULAR_COMPONENT", 239, 265], ["TGEV", "ORGANISM", 299, 303], ["mitochondrial", "CELLULAR_COMPONENT", 321, 334], ["mitochondria", "CELLULAR_COMPONENT", 389, 401], ["autophagosomes", "CELLULAR_COMPONENT", 458, 472], ["TGEV", "ORGANISM", 544, 548], ["LC3", "GENE_OR_GENE_PRODUCT", 608, 611], ["TGEV", "ORGANISM", 627, 631], ["cells", "CELL", 641, 646], ["mock and infected cells", "CELL_TYPE", 131, 154], ["autophagy marker", "PROTEIN", 590, 606], ["LC3", "PROTEIN", 608, 611], ["TGEV-infected cells", "CELL_TYPE", 627, 646], ["TGEV", "SPECIES", 299, 303], ["TGEV", "SPECIES", 544, 548], ["TGEV", "SPECIES", 627, 631], ["The microscopy data", "TEST", 0, 19], ["dysfunctional mitochondria", "PROBLEM", 92, 118], ["infected cells", "PROBLEM", 140, 154], ["tGeV infection", "PROBLEM", 163, 177], ["mitochondrial damage", "PROBLEM", 186, 206], ["mitophagosomelike vesicles", "PROBLEM", 239, 265], ["these data", "TEST", 275, 285], ["TGEV infection", "PROBLEM", 299, 313], ["mitochondrial damage", "PROBLEM", 321, 341], ["damaged mitochondria", "PROBLEM", 381, 401], ["infection", "PROBLEM", 420, 429], ["the accumulation of autophagosomes", "PROBLEM", 438, 472], ["autophagy", "PROBLEM", 518, 527], ["TGEV infection", "PROBLEM", 544, 558], ["LC3 conversion", "TEST", 608, 622], ["TGEV", "PROBLEM", 627, 631], ["infected cells", "PROBLEM", 632, 646], ["dysfunctional mitochondria", "OBSERVATION", 92, 118], ["infected cells", "OBSERVATION", 140, 154], ["infection", "OBSERVATION", 168, 177], ["mitochondrial damage", "OBSERVATION", 186, 206], ["reduction", "OBSERVATION_MODIFIER", 208, 217], ["mitophagosomelike vesicles", "OBSERVATION", 239, 265], ["autophagic flux", "OBSERVATION", 487, 502], ["infected cells", "OBSERVATION", 632, 646]]], ["We also examined the levels of beclin 1(BECN1) expression, an important regulator in autophagy, in TGEVinfected cells (Figure 2A and 2B).", [["TGEVinfected cells", "ANATOMY", 99, 117], ["beclin 1", "GENE_OR_GENE_PRODUCT", 31, 39], ["BECN1", "GENE_OR_GENE_PRODUCT", 40, 45], ["TGEVinfected cells", "CELL", 99, 117], ["beclin 1", "PROTEIN", 31, 39], ["BECN1", "PROTEIN", 40, 45], ["TGEVinfected cells", "CELL_LINE", 99, 117]]], ["TGEV nucleocapsid protein (N) was used to monitor the progression of infection.", [["infection", "DISEASE", 69, 78], ["TGEV", "ORGANISM", 0, 4], ["TGEV nucleocapsid protein", "PROTEIN", 0, 25], ["N", "PROTEIN", 27, 28], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 0, 4], ["TGEV nucleocapsid protein (N)", "TREATMENT", 0, 29], ["infection", "PROBLEM", 69, 78], ["progression", "OBSERVATION_MODIFIER", 54, 65], ["infection", "OBSERVATION", 69, 78]]], ["LC3 (microtubule associated protein 1 light chain 3) is a marker for assessing autophagy and correlates well with the formation of the autophagosome [23] .", [["autophagosome", "ANATOMY", 135, 148], ["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["microtubule associated protein 1 light chain 3", "GENE_OR_GENE_PRODUCT", 5, 51], ["autophagosome", "CELLULAR_COMPONENT", 135, 148], ["LC3", "PROTEIN", 0, 3], ["microtubule associated protein 1 light chain 3", "PROTEIN", 5, 51]]], ["Our results show that LC3-II/LC3-I is more abundant in TGEV-infected IPEC-J2 cells relative to levels in mockinfected cells.", [["IPEC-J2 cells", "ANATOMY", 69, 82], ["cells", "ANATOMY", 118, 123], ["LC3-II", "GENE_OR_GENE_PRODUCT", 22, 28], ["LC3-I", "GENE_OR_GENE_PRODUCT", 29, 34], ["TGEV", "ORGANISM", 55, 59], ["IPEC-J2 cells", "CELL", 69, 82], ["cells", "CELL", 118, 123], ["LC3", "PROTEIN", 22, 25], ["LC3-I", "PROTEIN", 29, 34], ["TGEV-infected IPEC-J2 cells", "CELL_LINE", 55, 82], ["mockinfected cells", "CELL_TYPE", 105, 123], ["TGEV", "SPECIES", 55, 59], ["LC3", "TEST", 22, 25], ["TGEV", "TEST", 55, 59], ["infected IPEC", "PROBLEM", 60, 73], ["J2 cells", "PROBLEM", 74, 82], ["levels in mockinfected cells", "PROBLEM", 95, 123], ["more abundant", "OBSERVATION_MODIFIER", 38, 51], ["infected", "OBSERVATION_MODIFIER", 60, 68], ["J2 cells", "OBSERVATION", 74, 82], ["mockinfected cells", "OBSERVATION", 105, 123]]], ["BECN1, the initial step of the autophagy pathway [24] , is also over-expressed in TGEV infected cells ( Figure 2C and 2D).", [["cells", "ANATOMY", 96, 101], ["BECN1", "GENE_OR_GENE_PRODUCT", 0, 5], ["TGEV", "ORGANISM", 82, 86], ["cells", "CELL", 96, 101], ["BECN1", "PROTEIN", 0, 5], ["TGEV infected cells", "CELL_TYPE", 82, 101], ["TGEV", "SPECIES", 82, 86], ["TGEV infected cells", "PROBLEM", 82, 101], ["infected cells", "OBSERVATION", 87, 101]]], ["Meanwhile, we detected autophagy by Cyto-ID Green Detection Reagent, which is induced at 12 h to 48 h post-infection ( Figure 2E and 2F).tGeV infection induces the accumulation of autophagosomes and preserves autophagic fluxTo determine whether a complete autophagic response is triggered by TGEV infection, we used western blot analysis to measure the degradation of SQSTM1 (p62), a marker for autophagy-mediated protein degradation pathway.", [["autophagosomes", "ANATOMY", 180, 194], ["infection", "DISEASE", 107, 116], ["tGeV", "CHEMICAL", 137, 141], ["infection", "DISEASE", 142, 151], ["TGEV infection", "DISEASE", 292, 306], ["tGeV", "GENE_OR_GENE_PRODUCT", 137, 141], ["autophagosomes", "CELLULAR_COMPONENT", 180, 194], ["TGEV", "ORGANISM", 292, 296], ["SQSTM1 (p62", "GENE_OR_GENE_PRODUCT", 368, 379], ["SQSTM1", "PROTEIN", 368, 374], ["p62", "PROTEIN", 376, 379], ["TGEV", "SPECIES", 292, 296], ["Cyto", "TEST", 36, 40], ["infection", "PROBLEM", 107, 116], ["tGeV infection", "PROBLEM", 137, 151], ["the accumulation of autophagosomes", "PROBLEM", 160, 194], ["preserves autophagic flux", "PROBLEM", 199, 224], ["a complete autophagic response", "PROBLEM", 245, 275], ["TGEV infection", "PROBLEM", 292, 306], ["western blot analysis", "TEST", 316, 337], ["a marker", "TEST", 382, 390], ["autophagy", "TEST", 395, 404], ["infection", "OBSERVATION", 107, 116], ["infection", "OBSERVATION", 142, 151], ["accumulation of autophagosomes", "OBSERVATION", 164, 194], ["autophagic flux", "OBSERVATION", 209, 224], ["autophagic response", "OBSERVATION", 256, 275]]], ["As shown in Figure 2G and 2H, TGEV-infected cells have lower levels of SQSTM1 protein at 12 h to 48 h post-infection, compared with mock-infected cells.", [["cells", "ANATOMY", 44, 49], ["cells", "ANATOMY", 146, 151], ["infection", "DISEASE", 107, 116], ["TGEV", "ORGANISM", 30, 34], ["cells", "CELL", 44, 49], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 71, 77], ["cells", "CELL", 146, 151], ["TGEV-infected cells", "CELL_LINE", 30, 49], ["SQSTM1 protein", "PROTEIN", 71, 85], ["mock-infected cells", "CELL_TYPE", 132, 151], ["TGEV", "SPECIES", 30, 34], ["TGEV", "TEST", 30, 34], ["infected cells", "PROBLEM", 35, 49], ["SQSTM1 protein", "PROBLEM", 71, 85], ["infection", "PROBLEM", 107, 116], ["infected cells", "PROBLEM", 137, 151], ["infection", "OBSERVATION", 107, 116], ["infected cells", "OBSERVATION", 137, 151]]], ["We also examined autophagic flux by using fluorescence microscopy with pLVX-mRFP-EGFP-LC3 lentiviral transfected cells ( Figure S1 ).", [["cells", "ANATOMY", 113, 118], ["LC3", "GENE_OR_GENE_PRODUCT", 86, 89], ["cells", "CELL", 113, 118], ["pLVX-mRFP-EGFP-LC3 lentiviral transfected cells", "CELL_LINE", 71, 118], ["autophagic flux", "TEST", 17, 32], ["fluorescence microscopy", "TEST", 42, 65], ["pLVX", "TEST", 71, 75], ["mRFP-EGFP", "TEST", 76, 85], ["autophagic flux", "OBSERVATION", 17, 32], ["LC3 lentiviral", "OBSERVATION", 86, 100], ["transfected cells", "OBSERVATION", 101, 118]]], ["In TGEV-infected cells, mRFP puncta have accumulated in the cytoplasm at 12 h to 48 h post-infection, whereas EGFP puncta are weak.", [["cells", "ANATOMY", 17, 22], ["mRFP puncta", "ANATOMY", 24, 35], ["cytoplasm", "ANATOMY", 60, 69], ["puncta", "ANATOMY", 115, 121], ["infection", "DISEASE", 91, 100], ["TGEV", "ORGANISM", 3, 7], ["cells", "CELL", 17, 22], ["mRFP", "GENE_OR_GENE_PRODUCT", 24, 28], ["cytoplasm", "ORGANISM_SUBSTANCE", 60, 69], ["EGFP", "GENE_OR_GENE_PRODUCT", 110, 114], ["TGEV-infected cells", "CELL_LINE", 3, 22], ["mRFP puncta", "PROTEIN", 24, 35], ["TGEV", "SPECIES", 3, 7], ["infected cells", "PROBLEM", 8, 22], ["mRFP puncta", "PROBLEM", 24, 35], ["infection", "PROBLEM", 91, 100], ["infected cells", "OBSERVATION", 8, 22], ["cytoplasm", "OBSERVATION_MODIFIER", 60, 69], ["infection", "OBSERVATION", 91, 100], ["weak", "OBSERVATION_MODIFIER", 126, 130]]], ["A similar response is seen in cells treated with rapamycin, indicating that complete autophagic flux is induced by TGEV infection.", [["cells", "ANATOMY", 30, 35], ["rapamycin", "CHEMICAL", 49, 58], ["TGEV infection", "DISEASE", 115, 129], ["rapamycin", "CHEMICAL", 49, 58], ["cells", "CELL", 30, 35], ["rapamycin", "SIMPLE_CHEMICAL", 49, 58], ["TGEV", "ORGANISM", 115, 119], ["TGEV", "SPECIES", 115, 119], ["rapamycin", "TREATMENT", 49, 58], ["complete autophagic flux", "PROBLEM", 76, 100], ["TGEV infection", "PROBLEM", 115, 129], ["autophagic flux", "OBSERVATION", 85, 100], ["TGEV", "OBSERVATION_MODIFIER", 115, 119], ["infection", "OBSERVATION", 120, 129]]], ["It is worth noting that chloroquine (CQ), an inhibiter of lysosomal degradation, could induce incomplete autophagy with or without Rapamycin in IPEC-J2 cells.", [["lysosomal", "ANATOMY", 58, 67], ["IPEC-J2 cells", "ANATOMY", 144, 157], ["chloroquine", "CHEMICAL", 24, 35], ["CQ", "CHEMICAL", 37, 39], ["Rapamycin", "CHEMICAL", 131, 140], ["chloroquine", "CHEMICAL", 24, 35], ["CQ", "CHEMICAL", 37, 39], ["Rapamycin", "CHEMICAL", 131, 140], ["chloroquine", "SIMPLE_CHEMICAL", 24, 35], ["CQ", "SIMPLE_CHEMICAL", 37, 39], ["lysosomal", "CELLULAR_COMPONENT", 58, 67], ["Rapamycin", "SIMPLE_CHEMICAL", 131, 140], ["IPEC-J2 cells", "CELL", 144, 157], ["IPEC-J2 cells", "CELL_LINE", 144, 157], ["chloroquine (CQ", "TREATMENT", 24, 39], ["lysosomal degradation", "TREATMENT", 58, 79], ["incomplete autophagy", "PROBLEM", 94, 114], ["Rapamycin", "TREATMENT", 131, 140], ["J2 cells", "OBSERVATION", 149, 157]]], ["Together, these data show that a complete autophagic response is induced in IPEC-J2 cells following TGEV infection.tGeV infection induces complete mitophagyThe degradation of damaged mitochondrial in autophagosomes is critical for mitophagy and mitochondrial turnover [25] .", [["IPEC-J2 cells", "ANATOMY", 76, 89], ["mitochondrial", "ANATOMY", 183, 196], ["autophagosomes", "ANATOMY", 200, 214], ["mitochondrial", "ANATOMY", 245, 258], ["infection", "DISEASE", 105, 114], ["infection", "DISEASE", 120, 129], ["IPEC-J2 cells", "CELL", 76, 89], ["TGEV", "ORGANISM", 100, 104], ["mitochondrial", "CELLULAR_COMPONENT", 183, 196], ["autophagosomes", "CELLULAR_COMPONENT", 200, 214], ["mitophagy", "CELLULAR_COMPONENT", 231, 240], ["mitochondrial", "CELLULAR_COMPONENT", 245, 258], ["IPEC-J2 cells", "CELL_LINE", 76, 89], ["TGEV", "SPECIES", 100, 104], ["these data", "TEST", 10, 20], ["a complete autophagic response", "PROBLEM", 31, 61], ["J2 cells", "PROBLEM", 81, 89], ["TGEV infection", "PROBLEM", 100, 114], ["infection", "PROBLEM", 120, 129], ["complete mitophagy", "PROBLEM", 138, 156], ["damaged mitochondrial in autophagosomes", "PROBLEM", 175, 214], ["mitophagy", "PROBLEM", 231, 240], ["J2 cells", "OBSERVATION_MODIFIER", 81, 89], ["damaged mitochondrial", "OBSERVATION", 175, 196]]], ["To examine whether TGEV infection could induce mitophagy, we constructed the multi-function lentiviral vector pLVX-EGFP-LC3B-IRES-mito-mCherry and transfected it into IPEC-J2 A. and b.", [["TGEV infection", "DISEASE", 19, 33], ["TGEV", "ORGANISM", 19, 23], ["lentiviral", "ORGANISM", 92, 102], ["LC3B", "GENE_OR_GENE_PRODUCT", 120, 124], ["IPEC-J2 A.", "CELL", 167, 177], ["multi-function lentiviral vector pLVX-EGFP-LC3B-IRES-mito-mCherry", "DNA", 77, 142], ["TGEV", "SPECIES", 19, 23], ["TGEV infection", "PROBLEM", 19, 33], ["mitophagy", "PROBLEM", 47, 56], ["mito-mCherry", "TREATMENT", 130, 142], ["infection", "OBSERVATION", 24, 33]]], ["IPEC-J2 cells were treated with or without CsA, followed by TGEV infection for 0 h, 12 h, 24 h, and 48 h.", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["CsA", "CHEMICAL", 43, 46], ["TGEV infection", "DISEASE", 60, 74], ["CsA", "CHEMICAL", 43, 46], ["IPEC-J2 cells", "CELL", 0, 13], ["CsA", "SIMPLE_CHEMICAL", 43, 46], ["TGEV", "ORGANISM", 60, 64], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["TGEV", "SPECIES", 60, 64], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["CsA", "TREATMENT", 43, 46], ["TGEV infection", "PROBLEM", 60, 74], ["J2 cells", "OBSERVATION", 5, 13], ["infection", "OBSERVATION", 65, 74]]], ["After infection, cells were harvested, stained with Rhodamine 123, and subjected to FACS to examine mitochondrial membrane potential.", [["cells", "ANATOMY", 17, 22], ["mitochondrial membrane", "ANATOMY", 100, 122], ["infection", "DISEASE", 6, 15], ["Rhodamine 123", "CHEMICAL", 52, 65], ["Rhodamine 123", "CHEMICAL", 52, 65], ["cells", "CELL", 17, 22], ["Rhodamine 123", "SIMPLE_CHEMICAL", 52, 65], ["mitochondrial membrane", "CELLULAR_COMPONENT", 100, 122], ["infection", "PROBLEM", 6, 15], ["Rhodamine", "TEST", 52, 61], ["infection", "OBSERVATION", 6, 15]]], ["Histograms representing mitochondrial membrane potential fluorescence intensity are shown in panel A and mean intensities are shown in panel B. c.", [["mitochondrial membrane", "ANATOMY", 24, 46], ["mitochondrial membrane", "CELLULAR_COMPONENT", 24, 46], ["B. c.", "SPECIES", 141, 146], ["Histograms", "TEST", 0, 10], ["mitochondrial membrane potential fluorescence intensity", "PROBLEM", 24, 79], ["mean intensities", "TEST", 105, 121], ["mitochondrial membrane", "OBSERVATION", 24, 46], ["potential fluorescence", "OBSERVATION", 47, 69]]], ["IPEC-J2 cells were infected with TGEV for 0 h, 3 h, 6 h, 12 h, 24 h, 36 h, and 48 h, after which, Annexin V-PI double staining was performed to differentiate cells in early apoptosis (Annexin V+, PI-) from those in late apoptosis (Annexin V+, PI+). d.", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["cells", "ANATOMY", 158, 163], ["Annexin V-PI", "CHEMICAL", 98, 110], ["IPEC-J2 cells", "CELL", 0, 13], ["TGEV", "ORGANISM", 33, 37], ["Annexin V-PI", "GENE_OR_GENE_PRODUCT", 98, 110], ["cells", "CELL", 158, 163], ["Annexin V+", "GENE_OR_GENE_PRODUCT", 184, 194], ["PI", "SIMPLE_CHEMICAL", 196, 198], ["Annexin V", "GENE_OR_GENE_PRODUCT", 231, 240], ["PI+", "SIMPLE_CHEMICAL", 243, 246], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["Annexin V", "PROTEIN", 184, 193], ["TGEV", "SPECIES", 33, 37], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["TGEV", "TEST", 33, 37], ["Annexin V", "TEST", 98, 107], ["PI double staining", "TEST", 108, 126], ["early apoptosis", "PROBLEM", 167, 182], ["Annexin V", "TEST", 184, 193], ["PI", "TEST", 196, 198], ["Annexin V", "TEST", 231, 240], ["PI", "TEST", 243, 245], ["J2 cells", "OBSERVATION_MODIFIER", 5, 13], ["early apoptosis", "OBSERVATION", 167, 182], ["late apoptosis", "OBSERVATION_MODIFIER", 215, 229]]], ["IPEC-J2 cells were infected with TGEV for 0 h, 12 h, 24 h, and 48 h.", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["IPEC-J2 cells", "CELL", 0, 13], ["TGEV", "ORGANISM", 33, 37], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["TGEV", "SPECIES", 33, 37], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["J2 cells", "OBSERVATION", 5, 13]]], ["Cells treated for 12 h with CsA or Rotenone were used as negative and positive controls, respectively.", [["Cells", "ANATOMY", 0, 5], ["CsA", "CHEMICAL", 28, 31], ["Rotenone", "CHEMICAL", 35, 43], ["CsA", "CHEMICAL", 28, 31], ["Rotenone", "CHEMICAL", 35, 43], ["Cells", "CELL", 0, 5], ["CsA", "SIMPLE_CHEMICAL", 28, 31], ["Rotenone", "SIMPLE_CHEMICAL", 35, 43], ["Cells", "TEST", 0, 5], ["CsA", "TREATMENT", 28, 31], ["Rotenone", "TREATMENT", 35, 43]]], ["Abnormal and normal mitochondria were quantitated by FACS using the fluorescent probes Mitotracker Green (stains all mitochondria) and Mitotracker Red (stains functional mitochondria).", [["mitochondria", "ANATOMY", 20, 32], ["mitochondria", "ANATOMY", 117, 129], ["mitochondria", "ANATOMY", 170, 182], ["Mitotracker Red", "CHEMICAL", 135, 150], ["mitochondria", "CELLULAR_COMPONENT", 20, 32], ["Mitotracker Green", "SIMPLE_CHEMICAL", 87, 104], ["mitochondria", "CELLULAR_COMPONENT", 117, 129], ["Mitotracker Red", "GENE_OR_GENE_PRODUCT", 135, 150], ["mitochondria", "CELLULAR_COMPONENT", 170, 182], ["Mitotracker Red", "PROTEIN", 135, 150], ["Abnormal and normal mitochondria", "PROBLEM", 0, 32], ["Mitotracker Red", "TEST", 135, 150], ["normal mitochondria", "OBSERVATION", 13, 32]]], ["The fraction of dysfunctional mitochondria was calculated for three independent experiments as 100% \u00d7 [(green stained mitochondria) -(red stained mitochondria)] / (green stained mitochondria). e. the statistical results of mitotracker Green in Figure 1D .", [["mitochondria", "ANATOMY", 30, 42], ["mitochondria", "ANATOMY", 118, 130], ["mitochondria", "ANATOMY", 146, 158], ["mitochondria", "ANATOMY", 178, 190], ["mitochondria", "CELLULAR_COMPONENT", 30, 42], ["mitochondria", "CELLULAR_COMPONENT", 118, 130], ["mitochondria", "CELLULAR_COMPONENT", 146, 158], ["mitochondria", "CELLULAR_COMPONENT", 178, 190], ["dysfunctional mitochondria", "PROBLEM", 16, 42], ["green stained mitochondria", "TEST", 104, 130], ["red stained mitochondria", "TEST", 134, 158], ["green stained mitochondria", "PROBLEM", 164, 190], ["dysfunctional mitochondria", "OBSERVATION", 16, 42]]], ["Cell proteins SQSTM1 and GAPDH were then analyzed by western blot with anti-SQSTM1 and anti-GAPDH (loading control) antibodies.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 14, 20], ["GAPDH", "GENE_OR_GENE_PRODUCT", 25, 30], ["anti-SQSTM1", "GENE_OR_GENE_PRODUCT", 71, 82], ["anti-GAPDH", "GENE_OR_GENE_PRODUCT", 87, 97], ["Cell proteins", "PROTEIN", 0, 13], ["SQSTM1", "PROTEIN", 14, 20], ["GAPDH", "PROTEIN", 25, 30], ["anti-SQSTM1", "PROTEIN", 71, 82], ["anti-GAPDH (loading control) antibodies", "PROTEIN", 87, 126], ["Cell proteins SQSTM1", "TEST", 0, 20], ["GAPDH", "TEST", 25, 30], ["anti-SQSTM1", "TREATMENT", 71, 82], ["anti-GAPDH (loading control) antibodies", "TREATMENT", 87, 126]]], ["H. Statistical results of SQSTM1.", [["SQSTM1", "PROTEIN", 26, 32]]], ["The data represent the mean \u00b1 SD of three independent experiments.", [["The data", "TEST", 0, 8]]], ["One-way ANOVA; *, P < 0.05; **, P < 0.01. www.impactjournals.com/oncotarget cells.", [["oncotarget cells", "ANATOMY", 65, 81], ["oncotarget cells", "CELL", 65, 81], ["www.impactjournals.com", "CELL_LINE", 42, 64], ["oncotarget cells", "CELL_LINE", 65, 81], ["oncotarget cells", "PROBLEM", 65, 81], ["oncotarget cells", "OBSERVATION", 65, 81]]], ["After TGEV infection, EGFP-LC3B clearly translocates to mitochondria 12 h and 24 h after infection, but co-localization of EGFP-LC3B and mito-mCherry decreases after 48 h ( Figure 3A and 3B).", [["mitochondria", "ANATOMY", 56, 68], ["TGEV infection", "DISEASE", 6, 20], ["infection", "DISEASE", 89, 98], ["TGEV", "ORGANISM", 6, 10], ["EGFP", "GENE_OR_GENE_PRODUCT", 22, 26], ["LC3B", "GENE_OR_GENE_PRODUCT", 27, 31], ["mitochondria", "CELLULAR_COMPONENT", 56, 68], ["EGFP", "GENE_OR_GENE_PRODUCT", 123, 127], ["LC3B", "GENE_OR_GENE_PRODUCT", 128, 132], ["mito-mCherry", "GENE_OR_GENE_PRODUCT", 137, 149], ["EGFP", "PROTEIN", 22, 26], ["LC3B", "PROTEIN", 27, 31], ["EGFP", "PROTEIN", 123, 127], ["LC3B", "PROTEIN", 128, 132], ["mito", "PROTEIN", 137, 141], ["mCherry", "PROTEIN", 142, 149], ["TGEV", "SPECIES", 6, 10], ["TGEV infection", "PROBLEM", 6, 20], ["EGFP", "TEST", 22, 26], ["infection", "PROBLEM", 89, 98], ["EGFP", "TEST", 123, 127], ["LC3B", "TEST", 128, 132], ["infection", "OBSERVATION", 11, 20]]], ["To examine whether mitophagic flux is complete, a sensitive dual fluorescence reporter expressing mRFP-EGFP-mito fused in-frame to a mitochondrial targeting sequence (transmembrane structure of Bcl-xL) was employed to observe the completion of the mitophagic process by delivery of the engulfed mitochondria to lysosomes for degradation.", [["mitochondrial", "ANATOMY", 133, 146], ["transmembrane", "ANATOMY", 167, 180], ["mitochondria", "ANATOMY", 295, 307], ["lysosomes", "ANATOMY", 311, 320], ["mRFP", "GENE_OR_GENE_PRODUCT", 98, 102], ["EGFP", "GENE_OR_GENE_PRODUCT", 103, 107], ["mitochondrial", "CELLULAR_COMPONENT", 133, 146], ["transmembrane", "CELLULAR_COMPONENT", 167, 180], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 194, 200], ["mitochondria", "CELLULAR_COMPONENT", 295, 307], ["lysosomes", "CELLULAR_COMPONENT", 311, 320], ["mRFP-EGFP-mito fused in-frame", "DNA", 98, 127], ["mitochondrial targeting sequence", "DNA", 133, 165], ["Bcl", "PROTEIN", 194, 197], ["xL", "PROTEIN", 198, 200], ["mitophagic flux", "PROBLEM", 19, 34], ["mRFP", "TEST", 98, 102], ["EGFP", "TEST", 103, 107], ["the mitophagic process", "TREATMENT", 244, 266]]], ["As show as in Figure S2 , lots of mitochondria present as puncta, with weak green florescent and bright red florescent, especially at 24 h and 48 h post TGEV infection.", [["mitochondria", "ANATOMY", 34, 46], ["puncta", "ANATOMY", 58, 64], ["TGEV infection", "DISEASE", 153, 167], ["mitochondria", "CELLULAR_COMPONENT", 34, 46], ["puncta", "CELLULAR_COMPONENT", 58, 64], ["TGEV", "ORGANISM", 153, 157], ["TGEV", "SPECIES", 153, 157], ["lots of mitochondria", "PROBLEM", 26, 46], ["puncta", "PROBLEM", 58, 64], ["weak green florescent", "PROBLEM", 71, 92], ["bright red florescent", "PROBLEM", 97, 118], ["TGEV infection", "PROBLEM", 153, 167], ["post TGEV", "OBSERVATION_MODIFIER", 148, 157], ["infection", "OBSERVATION", 158, 167]]], ["Combined with the complete autophagic flux ( Figure 2G , 2H and Figure S1 ), we presumed the mitophagic degradation is not inhibited by TGEV infection.tGeV infection induces complete mitophagySurprisingly, TGEV N protein is observed in mitochondria and mitophagosomes during infection.tGeV infection induces complete mitophagyTo confirm the location of autophagic proteins and N, mitochondrial and cytoplasmic proteins were separated and subjected to western blot analysis.", [["mitochondria", "ANATOMY", 236, 248], ["mitophagosomes", "ANATOMY", 253, 267], ["autophagic", "ANATOMY", 353, 363], ["mitochondrial", "ANATOMY", 380, 393], ["cytoplasmic", "ANATOMY", 398, 409], ["infection", "DISEASE", 141, 150], ["infection", "DISEASE", 156, 165], ["infection", "DISEASE", 275, 284], ["infection", "DISEASE", 290, 299], ["TGEV", "ORGANISM", 136, 140], ["TGEV N protein", "GENE_OR_GENE_PRODUCT", 206, 220], ["mitochondria", "CELLULAR_COMPONENT", 236, 248], ["mitophagosomes", "CELLULAR_COMPONENT", 253, 267], ["mitochondrial", "CELLULAR_COMPONENT", 380, 393], ["cytoplasmic", "ORGANISM_SUBSTANCE", 398, 409], ["TGEV N protein", "PROTEIN", 206, 220], ["autophagic proteins", "PROTEIN", 353, 372], ["N", "PROTEIN", 377, 378], ["mitochondrial and cytoplasmic proteins", "PROTEIN", 380, 418], ["TGEV", "SPECIES", 136, 140], ["TGEV", "SPECIES", 206, 210], ["the complete autophagic flux", "PROBLEM", 14, 42], ["the mitophagic degradation", "PROBLEM", 89, 115], ["TGEV infection", "PROBLEM", 136, 150], ["infection", "PROBLEM", 156, 165], ["complete mitophagy", "PROBLEM", 174, 192], ["mitochondria", "PROBLEM", 236, 248], ["mitophagosomes during infection.tGeV infection", "PROBLEM", 253, 299], ["complete mitophagy", "PROBLEM", 308, 326], ["autophagic proteins", "TEST", 353, 372], ["mitochondrial and cytoplasmic proteins", "PROBLEM", 380, 418], ["blot analysis", "TEST", 459, 472], ["autophagic flux", "OBSERVATION", 27, 42], ["autophagic proteins", "OBSERVATION", 353, 372]]], ["Result displayed that protein N is highly enriched in the mitochondrial fraction ( Figure 3C ).", [["mitochondrial", "ANATOMY", 58, 71], ["mitochondrial", "CELLULAR_COMPONENT", 58, 71], ["protein N", "PROTEIN", 22, 31], ["protein N", "TEST", 22, 31], ["mitochondrial fraction", "OBSERVATION", 58, 80]]], ["In addition, we found that SQSTM1, a mediator of mitophagy [26] is relatively more abundant in mitochondria after TGEV infection ( Figure 3C and 3D).", [["mitochondria", "ANATOMY", 95, 107], ["infection", "DISEASE", 119, 128], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 27, 33], ["mitophagy [26]", "GENE_OR_GENE_PRODUCT", 49, 63], ["mitochondria", "CELLULAR_COMPONENT", 95, 107], ["SQSTM1", "PROTEIN", 27, 33], ["TGEV", "SPECIES", 114, 118], ["SQSTM1", "PROBLEM", 27, 33], ["mitophagy", "PROBLEM", 49, 58], ["TGEV infection", "PROBLEM", 114, 128], ["SQSTM1", "OBSERVATION", 27, 33], ["more abundant", "OBSERVATION_MODIFIER", 78, 91], ["infection", "OBSERVATION", 119, 128]]], ["To examine the location of N on mitochondrial dependent viral infection, we constructed the lentiviral vector pLVX-N-Flag (resistance to puromycin) and transfected to IPEC-J2 cells.", [["mitochondrial", "ANATOMY", 32, 45], ["IPEC-J2 cells", "ANATOMY", 167, 180], ["viral infection", "DISEASE", 56, 71], ["puromycin", "CHEMICAL", 137, 146], ["puromycin", "CHEMICAL", 137, 146], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["lentiviral", "ORGANISM", 92, 102], ["N-Flag", "GENE_OR_GENE_PRODUCT", 115, 121], ["puromycin", "SIMPLE_CHEMICAL", 137, 146], ["IPEC-J2 cells", "CELL", 167, 180], ["pLVX", "PROTEIN", 110, 114], ["N", "PROTEIN", 115, 116], ["Flag", "PROTEIN", 117, 121], ["IPEC-J2 cells", "CELL_LINE", 167, 180], ["mitochondrial dependent viral infection", "PROBLEM", 32, 71], ["Flag (resistance to puromycin", "TREATMENT", 117, 146], ["mitochondrial dependent", "OBSERVATION_MODIFIER", 32, 55], ["viral infection", "OBSERVATION", 56, 71], ["J2 cells", "OBSERVATION", 172, 180]]], ["The co-localization with N-Flag and mitochondria is presented in Figure S3A .", [["mitochondria", "ANATOMY", 36, 48], ["N-Flag", "GENE_OR_GENE_PRODUCT", 25, 31], ["mitochondria", "CELLULAR_COMPONENT", 36, 48], ["N-Flag", "PROTEIN", 25, 31]]], ["Moreover, the morphology of mitochondria in N-Flag cells is different with control cells ( Figure S3A ).", [["mitochondria", "ANATOMY", 28, 40], ["N-Flag cells", "ANATOMY", 44, 56], ["cells", "ANATOMY", 83, 88], ["mitochondria", "CELLULAR_COMPONENT", 28, 40], ["cells", "CELL", 83, 88], ["N-Flag cells", "CELL_LINE", 44, 56], ["control cells", "CELL_TYPE", 75, 88], ["mitochondria in N-Flag cells", "PROBLEM", 28, 56]]], ["In addition, the ROS and mtROS ( Figure S3B and S3C) is also increased, but does not cause obvious apoptosis ( Figure S3D ) by N-Flag protein expression.", [["ROS", "SIMPLE_CHEMICAL", 17, 20], ["mtROS ( Figure S3B", "GENE_OR_GENE_PRODUCT", 25, 43], ["S3C", "GENE_OR_GENE_PRODUCT", 48, 51], ["N-Flag", "GENE_OR_GENE_PRODUCT", 127, 133], ["mtROS", "PROTEIN", 25, 30], ["S3C", "PROTEIN", 48, 51], ["Flag protein", "PROTEIN", 129, 141], ["the ROS", "TEST", 13, 20], ["mtROS", "TEST", 25, 30], ["Figure S3B", "TEST", 33, 43], ["obvious apoptosis", "PROBLEM", 91, 108], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["does not cause", "UNCERTAINTY", 76, 90]]], ["The total mitochondrial mass is also decreased ( Figure S3E ) in N-Flag cells, which indicate mitophagy may be actived.", [["mitochondrial", "ANATOMY", 10, 23], ["N-Flag cells", "ANATOMY", 65, 77], ["mitochondrial", "CELLULAR_COMPONENT", 10, 23], ["N-Flag cells", "CELL_LINE", 65, 77], ["The total mitochondrial mass", "PROBLEM", 0, 28], ["mitophagy", "PROBLEM", 94, 103], ["total", "OBSERVATION_MODIFIER", 4, 9], ["mitochondrial", "OBSERVATION_MODIFIER", 10, 23], ["mass", "OBSERVATION", 24, 28], ["decreased", "OBSERVATION_MODIFIER", 37, 46], ["Flag cells", "OBSERVATION", 67, 77], ["mitophagy", "OBSERVATION", 94, 103], ["may be", "UNCERTAINTY", 104, 110]]], ["To confirm that, we constructed the pLVX-EGFP-LC3B (resistance to blasticidin) lentiviral and transfected to N-Flag cells.", [["N-Flag cells", "ANATOMY", 109, 121], ["blasticidin", "CHEMICAL", 66, 77], ["blasticidin", "CHEMICAL", 66, 77], ["pLVX", "GENE_OR_GENE_PRODUCT", 36, 40], ["EGFP", "GENE_OR_GENE_PRODUCT", 41, 45], ["LC3B", "GENE_OR_GENE_PRODUCT", 46, 50], ["blasticidin", "GENE_OR_GENE_PRODUCT", 66, 77], ["lentiviral", "ORGANISM", 79, 89], ["N-Flag cells", "CELL", 109, 121], ["pLVX", "PROTEIN", 36, 40], ["EGFP", "PROTEIN", 41, 45], ["LC3B", "PROTEIN", 46, 50], ["N-Flag cells", "CELL_LINE", 109, 121], ["the pLVX", "TEST", 32, 40], ["blasticidin) lentiviral", "TREATMENT", 66, 89], ["Flag cells", "OBSERVATION", 111, 121]]], ["As show as in Figure S3G , the co-localization of mitochondria, N-Flag and EGFP-LC3B puncta is presented in N-Flag cells.", [["mitochondria", "ANATOMY", 50, 62], ["N-Flag cells", "ANATOMY", 108, 120], ["mitochondria", "CELLULAR_COMPONENT", 50, 62], ["N-Flag", "GENE_OR_GENE_PRODUCT", 64, 70], ["EGFP", "GENE_OR_GENE_PRODUCT", 75, 79], ["LC3B", "GENE_OR_GENE_PRODUCT", 80, 84], ["N-Flag", "PROTEIN", 64, 70], ["EGFP", "PROTEIN", 75, 79], ["LC3B", "PROTEIN", 80, 84], ["N-Flag cells", "CELL_LINE", 108, 120], ["mitochondria", "TEST", 50, 62], ["EGFP", "TEST", 75, 79], ["LC3B puncta", "TEST", 80, 91], ["LC3B puncta", "OBSERVATION", 80, 91], ["Flag cells", "OBSERVATION", 110, 120]]], ["Together, these data indicate that the nucleocapsid protein of TGEV may contribute to mitochondrial dysfunction and induces mitophagy in IPEC-J2 cells.Mitophagy enhances tGeV infection by mitigating cell apoptosisTo explore the role of autophagy in TGEV infection, IPEC-J2 cells were treated with rapamycin or CCCP, and then infected with TGEV.", [["mitochondrial", "ANATOMY", 86, 99], ["IPEC-J2 cells", "ANATOMY", 137, 150], ["cell", "ANATOMY", 199, 203], ["IPEC-J2 cells", "ANATOMY", 265, 278], ["mitochondrial dysfunction", "DISEASE", 86, 111], ["infection", "DISEASE", 175, 184], ["TGEV infection", "DISEASE", 249, 263], ["rapamycin", "CHEMICAL", 297, 306], ["CCCP", "CHEMICAL", 310, 314], ["rapamycin", "CHEMICAL", 297, 306], ["CCCP", "CHEMICAL", 310, 314], ["TGEV", "ORGANISM", 63, 67], ["mitochondrial", "CELLULAR_COMPONENT", 86, 99], ["IPEC-J2 cells", "CELL", 137, 150], ["tGeV", "GENE_OR_GENE_PRODUCT", 170, 174], ["cell", "CELL", 199, 203], ["TGEV", "ORGANISM", 249, 253], ["IPEC-J2 cells", "CELL", 265, 278], ["rapamycin", "SIMPLE_CHEMICAL", 297, 306], ["CCCP", "SIMPLE_CHEMICAL", 310, 314], ["TGEV", "ORGANISM", 339, 343], ["nucleocapsid protein", "PROTEIN", 39, 59], ["IPEC-J2 cells", "CELL_LINE", 137, 150], ["IPEC-J2 cells", "CELL_LINE", 265, 278], ["TGEV", "SPECIES", 63, 67], ["TGEV", "SPECIES", 249, 253], ["TGEV", "SPECIES", 339, 343], ["these data", "TEST", 10, 20], ["the nucleocapsid protein of TGEV", "PROBLEM", 35, 67], ["mitochondrial dysfunction", "PROBLEM", 86, 111], ["mitophagy in IPEC-J2 cells", "PROBLEM", 124, 150], ["Mitophagy enhances tGeV infection", "PROBLEM", 151, 184], ["mitigating cell apoptosis", "PROBLEM", 188, 213], ["autophagy", "PROBLEM", 236, 245], ["TGEV infection", "PROBLEM", 249, 263], ["IPEC-J2 cells", "TREATMENT", 265, 278], ["rapamycin", "TREATMENT", 297, 306], ["CCCP", "TREATMENT", 310, 314], ["TGEV", "PROBLEM", 339, 343], ["mitochondrial dysfunction", "OBSERVATION", 86, 111], ["J2 cells", "OBSERVATION", 142, 150], ["tGeV", "OBSERVATION_MODIFIER", 170, 174], ["infection", "OBSERVATION", 175, 184], ["mitigating cell apoptosis", "OBSERVATION", 188, 213], ["infection", "OBSERVATION", 254, 263], ["J2 cells", "OBSERVATION_MODIFIER", 270, 278]]], ["The expression of N was monitored as a proxy for viral infection.", [["viral infection", "DISEASE", 49, 64], ["viral infection", "PROBLEM", 49, 64], ["infection", "OBSERVATION", 55, 64]]], ["An increase in N expression was found in both rapamycin-and CCCPtreated cells at 48 h post-infection ( Figures 4A and 4B ).Mitophagy enhances tGeV infection by mitigating cell apoptosisIn the same experiment, cells were also exposed to 3-MA, which inhibits autophagy by blocking the formation of autophagosomes [27, 28] .", [["CCCPtreated cells", "ANATOMY", 60, 77], ["cell", "ANATOMY", 171, 175], ["cells", "ANATOMY", 209, 214], ["autophagosomes", "ANATOMY", 296, 310], ["rapamycin", "CHEMICAL", 46, 55], ["infection", "DISEASE", 91, 100], ["infection", "DISEASE", 147, 156], ["3-MA", "CHEMICAL", 236, 240], ["rapamycin", "CHEMICAL", 46, 55], ["3-MA", "CHEMICAL", 236, 240], ["rapamycin", "SIMPLE_CHEMICAL", 46, 55], ["CCCPtreated cells", "CELL", 60, 77], ["Mitophagy", "GENE_OR_GENE_PRODUCT", 123, 132], ["tGeV", "GENE_OR_GENE_PRODUCT", 142, 146], ["cell", "CELL", 171, 175], ["cells", "CELL", 209, 214], ["3-MA", "SIMPLE_CHEMICAL", 236, 240], ["autophagosomes", "CELLULAR_COMPONENT", 296, 310], ["CCCPtreated cells", "CELL_LINE", 60, 77], ["An increase in N expression", "PROBLEM", 0, 27], ["both rapamycin", "TREATMENT", 41, 55], ["CCCPtreated cells", "PROBLEM", 60, 77], ["infection", "PROBLEM", 91, 100], ["Mitophagy enhances tGeV infection", "PROBLEM", 123, 156], ["mitigating cell apoptosisIn", "PROBLEM", 160, 187], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["N expression", "OBSERVATION", 15, 27], ["rapamycin", "ANATOMY", 46, 55], ["infection", "OBSERVATION", 91, 100], ["tGeV", "OBSERVATION_MODIFIER", 142, 146], ["infection", "OBSERVATION", 147, 156], ["mitigating cell apoptosisIn", "OBSERVATION", 160, 187]]], ["3-MA treatment reduced the expression of LC3-II and N at 48 h post-infection ( Figure 4A and 4B) and decreased virus titer both at 24 h and 48 h post-infection ( Figure 4C ).Mitophagy enhances tGeV infection by mitigating cell apoptosisOur results using pharmacological regulators support that autophagy may increase TGEV infection.", [["cell", "ANATOMY", 222, 226], ["3-MA", "CHEMICAL", 0, 4], ["infection", "DISEASE", 67, 76], ["infection", "DISEASE", 198, 207], ["TGEV infection", "DISEASE", 317, 331], ["3-MA", "CHEMICAL", 0, 4], ["3-MA", "SIMPLE_CHEMICAL", 0, 4], ["LC3-II", "GENE_OR_GENE_PRODUCT", 41, 47], ["tGeV", "GENE_OR_GENE_PRODUCT", 193, 197], ["cell", "CELL", 222, 226], ["TGEV", "ORGANISM", 317, 321], ["LC3", "PROTEIN", 41, 44], ["TGEV", "SPECIES", 317, 321], ["MA treatment", "TREATMENT", 2, 14], ["infection", "PROBLEM", 67, 76], ["Figure 4A", "TEST", 79, 88], ["decreased virus titer", "PROBLEM", 101, 122], ["Mitophagy enhances tGeV infection", "PROBLEM", 174, 207], ["pharmacological regulators support", "TREATMENT", 254, 288], ["autophagy", "PROBLEM", 294, 303], ["TGEV infection", "PROBLEM", 317, 331], ["infection", "OBSERVATION", 67, 76], ["tGeV", "OBSERVATION_MODIFIER", 193, 197], ["infection", "OBSERVATION", 198, 207], ["TGEV", "OBSERVATION_MODIFIER", 317, 321], ["infection", "OBSERVATION", 322, 331]]], ["To examine the relationship between autophagy and virus infection further, shRNA knockdown experiments were performed to specifically deplete endogenous ATG5 protein.", [["infection", "DISEASE", 56, 65], ["ATG5", "GENE_OR_GENE_PRODUCT", 153, 157], ["ATG5 protein", "PROTEIN", 153, 165], ["autophagy", "PROBLEM", 36, 45], ["virus infection", "PROBLEM", 50, 65], ["shRNA knockdown experiments", "TEST", 75, 102]]], ["As shown in Figure 4D and 4E, IPEC-J2 cells transfected with shATG5 exhibit significantly decreased levels of endogenous ATG5 protein compared with cells transfected with control (scrambled) shRNA.", [["IPEC-J2 cells", "ANATOMY", 30, 43], ["cells", "ANATOMY", 148, 153], ["IPEC-J2 cells", "CELL", 30, 43], ["shATG5", "GENE_OR_GENE_PRODUCT", 61, 67], ["ATG5", "GENE_OR_GENE_PRODUCT", 121, 125], ["cells", "CELL", 148, 153], ["IPEC-J2 cells", "CELL_LINE", 30, 43], ["shATG5", "PROTEIN", 61, 67], ["ATG5 protein", "PROTEIN", 121, 133], ["IPEC", "TEST", 30, 34], ["J2 cells", "PROBLEM", 35, 43], ["significantly decreased levels of endogenous ATG5 protein", "PROBLEM", 76, 133], ["control (scrambled) shRNA", "PROBLEM", 171, 196], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["decreased", "OBSERVATION", 90, 99], ["endogenous ATG5", "OBSERVATION", 110, 125]]], ["Importantly, suppression of ATG5 expression reduced the expression of N and the viral progeny yield in TGEV infected IPEC-J2 cells compared with the control shRNA transfection ( Figure 4F ).Mitophagy enhances tGeV infection by mitigating cell apoptosisApoptosis is suppressed by mitophagy by a wide variety of viruses during infection [16, [29] [30] [31] [32] [33] .", [["IPEC-J2 cells", "ANATOMY", 117, 130], ["cell", "ANATOMY", 238, 242], ["infection", "DISEASE", 214, 223], ["infection", "DISEASE", 325, 334], ["ATG5", "GENE_OR_GENE_PRODUCT", 28, 32], ["TGEV", "ORGANISM", 103, 107], ["IPEC-J2 cells", "CELL", 117, 130], ["tGeV", "GENE_OR_GENE_PRODUCT", 209, 213], ["cell", "CELL", 238, 242], ["[29] [30] [31] [32", "SIMPLE_CHEMICAL", 340, 358], ["ATG5", "PROTEIN", 28, 32], ["TGEV infected IPEC-J2 cells", "CELL_LINE", 103, 130], ["TGEV", "SPECIES", 103, 107], ["ATG5 expression", "PROBLEM", 28, 43], ["N", "PROBLEM", 70, 71], ["the viral progeny yield", "PROBLEM", 76, 99], ["TGEV infected IPEC", "PROBLEM", 103, 121], ["J2 cells", "PROBLEM", 122, 130], ["the control shRNA transfection", "TREATMENT", 145, 175], ["Mitophagy enhances tGeV infection", "PROBLEM", 190, 223], ["mitigating cell apoptosisApoptosis", "PROBLEM", 227, 261], ["mitophagy", "PROBLEM", 279, 288], ["a wide variety of viruses during infection", "PROBLEM", 292, 334], ["J2 cells", "OBSERVATION", 122, 130], ["tGeV", "OBSERVATION_MODIFIER", 209, 213], ["infection", "OBSERVATION", 214, 223], ["mitigating cell apoptosisApoptosis", "OBSERVATION", 227, 261]]], ["To determine whether mitophagy attenuates apoptosis during TGEV infection, IPEC-J2 cells were simultaneously stained with Propidium Iodide (PI) and Annexin V at 0 h, 24 h, and 48 h post-infection, and analyzed by flow cytometry.", [["IPEC-J2 cells", "ANATOMY", 75, 88], ["TGEV infection", "DISEASE", 59, 73], ["Propidium Iodide", "CHEMICAL", 122, 138], ["Propidium Iodide", "CHEMICAL", 122, 138], ["TGEV", "ORGANISM", 59, 63], ["IPEC-J2 cells", "CELL", 75, 88], ["Propidium Iodide", "SIMPLE_CHEMICAL", 122, 138], ["PI", "SIMPLE_CHEMICAL", 140, 142], ["Annexin V", "GENE_OR_GENE_PRODUCT", 148, 157], ["IPEC-J2 cells", "CELL_LINE", 75, 88], ["TGEV", "SPECIES", 59, 63], ["mitophagy attenuates apoptosis", "PROBLEM", 21, 51], ["TGEV infection", "PROBLEM", 59, 73], ["IPEC", "TEST", 75, 79], ["J2 cells", "PROBLEM", 80, 88], ["Propidium Iodide (PI", "TREATMENT", 122, 142], ["Annexin V", "TREATMENT", 148, 157], ["infection", "PROBLEM", 186, 195], ["flow cytometry", "TEST", 213, 227], ["infection", "OBSERVATION", 186, 195]]], ["The apoptosis of IPEC-J2 cells treated with CCCP was similar to that observed in untreated cells.", [["IPEC-J2 cells", "ANATOMY", 17, 30], ["cells", "ANATOMY", 91, 96], ["CCCP", "CHEMICAL", 44, 48], ["CCCP", "CHEMICAL", 44, 48], ["IPEC-J2 cells", "CELL", 17, 30], ["CCCP", "SIMPLE_CHEMICAL", 44, 48], ["cells", "CELL", 91, 96], ["IPEC-J2 cells", "CELL_LINE", 17, 30], ["untreated cells", "CELL_TYPE", 81, 96], ["IPEC-J2 cells", "TREATMENT", 17, 30], ["CCCP", "TREATMENT", 44, 48], ["J2 cells", "OBSERVATION_MODIFIER", 22, 30], ["untreated cells", "OBSERVATION", 81, 96]]], ["In contrast, 3-MA treatment ( Figure 4G ) and ATG5 knockdown ( Figure 4H ) both increased apoptosis in infected cells.", [["cells", "ANATOMY", 112, 117], ["3-MA", "CHEMICAL", 13, 17], ["3-MA", "CHEMICAL", 13, 17], ["3-MA", "SIMPLE_CHEMICAL", 13, 17], ["ATG5", "GENE_OR_GENE_PRODUCT", 46, 50], ["cells", "CELL", 112, 117], ["ATG5", "PROTEIN", 46, 50], ["infected cells", "CELL_TYPE", 103, 117], ["MA treatment ( Figure 4G", "TREATMENT", 15, 39], ["ATG5 knockdown", "TEST", 46, 60], ["both increased apoptosis in infected cells", "PROBLEM", 75, 117], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["apoptosis", "OBSERVATION_MODIFIER", 90, 99], ["infected cells", "OBSERVATION", 103, 117]]], ["However, the moderate increase of apoptosis by inhibition of autophagy, drug or knockdown, indicate autophagy play multiple roles in promotion TGEV infection.", [["TGEV infection", "DISEASE", 143, 157], ["TGEV", "ORGANISM", 143, 147], ["TGEV", "SPECIES", 143, 147], ["the moderate increase of apoptosis", "PROBLEM", 9, 43], ["autophagy", "PROBLEM", 61, 70], ["autophagy", "PROBLEM", 100, 109], ["TGEV infection", "PROBLEM", 143, 157], ["moderate", "OBSERVATION_MODIFIER", 13, 21], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["apoptosis", "OBSERVATION", 34, 43], ["TGEV", "OBSERVATION_MODIFIER", 143, 147], ["infection", "OBSERVATION", 148, 157]]], ["Finally, TGEV infection increased early apoptosis and inhibited late apoptosis when IPEC-J2 cells were pre-treated with Rotenone ( Figure 4G ), a drug that stimulates apoptosis by increasing mitochondrial ROS.", [["IPEC-J2 cells", "ANATOMY", 84, 97], ["mitochondrial", "ANATOMY", 191, 204], ["infection", "DISEASE", 14, 23], ["Rotenone", "CHEMICAL", 120, 128], ["ROS", "CHEMICAL", 205, 208], ["Rotenone", "CHEMICAL", 120, 128], ["TGEV", "ORGANISM", 9, 13], ["IPEC-J2 cells", "CELL", 84, 97], ["Rotenone", "SIMPLE_CHEMICAL", 120, 128], ["mitochondrial", "CELLULAR_COMPONENT", 191, 204], ["ROS", "SIMPLE_CHEMICAL", 205, 208], ["IPEC-J2 cells", "CELL_LINE", 84, 97], ["TGEV", "SPECIES", 9, 13], ["TGEV infection", "PROBLEM", 9, 23], ["early apoptosis", "PROBLEM", 34, 49], ["late apoptosis", "PROBLEM", 64, 78], ["IPEC", "TEST", 84, 88], ["J2 cells", "PROBLEM", 89, 97], ["Rotenone ( Figure 4G", "TREATMENT", 120, 140], ["increasing mitochondrial ROS", "PROBLEM", 180, 208], ["TGEV", "OBSERVATION_MODIFIER", 9, 13], ["infection", "OBSERVATION_MODIFIER", 14, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["early apoptosis", "OBSERVATION_MODIFIER", 34, 49], ["late apoptosis", "OBSERVATION_MODIFIER", 64, 78], ["J2 cells", "OBSERVATION_MODIFIER", 89, 97], ["increasing", "OBSERVATION_MODIFIER", 180, 190], ["mitochondrial ROS", "OBSERVATION", 191, 208]]], ["Together, these experiments demonstrate that mitophagy promote the infection of TGEV partly by attenuating cell apoptosis.Mitophagy attenuates cell apoptosis by eliminating rosSince the damaged of mitochondria may release ROS to induce mitophagy or apoptosis, we measured ROS levels using Dichlorofluorescein Diacetate (DCFH-DA) staining and FACS ( Figure 5A ).", [["cell", "ANATOMY", 107, 111], ["cell", "ANATOMY", 143, 147], ["mitochondria", "ANATOMY", 197, 209], ["infection", "DISEASE", 67, 76], ["ROS", "CHEMICAL", 222, 225], ["ROS", "CHEMICAL", 272, 275], ["Dichlorofluorescein Diacetate", "CHEMICAL", 289, 318], ["DCFH-DA", "CHEMICAL", 320, 327], ["Dichlorofluorescein Diacetate", "CHEMICAL", 289, 318], ["DCFH-DA", "CHEMICAL", 320, 327], ["TGEV", "ORGANISM", 80, 84], ["cell", "CELL", 107, 111], ["cell", "CELL", 143, 147], ["rosSince", "SIMPLE_CHEMICAL", 173, 181], ["mitochondria", "CELLULAR_COMPONENT", 197, 209], ["ROS", "SIMPLE_CHEMICAL", 222, 225], ["ROS", "SIMPLE_CHEMICAL", 272, 275], ["Dichlorofluorescein Diacetate", "SIMPLE_CHEMICAL", 289, 318], ["DCFH-DA", "SIMPLE_CHEMICAL", 320, 327], ["TGEV", "SPECIES", 80, 84], ["mitophagy", "PROBLEM", 45, 54], ["the infection of TGEV", "PROBLEM", 63, 84], ["attenuating cell apoptosis", "PROBLEM", 95, 121], ["Mitophagy attenuates cell apoptosis", "PROBLEM", 122, 157], ["mitophagy", "PROBLEM", 236, 245], ["apoptosis", "PROBLEM", 249, 258], ["ROS levels", "TEST", 272, 282], ["Dichlorofluorescein Diacetate", "TREATMENT", 289, 318], ["infection", "OBSERVATION", 67, 76], ["attenuating cell apoptosis", "OBSERVATION", 95, 121], ["attenuates cell apoptosis", "OBSERVATION", 132, 157]]], ["Our data show that ROS levels is fluctuated without abnormally high level.", [["ROS", "CHEMICAL", 19, 22], ["ROS", "SIMPLE_CHEMICAL", 19, 22], ["Our data", "TEST", 0, 8], ["ROS levels", "TEST", 19, 29], ["abnormally high level", "PROBLEM", 52, 73], ["abnormally", "OBSERVATION_MODIFIER", 52, 62], ["high", "OBSERVATION_MODIFIER", 63, 67]]], ["We also examined mitochondrial ROS (mtROS) production during TGEV infection by measuring the fluorescence of DHE.", [["mitochondrial", "ANATOMY", 17, 30], ["ROS", "CHEMICAL", 31, 34], ["TGEV infection", "DISEASE", 61, 75], ["DHE", "CHEMICAL", 109, 112], ["DHE", "CHEMICAL", 109, 112], ["mitochondrial", "CELLULAR_COMPONENT", 17, 30], ["ROS", "SIMPLE_CHEMICAL", 31, 34], ["mtROS", "SIMPLE_CHEMICAL", 36, 41], ["TGEV", "ORGANISM", 61, 65], ["DHE", "SIMPLE_CHEMICAL", 109, 112], ["TGEV", "SPECIES", 61, 65], ["mitochondrial ROS", "PROBLEM", 17, 34], ["TGEV infection", "PROBLEM", 61, 75], ["infection", "OBSERVATION", 66, 75]]], ["Between 0.5 h to 12h after infection, mtROS production decreased, but was restored and increased after 24 h ( Figure 5B ).", [["infection", "DISEASE", 27, 36], ["mtROS", "GENE_OR_GENE_PRODUCT", 38, 43], ["mtROS", "PROTEIN", 38, 43], ["infection", "PROBLEM", 27, 36], ["infection", "OBSERVATION", 27, 36], ["decreased", "OBSERVATION_MODIFIER", 55, 64], ["increased", "OBSERVATION_MODIFIER", 87, 96]]], ["To further examine oxidative stress status, we measured mRNA levels for three proteins known to be involved in modulating ROS levels: As shown as in www.impactjournals.com/oncotarget and analyzed for indirect immunofluorescence using an anti-TGEV N protein antibody, followed by the corresponding secondary antibodies conjugated to Alexa Flour 647, as described in Materials and Methods.", [["ROS", "CHEMICAL", 122, 125], ["ROS", "SIMPLE_CHEMICAL", 122, 125], ["Alexa Flour 647", "SIMPLE_CHEMICAL", 332, 347], ["anti-TGEV N protein antibody", "PROTEIN", 237, 265], ["secondary antibodies", "PROTEIN", 297, 317], ["Alexa Flour 647", "PROTEIN", 332, 347], ["Alexa Flour 647", "SPECIES", 332, 347], ["mRNA levels", "TEST", 56, 67], ["three proteins", "PROBLEM", 72, 86], ["impactjournals", "TREATMENT", 153, 167], ["indirect immunofluorescence", "TEST", 200, 227], ["an anti-TGEV N protein antibody", "TEST", 234, 265], ["Alexa Flour", "TEST", 332, 343]]], ["Cell nuclei were counterstained with DAPI and fluorescence signals were visualized by confocal immunofluorescence microscopy.", [["Cell nuclei", "ANATOMY", 0, 11], ["DAPI", "CHEMICAL", 37, 41], ["Cell nuclei", "CELL", 0, 11], ["DAPI", "SIMPLE_CHEMICAL", 37, 41], ["DAPI and fluorescence signals", "TEST", 37, 66], ["confocal immunofluorescence microscopy", "TEST", 86, 124]]], ["In the images, the colors correspond to nuclei (white), N (blue), EGFP-LC3 (green), and mito-mCherry (red).", [["nuclei", "ANATOMY", 40, 46], ["nuclei", "CELLULAR_COMPONENT", 40, 46], ["EGFP-LC3", "GENE_OR_GENE_PRODUCT", 66, 74], ["mito-mCherry", "GENE_OR_GENE_PRODUCT", 88, 100], ["EGFP", "PROTEIN", 66, 70], ["LC3", "PROTEIN", 71, 74], ["mito-mCherry", "PROTEIN", 88, 100], ["nuclei (white), N (blue)", "PROBLEM", 40, 64], ["EGFP", "TEST", 66, 70], ["nuclei", "ANATOMY", 40, 46]]], ["Co-localized signals for N, EGFP-LC3 and mitochondria are white in the cytoplasm of the merged images.", [["mitochondria", "ANATOMY", 41, 53], ["cytoplasm", "ANATOMY", 71, 80], ["EGFP", "GENE_OR_GENE_PRODUCT", 28, 32], ["LC3", "GENE_OR_GENE_PRODUCT", 33, 36], ["mitochondria", "CELLULAR_COMPONENT", 41, 53], ["cytoplasm", "ORGANISM_SUBSTANCE", 71, 80], ["EGFP", "PROTEIN", 28, 32], ["LC3", "PROTEIN", 33, 36], ["Co-localized signals", "TEST", 0, 20], ["N, EGFP-LC3", "TEST", 25, 36]]], ["Higher magnification images represent the regions enclosed in white squares.", [["Higher magnification images", "TEST", 0, 27], ["regions", "ANATOMY_MODIFIER", 42, 49]]], ["The co-location of EGFP and mCherry punctra was counted and showed in b. c.", [["EGFP", "GENE_OR_GENE_PRODUCT", 19, 23], ["mCherry", "GENE_OR_GENE_PRODUCT", 28, 35], ["EGFP", "DNA", 19, 23], ["mCherry punctra", "PROTEIN", 28, 43], ["b. c.", "SPECIES", 70, 75], ["mCherry punctra", "TEST", 28, 43], ["EGFP", "OBSERVATION", 19, 23]]], ["IPEC-J2 cells were pre-treated with or without CCCP, followed by mock or TGEV infection for 24 h.", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["CCCP", "CHEMICAL", 47, 51], ["TGEV infection", "DISEASE", 73, 87], ["CCCP", "CHEMICAL", 47, 51], ["IPEC-J2 cells", "CELL", 0, 13], ["CCCP", "SIMPLE_CHEMICAL", 47, 51], ["TGEV", "ORGANISM", 73, 77], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["TGEV", "SPECIES", 73, 77], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["CCCP", "TREATMENT", 47, 51], ["TGEV infection", "PROBLEM", 73, 87], ["J2 cells", "OBSERVATION", 5, 13]]], ["SQSTM1, N and HSP60 were then detected by western blot in mitochondrial or cytoplasmic cell fractions. mtHSP60 and GAPDH were used as loading controls for mitochondrial and cytoplasmic fractions, respectively. d.", [["mitochondrial", "ANATOMY", 58, 71], ["cytoplasmic cell fractions", "ANATOMY", 75, 101], ["mitochondrial", "ANATOMY", 155, 168], ["cytoplasmic fractions", "ANATOMY", 173, 194], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 0, 6], ["HSP60", "GENE_OR_GENE_PRODUCT", 14, 19], ["mitochondrial", "CELLULAR_COMPONENT", 58, 71], ["cytoplasmic", "ORGANISM_SUBSTANCE", 75, 86], ["cell", "CELLULAR_COMPONENT", 87, 91], ["mtHSP60", "GENE_OR_GENE_PRODUCT", 103, 110], ["GAPDH", "GENE_OR_GENE_PRODUCT", 115, 120], ["mitochondrial", "CELLULAR_COMPONENT", 155, 168], ["cytoplasmic", "ORGANISM_SUBSTANCE", 173, 184], ["SQSTM1", "PROTEIN", 0, 6], ["N", "PROTEIN", 8, 9], ["HSP60", "PROTEIN", 14, 19], ["mtHSP60", "PROTEIN", 103, 110], ["GAPDH", "PROTEIN", 115, 120], ["SQSTM1", "TEST", 0, 6], ["HSP60", "TEST", 14, 19], ["cytoplasmic cell fractions", "TEST", 75, 101], ["GAPDH", "TEST", 115, 120], ["mitochondrial and cytoplasmic fractions", "PROBLEM", 155, 194], ["cytoplasmic cell fractions", "OBSERVATION", 75, 101], ["cytoplasmic fractions", "OBSERVATION", 173, 194]]], ["Quantitative results for SQSTM1 in mitochondria fraction, the data represent the mean \u00b1 SD of three independent experiments.", [["mitochondria", "ANATOMY", 35, 47], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 25, 31], ["mitochondria", "CELLULAR_COMPONENT", 35, 47], ["SQSTM1", "PROTEIN", 25, 31], ["SQSTM1 in mitochondria fraction", "TEST", 25, 56], ["the data", "TEST", 58, 66]]], ["Figure 5C -5E, the expression of SCD and eNOS begins to increase 12 h after TGEV infection, and reaches the highest level at 48 h (P < 0.01).", [["SCD", "DISEASE", 33, 36], ["infection", "DISEASE", 81, 90], ["eNOS", "GENE_OR_GENE_PRODUCT", 41, 45], ["TGEV", "ORGANISM", 76, 80], ["SCD", "PROTEIN", 33, 36], ["eNOS", "PROTEIN", 41, 45], ["TGEV", "SPECIES", 76, 80], ["SCD", "PROBLEM", 33, 36], ["TGEV infection", "PROBLEM", 76, 90], ["SCD", "ANATOMY", 33, 36], ["infection", "OBSERVATION", 81, 90]]], ["The expression of Nrf2 decreases at 3 h and 6 h after TGEV infection and then increases from 12 h to 72 h, with a maximum at 24 h (P < 0.01).", [["infection", "DISEASE", 59, 68], ["Nrf2", "GENE_OR_GENE_PRODUCT", 18, 22], ["TGEV", "ORGANISM", 54, 58], ["Nrf2", "PROTEIN", 18, 22], ["TGEV", "SPECIES", 54, 58], ["Nrf2 decreases", "PROBLEM", 18, 32], ["TGEV infection", "PROBLEM", 54, 68], ["Nrf2", "OBSERVATION_MODIFIER", 18, 22], ["decreases", "OBSERVATION_MODIFIER", 23, 32], ["infection", "OBSERVATION", 59, 68]]], ["Since oxidative stress plays important roles in mitophagy [34, 35] , we then explored the relationship between oxidative stress and mitophagy during TGEV infection.", [["TGEV infection", "DISEASE", 149, 163], ["TGEV", "ORGANISM", 149, 153], ["TGEV", "SPECIES", 149, 153], ["oxidative stress", "PROBLEM", 111, 127], ["mitophagy", "PROBLEM", 132, 141], ["TGEV infection", "PROBLEM", 149, 163]]], ["As shown as in Figure 6A and 6B lift and middle panel, the expression of LC3-I, LC3-II decreased and N expression increased at 6 h, 12 h, and 24 h after TGEV infection in GSH-treated cells ( Figure 6A and 6B right panel).", [["cells", "ANATOMY", 183, 188], ["infection", "DISEASE", 158, 167], ["GSH", "CHEMICAL", 171, 174], ["GSH", "CHEMICAL", 171, 174], ["LC3-I", "GENE_OR_GENE_PRODUCT", 73, 78], ["LC3-II", "GENE_OR_GENE_PRODUCT", 80, 86], ["TGEV", "ORGANISM", 153, 157], ["GSH", "SIMPLE_CHEMICAL", 171, 174], ["cells", "CELL", 183, 188], ["LC3", "PROTEIN", 73, 76], ["LC3-II", "PROTEIN", 80, 86], ["GSH-treated cells", "CELL_LINE", 171, 188], ["TGEV", "SPECIES", 153, 157], ["middle panel", "TEST", 41, 53], ["LC3", "TEST", 73, 76], ["LC3", "TEST", 80, 83], ["TGEV infection", "PROBLEM", 153, 167], ["GSH", "TEST", 171, 174], ["Figure 6A", "TEST", 191, 200], ["6B right panel", "TEST", 205, 219], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["expression", "OBSERVATION_MODIFIER", 103, 113], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["infection", "OBSERVATION", 158, 167]]], ["To exclude the possibility of decreased mitochondrial injury by GSH, mitochondrial membrane potential and mitochondrial mass were monitored.", [["mitochondrial", "ANATOMY", 40, 53], ["mitochondrial membrane", "ANATOMY", 69, 91], ["mitochondrial", "ANATOMY", 106, 119], ["mitochondrial injury", "DISEASE", 40, 60], ["GSH", "CHEMICAL", 64, 67], ["GSH", "CHEMICAL", 64, 67], ["mitochondrial", "CELLULAR_COMPONENT", 40, 53], ["GSH", "SIMPLE_CHEMICAL", 64, 67], ["mitochondrial membrane", "CELLULAR_COMPONENT", 69, 91], ["mitochondrial", "CELLULAR_COMPONENT", 106, 119], ["decreased mitochondrial injury", "PROBLEM", 30, 60], ["mitochondrial membrane potential", "PROBLEM", 69, 101], ["mitochondrial mass", "PROBLEM", 106, 124], ["exclude the possibility of", "UNCERTAINTY", 3, 29], ["decreased", "OBSERVATION_MODIFIER", 30, 39], ["mitochondrial injury", "OBSERVATION", 40, 60], ["mitochondrial mass", "OBSERVATION", 106, 124]]], ["Results ( Figure 7A and 7B) show that, in GSH-treated cells, the mitochondrial membrane potential also decreases after TGEV infection, but the total mitochondrial mass increases after TGEV infection, indicating the quality of mitochondria decreased and mitophagic degradation inhibited.Mitophagy attenuates cell apoptosis by eliminating rosAntioxidant treatment generally efficiently suppress apoptosis [36] .", [["cells", "ANATOMY", 54, 59], ["mitochondrial membrane", "ANATOMY", 65, 87], ["mitochondrial", "ANATOMY", 149, 162], ["mitochondria", "ANATOMY", 226, 238], ["mitophagic", "ANATOMY", 253, 263], ["cell", "ANATOMY", 307, 311], ["GSH", "CHEMICAL", 42, 45], ["infection", "DISEASE", 124, 133], ["infection", "DISEASE", 189, 198], ["rosAntioxidant", "CHEMICAL", 337, 351], ["GSH", "CHEMICAL", 42, 45], ["GSH", "SIMPLE_CHEMICAL", 42, 45], ["cells", "CELL", 54, 59], ["mitochondrial membrane", "CELLULAR_COMPONENT", 65, 87], ["TGEV", "ORGANISM", 119, 123], ["mitochondrial", "CELLULAR_COMPONENT", 149, 162], ["TGEV", "ORGANISM", 184, 188], ["mitochondria", "CELLULAR_COMPONENT", 226, 238], ["cell", "CELL", 307, 311], ["rosAntioxidant", "SIMPLE_CHEMICAL", 337, 351], ["GSH-treated cells", "CELL_LINE", 42, 59], ["TGEV", "SPECIES", 119, 123], ["TGEV", "SPECIES", 184, 188], ["Figure 7A and 7B)", "TEST", 10, 27], ["GSH-treated cells", "TREATMENT", 42, 59], ["the mitochondrial membrane potential", "PROBLEM", 61, 97], ["TGEV infection", "PROBLEM", 119, 133], ["the total mitochondrial mass", "PROBLEM", 139, 167], ["TGEV infection", "PROBLEM", 184, 198], ["mitophagic degradation", "PROBLEM", 253, 275], ["Mitophagy attenuates cell apoptosis", "PROBLEM", 286, 321], ["rosAntioxidant treatment", "TREATMENT", 337, 361], ["mitochondrial membrane", "OBSERVATION", 65, 87], ["decreases", "OBSERVATION_MODIFIER", 103, 112], ["TGEV", "OBSERVATION_MODIFIER", 119, 123], ["infection", "OBSERVATION", 124, 133], ["mass", "OBSERVATION", 163, 167], ["TGEV", "OBSERVATION_MODIFIER", 184, 188], ["infection", "OBSERVATION", 189, 198], ["decreased", "OBSERVATION_MODIFIER", 239, 248], ["attenuates cell apoptosis", "OBSERVATION", 296, 321]]], ["However, as shown in Figure 7C and 7E, the apoptosis ratio has a weak increase after TGEV infection in GSH pre-treated cells.", [["cells", "ANATOMY", 119, 124], ["infection", "DISEASE", 90, 99], ["GSH", "CHEMICAL", 103, 106], ["GSH", "CHEMICAL", 103, 106], ["TGEV", "ORGANISM", 85, 89], ["GSH", "SIMPLE_CHEMICAL", 103, 106], ["cells", "CELL", 119, 124], ["GSH pre-treated cells", "CELL_LINE", 103, 124], ["TGEV", "SPECIES", 85, 89], ["the apoptosis ratio", "TEST", 39, 58], ["a weak increase", "PROBLEM", 63, 78], ["TGEV infection in GSH pre-treated cells", "PROBLEM", 85, 124], ["weak", "OBSERVATION_MODIFIER", 65, 69], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["TGEV", "OBSERVATION_MODIFIER", 85, 89], ["infection", "OBSERVATION", 90, 99], ["GSH pre-treated cells", "OBSERVATION", 103, 124]]], ["According to the pro-apoptotic effect of ROS eliminated by GSH, the weak increase of apoptosis may be induced by other pro-apoptotic substance released by the abnormal mitochondria.", [["mitochondria", "ANATOMY", 168, 180], ["ROS", "CHEMICAL", 41, 44], ["GSH", "CHEMICAL", 59, 62], ["GSH", "CHEMICAL", 59, 62], ["ROS", "SIMPLE_CHEMICAL", 41, 44], ["GSH", "SIMPLE_CHEMICAL", 59, 62], ["mitochondria", "CELLULAR_COMPONENT", 168, 180], ["the weak increase of apoptosis", "PROBLEM", 64, 94], ["the abnormal mitochondria", "PROBLEM", 155, 180], ["weak", "OBSERVATION_MODIFIER", 68, 72], ["increase", "OBSERVATION_MODIFIER", 73, 81], ["apoptosis", "OBSERVATION", 85, 94], ["may be", "UNCERTAINTY", 95, 101]]], ["These results indicated that oxidative stress is an important factor in the mitophagy induced by TGEV infection.dJ-1 play an important role in tGeV-induced mitophagy and viral infectionDJ-1, a multifunctional redox-sensitive protein, is associated with the oxidative stress cell death cascade [37] [38] [39] [40] .", [["cell", "ANATOMY", 274, 278], ["TGEV infection", "DISEASE", 97, 111], ["tGeV", "CHEMICAL", 143, 147], ["death", "DISEASE", 279, 284], ["TGEV", "ORGANISM", 97, 101], ["dJ-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["tGeV", "GENE_OR_GENE_PRODUCT", 143, 147], ["infectionDJ-1", "GENE_OR_GENE_PRODUCT", 176, 189], ["cell", "CELL", 274, 278], ["dJ-1", "PROTEIN", 112, 116], ["tGeV", "PROTEIN", 143, 147], ["viral infectionDJ-1", "PROTEIN", 170, 189], ["multifunctional redox-sensitive protein", "PROTEIN", 193, 232], ["TGEV", "SPECIES", 97, 101], ["oxidative stress", "PROBLEM", 29, 45], ["the mitophagy", "PROBLEM", 72, 85], ["TGEV infection", "PROBLEM", 97, 111], ["mitophagy", "PROBLEM", 156, 165], ["viral infectionDJ", "PROBLEM", 170, 187], ["a multifunctional redox", "TEST", 191, 214], ["the oxidative stress cell death cascade", "PROBLEM", 253, 292], ["TGEV", "OBSERVATION_MODIFIER", 97, 101], ["infection", "OBSERVATION", 102, 111]]], ["The loss of DJ-1 contributes to mitochondrial injury and apoptosis in many mammalian cells [40] [41] [42] .", [["mitochondrial", "ANATOMY", 32, 45], ["cells", "ANATOMY", 85, 90], ["mitochondrial injury", "DISEASE", 32, 52], ["DJ-1", "GENE_OR_GENE_PRODUCT", 12, 16], ["mitochondrial", "CELLULAR_COMPONENT", 32, 45], ["mammalian cells", "CELL", 75, 90], ["DJ-1", "PROTEIN", 12, 16], ["mammalian cells", "CELL_TYPE", 75, 90], ["The loss of DJ", "PROBLEM", 0, 14], ["mitochondrial injury", "PROBLEM", 32, 52], ["apoptosis in many mammalian cells", "PROBLEM", 57, 90], ["mitochondrial injury", "OBSERVATION", 32, 52]]], ["We found that the expression of DJ-1 increased significantly 24 h and 48 h post TGEV infection ( Figure 8A and 8B) .dJ-1 play an important role in tGeV-induced mitophagy and viral infectionTo determine whether DJ-1 mediates mitophagy during TGEV infection, we decreased DJ-1 gene expression in IPEC-J2 cells by using a lentiviral vector, pLVX-shRNA-DJ1.", [["IPEC-J2 cells", "ANATOMY", 294, 307], ["infection", "DISEASE", 85, 94], ["tGeV", "CHEMICAL", 147, 151], ["TGEV infection", "DISEASE", 241, 255], ["DJ-1", "GENE_OR_GENE_PRODUCT", 32, 36], ["TGEV", "ORGANISM", 80, 84], [".dJ-1", "GENE_OR_GENE_PRODUCT", 115, 120], ["tGeV", "GENE_OR_GENE_PRODUCT", 147, 151], ["DJ-1", "GENE_OR_GENE_PRODUCT", 210, 214], ["TGEV", "ORGANISM", 241, 245], ["DJ-1", "GENE_OR_GENE_PRODUCT", 270, 274], ["IPEC-J2 cells", "CELL", 294, 307], ["lentiviral", "ORGANISM", 319, 329], ["pLVX", "GENE_OR_GENE_PRODUCT", 338, 342], ["DJ-1", "PROTEIN", 32, 36], ["DJ-1", "PROTEIN", 210, 214], ["DJ-1 gene", "DNA", 270, 279], ["IPEC-J2 cells", "CELL_LINE", 294, 307], ["pLVX-shRNA-DJ1", "DNA", 338, 352], ["TGEV", "SPECIES", 80, 84], ["TGEV", "SPECIES", 241, 245], ["DJ", "TEST", 32, 34], ["TGEV infection", "PROBLEM", 80, 94], ["Figure 8A", "TEST", 97, 106], ["tGeV", "PROBLEM", 147, 151], ["mitophagy", "PROBLEM", 160, 169], ["viral infectionTo", "PROBLEM", 174, 191], ["DJ", "TEST", 210, 212], ["mitophagy", "PROBLEM", 224, 233], ["TGEV infection", "PROBLEM", 241, 255], ["decreased DJ", "PROBLEM", 260, 272], ["a lentiviral vector", "TREATMENT", 317, 336], ["infection", "OBSERVATION", 85, 94], ["infection", "OBSERVATION", 246, 255], ["shRNA", "ANATOMY", 343, 348]]], ["As shown in Figure 8C and 8E, DJ-1 knockdown decreases the expression of LC3-II significantly.", [["DJ-1", "GENE_OR_GENE_PRODUCT", 30, 34], ["LC3-II", "GENE_OR_GENE_PRODUCT", 73, 79], ["LC3-II", "PROTEIN", 73, 79], ["DJ", "TEST", 30, 32]]], ["Importantly, suppression of DJ-1 expression strongly reduces the expression of viral protein N and the viral progeny yield in TGEV infected IPEC-J2 cells compared with controls ( Figure 8D and 8F).", [["IPEC-J2 cells", "ANATOMY", 140, 153], ["DJ-1", "GENE_OR_GENE_PRODUCT", 28, 32], ["viral protein N", "GENE_OR_GENE_PRODUCT", 79, 94], ["TGEV", "ORGANISM", 126, 130], ["IPEC-J2 cells", "CELL", 140, 153], ["DJ-1", "PROTEIN", 28, 32], ["viral protein N", "PROTEIN", 79, 94], ["TGEV infected IPEC-J2 cells", "CELL_LINE", 126, 153], ["TGEV", "SPECIES", 126, 130], ["viral protein N", "PROBLEM", 79, 94], ["the viral progeny yield", "PROBLEM", 99, 122], ["TGEV infected IPEC", "PROBLEM", 126, 144], ["J2 cells", "PROBLEM", 145, 153], ["viral protein", "OBSERVATION", 79, 92], ["J2 cells", "OBSERVATION_MODIFIER", 145, 153]]], ["In contrast, the ROS level in DJ-1 knockdown cells is extremely high during TGEV infection compared with controls ( Figure 8G ).", [["DJ-1 knockdown cells", "ANATOMY", 30, 50], ["ROS", "CHEMICAL", 17, 20], ["infection", "DISEASE", 81, 90], ["ROS", "SIMPLE_CHEMICAL", 17, 20], ["DJ-1", "GENE_OR_GENE_PRODUCT", 30, 34], ["cells", "CELL", 45, 50], ["TGEV", "ORGANISM", 76, 80], ["DJ-1 knockdown cells", "CELL_LINE", 30, 50], ["TGEV", "SPECIES", 76, 80], ["the ROS level", "TEST", 13, 26], ["DJ", "TEST", 30, 32], ["1 knockdown cells", "PROBLEM", 33, 50], ["TGEV infection", "PROBLEM", 76, 90], ["DJ", "ANATOMY", 30, 32], ["knockdown cells", "OBSERVATION", 35, 50], ["high", "OBSERVATION_MODIFIER", 64, 68], ["infection", "OBSERVATION", 81, 90]]], ["Additionally, GSH treatment partially relieves oxidative stress in DJ-1 knockdown cells, but fails to do so in control cells ( Figure 8G ).", [["DJ-1 knockdown cells", "ANATOMY", 67, 87], ["cells", "ANATOMY", 119, 124], ["GSH", "CHEMICAL", 14, 17], ["GSH", "CHEMICAL", 14, 17], ["GSH", "SIMPLE_CHEMICAL", 14, 17], ["DJ-1", "GENE_OR_GENE_PRODUCT", 67, 71], ["cells", "CELL", 82, 87], ["cells", "CELL", 119, 124], ["DJ-1 knockdown cells", "CELL_LINE", 67, 87], ["control cells", "CELL_TYPE", 111, 124], ["GSH treatment", "TREATMENT", 14, 27], ["oxidative stress in DJ", "PROBLEM", 47, 69], ["1 knockdown cells", "PROBLEM", 70, 87]]], ["The dysfunctional mitochondrial ratio in DJ-1 knockdown cells is nearly double than observed in control cells before TGEV infection, and triples 24 h after TGEV infection ( Figure 8H ).", [["mitochondrial", "ANATOMY", 18, 31], ["DJ-1 knockdown cells", "ANATOMY", 41, 61], ["cells", "ANATOMY", 104, 109], ["infection", "DISEASE", 122, 131], ["TGEV infection", "DISEASE", 156, 170], ["mitochondrial", "CELLULAR_COMPONENT", 18, 31], ["DJ-1", "GENE_OR_GENE_PRODUCT", 41, 45], ["cells", "CELL", 56, 61], ["cells", "CELL", 104, 109], ["TGEV", "ORGANISM", 117, 121], ["TGEV", "ORGANISM", 156, 160], ["DJ-1 knockdown cells", "CELL_LINE", 41, 61], ["control cells", "CELL_TYPE", 96, 109], ["TGEV", "SPECIES", 117, 121], ["TGEV", "SPECIES", 156, 160], ["The dysfunctional mitochondrial ratio", "TEST", 0, 37], ["knockdown cells", "PROBLEM", 46, 61], ["TGEV infection", "PROBLEM", 117, 131], ["TGEV infection", "PROBLEM", 156, 170], ["dysfunctional", "OBSERVATION_MODIFIER", 4, 17], ["mitochondrial ratio", "OBSERVATION", 18, 37], ["infection", "OBSERVATION", 122, 131], ["infection", "OBSERVATION", 161, 170]]], ["Finally, apoptosis is detected in pLVX-shRNA-DJ-1 transduction cells after TGEV infection.", [["cells", "ANATOMY", 63, 68], ["TGEV infection", "DISEASE", 75, 89], ["pLVX", "GENE_OR_GENE_PRODUCT", 34, 38], ["DJ-1", "GENE_OR_GENE_PRODUCT", 45, 49], ["cells", "CELL", 63, 68], ["TGEV", "ORGANISM", 75, 79], ["pLVX-shRNA-DJ-1 transduction cells", "CELL_LINE", 34, 68], ["TGEV", "SPECIES", 75, 79], ["apoptosis", "TEST", 9, 18], ["pLVX", "TEST", 34, 38], ["DJ-1 transduction cells", "TREATMENT", 45, 68], ["TGEV infection", "PROBLEM", 75, 89], ["infection", "OBSERVATION", 80, 89]]], ["The apoptosis increased significantly in DJ-1 knockdown cells compared with controls at 12 h, 24 h, and 48 h after TGEV infection ( Figure 8I ).", [["cells", "ANATOMY", 56, 61], ["TGEV infection", "DISEASE", 115, 129], ["DJ-1", "GENE_OR_GENE_PRODUCT", 41, 45], ["cells", "CELL", 56, 61], ["TGEV", "ORGANISM", 115, 119], ["DJ-1 knockdown cells", "CELL_LINE", 41, 61], ["TGEV", "SPECIES", 115, 119], ["The apoptosis", "PROBLEM", 0, 13], ["DJ-1 knockdown cells", "TREATMENT", 41, 61], ["TGEV infection", "PROBLEM", 115, 129], ["apoptosis", "OBSERVATION_MODIFIER", 4, 13], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["significantly", "OBSERVATION_MODIFIER", 24, 37], ["infection", "OBSERVATION", 120, 129]]], ["These results suggest that DJ-1 play an important role in suppression oxidative stress and induction mitophagy during TGEV infection.dIscussIonOur study demonstrates for the first time that TGEV provokes mitophagy in intestinal epithelial cells.", [["intestinal epithelial cells", "ANATOMY", 217, 244], ["DJ-1", "GENE_OR_GENE_PRODUCT", 27, 31], ["TGEV", "ORGANISM", 118, 122], ["TGEV", "ORGANISM", 190, 194], ["intestinal epithelial cells", "CELL", 217, 244], ["DJ-1", "PROTEIN", 27, 31], ["intestinal epithelial cells", "CELL_TYPE", 217, 244], ["TGEV", "SPECIES", 118, 122], ["TGEV", "SPECIES", 190, 194], ["suppression oxidative stress", "TREATMENT", 58, 86], ["induction mitophagy", "TREATMENT", 91, 110], ["IonOur study", "TEST", 140, 152], ["TGEV", "PROBLEM", 190, 194], ["mitophagy in intestinal epithelial cells", "PROBLEM", 204, 244], ["intestinal epithelial cells", "OBSERVATION", 217, 244]]], ["Using in vitro experiments, we have shown that TGEV infection induces DJ-1-mediated mitophagy to counteract oxidative stress and confers protection against apoptotic cell death in virus-infected intestinal epithelia cells.", [["cell", "ANATOMY", 166, 170], ["intestinal epithelia cells", "ANATOMY", 195, 221], ["infection", "DISEASE", 52, 61], ["TGEV", "ORGANISM", 47, 51], ["DJ-1", "GENE_OR_GENE_PRODUCT", 70, 74], ["cell", "CELL", 166, 170], ["intestinal epithelia cells", "CELL", 195, 221], ["DJ-1", "PROTEIN", 70, 74], ["virus-infected intestinal epithelia cells", "CELL_TYPE", 180, 221], ["TGEV", "SPECIES", 47, 51], ["TGEV infection", "PROBLEM", 47, 61], ["DJ", "TEST", 70, 72], ["oxidative stress", "PROBLEM", 108, 124], ["confers protection", "TREATMENT", 129, 147], ["apoptotic cell death", "PROBLEM", 156, 176], ["virus", "PROBLEM", 180, 185], ["infected intestinal epithelia cells", "PROBLEM", 186, 221], ["infection", "OBSERVATION", 52, 61], ["apoptotic cell death", "OBSERVATION", 156, 176], ["infected", "OBSERVATION_MODIFIER", 186, 194], ["intestinal epithelia cells", "OBSERVATION", 195, 221]]], ["This is also likely to facilitate persistent virus infection, and may be one reason why the virus is carried for long periods in recovered pigs.dIscussIonRecent evidence suggests that autophagic digestion of mitochondria is a selective process [43, 44] .", [["autophagic", "ANATOMY", 184, 194], ["mitochondria", "ANATOMY", 208, 220], ["infection", "DISEASE", 51, 60], ["pigs", "ORGANISM", 139, 143], ["mitochondria", "CELLULAR_COMPONENT", 208, 220], ["pigs", "SPECIES", 139, 143], ["persistent virus infection", "PROBLEM", 34, 60], ["the virus", "PROBLEM", 88, 97], ["autophagic digestion of mitochondria", "PROBLEM", 184, 220], ["also likely to", "UNCERTAINTY", 8, 22], ["persistent", "OBSERVATION_MODIFIER", 34, 44], ["virus", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60], ["virus", "OBSERVATION", 92, 97], ["autophagic digestion", "OBSERVATION", 184, 204]]], ["Despite of the powerful function in energy generation, mitochondria could release a lot of pro-apoptotic factors, such as ROS and cytochrome c, after injury [45] .", [["mitochondria", "ANATOMY", 55, 67], ["mitochondria", "CELLULAR_COMPONENT", 55, 67], ["ROS", "SIMPLE_CHEMICAL", 122, 125], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 130, 142], ["pro-apoptotic factors", "PROTEIN", 91, 112], ["cytochrome c", "PROTEIN", 130, 142], ["pro-apoptotic factors", "PROBLEM", 91, 112], ["injury", "PROBLEM", 150, 156]]], ["Thus, the moderate and timely mitophagy promotes cell survival and homeostatic by regulating of energy generation and by clearing dysfunctional mitochondria that signal for apoptosis.", [["cell", "ANATOMY", 49, 53], ["mitochondria", "ANATOMY", 144, 156], ["cell", "CELL", 49, 53], ["mitochondria", "CELLULAR_COMPONENT", 144, 156], ["clearing dysfunctional mitochondria", "PROBLEM", 121, 156], ["apoptosis", "PROBLEM", 173, 182], ["moderate", "OBSERVATION_MODIFIER", 10, 18], ["mitophagy promotes cell survival", "OBSERVATION", 30, 62]]], ["In addition, mitophagy is essential for mitochondrial turnover [46] to avoid ATP exhausting, which will consequently leading to necrosis [47] .", [["mitochondrial", "ANATOMY", 40, 53], ["ATP", "CHEMICAL", 77, 80], ["necrosis", "DISEASE", 128, 136], ["ATP", "CHEMICAL", 77, 80], ["mitochondrial", "CELLULAR_COMPONENT", 40, 53], ["ATP", "SIMPLE_CHEMICAL", 77, 80], ["mitochondrial turnover", "PROBLEM", 40, 62], ["ATP exhausting", "PROBLEM", 77, 91], ["necrosis", "PROBLEM", 128, 136], ["necrosis", "OBSERVATION", 128, 136]]], ["In our study, the decrease in mitochondrial mass and increase in SQSTM1 in the mitochondrial cell fraction further supports the emergence of mitophagy after TGEV infection.", [["mitochondrial", "ANATOMY", 30, 43], ["mitochondrial cell", "ANATOMY", 79, 97], ["TGEV infection", "DISEASE", 157, 171], ["mitochondrial", "CELLULAR_COMPONENT", 30, 43], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 65, 71], ["mitochondrial cell", "CELL", 79, 97], ["TGEV", "ORGANISM", 157, 161], ["SQSTM1", "PROTEIN", 65, 71], ["TGEV", "SPECIES", 157, 161], ["our study", "TEST", 3, 12], ["the decrease in mitochondrial mass", "PROBLEM", 14, 48], ["increase in SQSTM1", "PROBLEM", 53, 71], ["the mitochondrial cell fraction", "PROBLEM", 75, 106], ["mitophagy", "PROBLEM", 141, 150], ["TGEV infection", "PROBLEM", 157, 171], ["decrease", "OBSERVATION_MODIFIER", 18, 26], ["mitochondrial", "ANATOMY", 30, 43], ["mass", "OBSERVATION", 44, 48], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["SQSTM1", "OBSERVATION", 65, 71], ["mitochondrial cell fraction", "OBSERVATION", 79, 106], ["infection", "OBSERVATION", 162, 171]]], ["The number of mitochondria within cells is regulated by the balance between mitochondrial biogenesis [48] and the removal of damaged mitochondria.", [["mitochondria", "ANATOMY", 14, 26], ["cells", "ANATOMY", 34, 39], ["mitochondrial", "ANATOMY", 76, 89], ["mitochondria", "ANATOMY", 133, 145], ["mitochondria", "CELLULAR_COMPONENT", 14, 26], ["cells", "CELL", 34, 39], ["mitochondrial", "CELLULAR_COMPONENT", 76, 89], ["mitochondria", "CELLULAR_COMPONENT", 133, 145], ["mitochondrial biogenesis", "TEST", 76, 100], ["the removal", "TREATMENT", 110, 121], ["damaged mitochondria", "PROBLEM", 125, 145], ["mitochondria within cells", "OBSERVATION", 14, 39], ["damaged mitochondria", "OBSERVATION", 125, 145]]], ["Damaged mitochondria, as well as other impaired organelles and proteins in cells are degraded by specific autophagy-lysosome pathway [11] .", [["mitochondria", "ANATOMY", 8, 20], ["organelles", "ANATOMY", 48, 58], ["cells", "ANATOMY", 75, 80], ["mitochondria", "CELLULAR_COMPONENT", 8, 20], ["organelles", "CELLULAR_COMPONENT", 48, 58], ["cells", "CELL", 75, 80], ["lysosome", "CELLULAR_COMPONENT", 116, 124], ["Damaged mitochondria", "PROBLEM", 0, 20], ["other impaired organelles and proteins in cells", "PROBLEM", 33, 80], ["mitochondria", "OBSERVATION", 8, 20]]], ["Using the dual fluorescence reporter lentivirial pLVX-mRFP-EGFP-Bcl-xL, we demonstrated that TGEV induces complete mitophagy evident by fusion of mitophagosome with lysosome.", [["mitophagosome", "ANATOMY", 146, 159], ["lysosome", "ANATOMY", 165, 173], ["mRFP", "GENE_OR_GENE_PRODUCT", 54, 58], ["EGFP", "GENE_OR_GENE_PRODUCT", 59, 63], ["Bcl", "GENE_OR_GENE_PRODUCT", 64, 67], ["TGEV", "ORGANISM", 93, 97], ["mitophagosome", "GENE_OR_GENE_PRODUCT", 146, 159], ["lysosome", "CELLULAR_COMPONENT", 165, 173], ["pLVX", "PROTEIN", 49, 53], ["mRFP", "PROTEIN", 54, 58], ["EGFP", "PROTEIN", 59, 63], ["Bcl-xL", "PROTEIN", 64, 70], ["mitophagosome", "PROTEIN", 146, 159], ["TGEV", "SPECIES", 93, 97], ["the dual fluorescence reporter", "TEST", 6, 36], ["mRFP", "TEST", 54, 58], ["TGEV", "PROBLEM", 93, 97], ["complete mitophagy", "PROBLEM", 106, 124], ["lysosome", "TREATMENT", 165, 173]]], ["Furthermore, CCCP treatment induces mitophagy by decreasing mitochondrial membrane potential [49] , causing mitochondrial fragments to appear in the cytoplasmic fraction ( Figure 3C ).", [["mitochondrial membrane", "ANATOMY", 60, 82], ["mitochondrial fragments", "ANATOMY", 108, 131], ["cytoplasmic", "ANATOMY", 149, 160], ["CCCP", "CHEMICAL", 13, 17], ["CCCP", "CHEMICAL", 13, 17], ["CCCP", "SIMPLE_CHEMICAL", 13, 17], ["mitochondrial membrane", "CELLULAR_COMPONENT", 60, 82], ["mitochondrial", "CELLULAR_COMPONENT", 108, 121], ["cytoplasmic", "ORGANISM_SUBSTANCE", 149, 160], ["CCCP treatment", "TREATMENT", 13, 27], ["mitophagy", "PROBLEM", 36, 45], ["decreasing mitochondrial membrane potential", "PROBLEM", 49, 92], ["mitochondrial fragments", "PROBLEM", 108, 131], ["decreasing", "OBSERVATION_MODIFIER", 49, 59], ["mitochondrial membrane", "OBSERVATION", 60, 82], ["mitochondrial fragments", "OBSERVATION", 108, 131]]], ["In contrast, TGEV infection decreased mitochondrial but we found the fluorescent intensity of EGFP was recovered after immunofluorescence (data not show).", [["mitochondrial", "ANATOMY", 38, 51], ["infection", "DISEASE", 18, 27], ["TGEV", "ORGANISM", 13, 17], ["mitochondrial", "CELLULAR_COMPONENT", 38, 51], ["EGFP", "GENE_OR_GENE_PRODUCT", 94, 98], ["EGFP", "PROTEIN", 94, 98], ["TGEV", "SPECIES", 13, 17], ["TGEV infection", "PROBLEM", 13, 27], ["the fluorescent intensity of EGFP", "PROBLEM", 65, 98], ["immunofluorescence", "TEST", 119, 137], ["TGEV", "OBSERVATION_MODIFIER", 13, 17], ["infection", "OBSERVATION", 18, 27]]], ["Therefore, the model of mRFP-EGFP fused with Bclxl transmembrane structure is only suitable for living cells.In general, the inhibition of apoptosis is a common strategy to persist viral infection in many chronic virus diseases [29, 33, 50] .", [["transmembrane", "ANATOMY", 51, 64], ["cells", "ANATOMY", 103, 108], ["viral infection", "DISEASE", 181, 196], ["chronic virus diseases", "DISEASE", 205, 227], ["mRFP", "GENE_OR_GENE_PRODUCT", 24, 28], ["EGFP", "GENE_OR_GENE_PRODUCT", 29, 33], ["Bclxl", "GENE_OR_GENE_PRODUCT", 45, 50], ["cells", "CELL", 103, 108], ["mRFP", "PROTEIN", 24, 28], ["EGFP", "PROTEIN", 29, 33], ["Bclxl transmembrane structure", "PROTEIN", 45, 74], ["mRFP", "TEST", 24, 28], ["Bclxl transmembrane structure", "PROBLEM", 45, 74], ["apoptosis", "PROBLEM", 139, 148], ["viral infection", "PROBLEM", 181, 196], ["many chronic virus diseases", "PROBLEM", 200, 227], ["viral", "OBSERVATION_MODIFIER", 181, 186], ["infection", "OBSERVATION", 187, 196], ["chronic", "OBSERVATION_MODIFIER", 205, 212], ["virus", "OBSERVATION", 213, 218]]], ["As mitochondria is regarded to function as the control point in apoptotic pathways [51] , it is plausible that mitophagy may play a role in the modulation of apoptosis.", [["mitochondria", "ANATOMY", 3, 15], ["mitochondria", "CELLULAR_COMPONENT", 3, 15], ["apoptosis", "PROBLEM", 158, 167], ["apoptosis", "OBSERVATION", 158, 167]]], ["Most notably, mitochondrial is the main ROS factory, which functions as a signaling molecule through oxidation of redox-sensitive cysteine residues and inhibition of protein phosphorylation [52] .", [["mitochondrial", "ANATOMY", 14, 27], ["cysteine", "CHEMICAL", 130, 138], ["mitochondrial", "CELLULAR_COMPONENT", 14, 27], ["ROS", "SIMPLE_CHEMICAL", 40, 43], ["cysteine", "AMINO_ACID", 130, 138], ["redox-sensitive cysteine residues", "TREATMENT", 114, 147], ["protein phosphorylation", "TEST", 166, 189]]], ["Because ROS can function as a destructive agent at high levels, resulting in cell death [53] [54] [55] , cellular ROS homeostasis is tightly regulated.", [["cell", "ANATOMY", 77, 81], ["cellular", "ANATOMY", 105, 113], ["ROS", "CHEMICAL", 8, 11], ["death", "DISEASE", 82, 87], ["ROS", "CHEMICAL", 114, 117], ["ROS", "SIMPLE_CHEMICAL", 8, 11], ["cell", "CELL", 77, 81], ["cellular", "CELL", 105, 113], ["ROS", "SIMPLE_CHEMICAL", 114, 117], ["a destructive agent", "PROBLEM", 28, 47], ["cell death", "PROBLEM", 77, 87], ["cellular ROS homeostasis", "TEST", 105, 129], ["destructive", "OBSERVATION_MODIFIER", 30, 41]]], ["A relationship between TGEV infection and ROS production has been reported [56] but infection did not induce a significant increase of ROS in IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 142, 155], ["TGEV infection", "DISEASE", 23, 37], ["ROS", "CHEMICAL", 42, 45], ["infection", "DISEASE", 84, 93], ["ROS", "CHEMICAL", 135, 138], ["TGEV", "ORGANISM", 23, 27], ["ROS", "SIMPLE_CHEMICAL", 42, 45], ["ROS", "SIMPLE_CHEMICAL", 135, 138], ["IPEC-J2 cells", "CELL", 142, 155], ["IPEC-J2 cells", "CELL_LINE", 142, 155], ["TGEV", "SPECIES", 23, 27], ["TGEV infection", "PROBLEM", 23, 37], ["ROS production", "PROBLEM", 42, 56], ["infection", "PROBLEM", 84, 93], ["ROS in IPEC-J2 cells", "PROBLEM", 135, 155], ["TGEV", "OBSERVATION_MODIFIER", 23, 27], ["infection", "OBSERVATION", 28, 37], ["significant", "OBSERVATION_MODIFIER", 111, 122], ["increase", "OBSERVATION_MODIFIER", 123, 131], ["J2 cells", "OBSERVATION", 147, 155]]], ["These results are in contrast with those reported for ST cells after TGEV infection [22] .", [["ST cells", "ANATOMY", 54, 62], ["TGEV infection", "DISEASE", 69, 83], ["ST cells", "CELL", 54, 62], ["TGEV", "ORGANISM", 69, 73], ["ST cells", "CELL_TYPE", 54, 62], ["TGEV", "SPECIES", 69, 73], ["ST cells", "PROBLEM", 54, 62], ["TGEV infection", "PROBLEM", 69, 83]]], ["Due to the strong energy and material basis metabolism and the large number of mitochondria [57] , the intestinal epithelial cells have the great potential to produce ROS leading to the powerful ability to control oxidative stress.dIscussIonIn our experiments, the expression of antioxidative genes indicate that oxidative stress is probably induced by TGEV infection, which may explain the moderate ROS level.", [["mitochondria", "ANATOMY", 79, 91], ["intestinal epithelial cells", "ANATOMY", 103, 130], ["ROS", "CHEMICAL", 167, 170], ["infection", "DISEASE", 358, 367], ["ROS", "CHEMICAL", 400, 403], ["mitochondria", "CELLULAR_COMPONENT", 79, 91], ["intestinal epithelial cells", "CELL", 103, 130], ["ROS", "SIMPLE_CHEMICAL", 167, 170], ["TGEV", "ORGANISM", 353, 357], ["ROS", "SIMPLE_CHEMICAL", 400, 403], ["intestinal epithelial cells", "CELL_TYPE", 103, 130], ["antioxidative genes", "DNA", 279, 298], ["TGEV", "SPECIES", 353, 357], ["the strong energy and material basis metabolism", "PROBLEM", 7, 54], ["the intestinal epithelial cells", "PROBLEM", 99, 130], ["oxidative stress", "PROBLEM", 313, 329], ["TGEV infection", "PROBLEM", 353, 367], ["the moderate ROS level", "PROBLEM", 387, 409], ["large", "OBSERVATION_MODIFIER", 63, 68], ["intestinal", "ANATOMY", 103, 113], ["epithelial cells", "OBSERVATION", 114, 130], ["probably induced", "UNCERTAINTY", 333, 349], ["infection", "OBSERVATION", 358, 367], ["moderate", "OBSERVATION_MODIFIER", 391, 399], ["ROS", "OBSERVATION", 400, 403]]], ["In addition, autophagy is required to degrade ROS-producing organelles such as mitochondria and peroxisomes [58] .", [["organelles", "ANATOMY", 60, 70], ["mitochondria", "ANATOMY", 79, 91], ["peroxisomes", "ANATOMY", 96, 107], ["ROS", "CHEMICAL", 46, 49], ["ROS", "SIMPLE_CHEMICAL", 46, 49], ["organelles", "CELLULAR_COMPONENT", 60, 70], ["mitochondria", "CELLULAR_COMPONENT", 79, 91], ["peroxisomes", "CELLULAR_COMPONENT", 96, 107]]], ["Mitochondrial ROS (mtROS) activates general mitophagy to suppress oxidative damage [59] .", [["Mitochondrial", "ANATOMY", 0, 13], ["ROS", "CHEMICAL", 14, 17], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["ROS", "SIMPLE_CHEMICAL", 14, 17], ["mtROS", "SIMPLE_CHEMICAL", 19, 24], ["Mitochondrial ROS", "TEST", 0, 17]]], ["We find that the peak of TGEV virus infection is accompanied by ROS or mtROS accumulation and mitochondrial degradation, but apoptosis is nearly undetectable.", [["mitochondrial", "ANATOMY", 94, 107], ["infection", "DISEASE", 36, 45], ["ROS", "CHEMICAL", 64, 67], ["TGEV virus", "ORGANISM", 25, 35], ["ROS", "SIMPLE_CHEMICAL", 64, 67], ["mtROS", "SIMPLE_CHEMICAL", 71, 76], ["mitochondrial", "CELLULAR_COMPONENT", 94, 107], ["TGEV virus", "SPECIES", 25, 35], ["TGEV virus infection", "PROBLEM", 25, 45], ["ROS", "PROBLEM", 64, 67], ["mtROS accumulation", "PROBLEM", 71, 89], ["mitochondrial degradation", "PROBLEM", 94, 119], ["apoptosis", "PROBLEM", 125, 134], ["TGEV virus infection", "OBSERVATION", 25, 45], ["mitochondrial degradation", "OBSERVATION", 94, 119]]], ["Obvious mitophagy can be observed 12 h after TGEV infection, and can be suppressed by GSH treatment.", [["infection", "DISEASE", 50, 59], ["GSH", "CHEMICAL", 86, 89], ["GSH", "CHEMICAL", 86, 89], ["TGEV", "ORGANISM", 45, 49], ["GSH", "SIMPLE_CHEMICAL", 86, 89], ["TGEV", "SPECIES", 45, 49], ["Obvious mitophagy", "PROBLEM", 0, 17], ["TGEV infection", "PROBLEM", 45, 59], ["GSH treatment", "TREATMENT", 86, 99], ["mitophagy", "OBSERVATION", 8, 17], ["infection", "OBSERVATION", 50, 59]]], ["Many reports have shown that GSH or other antioxidants treatment could effectively inhibit apoptosis caused by oxidative stress [60] [61] [62] .", [["GSH", "CHEMICAL", 29, 32], ["GSH", "CHEMICAL", 29, 32], ["GSH", "SIMPLE_CHEMICAL", 29, 32], ["GSH", "PROBLEM", 29, 32], ["other antioxidants treatment", "TREATMENT", 36, 64]]], ["The impaired mitochondria could release ROS and other pro-apoptotic substances, such as cytochrome c, etc., to promote apoptosis.", [["mitochondria", "ANATOMY", 13, 25], ["ROS", "CHEMICAL", 40, 43], ["mitochondria", "CELLULAR_COMPONENT", 13, 25], ["ROS", "SIMPLE_CHEMICAL", 40, 43], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 88, 100], ["cytochrome c", "PROTEIN", 88, 100], ["The impaired mitochondria", "PROBLEM", 0, 25], ["pro-apoptotic substances", "TREATMENT", 54, 78], ["cytochrome c", "TREATMENT", 88, 100], ["impaired", "OBSERVATION", 4, 12], ["apoptosis", "OBSERVATION", 119, 128]]], ["The inhibition of autophagy by GSH, suppress the removing of damaged mitochondria, which may release other pro-apoptotic substances, and promote the apoptosis after TGEV infection.", [["mitochondria", "ANATOMY", 69, 81], ["GSH", "CHEMICAL", 31, 34], ["TGEV infection", "DISEASE", 165, 179], ["GSH", "CHEMICAL", 31, 34], ["GSH", "SIMPLE_CHEMICAL", 31, 34], ["mitochondria", "CELLULAR_COMPONENT", 69, 81], ["TGEV", "ORGANISM", 165, 169], ["TGEV", "SPECIES", 165, 169], ["damaged mitochondria", "PROBLEM", 61, 81], ["the apoptosis", "PROBLEM", 145, 158], ["TGEV infection", "PROBLEM", 165, 179], ["infection", "OBSERVATION", 170, 179]]], ["While, the suppressing ROS by antioxidants also inhibits apoptosis.", [["ROS", "CHEMICAL", 23, 26], ["ROS", "SIMPLE_CHEMICAL", 23, 26], ["apoptosis", "PROBLEM", 57, 66], ["apoptosis", "OBSERVATION", 57, 66]]], ["The final effect of GSH on cell apoptosis may be combined with the inhibition of mitophagy and elimination of abnormal ROS.", [["cell", "ANATOMY", 27, 31], ["GSH", "CHEMICAL", 20, 23], ["ROS", "CHEMICAL", 119, 122], ["GSH", "CHEMICAL", 20, 23], ["GSH", "SIMPLE_CHEMICAL", 20, 23], ["cell", "CELL", 27, 31], ["ROS", "SIMPLE_CHEMICAL", 119, 122], ["GSH on cell apoptosis", "PROBLEM", 20, 41], ["mitophagy", "PROBLEM", 81, 90], ["abnormal ROS", "PROBLEM", 110, 122], ["cell apoptosis", "OBSERVATION", 27, 41]]], ["These data suggest that oxidative stress play an important role in mitophagy and apoptosis post TGEV infection.dIscussIonAutophagy is an effective way to resist viral invasion [63] and replication [64] [65] [66] [67] .", [["infection", "DISEASE", 101, 110], ["TGEV", "ORGANISM", 96, 100], ["TGEV", "SPECIES", 96, 100], ["These data", "TEST", 0, 10], ["oxidative stress play", "PROBLEM", 24, 45], ["mitophagy", "PROBLEM", 67, 76], ["apoptosis", "PROBLEM", 81, 90], ["TGEV infection", "PROBLEM", 96, 110]]], ["The immune response, especially Type I IFN responses, promote autophagy to inhibit virus replication [68] .", [["Type I IFN", "GENE_OR_GENE_PRODUCT", 32, 42], ["Type I IFN", "PROTEIN", 32, 42], ["Type I IFN responses", "PROBLEM", 32, 52], ["immune response", "OBSERVATION", 4, 19]]], ["However, some viruses can highjack the autophagic structure as viral replication sites [66, 67] .", [["viral replication sites", "DNA", 63, 86], ["some viruses", "PROBLEM", 9, 21], ["viruses", "OBSERVATION", 14, 21], ["autophagic structure", "OBSERVATION", 39, 59], ["viral replication", "OBSERVATION", 63, 80]]], ["Accumulated studies indicate that many coronavirus utilise the autophagy membrane structures to replication [69] .", [["membrane structures", "ANATOMY", 73, 92], ["coronavirus", "ORGANISM", 39, 50], ["Accumulated studies", "TEST", 0, 19], ["many coronavirus", "PROBLEM", 34, 50], ["many", "OBSERVATION_MODIFIER", 34, 38], ["coronavirus", "OBSERVATION", 39, 50], ["autophagy membrane", "OBSERVATION", 63, 81]]], ["Moreover, SARS-CoV ORF9b could localize to mitochondria and induce autophagy, which caused the MAVS signalosome degradation to further suppress antiviral transcriptional responses [70] .", [["mitochondria", "ANATOMY", 43, 55], ["SARS-CoV ORF9b", "GENE_OR_GENE_PRODUCT", 10, 24], ["mitochondria", "CELLULAR_COMPONENT", 43, 55], ["MAVS", "GENE_OR_GENE_PRODUCT", 95, 99], ["SARS-CoV ORF9b", "PROTEIN", 10, 24], ["MAVS", "PROTEIN", 95, 99], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "PROBLEM", 10, 14], ["autophagy", "PROBLEM", 67, 76], ["the MAVS signalosome degradation", "PROBLEM", 91, 123]]], ["TGEV coronavirus contains 4 major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins.", [["membrane", "ANATOMY", 80, 88], ["TGEV coronavirus", "ORGANISM", 0, 16], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 55, 78], ["membrane", "CELLULAR_COMPONENT", 80, 88], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 98, 123], ["structural proteins", "PROTEIN", 34, 53], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 55, 92], ["nucleocapsid (N) proteins", "PROTEIN", 98, 123], ["TGEV coronavirus", "SPECIES", 0, 16], ["TGEV coronavirus", "SPECIES", 0, 16], ["TGEV coronavirus", "PROBLEM", 0, 16], ["spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins", "PROBLEM", 55, 123]]], ["Previous study has demonstrated that, the nucleocapsid protein of CoVs facilitated virus RNA switching and was required for efficient transcription [71] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 66, 70], ["nucleocapsid protein", "PROTEIN", 42, 62], ["CoVs", "PROTEIN", 66, 70], ["Previous study", "TEST", 0, 14], ["the nucleocapsid protein", "PROBLEM", 38, 62], ["CoVs", "PROBLEM", 66, 70], ["virus RNA switching", "TREATMENT", 83, 102]]], ["Moreover, TGEV nucleocapsid protein could interact with EF1a and facilitate viral replication [72] .", [["TGEV", "ORGANISM", 10, 14], ["EF1a", "GENE_OR_GENE_PRODUCT", 56, 60], ["TGEV nucleocapsid protein", "PROTEIN", 10, 35], ["EF1a", "PROTEIN", 56, 60], ["TGEV", "SPECIES", 10, 14], ["TGEV nucleocapsid protein", "PROBLEM", 10, 35], ["EF1a", "TREATMENT", 56, 60]]], ["Coronavirus nucleocapsid could localize in cytoplasm and nucleus [73] [74] [75] .", [["cytoplasm", "ANATOMY", 43, 52], ["nucleus", "ANATOMY", 57, 64], ["Coronavirus nucleocapsid", "ORGANISM", 0, 24], ["cytoplasm", "ORGANISM_SUBSTANCE", 43, 52], ["nucleus", "CELLULAR_COMPONENT", 57, 64], ["Coronavirus nucleocapsid", "PROTEIN", 0, 24], ["Coronavirus nucleocapsid", "PROBLEM", 0, 24]]], ["While, in our results, the subcellular localization of TGEV nucleocapsid was mainly found in mitochondria, which was inconsistent with different studies [76, 77] .", [["subcellular", "ANATOMY", 27, 38], ["mitochondria", "ANATOMY", 93, 105], ["TGEV nucleocapsid", "ORGANISM", 55, 72], ["mitochondria", "CELLULAR_COMPONENT", 93, 105], ["TGEV nucleocapsid", "PROTEIN", 55, 72], ["TGEV", "SPECIES", 55, 59], ["TGEV nucleocapsid", "PROBLEM", 55, 72], ["TGEV nucleocapsid", "OBSERVATION", 55, 72]]], ["Although, the ROS and mtROS are elevated, distinct fragmented mitochondrial morphology is observed, and the total mitochondrial mass is decreased by N protein expression, but the mitochondrial membrane potential is not changed ( Figure S3 ).", [["mitochondrial", "ANATOMY", 62, 75], ["mitochondrial", "ANATOMY", 114, 127], ["mitochondrial membrane", "ANATOMY", 179, 201], ["ROS", "SIMPLE_CHEMICAL", 14, 17], ["mt", "GENE_OR_GENE_PRODUCT", 22, 24], ["ROS", "SIMPLE_CHEMICAL", 24, 27], ["mitochondrial", "CELLULAR_COMPONENT", 62, 75], ["mitochondrial", "CELLULAR_COMPONENT", 114, 127], ["mitochondrial membrane", "CELLULAR_COMPONENT", 179, 201], ["N protein", "PROTEIN", 149, 158], ["the ROS", "TEST", 10, 17], ["mtROS", "TEST", 22, 27], ["elevated", "PROBLEM", 32, 40], ["distinct fragmented mitochondrial morphology", "PROBLEM", 42, 86], ["the total mitochondrial mass", "PROBLEM", 104, 132], ["elevated", "OBSERVATION", 32, 40], ["distinct", "OBSERVATION_MODIFIER", 42, 50], ["fragmented", "OBSERVATION_MODIFIER", 51, 61], ["mitochondrial morphology", "OBSERVATION", 62, 86], ["total", "OBSERVATION_MODIFIER", 108, 113], ["mitochondrial", "OBSERVATION_MODIFIER", 114, 127], ["mass", "OBSERVATION", 128, 132], ["decreased", "OBSERVATION_MODIFIER", 136, 145], ["protein expression", "OBSERVATION", 151, 169], ["mitochondrial membrane", "OBSERVATION", 179, 201], ["not", "UNCERTAINTY", 215, 218], ["changed", "OBSERVATION_MODIFIER", 219, 226]]], ["These results indicate the balance of mitochondrial quality and quantity in IPEC-J2 cells is very successful.", [["mitochondrial", "ANATOMY", 38, 51], ["IPEC-J2 cells", "ANATOMY", 76, 89], ["mitochondrial", "CELLULAR_COMPONENT", 38, 51], ["IPEC-J2 cells", "CELL", 76, 89], ["IPEC-J2 cells", "CELL_LINE", 76, 89], ["IPEC-J2 cells", "TREATMENT", 76, 89], ["J2 cells", "OBSERVATION", 81, 89]]], ["Despite the N protein localizing on almost mitochondria ( Figure S3A ), the number of mitophagosames are limited ( Figure S3G ).", [["mitochondria", "ANATOMY", 43, 55], ["mitochondria", "CELLULAR_COMPONENT", 43, 55], ["Figure S3A", "GENE_OR_GENE_PRODUCT", 58, 68], ["mitophagosames", "GENE_OR_GENE_PRODUCT", 86, 100], ["N protein", "PROTEIN", 12, 21], ["mitophagosames", "PROTEIN", 86, 100], ["the N protein localizing", "PROBLEM", 8, 32]]], ["These results indicate the mitochondrial localization of N protein may create same injury but be not directly related to the mitophagy.", [["mitochondrial", "ANATOMY", 27, 40], ["mitochondrial", "CELLULAR_COMPONENT", 27, 40], ["N protein", "GENE_OR_GENE_PRODUCT", 57, 66], ["N protein", "PROTEIN", 57, 66], ["the mitochondrial localization of N protein", "PROBLEM", 23, 66], ["same injury", "PROBLEM", 78, 89]]], ["The directly inducer may be the injured mitochondria, which is eliminated by fission form normal mitochondrial and degraded by mitophagy.", [["mitochondria", "ANATOMY", 40, 52], ["mitochondrial", "ANATOMY", 97, 110], ["mitochondria", "CELLULAR_COMPONENT", 40, 52], ["mitochondrial", "CELLULAR_COMPONENT", 97, 110], ["the injured mitochondria", "PROBLEM", 28, 52], ["may be", "UNCERTAINTY", 21, 27], ["injured", "OBSERVATION", 32, 39]]], ["Together, the nucleocapsid of TGEV may contribute to the mitochondrial injury and induction of mitophagy during TGEV infection.dIscussIonMitochondrial dysfunction is monitored by several proteins, such as NIX, BNIP3, PINK1, parkin, SQSTM1 (p62) [31, 78, 79] .", [["mitochondrial", "ANATOMY", 57, 70], ["mitochondrial injury", "DISEASE", 57, 77], ["infection", "DISEASE", 117, 126], ["TGEV", "ORGANISM", 30, 34], ["mitochondrial", "CELLULAR_COMPONENT", 57, 70], ["TGEV", "ORGANISM", 112, 116], ["NIX", "GENE_OR_GENE_PRODUCT", 205, 208], ["BNIP3", "GENE_OR_GENE_PRODUCT", 210, 215], ["PINK1", "GENE_OR_GENE_PRODUCT", 217, 222], ["parkin", "GENE_OR_GENE_PRODUCT", 224, 230], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 232, 238], ["p62", "GENE_OR_GENE_PRODUCT", 240, 243], ["NIX", "PROTEIN", 205, 208], ["BNIP3", "PROTEIN", 210, 215], ["PINK1", "PROTEIN", 217, 222], ["parkin", "PROTEIN", 224, 230], ["SQSTM1", "PROTEIN", 232, 238], ["p62", "PROTEIN", 240, 243], ["TGEV", "SPECIES", 30, 34], ["TGEV", "SPECIES", 112, 116], ["TGEV", "PROBLEM", 30, 34], ["the mitochondrial injury", "PROBLEM", 53, 77], ["mitophagy", "PROBLEM", 95, 104], ["TGEV infection", "PROBLEM", 112, 126], ["IonMitochondrial dysfunction", "PROBLEM", 134, 162], ["mitochondrial injury", "OBSERVATION", 57, 77]]], ["Recent work reveals that DJ-1 (PARK7) acts as a signaling hub through its ability to recognize oxidative damaged in mitochondria and induce mitophagy, thus eliminating damaged mitochondria in mammalian cells [39, [80] [81] [82] .", [["mitochondria", "ANATOMY", 116, 128], ["mitochondria", "ANATOMY", 176, 188], ["cells", "ANATOMY", 202, 207], ["DJ-1", "GENE_OR_GENE_PRODUCT", 25, 29], ["PARK7", "GENE_OR_GENE_PRODUCT", 31, 36], ["mitochondria", "CELLULAR_COMPONENT", 116, 128], ["mitochondria", "CELLULAR_COMPONENT", 176, 188], ["mammalian cells", "CELL", 192, 207], ["DJ-1", "PROTEIN", 25, 29], ["PARK7", "PROTEIN", 31, 36], ["mammalian cells", "CELL_TYPE", 192, 207], ["oxidative damaged in mitochondria", "PROBLEM", 95, 128], ["mitophagy", "PROBLEM", 140, 149], ["damaged mitochondria in mammalian cells", "PROBLEM", 168, 207]]], ["The role of DJ-1 in the regulation of oxidative stress has been extensively studied in neurodegenerative diseases [82] [83] [84] .", [["neurodegenerative diseases", "DISEASE", 87, 113], ["DJ-1", "GENE_OR_GENE_PRODUCT", 12, 16], ["DJ-1", "PROTEIN", 12, 16], ["oxidative stress", "PROBLEM", 38, 54], ["neurodegenerative diseases", "PROBLEM", 87, 113]]], ["In addition, DJ-1 plays an important role in reducing inflammation and antioxidation in gastrointestinal mucosa [85] .", [["gastrointestinal mucosa", "ANATOMY", 88, 111], ["inflammation", "DISEASE", 54, 66], ["DJ-1", "GENE_OR_GENE_PRODUCT", 13, 17], ["gastrointestinal mucosa", "MULTI-TISSUE_STRUCTURE", 88, 111], ["DJ-1", "PROTEIN", 13, 17], ["reducing inflammation", "PROBLEM", 45, 66], ["inflammation", "OBSERVATION", 54, 66], ["gastrointestinal mucosa", "ANATOMY", 88, 111]]], ["Despite of much work for DJ-1 in regulation of oxidative stress and mitophagy, the role of DJ-1 in autophagy/mitophagy is poorly understood.", [["DJ-1", "GENE_OR_GENE_PRODUCT", 25, 29], ["DJ-1", "GENE_OR_GENE_PRODUCT", 91, 95], ["DJ-1", "PROTEIN", 91, 95], ["oxidative stress", "PROBLEM", 47, 63], ["mitophagy", "PROBLEM", 68, 77]]], ["Our work indicates that mitophagy benefits TGEV infection by eliminating damaged mitochondria, thereby controlling ROS release and blocking oxidative damage.", [["mitochondria", "ANATOMY", 81, 93], ["infection", "DISEASE", 48, 57], ["ROS", "CHEMICAL", 115, 118], ["TGEV", "ORGANISM", 43, 47], ["mitochondria", "CELLULAR_COMPONENT", 81, 93], ["ROS", "SIMPLE_CHEMICAL", 115, 118], ["TGEV", "SPECIES", 43, 47], ["TGEV infection", "PROBLEM", 43, 57], ["damaged mitochondria", "PROBLEM", 73, 93], ["blocking oxidative damage", "PROBLEM", 131, 156]]], ["TGEV infection increases DJ-1 expression, and DJ-1 knockdown reduces autophagy and mitophagy, causing an increase in apoptosis and a decrease in TGEV infection.", [["infection", "DISEASE", 5, 14], ["TGEV infection", "DISEASE", 145, 159], ["TGEV", "ORGANISM", 0, 4], ["DJ-1", "GENE_OR_GENE_PRODUCT", 25, 29], ["DJ-1", "GENE_OR_GENE_PRODUCT", 46, 50], ["TGEV", "ORGANISM", 145, 149], ["DJ", "PROTEIN", 25, 27], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 145, 149], ["TGEV infection", "PROBLEM", 0, 14], ["DJ", "TEST", 46, 48], ["autophagy", "PROBLEM", 69, 78], ["mitophagy", "PROBLEM", 83, 92], ["an increase in apoptosis", "PROBLEM", 102, 126], ["a decrease in TGEV infection", "PROBLEM", 131, 159], ["infection", "OBSERVATION", 5, 14], ["DJ", "ANATOMY", 46, 48], ["increase", "OBSERVATION_MODIFIER", 105, 113], ["apoptosis", "OBSERVATION", 117, 126], ["decrease", "OBSERVATION_MODIFIER", 133, 141], ["TGEV", "OBSERVATION_MODIFIER", 145, 149], ["infection", "OBSERVATION", 150, 159]]], ["Furthermore, mitochondria become vulnerable in IPEC-J2 cell after DJ-1 knockdown, especially after infection with TGEV, and ROS release increases significantly, which is partly counteracted by GSH treatment.", [["mitochondria", "ANATOMY", 13, 25], ["IPEC-J2 cell", "ANATOMY", 47, 59], ["infection", "DISEASE", 99, 108], ["ROS", "CHEMICAL", 124, 127], ["GSH", "CHEMICAL", 193, 196], ["GSH", "CHEMICAL", 193, 196], ["mitochondria", "CELLULAR_COMPONENT", 13, 25], ["IPEC-J2 cell", "CELL", 47, 59], ["DJ-1", "GENE_OR_GENE_PRODUCT", 66, 70], ["TGEV", "ORGANISM", 114, 118], ["ROS", "SIMPLE_CHEMICAL", 124, 127], ["GSH", "SIMPLE_CHEMICAL", 193, 196], ["IPEC-J2 cell", "CELL_LINE", 47, 59], ["TGEV", "SPECIES", 114, 118], ["DJ-1 knockdown", "TREATMENT", 66, 80], ["infection", "PROBLEM", 99, 108], ["TGEV", "PROBLEM", 114, 118], ["GSH treatment", "TREATMENT", 193, 206], ["vulnerable", "OBSERVATION_MODIFIER", 33, 43], ["J2 cell", "OBSERVATION_MODIFIER", 52, 59], ["infection", "OBSERVATION", 99, 108], ["GSH treatment", "OBSERVATION", 193, 206]]], ["Our results are consistent with recent work in DJ-1 -/mice exhibit increased sensitivity to oxidative stress [86] , and glutathione or NAC treatment attenuates DJ-1-deficiency-induced phenotypes [82] .", [["glutathione", "CHEMICAL", 120, 131], ["NAC", "CHEMICAL", 135, 138], ["glutathione", "CHEMICAL", 120, 131], ["NAC", "CHEMICAL", 135, 138], ["DJ-1", "GENE_OR_GENE_PRODUCT", 47, 51], ["mice", "ORGANISM", 54, 58], ["glutathione", "SIMPLE_CHEMICAL", 120, 131], ["NAC", "SIMPLE_CHEMICAL", 135, 138], ["DJ-1", "GENE_OR_GENE_PRODUCT", 160, 164], ["mice", "SPECIES", 54, 58], ["increased sensitivity", "PROBLEM", 67, 88], ["oxidative stress", "TEST", 92, 108], ["glutathione", "TREATMENT", 120, 131], ["NAC treatment", "TREATMENT", 135, 148], ["DJ", "TEST", 160, 162], ["deficiency", "PROBLEM", 165, 175], ["induced phenotypes", "PROBLEM", 176, 194], ["consistent with", "UNCERTAINTY", 16, 31]]], ["Given that DJ-1-mediated mitophagy is required to prevent TGEVinduced apoptosis, and thus favors viral infection and persistence.dIscussIonIn summary, this study provides evidence for the likely involvement of TGEV-induced mitophagy in facilitating the infection and the pathogenesis of gastrointestinal disease associated with infection ( Figure 9 ) in vitro.", [["gastrointestinal", "ANATOMY", 287, 303], ["viral infection", "DISEASE", 97, 112], ["infection", "DISEASE", 253, 262], ["gastrointestinal disease", "DISEASE", 287, 311], ["infection", "DISEASE", 328, 337], ["DJ-1", "GENE_OR_GENE_PRODUCT", 11, 15], ["TGEV", "ORGANISM", 210, 214], ["gastrointestinal", "ORGAN", 287, 303], ["DJ-1", "PROTEIN", 11, 15], ["TGEV", "SPECIES", 210, 214], ["DJ", "TEST", 11, 13], ["mitophagy", "PROBLEM", 25, 34], ["TGEVinduced apoptosis", "PROBLEM", 58, 79], ["viral infection", "PROBLEM", 97, 112], ["this study", "TEST", 151, 161], ["TGEV", "PROBLEM", 210, 214], ["induced mitophagy", "PROBLEM", 215, 232], ["the infection", "PROBLEM", 249, 262], ["gastrointestinal disease", "PROBLEM", 287, 311], ["infection", "PROBLEM", 328, 337], ["apoptosis", "OBSERVATION", 70, 79], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["infection", "OBSERVATION", 103, 112], ["infection", "OBSERVATION", 253, 262], ["gastrointestinal", "ANATOMY", 287, 303], ["infection", "OBSERVATION", 328, 337]]], ["Our study demonstrates for the first time that the nucleocapsid protein of TGEV is located in mitochondria.", [["mitochondria", "ANATOMY", 94, 106], ["TGEV", "ORGANISM", 75, 79], ["mitochondria", "CELLULAR_COMPONENT", 94, 106], ["nucleocapsid protein", "PROTEIN", 51, 71], ["TGEV", "SPECIES", 75, 79], ["Our study", "TEST", 0, 9], ["the nucleocapsid protein of TGEV", "PROBLEM", 47, 79]]], ["More research is needed to explain the association between mitophagy and TGEV infection, especially in vivo.", [["TGEV infection", "DISEASE", 73, 87], ["TGEV", "ORGANISM", 73, 77], ["TGEV", "SPECIES", 73, 77], ["mitophagy", "PROBLEM", 59, 68], ["TGEV infection", "PROBLEM", 73, 87], ["TGEV", "OBSERVATION_MODIFIER", 73, 77], ["infection", "OBSERVATION", 78, 87]]], ["A closer look at the relationship between the mitochondrial location of nucleocapsid protein and the elimination of dysfunction mitochondria may provide new strategies for the control of viral infection.cells, antibodies and reagentsIPEC-J2 cell lines (Guangzhou Jennio Biotech Co, Ltd., China) used in this study were cultured in Dulbecco's Modified Eagle's Medium nutrient ( DMEM from Life Technologies, Shanghai, China) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 16 mM HEPES (Life Technologies), and 100 \u03bcg/mL penicillinstreptomycin (Life Technologies), and incubated in an atmosphere of 5% CO 2 at 37 \u00b0C. Cells were routinely seeded at a density of 2 \u00d7 10 5 /mL in plastic tissue culture flasks (25 cm 2 flasks, Corning, Shanghai, China) and passaged every 3-4 days for a maximum of 20 passages.", [["mitochondrial", "ANATOMY", 46, 59], ["mitochondria", "ANATOMY", 128, 140], ["cells", "ANATOMY", 203, 208], ["reagentsIPEC-J2 cell lines", "ANATOMY", 225, 251], ["fetal bovine serum", "ANATOMY", 445, 463], ["FBS", "ANATOMY", 465, 468], ["Cells", "ANATOMY", 633, 638], ["tissue", "ANATOMY", 701, 707], ["viral infection", "DISEASE", 187, 202], ["penicillinstreptomycin", "CHEMICAL", 537, 559], ["HEPES", "CHEMICAL", 496, 501], ["penicillinstreptomycin", "CHEMICAL", 537, 559], ["CO 2", "CHEMICAL", 618, 622], ["mitochondrial", "CELLULAR_COMPONENT", 46, 59], ["mitochondria", "CELLULAR_COMPONENT", 128, 140], ["cells", "CELL", 203, 208], ["reagentsIPEC-J2 cell lines", "CELL", 225, 251], ["bovine", "ORGANISM", 451, 457], ["serum", "ORGANISM_SUBSTANCE", 458, 463], ["FBS", "ORGANISM_SUBSTANCE", 465, 468], ["penicillinstreptomycin", "SIMPLE_CHEMICAL", 537, 559], ["Cells", "CELL", 633, 638], ["nucleocapsid protein", "PROTEIN", 72, 92], ["antibodies", "PROTEIN", 210, 220], ["reagentsIPEC-J2 cell lines", "CELL_LINE", 225, 251], ["bovine", "SPECIES", 451, 457], ["bovine", "SPECIES", 451, 457], ["nucleocapsid protein", "PROBLEM", 72, 92], ["dysfunction mitochondria", "PROBLEM", 116, 140], ["new strategies", "TREATMENT", 153, 167], ["viral infection", "PROBLEM", 187, 202], ["cells", "TEST", 203, 208], ["antibodies", "TEST", 210, 220], ["reagentsIPEC", "TEST", 225, 237], ["J2 cell lines", "TREATMENT", 238, 251], ["this study", "TEST", 303, 313], ["10% fetal bovine serum (FBS", "TREATMENT", 441, 468], ["16 mM HEPES (Life Technologies", "TREATMENT", 490, 520], ["Cells", "TEST", 633, 638], ["plastic tissue culture flasks", "TEST", 693, 722], ["nucleocapsid protein", "OBSERVATION", 72, 92], ["viral", "OBSERVATION_MODIFIER", 187, 192], ["infection", "OBSERVATION", 193, 202], ["J2 cell lines", "OBSERVATION", 238, 251], ["plastic tissue", "OBSERVATION_MODIFIER", 693, 707]]], ["In our experiments, IPEC-J2 cells were grown on 24-,6well or 100 mm plastic tissue culture plates (Corning) at a density of 3 \u00d7 10 5 /well, 1.5 \u00d7 10 6 /well or 7.5 \u00d7 10 6 /well, respectively.cells, antibodies and reagentsAntibodies used in this study were: anti-LC3BPlasmids and transfections gene transductionATG5 (Autophagy related 5) and DJ-1 (deglycase 1 also calls PARK7) knockdown in IPEC-J2 cells was performed using the vector-based shRNA approach. shRNA targeting sequences against ATG5 and DJ-1 were designed using online design tools (http://rnaidesigner. lifetechnologies.com/rnaiexpress/insert.do), BLOCK-iT RNAi Designer, Life Technologies); we selected three short target sequences with the best scores for each gene.", [["IPEC-J2 cells", "ANATOMY", 20, 33], ["tissue", "ANATOMY", 76, 82], ["cells", "ANATOMY", 191, 196], ["IPEC-J2 cells", "ANATOMY", 390, 403], ["IPEC-J2 cells", "CELL", 20, 33], ["cells", "CELL", 191, 196], ["anti-LC3BPlasmids", "SIMPLE_CHEMICAL", 257, 274], ["Autophagy related 5", "GENE_OR_GENE_PRODUCT", 316, 335], ["DJ-1", "GENE_OR_GENE_PRODUCT", 341, 345], ["deglycase 1", "GENE_OR_GENE_PRODUCT", 347, 358], ["PARK7", "GENE_OR_GENE_PRODUCT", 370, 375], ["IPEC-J2 cells", "CELL", 390, 403], ["ATG5", "GENE_OR_GENE_PRODUCT", 491, 495], ["DJ-1", "GENE_OR_GENE_PRODUCT", 500, 504], ["IPEC-J2 cells", "CELL_LINE", 20, 33], ["cells", "CELL_TYPE", 191, 196], ["antibodies", "PROTEIN", 198, 208], ["transfections gene transductionATG5", "DNA", 279, 314], ["Autophagy related 5", "DNA", 316, 335], ["DJ-1", "DNA", 341, 345], ["deglycase 1", "DNA", 347, 358], ["PARK7", "DNA", 370, 375], ["IPEC-J2 cells", "CELL_LINE", 390, 403], ["ATG5", "PROTEIN", 491, 495], ["DJ-1", "DNA", 500, 504], ["IPEC", "TEST", 20, 24], ["J2 cells", "PROBLEM", 25, 33], ["plastic tissue culture plates", "TEST", 68, 97], ["cells", "TEST", 191, 196], ["antibodies", "TEST", 198, 208], ["reagents", "TREATMENT", 213, 221], ["Antibodies", "TEST", 221, 231], ["this study", "TEST", 240, 250], ["anti-LC3BPlasmids", "TREATMENT", 257, 274], ["Autophagy", "TEST", 316, 325], ["DJ", "TEST", 341, 343], ["the vector-based shRNA approach", "TREATMENT", 424, 455], ["J2 cells", "OBSERVATION_MODIFIER", 25, 33], ["J2", "ANATOMY", 395, 397]]], ["Table 1 lists the oligonucleotides used.", [["the oligonucleotides", "TREATMENT", 14, 34]]], ["The shRNAs were cloned into the pLVX-shRNA1 vector (Takara, Dalian, China) containing EcoRI and BamHI sites.", [["pLVX", "GENE_OR_GENE_PRODUCT", 32, 36], ["EcoRI", "GENE_OR_GENE_PRODUCT", 86, 91], ["BamHI", "GENE_OR_GENE_PRODUCT", 96, 101], ["shRNAs", "DNA", 4, 10], ["pLVX-shRNA1 vector", "DNA", 32, 50], ["EcoRI and BamHI sites", "DNA", 86, 107], ["The shRNAs", "TREATMENT", 0, 10], ["Dalian", "TREATMENT", 60, 66], ["EcoRI and BamHI sites", "TREATMENT", 86, 107], ["shRNAs", "OBSERVATION", 4, 10], ["shRNA1 vector", "ANATOMY", 37, 50], ["BamHI sites", "OBSERVATION", 96, 107]]], ["The pmCherry-EGFP-LC3B vector was purchased from Addgene (Cambridge, MA, USA).", [["pmCherry-EGFP-LC3B", "GENE_OR_GENE_PRODUCT", 4, 22], ["pmCherry-EGFP-LC3B vector", "DNA", 4, 29], ["LC3B vector", "OBSERVATION", 18, 29]]], ["The DNA fragment of mitosignal peptide was amplified from human genome using the primers PDHA1-F and PDHA1-R, and inserted into the lentiviral vector pLVX-mCherry-N1; the resulting plasmid was named pLVX-mitomCherry.", [["plasmid", "ANATOMY", 181, 188], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["mitosignal peptide", "GENE_OR_GENE_PRODUCT", 20, 38], ["human", "ORGANISM", 58, 63], ["PDHA1-F", "GENE_OR_GENE_PRODUCT", 89, 96], ["PDHA1-R", "GENE_OR_GENE_PRODUCT", 101, 108], ["lentiviral", "ORGANISM", 132, 142], ["pLVX", "GENE_OR_GENE_PRODUCT", 150, 154], ["pLVX-mitomCherry", "GENE_OR_GENE_PRODUCT", 199, 215], ["DNA fragment", "DNA", 4, 16], ["human genome", "DNA", 58, 70], ["PDHA1", "DNA", 89, 94], ["F", "DNA", 95, 96], ["PDHA1", "DNA", 101, 106], ["R", "DNA", 107, 108], ["pLVX", "DNA", 150, 154], ["mCherry", "DNA", 155, 162], ["N1", "DNA", 163, 165], ["pLVX", "DNA", 199, 203], ["mitomCherry", "DNA", 204, 215], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["The DNA fragment of mitosignal peptide", "PROBLEM", 0, 38], ["the primers PDHA1", "TEST", 77, 94], ["PDHA1", "TEST", 101, 106], ["fragment", "OBSERVATION_MODIFIER", 8, 16], ["lentiviral vector", "OBSERVATION", 132, 149]]], ["The DNA fragment of IRES-EGFP was amplified from pIRES-EGFP-N1 and the LC3B (microtubule associated protein 1 light chain 3 beta) fragment was amplified from the cDNA of IPEC-J2 cells.", [["IPEC-J2 cells", "ANATOMY", 170, 183], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["IRES-EGFP", "GENE_OR_GENE_PRODUCT", 20, 29], ["LC3B", "GENE_OR_GENE_PRODUCT", 71, 75], ["microtubule associated protein 1 light chain 3 beta", "GENE_OR_GENE_PRODUCT", 77, 128], ["IPEC-J2 cells", "CELL", 170, 183], ["DNA fragment", "DNA", 4, 16], ["IRES", "DNA", 20, 24], ["EGFP", "DNA", 25, 29], ["pIRES", "DNA", 49, 54], ["EGFP", "DNA", 55, 59], ["N1", "DNA", 60, 62], ["LC3B (microtubule associated protein 1 light chain 3 beta) fragment", "DNA", 71, 138], ["IPEC-J2 cells", "CELL_LINE", 170, 183], ["The DNA fragment of IRES", "TEST", 0, 24], ["EGFP", "TEST", 25, 29], ["pIRES", "TEST", 49, 54], ["EGFP", "TEST", 55, 59], ["the LC3B", "TEST", 67, 75], ["protein", "TEST", 100, 107], ["light chain 3 beta) fragment", "PROBLEM", 110, 138], ["the cDNA", "TEST", 158, 166], ["J2 cells", "PROBLEM", 175, 183], ["fragment", "OBSERVATION_MODIFIER", 8, 16], ["J2 cells", "OBSERVATION", 175, 183]]], ["The primers were IRES-F, EGFP-R and LC3B-F, LC3B-R, respectively.", [["EGFP-R", "GENE_OR_GENE_PRODUCT", 25, 31], ["LC3B-F", "GENE_OR_GENE_PRODUCT", 36, 42], ["LC3B-R", "GENE_OR_GENE_PRODUCT", 44, 50], ["IRES", "DNA", 17, 21], ["F", "DNA", 22, 23], ["EGFP", "DNA", 25, 29], ["R", "DNA", 30, 31], ["LC3B", "DNA", 36, 40], ["F", "DNA", 41, 42], ["LC3B", "DNA", 44, 48], ["R", "DNA", 49, 50], ["The primers", "TEST", 0, 11], ["IRES", "TEST", 17, 21], ["EGFP", "TEST", 25, 29], ["LC3B", "TEST", 36, 40]]], ["The amplified fragments were then overlapped with each other and inserted into the lentiviral vector pLVX-mitomCherry; the resulting plasmid was named pLVX-mitomCherry-IRES-EGFPLC3B.Plasmids and transfections gene transductionTo construct pLVX-EGFPLC3, the EGFP-LC3 fragment was amplified from pLVX-mitomCherry-IRES-EGFPLC3B by primers EGFP-F and LC3B-R, and inserted into the vector pLVX-puro, which was linearized by BamHI and XbaI digestion.", [["fragments", "ANATOMY", 14, 23], ["plasmid", "ANATOMY", 133, 140], ["lentiviral", "ORGANISM", 83, 93], ["pLVX", "GENE_OR_GENE_PRODUCT", 101, 105], ["mitomCherry", "GENE_OR_GENE_PRODUCT", 106, 117], ["pLVX", "GENE_OR_GENE_PRODUCT", 151, 155], ["pLVX-EGFPLC3", "GENE_OR_GENE_PRODUCT", 239, 251], ["EGFP", "GENE_OR_GENE_PRODUCT", 257, 261], ["LC3", "GENE_OR_GENE_PRODUCT", 262, 265], ["EGFP-F", "GENE_OR_GENE_PRODUCT", 336, 342], ["LC3B-R", "GENE_OR_GENE_PRODUCT", 347, 353], ["pLVX", "GENE_OR_GENE_PRODUCT", 384, 388], ["BamHI", "GENE_OR_GENE_PRODUCT", 419, 424], ["XbaI", "GENE_OR_GENE_PRODUCT", 429, 433], ["amplified fragments", "DNA", 4, 23], ["pLVX", "DNA", 101, 105], ["mitomCherry", "DNA", 106, 117], ["pLVX", "DNA", 151, 155], ["mitomCherry", "DNA", 156, 167], ["IRES", "DNA", 168, 172], ["EGFPLC3B", "DNA", 173, 181], ["transfections gene transductionTo construct", "DNA", 195, 238], ["pLVX", "DNA", 239, 243], ["EGFPLC3", "DNA", 244, 251], ["EGFP-LC3 fragment", "DNA", 257, 274], ["pLVX-mitomCherry-IRES-EGFPLC3B", "DNA", 294, 324], ["EGFP", "DNA", 336, 340], ["F", "DNA", 341, 342], ["LC3B", "DNA", 347, 351], ["R", "DNA", 352, 353], ["pLVX", "DNA", 384, 388], ["puro", "DNA", 389, 393], ["The amplified fragments", "PROBLEM", 0, 23], ["the resulting plasmid", "TREATMENT", 119, 140], ["Plasmids", "TREATMENT", 182, 190], ["pLVX", "TEST", 239, 243], ["the EGFP", "TEST", 253, 261], ["LC3 fragment", "PROBLEM", 262, 274], ["pLVX", "TEST", 294, 298], ["EGFP", "TEST", 336, 340], ["fragments", "OBSERVATION_MODIFIER", 14, 23], ["lentiviral vector", "OBSERVATION", 83, 100], ["LC3 fragment", "OBSERVATION", 262, 274]]], ["The construction of PLVX-mRFP-EGFP-LC3 was based on pLVX-EGFPLC3.", [["PLVX", "GENE_OR_GENE_PRODUCT", 20, 24], ["mRFP", "GENE_OR_GENE_PRODUCT", 25, 29], ["EGFP", "GENE_OR_GENE_PRODUCT", 30, 34], ["LC3", "GENE_OR_GENE_PRODUCT", 35, 38], ["pLVX-EGFPLC3", "GENE_OR_GENE_PRODUCT", 52, 64], ["PLVX", "PROTEIN", 20, 24], ["mRFP", "PROTEIN", 25, 29], ["EGFP", "PROTEIN", 30, 34], ["LC3", "PROTEIN", 35, 38], ["pLVX", "PROTEIN", 52, 56], ["EGFPLC3", "PROTEIN", 57, 64], ["PLVX", "TEST", 20, 24], ["mRFP", "TEST", 25, 29], ["LC3", "PROBLEM", 35, 38], ["pLVX", "TEST", 52, 56]]], ["Fragment mRFP was amplified from pTagRFP N1 using primers mRFP-F and mRFP-R, and then inserted into pLVX-EGFPLC3 linearized by XhoI and BamHI digestion.", [["mRFP", "GENE_OR_GENE_PRODUCT", 9, 13], ["mRFP-F", "GENE_OR_GENE_PRODUCT", 58, 64], ["mRFP-R", "GENE_OR_GENE_PRODUCT", 69, 75], ["pLVX", "GENE_OR_GENE_PRODUCT", 100, 104], ["XhoI", "GENE_OR_GENE_PRODUCT", 127, 131], ["BamHI", "GENE_OR_GENE_PRODUCT", 136, 141], ["mRFP", "DNA", 9, 13], ["pTagRFP N1", "DNA", 33, 43], ["mRFP", "DNA", 58, 62], ["F", "DNA", 63, 64], ["mRFP", "DNA", 69, 73], ["R", "DNA", 74, 75], ["pLVX-EGFPLC3", "DNA", 100, 112], ["Fragment mRFP", "TEST", 0, 13], ["primers mRFP", "TEST", 50, 62], ["mRFP", "TEST", 69, 73], ["BamHI digestion", "TREATMENT", 136, 151]]], ["The construction of pLVX-mRFP-EGFP-Bcl-xL was based on PLVX-mRFP-EGFP-LC3, the fragment LC3 in pLVX-mRFP-EGFP-LC3 was digested by HpaI and XbaI, and replaced with the transmembrane structure of fragment Bcl-xL at the same site, which was amplified from human genome by primers Bcl-xL-F and Bcl-xL-R.", [["transmembrane", "ANATOMY", 167, 180], ["pLVX", "GENE_OR_GENE_PRODUCT", 20, 24], ["EGFP", "GENE_OR_GENE_PRODUCT", 30, 34], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 35, 41], ["PLVX-mRFP", "GENE_OR_GENE_PRODUCT", 55, 64], ["EGFP", "GENE_OR_GENE_PRODUCT", 65, 69], ["LC3", "GENE_OR_GENE_PRODUCT", 70, 73], ["LC3", "GENE_OR_GENE_PRODUCT", 88, 91], ["pLVX-mRFP-EGFP-LC3", "GENE_OR_GENE_PRODUCT", 95, 113], ["HpaI", "GENE_OR_GENE_PRODUCT", 130, 134], ["XbaI", "GENE_OR_GENE_PRODUCT", 139, 143], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 203, 209], ["human", "ORGANISM", 253, 258], ["Bcl-xL-F", "GENE_OR_GENE_PRODUCT", 277, 285], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 290, 296], ["pLVX", "PROTEIN", 20, 24], ["mRFP-EGFP", "PROTEIN", 25, 34], ["Bcl", "PROTEIN", 35, 38], ["xL", "PROTEIN", 39, 41], ["PLVX", "PROTEIN", 55, 59], ["mRFP", "PROTEIN", 60, 64], ["EGFP", "PROTEIN", 65, 69], ["LC3", "PROTEIN", 70, 73], ["LC3", "PROTEIN", 88, 91], ["pLVX", "PROTEIN", 95, 99], ["-mRFP-EGFP", "PROTEIN", 99, 109], ["LC3", "PROTEIN", 110, 113], ["HpaI", "PROTEIN", 130, 134], ["XbaI", "PROTEIN", 139, 143], ["Bcl", "PROTEIN", 203, 206], ["xL", "PROTEIN", 207, 209], ["human genome", "DNA", 253, 265], ["Bcl", "PROTEIN", 277, 280], ["F", "DNA", 284, 285], ["Bcl", "DNA", 290, 293], ["xL", "DNA", 294, 296], ["human", "SPECIES", 253, 258], ["human", "SPECIES", 253, 258], ["pLVX", "TEST", 20, 24], ["mRFP-EGFP", "TEST", 25, 34], ["Bcl", "TEST", 35, 38], ["PLVX", "TEST", 55, 59], ["mRFP", "TEST", 60, 64], ["EGFP", "TEST", 65, 69], ["the fragment LC3", "TEST", 75, 91], ["LC3", "PROBLEM", 110, 113], ["XbaI", "TREATMENT", 139, 143], ["the transmembrane structure of fragment Bcl", "TREATMENT", 163, 206], ["Bcl", "TEST", 277, 280], ["xL", "TEST", 281, 283], ["Bcl", "TEST", 290, 293], ["fragment Bcl", "OBSERVATION", 194, 206], ["R.", "ANATOMY", 297, 299]]], ["To construct pLVX-N-Flag, the DNA fragment of TGEV N gene was amplified from TGEV-infected IPEC-J2 cells cDNA by primers N-F and N-R, subsequently, fused with Flag tag at 3' end by primers N-F and Flag-R.", [["IPEC-J2 cells", "ANATOMY", 91, 104], ["pLVX", "GENE_OR_GENE_PRODUCT", 13, 17], ["Flag", "GENE_OR_GENE_PRODUCT", 20, 24], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["TGEV", "ORGANISM", 46, 50], ["TGEV", "ORGANISM", 77, 81], ["IPEC-J2 cells", "CELL", 91, 104], ["N-F", "GENE_OR_GENE_PRODUCT", 121, 124], ["N-R", "GENE_OR_GENE_PRODUCT", 129, 132], ["Flag", "GENE_OR_GENE_PRODUCT", 159, 163], ["pLVX", "PROTEIN", 13, 17], ["N", "DNA", 18, 19], ["Flag", "PROTEIN", 20, 24], ["DNA fragment", "DNA", 30, 42], ["TGEV N gene", "DNA", 46, 57], ["TGEV-infected IPEC-J2 cells cDNA", "DNA", 77, 109], ["primers N-F and N-R", "DNA", 113, 132], ["Flag tag", "DNA", 159, 167], ["3' end", "DNA", 171, 177], ["Flag", "DNA", 197, 201], ["TGEV", "SPECIES", 46, 50], ["TGEV", "SPECIES", 77, 81], ["Flag", "TREATMENT", 20, 24], ["the DNA fragment", "PROBLEM", 26, 42], ["TGEV N gene", "TREATMENT", 46, 57], ["TGEV", "TEST", 77, 81], ["primers", "TEST", 113, 120], ["Flag tag", "TREATMENT", 159, 167], ["R.", "ANATOMY", 202, 204]]], ["Then the N-Flag fragment was inserted into the linearized pLVXpuro mentioned above.Plasmids and transfections gene transductionLentiviral production was achieved through calcium phosphate transfection of four plasmids, following the lentivirus packaging protocol [87] .", [["plasmids", "ANATOMY", 209, 217], ["calcium phosphate", "CHEMICAL", 170, 187], ["calcium phosphate", "CHEMICAL", 170, 187], ["Lentiviral", "ORGANISM", 127, 137], ["calcium", "SIMPLE_CHEMICAL", 170, 177], ["lentivirus", "ORGANISM", 233, 243], ["N-Flag fragment", "DNA", 9, 24], ["pLVXpuro", "PROTEIN", 58, 66], ["plasmids", "DNA", 209, 217], ["lentivirus", "SPECIES", 233, 243], ["the N-Flag fragment", "TREATMENT", 5, 24], ["Plasmids", "TREATMENT", 83, 91], ["transfections gene transductionLentiviral production", "TREATMENT", 96, 148], ["calcium phosphate transfection", "TREATMENT", 170, 200], ["four plasmids", "TREATMENT", 204, 217], ["the lentivirus packaging protocol", "TREATMENT", 229, 262], ["Flag fragment", "OBSERVATION", 11, 24]]], ["For infection 1 \u00d7 10 5 IPEC-J2 cells were plated in 9 cm 2 dishes a day prior to infection.", [["IPEC-J2 cells", "ANATOMY", 23, 36], ["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 81, 90], ["IPEC-J2 cells", "CELL", 23, 36], ["IPEC-J2 cells", "CELL_LINE", 23, 36], ["infection", "PROBLEM", 4, 13], ["IPEC-J2 cells", "TREATMENT", 23, 36], ["infection", "PROBLEM", 81, 90], ["infection", "OBSERVATION", 4, 13], ["9 cm", "OBSERVATION_MODIFIER", 52, 56], ["infection", "OBSERVATION", 81, 90]]], ["The day of infection the viral supernatant was supplemented with Polybrene (8 mg/mL) and added to the cells for 8 h. at a MOI (multiplicity of infection) of 1 to obtain single copy integration of the synthetic gene circuit.", [["supernatant", "ANATOMY", 31, 42], ["cells", "ANATOMY", 102, 107], ["infection", "DISEASE", 11, 20], ["Polybrene", "CHEMICAL", 65, 74], ["infection", "DISEASE", 143, 152], ["Polybrene", "CHEMICAL", 65, 74], ["Polybrene", "SIMPLE_CHEMICAL", 65, 74], ["cells", "CELL", 102, 107], ["synthetic gene circuit", "DNA", 200, 222], ["infection", "PROBLEM", 11, 20], ["the viral supernatant", "TREATMENT", 21, 42], ["Polybrene", "TREATMENT", 65, 74], ["infection", "PROBLEM", 143, 152], ["the synthetic gene circuit", "TREATMENT", 196, 222], ["infection", "OBSERVATION", 11, 20], ["viral supernatant", "OBSERVATION", 25, 42], ["infection", "OBSERVATION", 143, 152]]], ["The cells were then expanded in DMEM with 5 \u03bcg/mL puromycin.", [["cells", "ANATOMY", 4, 9], ["puromycin", "CHEMICAL", 50, 59], ["puromycin", "CHEMICAL", 50, 59], ["cells", "CELL", 4, 9], ["puromycin", "SIMPLE_CHEMICAL", 50, 59], ["puromycin", "TREATMENT", 50, 59]]], ["Cell lines infected with the ATG5 and DJ-1 shRNA vectors, and the negative control (scrambled) vector-infected cells, were designated shRNA-ATG5, shRNA-DJ1 and shRNA-control, respectively.Autophagic and mitophagic flux detectionThe principle of autophagy flux detection by mRFP-EGFP-LC3 is based on the differential stability of green and red fluorescent proteins at varying pH.", [["Cell lines", "ANATOMY", 0, 10], ["cells", "ANATOMY", 111, 116], ["Cell lines", "CELL", 0, 10], ["ATG5", "GENE_OR_GENE_PRODUCT", 29, 33], ["DJ-1", "GENE_OR_GENE_PRODUCT", 38, 42], ["cells", "CELL", 111, 116], ["ATG5", "GENE_OR_GENE_PRODUCT", 140, 144], ["shRNA-DJ1", "GENE_OR_GENE_PRODUCT", 146, 155], ["mRFP-EGFP-LC3", "GENE_OR_GENE_PRODUCT", 273, 286], ["red fluorescent proteins", "GENE_OR_GENE_PRODUCT", 339, 363], ["ATG5 and DJ-1 shRNA vectors", "DNA", 29, 56], ["negative control (scrambled) vector", "DNA", 66, 101], ["shRNA-ATG5, shRNA-DJ1 and shRNA-control", "DNA", 134, 173], ["mRFP-EGFP", "PROTEIN", 273, 282], ["LC3", "PROTEIN", 283, 286], ["green and red fluorescent proteins", "PROTEIN", 329, 363], ["Cell lines", "TREATMENT", 0, 10], ["the ATG5", "TREATMENT", 25, 33], ["DJ-1 shRNA vectors", "TREATMENT", 38, 56], ["infected cells", "PROBLEM", 102, 116], ["shRNA", "TEST", 134, 139], ["ATG5", "TEST", 140, 144], ["shRNA", "TEST", 146, 151], ["shRNA", "TEST", 160, 165], ["Autophagic and mitophagic flux detection", "PROBLEM", 188, 228], ["autophagy flux detection", "TEST", 245, 269], ["mRFP-EGFP", "TEST", 273, 282], ["green and red fluorescent proteins at varying pH", "PROBLEM", 329, 377], ["infected cells", "OBSERVATION", 102, 116], ["mitophagic flux", "OBSERVATION", 203, 218], ["autophagy flux", "OBSERVATION", 245, 259]]], ["The acidic environment (pH below 5) inside the lysosome quenches the fluorescent signal of EGFP, yet has much less effect on mRFP.", [["lysosome", "ANATOMY", 47, 55], ["lysosome", "CELLULAR_COMPONENT", 47, 55], ["EGFP", "GENE_OR_GENE_PRODUCT", 91, 95], ["mRFP", "GENE_OR_GENE_PRODUCT", 125, 129], ["EGFP", "PROTEIN", 91, 95], ["mRFP", "PROTEIN", 125, 129], ["EGFP", "TEST", 91, 95], ["acidic", "OBSERVATION_MODIFIER", 4, 10], ["less effect", "OBSERVATION_MODIFIER", 110, 121]]], ["In green/red merged images, yellow puncta (mRFP+ EGFP+) indicate autophagosomes, while red puncta (mRFP+ EGFP-) indicate autolysosomes.", [["yellow puncta", "ANATOMY", 28, 41], ["autophagosomes", "ANATOMY", 65, 79], ["red puncta", "ANATOMY", 87, 97], ["yellow puncta", "CELLULAR_COMPONENT", 28, 41], ["mRFP", "GENE_OR_GENE_PRODUCT", 43, 47], ["EGFP", "GENE_OR_GENE_PRODUCT", 49, 53], ["autophagosomes", "CELLULAR_COMPONENT", 65, 79], ["red puncta", "CELLULAR_COMPONENT", 87, 97], ["mRFP", "GENE_OR_GENE_PRODUCT", 99, 103], ["EGFP", "GENE_OR_GENE_PRODUCT", 105, 109], ["autolysosomes", "PATHOLOGICAL_FORMATION", 121, 134], ["yellow puncta", "PROTEIN", 28, 41], ["mRFP", "PROTEIN", 43, 47], ["EGFP", "PROTEIN", 49, 53], ["red puncta", "PROTEIN", 87, 97], ["mRFP", "PROTEIN", 99, 103], ["EGFP", "PROTEIN", 105, 109], ["autolysosomes", "PROTEIN", 121, 134], ["green/red merged images", "TEST", 3, 26], ["yellow puncta", "TEST", 28, 41], ["mRFP", "TEST", 43, 47], ["EGFP", "TEST", 49, 53], ["autophagosomes", "PROBLEM", 65, 79], ["red puncta", "TEST", 87, 97], ["mRFP", "TEST", 99, 103], ["EGFP", "TEST", 105, 109], ["autolysosomes", "PROBLEM", 121, 134], ["yellow puncta", "OBSERVATION", 28, 41]]], ["Rapamycin can efficiently induce autophagic flux resulting in red puncta accumulation [88, 89] , while CQ can efficiently inhibit the fusion of autophagosomes and lysosomes resulting in yellow puncta accumulation [90, 91] .", [["red puncta", "ANATOMY", 62, 72], ["autophagosomes", "ANATOMY", 144, 158], ["lysosomes", "ANATOMY", 163, 172], ["puncta", "ANATOMY", 193, 199], ["Rapamycin", "CHEMICAL", 0, 9], ["CQ", "CHEMICAL", 103, 105], ["Rapamycin", "CHEMICAL", 0, 9], ["Rapamycin", "SIMPLE_CHEMICAL", 0, 9], ["red puncta", "CELLULAR_COMPONENT", 62, 72], ["CQ", "SIMPLE_CHEMICAL", 103, 105], ["autophagosomes", "CELLULAR_COMPONENT", 144, 158], ["lysosomes", "CELLULAR_COMPONENT", 163, 172], ["yellow puncta", "CELLULAR_COMPONENT", 186, 199], ["Rapamycin", "TREATMENT", 0, 9], ["autophagic flux", "PROBLEM", 33, 48], ["red puncta accumulation", "PROBLEM", 62, 85], ["the fusion of autophagosomes", "PROBLEM", 130, 158], ["yellow puncta accumulation", "PROBLEM", 186, 212], ["autophagic flux", "OBSERVATION", 33, 48], ["puncta accumulation", "OBSERVATION", 66, 85], ["yellow puncta", "OBSERVATION", 186, 199]]], ["To detect autophagic flux in IPEC-J2 cells, we transfected pLVX-mRFP-EGFP-LC3 into IPEC-J2 cells and then infected with TGEV.", [["IPEC-J2 cells", "ANATOMY", 29, 42], ["IPEC-J2 cells", "ANATOMY", 83, 96], ["IPEC-J2 cells", "CELL", 29, 42], ["LC3", "GENE_OR_GENE_PRODUCT", 74, 77], ["IPEC-J2 cells", "CELL", 83, 96], ["TGEV", "ORGANISM", 120, 124], ["IPEC-J2 cells", "CELL_LINE", 29, 42], ["pLVX", "PROTEIN", 59, 63], ["mRFP-EGFP", "PROTEIN", 64, 73], ["LC3", "PROTEIN", 74, 77], ["IPEC-J2 cells", "CELL_LINE", 83, 96], ["TGEV", "SPECIES", 120, 124], ["autophagic flux", "TEST", 10, 25], ["IPEC", "TEST", 29, 33], ["J2 cells", "PROBLEM", 34, 42], ["pLVX", "TEST", 59, 63], ["EGFP", "TEST", 69, 73], ["J2 cells", "PROBLEM", 88, 96], ["TGEV", "PROBLEM", 120, 124], ["autophagic flux", "OBSERVATION", 10, 25], ["J2", "ANATOMY", 34, 36], ["J2 cells", "OBSERVATION", 88, 96]]], ["To induce complete autophagy flux, the cells were treated with 100 nmol/L rapamycin for 12 hours, to inhibit the autophagy flux, the cells were treated with 50 \u03bcmol/L CQ and 100 nmol/L rapamycin for 12 hours.Autophagic and mitophagic flux detectionThe principle of mitophagy flux detection by mRFP-EGFP-Bcl-xL is similar with mRFP-EGFP-LC3.", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 133, 138], ["rapamycin", "CHEMICAL", 74, 83], ["CQ", "CHEMICAL", 167, 169], ["rapamycin", "CHEMICAL", 185, 194], ["rapamycin", "CHEMICAL", 74, 83], ["CQ", "CHEMICAL", 167, 169], ["rapamycin", "CHEMICAL", 185, 194], ["cells", "CELL", 39, 44], ["rapamycin", "SIMPLE_CHEMICAL", 74, 83], ["cells", "CELL", 133, 138], ["CQ", "SIMPLE_CHEMICAL", 167, 169], ["rapamycin", "SIMPLE_CHEMICAL", 185, 194], ["mRFP-EGFP-Bcl-xL", "GENE_OR_GENE_PRODUCT", 293, 309], ["mRFP-EGFP-LC3", "GENE_OR_GENE_PRODUCT", 326, 339], ["mRFP-EGFP", "PROTEIN", 293, 302], ["Bcl", "PROTEIN", 303, 306], ["xL", "PROTEIN", 307, 309], ["mRFP-EGFP", "PROTEIN", 326, 335], ["LC3", "PROTEIN", 336, 339], ["complete autophagy flux", "PROBLEM", 10, 33], ["100 nmol/L rapamycin", "TREATMENT", 63, 83], ["the autophagy flux", "PROBLEM", 109, 127], ["L rapamycin", "TREATMENT", 183, 194], ["Autophagic and mitophagic flux detection", "PROBLEM", 208, 248], ["mitophagy flux detection", "TEST", 265, 289], ["mRFP-EGFP", "TEST", 293, 302], ["Bcl", "TEST", 303, 306], ["mRFP-EGFP", "TEST", 326, 335], ["autophagy flux", "OBSERVATION", 19, 33], ["mitophagic flux", "OBSERVATION", 223, 238], ["mitophagy flux", "OBSERVATION", 265, 279]]], ["To induce complete mitophagy flux, the cells were treated with 10 nmol/L CCCP for 3 hours.", [["cells", "ANATOMY", 39, 44], ["CCCP", "CHEMICAL", 73, 77], ["CCCP", "CHEMICAL", 73, 77], ["cells", "CELL", 39, 44], ["CCCP", "SIMPLE_CHEMICAL", 73, 77], ["complete mitophagy flux", "PROBLEM", 10, 33], ["10 nmol/L CCCP", "TREATMENT", 63, 77], ["mitophagy flux", "OBSERVATION", 19, 33]]], ["On the contrast, to inhibit the mitophagy flux, the cells were treated with 50 \u03bcmol/L CQ and 10 nmol/L CCCP for 3 hours.Autophagy inhibition and induction, mitochondrial membrane potential stabilization, and apoptosis inductionTo inhibit autophagy, cells were pre-treated with 5 mmol/L 3-MA in culture media for 12 hours prior to TGEV infection, then treated with 5 mmol/L 3-MA in fresh culture media after infection.", [["cells", "ANATOMY", 52, 57], ["mitochondrial membrane", "ANATOMY", 156, 178], ["cells", "ANATOMY", 249, 254], ["CQ", "CHEMICAL", 86, 88], ["CCCP", "CHEMICAL", 103, 107], ["3-MA", "CHEMICAL", 286, 290], ["TGEV infection", "DISEASE", 330, 344], ["3-MA", "CHEMICAL", 373, 377], ["infection", "DISEASE", 407, 416], ["CQ", "CHEMICAL", 86, 88], ["CCCP", "CHEMICAL", 103, 107], ["3-MA", "CHEMICAL", 286, 290], ["3-MA", "CHEMICAL", 373, 377], ["cells", "CELL", 52, 57], ["CQ", "SIMPLE_CHEMICAL", 86, 88], ["CCCP", "SIMPLE_CHEMICAL", 103, 107], ["mitochondrial membrane", "CELLULAR_COMPONENT", 156, 178], ["cells", "CELL", 249, 254], ["3-MA", "SIMPLE_CHEMICAL", 286, 290], ["TGEV", "ORGANISM", 330, 334], ["3-MA", "SIMPLE_CHEMICAL", 373, 377], ["TGEV", "SPECIES", 330, 334], ["Autophagy inhibition", "TREATMENT", 120, 140], ["induction", "TREATMENT", 145, 154], ["mitochondrial membrane potential stabilization", "TREATMENT", 156, 202], ["autophagy", "PROBLEM", 238, 247], ["MA in culture media", "TREATMENT", 288, 307], ["TGEV infection", "PROBLEM", 330, 344], ["fresh culture media", "TREATMENT", 381, 400], ["infection", "PROBLEM", 407, 416], ["mitophagy flux", "OBSERVATION", 32, 46], ["infection", "OBSERVATION", 335, 344], ["infection", "OBSERVATION", 407, 416]]], ["To induce macroautophagy, cells were pre-treated with 100 nmol/L rapamycin in culture media for 12 hours prior to infection, then treated with 100 nmol/L rapamycin in fresh culture media after TGEV infection.", [["cells", "ANATOMY", 26, 31], ["rapamycin", "CHEMICAL", 65, 74], ["infection", "DISEASE", 114, 123], ["rapamycin", "CHEMICAL", 154, 163], ["TGEV infection", "DISEASE", 193, 207], ["rapamycin", "CHEMICAL", 65, 74], ["rapamycin", "CHEMICAL", 154, 163], ["cells", "CELL", 26, 31], ["rapamycin", "SIMPLE_CHEMICAL", 65, 74], ["rapamycin", "SIMPLE_CHEMICAL", 154, 163], ["TGEV", "ORGANISM", 193, 197], ["TGEV", "SPECIES", 193, 197], ["macroautophagy", "PROBLEM", 10, 24], ["L rapamycin", "TREATMENT", 63, 74], ["culture media", "TREATMENT", 78, 91], ["infection", "PROBLEM", 114, 123], ["L rapamycin", "TREATMENT", 152, 163], ["fresh culture media", "TREATMENT", 167, 186], ["TGEV infection", "PROBLEM", 193, 207], ["infection", "OBSERVATION", 114, 123], ["infection", "OBSERVATION", 198, 207]]], ["To induce mitophagy, cells were pre-treated with 10 \u03bcmol/L CCCP in culture media for 3 hours prior to infection then 10 \u03bcmol/L CCCP in fresh culture media post TGEV infection.", [["cells", "ANATOMY", 21, 26], ["CCCP", "CHEMICAL", 59, 63], ["infection", "DISEASE", 102, 111], ["CCCP", "CHEMICAL", 127, 131], ["TGEV infection", "DISEASE", 160, 174], ["CCCP", "CHEMICAL", 59, 63], ["CCCP", "CHEMICAL", 127, 131], ["cells", "CELL", 21, 26], ["CCCP", "SIMPLE_CHEMICAL", 59, 63], ["CCCP", "SIMPLE_CHEMICAL", 127, 131], ["TGEV", "ORGANISM", 160, 164], ["TGEV", "SPECIES", 160, 164], ["mitophagy", "PROBLEM", 10, 19], ["L CCCP in culture media", "TREATMENT", 57, 80], ["infection", "PROBLEM", 102, 111], ["L CCCP", "TREATMENT", 125, 131], ["fresh culture media", "TREATMENT", 135, 154], ["TGEV infection", "PROBLEM", 160, 174], ["mitophagy", "OBSERVATION", 10, 19], ["TGEV infection", "OBSERVATION", 160, 174]]], ["To inhibit mitochondrial membrane potential decrease, the cells were pre-treated with 10 \u03bcmol/L CsA, an inhibitor for mPTP (mitochondrial permeability transition pore), in culture media for 12 hours prior to TGEV infection and 10 \u03bcmol/L CsA in fresh culture media after TGEV infection.", [["mitochondrial membrane", "ANATOMY", 11, 33], ["cells", "ANATOMY", 58, 63], ["mitochondrial", "ANATOMY", 124, 137], ["CsA", "CHEMICAL", 96, 99], ["mPTP", "CHEMICAL", 118, 122], ["TGEV infection", "DISEASE", 208, 222], ["CsA", "CHEMICAL", 237, 240], ["TGEV infection", "DISEASE", 270, 284], ["CsA", "CHEMICAL", 96, 99], ["CsA", "CHEMICAL", 237, 240], ["mitochondrial membrane", "CELLULAR_COMPONENT", 11, 33], ["cells", "CELL", 58, 63], ["CsA", "SIMPLE_CHEMICAL", 96, 99], ["mPTP", "SIMPLE_CHEMICAL", 118, 122], ["mitochondrial", "CELLULAR_COMPONENT", 124, 137], ["TGEV", "ORGANISM", 208, 212], ["CsA", "SIMPLE_CHEMICAL", 237, 240], ["TGEV", "ORGANISM", 270, 274], ["TGEV", "SPECIES", 208, 212], ["TGEV", "SPECIES", 270, 274], ["the cells", "PROBLEM", 54, 63], ["10 \u03bcmol/L CsA", "TREATMENT", 86, 99], ["an inhibitor", "TREATMENT", 101, 113], ["mPTP (mitochondrial permeability transition pore", "TREATMENT", 118, 166], ["culture media", "TREATMENT", 172, 185], ["TGEV infection", "PROBLEM", 208, 222], ["L CsA", "TREATMENT", 235, 240], ["fresh culture media", "TREATMENT", 244, 263], ["TGEV infection", "PROBLEM", 270, 284], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["infection", "OBSERVATION", 213, 222], ["infection", "OBSERVATION", 275, 284]]], ["To induce apoptosis, the cells were pre-treated with 100 \u03bcmol/L Rotenone in culture media, inducing apoptosis through the mitochondrial pathway [92] , for 24 hours prior to infection and 100 \u03bcmol/L Rotenone in fresh culture media after TGEV infection.", [["cells", "ANATOMY", 25, 30], ["mitochondrial", "ANATOMY", 122, 135], ["Rotenone", "CHEMICAL", 64, 72], ["infection", "DISEASE", 173, 182], ["Rotenone", "CHEMICAL", 198, 206], ["TGEV infection", "DISEASE", 236, 250], ["Rotenone", "CHEMICAL", 64, 72], ["Rotenone", "CHEMICAL", 198, 206], ["cells", "CELL", 25, 30], ["Rotenone", "SIMPLE_CHEMICAL", 64, 72], ["mitochondrial", "CELLULAR_COMPONENT", 122, 135], ["Rotenone", "SIMPLE_CHEMICAL", 198, 206], ["TGEV", "ORGANISM", 236, 240], ["TGEV", "SPECIES", 236, 240], ["apoptosis", "PROBLEM", 10, 19], ["Rotenone", "TREATMENT", 64, 72], ["culture media", "TREATMENT", 76, 89], ["infection", "PROBLEM", 173, 182], ["Rotenone", "TREATMENT", 198, 206], ["fresh culture media", "TREATMENT", 210, 229], ["TGEV infection", "PROBLEM", 236, 250], ["apoptosis", "OBSERVATION", 10, 19], ["infection", "OBSERVATION", 173, 182], ["infection", "OBSERVATION", 241, 250]]], ["Culture media in all cases was DMEM supplemented with 2% FBS.tGeV propagations and infectionsTGEV (SHXB strain) was provided by Jiangsu Provincial Academy of Environmental Science (JAAS), and propagated in ST cells.", [["FBS", "ANATOMY", 57, 60], ["ST cells", "ANATOMY", 206, 214], ["infections", "DISEASE", 83, 93], ["FBS", "ORGANISM_SUBSTANCE", 57, 60], ["tGeV", "GENE_OR_GENE_PRODUCT", 61, 65], ["TGEV", "ORGANISM", 93, 97], ["ST cells", "CELL", 206, 214], ["ST cells", "CELL_TYPE", 206, 214], ["TGEV", "SPECIES", 93, 97], ["Culture media", "TEST", 0, 13], ["2% FBS", "TREATMENT", 54, 60], ["tGeV propagations", "PROBLEM", 61, 78], ["infectionsTGEV (SHXB strain", "PROBLEM", 83, 110], ["infections", "OBSERVATION", 83, 93]]], ["50% Confluent IPEC-J2 cells were inoculated with TGEV at a MOI of 5 for 1 h at 37 \u00b0C. The inoculum and unattached virus were removed and fresh growth medium was added.", [["IPEC-J2 cells", "ANATOMY", 14, 27], ["IPEC-J2 cells", "CELL", 14, 27], ["TGEV", "ORGANISM", 49, 53], ["IPEC-J2 cells", "CELL_LINE", 14, 27], ["TGEV", "SPECIES", 49, 53], ["Confluent IPEC", "TEST", 4, 18], ["J2 cells", "PROBLEM", 19, 27], ["TGEV", "PROBLEM", 49, 53], ["The inoculum", "TREATMENT", 86, 98], ["unattached virus", "PROBLEM", 103, 119], ["fresh growth medium", "TREATMENT", 137, 156], ["Confluent", "OBSERVATION_MODIFIER", 4, 13], ["J2 cells", "OBSERVATION", 19, 27], ["inoculum", "OBSERVATION", 90, 98], ["unattached virus", "OBSERVATION", 103, 119], ["growth", "OBSERVATION_MODIFIER", 143, 149], ["medium", "OBSERVATION_MODIFIER", 150, 156]]], ["Infected cells were analyzed after the required incubation period.Plaque assayConfluent monolayers of ST cells grown in 6-well tissue culture plates were infected with 250 \u03bcL of serialWestern blot analysisCells were lysed in RIPA buffer (50 mMTris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40) containing a protease inhibitor cocktail (Thermo Scientific).", [["cells", "ANATOMY", 9, 14], ["monolayers", "ANATOMY", 88, 98], ["ST cells", "ANATOMY", 102, 110], ["tissue", "ANATOMY", 127, 133], ["Cells", "ANATOMY", 205, 210], ["mMTris-HCl", "CHEMICAL", 241, 251], ["NaCl", "CHEMICAL", 269, 273], ["NP-40", "CHEMICAL", 278, 283], ["HCl", "CHEMICAL", 248, 251], ["NaCl", "CHEMICAL", 269, 273], ["cells", "CELL", 9, 14], ["Plaque assayConfluent monolayers", "CELL", 66, 98], ["ST cells", "CELL", 102, 110], ["tissue culture plates", "CELL", 127, 148], ["Cells", "CELL", 205, 210], ["Plaque assayConfluent monolayers", "CELL_LINE", 66, 98], ["ST cells", "CELL_LINE", 102, 110], ["Infected cells", "PROBLEM", 0, 14], ["Plaque assayConfluent monolayers of ST cells", "PROBLEM", 66, 110], ["blot analysis", "TEST", 192, 205], ["Cells", "TEST", 205, 210], ["RIPA buffer", "TREATMENT", 225, 236], ["pH", "TEST", 253, 255], ["NaCl", "TEST", 269, 273], ["NP", "TEST", 278, 280], ["a protease inhibitor cocktail", "TREATMENT", 296, 325], ["ST cells", "OBSERVATION_MODIFIER", 102, 110]]], ["Protein concentration was determined by BCA protein quantification kit (Thermo Scientific).", [["Protein concentration", "TEST", 0, 21]]], ["Equal amounts of protein were separated by SDS-PAGE and electrophoretically transferred onto a PVDF membrane (Millipore, Shanghai, China).", [["PVDF membrane", "ANATOMY", 95, 108], ["PVDF", "CHEMICAL", 95, 99], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["a PVDF membrane", "TREATMENT", 93, 108], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["After blocking with 5% nonfat milk in Tris-buffered saline containing 0.1% Tween-20, the membrane was incubated with specific primary antibodies (1:1000), followed by incubation with appropriate horseradish peroxidase-conjugated secondary antibodies.", [["nonfat milk", "ANATOMY", 23, 34], ["membrane", "ANATOMY", 89, 97], ["Tween-20", "CHEMICAL", 75, 83], ["Tris", "CHEMICAL", 38, 42], ["Tween-20", "CHEMICAL", 75, 83], ["milk", "ORGANISM_SUBSTANCE", 30, 34], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 38, 58], ["Tween-20", "SIMPLE_CHEMICAL", 75, 83], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 195, 217], ["primary antibodies", "PROTEIN", 126, 144], ["horseradish peroxidase", "PROTEIN", 195, 217], ["conjugated secondary antibodies", "PROTEIN", 218, 249], ["horseradish", "SPECIES", 195, 206], ["blocking", "TREATMENT", 6, 14], ["5% nonfat milk in Tris-buffered saline", "TREATMENT", 20, 58], ["appropriate horseradish peroxidase", "TREATMENT", 183, 217], ["conjugated secondary antibodies", "PROBLEM", 218, 249]]], ["Signals were detected using SuperSignal WestPico kit (Thermo Scientific), and subjected to Image Reader LAS-4000 imaging system (FUJIFLIM, Japan).Quantitative RT-PCRFor quantitative reverse transcription-polymerase chain reaction (qRT-PCR), total cellular RNA was extracted with TRIZOL (Life Technologies) and RNA was reverse-transcribed (TaKaRa, Dalian, China). qPCR was performed using the Real-Time PCR system (ABI 7500, Life Technologies, USA).", [["cellular", "ANATOMY", 247, 255], ["cellular", "CELL", 247, 255], ["cellular RNA", "RNA", 247, 259], ["Quantitative RT", "TEST", 146, 161], ["polymerase chain reaction", "PROBLEM", 204, 229], ["qRT", "TEST", 231, 234], ["PCR", "TEST", 235, 238], ["total cellular RNA", "PROBLEM", 241, 259], ["TRIZOL (Life Technologies", "TREATMENT", 279, 304], ["qPCR", "TEST", 363, 367], ["ABI", "TEST", 414, 417], ["cellular RNA", "OBSERVATION", 247, 259]]], ["Gene expression was calculated with the comparative Ct method and normalized to the endogenous levels of GAPDH.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 105, 110], ["GAPDH", "PROTEIN", 105, 110], ["the comparative Ct method", "TEST", 36, 61], ["GAPDH", "PROBLEM", 105, 110]]], ["Primer sequences used for qRT-PCR are listed in Table 2 .Fluorescence microscopyIPEC-J2 cells were transiently transfected with pmCherry-EGFP-LC3 24 h prior to virus infection.", [["microscopyIPEC-J2 cells", "ANATOMY", 70, 93], ["infection", "DISEASE", 166, 175], ["microscopyIPEC-J2 cells", "CELL", 70, 93], ["LC3", "GENE_OR_GENE_PRODUCT", 142, 145], ["Primer sequences", "DNA", 0, 16], ["qRT", "DNA", 26, 29], ["microscopyIPEC-J2 cells", "CELL_LINE", 70, 93], ["pmCherry", "PROTEIN", 128, 136], ["-EGFP", "PROTEIN", 136, 141], ["LC3", "PROTEIN", 142, 145], ["Primer sequences", "TEST", 0, 16], ["qRT", "TEST", 26, 29], ["Fluorescence microscopyIPEC", "TEST", 57, 84], ["J2 cells", "PROBLEM", 85, 93], ["pmCherry-EGFP", "TEST", 128, 141], ["virus infection", "PROBLEM", 160, 175], ["J2 cells", "OBSERVATION", 85, 93], ["infection", "OBSERVATION", 166, 175]]], ["IPEC-J2 cells were transfected with pLVX-mitomCherry-IRES-EGFPLC3B or pLVX-mito-mCherry and cultured 1 week in DMEM/10% FBS containing 3 \u03bcg/mL puromycin.", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["FBS", "ANATOMY", 120, 123], ["puromycin", "CHEMICAL", 143, 152], ["puromycin", "CHEMICAL", 143, 152], ["IPEC-J2 cells", "CELL", 0, 13], ["pLVX-mitomCherry-IRES-EGFPLC3B", "GENE_OR_GENE_PRODUCT", 36, 66], ["pLVX-mito-mCherry", "GENE_OR_GENE_PRODUCT", 70, 87], ["FBS", "ORGANISM_SUBSTANCE", 120, 123], ["puromycin", "SIMPLE_CHEMICAL", 143, 152], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["pLVX-mitomCherry-IRES-EGFPLC3B", "DNA", 36, 66], ["pLVX", "DNA", 70, 74], ["mito", "DNA", 75, 79], ["mCherry", "DNA", 80, 87], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["pLVX", "TEST", 36, 40], ["mitomCherry", "TEST", 41, 52], ["pLVX", "TEST", 70, 74], ["FBS", "TEST", 120, 123], ["puromycin", "TREATMENT", 143, 152], ["J2 cells", "OBSERVATION", 5, 13]]], ["Cells were grown on coverslips and fixed with 4% paraformaldehyde for observation with a Zeiss LSM710 confocal microscope (Carl Zeiss, Germany), the images were analyzed using ZEN 2012 (Blue edition) (Carl Zeiss).Flow cytometryApoptotic cell death was detected by Annexin V/ propidium iodide (PI) staining assay (Miltenyi Biotec, Shanghai, China) according to the manufacturer's protocols.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 237, 241], ["death", "DISEASE", 242, 247], ["Annexin V", "CHEMICAL", 264, 273], ["propidium iodide", "CHEMICAL", 275, 291], ["paraformaldehyde", "CHEMICAL", 49, 65], ["propidium iodide", "CHEMICAL", 275, 291], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 49, 65], ["cell", "CELL", 237, 241], ["Annexin V", "GENE_OR_GENE_PRODUCT", 264, 273], ["propidium iodide", "SIMPLE_CHEMICAL", 275, 291], ["PI", "SIMPLE_CHEMICAL", 293, 295], ["Miltenyi Biotec", "PROTEIN", 313, 328], ["coverslips", "TEST", 20, 30], ["4% paraformaldehyde", "TREATMENT", 46, 65], ["the images", "TEST", 145, 155], ["Flow cytometryApoptotic cell death", "PROBLEM", 213, 247], ["Annexin V/ propidium iodide", "TREATMENT", 264, 291], ["staining assay", "TEST", 297, 311], ["the manufacturer's protocols", "TREATMENT", 360, 388], ["cytometryApoptotic cell death", "OBSERVATION", 218, 247]]], ["Briefly, cells were harvested and washed once with PBS, then resuspended in 100 \u03bcL binding buffer followed by incubation with 10 \u03bcL Annexin V per test for 20 min.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["Annexin V", "GENE_OR_GENE_PRODUCT", 132, 141], ["PBS", "TREATMENT", 51, 54], ["10 \u03bcL Annexin V", "TREATMENT", 126, 141]]], ["Cells was washed again, suspended in 500 \u03bcL of binding buffer and 5 \u03bcL PI per test was added and immediately analysis by flow cytometry (FACS) (Becton, Dickinson and Company, USA).Flow cytometryDysfunctional mitochondria were monitored by fluorescence levels upon staining with 100 nM MitoTracker Green FM (total mitochondria) (Life Technologies) and 500 nM MitoTracker Red CMXRos (functional mitochondria) (Life Technologies) for 25 min at 37 \u00b0C, after which, cells washed with PBS and analyzed at FL-1 and FL-3 by FACS.", [["Cells", "ANATOMY", 0, 5], ["mitochondria", "ANATOMY", 208, 220], ["mitochondria", "ANATOMY", 313, 325], ["mitochondria", "ANATOMY", 393, 405], ["cells", "ANATOMY", 461, 466], ["Cells", "CELL", 0, 5], ["mitochondria", "CELLULAR_COMPONENT", 208, 220], ["mitochondria", "CELLULAR_COMPONENT", 313, 325], ["mitochondria", "CELLULAR_COMPONENT", 393, 405], ["cells", "CELL", 461, 466], ["FL-1", "GENE_OR_GENE_PRODUCT", 499, 503], ["FL-3", "CELL", 508, 512], ["FACS", "CELL", 516, 520], ["binding buffer", "TREATMENT", 47, 61], ["flow cytometry", "TEST", 121, 135], ["Flow cytometryDysfunctional mitochondria", "TEST", 180, 220], ["fluorescence levels", "TEST", 239, 258], ["Red CMXRos", "TEST", 370, 380], ["PBS", "TREATMENT", 479, 482], ["FL", "TEST", 499, 501], ["FL", "TEST", 508, 510]]], ["Mitochondrial mass was measured by fluorescence levels upon staining with 100 nM Mitotracker Green FM for 25 min at 37 \u00b0C, after which, cells were then washed with PBS and analyzed at FL-1 by FACS.", [["Mitochondrial", "ANATOMY", 0, 13], ["cells", "ANATOMY", 136, 141], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["cells", "CELL", 136, 141], ["Mitochondrial mass", "PROBLEM", 0, 18], ["fluorescence levels", "TEST", 35, 54], ["100 nM Mitotracker Green FM", "TREATMENT", 74, 101], ["PBS", "TREATMENT", 164, 167], ["mass", "OBSERVATION", 14, 18]]], ["In parallel, the mean of mCherry in mito-mCherry positive cells were also used to detect the mass of mitochondria at FL-3 by FACS.Flow cytometryTo detect the degree of mitochondria injury after TGEV infection, the mitochondrial membrane potential (\u0394\u03c8) was monitored by fluorescence levels upon staining with 1\u03bcg/mL Rhodamine 123 for 25 min at 37 \u00b0C. After staining, cells were then washed with PBS and analyzed at FL-1 by FACS.Flow cytometryTo detect the degree of autophagy after TGEV infection, cells were incubated in Cyto-ID (1 \u03bcL Cyto-ID/1mL cell culture medium without phenol red indicator) for 30 minutes and washed prior to analysis by FACS.", [["mito-mCherry positive cells", "ANATOMY", 36, 63], ["mitochondria", "ANATOMY", 101, 113], ["mitochondria", "ANATOMY", 168, 180], ["mitochondrial membrane", "ANATOMY", 214, 236], ["cells", "ANATOMY", 366, 371], ["cells", "ANATOMY", 497, 502], ["cell", "ANATOMY", 547, 551], ["TGEV infection", "DISEASE", 194, 208], ["Rhodamine 123", "CHEMICAL", 315, 328], ["TGEV infection", "DISEASE", 481, 495], ["phenol", "CHEMICAL", 575, 581], ["Rhodamine 123", "CHEMICAL", 315, 328], ["phenol red", "CHEMICAL", 575, 585], ["mCherry", "GENE_OR_GENE_PRODUCT", 25, 32], ["mCherry", "GENE_OR_GENE_PRODUCT", 41, 48], ["mitochondria", "CELLULAR_COMPONENT", 101, 113], ["FL-3", "GENE_OR_GENE_PRODUCT", 117, 121], ["mitochondria", "CELLULAR_COMPONENT", 168, 180], ["TGEV", "ORGANISM", 194, 198], ["mitochondrial membrane", "CELLULAR_COMPONENT", 214, 236], ["Rhodamine 123", "SIMPLE_CHEMICAL", 315, 328], ["cells", "CELL", 366, 371], ["TGEV", "ORGANISM", 481, 485], ["cells", "CELL", 497, 502], ["cell", "CELL", 547, 551], ["mCherry", "PROTEIN", 25, 32], ["mito-mCherry positive cells", "CELL_LINE", 36, 63], ["FL", "PROTEIN", 117, 119], ["TGEV", "SPECIES", 194, 198], ["TGEV", "SPECIES", 481, 485], ["the mass of mitochondria", "PROBLEM", 89, 113], ["Flow cytometry", "TEST", 130, 144], ["mitochondria injury", "PROBLEM", 168, 187], ["TGEV infection", "PROBLEM", 194, 208], ["fluorescence levels", "TEST", 269, 288], ["Rhodamine", "TREATMENT", 315, 324], ["PBS", "TREATMENT", 394, 397], ["Flow cytometry", "TEST", 427, 441], ["autophagy", "PROBLEM", 465, 474], ["TGEV infection", "PROBLEM", 481, 495], ["Cyto", "TEST", 521, 525], ["Cyto", "TEST", 535, 539], ["phenol red indicator", "TREATMENT", 575, 595], ["parallel", "OBSERVATION_MODIFIER", 3, 11], ["positive cells", "OBSERVATION", 49, 63], ["mass", "OBSERVATION", 93, 97], ["mitochondria injury", "OBSERVATION", 168, 187], ["TGEV", "OBSERVATION_MODIFIER", 194, 198], ["infection", "OBSERVATION", 199, 208]]], ["The Cyto-ID assay (Enzo Life Sciences, Shanghai, China) incorporates a 488 nm-excitable green fluorescent detection reagent that specifically fluoresces in autophagic vesicles.", [["autophagic vesicles", "ANATOMY", 156, 175], ["autophagic vesicles", "CELLULAR_COMPONENT", 156, 175], ["excitable green fluorescent detection reagent", "TREATMENT", 78, 123], ["autophagic vesicles", "OBSERVATION", 156, 175]]], ["An increase in the number of autophagic vesicles labeled with green is detected as an increase in fluorescence in the FL-1 channel.Flow cytometryThe intracellular production of ROS and mitochondrial ROS was measured by using the fluorescent probe 6-carboxy-2', 7'-dichorodihydrofluorescein diacetate (DCFH-DA) and Dihydroethidium (DHE), respectively.", [["autophagic vesicles", "ANATOMY", 29, 48], ["intracellular", "ANATOMY", 149, 162], ["mitochondrial", "ANATOMY", 185, 198], ["ROS", "CHEMICAL", 177, 180], ["ROS", "CHEMICAL", 199, 202], ["6-carboxy-2', 7'-dichorodihydrofluorescein diacetate", "CHEMICAL", 247, 299], ["DCFH-DA", "CHEMICAL", 301, 308], ["Dihydroethidium", "CHEMICAL", 314, 329], ["DHE", "CHEMICAL", 331, 334], ["6-carboxy-2', 7'-dichorodihydrofluorescein diacetate", "CHEMICAL", 247, 299], ["DCFH-DA", "CHEMICAL", 301, 308], ["Dihydroethidium", "CHEMICAL", 314, 329], ["DHE", "CHEMICAL", 331, 334], ["autophagic vesicles", "CELLULAR_COMPONENT", 29, 48], ["FL-1", "GENE_OR_GENE_PRODUCT", 118, 122], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 149, 162], ["ROS", "SIMPLE_CHEMICAL", 177, 180], ["mitochondrial", "CELLULAR_COMPONENT", 185, 198], ["ROS", "SIMPLE_CHEMICAL", 199, 202], ["6-carboxy-2', 7'-dichorodihydrofluorescein diacetate", "SIMPLE_CHEMICAL", 247, 299], ["DCFH-DA", "SIMPLE_CHEMICAL", 301, 308], ["Dihydroethidium", "SIMPLE_CHEMICAL", 314, 329], ["DHE", "SIMPLE_CHEMICAL", 331, 334], ["FL-1 channel", "PROTEIN", 118, 130], ["Flow cytometry", "TEST", 131, 145], ["mitochondrial ROS", "TEST", 185, 202], ["the fluorescent probe", "TREATMENT", 225, 246], ["carboxy", "TREATMENT", 249, 256], ["7'-dichorodihydrofluorescein diacetate", "TREATMENT", 261, 299], ["Dihydroethidium (DHE)", "TREATMENT", 314, 335], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["number", "OBSERVATION_MODIFIER", 19, 25], ["autophagic vesicles", "OBSERVATION", 29, 48], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["FL", "ANATOMY", 118, 120], ["intracellular", "OBSERVATION_MODIFIER", 149, 162], ["production", "OBSERVATION_MODIFIER", 163, 173]]], ["After treatment or TGEV infection, cells were incubated with 10 \u03bcM DCFH-DA or 40 \u03bcM DHE in serum-free medium for 10 minutes at 37 \u00b0C. Afterwards, cells were harvested and resuspended in 500 \u03bcL of PBS, and DCF and DHE fluorescence was measured by FACS.", [["cells", "ANATOMY", 35, 40], ["serum", "ANATOMY", 91, 96], ["cells", "ANATOMY", 146, 151], ["TGEV infection", "DISEASE", 19, 33], ["DCFH", "CHEMICAL", 67, 71], ["DA", "CHEMICAL", 72, 74], ["DHE", "CHEMICAL", 84, 87], ["DCF", "CHEMICAL", 205, 208], ["DHE", "CHEMICAL", 213, 216], ["DHE", "CHEMICAL", 84, 87], ["DCF", "CHEMICAL", 205, 208], ["DHE", "CHEMICAL", 213, 216], ["TGEV", "ORGANISM", 19, 23], ["cells", "CELL", 35, 40], ["DCFH-DA", "SIMPLE_CHEMICAL", 67, 74], ["DHE", "SIMPLE_CHEMICAL", 84, 87], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["cells", "CELL", 146, 151], ["DCF", "SIMPLE_CHEMICAL", 205, 208], ["DHE", "SIMPLE_CHEMICAL", 213, 216], ["TGEV", "SPECIES", 19, 23], ["treatment", "TREATMENT", 6, 15], ["TGEV infection", "PROBLEM", 19, 33], ["serum", "TEST", 91, 96], ["PBS", "TREATMENT", 196, 199], ["DCF", "TREATMENT", 205, 208], ["DHE fluorescence", "TEST", 213, 229], ["infection", "OBSERVATION", 24, 33]]], ["All data were analyzed using FlowJo software (Version 7.6.5, Tree Star Inc., Ashland, Oregon).cell fractionationMitochondrial and cytoplasmic proteins were separated using a Mitochondria/Cytosol Fractionation Kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol.", [["cell", "ANATOMY", 94, 98], ["Mitochondrial", "ANATOMY", 112, 125], ["cytoplasmic", "ANATOMY", 130, 141], ["Mitochondria", "ANATOMY", 174, 186], ["cell", "CELL", 94, 98], ["Mitochondrial", "CELLULAR_COMPONENT", 112, 125], ["cytoplasmic", "ORGANISM_SUBSTANCE", 130, 141], ["Mitochondrial and cytoplasmic proteins", "PROTEIN", 112, 150], ["All data", "TEST", 0, 8], ["FlowJo software", "TEST", 29, 44], ["Version", "TEST", 46, 53], ["cell fractionation", "TREATMENT", 94, 112], ["cytoplasmic proteins", "TEST", 130, 150], ["a Mitochondria/Cytosol Fractionation", "TREATMENT", 172, 208], ["the manufacturer's protocol", "TREATMENT", 264, 291], ["cytoplasmic proteins", "OBSERVATION", 130, 150]]], ["Briefly, 5 \u00d7 10 7 cells were harvested and washed twice with ice-cold PBS, cells were then incubated in 500 \u03bcL ice-cold mitochondrial lysis buffer on ice for 10 min.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 75, 80], ["mitochondrial", "ANATOMY", 120, 133], ["cells", "CELL", 18, 23], ["cells", "CELL", 75, 80], ["mitochondrial", "CELLULAR_COMPONENT", 120, 133], ["ice-cold PBS", "TREATMENT", 61, 73], ["cold mitochondrial lysis buffer", "TREATMENT", 115, 146], ["mitochondrial lysis", "OBSERVATION", 120, 139]]], ["Using a glass Dounce homogenizer with a tight pestle, the cell suspension was then homogenized for 50 strokes on ice.", [["cell", "ANATOMY", 58, 62], ["strokes", "DISEASE", 102, 109], ["cell", "CELL", 58, 62], ["a glass Dounce homogenizer", "TREATMENT", 6, 32], ["a tight pestle", "TREATMENT", 38, 52], ["the cell suspension", "TREATMENT", 54, 73]]], ["The homogenate was centrifuged at 800 g for 10 min at 4 \u00b0C to remove any unbroken cells.", [["homogenate", "ANATOMY", 4, 14], ["cells", "ANATOMY", 82, 87], ["cells", "CELL", 82, 87], ["unbroken cells", "CELL_TYPE", 73, 87], ["any unbroken cells", "PROBLEM", 69, 87], ["unbroken cells", "OBSERVATION", 73, 87]]], ["The supernatant was further centrifuged at 12000 g for 10 min at 4 \u00b0C to remove the mitochondrial fraction (pellet) and cytoplasmic proteins (supernatant).", [["supernatant", "ANATOMY", 4, 15], ["mitochondrial", "ANATOMY", 84, 97], ["pellet", "ANATOMY", 108, 114], ["cytoplasmic", "ANATOMY", 120, 131], ["supernatant", "ANATOMY", 142, 153], ["mitochondrial", "CELLULAR_COMPONENT", 84, 97], ["cytoplasmic", "ORGANISM_SUBSTANCE", 120, 131], ["cytoplasmic proteins", "PROTEIN", 120, 140], ["The supernatant", "TREATMENT", 0, 15], ["the mitochondrial fraction", "TEST", 80, 106], ["cytoplasmic proteins", "TEST", 120, 140]]], ["Proteins were quantified and subjected to immune blotting.statisticsData are presented as means \u00b1 SEM.", [["Proteins", "TEST", 0, 8], ["immune blotting", "PROBLEM", 42, 57], ["immune blotting", "OBSERVATION", 42, 57]]], ["Statistical analysis was performed using Statistical Program for Social Sciences (SPSS) 16.0.", [["Statistical analysis", "TEST", 0, 20]]], ["A P value less than 0.05 was considered to be significant, and less than 0.01 was considered to be highly significant.", [["A P value", "TEST", 0, 9]]]], "70aa6885b1447f289838ae767e04dead78e76514": [["Door verbetering van de medische zorg neemt de conditie van pati\u00ebnten met chronische aandoeningen toe en stijgt het aantal vrouwen met dergelijke aandoeningen dat zwanger wordt.", [["toe", "ANATOMY", 98, 101]]], ["Dit vereist ook van de verloskundig hulpverlener kennis van het onderliggend lijden, kennis van de invloed ervan op de zwangerschap en kennis van de gevolgen van de zwangerschap op het verloop van de chronische ziekte.", [["Dit vereist ook van de verloskundig hulpverlener kennis van het onderliggend lijden, kennis van de invloed ervan op de zwangerschap en kennis van de gevolgen van de zwangerschap op het verloop van de chronische ziekte", "SPECIES", 0, 217]]], ["Ook hierbij is het van belang goed op de hoogte te zijn van de effecten van infecties op het zwangerschapsbeloop en de foetale ontwikkeling.InleidingDe bijzondere omstandigheden die de zwangerschap cre\u00ebert, maken de bestudering van de interactie met chronische aandoeningen en infecties uitermate boeiend.InfectieziektenDe kans om geconfronteerd te worden met een infectieziekte verschilt weinig tussen een zwangere en een niet-zwangere van dezelfde leeftijd.", [["InfectieziektenDe kans om geconfronteerd te worden met een infectieziekte verschilt weinig tussen een zwangere en een niet-zwangere van dezelfde leeftijd", "SPECIES", 305, 458], ["InfectieziektenDe", "TREATMENT", 305, 322], ["een infectieziekte verschilt", "TREATMENT", 360, 388], ["een zwangere", "TREATMENT", 403, 415]]], ["Voorts is bij de behandeling van een infectie de keuze van de geneesmiddelen beperkt door de aanwezigheid van de foetus of moet die juist zelfs worden toegespitst op medebehandeling van de foetus.InfectieziektenHet aantal infectieziekten dat invloed heeft op de zwangerschap, lijkt nog steeds te stijgen, niet in de laatste plaats door een toename van de diagnostische mogelijkheden.", [["Infectieziekten", "TEST", 196, 211]]], ["Neurologische stoornissen na een rubella-, toxoplasmose-of cytomegalie-infectie zijn een ieder bekend, maar dat schizofrenie ook het gevolg kan zijn van maternale infecties (influenza, rubella en toxoplasmose, met name in het tweede trimester) is minder bekend.", [["na", "CHEMICAL", 26, 28], ["maternale infecties", "DISEASE", 153, 172], ["influenza", "DISEASE", 174, 183], ["rubella en toxoplasmose", "DISEASE", 185, 208], ["Neurologische", "TEST", 0, 13], ["een rubella-", "TEST", 29, 41], ["toxoplasmose", "TEST", 43, 55], ["cytomegalie", "PROBLEM", 59, 70], ["infectie", "PROBLEM", 71, 79], ["influenza", "PROBLEM", 174, 183], ["rubella", "PROBLEM", 185, 192]]], ["Ook diabetes en de ziekte van Crohn worden verhoogd waargenomen na een prenatale infectie met respectievelijk een enterovirus en mazelen.", [["Ook diabetes", "DISEASE", 0, 12], ["diabetes", "PROBLEM", 4, 12], ["na een prenatale infectie", "TREATMENT", 64, 89], ["een enterovirus en mazelen", "TREATMENT", 110, 136]]], ["Schizofrenie na influenza in de zwangerschap lijkt Historie Infecties hebben in de verloskunde altijd een belangrijke rol gespeeld.", [["na", "CHEMICAL", 13, 15], ["influenza", "PROBLEM", 16, 25]]], ["Lehman verzette zich tegen de asepsis en de antisepsis, die respectievelijk door Semmelweis en Lister werden gepropageerd.", [["Lehman verzette zich tegen de asepsis en de antisepsis, die respectievelijk door Semmelweis en Lister werden gepropageerd", "SPECIES", 0, 121], ["Lehman verzette zich", "TREATMENT", 0, 20]]], ["Het onderzoek dat Leopold Lehman zelf verrichtte naar het ontstaan van kraamvrouwenkoorts, bestond uit het met dezelfde thermometer, zonder tussentijdse reiniging, opnemen van de temperatuur in de baarmoedermond van afwisselend vrouwen met en vrouwen zonder kraamvrouwenkoorts.InfectieziektenNa zijn overlijden nam in 1881 professor Gerrit Hendrik van der Meij het roer van Lehman over.", [["Het", "TEST", 0, 3], ["Leopold", "TEST", 18, 25]]], ["Treub noemde hierin als veroorzakende micro-organismen van de kraamvrouwenkoorts onder meer de Gonococcus, de Staphylococcus pyogenes, de Streptococcus pyogenes, de Bacterium coli en de Pneumococcus.", [["Staphylococcus pyogenes", "DISEASE", 110, 133], ["Streptococcus pyogenes", "DISEASE", 138, 160], ["Staphylococcus pyogenes", "ORGANISM", 110, 133], ["Streptococcus pyogenes", "ORGANISM", 138, 160], ["Bacterium coli", "ORGANISM", 165, 179], ["Pneumococcus", "ORGANISM", 186, 198], ["Staphylococcus pyogenes", "SPECIES", 110, 133], ["Streptococcus pyogenes", "SPECIES", 138, 160], ["Bacterium coli", "SPECIES", 165, 179], ["Staphylococcus pyogenes", "SPECIES", 110, 133], ["Streptococcus pyogenes", "SPECIES", 138, 160], ["Bacterium coli", "SPECIES", 165, 179], ["Staphylococcus pyogenes", "PROBLEM", 110, 133], ["Streptococcus pyogenes", "PROBLEM", 138, 160], ["Bacterium coli", "PROBLEM", 165, 179], ["Pneumococcus", "PROBLEM", 186, 198], ["Staphylococcus pyogenes", "OBSERVATION", 110, 133], ["Pneumococcus", "OBSERVATION", 186, 198]]], ["Als specifieke behandeling werd gebruikgemaakt van vaginale en eventuele intrauteriene irrigaties met een antiseptische oplossing.", [["intrauteriene irrigaties", "TREATMENT", 73, 97]]], ["Het curetteren van placentaresten werd als gevaarlijk van de hand gewezen.", [["Het curetteren van placentaresten", "TREATMENT", 0, 33]]], ["Kan men over goeden wijn beschikken, dan laat men de pati\u00ebnte liefst zwaren wijn, bijvoorbeeld Bourgogne, drinken dien men ook met portwijn kan afwisselen.", [["men", "SPECIES", 4, 7], ["men", "SPECIES", 46, 49], ["men", "SPECIES", 119, 122]]], ["Verder wordt cognac toegediend...'InfectieziektenAfgezien van de behandeling is er sinds die tijd voornamelijk verandering gekomen in het aantal microorganismen dat endometritis en puerperale sepsis veroorzaakt.", [["endometritis", "DISEASE", 165, 177], ["sepsis veroorzaakt", "DISEASE", 192, 210], ["endometritis", "PROBLEM", 165, 177], ["sepsis veroorzaakt", "PROBLEM", 192, 210], ["sepsis", "OBSERVATION", 192, 198]]], ["Vooral de anaeroben, zoals Bacteroides, zijn daar bijgekomen en ook de Chlamydia is een potenti\u00eble verwekker van endometritis.InfectieziektenDat de kraamvrouwenkoorts een belangrijk deel zou uitmaken van het genoemde Leerboek der verloskunde is gezien de dramatische voorgeschiedenis en het toen nog ontbreken van antibiotica niet zo verwonderlijk.", [["Chlamydia", "DISEASE", 71, 80], ["endometritis", "DISEASE", 113, 125], ["zoals Bacteroides", "ORGANISM", 21, 38], ["zijn daar", "ORGANISM", 40, 49], ["Vooral de anaeroben, zoals Bacteroides", "TREATMENT", 0, 38], ["zijn daar bijgekomen", "TREATMENT", 40, 60], ["van endometritis", "PROBLEM", 109, 125], ["een belangrijk", "TREATMENT", 167, 181]]], ["Acute infectieziekten konden een abortus veroorzaken, maar ook (zoals aangetoond voor variola en erysipelas) direct overgaan als ziekte op de vrucht.", [["erysipelas", "DISEASE", 97, 107], ["Acute infectieziekten konden", "PROBLEM", 0, 28], ["variola en erysipelas", "TREATMENT", 86, 107]]], ["Zeer interessant zijn de veranderde idee\u00ebn over de besmetting van de vrucht in de periode tussen de vierde druk in 1909 en de zevende druk in 1925 (geheel herzien door Van Rooy).", [["periode tussen de vierde druk in 1909 en de zevende druk in 1925 (geheel herzien door Van Rooy", "SPECIES", 82, 176]]], ["Het interessante van deze theorie is dat hij weer opdook bij hiv-infecties, maar ook bij die infecties moet deze mogelijkheid als zeer onwaarschijnlijk worden afgedaan. niet het gevolg van een directe infectie van de foetus maar van de immuunactivatie bij de moeder via de geproduceerde interleukinen (IL-6 en IL-8) en TNF-\u03b1, die via de placenta de foetus bereiken.", [["TNF-\u03b1", "SIMPLE_CHEMICAL", 319, 324], ["placenta", "ORGANISM", 337, 345], ["TNF", "PROTEIN", 319, 322], ["bij de moeder via de geproduceerde interleukinen (IL-6 en IL", "TREATMENT", 252, 312]]], ["Bij medicamenteuze behandeling zal dat vaak betekenen dat een aantal antibiotica beter niet gebruikt kan worden.", [["Bij medicamenteuze behandeling zal dat vaak betekenen dat een aantal antibiotica beter niet gebruikt kan worden", "SPECIES", 0, 111], ["een aantal antibiotica", "TREATMENT", 58, 80]]], ["Doordat (multi)resistentievorming van bacteri\u00ebn een steeds vaker voorkomend verschijnsel is, zal het in de toekomst wel steeds moeilijker worden om nog goede antibiotica te geven die niet toxisch zijn voor de foetus.", [["Doordat (multi)resistentievorming van bacteri\u00ebn een", "TREATMENT", 0, 51]]], ["Een mogelijke (oude) oplossing is het gebruik als medicament van bacteriofagen die bacteriespecifiek zijn, ongeacht of deze nu wel of niet resistent is tegen antibiotica.InfectieziektenIn de komende jaren zullen zich door nanotechnologie grote veranderingen voordoen in de diagnostiek van allerlei infectieziekten.", [["Een mogelijke (oude)", "TREATMENT", 0, 20], ["het gebruik als medicament", "TREATMENT", 34, 60], ["Infectieziekten", "PROBLEM", 170, 185]]], ["Daarbij wordt gebruikgemaakt van ELISA-technieken in een mChip (microfluidic chip for immunoassay on protein markers) ter grootte van een pakje sigaretten.", [["een mChip (microfluidic chip", "TREATMENT", 53, 81], ["immunoassay on protein markers", "TREATMENT", 86, 116]]], ["De sensitiviteit voor gedocumenteerde hiv-infecties was 100% (98-100%) en de specificiteit 94%.", [["hiv-infecties", "PROBLEM", 38, 51]]], ["Bevestiging van een positieve uitslag zal dus in een westerse setting nodig zijn.ChorioamnionitisChorioamnionitis is een intra-uteriene infectie, waarbij zich in de vliezen en placenta histologische kenmerken van ontsteking voordoen en microorganismen tussen de vruchtvliezen worden aangetroffen en/of waarbij sprake is van koorts en eventueel van sepsis.", [["Chorioamnionitis", "DISEASE", 97, 113], ["waarbij sprake", "DISEASE", 302, 316], ["sepsis", "DISEASE", 348, 354], ["ChorioamnionitisChorioamnionitis", "PROBLEM", 81, 113], ["een intra-uteriene infectie", "PROBLEM", 117, 144], ["van sepsis", "PROBLEM", 344, 354], ["Chorioamnionitis", "OBSERVATION", 97, 113]]], ["Zelden is sprake van een klinisch manifeste intra-uteriene infectie met staande vliezen.", [["van een klinisch", "TREATMENT", 17, 33]]], ["Subklinische intra-amniotische infectie kan opgespoord worden door op vruchtwater via amniocentese tests te doen voor glucose (verlaagd bij amnionitis), bacteri\u00ebn op te sporen via kweek of, sneller, via een gram-kleuring, en door MMP-9 of IL-6 of -8 te bepalen.", [["glucose", "CHEMICAL", 118, 125], ["glucose", "CHEMICAL", 118, 125], ["glucose", "SIMPLE_CHEMICAL", 118, 125], ["MMP", "PROTEIN", 230, 233], ["IL", "PROTEIN", 239, 241], ["amniocentese tests", "TEST", 86, 104], ["glucose", "TEST", 118, 125], ["verlaagd bij amnionitis", "TREATMENT", 127, 150], ["bacteri\u00ebn", "TEST", 153, 162], ["MMP", "TEST", 230, 233], ["IL", "TEST", 239, 241]]], ["De interleukinen zijn merkers van de immunologische gastheerreactie op de aanwezigheid van bacteri\u00ebn en stijgen in het vruchtwater niet alleen voor een spontane normale partus, maar ook reeds vroeg in de zwangerschap in het geval van een dreigende partus immaturus.", [["dreigende partus", "SPECIES", 238, 254]]], ["Voor de meeste bacteri\u00ebn (GBS, Escherichia coli) is een realtime PCR ontwikkeld, waarmee de verwekker al kan worden aangetoond voordat kweekresultaten bekend zijn.", [["Escherichia coli", "ORGANISM", 31, 47], ["Escherichia coli", "SPECIES", 31, 47], ["Escherichia coli", "SPECIES", 31, 47], ["GBS", "PROBLEM", 26, 29], ["Escherichia coli", "PROBLEM", 31, 47], ["Escherichia coli", "OBSERVATION", 31, 47]]], ["In de toekomst zou dit ook een plaats kunnen krijgen bij het opsporen en behandelen van intra-uteriene infecties.ChorioamnionitisDe incidentie van chorioamnionitis is afhankelijk van de definitie (histologisch of met een positieve kweek of met koorts) en varieert van 0,5-10,5%.", [["chorioamnionitis", "DISEASE", 147, 163], ["een plaats", "TREATMENT", 27, 37], ["van chorioamnionitis", "PROBLEM", 143, 163]]], ["De risicofactoren voor een acute chorioamnionitis staan vermeld in tabel 21.1.ChorioamnionitisDe verwekkers van chorioamnionitis zijn vaak bacteri\u00ebn, zowel aerobe (Streptococcus agalactiae, Escherichia coli, Staphylococcus aureus) als anaerobe (Gardnerella vaginalis, Bacteroides fragilis, Bacteroides species).ChorioamnionitisDe diagnose chorioamnionitis voor de geboorte wordt gesteld op basis van koorts bij de zwangere, al dan niet voorafgegaan door foetale tachycardie.", [["chorioamnionitis", "DISEASE", 112, 128], ["Streptococcus agalactiae", "DISEASE", 164, 188], ["chorioamnionitis", "DISEASE", 339, 355], ["zowel aerobe (", "ORGANISM", 150, 164], ["Streptococcus agalactiae", "ORGANISM", 164, 188], ["Escherichia coli", "ORGANISM", 190, 206], ["Staphylococcus aureus", "ORGANISM", 208, 229], ["Gardnerella vaginalis", "ORGANISM", 245, 266], ["Bacteroides fragilis", "ORGANISM", 268, 288], ["Bacteroides species", "ORGANISM", 290, 309], ["Streptococcus agalactiae", "SPECIES", 164, 188], ["Escherichia coli", "SPECIES", 190, 206], ["Staphylococcus aureus", "SPECIES", 208, 229], ["Gardnerella vaginalis", "SPECIES", 245, 266], ["Bacteroides fragilis", "SPECIES", 268, 288], ["ChorioamnionitisDe verwekkers van chorioamnionitis zijn vaak bacteri\u00ebn", "SPECIES", 78, 148], ["Streptococcus agalactiae", "SPECIES", 164, 188], ["Escherichia coli", "SPECIES", 190, 206], ["Staphylococcus aureus", "SPECIES", 208, 229], ["Gardnerella vaginalis", "SPECIES", 245, 266], ["Bacteroides fragilis", "SPECIES", 268, 288], ["een acute chorioamnionitis", "PROBLEM", 23, 49], ["ChorioamnionitisDe", "TEST", 78, 96], ["van chorioamnionitis", "PROBLEM", 108, 128], ["vaak bacteri\u00ebn", "PROBLEM", 134, 148], ["zowel aerobe (Streptococcus agalactiae", "PROBLEM", 150, 188], ["Escherichia coli", "PROBLEM", 190, 206], ["Staphylococcus aureus", "PROBLEM", 208, 229], ["als anaerobe (Gardnerella vaginalis", "PROBLEM", 231, 266], ["Bacteroides fragilis", "PROBLEM", 268, 288], ["Bacteroides species", "PROBLEM", 290, 309], ["chorioamnionitis", "PROBLEM", 339, 355], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["chorioamnionitis", "OBSERVATION", 33, 49], ["Gardnerella vaginalis", "ANATOMY", 245, 266]]], ["De baarmoeder kan gevoelig zijn en meestal is er beginnende wee\u00ebnactiviteit.", [["De baarmoeder kan gevoelig zijn", "TREATMENT", 0, 31]]], ["Wanneer daarbij de vliezen gebroken zijn en het vruchtwater een groenige kleur heeft (meconium, pus), is de diagnose duidelijk.", [["pus", "PROBLEM", 96, 99]]], ["Bij staande vliezen is de diagnose moeilijker en kan het nuttig zijn een amnionpunctie te verrichten om een gram-preparaat te maken en een kweek in te zetten.", [["kan het nuttig zijn een amnionpunctie te verrichten om een gram-preparaat te maken en een kweek", "SPECIES", 49, 144], ["Bij staande vliezen", "TREATMENT", 0, 19], ["een amnionpunctie", "TREATMENT", 69, 86], ["preparaat te", "TREATMENT", 113, 125]]], ["Leukocytose en C-reactief prote\u00efne (CRP) in het maternale bloed zijn nuttig om een infectie in het algemeen, waaronder chorioamnionitis, op het spoor te komen en om het verloop van een infectie en de invloed van behandeling te volgen.", [["chorioamnionitis", "DISEASE", 119, 135], ["op het spoor te komen en om het verloop van een infectie en de invloed van behandeling te volgen", "SPECIES", 137, 233], ["Leukocytose", "TEST", 0, 11], ["prote\u00efne", "TEST", 26, 34], ["CRP", "TEST", 36, 39], ["chorioamnionitis", "PROBLEM", 119, 135], ["chorioamnionitis", "OBSERVATION", 119, 135]]], ["Serum-IL-6 bleek ook voorspellend voor de kans op een vroeggeboorte onder 32 weken.ChorioamnionitisNaast een chorioamnionitis met maternale complicaties zoals een sepsis kan ook de foetus ge\u00efnfecteerd zijn of worden.", [["Chorioamnionitis", "DISEASE", 83, 99], ["chorioamnionitis", "DISEASE", 109, 125], ["sepsis", "DISEASE", 163, 169], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IL", "GENE_OR_GENE_PRODUCT", 6, 8], ["Serum", "TEST", 0, 5], ["IL", "TEST", 6, 8], ["Chorioamnionitis", "PROBLEM", 83, 99], ["een chorioamnionitis", "PROBLEM", 105, 125], ["een sepsis", "PROBLEM", 159, 169], ["chorioamnionitis", "OBSERVATION", 109, 125]]], ["We spreken van FIRS (fetal inflammatory response syndrome) wanneer de foetus systemisch ge\u00efnfecteerd is en zich teweer stelt getuige bijvoorbeeld een verhoogd IL-6 in het serum (en vandaar in het vruchtwater).", [["serum", "ANATOMY", 171, 176], ["fetal inflammatory response syndrome", "DISEASE", 21, 57], ["fetal", "ORGANISM_SUBDIVISION", 21, 26], ["IL-6", "GENE_OR_GENE_PRODUCT", 159, 163], ["serum", "ORGANISM_SUBSTANCE", 171, 176], ["fetal inflammatory response syndrome", "PROBLEM", 21, 57]]], ["Naast de foetale tachycardie kunnen ook echografisch debris in het vruchtwater en een kleinere omvang van de thymus worden gezien.", [["echografisch debris", "PROBLEM", 40, 59], ["debris", "OBSERVATION", 53, 59], ["thymus", "ANATOMY", 109, 115]]], ["De behandeling van acute chorioamnionitis moet nog voor de bevalling worden ingezet met intraveneus ampicilline en gentamicine of antibiotica met een soortgelijk spectrum, tenzij op grond van een aangetoonde verwekker een antibioticum met een smaller spectrum kan worden gegeven, zoals penicilline bij de groep-B-streptokokken (GBS).", [["acute chorioamnionitis", "DISEASE", 19, 41], ["GBS", "DISEASE", 328, 331], ["acute chorioamnionitis", "PROBLEM", 19, 41], ["intraveneus ampicilline", "TREATMENT", 88, 111], ["antibiotica", "TREATMENT", 130, 141], ["een soortgelijk spectrum", "TREATMENT", 146, 170], ["tenzij op grond van een", "TREATMENT", 172, 195], ["een antibioticum", "TREATMENT", 218, 234], ["GBS", "PROBLEM", 328, 331]]], ["Wanneer anaeroben in het spel kunnen zijn, moet metronidazol worden bijgegeven.", [["anaeroben", "CHEMICAL", 8, 17], ["metronidazol", "CHEMICAL", 48, 60], ["anaeroben", "CHEMICAL", 8, 17], ["metronidazol", "CHEMICAL", 48, 60], ["metronidazol", "TREATMENT", 48, 60]]], ["In dat geval kan men het natuurlijk beloop afwachten, wetend dat men hiermee een sepsis bij de zwangere riskeert.", [["sepsis", "DISEASE", 81, 87], ["men", "SPECIES", 17, 20], ["men", "SPECIES", 65, 68], ["een sepsis", "PROBLEM", 77, 87], ["sepsis", "OBSERVATION", 81, 87]]], ["Toediening van corticostero\u00efden om de longrijping te bevorderen en toch te kunnen interveni\u00ebren verhoogt deze kans niet.Abnormale vaginale bacteri\u00eble en cervicale flora en zwangerschapsverloopEr zijn goede redenen om aan te nemen dat abnormale vaginale en cervicale flora de aanleiding kunnen zijn van een verhoogde kans om vroegtijdig te bevallen.", [["Abnormale vaginale bacteri\u00eble en cervicale flora en zwangerschapsverloopEr zijn goede redenen om aan te nemen dat abnormale vaginale en cervicale flora de aanleiding kunnen zijn van een verhoogde kans om vroegtijdig te bevallen", "SPECIES", 120, 347], ["Abnormale vaginale bacteri\u00eble en cervicale flora", "PROBLEM", 120, 168], ["vaginale en cervicale flora", "TREATMENT", 244, 271], ["aanleiding kunnen zijn van een", "TREATMENT", 275, 305]]], ["Onbehandelde cervicitis door gonokokken, en waarschijnlijk ook door Chlamydia trachomatis, is aanleiding tot, soms ernstige, prematuriteit.", [["cervicitis", "DISEASE", 13, 23], ["Chlamydia trachomatis", "DISEASE", 68, 89], ["Chlamydia trachomatis", "SPECIES", 68, 89], ["Onbehandelde cervicitis", "PROBLEM", 0, 23], ["Chlamydia trachomatis", "PROBLEM", 68, 89], ["cervicitis", "OBSERVATION", 13, 23], ["trachomatis", "OBSERVATION", 78, 89]]], ["Andere omstandigheden waarbij de schede geen natuurlijke lactobacillen meer bezit (abnormale bacteri\u00eble flora), kunnen veroorzaakt worden door trichomoniasis, door overgroei met anaeroben (bacteri\u00eble vaginose), of door aanwezigheid van aeroben in een schede met een ontsteking (aerobe vaginitis en desquamatieve atrofe vaginitis).Abnormale vaginale bacteri\u00eble en cervicale flora en zwangerschapsverloopIn het geval van bacteri\u00eble vaginose wordt de diagnose gesteld op basis van de aminegeur (rotte vis) van de fluor, verhoogde vaginale pH en de aanwezigheid van cluecellen in het directe preparaat (de plaveiselepitheelcellen zijn in het directe preparaat zichtbaar met vele zwarte stipjes bezet).", [["trichomoniasis", "DISEASE", 143, 157], ["anaeroben", "CHEMICAL", 178, 187], ["aeroben", "CHEMICAL", 236, 243], ["vaginitis", "DISEASE", 285, 294], ["vaginitis", "DISEASE", 319, 328], ["abnormale bacteri\u00eble flora", "ORGANISM", 83, 109], ["abnormale bacteri\u00eble flora", "PROBLEM", 83, 109], ["trichomoniasis", "PROBLEM", 143, 157], ["een schede", "TREATMENT", 247, 257], ["aerobe vaginitis", "PROBLEM", 278, 294], ["atrofe vaginitis", "PROBLEM", 312, 328], ["Abnormale vaginale bacteri\u00eble en cervicale flora", "PROBLEM", 330, 378]]], ["Daarnaast is bij bacteri\u00eble vaginose ook vaak sprake van een co-infectie met Mycoplasmata, zoals Ureaplasma urealyticum en Mycoplasma hominis.Abnormale vaginale bacteri\u00eble en cervicale flora en zwangerschapsverloopEr zijn veel studies die laten zien dat in het begin van de zwangerschap aangetoonde bacteri\u00eble vaginose in verband staat met een verhoogde kans op vroegtijdige bevalling, preterm breken van de vliezen en chorioamnionitis.", [["Daarnaast", "CHEMICAL", 0, 9], ["Ureaplasma urealyticum", "DISEASE", 97, 119], ["chorioamnionitis", "DISEASE", 419, 435], ["zoals", "ORGANISM", 91, 96], ["Ureaplasma urealyticum", "ORGANISM", 97, 119], ["Mycoplasma hominis", "ORGANISM", 123, 141], ["Ureaplasma urealyticum", "SPECIES", 97, 119], ["Mycoplasma hominis", "SPECIES", 123, 141], ["Ureaplasma urealyticum", "SPECIES", 97, 119], ["Mycoplasma hominis", "SPECIES", 123, 141], ["Daarnaast", "TREATMENT", 0, 9], ["Mycoplasmata", "TEST", 77, 89], ["Ureaplasma urealyticum en Mycoplasma hominis", "PROBLEM", 97, 141], ["Abnormale vaginale bacteri\u00eble en cervicale flora", "PROBLEM", 142, 190], ["chorioamnionitis", "PROBLEM", 419, 435], ["Mycoplasma hominis", "OBSERVATION", 123, 141], ["chorioamnionitis", "OBSERVATION", 419, 435]]], ["Toch is er volgens een Cochrane-review uit 2007 nog geen plaats voor een algehele screening op bacteri\u00eble vaginose.Abnormale vaginale bacteri\u00eble en cervicale flora en zwangerschapsverloopIs er geen sprake van acute chorioamnionitis, maar wel van een bacteri\u00eble vaginose, dan is tot nu toe nog geen overtuigend bewijs geleverd dat behandeling van de infectie met metronidazol zinvol is.", [["acute chorioamnionitis", "DISEASE", 209, 231], ["metronidazol", "CHEMICAL", 362, 374], ["metronidazol zinvol", "SIMPLE_CHEMICAL", 362, 381], ["Abnormale vaginale bacteri\u00eble en cervicale flora", "PROBLEM", 115, 163], ["van acute chorioamnionitis", "PROBLEM", 205, 231], ["metronidazol zinvol", "TREATMENT", 362, 381], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["chorioamnionitis", "OBSERVATION", 215, 231], ["toe", "ANATOMY", 285, 288]]], ["Daarentegen is uit twee gerandomiseerde studies gebleken dat het zinvol is een bacteri\u00eble vaginose met clindamycine te behandelen.", [["Daarentegen", "CHEMICAL", 0, 11], ["Daarentegen", "TREATMENT", 0, 11], ["een bacteri\u00eble vaginose", "TREATMENT", 75, 98], ["clindamycine te behandelen", "TREATMENT", 103, 129]]], ["Wanneer gedurende vijf dagen 2 dd 300 mg clindamycine p.o. werd gegeven aan zwangeren onder de 20 weken met een bacteri\u00eble vaginose, daalde de kans op vroeggeboorte <37 weken tot de helft; dit effect was nog groter bij vrouwen die eerder een vroeggeboorte hadden doorgemaakt.", [["clindamycine", "TREATMENT", 41, 53]]], ["Om die reden worden in sommige protocollen vrouwen met een vroeggeboorte onder de 32 weken in de voorgeschiedenis, in het eerste trimester gescreend op bacteri\u00eble vaginose en vervolgens op indicatie (NUGENT-score \u22656) behandeld met clindamycine.", [["clindamycine", "CHEMICAL", 231, 243], ["clindamycine", "SIMPLE_CHEMICAL", 231, 243], ["clindamycine", "TREATMENT", 231, 243]]], ["Dat clindamycine eventueel wel en metronidazol niet effectief blijkt in het verlagen van de kans op vroeggeboorte past bij andere studies, die erop wijzen dat mogelijk niet bacteri\u00eble vaginose, maar wel de andere vormen van abnormale vaginale flora een belangrijke rol zouden kunnen spelen in het veroorzaken van bovengenoemde infectiegerelateerde zwangerschapscomplicaties, onder andere via de productie van grote hoeveelheden pro-inflammatoire cytokinen die kunnen leiden tot prostaglandinevrijzetting en aldus vroegtijdige wee\u00ebn kunnen uitlokken.", [["Dat clindamycine", "TREATMENT", 0, 16], ["wel en metronidazol", "TREATMENT", 27, 46], ["vaginose", "PROBLEM", 184, 192], ["vaginale flora", "PROBLEM", 234, 248]]], ["Een van deze aandoeningen is aerobe vaginitis, een aandoening waarbij de lactobacillen niet door anaeroben, maar door aerobe micro-organismen vervangen worden en er gewoonlijk een hevige leukocytaire reactie van de gastheer aanwezig is.", [["vaginitis", "DISEASE", 36, 45], ["Een van deze aandoeningen", "TREATMENT", 0, 25], ["aerobe vaginitis", "PROBLEM", 29, 45]]], ["Aerobe vaginitis, mede door de productie van IL-1 en IL-8, is mogelijk nog een belangrijkere oorzaak van chorioamnionitis en vroeggeboorte dan bacteri\u00eble vaginose.", [["vaginitis", "DISEASE", 7, 16], ["IL-8", "SIMPLE_CHEMICAL", 53, 57], ["Aerobe vaginitis", "PROBLEM", 0, 16], ["van chorioamnionitis", "PROBLEM", 101, 121], ["vaginitis", "OBSERVATION", 7, 16]]], ["De ideale therapie van aerobe vaginitis staat echter nog niet vast.Abnormale vaginale bacteri\u00eble en cervicale flora en zwangerschapsverloopCandida-vaginitis is geen oorzaak van chorioamnionitis, behoudens in uitzonderlijke gevallen waarbij er een zwangerschap ontstond met een intra-uterien contraceptivum in situ.Infectie met Chlamydia trachomatisChlamydia trachomatis is een kleine gram-negatieve bacterie die zich vrijwel altijd intracellulair bevindt, waar ze adenosinetrifosfaat (ATP) en aminozuren van de gastheercel betrekt.", [["vaginitis", "DISEASE", 30, 39], ["Candida-vaginitis", "DISEASE", 139, 156], ["chorioamnionitis", "DISEASE", 177, 193], ["Chlamydia trachomatis", "DISEASE", 327, 348], ["Chlamydia trachomatis", "DISEASE", 348, 369], ["ATP", "CHEMICAL", 485, 488], ["ATP", "CHEMICAL", 485, 488], ["Chlamydia trachomatis", "ORGANISM", 327, 348], ["ATP", "SIMPLE_CHEMICAL", 485, 488], ["intra-uterien contraceptivum", "SPECIES", 277, 305], ["Chlamydia trachomatis", "SPECIES", 327, 348], ["Chlamydia trachomatis", "SPECIES", 348, 369], ["Chlamydia trachomatis", "SPECIES", 327, 348], ["vaginitis", "PROBLEM", 30, 39], ["Abnormale vaginale bacteri\u00eble en cervicale flora", "PROBLEM", 67, 115], ["Candida", "PROBLEM", 139, 146], ["vaginitis", "PROBLEM", 147, 156], ["van chorioamnionitis", "PROBLEM", 173, 193], ["behoudens", "PROBLEM", 195, 204], ["een intra-uterien contraceptivum", "TREATMENT", 273, 305], ["Infectie met Chlamydia trachomatis", "PROBLEM", 314, 348], ["Chlamydia trachomatis", "PROBLEM", 348, 369], ["een kleine gram", "TEST", 373, 388], ["vaginitis", "OBSERVATION", 147, 156], ["van chorioamnionitis", "OBSERVATION", 173, 193], ["Chlamydia", "OBSERVATION_MODIFIER", 327, 336], ["trachomatis", "OBSERVATION", 337, 348]]], ["Chlamydiasis is een frequente geslachtsziekte, die echter in de meeste ontwikkelde landen snel vermindert.Infectie met Chlamydia trachomatisBij een (persisterende) cervicale infectie in de zwangerschap kan deze bij de geboorte ook verticaal worden overgebracht van moeder op kind.", [["Chlamydiasis", "DISEASE", 0, 12], ["Chlamydia trachomatis", "DISEASE", 119, 140], ["Chlamydia trachomatis", "ORGANISM", 119, 140], ["Chlamydia trachomatis", "SPECIES", 119, 140], ["Chlamydia trachomatis", "SPECIES", 119, 140], ["Chlamydiasis", "PROBLEM", 0, 12], ["Infectie met Chlamydia trachomatis", "PROBLEM", 106, 140], ["Chlamydia", "OBSERVATION_MODIFIER", 119, 128], ["trachomatis", "OBSERVATION", 129, 140]]], ["De gevolgen hiervan zijn niet altijd even duidelijk.", [["De gevolgen hiervan zijn", "TREATMENT", 0, 24]]], ["Een klinisch herkenbare conjunctivitis zou optreden in 18-50% van de gevallen, meestal in de vorm van een zich mild voordoend 'plakoog' enige weken na de geboorte.", [["conjunctivitis", "DISEASE", 24, 38], ["Een klinisch", "TREATMENT", 0, 12], ["conjunctivitis", "PROBLEM", 24, 38]]], ["Direct bij de geboorte of mogelijk ook secundair aan een conjunctivitis kan nasofaryngeale besmetting optreden en bij \u00e9\u00e9n op de tien kinderen van ge\u00efnfecteerde zwangeren zou zich een chlamydia-pneumonie ontwikkelen vanaf zes weken tot een halfjaar na de geboorte.", [["een chlamydia", "PROBLEM", 179, 192], ["pneumonie", "PROBLEM", 193, 202], ["vanaf zes", "TREATMENT", 215, 224]]], ["Het Amerikaanse Center for Disease Control (CDC) raadt sinds 1989 een screening op Chlamydia in de zwangerschap aan en behandeling met erytromycine of amoxicilline, met medebehandeling van de partner (met tetracyclinen), maar wegens de dalende prevalentie moet dat advies aangepast worden aan de lokale omstandigheden.Infectie met Chlamydia trachomatisNaast de neonatale schade via infectie bij de geboorte is een chlamydia-infectie van de tractus genitalis in de zwangerschap in verband gebracht met het optreden van vroegtijdig gebroken vliezen, vroeggeboorte en dysmaturiteit.", [["op Chlamydia", "DISEASE", 80, 92], ["Chlamydia trachomatis", "DISEASE", 331, 352], ["Chlamydia trachomatis", "ORGANISM", 331, 352], ["Chlamydia trachomatis", "SPECIES", 331, 352], ["Chlamydia trachomatis", "SPECIES", 331, 352], ["een screening", "TEST", 66, 79], ["Chlamydia", "PROBLEM", 83, 92], ["amoxicilline", "TREATMENT", 151, 163], ["Infectie met Chlamydia trachomatis", "PROBLEM", 318, 352], ["Naast de neonatale schade", "TREATMENT", 352, 377], ["een chlamydia", "PROBLEM", 410, 423], ["Chlamydia", "OBSERVATION_MODIFIER", 331, 340], ["trachomatis", "OBSERVATION", 341, 352]]], ["De verklaring wordt gezocht in een verminderde immunologische tolerantie, mogelijk samenhangend met door Chlamydia in de ge\u00efnfecteerde cellen afgegeven membraancomplexen, die immunogeen zijn.", [["Chlamydia", "PROBLEM", 105, 114]]], ["Infectie met Chlamydia van het endometrium en de trofoblast, die bij een chlamydia-cervicitis in een derde van de gevallen optreedt, zou gevolgen hebben voor de immunologische herkenbaarheid van deze weefsels, die normaal lokaal onderdrukt is.Infectie met Chlamydia trachomatisUit diverse prospectieve onderzoeken blijkt het verband tussen chlamydia-infectie en minder gunstige zwangerschapsuitkomst alleen te bestaan wanneer de infectie recent is en er anti-Chlamydia-IgM bij de vrouw wordt aangetroffen.", [["chlamydia-cervicitis", "DISEASE", 73, 93], ["Chlamydia trachomatis", "DISEASE", 256, 277], ["Chlamydia trachomatis", "ORGANISM", 256, 277], ["Chlamydia trachomatis", "SPECIES", 256, 277], ["Chlamydia trachomatis", "SPECIES", 256, 277], ["Infectie", "PROBLEM", 0, 8], ["Chlamydia", "PROBLEM", 13, 22], ["een chlamydia", "PROBLEM", 69, 82], ["cervicitis", "PROBLEM", 83, 93], ["Infectie met Chlamydia trachomatis", "PROBLEM", 243, 277], ["chlamydia", "PROBLEM", 340, 349], ["infectie", "PROBLEM", 350, 358], ["cervicitis", "OBSERVATION", 83, 93], ["Chlamydia", "OBSERVATION_MODIFIER", 256, 265], ["trachomatis", "OBSERVATION", 266, 277]]], ["In een in 2010 gepubliceerde prospectieve non-interventiestudie uit het grote Generation R-project uit Rotterdam bleek een positieve PCR voor Chlamydia in ochtendurine in het eerste trimester gerelateerd aan een meer dan viervoudig verhoogde kans op vroeggeboorte onder 32 weken.", [["PCR", "TEST", 133, 136], ["Chlamydia", "PROBLEM", 142, 151]]], ["Een positief effect van behandeling met antibiotica op de zwangerschapsuitkomst is nog onvoldoende aangetoond in gerandomiseerde placebogecontroleerde onderzoeken.Infectie met Chlamydia trachomatisDe betrokkenheid van Chlamydia bij een endometritis post partum is minder duidelijk aangetoond dan na een abortus provocatus.", [["Chlamydia bij een endometritis", "DISEASE", 218, 248], ["na", "CHEMICAL", 296, 298], ["Chlamydia bij", "SPECIES", 218, 231], ["een abortus provocatus", "SPECIES", 299, 321], ["dan na een abortus provocatus", "SPECIES", 292, 321], ["Infectie", "PROBLEM", 163, 171], ["Chlamydia", "PROBLEM", 176, 185], ["van Chlamydia", "PROBLEM", 214, 227], ["een endometritis", "PROBLEM", 232, 248], ["Chlamydia", "OBSERVATION", 176, 185]]], ["Het valt te overwegen Chlamydia in de diagnostiek van endometritis op te nemen, hoewel het doorgaans niet nodig is dat de behandeling verandert.", [["endometritis", "DISEASE", 54, 66], ["Chlamydia", "PROBLEM", 22, 31]]], ["Voor de diagnostiek van Chlamydia maakt men het beste gebruik van een DNAbepaling door middel van een PCR.", [["men", "SPECIES", 40, 43]]], ["De test blijkt ook betrouwbaar wanneer door de pati\u00ebnt zelf met een wattenstok materiaal uit de vagina wordt verkregen.GonorroeTwee jaar na de observatie in 1879 door Neisser van de gonokok in urethra-exsudaat werd deze aerobe gram-negatieve diplococcus al aangetoond als verwekker van ophthalmia neonatorum.", [["na", "CHEMICAL", 137, 139], ["ophthalmia neonatorum", "DISEASE", 286, 307], ["vagina", "ANATOMY", 96, 102], ["urethra", "ANATOMY", 193, 200]]], ["Onbehandeld leidt deze purulente conjunctivitis vaak tot corneabeschadiging en blindheid.", [["conjunctivitis", "DISEASE", 33, 47], ["conjunctivitis", "PROBLEM", 33, 47]]], ["Wanneer dat niet routineus plaatsvindt, moet het zeker gebeuren bij de combinatie van dysurie en steriele pyurie, bij een purulente cervicitis, een proctitis of een acute bartholinitis.", [["steriele pyurie", "DISEASE", 97, 112], ["cervicitis", "DISEASE", 132, 142], ["proctitis", "DISEASE", 148, 157], ["acute bartholinitis", "DISEASE", 165, 184], ["bij een purulente cervicitis", "PROBLEM", 114, 142], ["een proctitis", "PROBLEM", 144, 157], ["een acute bartholinitis", "PROBLEM", 161, 184], ["purulente cervicitis", "OBSERVATION", 122, 142], ["een proctitis", "OBSERVATION", 144, 157], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["bartholinitis", "OBSERVATION", 171, 184]]], ["Ook bij de zelden optredende salpingitis in het begin van de zwangerschap moet op gonorroe worden gekweekt.GonorroeBehalve bovenstaande ziektebeelden kan Neisseria gonorrhoeae bij de zwangere, waarschijnlijk eerder dan bij de niet-zwangere vrouw, een gedissemineerde infectie veroorzaken met koorts, koude rillingen, huiduitslag (purpura, petechi\u00ebn en pustels), gevolgd door mono-of oligoartritis.GonorroeInfectie van moeder op kind ontstaat vooral door rechtstreeks contact in het baringskanaal bij de baring, hoewel een septische abortus of een preterme geboorte op basis van een chorioamnionitis een mogelijk gevolg kan zijn van een ascenderende gonokokkeninfectie.", [["salpingitis", "DISEASE", 29, 40], ["purpura", "DISEASE", 330, 337], ["oligoartritis", "DISEASE", 383, 396], ["salpingitis", "PROBLEM", 29, 40], ["GonorroeBehalve", "TREATMENT", 107, 122], ["een gedissemineerde", "TREATMENT", 247, 266], ["koude rillingen", "TREATMENT", 300, 315], ["purpura", "PROBLEM", 330, 337], ["oligoartritis", "PROBLEM", 383, 396], ["chorioamnionitis", "PROBLEM", 582, 598]]], ["Prospectieve studies over gonorroe in de zwangerschap zijn zeldzaam, maar tonen alle een duidelijk verhoogd risico op preterme geboorte en chorioamnionitis aan bij onbehandelde vrouwen.", [["Prospectieve studies", "TEST", 0, 20], ["chorioamnionitis", "OBSERVATION", 139, 155]]], ["Daarom moet men bedacht blijven op deze infectie en kweken afnemen van cervix en urethra bij risicogroepen, zoals promiscue vrouwen, aan harddrugs verslaafde zwangeren of zwangeren die uit landen komen waar gonorroe veelvuldig voorkomt.GonorroeOmdat bij driekwart van de vrouwen een infectie met Neisseria gonorrhoeae symptoomloos blijft, werden vroeger alle neonaten uit profylactische overwegingen direct na de geboorte gedruppeld met een verse 1%-oplossing van zilvernitraat volgens Cred\u00e9.", [["na", "CHEMICAL", 407, 409], ["men", "SPECIES", 12, 15], ["Daarom", "TREATMENT", 0, 6], ["van cervix en urethra bij risicogroepen", "TREATMENT", 67, 106], ["Neisseria gonorrhoeae symptoomloos blijft", "PROBLEM", 296, 337], ["een verse", "TREATMENT", 437, 446], ["urethra", "ANATOMY", 81, 88]]], ["Vanwege de gedaalde incidentie van gonorroe onder zwangeren (na 1970 werden minder dan tien gevallen van ophthalmia gonorrhoica neonatorum per jaar gemeld, tot deze aparte melding in 1980 kwam te vervallen) en de op zichzelf soms etsende werking van zilvernitraat is dit 'crederen' universeel vervangen door het laagdrempelig bepalen van een gonorroe bij de neonatus met pusoogjes in de eerste week na de geboorte en het gericht of routineus diepvaginaal of intracervicaal bepalen bij zwangeren.", [["na", "CHEMICAL", 61, 63], ["ophthalmia gonorrhoica", "DISEASE", 105, 127], ["neonatorum", "DISEASE", 128, 138], ["na", "CHEMICAL", 399, 401], ["gedaalde incidentie van gonorroe onder zwangeren (na 1970 werden minder dan tien gevallen van ophthalmia gonorrhoica neonatorum per jaar gemeld, tot deze aparte melding in 1980 kwam te vervallen) en de op zichzelf soms etsende werking van zilvernitraat is dit 'crederen' universeel vervangen door het laagdrempelig bepalen van een gonorroe bij de neonatus met pusoogjes in de eerste week na de geboorte en het gericht", "SPECIES", 11, 428], ["intracervicaal bepalen bij zwangeren", "TREATMENT", 458, 494]]], ["De bepaling gebeurt met een PCR, de nucle\u00efnezuuramplificatietest (NAAT), gecombineerd met of gevolgd door een kweek met resistentiebepaling.", [["een PCR", "TEST", 24, 31]]], ["Een grampreparaat moet bij een klinische verdenking op gonorroe niet worden nagelaten, want deze geeft in de meeste gevallen een snelle uitslag.", [["Een grampreparaat", "TREATMENT", 0, 17]]], ["In kraamklinieken waar de systematische profylaxe tegen de ontwikkeling van neonatale conjunctivitis behouden bleef, werd overgegaan op een oogzalf met erytromycine of tetracycline, omwille van de betere activiteit tegen Chlamydia.GonorroeBij de behandeling van gonorroe moet in toenemende mate rekening worden gehouden met antibioticaresistente stammen: uit een surveillance van 2006-2010 bleek een penicillineresistentie van rond de 10%, en tetracyclineresistentie en resistentie tegen ciprofloxacine tot bijna 50%.", [["conjunctivitis behouden bleef", "DISEASE", 86, 115], ["erytromycine", "CHEMICAL", 152, 164], ["tetracycline", "CHEMICAL", 168, 180], ["Chlamydia", "DISEASE", 221, 230], ["tetracycline", "TREATMENT", 168, 180], ["en tetracyclineresistentie en resistentie", "TREATMENT", 440, 481], ["ciprofloxacine tot bijna", "TREATMENT", 488, 512]]], ["Daarom werd in plaats van 3 g amoxicilline (Clamoxyl \u00ae ) + 2 tabletten probenecide (Benemid \u00ae ) p.o. ineens, het laatste decennium meestal direct overgegaan tot eenmalig 1,5 g cefuroxim i.m., maar ook daar bleek in 2010 al 10% resistentie tegen voor te komen.", [["amoxicilline", "CHEMICAL", 30, 42], ["Clamoxyl \u00ae", "CHEMICAL", 44, 54], ["probenecide", "CHEMICAL", 71, 82], ["cefuroxim", "CHEMICAL", 176, 185], ["amoxicilline", "CHEMICAL", 30, 42], ["probenecide", "CHEMICAL", 71, 82], ["Benemid", "CHEMICAL", 84, 91], ["amoxicilline", "SIMPLE_CHEMICAL", 30, 42], ["Clamoxyl \u00ae", "SIMPLE_CHEMICAL", 44, 54], ["2 tabletten probenecide", "SIMPLE_CHEMICAL", 59, 82], ["Benemid \u00ae", "SIMPLE_CHEMICAL", 84, 93], ["Daarom", "TREATMENT", 0, 6], ["amoxicilline (Clamoxyl \u00ae )", "TREATMENT", 30, 56]]], ["Inmiddels (2012) wordt als eerste keus ceftriaxon 500 mg intramusculair eenmalig aanbevolen ook voor zwangeren.", [["ceftriaxon", "TREATMENT", 39, 49]]], ["Infectie bij volwassenen uit zich als een griepje met diarree.GonorroeWanneer de vrucht (transplacentair) ge\u00efnfecteerd wordt, krijgt het vruchtwater een karakteristieke heldergroene kleur die verward kan worden met meconium.", [["meconium", "ORGANISM_SUBSTANCE", 215, 223], ["Infectie", "PROBLEM", 0, 8], ["meconium", "PROBLEM", 215, 223], ["meconium", "OBSERVATION", 215, 223]]], ["Het gram-preparaat toont een overvloedige hoeveelheid bacteri\u00ebn.", [["Het gram", "TEST", 0, 8]]], ["Een infectie is soms oorzaak van preterme wee\u00ebnactiviteit en van een perinatale asfyxie van het kind, dat intra-uterien kan overlijden of postnataal het beeld van een GBS-infectie vertoont.", [["van een perinatale asfyxie van het kind, dat intra-uterien kan overlijden of postnataal het beeld van een GBS-infectie vertoont", "SPECIES", 61, 188], ["infectie vertoont", "PROBLEM", 171, 188]]], ["De neonaat heeft rode verheven vlekjes op het lichaam en soms granulomen in de farynx.", [["farynx", "ANATOMY", 79, 85], ["farynx", "CANCER", 79, 85], ["de farynx", "ANATOMY", 76, 85]]], ["Vooral bij de veelvuldig optredende meningitis bestaat een hoge mortaliteit (20-40%).GonorroeNaast de vroege vorm, die waarschijnlijk op een infectie voor de geboorte berust, is er ook nog een late vorm van listeriose van de neonaat, die optreedt tussen 2 en 5 weken postnataal en die meestal gepaard gaat met meningitis.", [["meningitis", "DISEASE", 36, 46], ["meningitis", "DISEASE", 310, 320], ["meningitis", "PROBLEM", 36, 46], ["meningitis", "PROBLEM", 310, 320], ["meningitis", "OBSERVATION", 310, 320]]], ["Deze infectie wordt waarschijnlijk durante partu of daarna opgelopen.", [["daarna opgelopen", "PROBLEM", 52, 68], ["daarna opgelopen", "OBSERVATION", 52, 68]]], ["Wereldwijd is Listeria een van de drie belangrijkste oorzaken van neonatale meningitis.GonorroeDe behandeling bestaat uit ampicilline of amoxicilline, aangevuld met gentamicine in geval van neonatale meningitis.Infectie met groep-A-streptokokken (GAS)Groep A \u03b2-hemolytische streptokok (GAS, S. pyogenes) komt voor als commensaal en als pathogeen op met name huid en mucosa.", [["mucosa", "ANATOMY", 366, 372], ["neonatale meningitis", "DISEASE", 66, 86], ["ampicilline", "CHEMICAL", 122, 133], ["amoxicilline", "CHEMICAL", 137, 149], ["gentamicine", "CHEMICAL", 165, 176], ["meningitis", "DISEASE", 200, 210], ["ampicilline", "CHEMICAL", 122, 133], ["amoxicilline", "CHEMICAL", 137, 149], ["gentamicine", "CHEMICAL", 165, 176], ["amoxicilline", "SIMPLE_CHEMICAL", 137, 149], ["gentamicine", "SIMPLE_CHEMICAL", 165, 176], ["S. pyogenes", "ORGANISM", 291, 302], ["mucosa", "MULTI-TISSUE_STRUCTURE", 366, 372], ["S. pyogenes", "SPECIES", 291, 302], ["Listeria een van de drie belangrijkste oorzaken van neonatale", "SPECIES", 14, 75], ["S. pyogenes", "SPECIES", 291, 302], ["meningitis", "PROBLEM", 76, 86], ["ampicilline", "TREATMENT", 122, 133], ["amoxicilline", "TREATMENT", 137, 149], ["gentamicine", "TREATMENT", 165, 176], ["meningitis", "PROBLEM", 200, 210], ["Infectie", "TEST", 211, 219], ["groep", "TEST", 224, 229], ["GAS", "TEST", 247, 250], ["S. pyogenes", "TEST", 291, 302], ["mucosa", "ANATOMY", 366, 372]]], ["Er zijn veel verschillende stammen met een wisselende virulentie.", [["Er zijn veel verschillende stammen", "TREATMENT", 0, 34]]], ["Overdracht vindt vooral via de handen plaats.Infectie met groep-A-streptokokken (GAS)Ziekte kan het gevolg zijn van een directe lokale invasie: faryngitis, angina, erysipelas, impetigo, cellulitis, necrotiserende fasciitis, pneumonie en endometritis ('kraamvrouwenkoorts'; zie Historie onder 21.1).", [["faryngitis", "ANATOMY", 144, 154], ["faryngitis, angina", "DISEASE", 144, 162], ["erysipelas", "DISEASE", 164, 174], ["impetigo", "DISEASE", 176, 184], ["cellulitis", "DISEASE", 186, 196], ["necrotiserende fasciitis", "DISEASE", 198, 222], ["pneumonie en endometritis", "DISEASE", 224, 249], ["Infectie", "TEST", 45, 53], ["faryngitis", "PROBLEM", 144, 154], ["angina", "PROBLEM", 156, 162], ["erysipelas", "PROBLEM", 164, 174], ["impetigo", "PROBLEM", 176, 184], ["cellulitis", "PROBLEM", 186, 196], ["necrotiserende fasciitis", "PROBLEM", 198, 222], ["pneumonie", "PROBLEM", 224, 233], ["endometritis", "PROBLEM", 237, 249], ["angina", "OBSERVATION", 156, 162], ["erysipelas", "OBSERVATION", 164, 174], ["cellulitis", "OBSERVATION", 186, 196], ["fasciitis", "OBSERVATION", 213, 222], ["endometritis", "OBSERVATION", 237, 249]]], ["Ziekte kan ook toxinegemedieerd en invasief zijn: necrotiserende infectie van de huid of fascie, myositis gangrenosum, 'tamponziekte' of toxisch shocksyndroom (TSS).", [["myositis gangrenosum", "DISEASE", 97, 117], ["fascie", "PROBLEM", 89, 95], ["myositis gangrenosum", "PROBLEM", 97, 117], ["myositis gangrenosum", "OBSERVATION", 97, 117]]], ["Ook kan een delayed host reaction optreden met glomerulonefritis, roodvonk en/of acuut reuma als gevolg.Infectie met groep-A-streptokokken (GAS)De pathogenese is ten dele bekend en berust op een complexe interactie tussen het humane afweersysteem en specifieke virulente factoren van de GAS.Infectie met groep-A-streptokokken (GAS)De porte d'entr\u00e9e van GAS in zwangerschap is vaak via keel, maar in het kraambed via een laesie van de mucosa.", [["mucosa", "ANATOMY", 434, 440], ["mucosa", "MULTI-TISSUE_STRUCTURE", 434, 440], ["Infectie", "TEST", 104, 112], ["Infectie", "TEST", 291, 299], ["keel", "ANATOMY", 385, 389], ["mucosa", "ANATOMY", 434, 440]]], ["In 45% van de gevallen is er geenKoorts in de zwangerschapEen 31-jarige para 3 had in de voorgeschiedenis tweemaal een partus immaturus bij 20 weken en een derde zwangerschap die na een cerclage bij 40 weken eindigde in de geboorte van een gezonde dochter.", [["na", "CHEMICAL", 179, 181], ["Een", "TEST", 58, 61], ["na een cerclage bij", "TREATMENT", 179, 198]]], ["Anamnestisch waren er verder geen bijzonderheden.Koorts in de zwangerschapIn de nieuwe zwangerschap wordt bij 13 weken weer een cerclage aangelegd.", [["een cerclage aangelegd", "TREATMENT", 124, 146], ["cerclage", "OBSERVATION", 128, 136]]], ["Vanaf 27 weken is sprake van verspringende artritiden (ellebogen), waarvan de pati\u00ebnt meldt dat dit ook in de vorige zwangerschap van vier jaar geleden het geval was.", [["Vanaf", "TREATMENT", 0, 5]]], ["Binnen een dag ontstaat koorts en worden intraveneus antibiotica (amoxicilline en gentamicine) toegediend in verband met een mogelijke intra-uteriene infectie.", [["amoxicilline en gentamicine", "CHEMICAL", 66, 93], ["amoxicilline", "CHEMICAL", 66, 78], ["amoxicilline en gentamicine", "SIMPLE_CHEMICAL", 66, 93], ["Binnen een dag", "TREATMENT", 0, 14], ["intraveneus antibiotica", "TREATMENT", 41, 64], ["amoxicilline en gentamicine)", "TREATMENT", 66, 94]]], ["De temperatuur loopt op tot 39,2 \u00b0C en wegens verdenking op een anaerobe sepsis wordt ook metronidazol toegediend.Koorts in de zwangerschapDe pati\u00ebnt raakt in partu en na een snelle ontsluiting en uitdrijving wordt een meisje van 1295 g geboren in een goede conditie, dat zich postnataal goed ontwikkelt en na 7 weken uit de couveuse ontslagen kan worden.Koorts in de zwangerschapDe placenta weegt 317 g, vertoont geen villitis, een lichte funicitis en een chorioamnionitis.", [["sepsis", "DISEASE", 73, 79], ["metronidazol", "CHEMICAL", 90, 102], ["na", "CHEMICAL", 307, 309], ["villitis", "DISEASE", 419, 427], ["chorioamnionitis", "DISEASE", 457, 473], ["De temperatuur loopt op tot", "TEST", 0, 27], ["C", "PROBLEM", 34, 35], ["metronidazol toegediend", "TREATMENT", 90, 113], ["Koorts", "TREATMENT", 355, 361], ["villitis", "PROBLEM", 419, 427], ["een lichte funicitis", "TREATMENT", 429, 449], ["chorioamnionitis", "PROBLEM", 457, 473], ["villitis", "OBSERVATION", 419, 427], ["chorioamnionitis", "OBSERVATION", 457, 473]]], ["Korte tijd na de bevalling blijkt dat uit de kweek van de cerclage een Gonococcus gekweekt kan worden en worden de antibiotica omgezet in cefotaxim.Koorts in de zwangerschapKennelijk was bij de pati\u00ebnt sprake van een systemische gonokokkeninfectie, die tijdens de zwangerschap door de veranderde immunologische afweer leidde tot een verspringende artritis en later tot chorioamnionitis vanwege de locus minoris resistentiae bij de cerclage.ListerioseListeria monocytogenes is een gram-positieve staafvormige bacterie, die bij veel dieren voorkomt.", [["na", "CHEMICAL", 11, 13], ["cefotaxim", "CHEMICAL", 138, 147], ["ListerioseListeria monocytogenes", "SPECIES", 440, 472], ["ListerioseListeria monocytogenes is een gram-positieve staafvormige bacterie", "SPECIES", 440, 516], ["cerclage een Gonococcus", "TREATMENT", 58, 81], ["tot een verspringende artritis", "TREATMENT", 325, 355], ["tot chorioamnionitis", "PROBLEM", 365, 385], ["ListerioseListeria monocytogenes", "PROBLEM", 440, 472], ["een gram", "TEST", 476, 484], ["cerclage", "OBSERVATION", 431, 439]]], ["Na orale besmetting komt Listeria bij de mens in de darm voor.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2]]], ["Ongewassen groente, rauwe melk, vis, diverse kaassoorten en fabrieksslaatjes zijn tussen 15 en 70% positief gebleken.", [["diverse kaassoorten en fabrieksslaatjes zijn tussen", "TREATMENT", 37, 88]]], ["Klinische listeriose is echter zeldzaam.", [["Klinische listeriose", "TREATMENT", 0, 20], ["echter zeldzaam", "OBSERVATION", 24, 39]]], ["Vooral neonaten en bejaarden duidelijke focus.", [["Vooral neonaten", "TREATMENT", 0, 15]]], ["Risicofactoren voor een GASendometritis post partum zijn langdurig gebroken vliezen, een keizersnede en een manuele placentaverwijdering.", [["Risicofactoren", "TREATMENT", 0, 14]]], ["Een GAS-endometritis kan overgaan in het TSS.ListerioseDe klinische symptomen van een endometritis zijn een snel ontstane hoge koorts 3 tot 5 dagen post partum, buikpijn, soms riekende lochia, vaak een atypische presentatie.", [["endometritis", "DISEASE", 8, 20], ["Een GAS", "TEST", 0, 7], ["endometritis", "PROBLEM", 8, 20], ["ListerioseDe klinische symptomen van een endometritis", "TREATMENT", 45, 98], ["zijn een", "TREATMENT", 99, 107], ["buikpijn", "TREATMENT", 161, 169], ["endometritis", "OBSERVATION", 8, 20]]], ["Er is sprake van een drukpijnlijke uterus, tachycardie en soms hypotensie.", [["uterus", "ORGAN", 35, 41], ["hypotensie", "PROBLEM", 63, 73], ["uterus", "ANATOMY", 35, 41]]], ["Er is leukocytose met linksverschuiving.", [["leukocytose", "SIMPLE_CHEMICAL", 6, 17]]], ["De definitie van TSS is de aanwezigheid van GAS gekweekt uit een normaal steriele omgeving (bloed, liquor, pleura/buikvocht, weefselbiopt, operatiewond), hypotensie en twee of meer van de volgende afwijkingen: nierfunctiestoornissen, stollingsstoornissen (trombopenie of diffuse intravasale stolling), leverfunctiestoornissen, ARDS (adult respiratory distress syndrome), huiduitslag of necrose van weke delen (necrotiserende fasciitis, myositis of gangreen).ListerioseHoewel de incidentie van GAS-infectie in/na de zwangerschap dus laag is en tot voor kort weinig pathogeen (in vergelijking met de 19e eeuw), is er kennelijk in de laatste jaren weer een toename van virulente stammen en zijn er diverse case reports van TSS ten gevolge van GAS in de zwangerschap met een veel hogere maternale mortaliteit (30-70%!) dan door een GAS-infectie in het kraambed (3,5%).", [["stollingsstoornissen", "CHEMICAL", 234, 254], ["ARDS", "DISEASE", 327, 331], ["respiratory distress syndrome", "DISEASE", 339, 368], ["necrotiserende fasciitis", "DISEASE", 410, 434], ["myositis", "DISEASE", 436, 444], ["ListerioseHoewel de incidentie van GAS-infectie in/na de zwangerschap dus laag is en tot voor kort weinig pathogeen", "SPECIES", 458, 573], ["diffuse intravasale stolling)", "PROBLEM", 271, 300], ["leverfunctiestoornissen", "PROBLEM", 302, 325], ["ARDS", "PROBLEM", 327, 331], ["adult respiratory distress syndrome", "PROBLEM", 333, 368], ["necrotiserende fasciitis", "PROBLEM", 410, 434], ["myositis of gangreen", "PROBLEM", 436, 456], ["van GAS", "TEST", 489, 496], ["infectie", "PROBLEM", 497, 505], ["van TSS", "TREATMENT", 716, 723], ["een GAS", "TEST", 824, 831], ["infectie", "PROBLEM", 832, 840], ["pleura", "ANATOMY", 107, 113], ["diffuse", "OBSERVATION_MODIFIER", 271, 278], ["ARDS", "OBSERVATION", 327, 331], ["fasciitis", "OBSERVATION", 425, 434], ["myositis", "OBSERVATION", 436, 444]]], ["Een infectie met GAS is de meest frequente veroorzaker van sepsis in zwangerschap en kraambed en moet bij sepsis daarom hoog in de differenti\u00eble diagnose staan vanwege het snelle beloop en de benodigde gerichte antibiotische behandeling.", [["sepsis", "DISEASE", 59, 65], ["sepsis", "DISEASE", 106, 112], ["van sepsis", "PROBLEM", 55, 65], ["sepsis", "OBSERVATION", 106, 112]]], ["Bij een endometritis kan gestart worden met amoxicilline/clavulaanzuur (Augmentin \u00ae ) en zodra GAS is vastgesteld kan worden overgeschakeld op penicilline.", [["endometritis", "DISEASE", 8, 20], ["amoxicilline/clavulaanzuur", "CHEMICAL", 44, 70], ["Augmentin \u00ae", "CHEMICAL", 72, 83], ["penicilline", "CHEMICAL", 143, 154], ["Augmentin \u00ae", "SIMPLE_CHEMICAL", 72, 83], ["Bij een endometritis kan", "TREATMENT", 0, 24], ["amoxicilline/clavulaanzuur (Augmentin \u00ae ) en zodra GAS", "TREATMENT", 44, 98], ["op penicilline", "TREATMENT", 140, 154], ["endometritis", "OBSERVATION", 8, 20]]], ["Hiertegen is bij GAS nog geen resistentie bekend.", [["Hiertegen", "CHEMICAL", 0, 9], ["GAS nog", "OBSERVATION", 17, 24]]], ["Clindamycine remt de vorming van de bacteri\u00eble toxinen en onderdrukt de aanmaak van tumornecrosefactor (TNF).", [["Clindamycine", "CHEMICAL", 0, 12], ["TNF", "GENE_OR_GENE_PRODUCT", 104, 107], ["TNF", "PROTEIN", 104, 107], ["Clindamycine", "TREATMENT", 0, 12]]], ["NSAID's worden bij een TSS ontraden, onder andere omdat hierdoor de vorming van TNF wordt gestimuleerd.Infectie met groep-B-streptokokken (GBS)Groep-B-streptokokken zijn in de jaren zestig herkend als de verwekkers van de belangrijkste perinatale infectie, vooral in de zin van foetale en neonatale mortaliteit en morbiditeit.", [["TNF", "PROTEIN", 80, 83], ["NSAID", "TREATMENT", 0, 5], ["Infectie", "TEST", 103, 111], ["groep", "TEST", 116, 121], ["GBS", "TEST", 139, 142], ["Groep", "TEST", 143, 148]]], ["De laatste decennia is er een stijging van het aantal neonatale GBS-infecties.", [["GBS-infecties", "DISEASE", 64, 77], ["infecties", "PROBLEM", 68, 77]]], ["Dit wordt in ruime mate veroorzaakt door het gestegen aantal levensvatbare prematuren; vooral deze groep wordt door deze infectie getroffen.Infectie met groep-B-streptokokken (GBS)Streptococcus agalactiae behoort met onder andere de groep-A-streptokokken tot de pyogene streptokokken.", [["getroffen", "CHEMICAL", 130, 139], ["groep-B-streptokokken", "CHEMICAL", 153, 174], ["GBS", "DISEASE", 176, 179], ["Streptococcus agalactiae", "SPECIES", 180, 204], ["Infectie", "TEST", 140, 148], ["groep", "TEST", 153, 158], ["GBS", "TEST", 176, 179], ["Streptococcus agalactiae behoort", "TEST", 180, 212]]], ["Deze zijn voor het merendeel \u03b1-hemolytisch, dat wil zeggen dat ze een grijswitte ring veroorzaken rond de kolonies op bloedagarplaten.", [["dat", "TEST", 44, 47]]], ["Van de GBS is slechts 2% non-hemolytisch.", [["Van de GBS", "TEST", 0, 10]]], ["Het zijn facultatief anaerobe, gram-positieve kokken, die op grond van verschillende celwandeigenschappen onderverdeeld kunnen worden in zeven typen: Ia, Ib, II, III, IV, V en VI, die serologisch van elkaar onderscheiden kunnen worden.Infectie met groep-B-streptokokken (GBS)GBS komt bij draagsters voor in de keel, het rectum of de vagina.", [["rectum", "ANATOMY", 320, 326], ["vagina", "ANATOMY", 333, 339], ["GBS", "DISEASE", 271, 274], ["rectum", "ORGAN", 320, 326], ["vagina", "ORGANISM_SUBDIVISION", 333, 339], ["Infectie", "TEST", 235, 243], ["groep", "TEST", 248, 253], ["B-streptokokken (GBS", "TEST", 254, 274], ["GBS", "TEST", 275, 278], ["rectum", "ANATOMY", 320, 326], ["de vagina", "ANATOMY", 330, 339]]], ["Dragerschap komt voor bij een derde tot de helft van alle vrouwen en bij een kleine helft daarvan in de vagina, waarvoor de bron doorgaans het rectum is.", [["rectum", "ANATOMY", 143, 149], ["vagina", "ORGANISM_SUBDIVISION", 104, 110], ["rectum", "ORGAN", 143, 149], ["vagina", "ANATOMY", 104, 110], ["rectum", "ANATOMY", 143, 149]]], ["Bij de seksuele partners van GBS-draagsters kunnen in de helft van de gevallen ook GBS uit de urethra worden gekweekt.", [["urethra", "ANATOMY", 94, 101], ["urethra", "ORGANISM_SUBDIVISION", 94, 101], ["GBS", "PROBLEM", 83, 86], ["urethra", "ANATOMY", 94, 101]]], ["Seksuele overdraagbaarheid lijkt derhalve mogelijk.Infectie met groep-B-streptokokken (GBS)Er zijn, omstreden, verbanden gevonden tussen het GBS-draagsterschap en het preterme breken van de vliezen (PPROM) of een preterme baring.", [["PPROM", "DISEASE", 199, 204], ["Seksuele overdraagbaarheid lijkt derhalve mogelijk", "SPECIES", 0, 50], ["verbanden gevonden tussen het GBS-draagsterschap en het preterme breken van de vliezen", "SPECIES", 111, 197], ["Infectie", "TEST", 51, 59], ["groep", "TEST", 64, 69], ["B-streptokokken (GBS)", "PROBLEM", 70, 91], ["het GBS", "PROBLEM", 137, 144]]], ["Bij draagsters van GBS is er viermaal zo vaak sprake van endometritis post partum als bij niet-draagsters, terwijl ook sepsis in het kraambed veroorzaakt kan worden door GBS.Infectie met groep-B-streptokokken (GBS)De belangrijkste neonatale ziektebeelden die door GBS worden veroorzaakt, zijn sepsis en meningitis.", [["endometritis", "DISEASE", 57, 69], ["sepsis", "DISEASE", 119, 125], ["GBS", "DISEASE", 170, 173], ["groep-B-streptokokken", "CHEMICAL", 187, 208], ["GBS", "DISEASE", 210, 213], ["sepsis", "DISEASE", 293, 299], ["meningitis", "DISEASE", 303, 313], ["van endometritis", "PROBLEM", 53, 69], ["sepsis", "PROBLEM", 119, 125], ["GBS", "PROBLEM", 170, 173], ["Infectie", "TEST", 174, 182], ["groep", "TEST", 187, 192], ["B-streptokokken (GBS)", "PROBLEM", 193, 214], ["GBS", "PROBLEM", 264, 267], ["zijn sepsis en meningitis", "PROBLEM", 288, 313], ["sepsis", "OBSERVATION", 119, 125], ["meningitis", "OBSERVATION", 303, 313]]], ["GBS-infectie van de neonaat kan via verticale besmetting door de met GBS gekoloniseerde moeder ontstaan, of via horizontale besmetting vanuit de omgeving.", [["GBS", "PROBLEM", 0, 3], ["infectie", "PROBLEM", 4, 12]]], ["In het eerste geval treden doorgaans vroeg na de geboorte ziekteverschijnselen op (early-onset, gemiddeld binnen 20 uur) of zijn al bij de geboorte aanwezig, in het tweede geval (late-onset) pas na een week tot drie maanden.", [["na", "CHEMICAL", 43, 45], ["na", "CHEMICAL", 195, 197]]], ["De helft van de kinderen van met GBS gekoloniseerde moeders wordt ook gekoloniseerd en bij 1% van deze kinderen ontstaat een ernstige infectie.", [["gekoloniseerd en bij", "TREATMENT", 70, 90]]], ["Sepsis komt kort na de geboorte voor in 75% van de gevallen en kan worden veroorzaakt door alle serotypen GBS.", [["Sepsis", "DISEASE", 0, 6], ["na", "CHEMICAL", 17, 19], ["GBS", "DISEASE", 106, 109], ["Sepsis", "PROBLEM", 0, 6]]], ["De verdeling van de serotypen, zoals die wordt aangetroffen bij de kinderen met een sepsis, is overeenkomstig de verdeling bij de moeders.", [["een sepsis", "DISEASE", 80, 90], ["een sepsis", "PROBLEM", 80, 90], ["sepsis", "OBSERVATION", 84, 90]]], ["Alleen wanneer er kort na de geboorte een meningitis is, blijkt deze in de meerderheid van de gevallen veroorzaakt te zijn door GBS serotype III.Infectie met groep-B-streptokokken (GBS)De overgrote meerderheid van late ziektebeelden, die in de helft van de gevallen door de omgeving worden veroorzaakt, is eveneens het gevolg van een infectie met GBS serotype III, terwijl bij de geboorte maar bij een derde van de gekoloniseerde neonaten serotype III wordt gekweekt.", [["Alleen wanneer er kort na", "CHEMICAL", 0, 25], ["meningitis", "DISEASE", 42, 52], ["meningitis", "PROBLEM", 42, 52], ["GBS serotype III", "PROBLEM", 128, 144], ["Infectie", "TEST", 145, 153], ["GBS serotype III", "PROBLEM", 347, 363], ["meningitis", "OBSERVATION", 42, 52]]], ["Bij de late ziekte is dan ook veel vaker sprake van een meningitis dan bij de vroege ziekte.Infectie met groep-B-streptokokken (GBS)Aan de vroeg ontstane ziekte als gevolg van een GBS-infectie overlijdt tot 15% van de kinderen, bij de late ziekte is dat 20%.", [["groep-B-streptokokken", "CHEMICAL", 105, 126], ["GBS", "DISEASE", 128, 131], ["Infectie", "TEST", 92, 100], ["groep", "TEST", 105, 110], ["B-streptokokken (GBS", "PROBLEM", 111, 131], ["GBS", "TEST", 180, 183], ["infectie", "PROBLEM", 184, 192]]], ["Ongeveer 30% van de kinderen met een meningitis houdt hier echter neurologisch letsel aan over, waaronder blindheid, doofheid en spasticiteit.Infectie met groep-B-streptokokken (GBS)De diagnose wordt bij de neonaat gesteld op een bloedkweek en/of een kweek van lumbaal vocht.", [["meningitis", "DISEASE", 37, 47], ["groep-B-streptokokken", "CHEMICAL", 155, 176], ["meningitis", "PROBLEM", 37, 47], ["Infectie", "TEST", 142, 150], ["meningitis", "OBSERVATION", 37, 47]]], ["Met de behandeling kan men niet wachten totdat de uitslag bekend is.", [["men", "SPECIES", 23, 26]]], ["De tests zijn weliswaar zeer specifiek (92-100%), maar weinig sensitief (30-66%).", [["De tests", "TEST", 0, 8], ["maar", "TEST", 50, 54]]], ["Ook de desoxyribonucle\u00efnezuur-PCR is nog onvoldoende sensitief en daarbij geen snelle test sensu strictu (enige uren).Infectie met groep-B-streptokokken (GBS)Voor het ontstaan van een neonatale infectie blijkt een aantal risicofactoren te kunnen worden onderscheiden, die ook een rol spelen bij de preventieve behandeling (tabel 21.2).Infectie met groep-B-streptokokken (GBS)Het is logisch dat voortdurend gezocht wordt naar methoden om neonatale infectie te voorkomen.", [["groep-B-streptokokken", "CHEMICAL", 348, 369], ["Infectie", "TEST", 118, 126], ["groep", "TEST", 131, 136], ["B-streptokokken (GBS", "PROBLEM", 137, 157], ["een aantal risicofactoren", "TREATMENT", 210, 235], ["Infectie", "TEST", 335, 343], ["groep", "TEST", 348, 353], ["B-streptokokken (GBS", "PROBLEM", 354, 374]]], ["GBS zijn doorgaans goed gevoelig voor penicilline, maar het blijkt niet goed mogelijk draagsters met een penicillinekuur permanent GBS-vrij te krijgen vanwege re-infectie vanuit het rectum.", [["rectum", "ANATOMY", 182, 188], ["penicilline", "CHEMICAL", 38, 49], ["penicilline", "CHEMICAL", 38, 49], ["rectum", "ORGAN", 182, 188], ["GBS", "TEST", 0, 3], ["permanent GBS", "TEST", 121, 134], ["vrij te krijgen", "TREATMENT", 135, 150], ["rectum", "ANATOMY", 182, 188]]], ["Vanwege het grillige gedrag van de GBS-kolonisaties en het relatief gering aantal kinderen dat ziek wordt, is er nog geen consensus over de preventie van neonatale GBS-infectie.", [["GBS-infectie", "DISEASE", 164, 176], ["Vanwege het grillige gedrag van de GBS-kolonisaties en het relatief gering aantal kinderen dat ziek wordt", "SPECIES", 0, 105], ["GBS", "TEST", 35, 38], ["infectie", "PROBLEM", 168, 176]]], ["In het kort komt dit advies erop neer dat urineweginfecties met GBS in de zwangerschap moeten worden behandeld en dat bij zwangeren met een verhoogd risico een selectieve kweek moet worden afgenomen met \u00e9\u00e9n wattenstok uit achtereenvolgens introitus vaginae en rectum (selectieve screening volgens risicofactoren).", [["rectum", "ANATOMY", 260, 266], ["GBS", "DISEASE", 64, 67], ["rectum", "ORGAN", 260, 266], ["GBS", "PROBLEM", 64, 67], ["rectum", "ANATOMY", 260, 266]]], ["Een alternatief dat ook door het CDC is toegestaan, maar vooralsnog niet is overgenomen in de NVOG-Richtlijn van 2008, is om elke zwangere tussen 35-37 weken te screenen door middel van een selectieve GBS-kweek, en in geval van positiviteit te behandelen, ongeacht het voorkomen van risicofactoren.", [["GBS", "TEST", 201, 204]]], ["Aan zwangeren met een positieve kweekuitslag of aan vrouwen van wie nog geen uitslag bekend is, moeten intrapartum profylactisch antibiotica intraveneus worden toegediend, bij voorkeur 2 miljoen IE penicilline G, of anders 2 g amoxicilline/ampicilline, zo mogelijk te geven minstens vier uur voor de te verwachten partus en daarna \u00e0 4 uur de helft tot de baby geboren is.SyfilisTreponema pallidum, de spirocheet die syfilis (lues) veroorzaakt, is een zeer dun (6-15 \u03bcm) micro-organisme dat slechts met zijbelichting in donkerveldmicroscopie waarneembaar is.", [["Treponema pallidum", "ORGANISM", 378, 396], ["Treponema pallidum", "SPECIES", 378, 396], ["amoxicilline", "TREATMENT", 227, 239], ["ampicilline", "TREATMENT", 240, 251], ["zo mogelijk te", "TREATMENT", 253, 267]]], ["Een infectie kan via slijmvliezen of huidlaesies ontstaan.", [["huidlaesies ontstaan", "TREATMENT", 37, 57]]], ["Bij onbeschermde co\u00eftus is de transmissiekans 33%.SyfilisSyfilis is een systemische infectie die zich snel door het gehele lichaam verspreidt en zo gedurende de gehele zwangerschap de foetus kan infecteren via de placenta naar de foetale circulatie of via de vruchtvliezen en het vruchtwater naar de slijmvliezen van het kind.", [["SyfilisSyfilis", "TREATMENT", 50, 64]]], ["Deze infectie leidt dan tot abortus of intra-uteriene vruchtdood of is soms klinisch manifest bij de geboorte door de aanwezigheid van hepatosplenomegalie, pneumonie, gegeneraliseerde lymfeklierzwelling, exantheem, uve\u00eftis, rinitis en dergelijke.", [["pneumonie", "PROBLEM", 156, 165], ["gegeneraliseerde lymfeklierzwelling", "PROBLEM", 167, 202]]], ["In meer dan de helft van de gevallen van een congenitale (of aangeboren) lues is sprake van petechi\u00ebn, icterus en anemie.", [["icterus", "DISEASE", 103, 110], ["icterus en anemie", "PROBLEM", 103, 120]]], ["Vaak kan de infectie bij de geboorte nog niet worden vastgesteld en zal de diagnose pas later duidelijk worden door tandafwijkingen, zadelneus, gewrichtsafwijkingen en andere symptomen.SyfilisDe luetische placenta is vaak groot, dik en bleek en vertoont histologisch het beeld van een focale villitis met vaatafwijkingen.", [["villitis", "PROBLEM", 292, 300], ["placenta", "ANATOMY", 205, 213], ["villitis", "OBSERVATION", 292, 300]]], ["De navelstreng kan het beeld van een necrotiserende funiculitis vertonen en ziet er dan heel karakteristiek uit als een 'uithangstok' van een oude kapperszaak, of als een roodwitte zuurstok.SyfilisDe diagnostiek van lues in de zwangerschap is serologisch en is in het algemeen gericht op het aantonen van de aspecifieke antistoffen tegen het cardiolipine-lecithine-antigeen met behulp van de VDRLreactie (Venereal Diseases Research Laboratory), of op het aantonen van de specifieke antistoffen met de TPPA-reactie (Treponema pallidum particle agglutinatiereactie) en de FTA-absorptietest (fluorescent treponemal antibody).", [["Venereal Diseases", "DISEASE", 405, 422], ["fluorescent treponemal antibody", "PROTEIN", 589, 620], ["Treponema pallidum", "SPECIES", 515, 533], ["De navelstreng kan het beeld van een necrotiserende funiculitis vertonen en ziet er dan heel karakteristiek uit als een 'uithangstok' van een oude kapperszaak", "SPECIES", 0, 158], ["Treponema pallidum", "SPECIES", 515, 533], ["TPPA", "TEST", 501, 505], ["fluorescent treponemal antibody", "TEST", 589, 620], ["heel", "ANATOMY", 88, 92]]], ["De VDRL stijgt na een infectie wat later (5-6 weken) dan de TPPA (4 weken), maar daalt weer onder invloed van behandeling met antibiotica (meestal penicilline) in tegenstelling tot de TPPA, die levenslang positief blijft.", [["na", "CHEMICAL", 15, 17], ["antibiotica (meestal penicilline", "TREATMENT", 126, 158]]], ["De VDRL is derhalve geschikt als screeningstest en als indicator van de effectiviteit van de behandeling (tabel 21.3).Tabel 21.2 Risicofactoren voor een neonatale infectie met groep-B-streptokokken-een eerder kind met een neonatale GBS-infectie -GBS-bacteriurie in de zwangerschap -preterme bevallen (<37 weken) -langdurig gebroken vliezen (>18 uur) -temperatuur \u226537,8 \u00baC De FTA-absorptietest wordt gebruikt als confirmatietest voor de TPPA.", [["GBS-bacteriurie", "DISEASE", 246, 261], ["voor een neonatale infectie met groep-B-streptokokken-een eerder kind met een neonatale GBS-infectie -GBS-bacteriurie in de zwangerschap -preterme bevallen (<37 weken) -langdurig gebroken vliezen (>18 uur) -temperatuur \u226537,8 \u00baC De FTA-absorptietest wordt gebruikt als confirmatietest voor de TPPA", "SPECIES", 144, 440], ["Tabel", "TEST", 118, 123], ["Risicofactoren", "TEST", 129, 143], ["een neonatale GBS", "TEST", 218, 235], ["infectie", "PROBLEM", 236, 244], ["GBS", "PROBLEM", 246, 249], ["bacteriurie", "PROBLEM", 250, 261], ["temperatuur", "TEST", 351, 362], ["C De FTA", "TEST", 370, 378]]], ["Na een positieve screeningstest wordt veelal een specifiekere PCR uitgevoerd ter bevestiging dat het om syfilis gaat.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na", "TEST", 0, 2]]], ["Voor diagnostiek bij de neonaat wordt de 19S-IgM-FTA-absorptietest uitgevoerd.", [["19S", "PROTEIN", 41, 44], ["IgM", "PROTEIN", 45, 48]]], ["Deze toont IgM-antistoffen tegen lues aan.", [["IgM", "PROTEIN", 11, 14]]], ["IgM-antistoffen passeren slechts in uitzonderingsgevallen de placenta en zijn dus van kinderlijke origine.Tabel 21.2 Risicofactoren voor een neonatale infectie met groep-B-streptokokkenBij een negatieve uitslag van de neonaat moet de test na drie maanden worden herhaald indien er sprake kan zijn van een foetale besmetting binnen drie maanden voor de geboorte.", [["na", "CHEMICAL", 239, 241], ["IgM", "PROTEIN", 0, 3], ["IgM", "TEST", 0, 3], ["Tabel", "TEST", 106, 111], ["Risicofactoren", "TEST", 117, 131]]], ["De serologische screening op lues, die in Belgi\u00eb en Nederland routineus wordt verricht bij het eerste consult, sluit infecties in de zwangerschap natuurlijk niet uit.", [["De serologische screening", "TEST", 0, 25]]], ["Bij risicozwangeren dient de test dan ook in het derde trimester herhaald te worden; vooral wanneer er sprake is van een onbegrepen exantheem of bij een vagina-of mondslijmvliesulcus.", [["vagina", "ANATOMY", 153, 159]]], ["Een ge\u00efsoleerde VDRL-stijging heeft geen betekenis, zeker niet bij lage titers.", [["Een ge\u00efsoleerde VDRL", "TEST", 0, 20]]], ["Een positieve TPPA (en FTA-absorptie) bij een negatieve VDRL kan duiden op een behandelde oude lues, een onbehandelde lues latens of een andere treponematose.", [["Een", "TEST", 0, 3], ["TPPA", "TEST", 14, 18]]], ["Het spreekt vanzelf dat dit geen behandeling behoeft, maar door het moeilijke onderscheid vaak wel uitlokt.Tabel 21.2 Risicofactoren voor een neonatale infectie met groep-B-streptokokkenDe behandeling van (vroege) lues in de zwangerschap bestaat uit minstens tweemaal 2,4 ME benzathinepenicilline i.m. wekelijks toe te dienen in alternerende bilspier (pijnlijk!).", [["Tabel", "TEST", 107, 112]]], ["Bij het kind moet dan bij de geboorte en na drie maanden met behulp van IgM-bepalingen worden onderzocht of er sprake is van een lues connata die behandeling behoeft.TuberculoseTuberculose wordt veroorzaakt door Mycobacterium tuberculosis, een 4 \u03bcm lange gebogen staafvormige bacil, die in 1882 door Robert Koch is ontdekt.", [["na", "CHEMICAL", 41, 43], ["TuberculoseTuberculose", "CHEMICAL", 166, 188], ["Mycobacterium tuberculosis", "DISEASE", 212, 238], ["Mycobacterium tuberculosis", "ORGANISM", 212, 238], ["Mycobacterium tuberculosis", "SPECIES", 212, 238], ["gebogen staafvormige", "SPECIES", 255, 275], ["Mycobacterium tuberculosis", "SPECIES", 212, 238], ["TuberculoseTuberculose", "TREATMENT", 166, 188], ["Mycobacterium tuberculosis", "PROBLEM", 212, 238]]], ["Hij kleurt niet in de gram-kleuring, maar na kleuring volgens Ziehl-Neelsen is de kleur bestendig tegen zuur en alcohol (zuurvast).", [["na", "CHEMICAL", 42, 44], ["alcohol", "CHEMICAL", 112, 119], ["alcohol", "CHEMICAL", 112, 119], ["alcohol", "SIMPLE_CHEMICAL", 112, 119]]], ["Hoewel tuberculose in Nederland weinig voorkomt, is het in de wereld de meest voorkomende infectieziekte, met in de jaren negentig naar schatting 90 miljoen gevallen en 30 miljoen sterfgevallen.TuberculoseTuberculose komt ook veel bij dieren voor, maar de verspreiding vindt vrijwel geheel van mens op mens plaats.", [["TuberculoseTuberculose", "TREATMENT", 194, 216]]], ["De besmetting geschiedt aerogeen of congenitaal.", [["congenitaal", "OBSERVATION_MODIFIER", 36, 47]]], ["Na inademing van ge\u00efnfecteerde druppels, afkomstig van iemand met open tuberculose, komt de primaire infectie gewoonlijk in de longen tot stand.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["open tuberculose", "TREATMENT", 66, 82]]], ["Binnen enkele dagen verspreidt de bacil zich van hieruit via de bloed-en lymfevaten.", [["Binnen", "TREATMENT", 0, 6]]], ["In afwijking van eerdere idee\u00ebn blijkt de zwangerschap geen verhoogd risico te vormen voor het opleven van tuberculose, in tegenstelling tot de kraamperiode.", [["tuberculose", "CHEMICAL", 107, 118], ["zwangerschap geen verhoogd risico te vormen voor het opleven van tuberculose", "SPECIES", 42, 118]]], ["Besmetting kan ook bij de geboorte plaatsvinden door een cervicitis van de moeder, en postnataal natuurlijk aerogeen, zoals bij volwassenen.TuberculoseEen prenatale hematogene infectie bereikt het lichaam via de vena umbilicalis en leidt dan ook tot een infectie van de periportale lymfeklieren (primair complex bij de congenitale infectie).", [["cervicitis", "DISEASE", 57, 67], ["TuberculoseEen", "TREATMENT", 140, 154], ["hematogene infectie", "PROBLEM", 165, 184], ["tot een infectie van de periportale lymfeklieren", "TREATMENT", 246, 294], ["vena", "ANATOMY", 212, 216]]], ["Na passage van de lever vormen de longen toch weer het belangrijkste doelorgaan.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2]]], ["Bij hematogene verspreiding worden ook andere Bij een actieve tuberculose is de kans op een miskraam vertienvoudigd, terwijl de kans op een vroeggeboorte twee-tot driemaal zo groot is.", [["een vroeggeboorte", "TREATMENT", 136, 153], ["tot driemaal zo groot", "TREATMENT", 159, 180]]], ["Bij een adequate behandeling is het risico op een slechte afloop niet verhoogd.TuberculoseDe diagnostiek bestaat uit het verrichten van de mantouxtest en bij een positieve uitslag uit het maken van een thoraxfoto.", [["TuberculoseDe diagnostiek bestaat uit het verrichten van de mantouxtest en bij een positieve uitslag uit het maken van een thoraxfoto", "SPECIES", 79, 212]]], ["Bij een hiv-ge\u00efnfecteerde vrouw zegt een negatieve mantouxtest niet veel, terwijl bij iemand uit een gebied waar tuberculose veel voorkomt, een positieve mantouxtest ook niet veel zegt.", [["ge\u00efnfecteerde", "TREATMENT", 12, 25]]], ["Wanneer geen sputum kan worden verkregen, kan ook ochtendmaagaspiraat worden onderzocht met behulp van de ziehl-neelsen-kleuring.", [["kan ook ochtendmaagaspiraat worden onderzocht met behulp van de ziehl-neelsen-kleuring", "SPECIES", 42, 128]]], ["Dit geldt ook voor neonaten die verdacht worden van een congenitale tuberculose.TuberculoseTuberculose moet met minstens drie tuberculostatica worden behandeld, waaronder isoniazide.", [["TuberculoseTuberculose", "CHEMICAL", 80, 102], ["isoniazide", "CHEMICAL", 171, 181], ["isoniazide", "CHEMICAL", 171, 181], ["TuberculoseTuberculose", "SIMPLE_CHEMICAL", 80, 102], ["waaronder isoniazide", "SIMPLE_CHEMICAL", 161, 181], ["TuberculoseTuberculose", "TREATMENT", 80, 102], ["waaronder isoniazide", "TREATMENT", 161, 181]]], ["Wanneer geen bijwerkingen optreden (toxische hepatitis bij 1-2%), begint men pas na enige weken met de behandeling van de hiv-infectie.", [["hepatitis", "DISEASE", 45, 54], ["na", "CHEMICAL", 81, 83], ["men", "SPECIES", 73, 76], ["toxische hepatitis bij", "TREATMENT", 36, 58]]], ["Om perifere neuritis te voorkomen moet vitamine B 6 worden bijgegeven.Q-koortsQ-koorts wordt veroorzaakt door een obligaat intracellulair groeiende gramnegatieve bacterie (Coxiella burnetii).", [["neuritis", "DISEASE", 12, 20], ["vitamine B", "CHEMICAL", 39, 49], ["vitamine B", "CHEMICAL", 39, 49], ["Coxiella burnetii", "ORGANISM", 172, 189], ["groeiende gramnegatieve", "SPECIES", 138, 161], ["Coxiella burnetii", "SPECIES", 172, 189], ["groeiende gramnegatieve bacterie", "SPECIES", 138, 170], ["Coxiella burnetii", "SPECIES", 172, 189], ["neuritis", "PROBLEM", 12, 20], ["vitamine B", "TREATMENT", 39, 49], ["koorts", "TREATMENT", 80, 86], ["Coxiella burnetii", "PROBLEM", 172, 189], ["neuritis", "OBSERVATION", 12, 20]]], ["C. burnetii wordt uitgescheiden via melk, urine, feces en vooral nageboorte-of abortusproducten en wordt via aerosolen verspreid.", [["aerosolen", "CHEMICAL", 109, 118], ["urine", "ORGANISM_SUBSTANCE", 42, 47], ["feces", "ORGANISM_SUBSTANCE", 49, 54], ["C. burnetii", "SPECIES", 0, 11], ["C. burnetii", "SPECIES", 0, 11], ["urine", "TEST", 42, 47], ["feces", "TEST", 49, 54], ["burnetii wordt", "OBSERVATION", 3, 17]]], ["De bacterie is zeer infectieus, \u00e9\u00e9n bacterie kan al een infectie teweegbrengen.", [["zeer infectieus", "PROBLEM", 15, 30]]], ["Transmissie na tekenbeten is beschreven maar is zeldzaam.", [["na", "CHEMICAL", 12, 14]]], ["De zeldzame overdracht tussen mensen is transplacentair van moeder naar kind of parenteraal door bijvoorbeeld transplantatie.Q-koortsDe bacterie blijft buiten het lichaam weken tot maanden in leven, afhankelijk van de drager (aerosol of afval), kan sporen vormen en is relatief bestendig tegen hitte (maar niet tegen pasteurisatie of sterilisatie), uitdroging en desinfectantia (maar niet tegen 0,05% chloor of 1:100 benzalkoniumchloride; Lysol).", [["Lysol", "CHEMICAL", 439, 444], ["benzalkoniumchloride", "CHEMICAL", 417, 437], ["Lysol", "CHEMICAL", 439, 444], ["De zeldzame overdracht tussen", "TREATMENT", 0, 29], ["Lysol", "TREATMENT", 439, 444]]], ["De incubatietijd is 1 tot 3 weken.Q-koortsEr wordt een onderscheid gemaakt tussen de voorbijgaande acute Q-koorts die zich manifesteert als een griep met soms een pneumonie of een hepatitis, en de chronische Q-koorts die meestal een endocarditis veroorzaakt.", [["een hepatitis", "DISEASE", 176, 189], ["endocarditis veroorzaakt", "DISEASE", 233, 257], ["een hepatitis", "PROBLEM", 176, 189], ["een hepatitis", "OBSERVATION", 176, 189], ["endocarditis", "OBSERVATION", 233, 245]]], ["De virulente (infectieuze) fase I van de bacterie geeft chronische Q-koorts en de minder virulente en pathogene fase II geeft de acute Q-koorts.Q-koortsVooral een infectie met C. burnetii vroeg in de zwangerschap kan bij zoogdieren via een placentitis een abortus, intra-uteriene groeiretardatie, vroeg-of doodgeboorte teweegbrengen en bij mensen is dit beschreven in een hoog percentage (80%) van onbehandelde zwangeren met Q-koorts.", [["C. burnetii", "SPECIES", 176, 187]]], ["Echter, omdat Q-koorts in 50% van de gevallen asymptomatisch verloopt, is dit percentage vermoedelijk te hoog.", [["Echter", "TEST", 0, 6]]], ["Opmerkelijk is ook dat bij de grote uitbraken van Q-koorts in Nederland tussen 2007 en 2010 in een retrospectieve studie in gebieden met hoge incidentie tussen 2007 en 2008 de (asymptomatische) aanwezigheid van antistoffen tegen C. burnetii in de vroege zwangerschap niet geassocieerd was met vroeggeboorte, een laag geboortegewicht of perinatale sterfte.Q-koortsDe klinische diagnose wordt bevestigd door een stijgende titer in de serologie, eventueel gevolgd door een PCR.", [["C. burnetii", "SPECIES", 229, 240], ["aanwezigheid van antistoffen tegen", "TREATMENT", 194, 228]]], ["Alleen serologisch is onderscheid te maken tussen fase I en fase II.", [["fase II", "PROTEIN", 60, 67], ["Alleen serologisch", "TREATMENT", 0, 18]]], ["De kans hierop is namelijk verhoogd bij immuungecompromitteerden en bij zwangeren.Q-koortsDe behandeling is afhankelijk van het stadium: acute Q-koorts met 200 mg dd doxycycline gedurende 14 dagen, maar chronische Q-koorts gedurende 2-3 jaar met een combinatie van 200 mg dd doxycycline en 600 mg dd hydroxychloroquine (gedurende een jaar en daarna op geleide van plasmaspiegels).", [["doxycycline", "CHEMICAL", 275, 286], ["hydroxychloroquine", "CHEMICAL", 300, 318], ["gedurende een jaar", "CHEMICAL", 320, 338], ["doxycycline", "CHEMICAL", 275, 286], ["hydroxychloroquine", "CHEMICAL", 300, 318], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 300, 318], ["en bij zwangeren", "TREATMENT", 65, 81], ["doxycycline gedurende", "TREATMENT", 166, 187], ["doxycycline", "TREATMENT", 275, 286], ["hydroxychloroquine (gedurende een jaar en daarna op geleide van plasmaspiegels", "TREATMENT", 300, 378]]], ["In de zwangerschap kan cotrimoxazol worden gegeven (dagelijks 1600 mg sulfamethoxazol/320 mg trimethoprim p.o.) of erytromycine bij allergie voor cotrimoxazol.Q-koortsBorstvoeding wordt afgeraden wanneer sprake was van Q-koorts in de zwangerschap.", [["cotrimoxazol", "CHEMICAL", 23, 35], ["gegeven", "CHEMICAL", 43, 50], ["sulfamethoxazol", "CHEMICAL", 70, 85], ["trimethoprim", "CHEMICAL", 93, 105], ["erytromycine", "CHEMICAL", 115, 127], ["cotrimoxazol", "CHEMICAL", 146, 158], ["cotrimoxazol", "CHEMICAL", 23, 35], ["sulfamethoxazol", "CHEMICAL", 70, 85], ["trimethoprim p.o.", "CHEMICAL", 93, 110], ["erytromycine", "CHEMICAL", 115, 127], ["cotrimoxazol", "CHEMICAL", 146, 158], ["cotrimoxazol", "SIMPLE_CHEMICAL", 23, 35], ["sulfamethoxazol", "SIMPLE_CHEMICAL", 70, 85], ["trimethoprim", "SIMPLE_CHEMICAL", 93, 105], ["erytromycine", "SIMPLE_CHEMICAL", 115, 127], ["cotrimoxazol", "SIMPLE_CHEMICAL", 146, 158], ["de zwangerschap kan cotrimoxazol", "TREATMENT", 3, 35], ["gegeven (dagelijks", "TREATMENT", 43, 61], ["sulfamethoxazol", "TREATMENT", 70, 85], ["trimethoprim", "TREATMENT", 93, 105], ["erytromycine", "TREATMENT", 115, 127], ["cotrimoxazol", "TREATMENT", 146, 158]]], ["Speciale aandacht moet worden besteed aan de begeleiding van de bevalling en het verwerken van de placenta.", [["placenta", "ANATOMY", 98, 106], ["placenta", "TISSUE", 98, 106], ["placenta", "ANATOMY", 98, 106]]], ["Het dragen van mondkapjes en handschoenen is belangrijk, alsook het voorkomen van luchtstromingen vanuit de verloskamer naar buiten.Cytomegalie (CMV)Cytomegalievirus is een in 1956 ontdekt DNA-virus, dat behoort tot de groep van herpesvirussen.", [["Cytomegalie", "CHEMICAL", 132, 143], ["CMV", "ORGANISM", 145, 148], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["Cytomegalie", "TEST", 132, 143], ["CMV", "TEST", 145, 148], ["Cytomegalievirus", "TEST", 149, 165]]], ["Sinds de invoering van de rubellavaccinatie is congenitale CMV-infectie de belangrijkste oorzaak van zowel aangeboren doofheid als mentale retardatie.", [["CMV", "PROBLEM", 59, 62], ["infectie", "PROBLEM", 63, 71]]], ["CMV geeft bij volwassenen meestal aanleiding tot een subklinische infectie, maar het kan ook gedurende twee weken een pfeifferachtig beeld geven met koortspieken, algehele malaise en een lichte tot matige hepatosplenomegalie zonder lymfadenopathie.", [["zonder lymfadenopathie", "DISEASE", 225, 247], ["CMV", "ORGANISM", 0, 3], ["CMV", "TEST", 0, 3], ["algehele malaise", "PROBLEM", 163, 179], ["zonder lymfadenopathie", "PROBLEM", 225, 247], ["zonder lymfadenopathie", "OBSERVATION", 225, 247]]], ["Het virus ontleent zijn naam aan de vorming van reuzencellen met opvallende intranucleaire insluitsels, ook wel uiloogcellen genoemd.", [["Het virus", "ORGANISM", 0, 9]]], ["Uit een grote steekproef van de hielprik in 2007 bleek 1 op de 200 Nederlandse kinderen congenitaal ge\u00efnfecteerd met CMV.Cytomegalie (CMV)De transmissie kan op diverse wijzen plaatsvinden omdat het virus in de meeste kernhoudende celsoorten gerepliceerd kan worden.", [["CMV", "ORGANISM", 117, 120], ["CMV", "ORGANISM", 134, 137], ["CMV", "PROBLEM", 117, 120], ["Cytomegalie", "TEST", 121, 132]]], ["Virusexcretie kan via urine en ontlasting plaatsvinden (verspreiding op kinderdagverblijven), maar ook via speeksel (speelgoed, knuffelen, kissing disease), sperma en cervixslijm, waardoor besmetting in de geslachtsrijpe periode plaatsvindt.", [["urine", "ORGANISM_SUBSTANCE", 22, 27], ["Virusexcretie kan via urine en ontlasting plaatsvinden", "TREATMENT", 0, 54], ["kissing disease)", "PROBLEM", 139, 155]]], ["Transmissie door transfusies van bloedproducten zou vooral tot stand komen door de leukocytenfractie van ongescreende erytrocytensuspensies, die niet gedeglyceroliseerd of gefiltreerd zijn.Cytomegalie (CMV)Bij het begin van de reproductieve periode is minder dan de helft van de vrouwen in aanraking geweest met CMV en dit zal oplopen tot meer dan 60% na die periode.", [["na", "CHEMICAL", 352, 354], ["CMV", "ORGANISM", 202, 205], ["CMV", "ORGANISM", 312, 315], ["Cytomegalie", "PROBLEM", 189, 200], ["CMV en dit zal oplopen", "TREATMENT", 312, 334]]], ["Zwangeren met een eerder kind dat op een cr\u00e8che zit, lopen dus het hoogste risico op een infectie.", [["Zwangeren", "TREATMENT", 0, 9]]], ["Een klein gerandomiseerd onderzoek waarin de helft van de immunologisch onbeschermde zwangeren profylactische hygi\u00ebnische maatregelen toepaste bij de verzorging en omgang met het kind (geen mondop-mondcontact), suggereerde een beschermend effect in vergelijking met de groep die alleen de gewone zwangerschapsadviezen kreeg.Cytomegalie (CMV)Na een primo-infectie treedt altijd een levenslange latentie op, waaruit door reactivatie herhaaldelijk recidiefinfecties met virusuitscheiding in de urine kunnen optreden.", [["Na", "CHEMICAL", 341, 343], ["CMV", "ORGANISM", 337, 340], ["Een klein gerandomiseerd onderzoek waarin de helft van de immunologisch onbeschermde zwangeren profylactische hygi\u00ebnische maatregelen toepaste bij de verzorging en omgang met het kind (geen mondop-mondcontact", "SPECIES", 0, 208], ["Een klein gerandomiseerd", "TREATMENT", 0, 24], ["Cytomegalie", "TEST", 324, 335], ["CMV", "TEST", 337, 340], ["Na", "TEST", 341, 343], ["een primo-infectie", "TEST", 344, 362], ["treedt", "TEST", 363, 369], ["herhaaldelijk recidiefinfecties", "PROBLEM", 431, 462]]], ["Daarnaast kan re-infectie plaatsvinden met andere dan de reeds verworven CMV-variant.Cytomegalie (CMV)Zowel bij een primo-infectie/re-infectie als na reactivatie kan verticale transmissie plaatsvinden: transplacentair, tijdens de baring of via de borstvoeding.", [["na", "CHEMICAL", 147, 149], ["CMV", "ORGANISM", 73, 76], ["CMV", "ORGANISM", 98, 101], ["Zowel bij een primo-infectie/re-infectie als na reactivatie kan verticale transmissie plaatsvinden", "SPECIES", 102, 200], ["Cytomegalie", "TEST", 85, 96], ["CMV", "TEST", 98, 101], ["Zowel bij een primo-infectie", "TREATMENT", 102, 130]]], ["Hoe ernstig de CMVinfectie voor het kind is, hangt voornamelijk af van de soort infectie die de moeder doormaakt (tabel 21.4) en het moment van infectie: het meeste risico wordt periconceptioneel gelopen en in het eerste trimester, terwijl preconceptionele infecties en infecties in het derde trimester geen klinische verschijnselen gaven in het grootste cohortonderzoek tot nu toe uit 2011.Cytomegalie (CMV)Intra-uteriene vruchtdood wordt zelden veroorzaakt door CMV.", [["CMV", "ORGANISM", 404, 407], ["CMV", "ORGANISM", 464, 467], ["CMV", "SPECIES", 404, 407], ["Cytomegalie", "TEST", 391, 402], ["Intra-uteriene vruchtdood", "TREATMENT", 408, 433], ["toe", "ANATOMY", 378, 381]]], ["Microcefalie, chorioretinitis, convulsies en intracraniale verkalkingen blijken prognostisch slecht te zijn.", [["Microcefalie", "CHEMICAL", 0, 12], ["chorioretinitis", "DISEASE", 14, 29], ["Microcefalie", "SIMPLE_CHEMICAL", 0, 12], ["Microcefalie", "TREATMENT", 0, 12], ["chorioretinitis", "PROBLEM", 14, 29], ["convulsies", "PROBLEM", 31, 41], ["chorioretinitis", "OBSERVATION", 14, 29]]], ["Maar ook bij 15% van de kinderen die bij de geboorte asymptomatisch zijn, komen later gehoorstoornissen en mentale retardatie voor (tabel 21.5).Cytomegalie (CMV)Bij de diagnostiek van een CMV-infectie wordt gebruikgemaakt van isolatie van het virus in een viruskweek van keel en urine en van serologie.", [["CMV", "ORGANISM", 157, 160], ["CMV", "ORGANISM", 188, 191], ["urine", "ORGANISM_SUBSTANCE", 279, 284], ["een CMV-infectie wordt gebruikgemaakt van isolatie van het virus in een viruskweek van keel en urine en van serologie", "SPECIES", 184, 301], ["Cytomegalie", "TEST", 144, 155], ["CMV", "TEST", 157, 160], ["Bij de diagnostiek van een CMV", "TREATMENT", 161, 191], ["infectie", "PROBLEM", 192, 200]]], ["De IgM-bepaling tegen CMV is moeilijk te interpreteren omdat deze zeer lang positief kan blijven.", [["CMV", "ORGANISM", 22, 25], ["IgM", "PROTEIN", 3, 6], ["De IgM", "TEST", 0, 6], ["bepaling tegen CMV", "TREATMENT", 7, 25]]], ["Daarentegen kan met een aviditeitsbepaling van het IgG en de titers in herhaalde metingen worden beoordeeld hoe recent een infectie is.", [["Daarentegen kan", "TREATMENT", 0, 15]]], ["Lage aviditeit past bij een recente infectie.", [["recente infectie", "OBSERVATION", 28, 44]]], ["Om een infectie bij de foetus vast te stellen of uit te sluiten, kan in de tweede helft van de zwangerschap en 5-6 weken na het begin van de infectie bij de zwangere een PCR op het vruchtwater worden verricht.", [["Om een infectie bij de foetus vast te stellen of uit te sluiten, kan in de tweede helft van de zwangerschap en 5-6 weken na het begin van de infectie bij de zwangere een PCR op het vruchtwater worden verricht", "SPECIES", 0, 208]]], ["Daarnaast geeft de kwantitatieve CMV-PCR een indruk van de titer van de viremie, waarmee het effect van een eventuele antivirale behandeling kan worden vervolgd.", [["CMV", "TEST", 33, 36]]], ["Ganciclovir kan intraveneus worden toegediend, maar wordt door de ernst van de bijwerkingen alleen in levensbedreigende situaties gegeven.", [["Ganciclovir", "TREATMENT", 0, 11]]], ["In lopend onderzoek wordt de beschermende werking van (het wel veilige) aciclovir tegen de klinische Het verloop van de acute infectie, die niet chronisch wordt, kan in drie stadia worden ingedeeld (tabel 21.6).", [["aciclovir", "CHEMICAL", 72, 81], ["van (het wel veilige", "TREATMENT", 50, 70], ["aciclovir", "TREATMENT", 72, 81], ["acute infectie", "PROBLEM", 120, 134]]], ["Men spreekt dan van dragerschap.", [["Men", "SPECIES", 0, 3]]], ["Ze zijn HBsAgen HBeAg-positief.", [["HBeAg", "CHEMICAL", 16, 21], ["Ze", "TEST", 0, 2], ["HBeAg", "TEST", 16, 21], ["HBeAg", "OBSERVATION", 16, 21]]], ["Bij een nog redelijk werkende afweer kan het HBeAg op den duur verdwijnen; er is dan sprake van een HBeAg-negatief dragerschap (in de chronisch actieve en inactieve HBeAg-negatieve fase).", [["HBeAg", "CHEMICAL", 45, 50], ["HBeAg", "CHEMICAL", 100, 105], ["HBeAg", "CHEMICAL", 165, 170], ["HBeAg", "TEST", 165, 170]]], ["Bij deze dragers is de hoeveelheid virus in het bloed veel lager en bij hen zal dus ook de besmettelijkheid minder zijn, hoewel zeker niet afwezig.", [["hen", "SPECIES", 72, 75]]], ["Transmissie via borstvoeding komt ook voor, tenzij de neonaat gevaccineerd wordt volgens protocol (zie verder).Cytomegalie (CMV)Gezien de landelijke HBV-dragersprevalentie van 0,8% en de mogelijkheid om infectie van de neonaat in verreweg de meeste gevallen te voorkomen, wordt sinds 1989 landelijk gescreend op de aanwezigheid van HBsAg bij zwangeren.", [["Cytomegalie", "CHEMICAL", 111, 122], ["HBsAg", "CHEMICAL", 332, 337], ["CMV", "ORGANISM", 124, 127], ["HBV-dragersprevalentie van 0,8% en de mogelijkheid om infectie van de neonaat in verreweg de meeste gevallen te voorkomen, wordt sinds 1989 landelijk gescreend op de aanwezigheid van HBsAg bij zwangeren", "SPECIES", 149, 351], ["Cytomegalie", "TEST", 111, 122], ["dragersprevalentie van", "TREATMENT", 153, 175], ["van HBsAg bij zwangeren", "TREATMENT", 328, 351]]], ["Het belang van deze screening wordt natuurlijk groter naarmate iemand tot een grotere risicogroep behoort (afkomstig uit Zuidoost-Azi\u00eb of uit landen rond de Middellandse Zee, ex-drugsgebruiksters, medisch personeel).Cytomegalie (CMV)Indien de zwangere HBsAg-positief is, wordt doorgaans de HBV-load bepaald en afhankelijk van de hoogte (meer dan 10 9 virussen/ml) kan lamivudine worden verstrekt vanaf 32 weken om de load te doen dalen en daarmee de kans dat de neonaat ontsnapt aan de tweede preventiemethode die altijd wordt toegepast, de gecombineerd passieve en actieve immunisatie.", [["Cytomegalie", "CHEMICAL", 216, 227], ["HBsAg", "CHEMICAL", 252, 257], ["lamivudine", "CHEMICAL", 368, 378], ["CMV", "ORGANISM", 229, 232], ["HBV-load bepaald en afhankelijk van de hoogte (meer dan 10 9 virussen/ml) kan lamivudine worden verstrekt vanaf 32 weken om de load te doen dalen en daarmee de kans dat de neonaat ontsnapt aan de tweede preventiemethode die altijd wordt toegepast", "SPECIES", 290, 536], ["Cytomegalie", "TEST", 216, 227], ["CMV", "TEST", 229, 232], ["HBsAg", "TEST", 252, 257], ["kan lamivudine worden verstrekt vanaf", "TREATMENT", 364, 401]]], ["Binnen 2 uur na de geboorte wordt passieve immunisatie gegeven met hepatitis B-immunoglobuline (HepBQuin 150 IE).", [["Binnen 2 uur na", "CHEMICAL", 0, 15], ["hepatitis B", "DISEASE", 67, 78], ["hepatitis B-immunoglobuline (HepBQuin", "TREATMENT", 67, 104]]], ["Dit valt in tegenstelling tot de actieve vaccinaties buiten het Rijksvaccinatieprogramma (RVP) en moet dus op recept worden verstrekt.", [["Dit valt", "PROBLEM", 0, 8]]], ["De eerste actieve vaccinatie (anno 2012: Engerix B junior 10 \u03bcg per 0,5 ml) wordt binnen 48 uur na de geboorte toegediend in een andere ledemaat dan waarin de passieve immunisatie wordt gegeven.", [["Engerix B junior", "TREATMENT", 41, 57]]], ["De actieve vervolgvaccinaties zijn gekoppeld aan de DKTP-Hib (het DKTP-Hib-HepB-vaccin (Infanrix hexa) bij 2, 3, 4 en 11 maanden).", [["DKTP-Hib-HepB-vaccin", "CHEMICAL", 66, 86], ["De actieve vervolgvaccinaties zijn gekoppeld aan de DKTP-Hib (het DKTP-Hib-HepB-vaccin", "SPECIES", 0, 86], ["Hib", "TEST", 57, 60], ["DKTP", "TEST", 66, 70], ["Hib", "TEST", 71, 74], ["HepB", "TREATMENT", 75, 79], ["vaccin (Infanrix hexa", "TREATMENT", 80, 101]]], ["Na neonatale vaccinatie binnen 24 uur na de geboorte ontstaat in meer dan 95% van de gevallen afdoende, levenslange immuniteit.Cytomegalie (CMV)Vanaf 1 augustus 2011 worden alle kinderen conform aanbevelingen van de Wereldgezondheidsorganisatie actief gevaccineerd met het DKTP-Hib-HepB-vaccin bij 2, 3, 4 en 11 maanden.Hepatitis CHet hepatitis-C-virus (HCV) -uit de groep van de flavivirussen -veroorzaakt een zeer groot deel van de voorheen als non-A, non-B bestempelde hepatitis.", [["Na", "CHEMICAL", 0, 2], ["uur na", "CHEMICAL", 34, 40], ["Hepatitis CHet hepatitis-C-virus", "DISEASE", 320, 352], ["hepatitis", "DISEASE", 472, 481], ["Na", "CHEMICAL", 0, 2], ["CMV", "ORGANISM", 140, 143], ["Hepatitis CHet hepatitis-C-virus", "ORGANISM", 320, 352], ["HCV", "ORGANISM", 354, 357], ["voorheen als non-A", "CANCER", 434, 452], ["aanbevelingen van de Wereldgezondheidsorganisatie actief gevaccineerd met het DKTP-Hib-HepB-vaccin bij", "SPECIES", 195, 297], ["Hepatitis CHet hepatitis-C-virus (HCV) -uit de groep van de flavivirussen -veroorzaakt een zeer groot deel van de voorheen als non-A", "SPECIES", 320, 452], ["Na neonatale vaccinatie binnen", "TREATMENT", 0, 30], ["Cytomegalie", "TEST", 127, 138], ["Hib", "TEST", 278, 281], ["HepB", "TREATMENT", 282, 286], ["vaccin bij", "TREATMENT", 287, 297], ["Hepatitis CHet hepatitis", "PROBLEM", 320, 344], ["C-virus (HCV)", "PROBLEM", 345, 358], ["veroorzaakt een", "TREATMENT", 395, 410], ["B bestempelde hepatitis", "PROBLEM", 458, 481], ["hepatitis", "OBSERVATION", 335, 344], ["hepatitis", "OBSERVATION", 472, 481]]], ["Er zijn verschillende genotypen waarvan de verspreiding geografisch sterk verschilt.", [["Er zijn verschillende genotypen waarvan", "TREATMENT", 0, 39]]], ["Seksuele transmissie komt waarschijnlijk nauwelijks voor.Hepatitis CHCV-infectie leidt zeer vaak (80%) tot een chronische infectie met als late complicaties cirrose en hepatocellulair carcinoom.Hepatitis CVerticale transmissie van ge\u00efnfecteerde moeders naar de kinderen komt weinig voor (<10%), maar de kans wordt groter bij vrouwen die ook met hiv zijn ge\u00efnfecteerd.", [["Hepatitis CHCV", "DISEASE", 57, 71], ["Hepatitis CVerticale", "DISEASE", 194, 214], ["Hepatitis CHCV-infectie", "ORGANISM", 57, 80], ["Hepatitis CHCV-infectie leidt zeer vaak", "SPECIES", 57, 96], ["Hepatitis CHCV", "PROBLEM", 57, 71], ["infectie", "PROBLEM", 72, 80], ["zeer vaak", "TREATMENT", 87, 96], ["tot een chronische infectie", "PROBLEM", 103, 130], ["als late complicaties", "PROBLEM", 135, 156], ["Hepatitis", "PROBLEM", 194, 203]]], ["De hoeveelheid HCV-RNA in het bloed is bepalend voor de kans op transmissie: <10 6 kopie\u00ebn: 9%, >10 6 kopie\u00ebn: tot 40%.", [["De hoeveelheid HCV", "ORGANISM", 0, 18], ["kopie\u00ebn", "TEST", 83, 90]]], ["Borstvoeding vergroot de kans op transmissie waarschijnlijk niet.Hepatitis CEr bestaan serologische methoden om een infectie met HCV aan te tonen, maar een HCV-PCR komt vele weken eerder op en maakt duidelijk of er een chronische infectie met viremie bestaat.", [["Hepatitis CEr", "DISEASE", 65, 78], ["Hepatitis CEr", "TEST", 65, 78], ["bestaan", "TEST", 79, 86], ["serologische", "TEST", 87, 99], ["methoden", "TEST", 100, 108], ["HCV aan te tonen", "TEST", 129, 145], ["maar", "TEST", 147, 151], ["een HCV", "TEST", 152, 159], ["PCR", "TEST", 160, 163], ["vele", "TEST", 169, 173]]], ["Alle bloeddonaties worden daarom vanaf juli 1999 ook gescreend met de HCV-PCR om de transmissie tot een minimum te beperken.Hepatitis CDe behandeling van HCV bestond tot voor kort uit interferon met ribavirine, en is, afhankelijk van het genotype, 50-80% effectief.", [["Hepatitis", "DISEASE", 124, 133], ["ribavirine", "CHEMICAL", 199, 209], ["Hepatitis CDe", "ORGANISM", 124, 137], ["ribavirine", "SIMPLE_CHEMICAL", 199, 209], ["interferon", "PROTEIN", 184, 194], ["Hepatitis CDe", "PROBLEM", 124, 137], ["interferon met ribavirine", "TREATMENT", 184, 209]]], ["Het hepatitis-E-virus (HEV) behoort tot de calicivirussen en is feco-oraal overdraagbaar.", [["Het hepatitis-E-virus", "DISEASE", 0, 21], ["Het hepatitis-E-virus", "ORGANISM", 0, 21], ["HEV", "ORGANISM", 23, 26], ["HEV", "SPECIES", 23, 26], ["Het hepatitis", "TEST", 0, 13], ["E-virus", "PROBLEM", 14, 21], ["feco-oraal overdraagbaar", "PROBLEM", 64, 88], ["hepatitis", "OBSERVATION", 4, 13], ["feco-oraal overdraagbaar", "OBSERVATION", 64, 88]]], ["Kinderen blijven meestal asymptomatisch, volwassenen reageren met een acute hepatitis, zonder chronische vormen.Hepatitis CBij zwangere vrouwen in het derde trimester kunnen zich zeer hevige ziektebeelden ontwikkelen door intravasale stolling, met 20% letaliteit.", [["acute hepatitis", "DISEASE", 70, 85], ["Hepatitis", "DISEASE", 112, 121], ["een acute hepatitis", "PROBLEM", 66, 85], ["Hepatitis", "PROBLEM", 112, 121], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["hepatitis", "OBSERVATION", 76, 85]]], ["Bij de besmette neonaat kan in zeldzame gevallen een gedissemineerde infectie ontstaan.", [["Bij de besmette neonaat kan", "TREATMENT", 0, 27], ["zeldzame", "TREATMENT", 31, 39]]], ["Diagnostiek kan bij Sanquin-CLB worden aangevraagd en bestaat uit serologie (IgG en IgM) of uit PCR op HEV-RNA.Hepatitis CRecentelijk is duidelijk geworden dat HEV-genotype 3 algemeen voorkomt bij varkens in het Westen.", [["Hepatitis CRecentelijk", "DISEASE", 111, 133], ["IgG en IgM", "GENE_OR_GENE_PRODUCT", 77, 87], ["Hepatitis CRecentelijk", "ORGANISM", 111, 133], ["bestaat uit serologie", "DNA", 54, 75], ["IgG", "PROTEIN", 77, 80], ["IgM", "PROTEIN", 84, 87], ["uit PCR op HEV-RNA", "RNA", 92, 110], ["Diagnostiek", "TEST", 0, 11], ["Sanquin", "TEST", 20, 27], ["aangevraagd", "TEST", 39, 50], ["serologie", "TEST", 66, 75], ["IgG en IgM", "TEST", 77, 87], ["uit PCR", "TEST", 92, 99], ["Hepatitis", "PROBLEM", 111, 120]]], ["Chronische infectie met dit virus is inmiddels gevonden bij meerdere transplantatiepati\u00ebnten, ook in Nederland.Herpes simplexHet herpessimplexvirus (HSV) behoort tot de groep van de herpesvirussen.", [["Herpes simplex", "DISEASE", 111, 125], ["dit virus", "ORGANISM", 24, 33], ["Herpes simplex", "ORGANISM", 111, 125], ["Het herpessimplexvirus", "ORGANISM", 125, 147], ["HSV", "ORGANISM", 149, 152], ["HSV", "SPECIES", 149, 152], ["Chronische infectie met dit virus", "PROBLEM", 0, 33], ["Herpes simplex", "PROBLEM", 111, 125], ["Het herpessimplexvirus (HSV)", "PROBLEM", 125, 153], ["dit virus", "OBSERVATION", 24, 33], ["simplex", "OBSERVATION", 118, 125]]], ["Het is een dubbelstrengs DNA-virus dat in twee serologisch te onderscheiden vormen voorkomt: het type-1-virus, dat voornamelijk herpes labialis veroorzaakt, en het type-2-virus, dat herpes genitalis kan geven.", [["herpes labialis", "DISEASE", 128, 143], ["herpes genitalis", "DISEASE", 182, 198], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["het type-1-virus", "ORGANISM", 93, 109], ["dat voornamelijk herpes labialis veroorzaakt", "ORGANISM", 111, 155], ["het type-2-virus", "ORGANISM", 160, 176], ["dat herpes genitalis", "ORGANISM", 178, 198], ["voornamelijk herpes labialis", "SPECIES", 115, 143], ["veroorzaakt", "SPECIES", 144, 155], ["dat herpes genitalis", "SPECIES", 178, 198], ["het type-2-virus", "SPECIES", 160, 176], ["virus dat", "TEST", 29, 38], ["dat", "TEST", 111, 114], ["voornamelijk herpes labialis veroorzaakt", "PROBLEM", 115, 155]]], ["De symptomen zijn ulcusvormende blaasjes die restloos genezen, maar die bij een primo-infectie, in het bijzonder bij herpes genitalis, soms gedurende enige weken kunnen opkomen en dan tot veel ongemak kunnen leiden.", [["herpes genitalis", "DISEASE", 117, 133], ["herpes", "ORGANISM", 117, 123], ["herpes", "SPECIES", 117, 123]]], ["Zwangeren met herpes genitalis die veel klachten veroorzaakt, kunnen in de gehele zwangerschap gedurende 5 dagen met aciclovir (200 mg 5 dd p.o.) behandeld worden en bij geringere klachten lokaal met zovirax.", [["herpes genitalis", "DISEASE", 14, 30], ["aciclovir", "CHEMICAL", 117, 126], ["aciclovir", "CHEMICAL", 117, 126], ["herpes", "ORGANISM", 14, 20], ["herpes", "SPECIES", 14, 20], ["Zwangeren", "TREATMENT", 0, 9], ["aciclovir", "TREATMENT", 117, 126], ["zovirax", "TREATMENT", 200, 207]]], ["Na de primo-infectie blijven de herpessimplexvirussen in de verzorgende ganglia achter en kunnen daar weer gereactiveerd worden, waarna endogene re-infecties ontstaan.", [["Na", "CHEMICAL", 0, 2], ["Na", "TEST", 0, 2]]], ["Het type-1-virus kan ook genitale infecties veroorzaken, maar recidiveert dan minder vaak.", [["Het type", "TEST", 0, 8]]], ["De seroprevalentie stijgt geleidelijk vanaf 0% kort na de geboorte tot 75% bij volwassenen.", [["De seroprevalentie stijgt geleidelijk vanaf 0% kort na de geboorte tot 75% bij volwassenen", "SPECIES", 0, 90], ["De seroprevalentie stijgt geleidelijk vanaf", "TREATMENT", 0, 43]]], ["Herpes genitalis daarentegen wordt voornamelijk door geslachtsverkeer overgebracht en komt pas voor het eerst voor in de puberteit; de incidentie loopt op tot een kwart van de volwassenen op 40-jarige leeftijd.", [["Herpes genitalis", "DISEASE", 0, 16], ["Herpes", "ORGANISM", 0, 6], ["Herpes", "SPECIES", 0, 6], ["Herpes genitalis daarentegen wordt voornamelijk door geslachtsverkeer overgebracht en komt pas voor het eerst voor in de puberteit; de incidentie loopt op tot een kwart van de volwassenen op 40-jarige leeftijd", "SPECIES", 0, 209], ["Herpes", "PROBLEM", 0, 6]]], ["Symptoomloze dragers zijn dan ook de grootste bron van infectie.Herpes simplexDe besmetting van moeder op kind kan plaatsvinden bij de geboorte door passage door een ge\u00efnfecteerd baringskanaal, of na de geboorte via de handen van een kraamvrouw met herpes labialis of rechtstreeks door knuffelen of kussen.", [["na", "CHEMICAL", 197, 199], ["herpes labialis", "DISEASE", 249, 264], ["Herpes simplexDe", "ORGANISM", 64, 80], ["herpes labialis", "ORGANISM", 249, 264], ["Herpes", "SPECIES", 64, 70], ["herpes", "SPECIES", 249, 255]]], ["Wanneer het hierbij gaat om een recidief bij de moeder, dan heeft het kind via de placenta passief anti-herpes-gammaglobulinen verworven en is relatief immuun tegen infectie (minder dan 5% kans op ziekte).", [["Wanneer het hierbij gaat om een recidief bij de moeder, dan heeft het kind via de placenta passief anti-herpes-gammaglobulinen verworven en is relatief immuun tegen infectie (minder dan 5% kans op ziekte", "SPECIES", 0, 203], ["placenta passief anti-herpes", "TREATMENT", 82, 110], ["gammaglobulinen verworven", "TREATMENT", 111, 136]]], ["Wanneer het daarentegen een primo-infectie van de zwangere of kraamvrouw betreft, of wanneer de besmetting optreedt via een andere verzorgende, terwijl de moeder niet ge\u00efnfecteerd was, dan heeft het kind die bescherming niet en kan een herpes neonatorum ontstaan.", [["herpes neonatorum", "DISEASE", 236, 253], ["herpes", "ORGANISM", 236, 242], ["herpes neonatorum", "SPECIES", 236, 253]]], ["De manifestaties kunnen zijn: laesies van de huid, mond of ogen, encefalitis, of een gedissemineerde infectie (zie tabel 21.5).", [["encefalitis", "TREATMENT", 65, 76], ["een gedissemineerde infectie", "TREATMENT", 81, 109]]], ["De laatste twee hebben een hoge letaliteit (>50% en >90%) die door behandeling met aciclovir teruggebracht kan worden tot respectievelijk 15% en 70%.Herpes simplexOmdat besmetting voor de geboorte nagenoeg niet optreedt en er een incubatietijd is van vijf (2-12) dagen, wordt bij een zwangere die bekend is met recidief herpes genitalis, bij de geboorte slechts overgegaan tot het afnemen van een gevoelige nucle\u00efnezuuramplificatietest (NAAT) van de cervix en van de gebruikelijke herpes-recidiefplaats.", [["aciclovir", "CHEMICAL", 83, 92], ["Herpes simplexOmdat", "DISEASE", 149, 168], ["herpes genitalis", "DISEASE", 320, 336], ["herpes-recidiefplaats", "DISEASE", 481, 502], ["aciclovir", "CHEMICAL", 83, 92], ["Herpes", "ORGANISM", 149, 155], ["herpes", "ORGANISM", 320, 326], ["herpes", "ORGANISM", 481, 487], ["Herpes", "SPECIES", 149, 155], ["herpes", "SPECIES", 320, 326], ["aciclovir", "TREATMENT", 83, 92], ["herpes genitalis", "PROBLEM", 320, 336]]], ["Bij een positieve uitslag wordt de neonatus profylactisch behandeld met aciclovir.", [["aciclovir", "CHEMICAL", 72, 81], ["aciclovir", "CHEMICAL", 72, 81], ["aciclovir", "SIMPLE_CHEMICAL", 72, 81], ["aciclovir", "TREATMENT", 72, 81]]], ["Neonaten met een symptomatische herpessimplexinfectie moeten behandeld worden met i.v. aciclovir.", [["aciclovir", "CHEMICAL", 87, 96], ["aciclovir", "CHEMICAL", 87, 96], ["aciclovir", "SIMPLE_CHEMICAL", 87, 96], ["Neonaten", "TREATMENT", 0, 8], ["aciclovir", "TREATMENT", 87, 96]]], ["Bij een vermoedelijke primaire anogenitale HSV-infectie in de laatste 6 weken van de zwangerschap wordt een sectio caesarea aanbevolen, tenzij de wekelijks afgenomen tests negatief zijn geworden en vooropgesteld dat de vliezen niet langer dan drie uur gebroken zijn.Herpes simplexIn het geval van gebroken vliezen wordt de kans op besmetting, zo die mocht plaatsvinden, niet significant kleiner met een sectio en kunnen de vrouw en de pasgeborene slechts medicamenteus worden behandeld.Infectie met hivHet humaan immunodefici\u00ebntievirus (hiv) is een RNA-bevattend retrovirus.", [["HSV-infectie", "DISEASE", 43, 55], ["Herpes simplex", "DISEASE", 266, 280], ["Herpes simplex", "ORGANISM", 266, 280], ["hivHet humaan immunodefici\u00ebntievirus", "ORGANISM", 499, 535], ["retrovirus", "ORGANISM", 563, 573], ["hivHet humaan immunodefici\u00ebntievirus", "SPECIES", 499, 535], ["HSV", "PROBLEM", 43, 46], ["infectie", "PROBLEM", 47, 55], ["Herpes simplex", "PROBLEM", 266, 280], ["Infectie", "TEST", 486, 494], ["een RNA", "TEST", 545, 552], ["retrovirus", "PROBLEM", 563, 573], ["simplex", "OBSERVATION", 273, 280]]], ["Hiv bestaat uit een omhulsel (enveloppe), een kern (core) en het genetisch materiaal.", [["Hiv", "PROBLEM", 0, 3]]], ["Het draagt in de kern twee enzymen het reversetranscriptase en de protease.", [["protease", "PROTEIN", 66, 74]]], ["Met het reversetranscriptase wordt na de infectie van een gastheercel intracellulair het RNA in DNA omgezet.", [["na", "CHEMICAL", 35, 37], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["Met het reversetranscriptase wordt na de infectie van een gastheercel intracellulair het RNA", "RNA", 0, 92], ["van een gastheercel", "TREATMENT", 50, 69]]], ["Het DNA bouwt zich vervolgens in het gastheer-DNA in, waarna bij stimulatie van de cel nieuw virusmateriaal wordt gevormd waarbij de protease een rol speelt.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["protease", "PROTEIN", 133, 141], ["Het DNA", "PROBLEM", 0, 7], ["vervolgens", "PROBLEM", 19, 29], ["DNA", "PROBLEM", 46, 49]]], ["Dit leidt tot een immunologische respons die vergelijkbaar is met die van hepatitis B: antilichamen gericht tegen delen van de enveloppe en antistoffen gericht tegen delen van de core.", [["hepatitis B", "DISEASE", 74, 85], ["antilichamen gericht tegen", "TREATMENT", 87, 113]]], ["In tegenstelling tot bij het HBV blijft besmettelijkheid echter bestaan wanneer antistoffen tegen beide virusdelen circuleren.Infectie met hivHiv infecteert met name de CD4-receptordragende lymfocyten, waardoor de cellulaire afweer geleidelijk vermindert en aids ontstaat.", [["echter bestaan", "SPECIES", 57, 71], ["Infectie", "PROBLEM", 126, 134], ["receptordragende lymfocyten", "TREATMENT", 173, 200]]], ["Besmetting met hiv vindt plaats via bloedproducten, seksueel of verticaal, dat wil zeggen van moeder op kind.Infectie met hivDe prevalentie van hiv-infectie onder zwangeren in Nederland is regionaal verschillend en varieert van zeer laag tot 2 per 1000.", [["zwangeren", "TREATMENT", 163, 172]]], ["Overig risicogedrag is onbeschermd seksueel contact met een man met biseksuele contacten of met hemofilie die bloedproducten heeft gehad tussen 1980 en 1985 (20% ge\u00efnfecteerd), tenzij bij hen een hiv-seronegatieve status bekend is.", [["man", "SPECIES", 60, 63], ["hen", "SPECIES", 188, 191]]], ["In doorgaande zwangerschappen vinden zonder preventieve maatregelen infecties laat in de zwangerschap plaats, waarvan driekwart tijdens de partus.", [["waarvan driekwart tijdens de partus", "ORGANISM", 110, 145], ["driekwart tijdens", "SPECIES", 118, 135]]], ["De kans op overdracht van moeder op kind wordt zeer sterk bepaald door de hoeveelheid nieuw gevormd virus, die in het bloed aantoonbaar is met behulp van een kwantitatieve hiv-RNA-PCR-meting.", [["kans op overdracht van moeder op kind wordt zeer sterk bepaald door de hoeveelheid nieuw gevormd virus", "SPECIES", 3, 105], ["gevormd virus", "PROBLEM", 92, 105], ["PCR", "TEST", 180, 183]]], ["Onafhankelijke risicofactoren voor hiv-overdracht zijn: primo-infectie tijdens zwangerschap of lactatie, vroeggeboorte, andere geslachtsziekten wanneer die leiden tot ulceratie van de genitali\u00ebn, vitamine-A-defici\u00ebntie, langer dan vier uur gebroken vliezen, invasieve diagnostiek bij het kind voor de geboorte en een vaginale geboorte.Infectie met hivWanneer er geen voorzorgen worden getroffen om overdracht te voorkomen, is de kans daarop voor hiv type 1 tussen 25 en 40%, waarvan 14% via de borstvoeding.", [["Onafhankelijke", "TREATMENT", 0, 14], ["vitamine", "TREATMENT", 196, 204], ["waarvan", "TREATMENT", 475, 482]]], ["Een deel van de profylaxe berust op post exposure profylaxe.", [["profylaxe", "CHEMICAL", 50, 59]]], ["De behandeling vindt plaats in (samenwerking met) aidscentrum-ziekenhuizen.Infectie met hivEen algehele screening op anti-enveloppe-antistoffen (hiv-seropositiviteit) volgens het opting-out principe werd in Nederland begin 2004 ingevoerd en heeft ertoe geleid dat het aantal ge\u00efnfecteerde kinderen van een tiental per jaar is gereduceerd tot een enkel kind, in de meeste gevallen omdat de moeder pas in de zwangerschap werd ge\u00efnfecteerd door haar niet-geteste partner.Infectie met hivEen ge\u00efnfecteerd kind zal zich bij de geboorte nagenoeg niet onderscheiden van een niet-ge\u00efnfecteerd kind bij vergelijkbare moeders.", [["Infectie", "TEST", 75, 83], ["screening", "TEST", 104, 113], ["anti-enveloppe", "TEST", 117, 131], ["antistoffen (hiv-seropositiviteit)", "TREATMENT", 132, 166], ["Infectie", "PROBLEM", 468, 476]]], ["Deze test is na de geboorte bij alle kinderen van hiv-ge\u00efnfecteerde vrouwen positief door de in de zwangerschap passief overgedragen IgG-antistoffen.Infectie met hivDe behandeling van de kinderen vindt gecentraliseerd plaats in drie tertiaire centra. voor in 2 op de 100.000 kinderen, zowel in de Verenigde Staten, als in Europa.", [["na", "CHEMICAL", 13, 15], ["IgG", "PROTEIN", 133, 136], ["Infectie", "PROBLEM", 149, 157]]], ["Een keizersnede lijkt niet in staat de incidentie van RRP te verlagen, wat begrijpelijk is gezien de horizontale overdracht die veelal plaatsvindt en het feit dat HPV bij baby's van HPV-negatieve moeders bij 6 weken ook net zo vaak positief is als bij (cervix-)HPV-positieve moeders.", [["cervix-)HPV-positieve moeders", "CANCER", 253, 282], ["veelal plaatsvindt en het feit dat HPV bij baby's van HPV-negatieve moeders bij 6 weken ook net zo vaak positief is als bij (cervix-)HPV-positieve moeders", "SPECIES", 128, 282], ["als bij (cervix", "PROBLEM", 244, 259], ["HPV", "PROBLEM", 261, 264], ["cervix", "ANATOMY", 253, 259]]], ["Er zijn in de literatuur aanwijzingen dat bij uitgebreide condylomata van de vulva het genezingsproces van rupturen of een episiotomie verstoord is.", [["Er zijn", "CHEMICAL", 0, 7], ["Er zijn in de literatuur aanwijzingen dat bij uitgebreide condylomata", "TREATMENT", 0, 69], ["vulva", "ANATOMY", 77, 82]]], ["Dat kan soms een overweging zijn om toch een keizersnede te verrichten.Infectie met hivDe gratis verstrekking van quadrivalent HPVvaccinatie in 2007 aan jonge meisjes/vrouwen heeft geleid tot een decimering van het aantal vrouwen en mannen dat zich meldde met genitale wratten bij een sexual health center in Melbourne.", [["Infectie", "PROBLEM", 71, 79]]], ["In Nederland is in 2009 een vaccinatie gestart met een bivalent vaccin, dat alleen gericht is tegen twee pathogenen voor cervixcarcinoom en niet tegen genitale wratten.Infectie met het humaan parvovirus B19Het humaan parvovirus B19 is een enkelstrengs DNA-virus dat in 1975 voor het eerst werd ge\u00efdentificeerd als veroorzaker van erythema infectiosum, de zogenoemde vijfde ziekte.", [["parvovirus B19", "DISEASE", 192, 206], ["parvovirus B19", "DISEASE", 217, 231], ["humaan parvovirus B19", "ORGANISM", 185, 206], ["Het humaan parvovirus B19", "ORGANISM", 206, 231], ["humaan parvovirus B19", "SPECIES", 185, 206], ["humaan parvovirus B19", "SPECIES", 210, 231], ["humaan parvovirus B19", "SPECIES", 185, 206], ["Het humaan parvovirus B19", "SPECIES", 206, 231], ["een vaccinatie gestart", "TREATMENT", 24, 46], ["een bivalent vaccin", "TREATMENT", 51, 70], ["Infectie", "TEST", 168, 176], ["het humaan parvovirus B19", "TEST", 181, 206], ["Het humaan parvovirus B19", "TEST", 206, 231], ["van erythema infectiosum", "PROBLEM", 326, 350], ["parvovirus B19", "OBSERVATION", 192, 206]]], ["Vanaf dat moment is men besmettelijk gedurende 1 week tot 10 dagen.", [["men", "ORGANISM", 20, 23], ["men", "SPECIES", 20, 23]]], ["Daarna ontstaat door de immuunrespons een licht jeukend exantheem (vlindervormig op de wangen: slapped cheeks, kantachtig op de strekzijde van de ledematen), dat overigens niet altijd voorkomt.", [["een licht jeukend exantheem (vlindervormig op de wangen: slapped cheeks, kantachtig op de strekzijde van de ledematen", "SPECIES", 38, 155], ["Daarna", "TEST", 0, 6], ["slapped cheeks", "PROBLEM", 95, 109], ["kantachtig op", "TREATMENT", 111, 124], ["cheeks", "ANATOMY", 103, 109]]], ["Vaker ziet men een atypisch exantheem dat verward kan worden met andere weinig typische infecties als rubella.", [["rubella", "DISEASE", 102, 109], ["men", "ORGANISM", 11, 14], ["men", "SPECIES", 11, 14], ["Vaker ziet", "TREATMENT", 0, 10], ["als rubella", "PROBLEM", 98, 109]]], ["Bij volwassenen ziet men vaak een symmetrische artritis, die soms langdurig is.", [["men", "SPECIES", 21, 24], ["Bij volwassenen ziet", "TREATMENT", 0, 20]]], ["In die gevallen leidt het parvovirus B19 tot een hemolytische crisis.", [["parvovirus B19", "DISEASE", 26, 40], ["parvovirus", "ORGANISM", 26, 36], ["B19", "ORGANISM", 37, 40], ["parvovirus B19", "SPECIES", 26, 40], ["het parvovirus", "TEST", 22, 36]]], ["Soms doen ook de andere componenten van het beenmerg mee.Infectie met het humaan parvovirus B19Immuniteit na een infectie is vermoedelijk permanent.", [["na", "CHEMICAL", 106, 108], ["het humaan parvovirus", "ORGANISM", 70, 91], ["humaan parvovirus", "SPECIES", 74, 91], ["Infectie", "TEST", 57, 65], ["het humaan parvovirus", "TEST", 70, 91]]], ["Bij sommige mensen komt de immuniteit echter niet goed op gang en dan kan de infectie chronisch worden.", [["Bij sommige mensen komt de immuniteit echter niet goed op gang en dan kan de infectie chronisch worden", "SPECIES", 0, 102]]], ["Het virus repliceert zich in delende cellen.", [["Het virus", "ORGANISM", 0, 9], ["Het virus", "TREATMENT", 0, 9]]], ["In de zeer jonge vrucht gebeurt dit in vele weefselsoorten en kan zo tot een abortus leiden.", [["een abortus", "SPECIES", 73, 84]]], ["Later worden vooral voorlopers van rode bloedcellen ge\u00efnfecteerd, waardoor massieve hemolyse, anemie, hartfalen en hydrops fetalis zouden optreden en vervolgens intra-uteriene vruchtdood.", [["hydrops fetalis", "DISEASE", 115, 130], ["anemie", "PROBLEM", 94, 100], ["hartfalen en hydrops fetalis", "PROBLEM", 102, 130]]], ["De incidentie van vruchtdood door parvovirus B19 bij ge\u00efnfecteerde moeders is 6,5% en van hydrops 0,6%.", [["parvovirus B19", "DISEASE", 34, 48], ["hydrops", "DISEASE", 90, 97], ["parvovirus B19", "SPECIES", 34, 48], ["parvovirus B19 bij ge\u00efnfecteerde moeders", "TREATMENT", 34, 74]]], ["Levend geboren kinderen vertonen vaak geen afwijkingen, maar myocarditis en foetale cerebrale afwijkingen zijn beschreven.", [["myocarditis", "DISEASE", 61, 72], ["Levend", "TEST", 0, 6], ["afwijkingen", "PROBLEM", 43, 54], ["maar myocarditis", "PROBLEM", 56, 72]]], ["De laatste afwijkingen blijken niet gerelateerd aan de mate van hydrops die bestaan heeft en zouden dus een rechtstreeks effect van het virus kunnen zijn.", [["hydrops die", "DISEASE", 64, 75], ["van hydrops die", "PROBLEM", 60, 75], ["en zouden dus een rechtstreeks", "TREATMENT", 90, 120]]], ["Wanneer sprake is van een parvovirusinfectie en een ernstige anemie al dan niet met hydrops van de foetus moet deze verwezen worden naar het Leids Universitair Medisch Centrum (LUMC) voor een intra-uteriene transfusie.", [["hydrops", "DISEASE", 84, 91], ["van een parvovirusinfectie en een ernstige anemie al dan niet met hydrops van de foetus moet deze verwezen worden naar het Leids Universitair Medisch Centrum (LUMC) voor een intra-uteriene transfusie", "SPECIES", 18, 217], ["hydrops van", "PROBLEM", 84, 95], ["Centrum (LUMC)", "TREATMENT", 168, 182], ["een intra-uteriene transfusie", "TREATMENT", 188, 217]]], ["Deze kan al vanaf 16 weken plaatsvinden.Infectie met het humaan parvovirus B19Er is nog geen vaccin voorhanden.", [["Infectie", "CHEMICAL", 40, 48], ["het humaan parvovirus B19Er", "ORGANISM", 53, 80], ["humaan parvovirus", "SPECIES", 57, 74], ["Infectie", "TEST", 40, 48]]], ["Ernstige hydrops op basis van infectie met parvovirus B19 lijkt op dezelfde manier als bij erythroblastosis fetalis met intra-uteriene of onmiddellijke postnatale transfusies te kunnen worden behandeld, maar de milde vormen kunnen spontaan genezen.", [["hydrops", "DISEASE", 9, 16], ["parvovirus B19", "DISEASE", 43, 57], ["erythroblastosis fetalis", "DISEASE", 91, 115], ["B19", "ORGANISM", 54, 57], ["parvovirus B19", "SPECIES", 43, 57], ["Ernstige hydrops op basis", "TEST", 0, 25], ["van infectie", "TEST", 26, 38], ["parvovirus B19", "PROBLEM", 43, 57], ["als bij erythroblastosis fetalis", "PROBLEM", 83, 115]]], ["Bij verdenking op een infectie met parvovirus B19 in de zwangerschap kan voor de diagnostiek, indien dat in huis niet mogelijk is, contact worden gezocht met het centraal klinisch virologisch laboratorium van het LUMC, waar een parvovirus-B19V-PCR beschikbaar is.Infectie met het humaan parvovirus B19Wanneer om wat voor reden dan ook in een van de eerste twee trimesters van de zwangerschap een bloedtransfusie nodig is, dan beveelt de CBO-richtlijn Bloedtransfusie aan om bij parvovirusnegatieve vrouwen bloed te geven dat negatief getest is op parvovirus B19.InfluenzaHet influenzavirus is een zeer infectieus RNA-virus met een korte incubatietijd.", [["parvovirus B19", "DISEASE", 35, 49], ["parvovirus B19", "DISEASE", 547, 561], ["parvovirus B19", "ORGANISM", 35, 49], ["parvovirus", "ORGANISM", 228, 238], ["B19V", "ORGANISM", 239, 243], ["parvovirus B19", "ORGANISM", 547, 561], ["parvovirus B19", "SPECIES", 35, 49], ["humaan parvovirus", "SPECIES", 280, 297], ["Bij verdenking op een infectie met parvovirus B19", "SPECIES", 0, 49], ["dan beveelt de CBO-richtlijn Bloedtransfusie aan om bij parvovirusnegatieve vrouwen bloed te geven dat negatief getest is op parvovirus B19", "SPECIES", 422, 561], ["Bij", "TEST", 0, 3], ["parvovirus B19", "PROBLEM", 35, 49], ["een parvovirus", "TEST", 224, 238], ["Infectie", "PROBLEM", 263, 271], ["op parvovirus B19", "TREATMENT", 544, 561], ["InfluenzaHet influenzavirus", "TEST", 562, 589]]], ["Er bestaan drie typen influenza: A, B en C. Influenza C komt weinig voor in tegenstelling tot A en B, waarvan influenza A het meest voorkomt en ook een ernstiger ziektebeeld veroorzaakt dan influenza B. Op grond van studies aan seizoensgebonden influenza-epidemie\u00ebn en pandemie\u00ebn blijken zwangere vrouwen met name in het derde trimester een verhoogd risico op ernstige morbiditeit en mortaliteit te hebben in vergelijking met niet-zwangere vrouwen, samenhangend met de hoogstand van het diafragma.", [["influenza", "DISEASE", 22, 31], ["C. Influenza", "SPECIES", 41, 53], ["waarvan influenza A het meest voorkomt en ook een ernstiger ziektebeeld veroorzaakt dan influenza B. Op grond van studies aan seizoensgebonden influenza-epidemie\u00ebn en pandemie\u00ebn blijken zwangere vrouwen met name in het derde trimester een verhoogd risico op ernstige morbiditeit en mortaliteit te hebben in vergelijking met niet-zwangere vrouwen, samenhangend met de hoogstand van het diafragma", "SPECIES", 102, 496], ["Influenza", "PROBLEM", 44, 53], ["weinig", "PROBLEM", 61, 67], ["influenza", "PROBLEM", 245, 254]]], ["De laatste pandemie was met het nieuwe influenza A (H1N1)-virus, die in Nederland duurde van medio september tot medio december 2009.", [["het nieuwe influenza A (H1N1)-virus", "ORGANISM", 28, 63], ["H1N1)-virus", "SPECIES", 52, 63], ["het nieuwe influenza A (H1N1)-virus", "SPECIES", 28, 63], ["virus", "PROBLEM", 58, 63]]], ["De meest voorkomende klachten waren hoesten en koorts (bijna 100%), rinorroe, keelpijn, hoofdpijn en kortademigheid (40-60%) en spier-en gewrichtspijn (35%).", [["De meest voorkomende klachten", "TREATMENT", 0, 29], ["hoesten en koorts (bijna", "TREATMENT", 36, 60], ["rinorroe", "TREATMENT", 68, 76], ["keelpijn", "TREATMENT", 78, 86], ["hoofdpijn en kortademigheid", "TREATMENT", 88, 115]]], ["Gastro-intestinale klachten en conjunctivitis werden weinig gezien.InfluenzaNieuwe influenza A kan evenals eerdere griepvarianten tijdens de zwangerschap leiden tot vroeggeboorte, pneumonie (soms met bacteri\u00eble superinfectie), respiratoire distresssyndroom bij volwassenen en sterfte.", [["conjunctivitis", "DISEASE", 31, 45], ["influenza", "DISEASE", 83, 92], ["InfluenzaNieuwe influenza", "ORGANISM", 67, 92], ["InfluenzaNieuwe influenza", "SPECIES", 67, 92], ["InfluenzaNieuwe influenza", "SPECIES", 67, 92], ["Gastro-intestinale klachten", "TREATMENT", 0, 27], ["influenza", "PROBLEM", 83, 92], ["A kan evenals eerdere griepvarianten tijdens", "TREATMENT", 93, 137], ["pneumonie", "PROBLEM", 180, 189], ["conjunctivitis", "OBSERVATION", 31, 45], ["influenza", "OBSERVATION", 83, 92]]], ["In geval van (sterke verdenking op) nieuwe influenza A werd aangeraden om zwangeren in het derde trimester te behandelen met een neuromidaseremmer.", [["influenza", "PROBLEM", 43, 52]]], ["Neuromidase is een structuur die in de wand van influenza A en B voorkomt (en niet bij de mens), waardoor het middel antiviraal is en niet gevaarlijk voor de foetus.InfluenzaEind 2009 kwam een vaccin tegen H1N1 ter beschikking en dit werd aanbevolen aan zwangeren na het eerste trimester.", [["na", "CHEMICAL", 264, 266], ["InfluenzaEind 2009 kwam een vaccin tegen H1N1 ter beschikking en dit werd aanbevolen aan zwangeren na het eerste", "SPECIES", 165, 277], ["InfluenzaEind", "TEST", 165, 178], ["een vaccin", "TREATMENT", 189, 199]]], ["Zwangeren worden anno 2012 niet tot de risicogroepen gerekend die een griepvaccinatie moeten ontvangen.", [["Zwangeren", "TREATMENT", 0, 9]]], ["Zonder bijkomende risicofactor moet voor de vaccinatie betaald worden.RubellaRubella of rodehond wordt veroorzaakt door een klein RNA-virus dat alleen voorkomt bij de mens.", [["Zonder bijkomende risicofactor", "TREATMENT", 0, 30]]], ["Het wordt overgedragen via de luchtwegen, door middel van druppeltjes, hoewel congenitaal ge\u00efnfecteerde kinderen (zie verder) het virus soms jarenlang in de urine kunnen uitscheiden en zo hun verzorgers besmetten.RubellaNa een incubatieperiode van 2 \u00e0 3 weken treedt, voornamelijk na de kindertijd, een griepachtig beeld op.", [["na", "CHEMICAL", 281, 283], ["het virus", "PROBLEM", 126, 135], ["RubellaNa een incubatieperiode van", "TREATMENT", 213, 247]]], ["Vooral bij volwassen vrouwen kan zich echter een artritisachtig beeld ontwikkelen.", [["Vooral bij volwassen", "TREATMENT", 0, 20]]], ["Besmettelijk is men vanaf vijf dagen v\u00f3\u00f3r tot vijf dagen na het exantheem, dat doorgaans twee dagen duurt.RubellaEen primo-infectie (of vaccinatie in 95% van de gevallen) leidt tot een IgM-respons en vervolgens tot een IgG-respons.", [["RubellaEen primo-infectie", "CHEMICAL", 106, 131], ["men", "ORGANISM", 16, 19], ["IgM", "PROTEIN", 185, 188], ["IgG", "PROTEIN", 219, 222], ["men", "SPECIES", 16, 19], ["RubellaEen primo-infectie", "PROBLEM", 106, 131], ["vaccinatie", "TEST", 136, 146], ["tot een IgM", "TEST", 177, 188]]], ["De IgM-antilichamen circuleren na een korte piek soms in lage titers nog vele maanden in het bloed; de IgG-antilichamen blijven meestal levenslang aantoonbaar.", [["IgM", "PROTEIN", 3, 6], ["De IgM", "TEST", 0, 6]]], ["Met allerlei serologische tests worden antilichamen in het bloed aangetoond.RubellaNaast de horizontale besmetting kan in de zwangerschap verticale transmissie van het virus plaatsvinden.", [["Met", "CHEMICAL", 0, 3], ["Met", "GENE_OR_GENE_PRODUCT", 0, 3], ["Met allerlei serologische tests", "TEST", 0, 31]]], ["Van hieruit vindt meestal verdere verspreiding van het virus in de foetale circulatie plaats.", [["Van hieruit vindt meestal verdere verspreiding van het virus", "SPECIES", 0, 60], ["Van hieruit vindt meestal verdere verspreiding van het virus", "TREATMENT", 0, 60]]], ["Een infectie tot de 16e week van de zwangerschap kan aangeboren afwijkingen veroorzaken zoals door de Australische oogarts Neil Gregg in 1941 voor het eerst werd onderkend.", [["Een infectie tot de 16e week van de zwangerschap kan aangeboren afwijkingen veroorzaken zoals door de Australische oogarts Neil Gregg in 1941 voor het eerst werd", "SPECIES", 0, 161]]], ["Het zogenoemde congenitale rubellasyndroom (zie tabel 21.5) omvat naast een laag geboortegewichtof zelfs intra-uteriene vruchtdood -oogafwijkingen (o.a. cataract, nystagmus), perceptiedoofheid, hartafwijkingen (o.a. ventrikelseptumdefect), mentale retardatie, hepatosplenomegalie, hepatitis, trombocytopenische purpura en longontsteking, die al dan niet in combinatie voorkomen.RubellaBij een zwangerschapsduur van minder dan 11 weken en \u00e0 terme vindt in vrijwel alle gevallen verticale transmissie plaats; daartussen daalt het percentage tot 25% rond de 24e week.", [["cataract, nystagmus", "DISEASE", 153, 172], ["hepatitis", "DISEASE", 281, 290], ["purpura", "DISEASE", 311, 318], ["Het zogenoemde congenitale rubellasyndroom", "TREATMENT", 0, 42], ["cataract", "PROBLEM", 153, 161], ["nystagmus", "PROBLEM", 163, 172], ["perceptiedoofheid", "PROBLEM", 175, 192], ["hepatosplenomegalie", "PROBLEM", 260, 279], ["hepatitis", "PROBLEM", 281, 290], ["trombocytopenische purpura", "PROBLEM", 292, 318], ["hepatitis", "OBSERVATION", 281, 290]]], ["Tussen 11 en 17 weken leidt infectie voornamelijk tot doofheid, na 14 weken eenzijdig.", [["na", "CHEMICAL", 64, 66], ["Tussen", "TEST", 0, 6], ["na", "TEST", 64, 66]]], ["Na 17 weken komen foetale afwijkingen bij immuuncompetente zwangeren niet voor.RubellaHet optreden van epidemie\u00ebn, met een periodiciteit van ongeveer 6-9 jaar, waarna veel gehandicapte kinderen werden geboren, heeft sinds 1974 geleid tot een landelijke rubellavaccinatie van meisjes op 11-jarige leeftijd, en sinds 1987 van meisjes en jongetjes op de leeftijd van 14 maanden, met een booster op 9-jarige leeftijd in het samengestelde BMR-vaccin (bof, mazelen, rubella).", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["waarna veel gehandicapte kinderen werden geboren, heeft sinds 1974 geleid tot een landelijke rubellavaccinatie van meisjes op 11-jarige leeftijd, en sinds 1987 van meisjes en jongetjes op de leeftijd van 14 maanden", "SPECIES", 160, 374], ["Na", "TEST", 0, 2], ["komen", "TEST", 12, 17], ["vaccin", "TREATMENT", 438, 444], ["rubella", "PROBLEM", 460, 467]]], ["Een (re)vaccinatie in het kraambed wordt dan geadviseerd (met BMR, omdat rubellavaccin niet meer apart verkrijgbaar is).RubellaAfhankelijk van de gebruikte test bestaat er een afkapwaarde tussen immuun en niet-immuun.", [["RubellaAfhankelijk van de gebruikte test bestaat er een afkapwaarde tussen immuun en niet-immuun", "SPECIES", 120, 216], ["Rubella", "TEST", 120, 127], ["immuun", "TEST", 195, 201]]], ["Wanneer in het verleden een vaccinatie is uitgevoerd en/of geen exantheem is voorafgegaan aan monsters met een geringe titerstijging of IgM-antistoffen in lage concentraties, dan hoede men zich voor een te snelle conclusie van bewezen infectie.", [["IgM", "PROTEIN", 136, 139], ["men", "SPECIES", 185, 188]]], ["Het is raadzaam hierover contact op te nemen met specialistische centra, zoals het Rijksinstituut voor Volksgezondheid en Milieu (RIVM) in Bilthoven.", [["Volksgezondheid en Milieu (RIVM)", "TREATMENT", 103, 135]]], ["Invasieve diagnostische technieken zoals de chorionvillusbiopsie of de navelstrengpunctie kunnen, bij een bewezen maternale infectie, de kans dat de foetus daadwerkelijk ge\u00efnfecteerd is, preciseren.RubellaRubelladiagnostiek heeft bij een besmetting na de 17e week geen enkele toegevoegde waarde meer.Infectie met het varicellazostervirusHet varicellazostervirus (VZV), dat waterpokken veroorzaakt, is een DNA-virus dat tot de groep herpesvirussen behoort.", [["na", "CHEMICAL", 249, 251], ["Het varicellazostervirus", "ORGANISM", 337, 361], ["VZV", "ORGANISM", 363, 366], ["DNA", "CELLULAR_COMPONENT", 405, 408], ["VZV", "SPECIES", 363, 366], ["RubellaRubelladiagnostiek", "TEST", 198, 223], ["Infectie", "PROBLEM", 300, 308], ["Het varicellazostervirus (VZV)", "PROBLEM", 337, 367], ["een DNA", "TEST", 401, 408]]], ["Een primo-infectie met waterpokken in de eerste trimester, met name tussen de 13e en 20e zwangerschapsweek, kan teratogeen zijn en veroorzaakt dan in 2% van de gevallen het foetale varicellazostersyndroom (oog-, huid-en/of extremiteitsafwijkingen).", [["kan teratogeen zijn en veroorzaakt dan", "TREATMENT", 108, 146]]], ["Bestudering van in totaal 71 beschreven gevallen leidt tot de conclusie dat na de primaire varicella-infectie in utero voor de geboorte ook al verscheidene herpeszosterepisoden worden doorgemaakt, waardoor de huidafwijkingen en extremiteitscontracturen verklaard kunnen worden.", [["na", "CHEMICAL", 76, 78], ["varicella-infectie", "DISEASE", 91, 109], ["varicella", "PROBLEM", 91, 100]]], ["Bij herpes zoster van de zwangere wordt dit syndroom niet gezien.Infectie met het varicellazostervirusLater in de zwangerschap kunnen waterpokken bij de moeder ook tot een foetale infectie leiden, maar met minder gevolgen, tenzij de infectie vijf dagen voor tot vijf dagen na de partus optreedt en de rash na de geboorte ontstaat.", [["herpes zoster", "DISEASE", 4, 17], ["Bij herpes", "ORGANISM", 0, 10], ["herpes zoster", "SPECIES", 4, 17], ["Bij herpes zoster", "PROBLEM", 0, 17], ["Infectie", "PROBLEM", 65, 73]]], ["Men geeft dan profylactisch zosterimmunoglobulinen direct post partum of, wanneer de ziekte is uitgebroken, systemisch aciclovir (3 dd 10 mg/kg i.v. gedurende tien dagen).Infectie met het varicellazostervirusOmdat een primaire waterpokkeninfectie in de zwangerschap een verhoogde kans geeft op een soms ernstige pneumonie, wordt geadviseerd om alle nietimmune zwangeren die minder dan vier dagen (de incubatietijd) tevoren in contact zijn geweest met iemand die waterpokken had of kort erna ontwikkelde, zosterimmunoglobulinen te geven.", [["aciclovir", "CHEMICAL", 119, 128], ["aciclovir", "CHEMICAL", 119, 128], ["aciclovir", "SIMPLE_CHEMICAL", 119, 128], ["Men", "SPECIES", 0, 3], ["systemisch aciclovir", "TREATMENT", 108, 128], ["Infectie", "PROBLEM", 171, 179], ["het varicellazostervirus", "PROBLEM", 184, 208], ["zosterimmunoglobulinen te", "TREATMENT", 504, 529]]], ["Wanneer eenmaal waterpokken uitgebroken zijn, moet systemisch aciclovir worden toegediend, met name bij immuungecompromitteerde zwangeren.", [["aciclovir", "TREATMENT", 62, 71]]], ["In de door de NVOG geaccordeerde richtlijn Varicella uit 2010 van de Nederlandse Vereniging voor Medische Microbiologie (NVMM) wordt aangeraden alle zwangeren die anamnestisch geen waterpokken hebben doorgemaakt en die ook geen eerder kind hebben dat waterpokken heeft doorgemaakt, te testen op de aanwezigheid van anti-varicellazoster-antistoffen.", [["Varicella", "SPECIES", 43, 52]]], ["In andere gevallen kan geruststelling plaatsvinden wegens de hoge waarschijnlijkheid dat er reeds weerstand is tegen VZV.", [["VZV", "ORGANISM", 117, 120]]], ["De screening in het eerste trimester versterkt de counseling en voorkomt tijdelijke onzekerheid over de behandeling na een risicocontact.Ziekte van LymeDe ziekte van Lyme wordt veroorzaakt door een spirocheet, Borrelia burgdorferi, en wordt overgebracht door teken.", [["na", "CHEMICAL", 116, 118], ["Borrelia burgdorferi", "DISEASE", 210, 230], ["Borrelia burgdorferi", "ORGANISM", 210, 230], ["Borrelia burgdorferi", "SPECIES", 210, 230], ["Borrelia burgdorferi", "SPECIES", 210, 230]]], ["Ook in Nederland is 5-20% van de teken ge\u00efnfecteerd met Borrelia.", [["Borrelia", "DISEASE", 56, 64], ["Borrelia", "ORGANISM", 56, 64]]], ["De kans op een infectie met Borrelia na een tekenbeet stijgt sterk wanneer de teek niet binnen 48 uur na de beet verwijderd is.", [["na", "CHEMICAL", 102, 104]]], ["In driekwart van de gevallen dat een tekenbeet tot een infectie leidt, ontstaan na 3-90 dagen een typische rode laesie (erythema migrans) en griepachtige verschijnselen.Ziekte van LymeBij een aantal onbehandelde pati\u00ebnten ontstaan na 4 tot 6 weken neurologische of cardiale verschijnselen of gewrichtsklachten.", [["na", "CHEMICAL", 80, 82], ["erythema migrans", "DISEASE", 120, 136], ["na", "TEST", 80, 82], ["erythema migrans", "PROBLEM", 120, 136]]], ["Verticale transmissie van Borrelia burgdorferi via de placenta is incidenteel aangetoond en kan in enkele gevallen leiden tot intrauteriene vruchtdood.Ziekte van LymeDe serologische diagnostiek van de ziekte van Lyme is weinig sensitief en mist in de vroege stadia de helft van de pati\u00ebnten.", [["Borrelia burgdorferi", "DISEASE", 26, 46], ["Lyme", "DISEASE", 212, 216], ["Borrelia burgdorferi", "ORGANISM", 26, 46], ["placenta", "ORGANISM", 54, 62], ["Borrelia burgdorferi", "SPECIES", 26, 46], ["Ziekte van LymeDe serologische", "TREATMENT", 151, 181], ["placenta", "ANATOMY", 54, 62]]], ["Daarom moet men bij het ontstaan van huidverschijnselen na een tekenbeet een empirische behandeling starten met 3 dd 500 mg amoxicilline gedurende drie weken (erytromycine bij allergie) en bij neuroborreliose ceftriaxon i.v. ook in de zwangerschap.", [["men", "SPECIES", 12, 15], ["Daarom", "TREATMENT", 0, 6], ["amoxicilline gedurende drie", "TREATMENT", 124, 151], ["erytromycine bij allergie", "TREATMENT", 159, 184], ["en bij neuroborreliose ceftriaxon", "TREATMENT", 186, 219]]], ["Hoewel een Amerikaanse studie liet zien dat profylaxe met eenmalig doxycycline binnen 72 uur na een tekenbeet 87% risicoreductie gaf op het ontwikkelen van erythema migrans, is er geen consensus over profylaxe in Nederland en is doxycycline gecontra-indiceerd in de zwangerschap.MalariaMeer dan 200 miljoen malariapati\u00ebnten worden per jaar gemeld; per jaar overlijden meer dan 800.000 mensen aan deze ziekte, van wie 90% kinderen jonger dan 5 jaar.", [["erythema migrans", "DISEASE", 156, 172], ["eenmalig doxycycline", "TREATMENT", 58, 78], ["van erythema migrans", "PROBLEM", 152, 172], ["doxycycline gecontra", "TREATMENT", 229, 249]]], ["Malaria wordt veroorzaakt door een protozo\u00f6n, Plasmodium, dat wordt verspreid door vrouwtjesmuggen van het geslacht Anopheles.", [["Plasmodium", "ORGANISM", 46, 56], ["dat wordt verspreid door vrouwtjesmuggen van het geslacht Anopheles", "SPECIES", 58, 125], ["Malaria", "PROBLEM", 0, 7], ["een protozo\u00f6n", "TREATMENT", 31, 44]]], ["De Nederlandse mug is niet gevoelig voor de tropische malariaparasiet, Plasmodium falciparum, wel voor de noordelijke variant P. vivax, de parasiet die de vorm van malaria veroorzaakt die derdedaagsekoorts wordt genoemd.", [["Plasmodium falciparum", "DISEASE", 71, 92], ["P. vivax", "DISEASE", 126, 134], ["Plasmodium falciparum", "PROBLEM", 71, 92]]], ["Momenteel komt malaria vooral voor in Afrika ten zuiden van de Sahara, in Zuidoost-Azi\u00eb (Indonesi\u00eb, Nieuw-Guinea), de Pacific, en verder in Zuid-Turkije, het Midden-Oosten, Zuid-Azi\u00eb en in Midden-en Zuid-Amerika tot Chili en Argentini\u00eb.", [["malaria", "DISEASE", 15, 22], ["Zuid", "TREATMENT", 173, 177], ["Azi\u00eb en", "TREATMENT", 178, 185], ["malaria", "OBSERVATION", 15, 22]]], ["In Suriname komt malaria voor in het binnenland.", [["malaria", "DISEASE", 17, 24]]], ["In Nederland moet men rekening houden met malaria bij mensen met koorts die in een land zijn geweest waar malaria voorkomt.MalariaVan de vier plasmodiumsoorten (P. falciparum, vivax, ovale en malariae) die bij de mens malaria veroorzaken, komen P. falciparum en P. vivax het meest voor.", [["malaria", "DISEASE", 42, 49], ["malaria", "DISEASE", 106, 113], ["P. falciparum, vivax, ovale en malariae", "DISEASE", 161, 200], ["P. falciparum", "DISEASE", 245, 258], ["men", "ORGANISM", 18, 21], ["vier plasmodiumsoorten", "ORGANISM", 137, 159], ["P. falciparum", "ORGANISM", 161, 174], ["vivax", "ORGANISM", 176, 181], ["ovale en malariae", "ORGANISM", 183, 200], ["komen P. falciparum", "ORGANISM", 239, 258], ["P.", "ORGANISM", 262, 264], ["vivax", "ORGANISM", 265, 270], ["men", "SPECIES", 18, 21], ["vier plasmodiumsoorten", "SPECIES", 137, 159], ["P. falciparum", "SPECIES", 161, 174], ["mens", "SPECIES", 213, 217], ["P. falciparum", "SPECIES", 245, 258], ["P. vivax", "SPECIES", 262, 270], ["P. falciparum", "SPECIES", 161, 174], ["P. falciparum", "SPECIES", 245, 258], ["P. vivax het meest voor", "SPECIES", 262, 285], ["MalariaVan", "TREATMENT", 123, 133], ["falciparum", "PROBLEM", 164, 174], ["vivax", "PROBLEM", 176, 181]]], ["Ernstige ziekte wordt voornamelijk veroorzaakt door P. falciparum, maar in Zuidoost-Azi\u00eb ook in toenemende mate door P. vivax.MalariaKoorts ontstaat door afbraak van ge\u00efnfecteerde rode bloedcellen, waarbij nieuwe parasieten worden gevormd.", [["P. falciparum", "DISEASE", 52, 65], ["P. vivax", "DISEASE", 117, 125], ["P. vivax", "ORGANISM", 117, 125], ["P. falciparum", "SPECIES", 52, 65], ["P. vivax", "SPECIES", 117, 125], ["Ernstige ziekte wordt voornamelijk veroorzaakt door P. falciparum", "SPECIES", 0, 65], ["P. vivax", "SPECIES", 117, 125], ["falciparum", "PROBLEM", 55, 65]]], ["De cycli van de parasieten worden synchroon bij P. vivax en ovale om de twee dagen, en bij P. malariae om de drie dagen, waardoor de karakteristieke koortspieken om de paar dagen ontstaan.", [["vivax en ovale", "DISEASE", 51, 65], ["P. malariae", "DISEASE", 91, 102], ["De cycli van de parasieten worden synchroon bij P. vivax en ovale om de twee dagen, en bij P. malariae om de drie dagen, waardoor de karakteristieke koortspieken om de paar dagen ontstaan", "SPECIES", 0, 187]]], ["Bij een P. falciparum-infectie doet zich deze regelmaat echter bij ongeveer 25% van de ge\u00efnfecteerden voor.MalariaNa een eerste infectie wordt men na 10-14 dagen ziek, maar na meer infecties ontstaat geleidelijk een parti\u00eble immuniteit waardoor men niet meer ernstig ziek wordt maar waarbij de parasieten af en toe in het bloed circuleren, men een vaak een grote milt krijgt en enige mate van bloedarmoede heeft.", [["na", "CHEMICAL", 147, 149], ["na", "CHEMICAL", 173, 175], ["men", "SPECIES", 143, 146], ["men", "SPECIES", 245, 248], ["men", "SPECIES", 340, 343], ["maar na meer infecties ontstaat geleidelijk een parti\u00eble immuniteit waardoor men niet meer ernstig ziek wordt maar waarbij de parasieten af en toe in het bloed circuleren", "SPECIES", 168, 338], ["MalariaNa", "TEST", 107, 116], ["na", "TEST", 147, 149], ["men een vaak een", "TREATMENT", 340, 356], ["P. falciparum", "OBSERVATION", 8, 21], ["toe", "ANATOMY", 311, 314]]], ["Bij het lichamelijk onderzoek worden een snelle pols, een vergrote lever en soms een vergrote milt gevonden.", [["een vergrote lever", "TREATMENT", 54, 72]]], ["De diagnostiek bestaat uit het aantonen van de parasieten in het bloed door middel van een 'dikkedruppelpreparaat' van de rode bloedcellen of door een PCR of een sneltest.MalariaTijdens de zwangerschap kan malaria de placenta infecteren en zo voor problemen zorgen.", [["problemen zorgen", "DISEASE", 248, 264], ["MalariaTijdens", "PROBLEM", 171, 185]]], ["Infecties met P. falciparum en vivax zijn geassocieerd met een laag geboortegewicht, vooral bij primigravidae.", [["P. falciparum", "ORGANISM", 14, 27], ["P. falciparum", "SPECIES", 14, 27], ["Infecties", "PROBLEM", 0, 9], ["falciparum en vivax zijn geassocieerd", "TREATMENT", 17, 54]]], ["Voorts worden bij malaria in de zwangerschap vaak foetale nood, vroeggeboorte, miskramen en intrauteriene vruchtdood gezien.", [["malaria", "DISEASE", 18, 25], ["malaria", "OBSERVATION", 18, 25]]], ["Congenitale malaria komt in slechts 5% van de gevallen voor.", [["malaria", "DISEASE", 12, 19], ["Congenitale malaria komt", "PROBLEM", 0, 24], ["malaria", "OBSERVATION", 12, 19]]], ["De ziekten be\u00efnvloeden elkaar in negatieve zin: meer en vaker malaria, hogere hiv-load.MalariaVoor de behandeling van malaria is sinds de 17e eeuw gebruikgemaakt van kinine en dit geneesmiddel is nog steeds effectief maar nu tweede keus voor de behandeling van ernstige malaria door P. falciparum en vivax.", [["malaria", "DISEASE", 62, 69], ["malaria", "DISEASE", 118, 125], ["ernstige malaria", "DISEASE", 261, 277], ["P. falciparum en vivax", "DISEASE", 283, 305], ["P. falciparum", "ORGANISM", 283, 296], ["P. falciparum", "SPECIES", 283, 296], ["P. falciparum en vivax", "SPECIES", 283, 305], ["falciparum en vivax", "TREATMENT", 286, 305]]], ["Hoewel het middel in hoge doseringen embryotoxisch is en teratogeen (doofheid en opticushypoplasie), is er geen risico verbonden aan de gewone dosering (een oplaaddosis van 20 mg/kg, gevolgd door driemaal daags 10 mg/kg gedurende tien dagen).", [["een oplaaddosis van 20 mg/kg, gevolgd door driemaal daags 10 mg/kg gedurende tien dagen", "SPECIES", 153, 240], ["een oplaaddosis van", "TREATMENT", 153, 172], ["door driemaal daags", "TREATMENT", 191, 210]]], ["Wel moet men beducht zijn op hypoglykemie.", [["men", "SPECIES", 9, 12]]], ["Eerste keus is behandeling met een artemisinine(derivaat) zoals artesunaat i.v., na enkele dagen en bij verbetering van de pati\u00ebnt gevolgd door een volledige kuur met een oraal middel, in Nederland artemether plus lumefantrine (Riamet \u00ae ) of atovaquon plus proguanil (Malarone \u00ae ).", [["een artemisinine", "CHEMICAL", 31, 47], ["na", "CHEMICAL", 81, 83], ["artemether", "CHEMICAL", 198, 208], ["lumefantrine", "CHEMICAL", 214, 226], ["atovaquon", "CHEMICAL", 242, 251], ["proguanil", "CHEMICAL", 257, 266], ["artemether", "CHEMICAL", 198, 208], ["lumefantrine", "CHEMICAL", 214, 226], ["atovaquon", "CHEMICAL", 242, 251], ["proguanil", "CHEMICAL", 257, 266], ["Malarone", "CHEMICAL", 268, 276], ["artemether", "SIMPLE_CHEMICAL", 198, 208], ["lumefantrine", "SIMPLE_CHEMICAL", 214, 226], ["atovaquon", "SIMPLE_CHEMICAL", 242, 251], ["proguanil", "SIMPLE_CHEMICAL", 257, 266], ["een volledige kuur", "TREATMENT", 144, 162], ["een oraal middel", "TREATMENT", 167, 183], ["Nederland artemether", "TREATMENT", 188, 208], ["lumefantrine (Riamet \u00ae", "TREATMENT", 214, 236], ["atovaquon", "TREATMENT", 242, 251], ["proguanil (Malarone \u00ae", "TREATMENT", 257, 278]]], ["Ook bij minder ernstige vormen van malaria is een artemisininecombinatietherapie ondanks de hogere kosten inmiddels eerste keus omdat tegen het vroeger gebruikte chloroquine veel resistentie is en het ook minder effectief is.", [["malaria", "DISEASE", 35, 42], ["chloroquine", "CHEMICAL", 162, 173]]], ["Artemisinine monotherapie heeft op beperkte schaal (Cambodja) voor resistentie gezorgd.", [["Artemisinine", "CHEMICAL", 0, 12], ["Artemisinine", "CHEMICAL", 0, 12], ["Artemisinine monotherapie", "TREATMENT", 0, 25]]], ["Omdat artemisinine malariaparasieten in het leverstadium niet bestrijdt, moet voor klaring van malaria door P. vivax en ovale altijd een 14-daagse kuur met primaquine worden gegeven (NB: geeft hemolyse bij G-6-PD-defici\u00ebntie).MalariaOver de teratogeniciteit van artemisinine in het eerste trimester bij de mens is onvoldoende bekend en moet behandeling alleen worden gegeven bij levensbedreigende malaria.", [["Omdat artemisinine", "CHEMICAL", 0, 18], ["primaquine", "CHEMICAL", 156, 166], ["levensbedreigende malaria", "DISEASE", 379, 404], ["moet voor klaring van malaria door P. vivax en ovale altijd een 14-daagse kuur met primaquine worden gegeven (NB: geeft hemolyse bij G-6-PD-defici\u00ebntie", "SPECIES", 73, 224], ["primaquine", "TREATMENT", 156, 166]]], ["Het gebruik tijdens het tweede en derde trimester van de zwangerschap lijkt wel veilig en wordt officieel door de WHO aanbevolen.MalariaVoor profylaxe met antimalariamiddelen wordt gezien de grillige verspreiding van resistente malaria verwezen naar reizigersklinieken (Tropencentrum AMC, Travel Clinic van het Havenziekenhuis en van de KLM) en de GGD.", [["verwezen naar reizigersklinieken (Tropencentrum AMC, Travel Clinic van het Havenziekenhuis en van de KLM) en de GGD", "SPECIES", 236, 351], ["MalariaVoor profylaxe", "TREATMENT", 129, 150]]], ["Gebruik van deze klamboes verlaagt in malaria endemische gebieden de kindersterfte met 25-50%.", [["malaria", "DISEASE", 38, 45]]], ["DEET bevattende sprays of cr\u00e8mes worden afgeraden in het eerste trimester.MalariaEr zijn reeds enige vaccins tegen malaria ontwikkeld, maar deze spelen in de praktijk anno 2012 nog geen rol van betekenis bij de profylaxe.ToxoplasmoseSinds 1939 is bekend dat een aangeboren infectie met Toxoplasma gondii neurologische afwijkingen kan veroorzaken.", [["DEET", "CHEMICAL", 0, 4], ["malaria ontwikkeld", "DISEASE", 115, 133], ["DEET", "CHEMICAL", 0, 4], ["Toxoplasma gondii", "ORGANISM", 286, 303], ["Toxoplasma gondii", "SPECIES", 286, 303], ["MalariaEr zijn", "TREATMENT", 74, 88], ["malaria", "PROBLEM", 115, 122], ["ToxoplasmoseSinds", "TEST", 221, 238], ["Toxoplasma gondii", "PROBLEM", 286, 303]]], ["Toxoplasma gondii is een protozo\u00f6n, dat zich alleen in katachtigen geslachtelijk kan voortplanten, maar dat zich in vele andere zoogdieren en gevogelte ongeslachtelijk kan voortplanten.", [["Toxoplasma gondii", "DISEASE", 0, 17], ["Toxoplasma gondii", "ORGANISM", 0, 17], ["Toxoplasma gondii", "SPECIES", 0, 17], ["Toxoplasma gondii", "SPECIES", 0, 17], ["Toxoplasma gondii", "PROBLEM", 0, 17]]], ["Dit laatste kan in iedere kernhoudende lichaamscel, hetgeen na de dood van de cel tot infectie van nieuwe cellen leidt.", [["na", "CHEMICAL", 60, 62]]], ["Verspreiding binnen het lichaam vindt plaats door lymfe en bloed.", [["Verspreiding", "TREATMENT", 0, 12]]], ["Door het eten of het bereiden van rauw vlees kunnen de weefselcysten tot besmetting leiden.ToxoplasmoseDe producten van de geslachtelijke voortplanting (o\u00f6cysten) komen met de ontlasting van de kat naar buiten, zijn na drie dagen infectieus en blijven tot enige jaren in leven.", [["zijn na drie", "TREATMENT", 211, 223]]], ["Besmetting per os kan dan optreden via de handen wanneer men zonder handschoenen de kattenbak verschoont of bijvoorbeeld met blote handen in de tuin werkt (aarde).", [["men", "SPECIES", 57, 60]]], ["Bij een primo-infectie in de zwangerschap bestaat er een positieve relatie tussen de zwangerschapsduur en de kans dat het kind ge\u00efnfecteerd wordt.", [["zwangerschap bestaat er een positieve relatie tussen de zwangerschapsduur en de kans dat het kind ge\u00efnfecteerd wordt", "SPECIES", 29, 145], ["Bij een primo-infectie", "TREATMENT", 0, 22]]], ["Daarentegen bestaat er een negatieve relatie tussen de zwangerschapsduur en het optreden van congenitale afwijkingen.", [["Daarentegen", "TREATMENT", 0, 11]]], ["Deze afwijkingen zijn: microftalmie, uni-of bilaterale chorioretinitis, hydrocefalus, epilepsie en intracraniale verkalkingen (zie tabel 21.5).", [["chorioretinitis", "DISEASE", 55, 70], ["uni-of bilaterale", "ORGANISM", 37, 54], ["hydrocefalus", "SPECIES", 72, 84], ["intracraniale verkalkingen", "SPECIES", 99, 125], ["uni-of bilaterale chorioretinitis", "PROBLEM", 37, 70], ["hydrocefalus", "PROBLEM", 72, 84], ["epilepsie en intracraniale verkalkingen", "TREATMENT", 86, 125], ["chorioretinitis", "OBSERVATION", 55, 70]]], ["Met name chorioretinitis kan nog vele jaren na de geboorte ontstaan, waardoor het percentage kinderen met een congenitale infectie bij wie problemen ontstaan, stijgt van 10% bij de geboorte tot meer dan 50% bij 18-jarigen.ToxoplasmoseVan een congenitale infectie wordt gesproken wanneer Toxoplasma gondii kan worden gekweekt uit navelstrengbloed, als anti-Toxoplasma-IgM en/of -IgA in het navelstrengbloed aanwezig is en wanneer specifiek IgG bij het kind langer dan circa 9 maanden na de geboorte aantoonbaar blijft.ToxoplasmoseOmdat de incidentie van congenitale toxoplasmose 1 op 1000 zwangerschappen is, wordt door sommigen een screening op toxoplasmose tijdens de zwangerschap gepropageerd.", [["chorioretinitis", "DISEASE", 9, 24], ["na", "CHEMICAL", 44, 46], ["Toxoplasma gondii", "SPECIES", 287, 304], ["Toxoplasma gondii kan worden gekweekt uit navelstrengbloed, als anti-Toxoplasma-IgM en/of -IgA in het navelstrengbloed aanwezig is en wanneer specifiek IgG bij het kind langer dan circa 9 maanden na de geboorte aantoonbaar blijft", "SPECIES", 287, 516], ["ToxoplasmoseVan", "TEST", 222, 237], ["als anti-Toxoplasma", "TEST", 347, 366], ["IgM", "TEST", 367, 370], ["IgA", "PROBLEM", 378, 381], ["IgG", "TEST", 439, 442]]], ["In landen als Frankrijk of Belgi\u00eb, waar de prevalentie van toxoplasmose onder de bevolking meer dan tweemaal zo hoog is, is screening respectievelijk verplicht of algemeen aanbevolen.ToxoplasmoseOnderzoek van het amnionvocht met behulp van de PCR-techniek voor Toxoplasma gondii (gevalideerd vanaf 20 weken) heeft de prenatale diagnostiek de laatste jaren sterk verbeterd.", [["Toxoplasma gondii", "DISEASE", 261, 278], ["Toxoplasma gondii", "ORGANISM", 261, 278], ["ToxoplasmoseOnderzoek van het amnionvocht met behulp van de PCR-techniek voor Toxoplasma gondii", "SPECIES", 183, 278], ["van de PCR", "TEST", 236, 246], ["Toxoplasma gondii", "PROBLEM", 261, 278]]], ["Hierdoor kunnen meer rationele keuzen worden gemaakt bij een congenitale toxoplasma-infectie.", [["Hierdoor", "TEST", 0, 8], ["een congenitale toxoplasma-infectie", "PROBLEM", 57, 92], ["congenitale toxoplasma-infectie", "OBSERVATION", 61, 92]]], ["Bij een positieve PCR zijn de twee belangrijkste opties het afbreken van de zwangerschap of het intra-uterien behandelen met pyrimethamine en sulfadiazine.", [["pyrimethamine en sulfadiazine", "CHEMICAL", 125, 154], ["pyrimethamine", "CHEMICAL", 125, 138], ["sulfadiazine", "CHEMICAL", 142, 154], ["pyrimethamine en sulfadiazine", "SIMPLE_CHEMICAL", 125, 154], ["Bij een", "TREATMENT", 0, 7], ["het intra-uterien behandelen", "TREATMENT", 92, 120], ["pyrimethamine en sulfadiazine", "TREATMENT", 125, 154]]], ["Bij een negatieve PCR zal men gedurende de zwangerschap in de regel additionele preventie toepassen door het geven van spiramycine, alhoewel het nut hiervan in deze groep niet bewezen is.ToxoplasmoseIn Nederland kan met een goede primaire preventie tijdens de zwangerschap het aantal gevallen van congenitale toxoplasmose zeer laag worden gehouden.", [["spiramycine", "CHEMICAL", 119, 130], ["men", "SPECIES", 26, 29], ["van spiramycine", "TREATMENT", 115, 130], ["alhoewel het nut hiervan", "TREATMENT", 132, 156], ["ToxoplasmoseIn", "TREATMENT", 187, 201]]], ["Ook in Belgi\u00eb, waar voorheen voornamelijk een screening in het eerste trimester plaatsvond en een diagnostisch traject bij de seronegatieve vrouwen, is uit onderzoek duidelijk gebleken dat profylactische maatregelen (zie verder) zeer effectief zijn bij het voorkomen van een congenitale toxoplasmose.", [["een screening", "TEST", 42, 55]]], ["Bij vrouwen die erom vragen, kan men (liefst) voorafgaand aan een zwangerschap serologisch onderzoek verrichten op weerstand tegen Toxoplasma.", [["men", "SPECIES", 33, 36], ["Toxoplasma", "PROBLEM", 131, 141]]], ["Vrouwen die seronegatief zijn voor Toxoplasma, of bij wie dit onbekend is, moeten goed ge\u00efnstrueerd worden over de mogelijkheden van preventie.", [["Toxoplasma", "PROBLEM", 35, 45]]], ["Profylactische maatregelen, waarmee infecties kunnen worden voorkomen, zijn: geen rauw vlees eten en handen en bestek goed wassen na het bereiden van vlees, de kattenbak niet zelf of anders dagelijks met handschoenen aan verschonen, zandbakken afdekken na het spelen van de kinderen, in de tuin met handschoenen werken en dergelijke.TrichomoniasisTrichomoniasis wordt veroorzaakt door Trichomonas vaginalis, een facultatief anaeroob eencellige protozo\u00f6n, dat voorkomt in vaginale afscheiding, kliervocht (klieren van Bartholin en Skene) en in de urethra.", [["urethra", "ANATOMY", 546, 553], ["Trichomonas vaginalis", "DISEASE", 385, 406], ["Trichomoniasis", "ORGANISM", 333, 347], ["Trichomoniasis wordt veroorzaakt door Trichomonas vaginalis", "ORGANISM", 347, 406], ["urethra", "ORGAN", 546, 553], ["Trichomonas vaginalis", "SPECIES", 385, 406], ["anaeroob eencellige", "SPECIES", 424, 443], ["geen rauw vlees eten en handen en bestek goed wassen na het bereiden van vlees, de kattenbak niet zelf of anders dagelijks met handschoenen aan verschonen, zandbakken afdekken na het spelen van de kinderen, in de tuin met handschoenen werken en dergelijke", "SPECIES", 77, 332], ["Trichomonas vaginalis", "SPECIES", 385, 406], ["TrichomoniasisTrichomoniasis", "PROBLEM", 333, 361], ["Trichomonas vaginalis", "PROBLEM", 385, 406], ["een facultatief", "TREATMENT", 408, 423], ["vaginale afscheiding", "TREATMENT", 471, 491], ["kliervocht (klieren van Bartholin en Skene)", "TREATMENT", 493, 536], ["urethra", "ANATOMY", 546, 553]]], ["De overdracht is seksueel, hoewel ook verticale transmissie van moeder op dochter is beschreven (2-17%).", [["seksueel", "PROBLEM", 17, 25]]], ["Bij een abundante ontsteking kunnen dyspareunie, contactbloeding en dysurie aanwezig zijn.", [["Bij een abundante ontsteking kunnen dyspareunie", "SPECIES", 0, 47]]], ["De kenmerkende ronddraaiende zweepdraden aan de voorzijde van een cel ter grootte van een witte bloedcel zijn bewijzend.", [["De kenmerkende ronddraaiende zweepdraden aan de voorzijde van een cel ter grootte van een", "TREATMENT", 0, 89]]], ["Bij een geringe concentratie of bij uitdroging zijn ze echter niet altijd waar te nemen.", [["Bij een geringe concentratie", "TREATMENT", 0, 28], ["bij uitdroging zijn ze echter", "TREATMENT", 32, 61]]], ["Ter uitsluiting kan een specifieke kweek worden ingezet, terwijl ook een EIA (enzyme immunoassay) en immunofluorescentie tot het diagnostisch arsenaal behoren.", [["een EIA", "TEST", 69, 76], ["enzyme immunoassay", "TEST", 78, 96]]], ["Ook in de pap-smear kan Trichomonas ontdekt worden, maar de test is ongeschikt als diagnosticum.TrichomoniasisEen trichomonasinfectie blijkt geassocieerd met een 30% verhoogde kans op een vroeggeboorte door een verhoogde kans op vroegtijdig gebroken vliezen.TrichomoniasisNitro-imidazolen (2 g ineens of driemaal daags 250 mg gedurende zeven dagen) zijn effectieve geneesmiddelen waartegen maar in minder dan 2% van de gevallen resistentie bestaat, in welk geval cotrimoxazol kan worden gebruikt.", [["TrichomoniasisNitro-imidazolen", "CHEMICAL", 258, 288], ["Nitro-imidazolen", "CHEMICAL", 272, 288], ["Nitro-imidazolen", "SIMPLE_CHEMICAL", 272, 288], ["ongeschikt als diagnosticum", "SPECIES", 68, 95], ["TrichomoniasisEen trichomonasinfectie blijkt geassocieerd met een 30% verhoogde kans op een vroeggeboorte door een verhoogde kans op vroegtijdig gebroken vliezen", "SPECIES", 96, 257], ["TrichomoniasisEen trichomonasinfectie", "PROBLEM", 96, 133], ["Trichomoniasis", "TREATMENT", 258, 272], ["Nitro-imidazolen", "TREATMENT", 272, 288], ["driemaal daags", "TREATMENT", 304, 318], ["zijn", "TREATMENT", 349, 353]]], ["Orale medicatie verdient de voorkeur boven lokale behandeling in de vagina in verband met de kans op het ontstaan van een ontsteking van de klieren en de urethra.", [["urethra", "ANATOMY", 154, 161], ["urethra", "ORGAN", 154, 161], ["vagina", "ANATOMY", 68, 74], ["urethra", "ANATOMY", 154, 161]]], ["Ook tijdens de zwangerschap zijn behandelingen met metronidazol toegestaan, ondanks vroegere verdenking op teratogeniciteit.", [["metronidazol toegestaan", "TREATMENT", 51, 74]]], ["De noodzaak tot behandeling van een asymptomatische trichomoniasis in de zwangerschap is onduidelijk, omdat in een gerandomiseerd onderzoek screening op en behandeling van een asymptomatische trichomonasinfectie de kans op vroeggeboorte verhoogde.", [["trichomoniasis", "PROBLEM", 52, 66]]], ["Een groot observationeel onderzoek naar symptomatische infecties liet ook geen effect zien op de incidentie van vroeggeboorte, die wel verhoogd was in deze groep.", [["Een groot", "TREATMENT", 0, 9]]], ["Men dient eraan te denken dat het vinden van deze infectie een aanwijzing kan zijn dat er ook andere seksueel overdraagbare aandoeningen aanwezig zijn, zoals hiv, HBV, CMV of Chlamydia.Candida-vaginitisCandida, meestal het genus albicans, is frequenter een oorzaak van vaginitis tijdens de zwangerschap dan buiten de zwangerschap.", [["Chlamydia", "DISEASE", 175, 184], ["vaginitis", "DISEASE", 269, 278], ["HBV", "ORGANISM", 163, 166], ["CMV", "ORGANISM", 168, 171], ["Men", "SPECIES", 0, 3], ["overdraagbare aandoeningen", "SPECIES", 110, 136], ["HBV", "SPECIES", 163, 166], ["Candida-vaginitisCandida, meestal het genus albicans", "SPECIES", 185, 237], ["hiv", "PROBLEM", 158, 161], ["HBV", "PROBLEM", 163, 166], ["Chlamydia", "PROBLEM", 175, 184], ["Candida", "TEST", 185, 192], ["vaginitisCandida", "PROBLEM", 193, 209], ["meestal het genus albicans", "PROBLEM", 211, 237], ["Chlamydia", "OBSERVATION", 175, 184]]], ["Doorgaans is candidavaginitis ongevaarlijk en veroorzaakt geen zwangerschapscomplicaties, maar in speciale gevallen, zoals bij het ter plaatse zijn van een intra-uterien contraceptief apparaat, of een cerclagehechting, of nog bij tweelingen indien er cervicale ontsluiting is, is opstijgende infectie met intra-uteriene candidasepsis en immature partus en/of vruchtdood mogelijk.", [["candidavaginitis", "PROBLEM", 13, 29], ["een cerclagehechting", "TREATMENT", 197, 217], ["intra-uteriene candidasepsis", "PROBLEM", 305, 333]]], ["Behandeling van candida-vaginitis gebeurt het beste met vaginale miconazol of andere lokale azolederivaten.", [["candida-vaginitis", "DISEASE", 16, 33], ["miconazol", "CHEMICAL", 65, 74], ["van candida", "PROBLEM", 12, 23], ["vaginitis", "PROBLEM", 24, 33], ["vaginitis", "OBSERVATION", 24, 33]]], ["Orale antimycotica zijn niet aangewezen vanwege de mogelijke functionele bijwerkingen ter hoogte van foetale bijnier en lever.FysiologieTijdens de zwangerschap stijgt het bloedvolume tot in het begin van het derde trimester met ongeveer 40%.", [["Orale antimycotica zijn", "TREATMENT", 0, 23]]], ["Doordat het erytrocytenvolume relatief minder stijgt, ontstaat door deze hemodilutie een milde anemie, de fysiologische anemie van de zwangerschap.", [["Doordat", "TREATMENT", 0, 7]]], ["Tijdens de zwangerschap neemt de dagelijkse ijzerbehoefte toe van 1 mg/dag buiten de zwangerschap tot 6-8 mg/ dag in het laatste trimester.FysiologieHet aantal trombocyten daalt geleidelijk met maximaal 10% tijdens de zwangerschap.", [["FysiologieHet", "TEST", 139, 152]]], ["De meeste natuurlijke anticoagulantia (o.a. prote\u00efne C en S) en stoffen van het fibrinolytisch systeem blijven gelijk of dalen in concentratie.", [["De meeste natuurlijke anticoagulantia", "TREATMENT", 0, 37], ["prote\u00efne C en S)", "TREATMENT", 44, 60]]], ["Het netto-effect is een toestand van hypercoagulabiliteit.AnemieAnemie wordt over het algemeen gedefinieerd als een verminderd aantal circulerende erytrocyten, klinisch betekent dit een verlaging van minimaal een van de erytrocytenparameters: hemoglobinegehalte, hematocriet, de concentratie erytrocyten (red blood cell count).", [["red blood cell", "ANATOMY", 305, 319], ["red blood cell", "CELL", 305, 319], ["AnemieAnemie", "PROBLEM", 58, 70], ["hematocriet", "TEST", 263, 274], ["red blood cell count", "TEST", 305, 325]]], ["Bij het defini\u00ebren van een anemie in de zwangerschap dient het natuurlijke beloop van het hemoglobinegehalte te worden meegenomen.", [["zwangerschap dient het natuurlijke beloop van het hemoglobinegehalte te worden meegenomen", "SPECIES", 40, 129]]], ["Hoewel deze waarden in Nederland veelal worden gebruikt voor het stellen van de diagnose anemie, wordt internationaal van anemie gesproken wanneer het hemoglobinegehalte zich meer dan 2 standaarddeviaties onder het gemiddelde bevindt.", [["Hoewel deze waarden in Nederland veelal worden gebruikt voor het stellen van de diagnose anemie, wordt internationaal van anemie gesproken wanneer het hemoglobinegehalte zich meer dan 2 standaarddeviaties onder het gemiddelde bevindt", "SPECIES", 0, 233]]], ["Risicogroepen voor het ontwikkelen van een anemie tijdens de zwangerschap zijn: tieners, vrouwen die binnen een jaar na de geboorte van een eerder kind weer zwanger worden, vrouwen van niet-Noord-Europese afkomst en vrouwen met een hemoglobinopathie.IJzergebreksanemieDe meest voorkomende vorm van anemie zowel binnen als buiten de zwangerschap is ferriprieve of ijzergebreksanemie.", [["Risicogroepen voor het ontwikkelen van een anemie tijdens de zwangerschap zijn: tieners, vrouwen die binnen een jaar na de geboorte van een eerder kind weer zwanger worden, vrouwen van niet-Noord-Europese afkomst en vrouwen met een hemoglobinopathie", "SPECIES", 0, 249], ["Risicogroepen", "TREATMENT", 0, 13], ["IJzergebreksanemieDe meest voorkomende", "TREATMENT", 250, 288]]], ["De diagnose kan eenvoudig gesteld worden door naast het hemoglobinegehalte tevens het mean corpuscular volume (MCV) van de erytrocyten te meten.", [["corpuscular volume", "TEST", 91, 109], ["MCV", "TEST", 111, 114], ["van de erytrocyten te meten", "TREATMENT", 116, 143]]], ["Een MCV van <80 fl (microcytaire anemie) wijst op ijzergebreksanemie.", [["Een MCV van", "TEST", 0, 11], ["microcytaire anemie", "TEST", 20, 39]]], ["Bij een MCV >100 fl spreekt men van macrocytaire anemie.IJzergebreksanemieDe oorzaak in de zwangerschap is vaak gelegen in het feit dat de ijzervoorraden aan het begin van de zwangerschap niet voldoende zijn om de toenemende behoefte tijdens de zwangerschap te dekken.", [["men", "SPECIES", 28, 31], ["Bij een MCV", "TEST", 0, 11]]], ["Vanuit de voeding kan, zeker aan het einde van de zwangerschap, onvoldoende ijzer worden betrokken.IJzergebreksanemieIn hoeverre ijzergebreksanemie debet is aan zwangerschapscomplicaties is niet aangetoond.", [["IJzergebreksanemieIn", "TREATMENT", 99, 119]]], ["Verschillende onderzoekers leggen wel een verband met cognitieve stoornissen bij neonaten.IJzergebreksanemieEr bestaat veel discussie over het nut van profylactische toediening van ijzerpreparaten tijdens de zwangerschap.", [["IJzergebreksanemieEr", "TREATMENT", 90, 110]]], ["Dergelijke toediening lijkt in ieder geval geen nadelige effecten op de zwangerschap te hebben, een duidelijk gunstig effect heeft dergelijke substitutie ook niet.IJzergebreksanemieDe minimale hoeveelheid ijzermedicatie die nodig is om te beschermen tegen ijzergebreksanemie in de zwangerschap, is 40 mg per dag.", [["IJzergebreksanemieDe", "TREATMENT", 163, 183]]], ["Er zijn geen bijwerkingen beschreven van het gebruik van minder dan 100 mg per dag.", [["Er zijn geen bijwerkingen beschreven van het gebruik van minder dan 100 mg per dag", "SPECIES", 0, 82], ["Er zijn geen", "TREATMENT", 0, 12]]], ["Honderd mg elementair ijzer komt overeen met 1,5 tablet ferrofumaraat (\u00e9\u00e9n tablet ferrofumaraat van 200 mg bevat 65 mg elementair ijzer).", [["1,5 tablet ferrofumaraat", "CHEMICAL", 45, 69], ["Honderd mg elementair ijzer komt overeen met", "TREATMENT", 0, 44], ["ferrofumaraat (\u00e9\u00e9n tablet ferrofumaraat van", "TREATMENT", 56, 99]]], ["Bij behandeling van ijzergebreksanemie met orale ijzerpreparaten kan niet binnen twee weken effect worden verwacht.", [["Bij behandeling van ijzergebreksanemie", "TREATMENT", 0, 38]]], ["Toediening van intraveneuze preparaten geeft sneller verbetering.IJzergebreksanemieBij meerlingzwangerschappen is te overwegen om naast profylactisch ijzersuppletie ook extra foliumzuur (1 mg per dag) voor te schrijven.Megaloblastaire anemieGebrek aan foliumzuur of vitamine B 12 resulteert in een megaloblastaire anemie.", [["foliumzuur", "CHEMICAL", 175, 185], ["Megaloblastaire anemieGebrek aan foliumzuur of vitamine B", "CHEMICAL", 219, 276], ["vitamine B", "CHEMICAL", 266, 276], ["IJzergebreksanemieBij meerlingzwangerschappen", "TREATMENT", 65, 110], ["extra foliumzuur", "TREATMENT", 169, 185], ["Megaloblastaire", "TREATMENT", 219, 234], ["vitamine B", "TREATMENT", 266, 276]]], ["Bij ernstig foliumzuurtekort ontstaan tevens leukopenie en trombocytopenie.", [["Bij ernstig foliumzuurtekort", "TREATMENT", 0, 28]]], ["Een tekort aan vitamine B 12 is zeldzaam en komt nog wel eens bij vegetari\u00ebrs voor.", [["Een tekort aan vitamine B", "TREATMENT", 0, 25]]], ["Het is verstandig om bij een megaloblastaire anemie vitamine B 12 te bepalen en niet zonder meer alleen foliumzuur toe te dienen, waardoor bij de moeder een vitamine-B 12 -gebrek zou kunnen verergeren en neurologische schade kan ontstaan.Hemoglobinopathie\u00ebn en thalassemie\u00ebnHemoglobinopathie\u00ebn zijn aangeboren stoornissen in de bouw van de hemoglobineketens.", [["Hemoglobinopathie\u00ebn zijn aangeboren stoornissen", "CHEMICAL", 274, 321], ["niet zonder meer alleen foliumzuur toe te dienen, waardoor bij de moeder een vitamine-B 12 -gebrek zou kunnen verergeren en neurologische schade kan ontstaan", "SPECIES", 80, 237], ["verstandig om bij een megaloblastaire", "TREATMENT", 7, 44], ["vitamine B", "TREATMENT", 52, 62], ["een vitamine", "TREATMENT", 153, 165], ["gebrek zou kunnen verergeren", "TREATMENT", 172, 200], ["Hemoglobinopathie\u00ebn en thalassemie\u00ebn", "TREATMENT", 238, 274]]], ["Bij de structurele hemoglobinopathie\u00ebn, zoals HbS of HbC, is de bouw van de hemoglobineketens afwijkend, bij de thalassemie\u00ebn is de synthesesnelheid van een of meer, overigens normale globineketens, gestoord, waardoor de getalsverhouding tussen de verschillende ketens verstoord is.", [["HbC", "PROBLEM", 53, 56]]], ["Combinaties van beide aandoeningen komen vaak voor.Hemoglobinopathie\u00ebn en thalassemie\u00ebnBij ongeveer 10% van de allochtonen in Nederland is er sprake van een dragerschap voor een van de hemoglobinopathie\u00ebn, bij de negro\u00efde bevolking is de incidentie het hoogst (20%).", [["Hemoglobinopathie\u00ebn en thalassemie\u00ebnBij", "TREATMENT", 51, 90]]], ["Bij Aziaten en mensen uit het Middellandse Zeegebied staan thalassemie\u00ebn op de voorgrond.Hemoglobinopathie\u00ebn of sikkelcelziektenVaso-occlusieve fenomenen en hemolyse zijn de belangrijkste klinische kenmerken van sikkelcelziekte.", [["Bij Aziaten", "TREATMENT", 0, 11], ["Hemoglobinopathie\u00ebn", "TEST", 89, 108], ["sikkelcelziektenVaso-occlusieve fenomenen en hemolyse zijn", "TREATMENT", 112, 170]]], ["Deoxygenatie leidt tot polymerisatie van het hemoglobine, waardoor de erytrocyt van vorm verandert.Hemoglobinopathie\u00ebn of sikkelcelziektenVaso-occlusie resulteert in recidiverende pijnlijke episoden (crises) en ernstige schade aan diverse orgaansystemen.", [["Deoxygenatie", "TREATMENT", 0, 12], ["recidiverende pijnlijke episoden", "PROBLEM", 166, 198]]], ["Hemoglobine S ontstaat door een erfelijke afwijking in het \u03b2-globinegen waarbij op positie 6 van de \u03b2-globineketen niet glutaminezuur maar valine wordt ingebouwd.", [["Hemoglobine S", "TEST", 0, 13], ["een erfelijke", "TREATMENT", 28, 41]]], ["Ongeveer 25% is samengesteld heterozygoot voor hemoglobine S en hemoglobine C (HbSC).", [["hemoglobine S en hemoglobine C", "CHEMICAL", 47, 77], ["hemoglobine S en hemoglobine C", "SIMPLE_CHEMICAL", 47, 77], ["HbSC", "CANCER", 79, 83], ["hemoglobine S", "TEST", 47, 60]]], ["De overblijvende 5% zijn andere samengestelde heterozygoten.Hemoglobinopathie\u00ebn of sikkelcelziektenKlinische symptomen van sikkelcelziekte in de zwangerschap bij dragers (sikkelcel-trait of HbAS) beperken zich tot anemie berustend op een foliumzuurtekort.", [["De overblijvende 5% zijn", "TREATMENT", 0, 24], ["sikkelcelziektenKlinische symptomen", "PROBLEM", 83, 118], ["HbAS", "TEST", 190, 194]]], ["Vanaf 1 januari 2007 vindt via de hielprik bij de neonaat screening plaats op sikkelcelziekte.Hemoglobinopathie\u00ebn of sikkelcelziektenBij homozygote sikkelcelziekte is er meer kans op sikkelcelcrises tijdens de zwangerschap.", [["Vanaf", "TREATMENT", 0, 5], ["sikkelcelziektenBij homozygote sikkelcelziekte", "PROBLEM", 117, 163]]], ["Pati\u00ebnten met een HbSS-genotype vertonen vaker sikkelcelcrises dan die met een HbSC-genotype.Hemoglobinopathie\u00ebn of sikkelcelziektenSikkelcelcrises uiten zich door pijnklachten in het hele lichaam, maar vooral in de extremiteiten.", [["een HbSS", "TEST", 14, 22], ["genotype vertonen vaker", "TREATMENT", 23, 46], ["sikkelcelziektenSikkelcelcrises", "PROBLEM", 116, 147]]], ["Het acute chest syndrome is een van de ernstigste complicaties van sikkelcelziekte, gekenmerkt door koorts, pleuraprikkeling, uitstralende pijn naar het abdomen, hoest, longinfiltraten, hypoxie en uiteindelijk respiratoire insuffici\u00ebntie.", [["chest syndrome", "DISEASE", 10, 24], ["Het acute chest syndrome", "PROBLEM", 0, 24], ["pleuraprikkeling", "PROBLEM", 108, 124], ["longinfiltraten", "PROBLEM", 169, 184], ["hypoxie", "PROBLEM", 186, 193], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["chest", "ANATOMY", 10, 15], ["syndrome", "OBSERVATION", 16, 24], ["abdomen", "ANATOMY", 153, 160]]], ["Behandeling van een sikkelcelcrisis bestaat uit pijnstilling, vocht-en (bij saturatiedaling) zuurstoftoediening en bestrijden van eventuele infecties.", [["en (bij saturatiedaling)", "TREATMENT", 68, 92]]], ["Bij ernstige anemie worden bloedtransfusies gegeven.", [["worden bloedtransfusies", "OBSERVATION", 20, 43]]], ["Een sikkelcelcrisis kan dagen tot weken duren.Hemoglobinopathie\u00ebn of sikkelcelziektenBehandeling met hydroxyureum ter voorkoming van een sikkelcelcrisis kan niet in de zwangerschap worden toegepast vanwege de teratogeniciteit van het middel.", [["sikkelcelziekten", "CHEMICAL", 69, 85], ["Een sikkelcelcrisis kan", "TREATMENT", 0, 23]]], ["Profylactisch toedienen van bloedtransfusies en wisseltransfusie/erytrocytaferese lijken wel invloed te hebben op het voorkomen van sikkelcelcrises, maar hebben geen effect op de zwangerschapsuitkomst.", [["Profylactisch toedienen van bloedtransfusies en wisseltransfusie/erytrocytaferese lijken wel invloed te hebben op het voorkomen van sikkelcelcrises, maar hebben geen effect op de zwangerschapsuitkomst", "SPECIES", 0, 200], ["Profylactisch", "TREATMENT", 0, 13], ["erytrocytaferese", "TREATMENT", 65, 81]]], ["De grote tekorten aan foliumzuur bij deze pati\u00ebnten worden bestreden door dagelijkse suppletie met 5 mg.Hemoglobinopathie\u00ebn of sikkelcelziektenPati\u00ebnten met sikkelcelziekte hebben meer kans op spontane abortus, vroeggeboorte, groeivertraging en intra-uteriene vruchtdood.", [["spontane abortus", "SPECIES", 193, 209]]], ["Deze pati\u00ebnten kunnen de reproductieve leeftijd bereiken door veelvoudige transfusies en ijzerchelatietherapie.", [["en ijzerchelatietherapie", "TREATMENT", 86, 110]]], ["De zwangerschapsuitkomsten zijn gunstig.Thalassemie\u00ebnPati\u00ebnten met een \u03b1-thalassemieen \u03b2-thalassemietrait ontwikkelen tijdens de zwangerschap een milde tot matige anemie.", [["De zwangerschapsuitkomsten zijn gunstig", "TREATMENT", 0, 39], ["Thalassemie\u00ebnPati\u00ebnten", "TREATMENT", 40, 62], ["een \u03b1-thalassemieen", "TREATMENT", 67, 86], ["thalassemietrait ontwikkelen tijdens", "TREATMENT", 89, 125], ["zijn gunstig", "OBSERVATION", 27, 39]]], ["De zwangerschapsuitkomsten zijn gunstig.", [["De zwangerschapsuitkomsten zijn gunstig", "TREATMENT", 0, 39], ["zijn gunstig", "OBSERVATION", 27, 39]]], ["Suppletie van foliumzuur (1 mg per dag) is ge\u00efndiceerd.", [["foliumzuur", "CHEMICAL", 14, 24], ["Suppletie van foliumzuur", "TREATMENT", 0, 24]]], ["IJzersuppletie mag alleen worden gegeven bij aangetoond ijzergebrek.TrombocytopenieDe oorzaken van een trombocytopenie zijn in de zwangerschap anders dan daarbuiten.", [["TrombocytopenieDe", "TREATMENT", 68, 85]]], ["Pre-eclampsie en HELLP-syndroom (20%), acute gele leveratrofie, trombotische trombocytopenische purpura (TTP) en een restgroep (hiv, SLE, antifosfolipidesyndroom, medicatiebijwerking) (10%) en immuuntrombocytopenie (ITP) (10%) dienen eerst te worden uitgesloten om tot deze diagnose te komen.", [["HELLP-syndroom", "DISEASE", 17, 31], ["purpura", "DISEASE", 96, 103], ["TTP", "DISEASE", 105, 108], ["SLE", "DISEASE", 133, 136], ["ITP", "DISEASE", 216, 219], ["acute gele leveratrofie", "PROBLEM", 39, 62], ["trombotische trombocytopenische purpura", "PROBLEM", 64, 103], ["TTP)", "PROBLEM", 105, 109], ["en een restgroep", "TREATMENT", 110, 126], ["SLE", "PROBLEM", 133, 136], ["antifosfolipidesyndroom", "TREATMENT", 138, 161], ["en immuuntrombocytopenie (ITP)", "TREATMENT", 190, 220], ["HELLP", "OBSERVATION", 17, 22], ["acute", "OBSERVATION_MODIFIER", 39, 44]]], ["In de meeste gevallen betreft het een toevalsbevinding.ZwangerschapstrombocytopenieDe diagnose zwangerschapstrombocytopenie wordt per exclusionem gesteld.", [["ZwangerschapstrombocytopenieDe", "CHEMICAL", 55, 85]]], ["Het aantal trombocyten ligt tussen 150 en 70\u00d710 9 trombocyten per liter.", [["Het", "TEST", 0, 3]]], ["Bij lagere aantallen moet opnieuw gezocht worden naar andere oorzaken.ZwangerschapstrombocytopenieZwangerschapstrombocytopenie heeft geen nadelige invloed op het verloop van de zwangerschap.", [["Bij lagere aantallen moet opnieuw gezocht worden naar andere oorzaken", "SPECIES", 0, 69], ["ZwangerschapstrombocytopenieZwangerschapstrombocytopenie", "PROBLEM", 70, 126]]], ["Een snel herstel van het trombocytenaantal na de partus bevestigt uiteindelijk de diagnose zwangerschapstrombocytopenie.Immuuntrombocytopenie (ITP)Autoantistoffen tegen oppervlakteantigenen van de trombocyten zijn de oorzaak van ITP.", [["Immuuntrombocytopenie", "DISEASE", 120, 141], ["ITP", "DISEASE", 143, 146], ["ITP", "DISEASE", 229, 232], ["Immuuntrombocytopenie (ITP", "TREATMENT", 120, 146], ["Autoantistoffen tegen oppervlakteantigenen van de trombocyten zijn", "TREATMENT", 147, 213]]], ["De ziekte treft vooral vrouwen in hun reproductieve levensfase.", [["hun reproductieve", "SPECIES", 34, 51]]], ["ITP wordt niet be\u00efnvloed door de zwangerschap.", [["ITP", "DISEASE", 0, 3]]], ["Tijdens de zwangerschap kan behandeling bij lage trombocytenaantallen (<20\u00d710 9 /l) medicamenteus met corticostero\u00efden (eerste keuze) en intraveneus immunoglobuline plaatsvinden.Immuuntrombocytopenie (ITP)Voor de partus wordt gestreefd naar een trombocytenaantal van minimaal 50\u00d710 9 /l.", [["Immuuntrombocytopenie", "CHEMICAL", 178, 199], ["ITP", "DISEASE", 201, 204], ["medicamenteus", "TEST", 84, 97], ["corticostero\u00efden (eerste keuze", "TREATMENT", 102, 132], ["Immuuntrombocytopenie", "PROBLEM", 178, 199], ["naar een trombocytenaantal van minimaal", "TREATMENT", 236, 275]]], ["De bevalling dient zo atraumatisch mogelijk plaats te vinden gezien de hoge kans (12%) op trombocytopenie bij de foetus.Immuuntrombocytopenie (ITP)Microbloedonderzoek, gebruik van een schedelelektrode, vaginale kunstverlossing met een vacu\u00fcmextractor, vaginale stuitbevalling en een langdurige uitdrijving worden zo veel mogelijk vermeden.", [["Immuuntrombocytopenie", "DISEASE", 120, 141], ["ITP", "DISEASE", 143, 146], ["Immuuntrombocytopenie (ITP)", "TREATMENT", 120, 147], ["Microbloedonderzoek", "TEST", 147, 166], ["vaginale kunstverlossing", "TREATMENT", 202, 226], ["een vacu\u00fcmextractor", "TREATMENT", 231, 250]]], ["Trombocytopenie bij de foetus ontstaat ongeacht het trombocytenaantal bij de moeder.", [["Trombocytopenie", "TREATMENT", 0, 15]]], ["Bij moeders die een splenectomie ondergingen, bestaat zelfs een hogere kans op foetale trombocytopenie.", [["een splenectomie", "SPECIES", 16, 32]]], ["Neonataal kan een trombocytopenie zich nog na enkele dagen tot een week ontwikkelen.", [["na", "CHEMICAL", 43, 45], ["Neonataal kan een trombocytopenie zich nog na enkele dagen tot een week ontwikkelen", "SPECIES", 0, 83]]], ["De kans op een neonatale bloeding als gevolg van de partus bedraagt ongeveer 1%.Trombotische trombocytopenische purpura (TTP) en hemolytisch uremisch syndroom (HUS)TTP is een zeldzame aandoening waarvan de diagnose berust op de volgende vijf klinische kenmerken: trombocytopenie, microangiopathische hemolyse, nierfunctiestoornissen, neurologische afwijkingen en koorts.", [["purpura", "DISEASE", 112, 119], ["TTP", "DISEASE", 121, 124], ["HUS", "DISEASE", 160, 163], ["Trombotische trombocytopenische purpura", "PROBLEM", 80, 119], ["TTP", "TEST", 121, 124], ["HUS", "TEST", 160, 163], ["TTP", "PROBLEM", 164, 167], ["trombocytopenie", "PROBLEM", 263, 278], ["purpura", "OBSERVATION", 112, 119]]], ["Bij TTP leidt een stoornis bij de aanmaak van von-willebrandfactor tot grote vonwillebrandmultimeren waardoor microtrombi in de microcirculatie ontstaan.", [["Bij TTP", "PROBLEM", 0, 7]]], ["Deze aanmaakstoornis wordt veroorzaakt door een defici\u00ebntie van de metalloprotease ADAMTS-13, een enzym dat normaliter von-willebrandmultimeren splitst.", [["metalloprotease ADAMTS", "TEST", 67, 89]]], ["Trombocytentransfusie is bij deze aandoening gecontra-indiceerd.", [["Trombocytentransfusie", "TREATMENT", 0, 21]]], ["TTP komt vaker tijdens de zwangerschap voor.", [["TTP", "PROBLEM", 0, 3]]], ["Er treden niet vaker zwangerschapscomplicaties op, mits de aandoening tijdig wordt behandeld.Trombotische trombocytopenische purpura (TTP) en hemolytisch uremisch syndroom (HUS)Hemolytisch uremisch syndroom (HUS) vormt een continu\u00fcm met TTP en treedt met name tijdens het kraambed op.", [["purpura", "DISEASE", 125, 132], ["TTP", "DISEASE", 134, 137], ["HUS", "DISEASE", 173, 176], ["HUS", "DISEASE", 208, 211], ["Trombotische trombocytopenische purpura", "PROBLEM", 93, 132], ["TTP", "TEST", 134, 137], ["en hemolytisch uremisch syndroom", "TEST", 139, 171], ["HUS", "TEST", 173, 176], ["Hemolytisch", "TEST", 177, 188], ["uremisch syndroom", "PROBLEM", 189, 206], ["HUS", "TEST", 208, 211], ["een continu\u00fcm", "TREATMENT", 219, 232], ["TTP", "PROBLEM", 237, 240], ["purpura", "OBSERVATION", 125, 132]]], ["Bij HUS staan de renale problemen op de voorgrond terwijl dat bij TTP de neurologische afwijkingen zijn.", [["HUS", "DISEASE", 4, 7], ["Bij HUS", "TEST", 0, 7]]], ["Plasmaferese is bij HUS niet erg zinvol.", [["Plasmaferese", "CHEMICAL", 0, 12], ["HUS", "DISEASE", 20, 23], ["Plasmaferese", "SIMPLE_CHEMICAL", 0, 12]]], ["Ondersteunende therapie bestaat uit nierdialyse en erytrocytentransfusie.", [["erytrocytentransfusie", "CHEMICAL", 51, 72]]], ["De kans op zowel obstetrische als maternale morbiditeit is groot.Ziekte van Von WillebrandDe meest voorkomende vorm van bloedingsneiging is de ziekte van Von Willebrand.", [["Willebrand", "GENE_OR_GENE_PRODUCT", 80, 90], ["De kans op zowel obstetrische", "TREATMENT", 0, 29]]], ["Deze erfelijke aandoening komt bij ongeveer 1% van de Nederlandse bevolking voor.Ziekte van Von WillebrandVon-willebrandfactor functioneert als kleefeiwit voor de adhesie van bloedplaatjes en als dragereiwit voor factor VIII.", [["Willebrand", "GENE_OR_GENE_PRODUCT", 96, 106], ["factor VIII", "GENE_OR_GENE_PRODUCT", 213, 224], ["factor VIII", "PROTEIN", 213, 224]]], ["Bij de ziekte van Von Willebrand is sprake van een verlaagde (type 1) of abnormaal functionerende (type 2) of afwezige (type 3) vonwillebrandfactor, leidend tot slijmvliesbloedingen en directe nabloedingen na operaties (type 1 en 2) en bij type 3 ook tot gewrichtsbloedingen.", [["na", "CHEMICAL", 206, 208], ["abnormaal functionerende (type 2", "PROBLEM", 73, 105], ["afwezige (type 3) vonwillebrandfactor", "PROBLEM", 110, 147], ["tot slijmvliesbloedingen en directe nabloedingen na operaties (type 1 en 2) en bij type", "TREATMENT", 157, 244]]], ["Type 2 wordt nog onderverdeeld in een vijftal subklassen (2a, 2b, platelet-type, 2m, 2n).", [["platelet", "CELL", 66, 74], ["platelet", "TEST", 66, 74]]], ["Type 1 komt het meest voor.Ziekte van Von WillebrandBij voorkeur voor de zwangerschap dient het subtype te worden vastgesteld en dient te worden gecontroleerd of toediening van desmopressine (DDAVP) leidt tot een verhoging van de von-willebrandfactor.Ziekte van Von WillebrandAangezien de concentratie von-willebrandfactor tijdens de zwangerschap fors toeneemt, worden bij type 1 en 2a zelden bloedingsproblemen tijdens de bevalling gezien.", [["desmopressine", "CHEMICAL", 177, 190], ["DDAVP", "CHEMICAL", 192, 197], ["desmopressine", "CHEMICAL", 177, 190], ["DDAVP", "CHEMICAL", 192, 197], ["Willebrand", "GENE_OR_GENE_PRODUCT", 42, 52], ["Willebrand", "GENE_OR_GENE_PRODUCT", 266, 276], ["Bij voorkeur voor de zwangerschap dient het subtype te worden vastgesteld en dient te worden gecontroleerd", "SPECIES", 52, 158], ["van desmopressine (DDAVP)", "TREATMENT", 173, 198]]], ["Bepaling van de von-willebrandfactor en factor VIII vindt plaats in het derde trimester.", [["factor VIII", "PROTEIN", 40, 51]]], ["Afhankelijk van deze bepalingen wordt Haemate P (complex van factor VIII en von-willebrandfactor bereid uit humaan plasma) of DDAVP rondom de bevalling en in het kraambed toegediend.", [["plasma", "ANATOMY", 115, 121], ["DDAVP", "CHEMICAL", 126, 131], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["complex van factor VIII", "PROTEIN", 49, 72], ["DDAVP", "TREATMENT", 126, 131]]], ["Bij type 2 en 3 wordt vrijwel standaard suppletie van stollingsfactoren toegepast.Ziekte van Von WillebrandBehoudens bloedingsproblemen doen zwangerschapscomplicaties zich niet vaker voor bij pati\u00ebnten met de ziekte van Von Willebrand.", [["Von Willebrand", "DISEASE", 220, 234], ["Willebrand", "GENE_OR_GENE_PRODUCT", 97, 107]]], ["Gezien de kans op ziekte van Von Willebrand bij de foetus wordt ook nu een atraumatische bevalling geadviseerd.", [["Gezien", "TREATMENT", 0, 6]]], ["Gebruik van DDAVP is gecontra-indiceerd tijdens de zwangerschap en wordt bij voorkeur pas na de geboorte toegediend.Ziekte van Von WillebrandNa de geboorte kan de stollingsstatus van het kind worden bepaald.", [["Na", "CHEMICAL", 141, 143], ["Willebrand", "GENE_OR_GENE_PRODUCT", 131, 141]]], ["Er kan sprake zijn van ernstige (stollingsfactor <1%), matig ernstige (stollingsfactor 1-5%) of milde (stollingsfactor >5%) hemofilie.", [["Er kan sprake zijn van ernstige", "SPECIES", 0, 31]]], ["Vrouwen die draagster zijn, kunnen wel degelijk een verlaagde hoeveelheid factor VIII of IX hebben, als gevolg waarvan ook bij hen bloedingscomplicaties kunnen ontstaan.HemofilieHemofilie is een zeldzame ziekte en komt bij een tot twee op de 10.000 mannen voor.", [["IX hebben", "TREATMENT", 89, 98], ["als gevolg waarvan", "TREATMENT", 100, 118], ["HemofilieHemofilie", "TREATMENT", 169, 187], ["een zeldzame ziekte", "TREATMENT", 191, 210]]], ["Tijdens de zwangerschap stijgt bij draagsters van hemofilie A het factor VIII-gehalte meestal naar normale waarden.", [["zwangerschap stijgt bij draagsters van hemofilie A het factor VIII-gehalte meestal naar normale waarden", "SPECIES", 11, 114]]], ["Factor IX doet dit echter niet.", [["Factor IX", "GENE_OR_GENE_PRODUCT", 0, 9], ["Factor IX", "PROTEIN", 0, 9]]], ["Het is daarom verstandig ook bij hemofiliedraagsters tijdens de zwangerschap hiermee rekening te houden en het factor VIII-of IX-gehalte in het derde trimester te controleren.", [["VIII", "PROTEIN", 118, 122], ["IX", "PROTEIN", 126, 128], ["IX-gehalte", "TREATMENT", 126, 136]]], ["Wanneer peri partum het factor VIII-of factor IX-gehalte lager is dan 50%, worden stollingsfactoren of desmopressine toegediend.", [["factor VIII", "GENE_OR_GENE_PRODUCT", 24, 35], ["IX", "GENE_OR_GENE_PRODUCT", 46, 48], ["Wanneer peri partum het factor VIII", "PROTEIN", 0, 35], ["IX", "PROTEIN", 46, 48]]], ["Naast een verhoogde kans op een primaire fluxus post partum bestaat bij deze pati\u00ebnten met name een verhoogde kans op een secundaire fluxus in het kraambed.", [["Naast een", "TREATMENT", 0, 9]]], ["Eventuele suppletie van stollingsfactoren moet gedurende enkele dagen post partum worden voortgezet.HemofilieMeestal wordt alleen prenatale diagnostiek verricht bij ernstige hemofilie A of B. Rond de 12e week van de zwangerschap kan een vlokkentest worden gedaan om het geslacht van de foetus te bepalen.", [["B. Rond de 12e week van de zwangerschap kan een vlokkentest worden gedaan om het geslacht van de foetus te bepalen", "SPECIES", 189, 303]]], ["Indien de mutatie bekend is en het een mannelijke foetus betreft, kan er vervolgens DNA-diagnostiek naar hemofilie A of B plaatsvinden.", [["B plaatsvinden", "SPECIES", 120, 134]]], ["Mocht er sprake zijn van hemofilie, dan kan de zwangerschap op verzoek van de ouders worden be\u00ebindigd, hetgeen tegenwoordig nog maar zelden gebeurt.", [["Mocht er sprake zijn van hemofilie, dan kan de zwangerschap op verzoek van de ouders worden be\u00ebindigd, hetgeen tegenwoordig nog maar zelden gebeurt", "SPECIES", 0, 147]]], ["Wordt er geen prenatale diagnostiek verricht, dan moet met behulp van echografie rond de 20e week van de zwangerschap het geslacht worden bepaald.HemofilieBij zwangerschappen waarbij er sprake is van een vrouwelijke foetus, hoeven geen speciale maatregelen te worden getroffen.", [["getroffen", "CHEMICAL", 267, 276], ["dan moet met behulp van echografie rond de 20e week van de zwangerschap het geslacht worden bepaald", "SPECIES", 46, 145]]], ["Zolang die niet bekend is, mogen geen intramusculaire injecties aan het kind worden toegediend.HemofilieBij ongeveer 30-50% van de jongetjes bij wie een ernstige hemofilie wordt geconstateerd, betreft het een nieuw ontstane mutatie.", [["HemofilieBij", "TEST", 95, 107]]], ["Vaak is een neonatale bloedingscomplicatie na de bevalling hier de eerste aanwijzing voor.HemofilieDe zorg voor pati\u00ebnten met hemofilie en andere vormen van bloedingsziekten is in Nederland geconcentreerd in hemofiliebehandelcentra, die zijn gevestigd in 13 ziekenhuizen verspreid over het land.", [["na", "CHEMICAL", 43, 45]]], ["Binnen deze centra vindt multidisciplinaire behandeling plaats van pati\u00ebnten met hemofilie en draagsters van hemofilie.TrombofilieTrombofilie kan zowel verworven als erfelijk zijn.", [["TrombofilieTrombofilie", "TREATMENT", 119, 141]]], ["Tijdens het leven kunnen antistoffen ontstaan, zoals lupus anticoagulans, \u03b2 2 -glycoprote\u00efnen en anticardiolipineantistoffen.", [["lupus anticoagulans", "DISEASE", 53, 72], ["\u03b2 2 -glycoprote\u00efnen en anticardiolipineantistoffen", "CHEMICAL", 74, 124], ["\u03b2 2 -glycoprote\u00efnen en anticardiolipineantistoffen", "SIMPLE_CHEMICAL", 74, 124], ["ontstaan", "SPECIES", 37, 45], ["lupus anticoagulans", "SPECIES", 53, 72], ["zoals lupus anticoagulans", "TREATMENT", 47, 72], ["glycoprote\u00efnen en anticardiolipineantistoffen", "TREATMENT", 79, 124]]], ["Het aanwezig zijn van lupus anticoagulans, al dan vergezeld van anticardiolipineantistoffen en/of \u03b2 2 -glycoprote\u00efnen, wordt in combinatie met bepaalde klinische problemen gedefinieerd als het antifosfolipidesyndroom (APS).TrombofilieErfelijke vormen van trombofilie zijn een tekort aan antitrombine III, prote\u00efne C en S en de genetische mutaties factor-V-Leiden en protrombine-of factor II-mutatie.TrombofilieEen speciale vorm van aangeboren trombofilie wordt veroorzaakt door een metabole stoornis: hyperhomocyste\u00efnemie.", [["lupus anticoagulans", "DISEASE", 22, 41], ["\u03b2 2 -glycoprote\u00efnen", "CHEMICAL", 98, 117], ["APS", "DISEASE", 218, 221], ["hyperhomocyste\u00efnemie", "CHEMICAL", 501, 521], ["\u03b2 2 -glycoprote\u00efnen", "SIMPLE_CHEMICAL", 98, 117], ["factor II", "PROTEIN", 381, 390], ["Het aanwezig zijn van lupus anticoagulans", "TREATMENT", 0, 41], ["glycoprote\u00efnen", "TREATMENT", 103, 117], ["TrombofilieErfelijke", "TEST", 223, 243], ["prote\u00efne C en S", "TREATMENT", 305, 320], ["factor", "TEST", 347, 353], ["TrombofilieEen", "TREATMENT", 399, 413], ["hyperhomocyste\u00efnemie", "PROBLEM", 501, 521]]], ["De afwijking is goed te corrigeren door suppletie met foliumzuur en vitamine B 6 .TrombofilieDe hier genoemde afwijkingen zijn waarschijnlijk slechts het topje van de ijsberg.", [["foliumzuur en vitamine B", "CHEMICAL", 54, 78], ["vitamine B", "CHEMICAL", 68, 78], ["foliumzuur en vitamine B", "TREATMENT", 54, 78], ["TrombofilieDe", "TREATMENT", 82, 95]]], ["Naarmate meer bekend wordt over het mechanisme van de bloedstolling, zullen de komende jaren meer stoffen en genetische mutaties bekend worden, die ook een rol spelen bij een verhoogde stollingsneiging.TrombofilieTrombofilie wordt vaak in verband gebracht met zwangerschapscomplicaties.", [["TrombofilieTrombofilie", "TREATMENT", 202, 224]]], ["Alleen bij APS komen meer spontane miskramen en mogelijk hypertensieve aandoeningen zoals pre-eclampsie en foetale groeivertraging voor.", [["Alleen", "TREATMENT", 0, 6], ["en mogelijk hypertensieve aandoeningen zoals", "TREATMENT", 45, 89]]], ["Aangetoond is dat met name de kans op een miskraam bij pati\u00ebnten met APS kan worden gereduceerd door behandeling met aspirine en laagmoleculaire heparine.", [["heparine", "CHEMICAL", 145, 153], ["aspirine en laagmoleculaire heparine", "TREATMENT", 117, 153]]], ["Bij andere vormen van trombofilie is het voork\u00f3men van zwangerschapscomplicaties laat staan het nut van behandeling ervan met anticoagulantia zoals coumarinederivaten en/of laagmoleculaire heparine nog niet aangetoond.", [["Bij andere vormen van trombofilie is het voork\u00f3men van zwangerschapscomplicaties laat staan het nut van behandeling ervan", "SPECIES", 0, 121], ["laagmoleculaire heparine", "TREATMENT", 173, 197]]], ["Meestal wordt deze medicatie tot zes weken post partum gecontinueerd.Diffuse intravasale stolling (DIS)DIS of verbruikscoagulopathie ontstaat altijd secundair door stimulatie van de stollingscascade.", [["Diffuse intravasale stolling (DIS)DIS of verbruikscoagulopathie", "PROBLEM", 69, 132], ["intravasale", "OBSERVATION_MODIFIER", 77, 88], ["stolling", "OBSERVATION", 89, 97]]], ["Deze stimuli bestaan uit endotheelcelschade of de aanwezigheid van vruchtwater, placentafragmenten, bacteri\u00eble producten of incompatibele erytrocyten in de circulatie.", [["Deze stimuli", "TEST", 0, 12]]], ["Het beeld kan vari\u00ebren van een gecompenseerde situatie zoals bij preeclampsie tot een ernstig niet-gecompenseerd beeld als bij vruchtwaterembolie.", [["tot een ernstig niet-gecompenseerd beeld als bij vruchtwaterembolie", "SPECIES", 78, 145], ["Het beeld kan vari\u00ebren van een gecompenseerde situatie", "TREATMENT", 0, 54], ["als bij vruchtwaterembolie", "PROBLEM", 119, 145]]], ["Naast typisch obstetrische oorzaken kan ook sepsis dit beeld veroorzaken, met name tijdens zwangerschap en kraambed.Diffuse intravasale stolling (DIS)De onderliggende oorzaak en de bloedingproblemen bepalen de prognose van het ziektebeeld voor moeder en kind.Diffuse intravasale stolling (DIS)De behandeling van DIS begint met de behandeling van de oorzaak.", [["Naast", "TREATMENT", 0, 5], ["sepsis dit", "PROBLEM", 44, 54], ["Diffuse intravasale stolling", "PROBLEM", 116, 144], ["Diffuse intravasale stolling", "PROBLEM", 259, 287]]], ["Aanvullen van het circulerend volume gebeurt met collo\u00efden of kristallo\u00efden.", [["Aanvullen van het circulerend volume gebeurt", "TREATMENT", 0, 44]]], ["Tegelijkertijd worden stollingsfactoren toegediend, zoals plasma, cryoprecipitaat en trombocyten.", [["plasma", "ANATOMY", 58, 64], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["zoals plasma", "TREATMENT", 52, 64], ["cryoprecipitaat en trombocyten", "TREATMENT", 66, 96]]], ["Buiten de zwangerschap is het middel effectief gebleken voor gebruik bij bloedingsproblemen als gevolg van DIS.Diffuse intravasale stolling (DIS)Het gebruik van heparine bij DIS dient beperkt te blijven tot die gevallen waarbij er sprake is van een chronisch gecompenseerde DIS met voornamelijk stollingscomplicaties.Trombo-embolische ziektenIn 1856 postuleerde de Duitse patholoog Rudolf Virchow zijn bekende trias voor het ontstaan van trombose: factoren in de vaatwand, factoren in het stromingspatroon van het bloed en de samenstelling van het bloed zelf.", [["factoren", "CHEMICAL", 473, 481], ["Trombo-embolische ziektenIn 1856 postuleerde de Duitse patholoog Rudolf Virchow zijn bekende trias voor het ontstaan van trombose: factoren in de vaatwand, factoren in het stromingspatroon van het bloed en de samenstelling van het bloed zelf", "SPECIES", 317, 558], ["Diffuse intravasale stolling (DIS)", "PROBLEM", 111, 145]]], ["Al deze factoren ondergaan tijdens de zwangerschap belangrijke veranderingen: beschadiging van de vaatwand door onder meer operatieve ingrepen en pre-eclampsie, stasis in de onderste extremiteiten en het kleine bekken door mechanische afvloedbelemmering, en verandering in de stollingseigenschappen van het bloed resulterend in een fysiologische trombogene status.", [["stasis", "OBSERVATION", 161, 167]]], ["Hiermee vormt het kraambed een relatief risicovolle periode.IncidentieLongembolie\u00ebn zijn meestal afkomstig uit een trombose in de onderste extremiteiten of het kleine bekken.", [["IncidentieLongembolie\u00ebn", "TREATMENT", 60, 83]]], ["Er is in de zwangerschap significant vaker een diepe veneuze trombose links.RisicofactorenTijdens de zwangerschap zijn de risicofactoren voor trombo-embolie dezelfde als buiten de zwangerschap.RisicofactorenLeeftijd is een belangrijke factor.", [["een belangrijke factor", "PROTEIN", 219, 241], ["RisicofactorenLeeftijd", "TREATMENT", 193, 215], ["een belangrijke", "OBSERVATION", 219, 234]]], ["Zwangeren die meer dan 40 jaar oud zijn, hebben een bijna honderdmaal hogere kans op longembolie als vrouwen tussen 20 en 25 jaar oud.", [["Zwangeren", "TREATMENT", 0, 9]]], ["Bedrust is een wat minder evidente risicofactor.", [["een wat", "OBSERVATION", 11, 18]]], ["Een aparte risicogroep zijn vrouwen met trombofilie.", [["Een aparte risicogroep zijn", "TREATMENT", 0, 27]]], ["Bij een defici\u00ebntie voor antitrombine ligt de kans op een tromboembolie tussen 12 en 60%.", [["een tromboembolie tussen", "TREATMENT", 54, 78]]], ["Compressie-echografie kan gebruikt worden om een diepe veneuze trombose vast te stellen.", [["Compressie", "TEST", 0, 10]]], ["Zo nodig kan dit onderzoek na enkele dagen worden herhaald.", [["na", "CHEMICAL", 27, 29]]], ["Een niet-afwijkend onderzoek sluit echter een trombose in de vena iliaca bij zwangeren niet uit.", [["vena iliaca", "ANATOMY", 61, 72]]], ["Bij sterke verdenking hierop kan aanvullend een duplex dopplerechografie, MRI-onderzoek of venografie worden verricht.", [["een duplex dopplerechografie", "TEST", 44, 72], ["MRI", "TEST", 74, 77]]], ["Omdat veel zwangeren last hebben van kortademigheid door het toegenomen ademvolume en de diafragmahoogstand is het soms moeilijk een longembolie uit te sluiten als deze klacht acuut is ontstaan.", [["Omdat veel zwangeren last hebben van kortademigheid door het toegenomen ademvolume en de diafragmahoogstand is het soms moeilijk een longembolie uit te sluiten als deze klacht acuut", "SPECIES", 0, 181], ["een longembolie", "TREATMENT", 129, 144]]], ["Een arteri\u00eble bloedgasbepaling geeft vaak uitsluitsel.", [["Een arteri\u00eble bloedgasbepaling geeft vaak uitsluitsel", "SPECIES", 0, 53]]], ["Bij een liggende zwangere daalt de zuurstofspanning namelijk al door een veranderde ventilatie-perfusieverhouding en een gereduceerde veneuze vulling van de rechterharthelft.", [["Bij een liggende zwangere daalt de zuurstofspanning namelijk al door een veranderde ventilatie-perfusieverhouding en een gereduceerde veneuze vulling van de rechterharthelft", "SPECIES", 0, 173], ["een veranderde ventilatie", "TREATMENT", 69, 94]]], ["Een elektrocardiogram is te aspecifiek om de diagnose te kunnen stellen.Diagnose en onderzoekDrie geavanceerde technieken komen in aanmerking voor het verrichten van nadere diagnostiek.", [["Een elektrocardiogram", "TREATMENT", 0, 21]]], ["Spiraal-CT-technieken en compressie-echografie van de onderste extremiteiten kunnen eveneens worden toegepast.", [["Spiraal", "TEST", 0, 7], ["CT", "TEST", 8, 10]]], ["Bij het falen van deze technieken en bij klinische verdenking op een longembolie kan nog conventionele of CT-angiografie van de arteria pulmonalis worden verricht.", [["CT", "TEST", 106, 108], ["arteria", "ANATOMY", 128, 135]]], ["Soms kan met echocardiografisch onderzoek een longembolie worden vastgesteld wanneer er een hemodynamisch relevante obstructie van de uitvloed van de rechterventrikel is ontstaan of wanneer de trombus uitsteekt tot in de rechterventrikel.Diagnose en onderzoekBij gezonde zwangeren is de D-dimeer plasmaspiegel rondom de bevalling en vier weken post partum dermate verhoogd dat deze bepaling tijdens zwangerschap en kraambed niet kan worden gebruikt voor het vaststellen van een tromboembolisch proces.AnticoagulantiaCoumarinederivaten zijn de antistollingstherapie van keuze buiten de zwangerschap.", [["D-dimeer plasmaspiegel rondom de bevalling en vier weken post partum dermate verhoogd dat deze bepaling tijdens zwangerschap en kraambed niet kan worden gebruikt voor het vaststellen van een tromboembolisch proces", "SPECIES", 287, 500], ["AnticoagulantiaCoumarinederivaten zijn", "TREATMENT", 501, 539]]], ["Het gebruik van coumarinederivaten kan echter leiden tot teratogene afwijkingen bij de foetus (nasale hypoplasie en afwijkingen van het centrale zenuwstelsel) en geeft een verhoogde kans op foetale bloedingen.", [["kan echter leiden tot teratogene afwijkingen bij de foetus (nasale hypoplasie en afwijkingen van het centrale zenuwstelsel) en geeft een verhoogde kans op foetale bloedingen", "SPECIES", 35, 208], ["nasale hypoplasie en afwijkingen van het centrale zenuwstelsel", "TREATMENT", 95, 157]]], ["Het grootste risico op congenitale afwijkingen bestaat bij gebruik van deze middelen bij een zwangerschapsduur van 6-9 weken.", [["afwijkingen", "PROBLEM", 35, 46]]], ["Fenprocoumon is schadelijker dan acenocoumarol en wordt, bij chronisch gebruik, bij voorkeur voor de zwangerschap vervangen.", [["Fenprocoumon", "CHEMICAL", 0, 12], ["Fenprocoumon", "CHEMICAL", 0, 12], ["Fenprocoumon", "SIMPLE_CHEMICAL", 0, 12], ["Fenprocoumon", "TREATMENT", 0, 12]]], ["Dosering vindt plaats op geleide van de International Normalized Ratio (INR).", [["INR", "PROTEIN", 72, 75], ["INR", "TEST", 72, 75]]], ["INR is de verhouding van de protrombinetijd van de pati\u00ebnt en een standaard protrombinetijd, gerelateerd aan het standaard tromboplastinepreparaat.", [["INR", "TEST", 0, 3]]], ["Overdosering wordt afhankelijk van de klinische verschijnselen behandeld met staken van de medicatie, toedienen van vitamine K 1 , vierstollingsfactorenconcentraat of quarantaineplasma.AnticoagulantiaOngefractioneerde heparine wordt subcutaan of intraveneus toegediend.", [["quarantaineplasma", "TREATMENT", 167, 184], ["AnticoagulantiaOngefractioneerde heparine", "TREATMENT", 185, 226]]], ["Langdurig gebruik kan echter leiden tot maternale osteoporose, alopecia en heparinege\u00efnduceerde trombocytopenie.", [["alopecia", "DISEASE", 63, 71], ["echter leiden", "SPECIES", 22, 35], ["tot maternale", "SPECIES", 36, 49], ["Langdurig", "TEST", 0, 9], ["osteoporose", "PROBLEM", 50, 61], ["alopecia en heparinege\u00efnduceerde trombocytopenie", "PROBLEM", 63, 111]]], ["Dosering vindt plaats op geleide van de APTT.AnticoagulantiaLaagmoleculaire heparine (LMWH) vertoont minder affiniteit voor trombine en remt de trombocytenaggregatie minder, waardoor er minder bloedingen en trombocytopenie optreden.", [["AnticoagulantiaLaagmoleculaire heparine", "CHEMICAL", 45, 84], ["LMWH", "CHEMICAL", 86, 90], ["AnticoagulantiaLaagmoleculaire heparine", "SIMPLE_CHEMICAL", 45, 84], ["APTT", "PROTEIN", 40, 44], ["AnticoagulantiaLaagmoleculaire heparine (LMWH) vertoont minder", "TREATMENT", 45, 107]]], ["LMWH's zijn nog niet geregistreerd voor gebruik tijdens de zwangerschap maar worden wel veelvuldig voorgeschreven.", [["LMWH", "TREATMENT", 0, 4]]], ["Het middel passeert de placenta niet en er zijn geen teratogene effecten bij het kind beschreven.", [["placenta niet en er zijn", "TREATMENT", 23, 47]]], ["Zoals bij ongefractioneerde heparine kan overdosering worden gecoupeerd met protamine.", [["protamine", "CHEMICAL", 76, 85], ["protamine", "SIMPLE_CHEMICAL", 76, 85], ["Zoals", "TREATMENT", 0, 5], ["protamine", "TREATMENT", 76, 85]]], ["LMWH's kunnen veilig tijdens borstvoeding worden gegeven.BehandelingDe behandeling van trombo-embolische processen, zowel diepe veneuze trombose als longembolie, bestaat uit het starten van heparinemedicatie, waarbij de keuze is tussen ongefractioneerde of laagmoleculaire heparine.", [["heparine", "CHEMICAL", 273, 281], ["LMWH", "TREATMENT", 0, 4], ["laagmoleculaire heparine", "TREATMENT", 257, 281]]], ["Voorkeur bestaat voor LMWH's vanwege het gebruiksgemak en de bijwerkingen van de andere anticoagulantia.", [["LMWH", "PROBLEM", 22, 26]]], ["Bij een vroeg in de zwangerschap opgetreden trombo-embolie wordt de medicatie tot in de eerste zes weken van het kraambed voortgezet.BehandelingMinimaal 24 uur voor de partus wordt de therapeutische dosering LMWH gestaakt of omgezet in een profylactische dosering.", [["omgezet", "TREATMENT", 225, 232]]], ["Ook kan de LMWH worden omgezet in intraveneus toegediende ongefractioneerde heparine, wat 4 tot 6 uur voor de partus kan worden gestaakt of vlak ervoor geantagoneerd met protamine.BehandelingBij hemodynamisch gecompromitteerde pati\u00ebnten in direct levensgevaar kan trombolyse worden toegepast.", [["protamine", "CHEMICAL", 170, 179], ["protamine", "SIMPLE_CHEMICAL", 170, 179], ["protamine", "TREATMENT", 170, 179]]], ["De gebruikte middelen zoals streptokinase passeren de placenta niet.", [["De gebruikte middelen zoals streptokinase", "TREATMENT", 0, 41]]], ["Belangrijke bijwerkingen zijn anafylactische reacties en bloedingen.", [["Belangrijke", "TREATMENT", 0, 11]]], ["Chirurgische pulmonale embolectomie is diverse malen in de literatuur beschreven, vooral direct aansluitend aan een sectio caesarea bij massale longembolie wanneer trombolyse niet goed gebruikt kan worden.", [["pulmonale embolectomie", "DISEASE", 13, 35], ["Chirurgische pulmonale embolectomie", "PROBLEM", 0, 35], ["pulmonale", "OBSERVATION", 13, 22]]], ["Het plaatsen van een filter in de vena cava inferior teneinde trombi vanuit de onderste lichaamshelft te kunnen wegvangen, heeft alleen nut bij pati\u00ebnten bij wie ondanks adequate antistolling recidiverende longembolie\u00ebn blijven optreden of waarbij antistolling is gecontra-indiceerd.", [["vena cava", "MULTI-TISSUE_STRUCTURE", 34, 43], ["Het plaatsen van een filter", "TREATMENT", 0, 27], ["vena cava inferior teneinde trombi vanuit", "TREATMENT", 34, 75], ["vena cava", "ANATOMY", 34, 43]]], ["Zwangerschap wordt gezien als een contra-indicatie voor het plaatsen van een vena cava-filter.ProfylaxeAlgemene maatregelen ter voorkoming van een trombo-embolisch proces zijn snelle mobilisatie in het kraambed vooral na operatieve ingrepen.", [["ProfylaxeAlgemene", "TREATMENT", 94, 111], ["maatregelen ter voorkoming van een trombo-embolisch proces", "TREATMENT", 112, 170], ["vena", "ANATOMY", 77, 81]]], ["Een voorbeeld van een schema voor gebruik van antistolling tijdens zwangerschap en kraambed is weergegeven in tabel 21.10.ProfylaxeBij de profylactische dosering met LMWH's kan gekozen worden voor een hoge en lage dosering (bijv.", [["ProfylaxeBij", "CHEMICAL", 122, 134], ["ProfylaxeBij", "TREATMENT", 122, 134]]], ["2850 aXa IE versus 5700 aXa IE nadroparine).", [["nadroparine", "CHEMICAL", 31, 42], ["nadroparine", "CHEMICAL", 31, 42]]], ["Er is helaas uit klinisch onderzoek nog niet duidelijk welke dosering het meest effectief is.TromboflebitisOppervlakkige tromboflebitis is een aseptische ontsteking van de vaatwand door een trombus in een oppervlakkige vene.", [["TromboflebitisOppervlakkige tromboflebitis", "PROBLEM", 93, 135]]], ["Een tromboflebitis van de vena saphena magna kan 6-12 dagen behandeld worden met een NSAID of 6-30 dagen met een LMWH in hoge profylactische dosering.", [["Een tromboflebitis van de vena saphena magna kan", "TREATMENT", 0, 48], ["een NSAID", "TREATMENT", 81, 90], ["een LMWH", "TREATMENT", 109, 117], ["LMWH", "OBSERVATION", 113, 117]]], ["Elastische kousen kunnen in alle gevallen baat geven.", [["Elastische kousen kunnen", "TREATMENT", 0, 24]]], ["Er is geen duidelijke relatie tussen oppervlakkige tromboflebitis en kans op een trombo-embolisch proces.TromboflebitisEen aparte vorm van tromboflebitis is de septische tromboflebitis van een of beide venae ovaricae.", [["beide venae ovaricae", "ORGANISM", 196, 216], ["venae ovaricae", "SPECIES", 202, 216], ["TromboflebitisEen aparte vorm van tromboflebitis", "SPECIES", 105, 153], ["beide venae ovaricae", "TREATMENT", 196, 216], ["venae", "ANATOMY", 202, 207], ["ovaricae", "OBSERVATION", 208, 216]]], ["Bij niet op antibiotica reagerende koorts, pijnklachten en algemene malaise moet de diagnose overwogen worden.", [["Bij niet op antibiotica", "TREATMENT", 0, 23]]], ["Als er bij gynaecologisch onderzoek een pijnlijke weerstand naast de uterus palpabel is, wordt de diagnose trombose van de vena ovarica gesteld.", [["trombose van de vena ovarica gesteld", "DISEASE", 107, 143], ["Als er bij gynaecologisch onderzoek", "TREATMENT", 0, 35], ["uterus", "ANATOMY", 69, 75], ["vena", "ANATOMY", 123, 127]]], ["Waarschijnlijk vormen de ziektebeelden septische tromboflebitis en trombose van de vena ovarica een continu\u00fcm.", [["vena", "ANATOMY", 83, 87]]], ["Beide diagnosen worden gesteld met computertomografie, echografie of MRI.", [["MRI", "TEST", 69, 72]]], ["Enerzijds zorgt de extra groeiTabel 21.10 Schema voor gebruik van antistolling tijdens zwangerschap en kraambedPati\u00ebnten zonder bekende risicofactoren en geen trombo-embolie in de voorgeschiedenis: -Indicaties: profylaxe is alleen ge\u00efndiceerd bij volledige immobilisatie, uitgebreid trauma en rondom grote operatieve ingrepen. -Beleid: profylactische antistolling, bij een sectio caesarea wordt bij voorkeur minimaal 6 uur na de ingreep gestart vanwege de grotere kans op buikwandhematomen in vergelijking met preoperatieve start.Pati\u00ebnten met een indicatie voor profylactische antistolling alleen post partum of bij langdurige bedrust:-Indicaties: eenmaal trombo-embolie met tijdelijke risicofactor in de voorgeschiedenis, hyperhomocyste\u00efnemie en tromboembolie in de voorgeschiedenis, prote\u00efne-C-defici\u00ebntie, prote\u00efne-S-defici\u00ebntie, factor-V-Leidenmutatie (heterozygoot), protrombinegenvariant (heterozygoot) en antifosfolipideantistoffen zonder trombo-embolie in de voorgeschiedenis. -Beleid: profylactische antistolling tijdens bedrust, bij de partus eenmaal overslaan, tijdens kraambed profylactische antistolling gedurende 6 weken.Pati\u00ebnten met een indicatie voor profylactische antistolling tijdens zwangerschap en kraambed:-Indicaties: idiopathische trombo-embolie in de voorgeschiedenis, spontane trombo-embolie tijdens eerdere zwangerschap of kraambed, antitrombinedefici\u00ebntie, antifosfolipidesyndroom (zie ook bij auto-immuunziekten), prote\u00efne-C-defici\u00ebntie, prote\u00efne-S-defici\u00ebntie, factor-V-Leidenmutatie (heterozygoot) en protrombinegenvariant (heterozygoot) met trombo-embolie in de voorgeschiedenis, factor-V-Leidenmutatie (homozygoot) en protrombinegenvariant (homozygoot) zonder trombo-embolie in de voorgeschiedenis en gecombineerde stollingsfactordefici\u00ebnties. -Beleid: profylactische antistolling tijdens de zwangerschap, bij de partus eenmaal overslaan, tijdens kraambed profylactische antistolling gedurende 6 weken.Pati\u00ebnten met ook voor de zwangerschap een indicatie voor therapeutische antistolling:-Indicaties: mechanische klepprotheses, ernstig hartkleplijden, recidiverende trombo-embolie met of zonder duidelijke oorzaak, antifosfolipidesyndroom met trombo-embolie in de voorgeschiedenis. -Beleid: preconceptioneel omzetten van fenprocoumon naar acenocoumarol, bij positieve zwangerschapstest coumarinederivaten vervangen door laagmoleculaire heparine, overwogen kan worden tussen 16 en 36 weken weer coumarinederivaten te gebruiken, bij de partus eenmaal overslaan, tijdens kraambed laagmoleculaire heparine continueren of starten met coumarinederivaten, fenprocoumon is gecontra-indiceerd bij borstvoeding.Pati\u00ebnten met ook voor de zwangerschap een indicatie voor therapeutische antistolling:Bron: Leebeek F, Kruip M, 2005. tijdens de zwangerschap voor extra insulinebehoefte.", [["uitgebreid trauma", "DISEASE", 272, 289], ["acenocoumarol", "CHEMICAL", 2274, 2287], ["coumarinederivaten", "CHEMICAL", 2564, 2582], ["fenprocoumon", "CHEMICAL", 2584, 2596], ["zie ook bij auto-immuunziekten), prote\u00efne-C-defici\u00ebntie, prote\u00efne-S-defici\u00ebntie, factor-V-Leidenmutatie (heterozygoot) en protrombinegenvariant", "SPECIES", 1412, 1555], ["profylaxe", "TREATMENT", 211, 220], ["profylactische antistolling", "TREATMENT", 336, 363], ["eenmaal trombo-embolie", "PROBLEM", 649, 671], ["hyperhomocyste\u00efnemie", "PROBLEM", 724, 744], ["prote\u00efne", "TEST", 786, 794], ["defici\u00ebntie", "TEST", 797, 808], ["prote\u00efne", "TEST", 810, 818], ["factor", "TEST", 834, 840], ["Leidenmutatie (heterozygoot)", "PROBLEM", 843, 871], ["protrombinegenvariant (heterozygoot)", "TREATMENT", 873, 909], ["profylactische", "TREATMENT", 995, 1009], ["idiopathische trombo-embolie", "PROBLEM", 1243, 1271], ["antifosfolipidesyndroom", "TREATMENT", 1387, 1410], ["prote\u00efne", "TEST", 1445, 1453], ["prote\u00efne", "TEST", 1469, 1477], ["factor", "TEST", 1493, 1499], ["Leidenmutatie (heterozygoot)", "TREATMENT", 1502, 1530], ["met trombo-embolie in de voorgeschiedenis", "PROBLEM", 1571, 1612], ["factor", "TEST", 1614, 1620], ["Leidenmutatie (homozygoot)", "PROBLEM", 1623, 1649], ["zonder trombo-embolie", "PROBLEM", 1688, 1709], ["mechanische klepprotheses", "PROBLEM", 2036, 2061], ["van fenprocoumon naar acenocoumarol", "TREATMENT", 2252, 2287], ["bij positieve zwangerschapstest", "TREATMENT", 2289, 2320], ["laagmoleculaire heparine", "TREATMENT", 2355, 2379]]], ["Deze insulineresistentie wordt veroorzaakt door de diverse zwangerschapshormonen zoals humaan placentair lactogeen, progesteron, oestrogenen en cortisol.", [["cortisol", "CHEMICAL", 144, 152], ["cortisol", "CHEMICAL", 144, 152], ["lactogeen", "TREATMENT", 105, 114], ["progesteron", "TREATMENT", 116, 127], ["oestrogenen en cortisol", "TREATMENT", 129, 152]]], ["De glucosedrempel van de nieren verlaagt drastisch waardoor vaak glucose in de urine wordt gevonden.", [["glucose", "CHEMICAL", 65, 72], ["glucose", "CHEMICAL", 65, 72], ["glucose", "SIMPLE_CHEMICAL", 65, 72], ["urine", "ORGANISM_SUBSTANCE", 79, 84]]], ["Dit is echter een fysiologisch verschijnsel en geen teken van diabetes mellitus.Pati\u00ebnten met ook voor de zwangerschap een indicatie voor therapeutische antistolling:Drie typen van diabetes mellitus worden in de zwangerschap onderscheiden: vrouwen met diabetes mellitus type 1 of type 2 of vrouwen die tijdens de zwangerschap diabetes mellitus ontwikkelen (zwangerschapsdiabetes).", [["diabetes mellitus", "DISEASE", 62, 79], ["diabetes mellitus worden", "DISEASE", 181, 205], ["diabetes mellitus", "DISEASE", 252, 269], ["diabetes mellitus ontwikkelen", "DISEASE", 326, 355], ["van diabetes mellitus", "PROBLEM", 58, 79], ["van diabetes mellitus", "PROBLEM", 177, 198], ["diabetes mellitus", "PROBLEM", 252, 269], ["vrouwen die tijdens", "PROBLEM", 290, 309], ["diabetes mellitus ontwikkelen (zwangerschapsdiabetes)", "PROBLEM", 326, 379]]], ["Bij diabetes mellitus type 1 bestaat er een onvermogen van de pancreas om insuline te maken.", [["pancreas", "ANATOMY", 62, 70], ["diabetes mellitus", "DISEASE", 4, 21], ["pancreas", "ORGAN", 62, 70], ["Bij diabetes mellitus type 1 bestaat er een onvermogen van de pancreas om insuline te maken", "SPECIES", 0, 91], ["Bij diabetes mellitus type 1", "PROBLEM", 0, 28], ["er een onvermogen van de pancreas om insuline te", "TREATMENT", 37, 85], ["pancreas", "ANATOMY", 62, 70]]], ["Bij diabetes mellitus type 2 en zwangerschapsdiabetes kan de pancreas niet voldoende insuline maken om de gestegen insulinebehoefte het hoofd te bieden.", [["diabetes mellitus", "DISEASE", 4, 21], ["Bij diabetes mellitus type 2 en zwangerschapsdiabetes kan de pancreas niet voldoende insuline maken om de gestegen insulinebehoefte het hoofd te bieden", "SPECIES", 0, 151], ["Bij diabetes mellitus", "PROBLEM", 0, 21], ["type 2", "PROBLEM", 22, 28], ["pancreas", "ANATOMY", 61, 69]]], ["Bij circa 6% van de zwangeren bij wie zwangerschapsdiabetes ontstaat, blijft deze stoornis in het glucosemetabolisme ook na de zwangerschap bestaan.IncidentieDiabetes mellitus is de meest voorkomende endocriene afwijking tijdens de zwangerschap.", [["mellitus", "DISEASE", 167, 175], ["Bij circa", "TREATMENT", 0, 9], ["IncidentieDiabetes mellitus", "PROBLEM", 148, 175]]], ["Afhankelijk van hun etnische afkomst heeft ongeveer 0,5% van de zwangeren diabetes mellitus type 1 en ongeveer 2% type 2.", [["diabetes mellitus", "DISEASE", 74, 91], ["Afhankelijk van hun etnische afkomst heeft ongeveer 0,5% van de zwangeren diabetes mellitus type 1", "SPECIES", 0, 98], ["diabetes mellitus type", "PROBLEM", 74, 96]]], ["Het aantal Nederlanders dat jaarlijks gediagnosticeerd wordt met een vorm van diabetes neemt met 9% per jaar toe, wat betekent dat dit probleem in omvang de komende jaren fors zal toenemen.Preconceptionele adviseringVrouwen met diabetes mellitus type 1 of 2 dienen voor hun zwangerschap te worden ingelicht over de extra risico's die een zwangerschap met zich meebrengt.", [["diabetes mellitus", "DISEASE", 228, 245], ["Vrouwen met diabetes mellitus", "PROBLEM", 216, 245], ["toe", "ANATOMY", 109, 112], ["wat", "ANATOMY", 114, 117], ["diabetes", "OBSERVATION", 228, 236]]], ["Verder is er meer kans op zwangerschapscomplicaties als spontane miskramen, het ontwikkelen van pre-eclampsie, onbegrepen intra-uteriene vruchtdood en infecties.Preconceptionele adviseringHiernaast is het goed voor de ouders zich te realiseren dat het kind zelf een verhoogd risico heeft op het ontwikkelen van diabetes mellitus type 1.", [["diabetes mellitus type", "DISEASE", 311, 333], ["zelf een verhoogd risico heeft op het ontwikkelen van diabetes mellitus type 1", "SPECIES", 257, 335], ["van diabetes mellitus type 1", "PROBLEM", 307, 335]]], ["Dit risico bedraagt 3% indien de moeder diabetes mellitus type 1 heeft, maar zelfs 6% als de vader diabetes heeft.Preconceptionele adviseringNaarmate de bloedsuikers in de maanden voor de zwangerschap beter zijn gereguleerd, kan het aantal gevallen van congenitale afwijkingen en spontane miskramen waarschijnlijk sterk worden gereduceerd.", [["indien", "CHEMICAL", 23, 29], ["diabetes mellitus type 1 heeft", "DISEASE", 40, 70], ["diabetes heeft", "DISEASE", 99, 113], ["diabetes mellitus type 1 heeft", "PROBLEM", 40, 70], ["maar zelfs", "PROBLEM", 72, 82], ["diabetes heeft", "PROBLEM", 99, 113]]], ["Er zijn aanwijzingen dat wanneer het HbA 1c binnen 4 standaarddeviaties van het gemiddelde blijft, het aantal kinderen met congenitale afwijkingen gelijk is als in de algemene populatie.Preconceptionele adviseringVrouwen die orale antidiabetica gebruiken, dienen vanwege het mogelijke teratogene effect hiervan preconceptioneel over te schakelen op insuline.", [["insuline", "CHEMICAL", 349, 357], ["hiervan preconceptioneel", "TREATMENT", 303, 327]]], ["Analoge langwerkende insulinen zijn voor gebruik in de zwangerschap nog niet geregistreerd.", [["Analoge", "TREATMENT", 0, 7]]], ["Pre-existente schildklierafwijkingen worden frequent gezien bij pati\u00ebnten met diabetes mellitus type 1.", [["diabetes mellitus type", "DISEASE", 78, 100], ["diabetes mellitus type 1", "PROBLEM", 78, 102]]], ["Regulier wordt foliumzuur geadviseerd.Prenatale diagnostiekVanwege de gestegen kans op kinderen met congenitale afwijkingen komen pati\u00ebnten met diabetes mellitus type 1 of 2 in aanmerking voor het verrichten van prenatale diagnostiek.Prenatale controlesBij voorkeur wordt de zwangere met diabetes mellitus gezamenlijk gecontroleerd door de gynaecoloog en de internist.", [["diabetes mellitus type", "DISEASE", 144, 166], ["diabetes mellitus gezamenlijk", "DISEASE", 288, 317], ["diabetes mellitus type 1", "PROBLEM", 144, 168], ["diabetes mellitus", "PROBLEM", 288, 305]]], ["Diabetische ketoacidose treedt als gevolg hiervan tijdens de zwangerschap minder op.", [["Diabetische ketoacidose", "PROBLEM", 0, 23]]], ["Retinopathie verslechtert, afhankelijk van de mate waarin het al pre-existent aanwezig was.", [["Retinopathie verslechtert", "TREATMENT", 0, 25]]], ["De invloed van de zwangerschap op de nierfunctie hangt eveneens af van de reeds bestaande nefropathie.Prenatale controlesTijdens de zwangerschapscontroles is het van belang de groei van de foetus goed te vervolgen.", [["De invloed van de zwangerschap op de nierfunctie hangt eveneens af van de reeds bestaande nefropathie", "SPECIES", 0, 101]]], ["Ook de kans op pre-eclampsie is fors toegenomen (12% bij diabetes mellitus type 1).Prenatale controlesIn hoeverre het ontwikkelen van macrosomie be\u00efnvloed kan worden door strikte bloedsuikerregulatie is niet duidelijk.", [["diabetes mellitus", "DISEASE", 57, 74], ["12% bij diabetes mellitus type", "PROBLEM", 49, 79]]], ["Macrosomie is zeker een risicofactor voor onbegrepen intra-uteriene vruchtdood.", [["Macrosomie", "TREATMENT", 0, 10], ["een risicofactor", "OBSERVATION", 20, 36]]], ["Scherpe instelling van de bloedsuikers is van groot belang om tenminste een deel van deze zwangerschapcomplicaties te kunnen voorkomen.Prenatale controlesDe insulinebehoefte zal tijdens de zwangerschap en met name bij pati\u00ebnten met diabetes mellitus type 2 enorm stijgen.De bevallingEen belangrijk discussiepunt is of vrouwen met diabetes mellitus moeten worden ingeleid en, zo ja, bij welke termijn.", [["diabetes mellitus", "DISEASE", 232, 249], ["diabetes mellitus", "DISEASE", 330, 347], ["Prenatale controlesDe insulinebehoefte zal tijdens", "TREATMENT", 135, 185], ["diabetes mellitus type 2 enorm stijgen", "PROBLEM", 232, 270], ["vrouwen met diabetes mellitus", "PROBLEM", 318, 347]]], ["Bij een geschat gewicht van >4500 g valt een primaire sectio caesarea te overwegen.De bevallingTijdens de bevalling is het van groot belang de maternale bloedsuikers goed te blijven reguleren.", [["Bij een geschat gewicht van >4500 g valt", "SPECIES", 0, 40], ["Bij een geschat gewicht van", "TREATMENT", 0, 27]]], ["De controles worden minimaal elke twee uur, liever nog elk uur, verricht.De bevallingVanwege de vaak ontstane macrosomie wordt vaker een vaginale kunstverlossing of sectio caesarea verricht.De bevallingDe neonaat moet post partum vaak op de kinderafdeling opgenomen worden vanwege de grote kans op hypoglykemie in de eerste uren en dagen.KraambedNa de bevalling is er bij de kraamvrouw direct minder insulinebehoefte.", [["Kraambed", "CHEMICAL", 338, 346], ["Na", "CHEMICAL", 346, 348], ["Na", "CHEMICAL", 346, 348], ["Kraambed", "SPECIES", 338, 346]]], ["Tijdens of na de borstvoeding kan een maternale hypoglykemie optreden.ZwangerschapsdiabetesEr is veel discussie over de definitie, klinische relevantie, diagnostiek en behandeling van zwangerschapsdiabetes.", [["na", "CHEMICAL", 11, 13]]], ["Er zijn duidelijke aanwijzingen dat maternale hyperglykemie leidt tot een hogere morbiditeit en mortaliteit bij zowel de foetus als de moeder.", [["Er zijn duidelijke aanwijzingen", "TREATMENT", 0, 31]]], ["Risicogroepen zijn: zwangerschapsdiabetes in de voorgeschiedenis, maternale BMI>30 (kg/m 2 ) bij de eerste prenatale controle, een eerder kind met een geboortegewicht >P95 of >4500 gram, eerstegraads familielid met diabetes, bepaalde etnische groepen waarin diabetes veel voorkomt (Zuid-Aziaten, o.a.", [["diabetes", "DISEASE", 215, 223], ["diabetes", "DISEASE", 258, 266], ["diabetes", "PROBLEM", 215, 223], ["bepaalde etnische", "TREATMENT", 225, 242]]], ["Hindoestanen, Afro-Cara\u00efbi\u00ebrs, vrouwen uit het Midden-Oosten, Marokko en Egypte), onverklaarde intra-uteriene vruchtdood in de voorgeschiedenis, polycysteus-ovariumsyndroom.ScreeningDe diagnose zwangerschapsdiabetes kan op verschillende manieren worden gesteld.", [["Hindoestanen", "CHEMICAL", 0, 12], ["Hindoestanen", "CHEMICAL", 0, 12], ["Hindoestanen", "SIMPLE_CHEMICAL", 0, 12], ["Hindoestanen", "TREATMENT", 0, 12]]], ["Een nuchtere glucosewaarde van minder dan 6,1 mmol/l betekent dat er geen sprake is van pre-existente diabetes mellitus.", [["diabetes mellitus", "DISEASE", 102, 119], ["Een nuchtere glucosewaarde van minder dan 6,1 mmol/l betekent dat er geen sprake", "SPECIES", 0, 80], ["van pre-existente diabetes mellitus", "PROBLEM", 84, 119]]], ["Bij een nuchtere glucosewaarde van meer dan 6,9 mmol/l wordt aangenomen dat er sprake is van diabetes mellitus.", [["diabetes mellitus", "DISEASE", 93, 110], ["van diabetes mellitus", "PROBLEM", 89, 110]]], ["Indien deze afwijkend is, is er sprake van een pre-existent afwijkende glucosestofwisseling.ScreeningNa 24-28 weken dient een orale glucosetolerantietest (OGTT) te worden verricht bij risicogroepen of bij het optreden van zwangerschapscomplicaties zoals polyhydramnion of macrosomie.", [["ScreeningNa", "TEST", 92, 103]]], ["Het door de pati\u00ebnten zelf laten controleren van de bloedglucosewaarden leidt tot een beter effect.BehandelingHoewel in Nederland nog relatief onbekend, is behandeling van zwangerschapsdiabetes met bepaalde vormen van orale antidiabetica mogelijk en veilig gebleken.BehandelingVoor het beleid rondom de partus gelden voor vrouwen met zwangerschapsdiabetes dezelfde adviezen als die voor zwangeren met diabetes mellitus type 1 of 2.BehandelingOmdat vrouwen die zwangerschapsdiabetes ontwikkelden, meer kans hebben op het ontwikkelen van diabetes mellitus type 2, wordt geadviseerd na de zwangerschap de glucosestofwisseling met enige regelmaat (elke 1-2 jaar) te controleren.", [["diabetes mellitus", "DISEASE", 401, 418], ["diabetes mellitus type", "DISEASE", 536, 558], ["diabetes mellitus type 1", "PROBLEM", 401, 425], ["mellitus type 2", "PROBLEM", 545, 560]]], ["Het is bij vrouwen met overgewicht raadzaam hen te adviseren af te vallen en vooral voldoende lichaamsbeweging te nemen.", [["hen", "SPECIES", 44, 47]]], ["Bij een nieuwe zwangerschap dient vroegtijdig op zwangerschapsdiabetes te worden gescreend.FysiologieZowel anatomisch als functioneel ondergaat de schildklier in de zwangerschap grote veranderingen.", [["Bij een nieuwe zwangerschap dient vroegtijdig op zwangerschapsdiabetes te worden gescreend", "SPECIES", 0, 90], ["Bij een nieuwe zwangerschap", "TREATMENT", 0, 27], ["FysiologieZowel", "TREATMENT", 91, 106]]], ["Dit is een gevolg van stijging van de concentratie thyroid-binding globuline, het transporteiwit voor schildklierhormoon, een relatieve afname in de beschikbaarheid van jodium door gestegen nierklaring en verlies naar de foetus en de placenta en ten slotte overstimulatie van de schildklier door andere hormonen zoals hCG, dat veel gelijkenis vertoont met TSH (thyro\u00efdstimulerend hormoon).", [["thyroid", "ORGAN", 51, 58], ["van jodium door gestegen nierklaring en verlies naar de foetus en de placenta en ten slotte overstimulatie van de schildklier door andere hormonen zoals", "SPECIES", 165, 317], ["hCG", "TEST", 318, 321], ["TSH", "TEST", 356, 359], ["thyroid", "ANATOMY", 51, 58]]], ["Met name voor de ontwikkeling van de foetale hersenen zijn schildklierhormonen van het grootste belang.FysiologieSchildklierziekten vormen na diabetes de meest voorkomende endocrinologische ziekten tijdens de zwangerschap.Hypothyreo\u00efdieVan elke 10.000 zwangerschappen is er bij \u00e9\u00e9n tot drie sprake van klinische hypothyreo\u00efdie.", [["FysiologieSchildklierziekten vormen na diabetes", "PROBLEM", 103, 150], ["Hypothyreo\u00efdieVan elke", "TREATMENT", 222, 244]]], ["Primaire hypothyreo\u00efdie is veelal het gevolg van de ziekte van Hashimoto (auto-immuunthyreo\u00efditis), maar kan ook secundair ontstaan zijn na behandeling van hyperthyreo\u00efdie, jodiumgebrek of schildklierchirurgie.", [["Hashimoto (auto-immuunthyreo\u00efditis", "DISEASE", 63, 97], ["na", "CHEMICAL", 137, 139], ["schildklierchirurgie", "CHEMICAL", 189, 209]]], ["Secundaire hypothyreo\u00efdie is hypofysair en tertiaire hypothyreo\u00efdie hypothalaam van origine.Hypothyreo\u00efdieEen van de belangrijkste kenmerken van klinische hypothyreo\u00efdie is anovulatie.", [["hypothyreo\u00efdie", "DISEASE", 11, 25], ["hypothyreo\u00efdie", "DISEASE", 155, 169], ["hypofysair", "PROBLEM", 29, 39]]], ["Verdere kenmerken zijn vermoeidheid, koude intolerantie, lethargie, obstipatie, spierkrampen, haaruitval en nagelafwijkingen.", [["lethargie", "PROBLEM", 57, 66], ["obstipatie", "PROBLEM", 68, 78], ["spierkrampen", "TREATMENT", 80, 92], ["haaruitval en nagelafwijkingen", "TREATMENT", 94, 124]]], ["Een hoog TSH in combinatie met een laag vrij thyroxine (T4)-gehalte is uiteindelijk bewijzend voor de diagnose primaire hypothyreo\u00efdie.Hypothyreo\u00efdieZwangerschapscomplicaties als spontane miskramen, pre-eclampsie, solutio placentae, groeiretardatie en intra-uteriene vruchtdood komen vaker voor.", [["thyroxine", "CHEMICAL", 45, 54], ["thyroxine", "CHEMICAL", 45, 54], ["thyroxine", "SIMPLE_CHEMICAL", 45, 54], ["T4", "SIMPLE_CHEMICAL", 56, 58], ["Hypothyreo\u00efdieZwangerschapscomplicaties als spontane miskramen", "PROBLEM", 135, 197]]], ["Levothyroxine kan veilig tijdens zwangerschap en kraambed worden toegediend.", [["Levothyroxine", "CHEMICAL", 0, 13], ["Levothyroxine kan veilig tijdens zwangerschap", "TREATMENT", 0, 45]]], ["In het eerste trimester moet de dosering levothyroxine al direct met 25-50% worden verhoogd.", [["levothyroxine", "CHEMICAL", 41, 54], ["levothyroxine", "CHEMICAL", 41, 54], ["levothyroxine al direct", "TREATMENT", 41, 64]]], ["De dosering levothyroxine moet in het kraambed direct weer worden verminderd.Hypothyreo\u00efdieDe laatste jaren is subklinische hypothyreo\u00efdie, waarbij het vrij T4 binnen de referentiewaarden valt en het serum-TSH verhoogd is, in de belangstelling gekomen doordat er ook bij deze vorm van hypothyreo\u00efdie sprake is van een toename aan zwangerschapscomplicaties zoals pre-eclampsie en perinatale mortaliteit.", [["levothyroxine", "CHEMICAL", 12, 25], ["levothyroxine", "CHEMICAL", 12, 25], ["levothyroxine", "SIMPLE_CHEMICAL", 12, 25], ["serum", "ORGANISM_SUBSTANCE", 200, 205], ["De dosering levothyroxine moet", "TREATMENT", 0, 30], ["hypothyreo\u00efdie", "PROBLEM", 124, 138]]], ["Er is echter nog geen bewijs dat suppletie met schildklierhormonen hier verbetering in kan brengen.Hyperthyreo\u00efdieVan elke 10.000 zwangerschappen is er bij twee sprake van klinische hyperthyreo\u00efdie.", [["Hyperthyreo\u00efdieVan elke", "TREATMENT", 99, 122]]], ["In meer dan 90% van de gevallen is de oorzaak de ziekte van Graves, een auto-immuunziekte.", [["een auto-immuunziekte", "TREATMENT", 68, 89]]], ["Andere oorzaken zijn schildklieradenoom of toxisch nodulair struma, thyreo\u00efditis en schildklierhormoonoverdosering.", [["struma", "DISEASE", 60, 66], ["toxisch nodulair struma", "PROBLEM", 43, 66], ["thyreo\u00efditis en schildklierhormoonoverdosering", "TREATMENT", 68, 114]]], ["Klinische symptomen zijn warmte-intolerantie, palpitaties, gewichtsverlies, exophthalmos, tachycardie en nervositas.", [["exophthalmos", "DISEASE", 76, 88], ["palpitaties", "PROBLEM", 46, 57], ["exophthalmos", "PROBLEM", 76, 88], ["tachycardie", "PROBLEM", 90, 101], ["exophthalmos", "OBSERVATION", 76, 88]]], ["Een laag TSH in combinatie met een hoog vrij T4 zijn de biochemische kenmerken.", [["Een laag TSH", "TEST", 0, 12]]], ["Koorts, tremor, hartkloppingen, braken en diarree, uitdroging, delirium en ten slotte coma zijn de klinische tekenen.", [["tremor", "DISEASE", 8, 14], ["delirium", "DISEASE", 63, 71], ["coma", "DISEASE", 86, 90], ["tremor", "PROBLEM", 8, 14], ["hartkloppingen", "PROBLEM", 16, 30], ["delirium", "PROBLEM", 63, 71]]], ["Behandeling dient plaats te vinden op de intensive care met propylthiouracil en jodium.", [["propylthiouracil", "CHEMICAL", 60, 76], ["propylthiouracil", "CHEMICAL", 60, 76], ["propylthiouracil en jodium", "TREATMENT", 60, 86]]], ["Een andere complicatie is decompensatio cordis op basis van cardiomyopathie, dit komt juist meer tijdens de zwangerschap voor.Hyperthyreo\u00efdieZwangerschapscomplicaties als spontane miskramen, pre-eclampsie, solutio placentae, vroeggeboorte en groeiretardatie komen bij hyperthyreo\u00efdie vaker voor.", [["Hyperthyreo\u00efdieZwangerschapscomplicaties als spontane miskramen", "PROBLEM", 126, 189]]], ["Thyreostatica, met name thiamazol en carbimazol, kunnen foetale afwijkingen veroorzaken.", [["Thyreostatica", "PROBLEM", 0, 13], ["thiamazol en carbimazol", "TREATMENT", 24, 47]]], ["Bij voorkeur wordt daarom propylthiouracil gebruikt.", [["propylthiouracil", "CHEMICAL", 26, 42], ["propylthiouracil", "CHEMICAL", 26, 42]]], ["Thiamazol kan agranulocytose en hepatitis veroorzaken.", [["Thiamazol", "CHEMICAL", 0, 9], ["hepatitis", "DISEASE", 32, 41], ["Thiamazol", "CHEMICAL", 0, 9], ["Thiamazol", "SIMPLE_CHEMICAL", 0, 9], ["Thiamazol kan agranulocytose en hepatitis veroorzaken", "TREATMENT", 0, 53], ["hepatitis", "OBSERVATION", 32, 41]]], ["De dosering van de medicatie wordt minimaal elk trimester gecontroleerd door schildklierfunctietests.Hyperthyreo\u00efdieTijdens de partus kan een thyreotoxische crisis worden geluxeerd.Hyperthyreo\u00efdieFoetale of neonatale thyreotoxicose kan in 1-2% van de gevallen voorkomen door passage van antistoffen zoals TSH-receptorantistoffen door de placenta.", [["placenta", "ANATOMY", 337, 345], ["placenta", "MULTI-TISSUE_STRUCTURE", 337, 345], ["Hyperthyreo\u00efdieFoetale", "TREATMENT", 181, 203], ["neonatale thyreotoxicose kan", "TREATMENT", 207, 235], ["TSH", "TEST", 305, 308], ["placenta", "ANATOMY", 337, 345]]], ["Bij tekenen van foetale thyreotoxicose moet behandeling van de moeder plaatsvinden met thyreostatica.", [["Bij tekenen van foetale thyreotoxicose", "TREATMENT", 0, 38]]], ["Hierdoor ontstane hypothyreo\u00efdie bij de moeder kan op haar beurt weer behandeld worden met thyreomimetica, die de placenta in mindere mate passeren.", [["placenta", "ANATOMY", 114, 122], ["placenta", "TISSUE", 114, 122], ["placenta", "ANATOMY", 114, 122]]], ["Thiamazol en carbimazol kunnen foetale hypothyreo\u00efdie veroorzaken.", [["Thiamazol", "CHEMICAL", 0, 9], ["Thiamazol", "CHEMICAL", 0, 9], ["carbimazol", "CHEMICAL", 13, 23], ["Thiamazol", "SIMPLE_CHEMICAL", 0, 9], ["Thiamazol en carbimazol", "TREATMENT", 0, 23]]], ["In navelstrengbloed en neonataal bloed kunnen de schildklierfuncties worden bepaald.Hyperthyreo\u00efdieAlle thyreostatica gaan over in de borstvoeding, propylthiouracil nog het minste.", [["propylthiouracil", "CHEMICAL", 148, 164], ["propylthiouracil", "CHEMICAL", 148, 164], ["propylthiouracil", "SIMPLE_CHEMICAL", 148, 164]]], ["Bij borstvoeding met de andere thyreostatica en bij hoge doseringen propylthiouracil wordt geadviseerd regelmatig de schildklierfunctie van de zuigeling te bepalen.Hyperthyreo\u00efdieSubklinische hyperthyreo\u00efdie wordt gedefinieerd als een verlaagde serum-TSH-concentratie bij een normaal vrij T4.", [["propylthiouracil", "CHEMICAL", 68, 84], ["serum", "ORGANISM_SUBSTANCE", 245, 250], ["thyreostatica en bij hoge doseringen propylthiouracil", "TREATMENT", 31, 84], ["Hyperthyreo\u00efdieSubklinische", "TEST", 164, 191], ["serum", "TEST", 245, 250], ["TSH", "TEST", 251, 254], ["concentratie", "TEST", 255, 267]]], ["Er zijn geen aanwijzingen dat subklinische hyperthyreo\u00efdie zou moeten worden behandeld buiten de zwangerschap, laat staan tijdens.Thyreo\u00efditis post partumBij 5-7% van de kraamvrouwen ontstaat binnen het eerste jaar een voorbijgaande auto-immuunthyreo\u00efditis.", [["Thyreo\u00efditis", "DISEASE", 130, 142], ["Thyreo\u00efditis post partumBij", "PROBLEM", 130, 157]]], ["Deze frequentie is zelfs hoger bij vrouwen met diabetes mellitus en schildklierantistoffen (anti-TPO).", [["diabetes mellitus", "DISEASE", 47, 64], ["TPO", "GENE_OR_GENE_PRODUCT", 97, 100], ["TPO", "PROTEIN", 97, 100], ["diabetes mellitus", "PROBLEM", 47, 64]]], ["Ongeveer 30% blijft hypothyreoot.", [["30% blijft hypothyreoot", "TREATMENT", 9, 32]]], ["De ziekte moet worden onderscheiden van andere schildklieraandoeningen zoals de ziekte van Graves en de ziekte van Hashimoto.HypofyseaandoeningenHyperprolactinemie komt in deze groep aandoeningen het meest voor en ontstaat als gevolg van een micro-of macroadenoom van de hypofyse, als bijwerking van bepaalde medicatie, door verhoogde stimulatie van de hypofyse bij hypothyreo\u00efdie of idiopathisch.", [["Hashimoto", "DISEASE", 115, 124], ["deze groep aandoeningen het meest voor en ontstaat als gevolg van een micro-of macroadenoom van de hypofyse, als bijwerking van bepaalde medicatie, door verhoogde stimulatie van de hypofyse bij hypothyreo\u00efdie", "SPECIES", 172, 380], ["Hypofyseaandoeningen", "TREATMENT", 125, 145]]], ["Met dopaminerge medicatie, zoals bromocriptine en cabergoline, kan de hyperprolactinemie genormaliseerd worden en herstelt de cyclus zich.", [["Met dopaminerge", "CHEMICAL", 0, 15], ["bromocriptine", "CHEMICAL", 33, 46], ["cabergoline", "CHEMICAL", 50, 61], ["bromocriptine", "CHEMICAL", 33, 46], ["Met dopaminerge medicatie", "TREATMENT", 0, 25], ["zoals bromocriptine en cabergoline", "TREATMENT", 27, 61]]], ["Zodra de zwangerschapstest positief is, kan de dopaminerge medicatie worden gestaakt.", [["Zodra", "TREATMENT", 0, 5]]], ["Eigenlijk alleen als er sprake is van een macroadenoom (>10 mm) kan dit consequenties hebben.", [["Eigenlijk alleen als er sprake", "SPECIES", 0, 30]]], ["Gezichtsveldonderzoek is bij deze subgroep regelmatig aangewezen.", [["Gezichtsveldonderzoek", "TREATMENT", 0, 21]]], ["Het bepalen van prolactinespiegels tijdens de zwangerschap is nutteloos omdat dit hormoon in grote hoeveelheden door de placenta wordt vervaardigd.HypofyseaandoeningenUiteraard hoeft na de partus de dopaminerge medicatie niet te worden herstart, tenzij gekozen wordt voor flesvoeding.", [["na", "CHEMICAL", 183, 185]]], ["Actieve remming van de borstvoeding met bromocriptine is gerelateerd met cardiovasculaire problemen.", [["bromocriptine", "CHEMICAL", 40, 53], ["bromocriptine", "CHEMICAL", 40, 53], ["bromocriptine", "SIMPLE_CHEMICAL", 40, 53], ["bromocriptine", "TREATMENT", 40, 53]]], ["Derhalve is het niet aan te raden post partum met dit dopaminergicum te starten.HypofyseaandoeningenDiabetes insipidus ontstaat als onvoldoende of geen vasopressine of antidiuretisch hormoon wordt geproduceerd, of als de nieren onvoldoende op dit hormoon reageren (nefrogene diabetes insipidus).", [["insipidus", "DISEASE", 109, 118], ["nefrogene diabetes insipidus", "DISEASE", 265, 293], ["dopaminergicum te starten", "TREATMENT", 54, 79], ["HypofyseaandoeningenDiabetes insipidus", "PROBLEM", 80, 118], ["antidiuretisch hormoon", "TREATMENT", 168, 190], ["op dit hormoon reageren", "TREATMENT", 240, 263], ["nefrogene diabetes insipidus", "PROBLEM", 265, 293]]], ["Vasopressine wordt geproduceerd door de hypofyseachterkwab.", [["Vasopressine", "TREATMENT", 0, 12]]], ["Bij verstoring van deze productie, wat door een scala aan hersenaandoeningen kan worden veroorzaakt, spreken we over centrale diabetes insipidus.", [["diabetes insipidus", "DISEASE", 126, 144], ["centrale diabetes insipidus", "PROBLEM", 117, 144]]], ["Suppletie van vasopressine vindt plaats met desmopressine, dat veilig nasaal in de zwangerschap kan worden toegepast.", [["desmopressine", "TREATMENT", 44, 57]]], ["Wel heeft het een gering oxytocisch effect.", [["een gering", "OBSERVATION", 14, 24]]], ["Diabetes insipidus openbaart zich ook weleens tijdens de zwangerschap (gestagene diabetes insipidus) en is dan vaak gerelateerd met preeclampsie of acute gele leveratrofie.FysiologieAl vroeg in de zwangerschap neemt de hartfunctie sterk toe.", [["Diabetes insipidus", "DISEASE", 0, 18], ["diabetes insipidus", "DISEASE", 81, 99], ["Diabetes insipidus", "PROBLEM", 0, 18], ["weleens tijdens de zwangerschap (gestagene diabetes insipidus", "PROBLEM", 38, 99], ["acute gele leveratrofie", "PROBLEM", 148, 171], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["gele leveratrofie", "OBSERVATION", 154, 171], ["toe", "ANATOMY", 237, 240]]], ["Dit gebeurt zowel door een stijging van de hartfrequentie als door een stijging van het slagvolume van het hart.", [["Dit gebeurt zowel door een stijging van de hartfrequentie als door een stijging van het slagvolume van het hart", "SPECIES", 0, 111]]], ["De systolische bloeddruk blijft tijdens de hele zwangerschap vrij constant.", [["De systolische bloeddruk blijft tijdens", "PROBLEM", 0, 39], ["blijft tijdens", "OBSERVATION", 25, 39]]], ["De veranderende hemodynamiek in de zwangerschap maakt waarden gemeten met automatische bloeddrukmeters onnauwkeurig.FysiologieHet totale bloedvolume stijgt in de zwangerschap ook fors tot een maximum bij 30 weken.", [["Fysiologie", "CHEMICAL", 116, 126], ["Fysiologie", "TREATMENT", 116, 126]]], ["De stijging van het bloedvolume komt veel meer op het conto van een stijging van het plasmavolume dan van het erytrocytenvolume.", [["De stijging van het bloedvolume komt veel meer op het conto van een stijging van het plasmavolume dan van het erytrocytenvolume", "SPECIES", 0, 127]]], ["Direct na de bevalling begint het bloedvolume na een kortdurende toename weer snel te dalen.FysiologieOngeveer 4% van alle zwangerschappen wordt gecompliceerd door een maternale hartaandoening.", [["na", "CHEMICAL", 7, 9], ["FysiologieOngeveer", "TREATMENT", 92, 110]]], ["Het kan hier handelen om aangeboren of verworven structurele hartaandoeningen of ritmestoornissen.", [["structurele hartaandoeningen", "SPECIES", 49, 77], ["Het kan hier handelen om aangeboren", "SPECIES", 0, 35], ["verworven structurele hartaandoeningen", "SPECIES", 39, 77]]], ["In de westerse wereld is de maternale sterfte als gevolg van cardiale aandoeningen relatief hoog.FysiologieHartfalen wordt geclassificeerd in vier categorie\u00ebn van ernst volgens de New York Heart Association (NYHA)-classificatie (tabel 21.11).", [["Heart", "ANATOMY", 189, 194]]], ["Be\u00ebindiging van de zwangerschap moet worden overwogen tenzij de hemodynamische situatie snel verbetert.FysiologieBestaande ziekten die een hoog risico voor de moeder tijdens de zwangerschap inhouden, zijn: -pulmonale hypertensie ongeacht de oorzaak; -obstructie van de linkerkamerinstroom of -uitstroom, mitralis-of aortaklepstenose en sommige gevallen van cardiomyopathie; -afwijkende aorta zoals bij het syndroom van Marfan en coarctatie; -de aanwezigheid van een klepprothese waar anticoagulantia voor ge\u00efndiceerd zijn; -preconceptioneel ernstig hartfalen (NYHA III of IV); -aangeboren hartafwijkingen die gepaard gaan met cyanose (arteri\u00eble zuurstofsaturatie <80%).", [["pulmonale hypertensie", "DISEASE", 207, 228], ["Marfan en coarctatie", "DISEASE", 419, 439], ["FysiologieBestaande ziekten die een hoog risico voor de moeder tijdens de zwangerschap inhouden, zijn: -pulmonale hypertensie ongeacht de oorzaak; -obstructie van de linkerkamerinstroom of -uitstroom, mitralis-of aortaklepstenose en sommige gevallen van cardiomyopathie; -afwijkende aorta zoals bij het syndroom van Marfan en coarctatie; -de aanwezigheid van een klepprothese waar anticoagulantia voor ge\u00efndiceerd zijn; -preconceptioneel ernstig hartfalen", "SPECIES", 103, 558], ["pulmonale hypertensie", "PROBLEM", 207, 228], ["aortaklepstenose", "PROBLEM", 316, 332], ["van cardiomyopathie", "PROBLEM", 353, 372], ["preconceptioneel ernstig hartfalen", "TREATMENT", 524, 558], ["arteri\u00eble zuurstofsaturatie", "TEST", 635, 662], ["pulmonale", "ANATOMY", 207, 216], ["aorta", "ANATOMY", 386, 391]]], ["Eigenlijk ontstaan pas echte problemen tijdens een zwangerschap als er sprake is van een aangeboren hartafwijking en van cyanose (blauwe verkleuring van de huid door een te lage verzadiging van het bloed met zuurstof).", [["Eigenlijk ontstaan pas echte problemen tijdens een zwangerschap als er sprake is van een aangeboren hartafwijking en van cyanose (blauwe verkleuring van de huid door een te lage verzadiging van het bloed met zuurstof", "SPECIES", 0, 216]]], ["Twee afwijkingen waarbij dit het geval kan zijn, zijn tetralogie van Fallot en syndroom van Eisenmenger.FysiologieBij vrouwen met een aangeboren hartafwijking bestaat een kans van 2,5-20% op een hartafwijking bij de foetus.", [["Eisenmenger", "DISEASE", 92, 103], ["een kans van", "TREATMENT", 167, 179]]], ["Geavanceerd ultrageluidonderzoek is voor deze groep pati\u00ebnten daarom ge\u00efndiceerd.KlepafwijkingenBij jonge vrouwen worden afwijkingen van de hartkleppen meestal veroorzaakt door acuut reuma op de kinderleeftijd.", [["Geavanceerd ultrageluidonderzoek", "TREATMENT", 0, 32], ["Klepafwijkingen", "TREATMENT", 81, 96]]], ["De meest voorkomende klepafwijking door acuut reuma is een mitralisstenose.", [["een mitralisstenose", "OBSERVATION", 55, 74]]], ["Mitralis-en aortastenose zijn de afwijkingen die tijdens de zwangerschap de meeste problemen kunnen geven.", [["Mitralis", "TEST", 0, 8]]], ["Insuffici\u00ebntie van deze kleppen leidt niet vaak tot cardiale problemen in de zwangerschap.", [["van deze kleppen leidt", "TREATMENT", 15, 37]]], ["Mitralisklepprolaps verbetert vaak juist tijdens de zwangerschap door de toegenomen hemodynamische belasting.", [["Mitralisklepprolaps", "TEST", 0, 19]]], ["Dit geldt dan met name ook voor de eerste 48 uur post partum, waarin de meeste hemodynamische veranderingen optreden.KlepafwijkingenZelden is het nodig tijdens de zwangerschap de klepafwijkingen te behandelen.", [["KlepafwijkingenZelden", "TREATMENT", 117, 138]]], ["Percutane ballonvalvotomie is een veilige procedure tijdens de zwangerschap.KlepafwijkingenAangedane hartkleppen kunnen worden vervangen door mechanische klepprothesen of bioprothesen (afkomstig van mensen of varkens).", [["Percutane ballonvalvotomie", "TREATMENT", 0, 26], ["een veilige procedure", "TREATMENT", 30, 51], ["Klepafwijkingen", "TREATMENT", 76, 91], ["bioprothesen", "TREATMENT", 171, 183]]], ["Bij de laatste soort kleppen is het meestal niet nodig antistolling toe te passen.", [["Bij de laatste soort kleppen", "TREATMENT", 0, 28]]], ["Als voor de zwangerschap profylactische antistolling werd toegepast, moet bij mechanische klepprothesen in de loop van de zwangerschap en gedurende zes weken in het kraambed vanwege het verhoogde risico op kleptrombose therapeutische antistolling worden toegepast.", [["zes", "TREATMENT", 148, 151]]], ["Rondom een bevalling moeten goede afspraken worden gemaakt over de antistolling; doorgaans wordt de laatste dosis voor de partus achterwege gelaten en wordt de antistolling na de partus hervat.Ischemische hartziektenDe incidentie van ischemische hartziekten in de zwangerschap is laag.", [["na", "CHEMICAL", 173, 175]]], ["De incidentie lijkt te stijgen met het stijgen van de gemiddelde leeftijd van de zwangere.Ischemische hartziektenAls angineuze klachten of een myocardinfarct vroeg in de zwangerschap optreden, kan overwogen worden de zwangerschap af te breken.", [["Ischemische", "TEST", 90, 101]]], ["Als ischemische klachten in het derde trimester ontstaan, kunnen problemen ontstaan rondom de partus.", [["Als ischemische klachten", "PROBLEM", 0, 24]]], ["De partus wordt bij voorkeur uitgesteld om het myocardium gelegenheid te geven te herstellen.", [["De partus wordt bij voorkeur uitgesteld om het myocardium gelegenheid te geven te herstellen", "SPECIES", 0, 92]]], ["De volumeveranderingen rondom de partus kunnen aanleiding geven tot nieuwe ischemie en decompensatio cordis.", [["decompensatio cordis", "DISEASE", 87, 107], ["en decompensatio cordis", "TREATMENT", 84, 107], ["cordis", "ANATOMY", 101, 107]]], ["De stress van een bevalling zou dit ook kunnen geven, zodat sommigen suggereren dat het beter is om een primaire sectio caesarea te verrichten omdat dit minder hemodynamische schommelingen zou geven.", [["zodat", "TREATMENT", 54, 59]]], ["Een goed gecontroleerde vaginale baring onder epidurale anesthesie is een andere goede optie.Ischemische hartziektenHet gebruik van oxytocine lijkt veilig.", [["Ischemische hartziekten", "SPECIES", 93, 116]]], ["Ermetrinepreparaten en zeker prostaglandinen hebben direct effect op de coronairvaten en zijn gecontra-indiceerd bij cardiale ischemie.RitmestoornissenDoor de fysiologische versnelling van het hartritme in de zwangerschap zullen hartkloppingen, palpitaties en duizeligheid vaker voorkomen.", [["Ermetrinepreparaten en zeker prostaglandinen", "TREATMENT", 0, 44], ["coronairvaten en zijn gecontra", "TREATMENT", 72, 102], ["cardiale ischemie", "OBSERVATION", 117, 134]]], ["Als medicament van keuze kan het beste worden gekozen voor een middel waarmee ervaring in de zwangerschap bestaat.", [["Als medicament", "TREATMENT", 0, 14]]], ["Dergelijke middelen zijn digoxine en b\u00e8tablokkers.", [["Dergelijke middelen zijn digoxine en b\u00e8tablokkers", "TREATMENT", 0, 49]]], ["Cardioversie kan veilig in de zwangerschap worden toegepast bij falen van medicamenteuze therapie.Syndroom van MarfanHet syndroom van Marfan is het gevolg van een autosomaal dominante genmutatie waardoor het fibrilline, een eiwit dat benodigd is voor de bindweefselsynthese, afwijkend is.", [["Marfan", "DISEASE", 111, 117], ["Marfan", "DISEASE", 134, 140]]], ["Verder zijn pati\u00ebnten met het syndroom van Marfan opvallend lang en slank.", [["Marfan", "DISEASE", 43, 49]]], ["Hun gewrichten vertonen een grotere beweeglijkheid.Syndroom van MarfanDoor deze aandoening kunnen op cardiovasculair gebied klepafwijkingen zoals aorta-en mitralisklepinsuffici\u00ebntie, maar vooral dilatatie van de (thoracale) aorta optreden.", [["Hun gewrichten vertonen een grotere beweeglijkheid", "SPECIES", 0, 50], ["maar vooral dilatatie van de (thoracale) aorta optreden", "TREATMENT", 183, 238], ["aorta", "ANATOMY", 224, 229]]], ["Tijdens de zwangerschap is de kans op een acute aortadissectie of -ruptuur toegenomen.", [["acute", "OBSERVATION_MODIFIER", 42, 47], ["aortadissectie", "OBSERVATION", 48, 62]]], ["Bij een diameter van de aortabasis van <4 cm bestaat er een kans van 1% op een dergelijke complicatie, mits er geen sprake is van een klepinsuffici\u00ebntie.", [["Bij een diameter van de aortabasis van", "TREATMENT", 0, 38]]], ["Bij een diameter van >4 cm stijgt het risico naar 10%.", [["Bij een diameter van", "TREATMENT", 0, 20], ["diameter", "OBSERVATION_MODIFIER", 8, 16]]], ["Bij voorkeur voor de zwangerschap wordt een aneurysma van de aorta vervangen door een vaatprothese.Syndroom van MarfanB\u00e8tablokkers moeten in de zwangerschap altijd worden gecontinueerd.", [["een vaatprothese", "TREATMENT", 82, 98], ["aorta", "ANATOMY", 61, 66]]], ["Epidurale anesthesie en een primaire vaginale kunstverlossing verminderen de cardiovasculaire belasting door de partus.", [["Epidurale anesthesie", "TREATMENT", 0, 20]]], ["Een ruptuur of dissectie van de aorta kan nog tot enkele weken na de partus optreden.Gedilateerde cardiomyopathieBij deze erfelijke vorm van cardiomyopathie is door de slechte hartspierfunctie het hart verwijd geraakt.", [["aorta", "ANATOMY", 32, 37]]], ["Bij zwangerschap is er meer kans op zwangerschapscomplicaties en peripartum cardiomyopathie (zie verder).Hypertrofische cardiomyopathieDeze eveneens frequent erfelijke vorm van cardiomyopathie is ook vaak asymptomatisch.", [["peripartum cardiomyopathie", "DISEASE", 65, 91], ["peripartum cardiomyopathie", "PROBLEM", 65, 91], ["Hypertrofische cardiomyopathieDeze", "PROBLEM", 105, 139], ["vaak asymptomatisch", "PROBLEM", 200, 219]]], ["De prognose voor een zwangerschap is gunstig, zowel wat betreft de cardiale status als voor de zwangerschapsuitkomst.Peripartum cardiomyopathieHierbij is er sprake van een zeldzaam (1 op 5000 zwangerschappen) onverklaard disfunctioneren van de linkerhartkamer, die kan beginnen in de laatste maand van de zwangerschap tot wel zes maanden post partum.", [["Peripartum cardiomyopathieHierbij", "PROBLEM", 117, 150], ["van een zeldzaam", "TREATMENT", 164, 180]]], ["De symptomen zijn decompensatio cordis, hartritmestoornissen en embolie\u00ebn.", [["De symptomen zijn decompensatio cordis", "TREATMENT", 0, 38], ["hartritmestoornissen en embolie\u00ebn", "TREATMENT", 40, 73], ["cordis", "ANATOMY", 32, 38]]], ["Bij echocardiografisch onderzoek is er sprake van een vergroot hart en met name verminderde linkerkamerfunctie.", [["Bij echocardiografisch onderzoek", "TEST", 0, 32]]], ["Als oorzaak wordt een viraal agens of auto-immuunfenomeen gesuggereerd.EndocarditisprofylaxeEndocarditisprofylaxe is een preventieve maatregel die wordt getroffen bij pati\u00ebnten die door een aangeboren of verworven hartaandoening een verhoogde kans op endocarditis hebben na een diagnostische of therapeutische ingreep waarbij een bacteri\u00ebmie kan ontstaan.", [["EndocarditisprofylaxeEndocarditisprofylaxe", "CHEMICAL", 71, 113], ["EndocarditisprofylaxeEndocarditisprofylaxe", "SIMPLE_CHEMICAL", 71, 113], ["EndocarditisprofylaxeEndocarditisprofylaxe", "TREATMENT", 71, 113], ["verworven hartaandoening", "TREATMENT", 204, 228], ["endocarditis", "PROBLEM", 251, 263], ["therapeutische", "TREATMENT", 295, 309]]], ["Pati\u00ebnten die hiervoor in aanmerking komen, zijn onder meer alle pati\u00ebnten met een klepafwijking.EndocarditisprofylaxeIn principe is bij een ongecompliceerde bevalling endocarditisprofylaxe niet noodzakelijk.", [["EndocarditisprofylaxeIn principe", "TREATMENT", 97, 129]]], ["Het schema dat door de Nederlandse Hartstichting wordt geadviseerd bestaat uit amoxicilline 2 g i.v. plus gentamicine 3 mg/kg i.m. of i.v.", [["amoxicilline", "CHEMICAL", 79, 91], ["gentamicine", "CHEMICAL", 106, 117], ["gentamicine", "CHEMICAL", 106, 117], ["amoxicilline", "TREATMENT", 79, 91], ["gentamicine", "TREATMENT", 106, 117]]], ["Bij penicillineallergie wordt vancomycine gegeven in plaats van amoxicilline.EndocarditisprofylaxeMocht de endocarditisprofylaxe niet zijn gegeven, kan het nuttig zijn deze na een gecompliceerde bevalling alsnog achteraf toe te dienen.Reanimatie van de zwangereEen acute hartstilstand komt ongeveer bij 1 op elke 30.000 zwangerschappen voor.", [["vancomycine", "CHEMICAL", 30, 41], ["amoxicilline", "CHEMICAL", 64, 76], ["Bij penicillineallergie wordt vancomycine", "TREATMENT", 0, 41], ["van amoxicilline", "TREATMENT", 60, 76], ["EndocarditisprofylaxeMocht de endocarditisprofylaxe niet zijn gegeven", "TREATMENT", 77, 146], ["een gecompliceerde", "TREATMENT", 176, 194], ["acute", "OBSERVATION_MODIFIER", 265, 270]]], ["Hoewel het een zeer zeldzame complicatie is, vereist de reanimatie op enkele belangrijke punten een andere aanpak dan bij de niet-zwangere pati\u00ebnt.Reanimatie van de zwangereDe kans op slagen van de reanimatie hangt af van de onderliggende oorzaak van de hartstilstand en de snelheid waarmee de reanimatie is opgestart.", [["De kans op slagen van de reanimatie hangt af van de onderliggende oorzaak van de hartstilstand en de snelheid waarmee de reanimatie", "SPECIES", 173, 304]]], ["De oorzaken zijn in volgorde van frequentie van voorkomen: trombo-embolische processen (longembolie), hypertensieve ziekten tijdens de zwangerschap, sepsis, vruchtwaterembolie, verbloeding, traumata, complicaties van anesthesiologische handelingen en medicatiebijwerkingen en allergie\u00ebn, congenitale of verworven hartafwijkingen.Fysiologische veranderingenDe basistechniek van de beademing en de hartmassage is in de zwangerschap dezelfde als buiten de zwangerschap.", [["sepsis", "DISEASE", 149, 155], ["sepsis", "PROBLEM", 149, 155], ["vruchtwaterembolie", "PROBLEM", 157, 175], ["verworven hartafwijkingen", "TREATMENT", 303, 328], ["sepsis", "OBSERVATION", 149, 155]]], ["De cardiovasculaire en pulmonale fysiologische veranderingen in de zwangerschap hebben echter een belangrijke invloed op het effect van de reanimatie.", [["De cardiovasculaire en pulmonale fysiologische veranderingen", "TREATMENT", 0, 60]]], ["Al deze fysiologische veranderingen werken nadelig en vereisen een zo optimaal mogelijke techniek van de reanimatie.Fysiologische veranderingenDefibrillatie dient ook bij de reanimatie van de zwangere op de gebruikelijke manier te worden toegepast.", [["Fysiologische veranderingenDefibrillatie dient ook bij de reanimatie van de zwangere op de gebruikelijke manier te worden toegepast", "SPECIES", 116, 247], ["Al deze fysiologische veranderingen", "TREATMENT", 0, 35]]], ["Hoe korter deze tijd, des te meer kans op herstel van het hartritme.Fysiologische veranderingenGebruik van medicatie bij de reanimatie is hetzelfde als in de protocollen bij de niet-zwangere pati\u00ebnt.Aanpassingen van de techniekDe grootte van de uterus in de tweede helft van de zwangerschap zorgt voor compressie van de vena cava.", [["vena cava", "ANATOMY", 320, 329], ["uterus", "ORGAN", 245, 251], ["vena cava", "MULTI-TISSUE_STRUCTURE", 320, 329], ["Hoe korter deze tijd, des te meer kans op herstel van het hartritme", "SPECIES", 0, 67], ["Aanpassingen van de techniek", "SPECIES", 199, 227], ["uterus", "ANATOMY", 245, 251], ["vena cava", "ANATOMY", 320, 329]]], ["Hierdoor vloeit er tijdens hartmassage in rugligging onvoldoende veneus bloed naar het hart terug, waardoor er te weinig hartminuutvolume wordt gegenereerd.", [["Hierdoor", "TREATMENT", 0, 8], ["tijdens hartmassage", "OBSERVATION", 19, 38]]], ["Er zijn diverse methoden om dit probleem (deels) te verhelpen.", [["Er zijn", "CHEMICAL", 0, 7]]], ["Deze Cardiff resuscitation wedge is niet commercieel verkrijgbaar, maar eenvoudig te maken ( fig. 21.3) .", [["Cardiff resuscitation wedge", "TREATMENT", 5, 32], ["verkrijgbaar", "PROBLEM", 53, 65], ["wedge", "OBSERVATION_MODIFIER", 27, 32]]], ["Bij gebrek aan een dergelijk hulpmiddel kan de uterus door helpers zo veel mogelijk naar links worden gehouden.", [["uterus", "ORGAN", 47, 53], ["uterus", "ANATOMY", 47, 53]]], ["Ook kan een kussen onder de rechterheup van de zwangere worden gelegd of kan de rug van de zwangere tegen de bovenbenen van een geknielde helper worden gedraaid.Aanpassingen van de techniekBij een niet-zwangere pati\u00ebnt met een ademstilstand kan de beademing langdurig door middel van mond-op-mond-of masker-en-ballonbeademing worden volgehouden.", [["Aanpassingen van de techniek", "SPECIES", 161, 189], ["Bij een niet-zwangere pati\u00ebnt met een ademstilstand kan de beademing langdurig door middel van mond-op-mond-of masker-en-ballonbeademing worden volgehouden", "SPECIES", 189, 344]]], ["Daarom is er bij een reanimatie de voorkeur voor een endotracheale intubatie om de ademweg zeker te stellen en aspiratie te kunnen voorkomen.Aanpassingen van de techniekBij langdurige reanimaties, bijvoorbeeld bij pati\u00ebnten met pulseless electrical activity door anafylaxie, kan mechanische apparatuur voor de hartmassage worden ingezet.", [["Aanpassingen van de techniek", "SPECIES", 141, 169]]], ["Deze regel is gebaseerd op het idee dat de reanimatie niet effectief is door de compressie door de uterus van de grote vaten in de buikholte waardoor er onvoldoende bloed terugstroomt naar het hart tijdens de reanimatie.", [["uterus", "ANATOMY", 99, 105]]], ["De vierminutenregel behelst de afspraak dat na vier minuten vergeefse reanimatie ter plekke een sectio caesarea wordt verricht, zodat na geboorte van het kind na ongeveer vijf minuten de reanimatie effectiever kan verlopen.", [["na", "TEST", 44, 46], ["vier", "TEST", 47, 51], ["minuten", "TEST", 52, 59]]], ["Een sectio caesarea peri mortem wordt geadviseerd bij een zwangerschapsduur vanaf ongeveer 24 weken.Sectio caesarea peri mortemHet primaire doel van de vierminutenregel is het effectiever maken van de reanimatie en niet het leven redden van het kind.", [["Sectio caesarea peri mortem", "SPECIES", 100, 127]]], ["Naarmate de sectio caesarea later wordt uitgevoerd, zal er uiteraard meer neurologische schade ontstaan.Sectio caesarea peri mortemUit een groot literatuuroverzicht over deze ingreep blijkt dat in meer dan de helft van de gevallen de moederlijke circulatie na de ingreep verbetert en soms zelfs spontaan weer op gang komt.Sectio caesarea peri mortemDoordat de circulatie is weggevallen, zal een sectio caesarea peri mortem niet gepaard gaan met enig bloedverlies.", [["na", "CHEMICAL", 257, 259], ["Sectio caesarea peri mortem", "SPECIES", 104, 131], ["Sectio caesarea peri mortem", "SPECIES", 322, 349], ["zal een sectio", "TREATMENT", 387, 401]]], ["De uterus kan eventueel ook in de mediaanlijn worden geopend.", [["uterus", "ANATOMY", 3, 9]]], ["De placentaverwijdering en het hechten van de wond kan na stabilisatie van de pati\u00ebnte op de operatiekamer plaatsvinden.Sectio caesarea peri mortemEen hartstilstand bij een zwangere zal het vaakst voorkomen in het ziekenhuis op de afdeling verloskunde.", [["De placentaverwijdering en het hechten van de wond kan na stabilisatie van de pati\u00ebnte op de operatiekamer plaatsvinden", "SPECIES", 0, 119], ["Sectio caesarea peri mortemEen hartstilstand bij een zwangere zal het vaakst voorkomen in het ziekenhuis op de afdeling verloskunde", "SPECIES", 120, 251], ["Sectio", "TEST", 120, 126]]], ["Hierdoor ontstaat een hyperventilatie, die ervoor zorgt dat relatief meer koolzuur wordt uitgeademd dan buiten de zwangerschap.", [["een hyperventilatie", "OBSERVATION", 18, 37]]], ["Verder speelt in de tweede helft van de zwangerschap de hoogstand van het diafragma ook een rol en kan de zwangere soms niet goed doorademen.FysiologieDoor de gestegen affiniteit van het foetaal hemoglobine voor zuurstof kan de foetus milde veranderingen in de maternale arteri\u00eble zuurstofspanning goed verdragen.", [["tweede helft van de zwangerschap de hoogstand van het diafragma ook een rol en kan de zwangere soms niet goed doorademen", "SPECIES", 20, 140]]], ["Echter, bij een vermindering van de zuurstofsaturatie onder de 90%, overeenkomend met een arteri\u00eble zuurstofspanning van minder dan 65 mmHg, zal de zuurstofvoorziening naar de foetus in gevaar komen.Cystische fibrose (taaislijmziekte)Van de aangeboren longafwijkingen is taaislijmziekte of cystische fibrose (CF) een steeds vaker voorkomende longaandoening bij jonge vrouwen.", [["cystische fibrose", "ORGANISM", 290, 307], ["Cystische fibrose (taaislijmziekte)Van de aangeboren longafwijkingen", "TREATMENT", 199, 267], ["cystische fibrose", "TREATMENT", 290, 307], ["een steeds", "TREATMENT", 313, 323]]], ["Uiteindelijk leidt dit tot beperking van de longfunctie en uitval van de pancreas.", [["pancreas", "ANATOMY", 73, 81], ["pancreas", "ORGAN", 73, 81], ["pancreas", "ANATOMY", 73, 81]]], ["Naast longproblemen kunnen hierdoor ook abdominale sequelae ontstaan: diabetes mellitus en biliaire cirrose, gecompliceerd door hepatosplenomegalie en oesofagusvarices.Cystische fibrose (taaislijmziekte)Door de sterk gestegen levensverwachting van deze pati\u00ebnten stijgt het aantal vrouwen met deze aandoening dat daadwerkelijk zwanger wil worden, de laatste jaren sterk.", [["diabetes mellitus", "DISEASE", 70, 87], ["kunnen", "SPECIES", 20, 26], ["ook abdominale", "SPECIES", 36, 50], ["Naast", "TREATMENT", 0, 5], ["abdominale sequelae", "PROBLEM", 40, 59], ["diabetes mellitus", "PROBLEM", 70, 87], ["biliaire cirrose", "TREATMENT", 91, 107], ["hepatosplenomegalie en oesofagusvarices", "PROBLEM", 128, 167], ["Cystische fibrose", "TREATMENT", 168, 185], ["diabetes", "OBSERVATION", 70, 78]]], ["Vrouwen met CF hebben vaak last van vruchtbaarheidsstoornissen, die het nodig maken vruchtbaarheidsbevorderende technieken toe te passen.Cystische fibrose (taaislijmziekte)Preconceptionele advisering en screening op dragerschap voor CF bij de partner dient in principe bij elke CF-pati\u00ebnt met kinderwens te worden verricht.", [["Cystische fibrose (taaislijmziekte)Preconceptionele advisering en screening op dragerschap voor CF bij de partner dient in principe bij elke CF-pati\u00ebnt met kinderwens te worden verricht", "SPECIES", 137, 322], ["Cystische fibrose", "TREATMENT", 137, 154]]], ["Bij een verminderde longfunctie (PEFR -expiratoire piekflow -of FEV 1 -geforceerd expiratoir volume in 1 seconde -<50% van de voorspelde waarde), kolonisatie met de bacterie Burkholderia cepacia en een slechte voedingstoestand (BMI<19) bestaat meer kans op een slechte zwangerschapsuitkomst.", [["PEFR", "TEST", 33, 37], ["FEV", "TEST", 64, 67], ["volume", "TEST", 93, 99], ["kolonisatie", "TREATMENT", 146, 157], ["Burkholderia cepacia", "PROBLEM", 174, 194]]], ["Bij pulmonale hypertensie en abdominale sequelae is bovendien ook nog de kans op maternale mortaliteit gestegen.Cystische fibrose (taaislijmziekte)Eenmaal zwanger dient behandeling van de CFpati\u00ebnt multidisciplinair plaats te vinden.", [["pulmonale hypertensie", "DISEASE", 4, 25], ["Bij pulmonale hypertensie en abdominale sequelae", "PROBLEM", 0, 48], ["Cystische fibrose (taaislijmziekte)", "TREATMENT", 112, 147], ["pulmonale", "OBSERVATION", 4, 13]]], ["De zwangerschap heeft in principe geen nadelige invloed op het natuurlijke beloop van CF.Cystische fibrose (taaislijmziekte)In het kraambed kan borstvoeding worden gegeven, tenzij er sprake is van een slechte voedingstoestand.", [["Cystische fibrose (taaislijmziekte)", "TREATMENT", 89, 124]]], ["Het vetgehalte van moedermelk van CF-pati\u00ebnten is iets verlaagd, maar de melk bevat voldoende om de pasgeborene te kunnen voeden.AstmaHoesten, dyspneu, piepen en sputumproductie zijn de belangrijkste klachten bij astma en COPD (chronisch obstructieve longziekten).", [["COPD", "DISEASE", 222, 226], ["AstmaHoesten", "PROBLEM", 129, 141], ["dyspneu", "PROBLEM", 143, 150], ["piepen", "PROBLEM", 152, 158], ["COPD", "PROBLEM", 222, 226], ["COPD", "OBSERVATION", 222, 226]]], ["De oude term CARA (chronische aspecifieke respiratoire aandoening) omvatte zowel het ziektebeeld astma als COPD.", [["COPD", "DISEASE", 107, 111], ["De oude term CARA (chronische aspecifieke respiratoire aandoening", "TREATMENT", 0, 65], ["als COPD", "PROBLEM", 103, 111], ["COPD", "OBSERVATION", 107, 111]]], ["Bij contact met prikkelende stoffen zoals parfum, rook, mist, kou of allergische prikkels (huisstofmijt), bij een verkoudheid of na een zware inspanning kan een astma-aanval optreden.", [["na", "CHEMICAL", 129, 131], ["na een zware", "TREATMENT", 129, 141]]], ["Een astma-aanval wordt veroorzaakt door reversibele spasmen en verstopping van de bronchi door gestegen mucussecretie.", [["Een astma-aanval wordt veroorzaakt door reversibele spasmen en verstopping van de bronchi door gestegen mucussecretie", "SPECIES", 0, 117], ["bronchi", "ANATOMY", 82, 89]]], ["Bij COPD is de obstructie vrijwel continu in ongeveer dezelfde mate aanwezig.", [["COPD", "DISEASE", 4, 8], ["Bij COPD", "PROBLEM", 0, 8], ["COPD", "OBSERVATION", 4, 8]]], ["COPD is een verzamelnaam voor de longaandoeningen bronchitis en longemfyseem, wordt merendeels door roken veroorzaakt en komt vrijwel alleen boven het 40e levensjaar voor.", [["COPD", "DISEASE", 0, 4], ["bronchitis", "DISEASE", 50, 60], ["COPD", "PROBLEM", 0, 4]]], ["COPD zal onder zwangeren dus nauwelijks voorkomen.AstmaAstma is de meest voorkomende, potentieel ernstige, chronische medische conditie die de zwangerschap kan compliceren.", [["COPD", "DISEASE", 0, 4], ["COPD", "PROBLEM", 0, 4]]], ["Ernstige en niet goed gereguleerde astma daarentegen is mogelijk gerelateerd met toegenomen kans op vroeggeboorte, pre-eclampsie, groeiretardatie en maternale morbiditeit en mortaliteit.AstmaOptimale behandeling van astma tijdens de zwangerschap is adequate oxygenatie van de foetus door preventie van hypoxie bij de moeder.", [["AstmaOptimale", "TREATMENT", 186, 199]]], ["Van nieuwere medicatie zoals de antileukotri\u00ebnen (ontstekingsremmers) lijkt het gebruik tijdens de zwangerschap veilig, maar wordt voorzichtigheid aangeraden.", [["Van nieuwere medicatie zoals", "TREATMENT", 0, 28]]], ["De behandeling van acute astma-aanvallen is tijdens de zwangerschap niet anders dan daarbuiten maar dient agressiever te worden behandeld omdat al een geringe daling van de maternale arteri\u00eble zuurstofspanning kan leiden tot hypoxie bij de foetus.AstmaAlleen astma-en COPD-pati\u00ebnten met klachtenvrije intervallen, al dan niet onder het gebruik van medicatie, kunnen in de eerste lijn begeleid worden tijdens de zwangerschap.AstmaBij voorkeur wordt de medicatie preconceptioneel optimaal ingesteld.", [["COPD", "PROBLEM", 268, 272], ["COPD", "OBSERVATION", 268, 272]]], ["Vrouwen die in het jaar voor de partus gedurende minimaal twee weken systemisch corticostero\u00efden gebruikten, dienen tijdens de baring en de eerste 24 uur post partum een zogenoemd cortison-stressschema te gebruiken (bijv. driemaal daags 100 mg hydrocortison parenteraal).", [["hydrocortison", "CHEMICAL", 244, 257], ["hydrocortison", "CHEMICAL", 244, 257], ["cortison", "TEST", 180, 188], ["driemaal daags", "TREATMENT", 222, 236]]], ["Het baringsinducerende middel prostaglandine E 2 (Prostin \u00ae ) is een bronchodilatator en kan veilig worden gebruikt.", [["Prostin \u00ae", "CHEMICAL", 50, 59], ["Prostin \u00ae", "SIMPLE_CHEMICAL", 50, 59], ["Het baringsinducerende middel prostaglandine E 2 (Prostin \u00ae )", "TREATMENT", 0, 61], ["een bronchodilatator", "TREATMENT", 65, 85]]], ["Sulproston (Nalador \u00ae ) zou theoretisch kunnen leiden tot een acute astmatische aanval.", [["Sulproston", "CHEMICAL", 0, 10], ["Sulproston", "CHEMICAL", 0, 10], ["Nalador", "CHEMICAL", 12, 19], ["Sulproston", "SIMPLE_CHEMICAL", 0, 10], ["Nalador \u00ae", "SIMPLE_CHEMICAL", 12, 21], ["Sulproston (Nalador \u00ae ) zou theoretisch kunnen leiden", "TREATMENT", 0, 53], ["een acute astmatische aanval", "TREATMENT", 58, 86], ["acute", "OBSERVATION_MODIFIER", 62, 67]]], ["Alle gebruikelijke medicatie kan tijdens borstvoeding gewoon worden gebruikt en is veilig voor de baby.PneumonieLongontsteking, een infectie van de distale bronchioli en de alveoli, komt net zo vaak voor in de zwangerschap als daarbuiten en evenveel tijdens alle trimesters.", [["PneumonieLongontsteking", "PROBLEM", 103, 126], ["alveoli", "ANATOMY", 173, 180]]], ["Er is vaak sprake van comorbiditeit, zoals astma, anemie, drugsgebruik of hiv-infectie.", [["hiv-infectie", "PROBLEM", 74, 86]]], ["De meest voorkomende vorm van pneumonie is de community-acquired pneumonie, die het vaakst wordt veroorzaakt door de Streptococcus pneumoniae.", [["Streptococcus pneumoniae", "DISEASE", 117, 141], ["Streptococcus pneumoniae", "ORGANISM", 117, 141], ["Streptococcus pneumoniae", "SPECIES", 117, 141], ["Streptococcus pneumoniae", "SPECIES", 117, 141], ["acquired pneumonie", "PROBLEM", 56, 74], ["Streptococcus pneumoniae", "PROBLEM", 117, 141], ["Streptococcus pneumoniae", "OBSERVATION", 117, 141]]], ["Onder een community-acquired pneumonie wordt een pneumonie verstaan die buiten het ziekenhuis (thuis) of meer dan drie dagen na opname in het ziekenhuis ontstaat.", [["na", "CHEMICAL", 125, 127]]], ["Van de virale longinfecties komt die met influenza en varicella het meest voor.", [["varicella", "SPECIES", 54, 63], ["influenza", "PROBLEM", 41, 50]]], ["In tegenstelling tot bacteri\u00eble pneumonie verloopt een virale pneumonie tijdens de zwangerschap ernstiger.PneumoniePneumonie leidt vaker tot het optreden van vroeggeboorte en foetale groeiretardatie.", [["tegenstelling tot bacteri\u00eble pneumonie", "TREATMENT", 3, 41], ["verloopt een virale pneumonie", "TREATMENT", 42, 71], ["PneumoniePneumonie", "TREATMENT", 106, 124]]], ["Indicaties voor opname op de intensive care en mechanische beademing zijn inadequate oxygenatie (zuurstofsaturatie <85%, of arteri\u00eble zuurstofspanning <60 mmHg), inadequate ventilatie (arteri\u00eble koolzuurspanning >50 mmHg), bescherming van de luchtweg, sepsis met de noodzaak tot invasieve hemodynamische bewaking of persisterende metabole acidose.", [["sepsis", "DISEASE", 252, 258], ["arteri\u00eble zuurstofspanning", "TREATMENT", 124, 150], ["inadequate ventilatie (arteri\u00eble koolzuurspanning", "TREATMENT", 162, 211], ["sepsis", "PROBLEM", 252, 258], ["persisterende metabole acidose", "PROBLEM", 316, 346], ["sepsis", "OBSERVATION", 252, 258]]], ["Dit is echter niet onomstotelijk bewezen.PneumonieDe diagnose pneumonie kan in 98% van de gevallen met een thoraxfoto worden gesteld.", [["pneumonie", "DISEASE", 62, 71]]], ["Thoraxfoto's zijn veilig in de zwangerschap toe te passen en zorgen voor een minimale stralingsbelasting van de foetus.PneumonieBehandeling bestaat uit het toedienen van antibiotica en/of antivirale medicatie, foetale bewaking en handhaven van de normale respiratoire functie.", [["Thoraxfoto", "TREATMENT", 0, 10], ["PneumonieBehandeling", "PROBLEM", 119, 139], ["antivirale medicatie", "TREATMENT", 188, 208]]], ["De meeste vormen van antibiotica zijn veilig in de zwangerschap toe te passen.", [["De meeste vormen van antibiotica zijn veilig", "TREATMENT", 0, 44]]], ["Omdat de nierfunctie en met name de glomerulaire filtratiesnelheid tijdens de zwangerschap sterk verandert, moet de dosering van sommige soorten antibiotica wel worden aangepast.PneumoniePreventie van pneumonie is effectief bij hoogrisicogroepen.", [["PneumoniePreventie van pneumonie", "TREATMENT", 178, 210]]], ["Vaccinatie van zwangeren met het influenzavaccin kan tijdens het winterseizoen na het eerste trimester worden overwogen.", [["na", "CHEMICAL", 79, 81], ["Vaccinatie van zwangeren", "TREATMENT", 0, 24]]], ["Influenzavaccinatie vermindert het aantal influenzagevallen met 70-90%.", [["Influenzavaccinatie", "TEST", 0, 19]]], ["Verder is vaccinatie mogelijk tegen pneumokokken en varicella.", [["varicella", "DISEASE", 52, 61], ["varicella", "SPECIES", 52, 61], ["varicella", "OBSERVATION", 52, 61]]], ["Het varicellavaccin kan niet Classificatie van astmaernst v\u00f3\u00f3r de behandeling, aangepast op basis van de GINA (Global Initiative for Asthma)-aanbevelingen. tijdens de zwangerschap of in de eerste zes maanden post partum worden toegediend en is in Nederland niet geregistreerd.", [["Asthma)-aanbevelingen", "DISEASE", 133, 154], ["Asthma", "PROBLEM", 133, 139], ["aanbevelingen", "TREATMENT", 141, 154]]], ["Het pneumokokkenvaccin wordt geadviseerd bij vrouwen met onderliggende ziekten zoals diabetes, status na splenectomie, sikkelcelziekte, chronische cardiopulmonale ziekten of weerstandsverminderende ziekten.", [["diabetes", "DISEASE", 85, 93], ["na", "CHEMICAL", 102, 104], ["diabetes", "PROBLEM", 85, 93], ["status na splenectomie", "PROBLEM", 95, 117], ["sikkelcelziekte", "PROBLEM", 119, 134]]], ["Na aspiratie van zure maaginhoud ontstaat binnen enkele uren een chemische pneumonie, waarna secundair een bacteri\u00eble infectie kan ontstaan.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na", "TEST", 0, 2], ["een chemische pneumonie", "TREATMENT", 61, 84], ["waarna", "TREATMENT", 86, 92]]], ["Tijdens de zwangerschap kan het syndroom vooral ontstaan na toediening van algehele anesthesie.", [["na", "CHEMICAL", 57, 59]]], ["Mogelijk speelt ook de toediening van middelen die de maagzuursecretie bij een operatieve ingreep be\u00efnvloeden, hierbij een rol.Sarco\u00efdoseSarco\u00efdose of de ziekte van Besnier-Boeck-Schaumann wordt gekenmerkt door het optreden van niet-verkazende granulomen in verschillende organen.", [["ziekte van Besnier-Boeck-Schaumann wordt gekenmerkt door het optreden van niet-verkazende granulomen", "SPECIES", 154, 254]]], ["Bij pati\u00ebnten met een milde vorm van de ziekte zal een zwangerschap geen problemen opleveren.", [["een milde vorm van de ziekte zal een zwangerschap", "TREATMENT", 18, 67]]], ["Alleen bij pati\u00ebnten met ernstige longfunctiebeperking en pulmonale hypertensie kan zwangerschap leiden tot maternale mortaliteit.", [["pulmonale", "DISEASE", 58, 67], ["pulmonale", "ORGAN", 58, 67], ["tot maternale", "SPECIES", 104, 117]]], ["Het is raadzaam het serumcalcium regelmatig te controleren.Ernstige obstructieve longziekteErnstig obstructief longlijden kan bijvoorbeeld ontstaan door aangeboren afwijkingen zoals kyfoscoliose.", [["Ernstige obstructieve longziekte", "SPECIES", 59, 91]]], ["Pati\u00ebnten met een ernstig obstructief longbeeld kunnen een zwangerschap over het algemeen beter doorstaan dan pati\u00ebnten met een ernstige cardiale aandoening.", [["een ernstig obstructief", "TREATMENT", 14, 37]]], ["Hoewel de normale extra aanpassing in de zwangerschap van zowel de longen als het hart ongeveer 40% bedraagt, hebben de longen toch nog meer relatieve reservecapaciteit dan het hart.Ernstige obstructieve longziekteWanneer de slechte longfunctie gepaard gaat met pulmonale hypertensie, maakt dit de prognose slechter.Ernstige obstructieve longziekteVanwege een verslechterende longfunctie door de mechanische veranderingen van de groeiende uterus kan het soms nodig zijn de baring eerder te induceren, soms zelfs bij een preterme termijn.", [["pulmonale hypertensie", "DISEASE", 262, 283], ["Ernstige obstructieve longziekte", "SPECIES", 316, 348], ["Vanwege een verslechterende longfunctie door de mechanische veranderingen van de groeiende uterus kan het soms nodig zijn de baring eerder te induceren, soms zelfs bij een preterme termijn", "SPECIES", 348, 536], ["pulmonale hypertensie", "PROBLEM", 262, 283], ["pulmonale hypertensie", "OBSERVATION", 262, 283], ["uterus", "ANATOMY", 439, 445]]], ["Hierdoor treedt relatief meer stasis op van darminhoud en verloopt de passage trager.", [["Hierdoor", "TREATMENT", 0, 8]]], ["Typische zwangerschapsklachten als zuurbranden en obstipatie zijn hierdoor goed te verklaren.FysiologieLeverfunctietests zijn in feite niet-specifieke tests van levercelverval.", [["Typische zwangerschapsklachten als zuurbranden en obstipatie zijn hierdoor goed te verklaren", "SPECIES", 0, 92], ["Typische zwangerschapsklachten als zuurbranden en obstipatie zijn hierdoor", "TREATMENT", 0, 74]]], ["Alleen het alkalische fosfatase laat een geleidelijke stijging zien door productie van een placentair iso-enzym.Ulcus ventriculi en duodeniEen maagulcus komt minder vaak in de zwangerschap voor.", [["Alleen", "TEST", 0, 6], ["Ulcus ventriculi", "PROBLEM", 112, 128]]], ["Zo nodig kan na het geven van leefregels (leefstijl en dieet) medicamenteuze behandeling worden ingesteld.", [["Zo nodig kan na het geven van leefregels (leefstijl en dieet", "SPECIES", 0, 60]]], ["Antacida en mucosaprotectiva zijn eerste keus, maagzuursecretieremmende medicatie tweede keus.", [["Antacida en mucosaprotectiva zijn eerste keus", "TREATMENT", 0, 45]]], ["Wanneer er sprake is van een actieve infectie met Helicobacter pylori wordt net als buiten de zwangerschap antibiotische behandeling ingesteld.", [["Helicobacter pylori", "PROBLEM", 50, 69]]], ["Soms moet daarom met deze behandeling worden gewacht tot na de zwangerschap.LeverfunctiestoornissenIn ongeveer 3% van alle zwangerschappen is er sprake van leverfunctiestoornissen.", [["LeverfunctiestoornissenIn", "TREATMENT", 76, 101]]], ["Tijdens de zwangerschap kunnen leverfunctiestoornissen ontstaan als gevolg van specifieke zwangerschapsaandoeningen, aandoeningen die meer tijdens de zwangerschap voorkomen (zoals cholecystitis en hepatitis E) en intercurrente aandoeningen (zoals hepatitis B en C).", [["zoals cholecystitis en hepatitis E", "DISEASE", 174, 208], ["hepatitis", "DISEASE", 247, 256], ["cholecystitis en hepatitis E", "TREATMENT", 180, 208], ["en intercurrente aandoeningen (zoals hepatitis B en C)", "TREATMENT", 210, 264]]], ["Het handelt dan om de volgende ziektebeelden: pre-eclampsie, HELLP-syndroom, acute gele leveratrofie of acute fatty liver of pregnancy (AFLP), zwangerschapscholestase en hyperemesis gravidarum.", [["fatty liver", "ANATOMY", 110, 121], ["HELLP-syndroom", "DISEASE", 61, 75], ["fatty liver", "DISEASE", 110, 121], ["hyperemesis gravidarum", "DISEASE", 170, 192], ["liver", "ORGAN", 116, 121], ["HELLP", "PROBLEM", 61, 66], ["acute fatty liver of pregnancy", "PROBLEM", 104, 134], ["zwangerschapscholestase en hyperemesis gravidarum", "PROBLEM", 143, 192], ["HELLP", "OBSERVATION", 61, 66], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["fatty", "OBSERVATION", 110, 115], ["liver", "ANATOMY", 116, 121]]], ["Pre-eclampsie, HELLP-syndroom en hyperemesis gravidarum worden elders besproken.Acute gele leveratrofie of acute fatty liver of pregnancy (AFLP)AFLP werd voor het eerst in de jaren tachtig beschreven.", [["fatty liver", "ANATOMY", 113, 124], ["Pre-eclampsie", "CHEMICAL", 0, 13], ["HELLP", "DISEASE", 15, 20], ["hyperemesis gravidarum", "DISEASE", 33, 55], ["fatty liver", "DISEASE", 113, 124], ["liver", "ORGAN", 119, 124], ["HELLP", "PROBLEM", 15, 20], ["hyperemesis gravidarum", "PROBLEM", 33, 55], ["acute fatty liver of pregnancy", "PROBLEM", 107, 137], ["AFLP", "PROBLEM", 144, 148], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["fatty", "OBSERVATION", 113, 118], ["liver", "ANATOMY", 119, 124]]], ["Gaandeweg de jaren bleek het ziektebeeld toch vaker voor te komen en wel in een incidentie van 1 op elke 1000 tot 15.000 zwangerschappen.", [["Gaandeweg de jaren bleek het ziektebeeld toch vaker voor te komen en wel in een incidentie van 1 op elke 1000 tot 15.000 zwangerschappen", "SPECIES", 0, 136]]], ["Histologisch onderzoek van de lever laat een karakteristiek beeld zien van gezwollen hepatocyten gevuld met microvesiculair vet.", [["Histologisch onderzoek van de lever laat een karakteristiek beeld zien van gezwollen hepatocyten gevuld", "SPECIES", 0, 103], ["Histologisch", "TEST", 0, 12], ["microvesiculair vet", "OBSERVATION", 108, 127]]], ["Dit beeld kan echter ook worden gezien bij andere leveraandoeningen.Acute gele leveratrofie of acute fatty liver of pregnancy (AFLP)Klinisch openbaart AFLP zich meestal in het laatste trimester van de zwangerschap met algemene malaise, misselijkheid, braken en pijn in de bovenbuik.", [["fatty liver", "ANATOMY", 101, 112], ["fatty liver of pregnancy", "DISEASE", 101, 125], ["liver", "ORGAN", 107, 112], ["gezien bij andere", "SPECIES", 32, 49], ["Acute gele leveratrofie", "PROBLEM", 68, 91], ["acute fatty liver of pregnancy", "PROBLEM", 95, 125], ["AFLP", "PROBLEM", 127, 131], ["malaise", "PROBLEM", 227, 234], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["fatty", "OBSERVATION", 101, 106], ["liver", "ANATOMY", 107, 112]]], ["Icterus en encefalopathie zijn latere symptomen.", [["Icterus", "PROBLEM", 0, 7]]], ["Vaak is er tevens sprake van preeclampsie, waardoor het soms moeilijk is te differenti\u00ebren tussen AFLP en HELLP-syndroom.", [["HELLP", "DISEASE", 106, 111]]], ["Polyurie en polydipsie ontstaan door verminderde afbraak van placentair vasopressinase door de lever.", [["Polyurie", "PROBLEM", 0, 8]]], ["Hypoglykemie en stollingsstoornissen zijn eveneens het gevolg van de verminderde leverfunctie.", [["Hypoglykemie", "PROBLEM", 0, 12]]], ["Ten slotte is een daling van het antitrombinegehalte vrij karakteristiek voor dit ziektebeeld.Acute gele leveratrofie of acute fatty liver of pregnancy (AFLP)AFLP verbetert pas nadat de zwangerschap is be\u00ebindigd.", [["fatty liver", "ANATOMY", 127, 138], ["fatty liver", "DISEASE", 127, 138], ["liver", "ORGAN", 133, 138], ["acute fatty liver of pregnancy", "PROBLEM", 121, 151], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["fatty", "OBSERVATION", 127, 132], ["liver", "ANATOMY", 133, 138]]], ["Op deze manier is maternale sterfte aan AFLP ongewoon geworden en is de perinatale sterfte gedaald tot ongeveer 10%.Acute gele leveratrofie of acute fatty liver of pregnancy (AFLP)Hoewel de exacte oorzaak van AFLP nog onbekend is, wordt in een deel van de gevallen een foetale defici\u00ebntie gezien van een enzym dat betrokken is bij de vetzuurstofwisseling, long chain 3-hydroxyacyl-coA dehydrogenase (LCHAD).", [["fatty liver", "ANATOMY", 149, 160], ["fatty liver", "DISEASE", 149, 160], ["3-hydroxyacyl-coA", "CHEMICAL", 367, 384], ["liver", "ORGAN", 155, 160], ["3-hydroxyacyl-coA dehydrogenase", "GENE_OR_GENE_PRODUCT", 367, 398], ["long chain 3-hydroxyacyl-coA dehydrogenase", "PROTEIN", 356, 398], ["acute fatty liver of pregnancy", "PROBLEM", 143, 173], ["long chain", "PROBLEM", 356, 366], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["fatty liver", "OBSERVATION", 149, 160], ["coA", "ANATOMY", 381, 384]]], ["De ongemetaboliseerde vetzuren van de foetus bereiken via de placenta de circulatie van de moeder, waardoor de vetzuuroxidatie van de moeder overbelast raakt.Acute gele leveratrofie of acute fatty liver of pregnancy (AFLP)Bij een volgende zwangerschap is er een geringe kans op herhaling van het ziektebeeld.ZwangerschapscholestaseZwangerschapscholestase wordt gekenmerkt door klachten van hevige jeuk zonder huidafwijkingen in combinatie met gestoorde leverfunctietests.", [["fatty liver", "ANATOMY", 191, 202], ["fatty liver", "DISEASE", 191, 202], ["liver", "ORGAN", 197, 202], ["Acute gele leveratrofie", "PROBLEM", 158, 181], ["acute fatty liver of pregnancy", "PROBLEM", 185, 215], ["ZwangerschapscholestaseZwangerschapscholestase", "TREATMENT", 308, 354], ["acute", "OBSERVATION_MODIFIER", 185, 190], ["fatty", "OBSERVATION", 191, 196], ["liver", "ANATOMY", 197, 202]]], ["De incidentie van de aandoening wisselt nogal en is vooral afhankelijk van ras, omgeving en hormonale (oestrogeen en progesteron) en genetische factoren.", [["omgeving en hormonale (oestrogeen en progesteron)", "TREATMENT", 80, 129]]], ["Bij het laboratoriumonderzoek wordt een verhoogde hoeveelheid galzure zouten aangetroffen die de jeukklachten veroorzaken.ZwangerschapscholestaseMeestal begint de aandoening tijdens de laatste zwangerschapsweken.", [["ZwangerschapscholestaseMeestal begint", "TREATMENT", 122, 159]]], ["Icterus komt zelden voor.", [["Icterus", "PROBLEM", 0, 7]]], ["Na de zwangerschap verdwijnen de klachten snel en treedt volledig herstel van de leverfuncties op.", [["Na", "CHEMICAL", 0, 2]]], ["Bij een volgende zwangerschap komen de klachten in 50-75% van de gevallen terug.ZwangerschapscholestaseDe echte ongerustheid rondom zwangerschapscholestase betreft echter niet zozeer de moeder als wel de foetus.", [["Bij een volgende zwangerschap komen", "TREATMENT", 0, 35], ["ZwangerschapscholestaseDe", "TREATMENT", 80, 105]]], ["Latere studies weerlegden dit gegeven mits er sprake is van behandeling van de zwangerschapscholestase.", [["Latere studies", "TEST", 0, 14]]], ["Er is wel een verhoogde kans op vroeggeboorte.", [["op vroeggeboorte", "OBSERVATION", 29, 45]]], ["Veel van deze vroeggeboorten zijn iatrogeen.ZwangerschapscholestaseUit proefdieronderzoek blijkt dat hoge concentraties galzure zouten kunnen leiden tot acuut hartfalen.", [["Zwangerschapscholestase", "CHEMICAL", 44, 67], ["Zwangerschapscholestase", "CHEMICAL", 44, 67], ["Zwangerschapscholestase", "SPECIES", 44, 67], ["Zwangerschapscholestase", "TREATMENT", 44, 67]]], ["De mogelijke nadelen van een dergelijke vroege inleiding dienen met de ouders te worden besproken.ZwangerschapscholestaseSymptomatische behandeling bestaat uit uitwendige verlichting van de jeuk met mentholpoeder.", [["De mogelijke nadelen van een dergelijke vroege", "TREATMENT", 0, 46], ["ZwangerschapscholestaseSymptomatische", "PROBLEM", 98, 135]]], ["Verder kunnen antihistaminica en colestyramine worden voorgeschreven.", [["Verder kunnen antihistaminica en colestyramine", "TREATMENT", 0, 46]]], ["Veel gebruikt is ursodeoxycholzuur, dat echter niet beter werkt dan colestyramine.", [["ursodeoxycholzuur", "CHEMICAL", 17, 34], ["ursodeoxycholzuur", "CHEMICAL", 17, 34], ["ursodeoxycholzuur", "SIMPLE_CHEMICAL", 17, 34]]], ["Gezien de lage kans op met name intra-uteriene vruchtdood zou er een zeer grote trial nodig zijn om de effecten van medicatie op de zwangerschapsuitkomst te kunnen vaststellen.", [["Gezien de lage kans op met name intra-uteriene vruchtdood zou er een zeer grote trial nodig zijn om de effecten van medicatie op de zwangerschapsuitkomst te kunnen vaststellen", "SPECIES", 0, 175]]], ["Dexamethason kan ook worden overwogen maar moet vanwege de neonatale effecten zeer terughoudend worden gebruikt.", [["Dexamethason", "CHEMICAL", 0, 12], ["Dexamethason", "TREATMENT", 0, 12]]], ["Over het algemeen wordt wel geadviseerd om vitamine-K-suppletie (10 mg per dag oraal) toe te passen om post partum bloedingen en een neonatale bloeding te voorkomen.ZwangerschapscholestaseOrale anticonceptiva zijn relatief gecontra-indiceerd bij pati\u00ebnten die een zwangerschapscholestase hebben doorgemaakt.ObstipatieEen van de meest voorkomende oorzaken van buikpijn in de zwangerschap is obstipatie.", [["vitamine-K-suppletie", "CHEMICAL", 43, 63], ["om vitamine", "TREATMENT", 40, 51], ["K-suppletie", "TREATMENT", 52, 63], ["toe te passen om post partum bloedingen en een", "TREATMENT", 86, 132], ["ZwangerschapscholestaseOrale anticonceptiva zijn", "TREATMENT", 165, 213], ["toe", "ANATOMY", 86, 89]]], ["Dit probleem dient in eerste instantie conservatief (veel drinken, vezelrijk voedsel) en in tweede instantie medicamenteus (lactulose en/of microklysma's) te worden opgelost.Ziekte van Crohn en colitis ulcerosaInflammatory bowel disease (IBD) is de verzamelnaam voor colitis ulcerosa en de ziekte van Crohn.", [["lactulose", "CHEMICAL", 124, 133], ["Crohn en colitis", "DISEASE", 185, 201], ["bowel disease", "DISEASE", 223, 236], ["IBD", "DISEASE", 238, 241], ["colitis", "DISEASE", 267, 274], ["lactulose", "CHEMICAL", 124, 133], ["bowel", "ORGAN", 223, 228], ["lactulose en/of microklysma's", "TREATMENT", 124, 153], ["Ziekte van Crohn en colitis ulcerosaInflammatory bowel disease", "PROBLEM", 174, 236], ["IBD)", "PROBLEM", 238, 242], ["de verzamelnaam voor colitis", "PROBLEM", 246, 274], ["bowel", "ANATOMY", 223, 228], ["disease", "OBSERVATION", 229, 236]]], ["Het zijn chronische darmontstekingen waarvan de ziekteactiviteit wisselt en zich niet laat voorspellen.", [["Het zijn chronische darmontstekingen waarvan de ziekteactiviteit wisselt en zich niet laat voorspellen", "SPECIES", 0, 102], ["Het zijn chronische darmontstekingen waarvan", "TREATMENT", 0, 44]]], ["Colitis ulcerosa beperkt zich tot het colon, terwijl de ziekte van Crohn kan voorkomen in de gehele tractus digestivus.", [["colon", "ANATOMY", 38, 43], ["Colitis", "DISEASE", 0, 7], ["colon", "ORGAN", 38, 43], ["gehele tractus digestivus", "ORGANISM", 93, 118], ["gehele tractus digestivus", "SPECIES", 93, 118], ["Colitis ulcerosa", "PROBLEM", 0, 16], ["tot het colon", "PROBLEM", 30, 43], ["colon", "ANATOMY", 38, 43]]], ["De ziekte van Crohn wordt gecompliceerd door darmstenosen, perianale problemen, abcesvorming en fistels, colitis ulcerosa door dilatatie van het colon en maligniteit.", [["colitis", "DISEASE", 105, 112], ["colitis ulcerosa door dilatatie van het colon en maligniteit", "SPECIES", 105, 165], ["abcesvorming en fistels", "PROBLEM", 80, 103], ["colitis", "PROBLEM", 105, 112], ["colitis", "OBSERVATION", 105, 112], ["colon", "ANATOMY", 145, 150]]], ["Soms is bij deze pati\u00ebnten een deel van het darmpakket gereseceerd en is een anus praeternaturalis aangelegd.Ziekte van Crohn en colitis ulcerosaTijdens de zwangerschap treden net zo vaak exacerbaties op van IBD als daarbuiten.", [["colitis", "DISEASE", 129, 136], ["anus praeternaturalis", "SPECIES", 77, 98], ["Ziekte van Crohn en colitis ulcerosaTijdens de zwangerschap treden net zo vaak exacerbaties op van IBD als daarbuiten", "SPECIES", 109, 226], ["Ziekte van Crohn en colitis ulcerosaTijdens", "PROBLEM", 109, 152], ["anus", "ANATOMY", 77, 81]]], ["Post partum kan de ziekte van Crohn opvlammen, colitis ulcerosa niet.Ziekte van Crohn en colitis ulcerosaIBD be\u00efnvloedt de zwangerschap niet nadelig, mits er sprake is van een goede voedingsstatus.", [["colitis", "DISEASE", 47, 54], ["colitis", "DISEASE", 89, 96], ["Post partum kan de ziekte van Crohn opvlammen", "TREATMENT", 0, 45], ["colitis ulcerosa niet", "PROBLEM", 47, 68], ["Ziekte van Crohn en colitis", "TREATMENT", 69, 96], ["colitis", "OBSERVATION", 47, 54]]], ["Tenzij er bij de ziekte van Crohn sprake is van actieve fistelvorming van het perineum, kan een vaginale baring worden nagestreefd.Endoscopische techniekenAlvorens een endoscopische procedure bij een zwangere uit te voeren, dienen de potenti\u00eble implicaties voor moeder en foetus te worden overwogen.", [["Crohn sprake", "DISEASE", 28, 40], ["Tenzij er bij de ziekte van Crohn sprake", "TREATMENT", 0, 40], ["Endoscopische techniekenAlvorens", "TREATMENT", 131, 163], ["een endoscopische procedure", "TREATMENT", 164, 191], ["perineum", "ANATOMY", 78, 86]]], ["Bij de moeder is er een verhoogde kans op aspiratie, hypotensie (rugligging) en beschadiging van darmpakket en uterus.", [["uterus", "ANATOMY", 111, 117], ["uterus", "ORGAN", 111, 117], ["hypotensie", "PROBLEM", 53, 63], ["uterus", "ANATOMY", 111, 117]]], ["De gevaren voor de foetus bestaan uit hypoxie door sedatie, hypoperfusie door verkeerde ligging (rugligging), teratogene effecten (medicatie), beschadiging van de uterus door endoscopisch trauma en abdominale compressie en vroeggeboorte.", [["trauma", "DISEASE", 188, 194], ["hypoperfusie", "PROBLEM", 60, 72], ["endoscopisch trauma", "PROBLEM", 175, 194], ["uterus", "ANATOMY", 163, 169]]], ["Het is belangrijk het klinisch belang van een endoscopie te wegen tegenover de risico's ervan en zo mogelijk de procedure uit te stellen tot na de zwangerschap.Auto-immuunziektenTijdens de zwangerschap verandert het maternale immuunsysteem.", [["'s ervan en zo mogelijk de procedure", "TREATMENT", 85, 121]]], ["Om de foetus te beschermen tegen afstoting treedt er een verschuiving op van cellulaire immuniteit (cell-mediated immunity) naar humorale immuniteit.", [["cell", "ANATOMY", 100, 104], ["cell", "CELL", 100, 104]]], ["Bij veel auto-immuunziekten spelen serologisch aantoonbare autoantistoffen een rol bij de beschadiging van de eigen weefsels.Reumato\u00efde artritis (RA)RA is een invaliderende chronische symmetrische artritis van de synoviale gewrichten, die op elke leeftijd kan voorkomen.", [["RA", "DISEASE", 149, 151], ["Bij", "TEST", 0, 3], ["Reumato\u00efde artritis (RA)RA", "PROBLEM", 125, 151], ["RA", "ANATOMY", 146, 148], ["RA", "ANATOMY", 149, 151]]], ["Het ziekteverloop is grillig en perioden met relatief weinig klachten worden afgewisseld door perioden waarin de ontstekingen oplaaien.", [["ontstekingen oplaaien", "SPECIES", 113, 134]]], ["Naast klachten van het bewegingsapparaat kunnen ook andere organen worden aangedaan.", [["Naast klachten van het bewegingsapparaat kunnen ook andere organen worden aangedaan", "SPECIES", 0, 83]]], ["Vermoeidheidsklachten, gewichtsverlies, algemene malaise en anemie komen vaak voor.Reumato\u00efde artritis (RA)Tijdens zwangerschap verbetert de ziekte vaak aanzienlijk.", [["Vermoeidheidsklachten", "TREATMENT", 0, 21], ["Reumato\u00efde artritis", "PROBLEM", 83, 102], ["RA", "ANATOMY", 104, 106]]], ["Na de zwangerschap verslechtert het beeld snel weer tot op het niveau van voor de zwangerschap.", [["Na", "CHEMICAL", 0, 2]]], ["Borstvoeding kan dit proces nadelig be\u00efnvloeden.Reumato\u00efde artritis (RA)De invloed van RA op de zwangerschap is waarschijnlijk te verwaarlozen.", [["Reumato\u00efde artritis", "DISEASE", 48, 67], ["Reumato\u00efde artritis", "PROBLEM", 48, 67], ["RA", "ANATOMY", 69, 71]]], ["Wel bestaat bij pati\u00ebnten met anti-Ro-antistoffen het risico op de ontwikkeling van een neonatale lupus.Reumato\u00efde artritis (RA)Het belangrijkste waar in de zwangerschap rekening mee moet worden gehouden, is het gebruik van antireumatica.", [["lupus", "DISEASE", 98, 103], ["Reumato\u00efde artritis", "DISEASE", 104, 123], ["Reumato\u00efde artritis", "PROBLEM", 104, 123], ["lupus", "OBSERVATION", 98, 103], ["RA", "ANATOMY", 125, 127]]], ["NSAID's en aspirine moeten, voor zover mogelijk, in ieder geval enkele weken voor de partus worden gestaakt.", [["NSAID", "TREATMENT", 0, 5]]], ["Hydroxychloroquine en sulfasalazine kunnen tijdens zwangerschap en lactatie worden gecontinueerd.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["sulfasalazine", "CHEMICAL", 22, 35], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["sulfasalazine", "CHEMICAL", 22, 35], ["Hydroxychloroquine en sulfasalazine kunnen tijdens zwangerschap en lactatie worden", "TREATMENT", 0, 82]]], ["Methotrexaat en leflunomide zijn gecontra-indiceerd tijdens zwangerschap en lactatie.", [["leflunomide", "CHEMICAL", 16, 27], ["leflunomide", "CHEMICAL", 16, 27], ["Methotrexaat en leflunomide zijn gecontra", "TREATMENT", 0, 41]]], ["Cyclofosfamide en mycofenolaatmofetil moeten eveneens worden vermeden.", [["Cyclofosfamide", "CHEMICAL", 0, 14], ["Cyclofosfamide", "CHEMICAL", 0, 14], ["Cyclofosfamide", "TREATMENT", 0, 14]]], ["Azathioprine en ciclosporine A kunnen worden gebruikt als het nodig is om de ziekteactiviteit verder te onderdrukken.", [["Azathioprine", "CHEMICAL", 0, 12], ["Azathioprine", "CHEMICAL", 0, 12], ["Azathioprine en ciclosporine", "TREATMENT", 0, 28]]], ["Over het gebruik van tumornecrosefactor (TNF)-antagonisten, anakinra en rituximab tijdens zwangerschap en lactatie is nog weinig bekend.", [["TNF", "GENE_OR_GENE_PRODUCT", 41, 44], ["antagonisten", "TREATMENT", 46, 58], ["anakinra en rituximab tijdens zwangerschap", "TREATMENT", 60, 102]]], ["Bij voorkeur moet voor de conceptie de medicatie worden aangepast.Systemische lupus erythematodes (SLE)SLE is een ziekte met een complex klinisch beeld.", [["Systemische lupus erythematodes", "DISEASE", 66, 97], ["SLE", "DISEASE", 99, 102], ["SLE", "DISEASE", 103, 106], ["Systemische lupus erythematodes (SLE)SLE", "PROBLEM", 66, 106], ["een ziekte", "TREATMENT", 110, 120], ["lupus", "OBSERVATION", 78, 83]]], ["Hematologische manifestaties uiten zich als hemolytische anemie, trombocytopenie en leukopenie.", [["Hematologische", "TREATMENT", 0, 14], ["als hemolytische anemie", "PROBLEM", 40, 63], ["trombocytopenie", "PROBLEM", 65, 80]]], ["Zoals bij de meeste auto-immuunziekten verloopt de ziekte in fasen van remissies en exacerbaties.", [["Zoals", "TREATMENT", 0, 5]]], ["Vermoeidheid en koorts zijn de meest voorkomende klinische klachten.", [["Vermoeidheid en koorts zijn", "TREATMENT", 0, 27]]], ["De ziekte komt bijna tien keer zo vaak voor onder vrouwen en twee tot vier keer vaker bij het negro\u00efde ras.Systemische lupus erythematodes (SLE)De diagnose wordt gebaseerd op het voorkomen van ten minste vier van elf criteria die zijn opgesteld door de American College of Rheumatology.", [["Systemische lupus erythematodes", "DISEASE", 107, 138], ["SLE", "DISEASE", 140, 143], ["ras", "GENE_OR_GENE_PRODUCT", 103, 106], ["ras", "PROTEIN", 103, 106], ["Systemische lupus erythematodes (SLE)", "PROBLEM", 107, 144], ["lupus", "OBSERVATION", 119, 124]]], ["Deze criteria omvatten een aantal klinische symptomen en laboratoriumafwijkingen: vlindervormig exantheem in het gelaat, schijfvormig exantheem over het gehele lichaam, lichtovergevoeligheid, ulcera in mond-en keelholte, artritis in minimaal twee gewrichten, pleuritis en/of pericarditis, nierfunctiestoornissen (prote\u00efnurie en celcilinders in het urinesediment), neurologische stoornissen, stoornissen in de bloedaanmaak (leukopenie, lymfocytopenie, trombocytopenie, anemie), antistoffen tegen speciale bestanddelen van celkernen (anti-dsDNA/Sm) en aanwezigheid van antinucleaire antistoffen (ANA).", [["pleuritis", "DISEASE", 259, 268], ["pericarditis", "DISEASE", 275, 287], ["Sm", "PROTEIN", 543, 545], ["ANA", "PROTEIN", 594, 597], ["antistoffen tegen speciale bestanddelen van celkernen (anti-dsDNA/Sm) en aanwezigheid van antinucleaire antistoffen", "SPECIES", 477, 592], ["Deze criteria", "TEST", 0, 13], ["artritis", "PROBLEM", 221, 229], ["pleuritis", "PROBLEM", 259, 268], ["pericarditis", "PROBLEM", 275, 287], ["nierfunctiestoornissen (prote\u00efnurie en celcilinders", "TREATMENT", 289, 340], ["lymfocytopenie", "TREATMENT", 435, 449], ["trombocytopenie", "TREATMENT", 451, 466], ["antistoffen", "TREATMENT", 477, 488], ["pleuritis", "OBSERVATION", 259, 268], ["pericarditis", "OBSERVATION", 275, 287]]], ["De volgende antistoffen spelen een rol bij SLE: ANA, autoantistoffen tegen DNA, autoantistoffen tegen nucleoprote\u00efnen, antistoffen tegen lupus anticoagulans en anticardiolipine antistoffen.", [["autoantistoffen tegen DNA", "TREATMENT", 53, 78], ["autoantistoffen tegen nucleoprote\u00efnen", "TREATMENT", 80, 117], ["antistoffen tegen lupus anticoagulans en anticardiolipine antistoffen", "TREATMENT", 119, 188]]], ["Anti-dsDNAantistoffen zijn het specifiekst en gerelateerd aan activiteit van de ziekte.Systemische lupus erythematodes (SLE)In hoeverre tijdens de zwangerschap meer exacerbaties van de ziekte optreden, is niet helemaal duidelijk.", [["Systemische lupus erythematodes", "DISEASE", 87, 118], ["SLE", "DISEASE", 120, 123], ["Anti-dsDNAantistoffen", "TREATMENT", 0, 21], ["Systemische lupus erythematodes (SLE)", "PROBLEM", 87, 124], ["lupus", "OBSERVATION", 99, 104]]], ["In 5-10% leidt dit tot een permanente verslechtering van de nierfunctie.Systemische lupus erythematodes (SLE)Pati\u00ebnten met SLE hebben meer kans op spontane miskramen, pre-eclampsie, vroeggeboorte, intra-uteriene groeirestrictie en intra-uteriene vruchtdood.", [["Systemische lupus erythematodes", "DISEASE", 72, 103], ["SLE", "DISEASE", 105, 108], ["Systemische lupus erythematodes (SLE)", "PROBLEM", 72, 109], ["lupus", "OBSERVATION", 84, 89]]], ["De aanwezigheid van lupus anticoagulans en anticardiolipine antistoffen, actieve ziekte en lupusnefritis be\u00efnvloeden de kans op complicaties negatief.", [["De aanwezigheid van lupus anticoagulans en anticardiolipine antistoffen", "TREATMENT", 0, 71]]], ["Het is van belang om met name dit onderscheid goed te maken omdat de behandeling van beide ziektebeelden wezenlijk verschilt.Systemische lupus erythematodes (SLE)In minder dan 5% van de gevallen ontstaat neonatale lupus erythematodes.", [["Systemische lupus erythematodes", "DISEASE", 125, 156], ["SLE", "DISEASE", 158, 161], ["lupus erythematodes", "DISEASE", 214, 233], ["Systemische lupus erythematodes (SLE)", "PROBLEM", 125, 162], ["neonatale lupus erythematodes", "PROBLEM", 204, 233], ["lupus", "OBSERVATION", 137, 142], ["lupus erythematodes", "OBSERVATION", 214, 233]]], ["Dit ziektebeeld bestaat uit huidafwijkingen, hematologische afwijkingen en hartafwijkingen (congenitaal compleet hartblok, cardiomyopathie).", [["cardiomyopathie", "PROBLEM", 123, 138]]], ["Een congenitaal compleet hartblok ontstaat bij 10% van de pati\u00ebnten waarbij er sprake is van anti-SSA-antistoffen.Systemische lupus erythematodes (SLE)Over het algemeen is het advies pas minimaal zes maanden na de laatste exacerbatie zwanger te worden.", [["Systemische lupus erythematodes", "DISEASE", 114, 145], ["SLE", "DISEASE", 147, 150], ["Systemische lupus erythematodes (SLE)", "PROBLEM", 114, 151], ["lupus", "OBSERVATION", 126, 131]]], ["Preconceptioneel dienen de risico's van zwangerschap te worden besproken.Antifosfolipidesyndroom (APS)APS is een auto-immuunziekte die zowel primair, zonder samenhang met een andere auto-immuunziekte, als secundair, in combinatie met bijvoorbeeld SLE, kan voorkomen.", [["APS", "DISEASE", 98, 101], ["APS", "DISEASE", 102, 105], ["SLE", "DISEASE", 247, 250], ["Antifosfolipidesyndroom (APS)APS", "TREATMENT", 73, 105]]], ["De diagnose antifosfolipidesyndroom berust op de aanwezigheid van antifosfolipideantistoffen (lupus anticoagulans, anti-\u03b2 2 -glycoprote\u00efne antistoffen en anticardiolipine antistoffen) in combinatie met bepaalde klinische verschijnselen, zoals veneuze of arteri\u00eble trombose, habituele miskramen, onverklaarde foetale sterfte of ernstige pre-eclampsie of placenta-insuffici\u00ebntie leidend tot een bevalling onder de 34 weken (tabel 21.12).Antifosfolipidesyndroom (APS)Recentelijk zijn anti-\u03b2 2 -glycoprote\u00efneantistoffen aan de definitie toegevoegd.", [["lupus anticoagulans", "DISEASE", 94, 113], ["Antifosfolipidesyndroom", "CHEMICAL", 435, 458], ["APS", "DISEASE", 460, 463], ["lupus anticoagulans", "TREATMENT", 94, 113], ["anti-\u03b2", "TREATMENT", 115, 121], ["glycoprote\u00efne antistoffen en anticardiolipine antistoffen", "TREATMENT", 125, 182], ["Antifosfolipidesyndroom (APS)", "TREATMENT", 435, 464], ["Recentelijk zijn anti-\u03b2", "TREATMENT", 464, 487], ["placenta", "ANATOMY", 353, 361]]], ["De bepaling van antifosfolipideantistoffen dient op twee onafhankelijke tijdstippen met een interval van ten minste 12 weken te worden bepaald.", [["De bepaling van antifosfolipideantistoffen dient op twee onafhankelijke tijdstippen met een interval van ten minste 12 weken te worden bepaald", "SPECIES", 0, 142]]], ["Bepalingen binnen tien weken na de zwangerschap kunnen vals-positieve resultaten opleveren.", [["na", "CHEMICAL", 29, 31]]], ["De incidentie van antistoffen bedraagt maximaal 5% bij gezonde personen en maximaal 35% bij SLE-pati\u00ebnten.Antifosfolipidesyndroom (APS)De relatie tussen APS en hypercoagulabiliteit is reeds jaren bekend.", [["Antifosfolipidesyndroom", "CHEMICAL", 106, 129], ["APS", "DISEASE", 131, 134], ["Antifosfolipidesyndroom", "SIMPLE_CHEMICAL", 106, 129], ["Antifosfolipidesyndroom (APS)De relatie tussen APS en hypercoagulabiliteit", "TREATMENT", 106, 180]]], ["Tijdens de zwangerschap bestaat bij pati\u00ebnten met APS, indien onbehandeld, een sterk verhoogde kans op tromboembolische processen.", [["APS", "DISEASE", 50, 53]]], ["Een bijzondere complicatie is het catastrophic APS of syndroom van Asherson, dat gekenmerkt wordt door multiorgaanfalen op basis van gegeneraliseerde trombose in kleine bloedvaten.Antifosfolipidesyndroom (APS)Antifosfolipideantistoffen worden verder in verband gebracht met diverse zwangerschapscomplicaties.", [["APS", "DISEASE", 47, 50], ["Antifosfolipidesyndroom", "CHEMICAL", 180, 203], ["APS", "DISEASE", 205, 208], ["Antifosfolipidesyndroom (APS)", "TREATMENT", 180, 209], ["Antifosfolipideantistoffen worden verder", "TREATMENT", 209, 249], ["diverse zwangerschapscomplicaties", "OBSERVATION", 274, 307]]], ["De mogelijke trombotische effecten van de antifosfolipideantistoffen zijn wellicht debet aan uteroplacentaire insuffici\u00ebntie, waardoor in 30% van de gevallen foetale groeivertraging ontstaat.", [["De mogelijke trombotische effecten van de antifosfolipideantistoffen zijn", "TREATMENT", 0, 73]]], ["Een zwangerschap bij zwangeren met APS moet beschouwd worden als een hoogrisicozwangerschap en vereist regelmatige prenatale controles.", [["Een zwangerschap bij zwangeren", "TREATMENT", 0, 30]]], ["Bij voorkeur is er sprake van multidisciplinaire behandeling tijdens de zwangerschap.Antifosfolipidesyndroom (APS)De aanbevelingen voor de behandeling van zwangeren met APS zijn samengevat tabel 21.13.", [["Antifosfolipidesyndroom", "CHEMICAL", 85, 108], ["APS", "DISEASE", 110, 113], ["Antifosfolipidesyndroom", "SIMPLE_CHEMICAL", 85, 108]]], ["Met name bij habituele miskramen halveert combinatietherapie van aspirine en laagmoleculaire heparine in profylactische dosering de kans op vernieuwd zwangerschapsverlies.", [["van aspirine en laagmoleculaire heparine", "TREATMENT", 61, 101]]], ["Het is raadzaam vroeg, zodra er sprake is van een positieve zwangerschapstest, met aspirine te beginnen, gevolgd door laagmoleculaire heparine zodra er sprake is van positieve foetale hartactie.", [["door laagmoleculaire heparine zodra", "TREATMENT", 113, 148]]], ["Hoe het effect van deze behandeling is op de andere zwangerschapscomplicaties, is niet goed bekend.Antifosfolipidesyndroom (APS)Voor de follow-up op lange termijn behoren pati\u00ebnten met APS te worden verwezen naar hematoloog of internist.", [["APS", "DISEASE", 124, 127]]], ["Bij voorkeur wordt geen hormonale contraceptie voorgeschreven aan deze groep pati\u00ebnten.Zeldzame auto-immuunziektenZeldzame auto-immuunziekten zoals sclerodermie, polymyositis, dermatomyositis, ongedifferentieerde bindweefselziekten en systemische vasculitisbeelden zoals wegeners granulomatosis, churg-strausssyndroom, polyarteriitis nodosa, takayasu-arteriitis en ziekte van Beh\u00e7et kunnen met name jonge vrouwen treffen.", [["polymyositis", "DISEASE", 162, 174], ["dermatomyositis", "DISEASE", 176, 191], ["granulomatosis", "DISEASE", 280, 294], ["churg-strausssyndroom", "DISEASE", 296, 317], ["polyarteriitis nodosa", "DISEASE", 319, 340], ["takayasu-arteriitis", "DISEASE", 342, 361], ["Zeldzame", "TREATMENT", 87, 95], ["Zeldzame auto-immuunziekten zoals sclerodermie", "TREATMENT", 114, 160], ["polymyositis", "PROBLEM", 162, 174], ["dermatomyositis", "PROBLEM", 176, 191], ["wegeners granulomatosis", "PROBLEM", 271, 294], ["churg", "TEST", 296, 301], ["polyarteriitis nodosa", "PROBLEM", 319, 340], ["takayasu", "PROBLEM", 342, 350], ["arteriitis", "PROBLEM", 351, 361], ["polymyositis", "OBSERVATION", 162, 174], ["dermatomyositis", "OBSERVATION", 176, 191], ["granulomatosis", "OBSERVATION", 280, 294]]], ["Bij een eerste uiting van de ziekte tijdens de zwangerschap is de prognose duidelijk minder goed.Neurologische aandoeningenNeurologische aandoeningen komen uiteraard ook tijdens de zwangerschap voor.", [["Neurologische aandoeningen", "SPECIES", 97, 123]]], ["Het antifosfolipidesyndroom is aanwezig als op zijn minst een van de klinische en een van de laboratoriumcriteria aanwezig zijn. anti-\u03b2 2 -glycoprote\u00efneantistoffen -drie of meer opeenvolgende spontane abortussen <10 weken of -een of meer onverklaarde gevallen van foetale sterfte \u226510 weken bij een structureel normale foetus of -een of meer vroeggeboorten <34 weken vanwege (ernstige) pre-eclampsie of ernstige placenta-insuffici\u00ebntie resulterend in foetale groeivertraging -onverklaarde veneuze trombose of -onverklaarde arteri\u00eble trombose of -trombose in kleine bloedvaten in elk weefsel of orgaan zonder duidelijke ontsteking van de vaatwand -anticardiolipineantistoffen van het IgG-of IgM-type in matig tot hoge titer gemeten op twee verschillende tijdstippen met een interval van ten minste 12 weken bepaald met een gestandaardiseerde ELISA-test -lupus anticoagulans gemeten op twee verschillende tijdstippen met een interval van ten minste 12 weken bepaald volgens internationale richtlijnen (International Society on Thrombosis and Hemostasis) -anti-\u03b22-glycoprote\u00efneantistoffen van het IgG-of IgM-type gemeten op twee verschillende tijdstippen met een interval van ten minste 12 weken bepaald met een gestandaardiseerde ELISA-test Bronnen: Wilson WA, et al. Arthritis Rheum.", [["anti-\u03b2 2 -glycoprote\u00efneantistoffen", "CHEMICAL", 129, 163], ["Thrombosis", "DISEASE", 1024, 1034], ["Arthritis", "DISEASE", 1265, 1274], ["anti-\u03b2 2 -glycoprote\u00efneantistoffen", "SIMPLE_CHEMICAL", 129, 163], ["IgM", "PROTEIN", 689, 692], ["IgM", "PROTEIN", 1100, 1103], ["orgaan zonder duidelijke ontsteking van de vaatwand -anticardiolipineantistoffen van het IgG-of IgM-type in matig tot hoge titer gemeten op twee verschillende tijdstippen met een interval van ten minste 12 weken bepaald met een gestandaardiseerde ELISA-test -lupus anticoagulans gemeten op twee verschillende tijdstippen met een interval van ten minste 12 weken bepaald volgens internationale richtlijnen", "SPECIES", 593, 997], ["Het antifosfolipidesyndroom", "TREATMENT", 0, 27], ["anti-\u03b2", "TREATMENT", 129, 135], ["glycoprote\u00efneantistoffen", "TREATMENT", 139, 163], ["groeivertraging", "TEST", 458, 473], ["trombose", "PROBLEM", 545, 553], ["van het IgG", "TEST", 674, 685], ["IgM", "TEST", 689, 692], ["een gestandaardiseerde ELISA", "TEST", 817, 845], ["test", "TEST", 846, 850], ["lupus anticoagulans", "TREATMENT", 852, 871], ["op twee verschillende tijdstippen", "TREATMENT", 880, 913], ["Thrombosis", "PROBLEM", 1024, 1034], ["Hemostasis", "TEST", 1039, 1049], ["anti-\u03b22", "TREATMENT", 1052, 1059], ["IgM", "TEST", 1100, 1103], ["Arthritis Rheum", "PROBLEM", 1265, 1280], ["Thrombosis", "OBSERVATION", 1024, 1034], ["Rheum", "OBSERVATION", 1275, 1280]]], ["1999; 42:1309-11; Miyakis S, et al. J Thromb Haemost.", [["Thromb Haemost", "OBSERVATION", 38, 52]]], ["2006; 4:295-306. toegepast wordt bij neurologische aandoeningen, moet vaak tijdens en bij voorkeur voor de zwangerschap worden aangepast.EpilepsieEpilepsie is een van meest voorkomende neurologische aandoeningen.", [["EpilepsieEpilepsie", "TREATMENT", 137, 155]]], ["Het betreft een veelvoud van ziekten en afwijkingen waardoor epileptische insulten kunnen optreden.", [["van ziekten", "TREATMENT", 25, 36]]], ["Daarnaast bestaat nog een kleine groep van aspecifieke aanvalsvormen.", [["Daarnaast", "TREATMENT", 0, 9]]], ["Als geen duidelijke oorzaak kan worden gevonden, spreken we van primaire of idiopathische epilepsie.", [["idiopathische epilepsie", "DISEASE", 76, 99], ["idiopathische epilepsie", "TREATMENT", 76, 99]]], ["Ten slotte kan er tijdens de zwangerschap ook door allerlei andere oorzaken een epileptiform insult optreden.", [["kan er tijdens de zwangerschap ook door allerlei andere oorzaken een epileptiform insult optreden", "SPECIES", 11, 108], ["een epileptiform insult", "PROBLEM", 76, 99], ["epileptiform insult", "OBSERVATION", 80, 99]]], ["Naast metabole aandoeningen, drugs en alcoholonttrekking, infecties en cerebrovasculaire accidenten dient in die gevallen altijd een eclamptisch insult te worden uitgesloten.", [["Naast metabole aandoeningen", "TREATMENT", 0, 27], ["drugs en alcoholonttrekking", "TREATMENT", 29, 56], ["infecties", "PROBLEM", 58, 67], ["een eclamptisch insult", "TREATMENT", 129, 151]]], ["Status epilepticus kan leiden tot ernstige schade aan moeder en foetus en dient snel en agressief te worden behandeld.", [["epilepticus", "DISEASE", 7, 18], ["kan leiden tot ernstige schade aan moeder en foetus en dient snel en agressief te worden behandeld", "SPECIES", 19, 117], ["Status epilepticus", "PROBLEM", 0, 18]]], ["Als gevolg van een convulsieve status epilepticus wordt de perinatale sterfte op 50% geschat.", [["epilepticus", "DISEASE", 38, 49], ["epilepticus", "PROBLEM", 38, 49]]], ["Goede leefregels en slaaphygi\u00ebne leiden mogelijk tot een vermindering van het aantal aanvallen.", [["Goede leefregels en slaaphygi\u00ebne leiden mogelijk tot een vermindering van het aantal aanvallen", "SPECIES", 0, 94]]], ["Spina bifida komt het frequentst voor bij gebruik van natriumvalproaat/valpro\u00efnezuur (2%) of carbamazepine (1%).", [["Spina bifida", "DISEASE", 0, 12], ["carbamazepine", "CHEMICAL", 93, 106], ["carbamazepine", "CHEMICAL", 93, 106], ["carbamazepine", "SIMPLE_CHEMICAL", 93, 106], ["Spina bifida komt het frequentst voor bij gebruik van natriumvalproaat/valpro\u00efnezuur", "SPECIES", 0, 84], ["Spina bifida", "PROBLEM", 0, 12], ["van natriumvalproaat/valpro\u00efnezuur", "TREATMENT", 50, 84], ["carbamazepine", "TREATMENT", 93, 106]]], ["Gebruik van natriumvalproaat gaat verder gepaard met een verhoogd risico op craniofaciale en urogenitale afwijkingen, carbamazepine met hypospadie.", [["carbamazepine", "CHEMICAL", 118, 131], ["carbamazepine", "CHEMICAL", 118, 131], ["carbamazepine", "SIMPLE_CHEMICAL", 118, 131], ["carbamazepine", "TREATMENT", 118, 131]]], ["Vanwege de toegenomen nierklaring, vermindering van de serumeiwitconcentratie, het veranderd levermetabolisme en het toegenomen plasmavolume tijdens de zwangerschap dient de dosering van de gebruikte medicatie te worden vervolgd door het bepalen van serumspiegels.", [["Vanwege de toegenomen nierklaring, vermindering van de serumeiwitconcentratie, het veranderd levermetabolisme en het toegenomen plasmavolume tijdens de zwangerschap dient de dosering van de gebruikte medicatie te worden vervolgd door het bepalen van serumspiegels", "SPECIES", 0, 263]]], ["Bij gebruik van leverenzyminducerende middelen dient, vanwege het effect van deze medicatie op de leverfunctie en indirect op de stollingsfactoren van de foetus, in de laatste maand van de zwangerschap extra vitamine K 1 (10 mg per dag oraal) te worden voorgeschreven.", [["K", "CHEMICAL", 217, 218], ["extra vitamine K", "TREATMENT", 202, 218]]], ["Direct post partum wordt aan de pasgeborene 1 mg vitamine K toegediend.", [["vitamine K", "CHEMICAL", 49, 59], ["vitamine K", "CHEMICAL", 49, 59]]], ["Gebruik van anti-epileptica is geen contra-indicatie voor Tabel 21.13 Aanbevelingen voor de behandeling van zwangere vrouwen met positieve antifosfolipideantistoffenDiagnoseBehandeling tijdens de zwangerschap antifosfolipideantistoffen zonder antifosfolipidesyndroom (ongestoorde obstetrische voorgeschiedenis, geen trombose in de voorgeschiedenis antifosfolipidesyndroom met habituele abortus in de voorgeschiedenis antifosfolipidesyndroom met pre-eclampsie of foetale groeivertraging in de voorgeschiedenis antifosfolipidesyndroom met eenmaal trombose in de voorgeschiedenis antifosfolipidesyndroom met recidiverende trombose in de voorgeschiedenis Het nut van behandeling tijdens de zwangerschap is niet bewezen; overwogen kan worden om post partum gedurende 6 weken antistolling te geven.DiagnoseTijdens de zwangerschap laagmoleculaire heparine in profylactische dosering in combinatie met een lage dosis aspirine, in het kraambed 6 weken antistolling met laagmoleculaire heparine in profylactische dosering of coumarinederivaten.", [["aspirine", "CHEMICAL", 909, 917], ["heparine", "CHEMICAL", 976, 984], ["coumarinederivaten", "CHEMICAL", 1015, 1033], ["eenmaal trombose", "PROBLEM", 537, 553], ["DiagnoseTijdens", "PROBLEM", 792, 807], ["een lage dosis aspirine", "TREATMENT", 894, 917], ["laagmoleculaire heparine", "TREATMENT", 960, 984], ["coumarinederivaten", "TREATMENT", 1015, 1033]]], ["Het is onzeker of het zinvol is laagmoleculaire heparine in combinatie met een lage dosis aspirine tijdens de zwangerschap toe te dienen.", [["het zinvol", "TREATMENT", 18, 28], ["laagmoleculaire heparine", "TREATMENT", 32, 56], ["een lage dosis aspirine tijdens", "TREATMENT", 75, 106]]], ["In het kraambed moet 6 weken antistolling gegeven worden met laagmoleculaire heparine in profylactische dosering of coumarinederivaten.", [["laagmoleculaire heparine", "CHEMICAL", 61, 85], ["coumarinederivaten", "CHEMICAL", 116, 134], ["heparine", "CHEMICAL", 77, 85], ["coumarinederivaten", "CHEMICAL", 116, 134], ["heparine", "SIMPLE_CHEMICAL", 77, 85], ["coumarinederivaten", "SIMPLE_CHEMICAL", 116, 134], ["laagmoleculaire heparine", "TREATMENT", 61, 85], ["coumarinederivaten", "TREATMENT", 116, 134]]], ["Men kan overwegen om tevens een lage dosis aspirine te geven.", [["Men", "SPECIES", 0, 3], ["Men kan overwegen om", "TREATMENT", 0, 20], ["een lage dosis aspirine", "TREATMENT", 28, 51]]], ["Na de zwangerschap de antistolling minstens 6 weken continueren.", [["Na", "CHEMICAL", 0, 2]]], ["Tijdens de zwangerschap laagmoleculaire heparine in therapeutische dosering in combinatie met een lage dosis aspirine; na de zwangerschap antistolling continueren, vaak is levenslang antistolling met coumarinederivaten ge\u00efndiceerd.DiagnoseBron: NVOG.", [["na", "CHEMICAL", 119, 121], ["een lage dosis aspirine", "TREATMENT", 94, 117], ["na de zwangerschap antistolling continueren", "TREATMENT", 119, 162]]], ["Richtlijn antifosfolipidesyndroom.", [["Richtlijn antifosfolipidesyndroom", "TREATMENT", 0, 33]]], ["2007.Diagnoseborstvoeding, wel dient de pasgeborene nog enkele weken te worden gesuppleerd met vitamine K. Als de dosering van de anti-epileptica tijdens de zwangerschap is verhoogd, dan wordt dit in het kraambed geleidelijk weer afgebouwd.", [["Diagnoseborstvoeding", "DISEASE", 5, 25], ["vitamine K", "CHEMICAL", 95, 105]]], ["Over de exacte dosering foliumzuur bestaat internationaal geen overeenstemming, de adviezen vari\u00ebren tussen 0,4 en 5 mg per dag.", [["adviezen vari\u00ebren tussen", "TREATMENT", 83, 107]]], ["In Nederland adviseert de Gezondheidsraad aan vrouwen met epilepsie in principe 0,4-0,5 mg per dag.Cerebrovasculaire accidenten (CVA)Cerebrovasculaire accidenten komen tijdens de zwangerschap niet vaker voor.", [["CVA", "DISEASE", 129, 132], ["Cerebrovasculaire accidenten (CVA)", "PROBLEM", 99, 133], ["Cerebrovasculaire", "PROBLEM", 133, 150]]], ["Het relatieve risico is tijdens de zwangerschap 0,7 en dat stijgt in het kraambed tot 8,7.Cerebrovasculaire accidenten (CVA)Bij de oorzaak van een CVA kunnen drie etiologische factoren betrokken zijn: aandoeningen van de arteri\u00ebn (o.a. atherosclerose, SLE), hematologische afwijkingen (o.a. antifosfolipidesyndroom, sikkelcelanemie, trombofilie), en cardiovasculaire aandoeningen waarbij emboli kunnen worden gevormd (o.a. atriumfibrillatie, klepziekten, endocarditis).Cerebrovasculaire accidenten (CVA)De behandeling van een CVA is tijdens de zwangerschap niet anders.", [["CVA", "DISEASE", 120, 123], ["SLE", "DISEASE", 252, 255], ["endocarditis", "DISEASE", 455, 467], ["CVA", "DISEASE", 499, 502], ["Cerebrovasculaire accidenten (CVA)", "PROBLEM", 90, 124], ["Bij de oorzaak van een CVA", "TREATMENT", 124, 150], ["SLE", "PROBLEM", 252, 255], ["emboli", "PROBLEM", 388, 394], ["endocarditis", "PROBLEM", 455, 467], ["Cerebrovasculaire accidenten (CVA)", "PROBLEM", 469, 503], ["emboli", "OBSERVATION", 388, 394], ["endocarditis", "OBSERVATION", 455, 467]]], ["Acute behandeling met trombolytica is in de zwangerschap waarschijnlijk veilig.", [["Acute behandeling met trombolytica", "PROBLEM", 0, 34]]], ["Het preventief gebruik van aspirine is eveneens veilig.Cerebrovasculaire accidenten (CVA)Bij vrouwen met een eerder CVA is het gestegen risico op een recidief CVA tijdens de zwangerschap 1-2%.Subarachno\u00efdale bloedingenTijdens 1-5 op de 10.000 zwangerschappen komt een subarachno\u00efdale bloeding voor.", [["aspirine", "CHEMICAL", 27, 35], ["CVA", "DISEASE", 85, 88], ["CVA", "DISEASE", 116, 119], ["Cerebrovasculaire accidenten", "PROBLEM", 55, 83], ["CVA", "PROBLEM", 85, 88], ["CVA", "PROBLEM", 116, 119], ["Subarachno\u00efdale bloedingenTijdens", "TREATMENT", 192, 225]]], ["De meeste bloedingen worden veroorzaakt door een gebarsten aneurysma, andere oorzaken zijn aangeboren arterioveneuze malformaties, drugsgebruik, trauma, vasculitiden en hemorragische diathese.Subarachno\u00efdale bloedingenBij een subarachno\u00efdale bloeding is er een arteri\u00eble bloeding die zorgt voor een acute stijging van de intracrani\u00eble druk.", [["trauma", "DISEASE", 145, 151], ["een gebarsten aneurysma", "PROBLEM", 45, 68], ["drugsgebruik", "PROBLEM", 131, 143], ["trauma", "PROBLEM", 145, 151], ["Subarachno\u00efdale bloedingenBij een subarachno\u00efdale bloeding", "PROBLEM", 192, 250], ["subarachno\u00efdale bloeding", "OBSERVATION", 226, 250], ["acute", "OBSERVATION_MODIFIER", 299, 304]]], ["De meest voorkomende typen zijn migraine en tension-type hoofdpijn of spanningshoofdpijn.", [["migraine", "DISEASE", 32, 40], ["migraine", "PROBLEM", 32, 40], ["spanningshoofdpijn", "TREATMENT", 70, 88]]], ["In tegenstelling tot migraine vermindert tension-type hoofdpijn tijdens de zwangerschap niet.", [["migraine", "DISEASE", 21, 29], ["tension", "OBSERVATION_MODIFIER", 41, 48]]], ["Hoofdpijn kan een van de belangrijkste en eerste klachten zijn bij pre-eclampsie.", [["Hoofdpijn kan een van de belangrijkste en eerste klachten zijn bij pre-eclampsie", "TREATMENT", 0, 80]]], ["In de differentiaaldiagnose van hoofdpijn tijdens de zwangerschap hoort ook zeker de sinus sagittalis trombose of het 'kraamhoofd'.", [["sinus", "ANATOMY", 85, 90]]], ["Koorts, leukocytose en neurologische problemen zijn andere klinische symptomen.Multiple scleroseMultiple sclerose is een auto-immuunziekte, waarbij het chronisch ontstekingsproces leidt tot demyelinisering van het centrale zenuwstelsel.", [["waarbij het chronisch ontstekingsproces leidt tot demyelinisering van het centrale zenuwstelsel", "SPECIES", 140, 235], ["Koorts", "TEST", 0, 6], ["leukocytose", "TREATMENT", 8, 19], ["Multiple scleroseMultiple sclerose", "PROBLEM", 79, 113], ["scleroseMultiple", "OBSERVATION_MODIFIER", 88, 104], ["sclerose", "OBSERVATION", 105, 113]]], ["Zoals meer neurologische aandoeningen verloopt de ziekte langzaam progressief met exacerbaties of schubs die een-tot tweemaal per jaar optreden.Multiple scleroseTijdens de zwangerschap verslechtert het ziektebeeld niet.", [["Zoals", "TREATMENT", 0, 5], ["Multiple scleroseTijdens", "PROBLEM", 144, 168], ["scleroseTijdens", "OBSERVATION", 153, 168]]], ["Het aantal exacerbaties daalt tijdens de zwangerschap om tijdens het kraambed weer toe te nemen.", [["zwangerschap om tijdens het kraambed weer toe te nemen", "SPECIES", 41, 95]]], ["Er zijn aanwijzingen dat zwangerschap de eerste tekenen of beginschub uitstelt en de langetermijnprognose van de ziekte gunstig be\u00efnvloedt.Multiple scleroseZwangerschapscomplicaties komen niet vaker voor bij pati\u00ebnten met multiple sclerose, ook aangeboren afwijkingen niet.", [["Multiple scleroseZwangerschapscomplicaties komen", "PROBLEM", 139, 187]]], ["Borstvoeding heeft geen invloed op de frequentie van de exacerbaties in het kraambed.MononeuropathieHet carpaletunnelsyndroom (CTS) is de meest voorkomende compressieneuropathie in de zwangerschap.", [["CTS", "DISEASE", 127, 130]]], ["Het lijkt aannemelijk dat de vochtretentie waarmee de zwangerschap gepaard gaat, hierbij een rol speelt.", [["een rol", "OBSERVATION", 89, 96]]], ["Na de zwangerschap laat het herstel vaak lang op zich wachten.MononeuropathieEvenals CTS komt meralgia paraesthetica frequent voor tijdens de zwangerschap.", [["Na", "CHEMICAL", 0, 2], ["CTS", "DISEASE", 85, 88], ["Na", "TEST", 0, 2], ["zwangerschap", "TEST", 6, 18], ["MononeuropathieEvenals", "TEST", 62, 84], ["meralgia", "PROBLEM", 94, 102], ["meralgia", "OBSERVATION", 94, 102]]], ["Hernia nuclei pulposi komt relatief weinig en zeker niet vaker in de zwangerschap voor.", [["Hernia", "PROBLEM", 0, 6]]], ["Wel vaker komt neuropathie van de nervus facialis (paralyse van Bell) in de zwangerschap voor.", [["nervus facialis", "DISEASE", 34, 49]]], ["De prognose is beter dan wanneer de aandoening ontstaat buiten de zwangerschap.Myasthenia gravisMyasthenia gravis is een chronische auto-immuunziekte die klinisch gepaard gaat met vermoeidheid en toenemende spierzwakte tijdens spierarbeid.", [["Myasthenia gravis", "DISEASE", 79, 96], ["Myasthenia gravis", "DISEASE", 96, 113], ["spierzwakte tijdens", "SPECIES", 207, 226], ["Myasthenia gravis", "PROBLEM", 79, 96], ["Myasthenia gravis", "PROBLEM", 96, 113]]], ["Antilichamen tegen acetylcholinereceptoren in de postsynaptische eindplaat zijn hier de oorzaak van.", [["Antilichamen tegen acetylcholinereceptoren", "TREATMENT", 0, 42]]], ["In de loop van de dag neemt de spierzwakte toe.", [["toe", "ANATOMY", 43, 46]]], ["Aangedane spiergroepen zijn de oog-en gelaatsmusculatuur, bulbaire spieren en spieren van de bovenste extremiteiten.Myasthenia gravisDe ernst van deze aandoening kan tijdens de zwangerschap wisselen tussen een sterke verbetering en een forse verslechtering.", [["Myasthenia", "DISEASE", 116, 126], ["Aangedane spiergroepen zijn", "TREATMENT", 0, 27], ["Myasthenia", "PROBLEM", 116, 126]]], ["Op de lange termijn lijkt zwangerschap geen invloed op het natuurlijke beloop van de ziekte te hebben.Myasthenia gravisZwangerschapscomplicaties komen niet vaker voor.", [["Myasthenia gravis", "DISEASE", 102, 119], ["Myasthenia gravis", "PROBLEM", 102, 119]]], ["Wel kunnen de antilichamen de placenta passeren en bij de pasgeborene een tijdelijke neonatale myasthenia gravis veroorzaken.", [["myasthenia gravis", "DISEASE", 95, 112], ["Wel kunnen de antilichamen de placenta passeren", "TREATMENT", 0, 47], ["myasthenia gravis", "OBSERVATION", 95, 112]]], ["Arthrogryposis multiplex congenita is een zeldzame aandoening die in verband wordt gebracht met myasthenia gravis.Myasthenia gravisBij deze pati\u00ebnten is er meer kans op een kunstverlossing.", [["Arthrogryposis multiplex congenita", "DISEASE", 0, 34], ["myasthenia gravis", "DISEASE", 96, 113], ["Myasthenia gravis", "DISEASE", 114, 131], ["Arthrogryposis multiplex congenita", "PROBLEM", 0, 34], ["myasthenia gravis", "PROBLEM", 96, 113], ["Myasthenia gravis", "PROBLEM", 114, 131], ["congenita", "OBSERVATION", 25, 34], ["myasthenia gravis", "OBSERVATION", 96, 113], ["gravis", "OBSERVATION", 125, 131]]], ["Lidoca\u00efne en bupivaca\u00efne zijn veilig toe te passen bij deze groep pati\u00ebnten.", [["Lidoca\u00efne", "CHEMICAL", 0, 9], ["Lidoca\u00efne", "CHEMICAL", 0, 9], ["Lidoca\u00efne en bupivaca\u00efne zijn", "TREATMENT", 0, 29]]], ["Infecties in het kraambed kunnen leiden tot een exacerbatie.Myasthenia gravisMedicamenteuze behandeling van myasthenia gravis vindt plaats met cholinesteraseremmers zoals neostigmine en pyridostigmine.", [["Infecties", "DISEASE", 0, 9], ["Myasthenia gravis", "DISEASE", 60, 77], ["myasthenia gravis", "DISEASE", 108, 125], ["neostigmine", "CHEMICAL", 171, 182], ["pyridostigmine", "CHEMICAL", 186, 200], ["neostigmine", "CHEMICAL", 171, 182], ["pyridostigmine", "CHEMICAL", 186, 200], ["pyridostigmine", "SIMPLE_CHEMICAL", 186, 200], ["kunnen", "SPECIES", 26, 32], ["Infecties", "PROBLEM", 0, 9], ["Myasthenia gravis", "PROBLEM", 60, 77], ["Medicamenteuze", "TREATMENT", 77, 91], ["van myasthenia gravis vindt plaats", "TREATMENT", 104, 138], ["neostigmine en pyridostigmine", "TREATMENT", 171, 200], ["gravis", "OBSERVATION", 71, 77]]], ["Corticostero\u00efden of immunosuppressiva kunnen worden gebruikt als met deze medicatie onvoldoende effect wordt bereikt.", [["Corticostero\u00efden", "TREATMENT", 0, 16], ["immunosuppressiva", "TREATMENT", 20, 37]]], ["Cholinesteraseremmers kunnen veilig in de zwangerschap en tijdens de borstvoeding worden gebruikt.Myasthenia gravisBij 10-20% van de neonaten ontstaat binnen de eerste vier dagen post partum een tijdelijke neonatale myasthenia gravis.", [["Myasthenia gravis", "DISEASE", 98, 115], ["myasthenia gravis", "DISEASE", 216, 233], ["Myasthenia gravisBij", "PROBLEM", 98, 118], ["myasthenia gravis", "OBSERVATION", 216, 233]]], ["Het eiwitverlies in de urine stijgt in de normale zwangerschap licht.", [["urine", "ORGANISM_SUBSTANCE", 23, 28]]], ["Tot 300 mg eiwitverlies per 24 uur wordt als fysiologisch beschouwd.", [["Tot", "TREATMENT", 0, 3]]], ["De gestegen klaring zorgt ook voor een hogere uitscheiding van glucose zonder dat er sprake hoeft te zijn van diabetes.21.11De hormonale veranderingen in de zwangerschap in combinatie met de mechanische compressie door de uterus zorgen voor een verslapping en verwijding van de urinewegen.", [["diabetes", "DISEASE", 110, 118], ["glucose", "CHEMICAL", 63, 70], ["uterus", "ANATOMY", 222, 228]]], ["Dit is het duidelijkst aan de rechterkant.21.11De mechanische druk van de uterus op de blaas geeft zwangeren een continu gevoel van aandrang, waardoor ze vaker de neiging hebben te moeten plassen.UrineweginfectiesDoor functionele, hormonale en anatomische veranderingen van de urinewegen komen urineweginfecties vaker voor in de zwangerschap.", [["uterus", "ANATOMY", 74, 80]]], ["De Escherichia coli is de meest voorkomende veroorzaker van urineweginfecties tijdens de zwangerschap.Asymptomatische bacteriurieBij 4,7% van de zwangeren ontstaat een asymptomatische bacteriurie: de aanwezigheid van een signifi-cante hoeveelheid bacteri\u00ebn in de urine zonder dat er klachten optreden.", [["Escherichia coli", "ORGANISM", 3, 19], ["Escherichia coli", "SPECIES", 3, 19], ["Escherichia coli", "SPECIES", 3, 19], ["De Escherichia coli", "PROBLEM", 0, 19], ["bacteriurieBij", "TEST", 118, 132], ["Escherichia coli", "OBSERVATION", 3, 19]]], ["Op zich levert dit geen direct gevaar of klachten op.", [["klachten op", "TREATMENT", 41, 52]]], ["Wel ontwikkelt 40% van deze vrouwen een manifeste urineweginfectie of pyelonefritis.", [["pyelonefritis", "DISEASE", 70, 83], ["pyelonefritis", "PROBLEM", 70, 83], ["pyelonefritis", "OBSERVATION", 70, 83]]], ["Uit meta-analyses blijkt het echter niet nuttig routineus te screenen op asymptomatische bacteriurie.Acute cystitisOngeveer 1% van de zwangerschappen wordt gecompliceerd door een blaasontsteking.", [["cystitis", "DISEASE", 107, 115], ["nuttig routineus", "SPECIES", 41, 57], ["meta-analyses", "TEST", 4, 17], ["Acute cystitis", "PROBLEM", 101, 115], ["cystitis", "OBSERVATION", 107, 115]]], ["De klinische verschijnselen en behandeling zijn dezelfde als buiten de zwangerschap.Acute pyelonefritisIn ongeveer 1-2% van de zwangerschappen ontstaat een acute pyelonefritis.", [["acute pyelonefritis", "DISEASE", 156, 175], ["Acute pyelonefritisIn", "PROBLEM", 84, 105], ["een acute pyelonefritis", "PROBLEM", 152, 175], ["acute", "OBSERVATION_MODIFIER", 156, 161], ["pyelonefritis", "OBSERVATION", 162, 175]]], ["Deze infectie gaat gepaard met hoge koorts en pijn in de flanken.", [["pijn", "DNA", 46, 50]]], ["Acute pyelonefritis is een ernstig ziektebeeld met belangrijke maternale en foetale morbiditeit.", [["pyelonefritis", "DISEASE", 6, 19], ["Acute pyelonefritis", "PROBLEM", 0, 19], ["pyelonefritis", "OBSERVATION", 6, 19]]], ["Behandeling dient klinisch plaats te vinden met in eerste instantie intraveneus toegediende antibiotica.UrolithiasisUrolithiasis kan ook in de zwangerschap koliekpijnen veroorzaken en compliceert 1 op elke 200 zwangerschappen.", [["instantie intraveneus", "SPECIES", 58, 79]]], ["Buiten de zwangerschap worden nierstenen primair gediagnosticeerd met behulp van CT-scanonderzoek.", [["van CT", "TEST", 77, 83]]], ["Met name stenen in de ureter kunnen hiermee moeilijk worden gevisualiseerd.", [["ureter", "ANATOMY", 22, 28]]], ["Een zogenoemd single-shot IVP kan uiteindelijk in meer dan 95% van de gevallen urolithiasis aantonen.", [["urolithiasis aantonen", "DISEASE", 79, 100], ["Een zogenoemd", "TREATMENT", 0, 13], ["urolithiasis aantonen", "PROBLEM", 79, 100], ["urolithiasis", "OBSERVATION", 79, 91]]], ["MRI-onderzoek is niet geschikt om in de zwangerschap nierstenen aan te tonen.", [["MRI", "TEST", 0, 3]]], ["Er kan in die gevallen worden gekozen voor (tijdelijke) drainage van het geobstrueerde systeem of voor verwijdering van de niersteen.", [["Er kan", "CHEMICAL", 0, 6], ["drainage", "TREATMENT", 56, 64]]], ["Extracorporele percutane lithotripsie is in de zwangerschap gecontra-indiceerd.Chronische nierziekteChronische nierziekte is een weinig voorkomend probleem.", [["Extracorporele percutane lithotripsie", "TREATMENT", 0, 37]]], ["Tijdens de zwangerschap kan verslechtering van de nierfunctie, stijging van de hypertensie en stijging van eiwitverlies in de urine optreden.Chronische nierziekteZwangerschap bij een pati\u00ebnt met een chronische nierziekte wordt gecompliceerd door meer spontane miskramen, hogere kans op pre-eclampsie, intrauteriene groeivertraging, vroeggeboorte en intrauteriene vruchtdood.", [["Chronische nierziekte", "CHEMICAL", 141, 162], ["urine", "ORGANISM_SUBSTANCE", 126, 131], ["Chronische nierziekte", "SPECIES", 141, 162], ["Chronische nierziekte", "TREATMENT", 141, 162]]], ["Bij een al bestaande prote\u00efnurie is het vaak moeilijk in de zwangerschap de diagnose pre-eclampsie te stellen.Chronische nierziekteDe prognose van deze complicaties hangt af van de volgende preconceptionele factoren: -de aanwezigheid en mate van nierinsuffici\u00ebntie; -de aanwezigheid en mate van hypertensie; -de aanwezigheid en mate van prote\u00efnurie; -de onderliggende oorzaak van de nierziekte.Chronische nierziekteBij vrouwen met ernstige nierinsuffici\u00ebntie (preconceptioneel serumcreatinine >180 \u03bcmol/l) wordt >90% van de kinderen te vroeg geboren en zal de nierfunctie bij 50% van de vrouwen met meer dan 25% verminderen.", [["Bij een al bestaande prote\u00efnurie", "TREATMENT", 0, 32], ["serumcreatinine", "TEST", 477, 492]]], ["Bij minder ernstige nierinsuffici\u00ebntie (preconceptioneel serumcreatinine 125-180 \u03bcmol/l) wordt 60% van de kinderen te vroeg geboren.", [["serumcreatinine", "TEST", 57, 72]]], ["Ongeveer 2% ontwikkelt na een jaar terminaal nierfalen.Chronische nierziekteDe behandeling van vrouwen met chronische nierziekten dient multidisciplinair te gebeuren.", [["na", "CHEMICAL", 23, 25], ["chronische nierziekten", "TREATMENT", 107, 129]]], ["Als gevolg van verminderde erytropo\u00ebtineproductie kan anemie ontstaan.Chronische nierziekteBelangrijk is voorts het preconceptioneel vastleggen van de nierfunctie en het bespreken van de kans op maternale en foetale complicaties tijdens en als gevolg van de zwangerschap.Acute buikpijnBuikpijn in de zwangerschap kan worden veroorzaakt door interne, psychiatrische, obstetrische, gynaecologische of chirurgische afwijkingen.", [["Acute buikpijnBuikpijn", "PROBLEM", 271, 293]]], ["Bij ongeveer 0,2% van alle zwangeren is het nodig abdominaal chirurgisch in te grijpen.", [["Bij", "TREATMENT", 0, 3]]], ["Afhankelijk van de zwangerschapsduur en de onderliggende oorzaak zal voorafgaand aan de chirurgische procedure een sectio caesarea moeten worden uitgevoerd.", [["aan de chirurgische procedure", "TREATMENT", 81, 110]]], ["De incisie, veelal een mediane of paramediane (onderbuiks) incisie, dient zo gekozen te worden dat inspectie van de overige buikorganen goed mogelijk is zonder daarbij de uterus overmatig te moeten manipuleren.Anamnese en lichamelijk onderzoekBij de beoordeling van buikpijnklachten dient zowel bij de anamnese als het lichamelijk onderzoek rekening te worden gehouden met de typische zwangerschapsveranderingen in de buikregio.", [["uterus", "ORGAN", 171, 177], ["Anamnese", "TREATMENT", 210, 218], ["uterus", "ANATOMY", 171, 177]]], ["De veranderende anatomie zorgt voor verplaatsing van organen, waardoor met name de locatie van de appendix kan wijzigen.", [["De veranderende anatomie zorgt voor verplaatsing van organen, waardoor met name de locatie van de appendix kan wijzigen", "SPECIES", 0, 119]]], ["Peritoneale prikkeling kan gemaskeerd worden door een voorliggende uterus.DiagnostiekBij beoordeling van het laboratoriumonderzoek is het goed zich te realiseren dat infectieparameters zoals het leukocytenaantal en het CRP (C-reactief prote\u00efne) in de normale zwangerschap licht verhoogd zijn.", [["uterus", "ANATOMY", 67, 73], ["uterus", "ORGAN", 67, 73], ["zoals", "TEST", 185, 190], ["CRP", "TEST", 219, 222], ["uterus", "ANATOMY", 67, 73]]], ["Durante partu zullen beide parameters nog verder stijgen.", [["Durante partu zullen", "TREATMENT", 0, 20]]], ["Na toediening van dexamethason ten bate van de foetale longrijping zal een leukemische reactie optreden.DiagnostiekGebruik van radiologische diagnostische technieken dient in de hele zwangerschap zo veel mogelijk beperkt te worden.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2]]], ["Bij buikpijnklachten is echoscopisch onderzoek van het abdomen het diagnosticum van eerste keuze.", [["abdomen", "ANATOMY", 55, 62]]], ["Uiteraard is dit onderzoek vaak minder betrouwbaar bij een vergrote uterus.", [["uterus", "ANATOMY", 68, 74], ["uterus", "ORGAN", 68, 74], ["een vergrote", "OBSERVATION", 55, 67], ["uterus", "ANATOMY", 68, 74]]], ["MRIonderzoek van het abdomen kan in veel gevallen ook uitkomst bieden.", [["abdomen", "ANATOMY", 21, 28]]], ["Een staand buikoverzicht is ook bij zwangeren nog steeds het eenvoudigste diagnosticum bij de verdenking op een ileus.DiagnostiekFoetale complicaties van radiologisch onderzoek, zoals structurele afwijkingen, groeivertraging en miskramen, worden niet gezien bij een stralingsbelasting van minder dan 50-100 mSv.", [["ileus", "DISEASE", 112, 117], ["eenvoudigste diagnosticum", "SPECIES", 61, 86], ["Een staand buikoverzicht", "TREATMENT", 0, 24], ["een ileus", "PROBLEM", 108, 117], ["ileus", "OBSERVATION", 112, 117]]], ["Het risico op ontwikkelen van een maligniteit op oudere leeftijd is waarschijnlijk erg klein.", [["erg klein", "OBSERVATION", 83, 92]]], ["Bij een belasting van >10 mSv wordt het risico op ontwikkeling van leukemie met een factor 1,5-2 vergroot.", [["een factor", "TEST", 80, 90]]], ["IQ-reductie wordt beschreven bij >100 mSv en ernstige mentale retardatie en microcefalie bij >1000 mSv.Cyste van het ovarium of steeldraaiMet name in het eerste trimester zal er nog vaak sprake zijn van een cyste aan een van beide ovaria.", [["Met", "CHEMICAL", 138, 141], ["Met", "GENE_OR_GENE_PRODUCT", 138, 141], ["het eerste trimester zal er nog vaak sprake zijn van een cyste aan een van beide ovaria", "SPECIES", 150, 237], ["IQ", "TEST", 0, 2]]], ["Deze ovariumcyste is het overblijfsel van het corpus luteum en heet dan ook het corpus luteum graviditatis.", [["corpus luteum", "TISSUE", 46, 59], ["corpus luteum graviditatis", "CANCER", 80, 106], ["het overblijfsel van het corpus luteum en heet dan ook het corpus luteum graviditatis", "SPECIES", 21, 106], ["corpus luteum", "ANATOMY", 80, 93]]], ["Na het eerste trimester verdwijnt deze cyste.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na", "TEST", 0, 2], ["deze cyste", "OBSERVATION", 34, 44]]], ["Een cyste na het eerste trimester is per definitie afwijkend.", [["na", "CHEMICAL", 10, 12]]], ["Zelden tordeert alleen de tuba, ook in die gevallen zal chirurgische interventie nodig zijn, het ovarium kan dan vaak wel gespaard blijven.MyomataOnder invloed van de zwangerschapshormonen en met name oestradiol zullen reeds prenataal aanwezige myomata in omvang kunnen toenemen.", [["oestradiol", "CHEMICAL", 201, 211], ["oestradiol", "CHEMICAL", 201, 211], ["oestradiol", "SIMPLE_CHEMICAL", 201, 211]]], ["Vooral in het tweede trimester zal dat aanleiding kunnen zijn tot pijnklachten, veroorzaakt door ischemie in het myoom.", [["Vooral", "TREATMENT", 0, 6]]], ["Na het tweede trimester verdwijnen de Tabel 21.14 Foetale stralingsbelasting bij radiologische proceduresProcedureFoetale stralingsbelasting (mSv) thoraxfoto (2 richtingen) buikoverzicht single-detector spiraal-CT-thorax multi-detector spiraal-CT-thorax intraveneus pyelogram coloninloop flebografie (unilateraal) CT-scan schedel CT-scan abdomen CT-scan bekken <0,01 4,2 0,06 0,013 1,7 6,8 <0,5 <0,005 8 25ProcedureBron: Nijkeuter et al. J Thromb Haemost.", [["Na", "CHEMICAL", 0, 2], ["buikoverzicht single-detector spiraal-CT-thorax multi-detector spiraal-CT-thorax intraveneus pyelogram coloninloop flebografie", "DNA", 173, 299], ["Na", "TEST", 0, 2], ["Foetale stralingsbelasting bij radiologische procedures", "TREATMENT", 50, 105], ["ProcedureFoetale", "TEST", 105, 121], ["thoraxfoto", "TEST", 147, 157], ["buikoverzicht", "TEST", 173, 186], ["detector spiraal", "TEST", 194, 210], ["CT", "TEST", 211, 213], ["multi-detector spiraal", "TEST", 221, 243], ["CT-thorax intraveneus pyelogram", "TEST", 244, 275], ["CT-scan schedel CT-scan abdomen CT", "TEST", 314, 348], ["scan bekken", "TEST", 349, 360], ["thorax", "ANATOMY", 214, 220], ["thorax", "ANATOMY", 247, 253], ["abdomen", "ANATOMY", 338, 345], ["Thromb Haemost", "OBSERVATION", 440, 454]]], ["2006; 4:496-500. pijnklachten vaak vanzelf.", [["pijnklachten vaak vanzelf", "TREATMENT", 17, 42]]], ["Adequate pijnstilling volstaat meestal.", [["pijnstilling volstaat", "OBSERVATION", 9, 30]]], ["Zelden is het noodzakelijk om chirurgisch in te grijpen.AppendicitisAppendicitis is de meest voorkomende oorzaak van acute buik in de zwangerschap en komt bij 1 op elke 1400 tot 6600 zwangerschappen voor.", [["Zelden", "CHEMICAL", 0, 6], ["AppendicitisAppendicitis", "DISEASE", 56, 80], ["Zelden", "SIMPLE_CHEMICAL", 0, 6]]], ["Bij elke zwangere pati\u00ebnt met acute buikpijnklachten dient de diagnose appendicitis te worden overwogen.", [["appendicitis", "DISEASE", 71, 83], ["appendicitis", "PROBLEM", 71, 83], ["acute", "OBSERVATION_MODIFIER", 30, 35]]], ["De klassieke pijnlokalisatie bij een appendicitis kan namelijk in de tweede helft van de zwangerschap afwezig zijn door verplaatsing van de appendix.", [["appendicitis", "DISEASE", 37, 49], ["De klassieke pijnlokalisatie", "TREATMENT", 0, 28], ["een appendicitis", "PROBLEM", 33, 49], ["appendix", "ANATOMY", 140, 148]]], ["De diagnose kan door middel van echoscopie vaak goed worden gesteld.AppendicitisVaak ontstaan preterme contracties na een appendectomie.", [["na", "CHEMICAL", 115, 117], ["AppendicitisVaak", "TEST", 68, 84]]], ["Vroeggeboorte komt derhalve ook vaker voor en zeker als er ook sprake is van peritonitis.CholecystitisIn de zwangerschap is er sprake van verminderde motiliteit en vertraagde lediging van de galblaas.", [["peritonitis", "DISEASE", 77, 88], ["Cholecystitis", "DISEASE", 89, 102], ["Vroeggeboorte komt derhalve ook vaker voor en zeker als er ook sprake", "SPECIES", 0, 69], ["van peritonitis", "PROBLEM", 73, 88], ["Cholecystitis", "PROBLEM", 89, 102]]], ["Mogelijk als gevolg hiervan en als gevolg van de hormonale veranderingen ontstaan tijdens de zwangerschap vaker uit cholesterol gevormde galstenen.", [["cholesterol", "CHEMICAL", 116, 127], ["cholesterol", "CHEMICAL", 116, 127], ["Mogelijk als gevolg hiervan en als gevolg van", "TREATMENT", 0, 45]]], ["Het klachtenpatroon van acute cholecystitis is te vergelijken met dat buiten de zwangerschap: pijn in epigastrio, het maagkuiltje en de bovenbuik.", [["acute cholecystitis", "DISEASE", 24, 43], ["acute cholecystitis", "PROBLEM", 24, 43], ["cholecystitis", "OBSERVATION", 30, 43]]], ["De prevalentie van acute cholecystitis in de zwangerschap is iets lager dan die van acute appendicitis.", [["acute cholecystitis", "DISEASE", 19, 38], ["acute appendicitis", "DISEASE", 84, 102], ["van acute cholecystitis", "PROBLEM", 15, 38], ["van acute appendicitis", "PROBLEM", 80, 102], ["cholecystitis", "OBSERVATION", 25, 38], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["appendicitis", "OBSERVATION", 90, 102]]], ["De behandeling van cholecystitis is dezelfde als buiten de zwangerschap en is in eerste instantie conservatief.", [["cholecystitis", "DISEASE", 19, 32]]], ["Bij falen hiervan of bij tekenen van peritonitis dient chirurgisch te worden ingegrepen.", [["peritonitis", "DISEASE", 37, 48], ["Bij falen hiervan", "TREATMENT", 0, 17], ["bij tekenen van peritonitis", "TREATMENT", 21, 48]]], ["Belangrijk is ten slotte bij pijn in de rechterbovenbuik uit te sluiten dat er sprake is van pre-eclamptische sequelae.PancreatitisAcute pancreatitis is zeldzaam, komt niet vaker voor tijdens de zwangerschap, ontstaat meestal in het derde trimester en de behandeling is identiek aan die buiten de zwangerschap.", [["Pancreatitis", "DISEASE", 119, 131], ["pancreatitis", "DISEASE", 137, 149], ["Belangrijk", "TREATMENT", 0, 10], ["Pancreatitis", "PROBLEM", 119, 131], ["Acute pancreatitis", "PROBLEM", 131, 149], ["zeldzaam", "PROBLEM", 153, 161], ["Acute", "OBSERVATION_MODIFIER", 131, 136], ["pancreatitis", "OBSERVATION", 137, 149]]], ["In de zwangerschap zijn galstenen de meest voorkomende oorzaak.Urologische oorzakenBuikpijnklachten kunnen veroorzaakt worden door een infectie van de blaas of hogere urinewegen.", [["urinewegen", "CHEMICAL", 167, 177]]], ["Pyelonefritis veroorzaakt veelal hoge koorts en behoeft directe behandeling.", [["Pyelonefritis", "PROBLEM", 0, 13]]], ["Tevens kunnen kolieken van de urinewegen een acute buik simuleren.", [["acute", "OBSERVATION_MODIFIER", 45, 50]]], ["Urolithiasis kan uiteraard ook in de zwangerschap voorkomen en koliekpijnen veroorzaken.Overige oorzakenNet als buiten de zwangerschap kunnen diverse interne ziekten klinische beelden laten zien die lijken op een acute buik.", [["Overige oorzaken", "SPECIES", 88, 104], ["Urolithiasis", "PROBLEM", 0, 12], ["Net als buiten", "PROBLEM", 104, 118]]], ["Voorbeelden hiervan zijn metabole stoornissen zoals een diabetische ketoacidose en hypercalci\u00ebmie.", [["Voorbeelden hiervan zijn", "TREATMENT", 0, 24], ["ketoacidose en hypercalci\u00ebmie", "TREATMENT", 68, 97]]], ["Dan meldt ze zich 's nachts op de spoedeisende hulp met sinds een dag bestaande klachten van algemene malaise, misselijkheid en braken en buikpijn.", [["malaise", "PROBLEM", 102, 109]]], ["Er is geen bewegingsdrang.", [["bewegingsdrang", "OBSERVATION", 11, 25]]], ["De fundus uteri reikt tot ruim halverwege navel-xifo\u00efd.", [["uteri", "ANATOMY", 10, 15], ["uteri", "ANATOMY", 10, 15]]], ["De uterus contraheert af en toe, maar er lijkt geen sprake van wee\u00ebnactiviteit.", [["De uterus contraheert af en toe, maar er lijkt geen sprake van wee\u00ebnactiviteit", "SPECIES", 0, 78], ["uterus", "ANATOMY", 3, 9], ["toe", "ANATOMY", 28, 31]]], ["De pati\u00ebnt is opvallend tachypno\u00efsch.Overige oorzakenLaboratoriumonderzoek laat een verhoogd leukocytenaantal en CRP zien, het urinesediment is zonder afwijkingen.", [["Overige oorzakenLaboratoriumonderzoek laat een verhoogd leukocytenaantal en CRP zien", "SPECIES", 37, 121], ["Overige", "TEST", 37, 44], ["oorzakenLaboratoriumonderzoek", "TEST", 45, 74]]], ["Echoscopisch onderzoek toont geen obstetrische afwijkingen, de appendix komt niet in beeld en er is een normale galblaas.", [["Echoscopisch", "TEST", 0, 12], ["obstetrische", "PROBLEM", 34, 46], ["appendix", "ANATOMY", 63, 71]]], ["Na afname van kweken wordt begonnen met antibiotica.Overige oorzakenTijdens de volgende dag lijkt de pati\u00ebnt wat op te knappen, de koorts neemt af en het laboratoriumonderzoek laat verbetering zien.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Overige oorzakenTijdens de volgende dag lijkt de pati\u00ebnt wat op te knappen, de koorts neemt af en het laboratoriumonderzoek laat verbetering zien", "SPECIES", 52, 197]]], ["Het cardiotocogram, dat tot dan toe behoudens een tachycardie ongestoord is gebleven, verliest variabiliteit en vertoont flauwe deceleraties.", [["Het cardiotocogram", "TEST", 0, 18], ["toe", "ANATOMY", 32, 35]]], ["Gezien de verslechtering van de algemene conditie van de pati\u00ebnt en die van de foetus wordt besloten, ondanks de jonge zwangerschapsduur, een proeflaparotomie via een mediane onderbuiksincisie te verrichten.Overige oorzakenReeds bij openen van het peritoneum stroomt pus uit de buikholte.", [["een proeflaparotomie", "TREATMENT", 138, 158], ["peritoneum", "ANATOMY", 248, 258]]], ["Na geboorte van placenta en sluiten van de uterus wordt de buik verder ge\u00efnspecteerd.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na geboorte van placenta en sluiten van de uterus", "TREATMENT", 0, 49], ["uterus", "ANATOMY", 43, 49]]], ["De adnexa zijn beiderzijds normaal van aspect.", [["De adnexa zijn beiderzijds", "TREATMENT", 0, 26], ["adnexa", "ANATOMY", 3, 9]]], ["Achter de uterus is de appendix verkleefd in het cavum Douglasi.", [["uterus", "ORGAN", 10, 16], ["uterus", "ANATOMY", 10, 16], ["de appendix", "OBSERVATION", 20, 31], ["het cavum", "ANATOMY", 45, 54]]], ["De appendix is opvallend lang en aan de basis verdikt.", [["appendix", "ANATOMY", 3, 11]]], ["De appendix wordt verwijderd.", [["appendix", "ANATOMY", 3, 11]]], ["Pathologisch-anatomisch onderzoek toont een appendicitis met peritonitis aan.Overige oorzakenHet postoperatief beloop is voorspoedig.", [["appendicitis", "DISEASE", 44, 56], ["peritonitis", "DISEASE", 61, 72], ["Overige oorzaken", "SPECIES", 77, 93], ["Pathologisch", "TEST", 0, 12], ["anatomisch", "PROBLEM", 13, 23], ["een appendicitis", "PROBLEM", 40, 56], ["peritonitis aan", "PROBLEM", 61, 76], ["appendicitis", "OBSERVATION", 44, 56], ["peritonitis", "OBSERVATION", 61, 72]]], ["Na enkele dagen is de pati\u00ebnt koortsvrij geworden.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2]]], ["Haar zoon kan na enkele weken de neonatale intensive care verlaten.BuiktraumaIn tegenstelling tot de situatie in de Angelsaksische landen is trauma in Nederland een weinig voorkomende oorzaak van maternale sterfte.", [["na", "CHEMICAL", 14, 16], ["trauma", "DISEASE", 141, 147], ["BuiktraumaIn", "TREATMENT", 67, 79], ["trauma", "PROBLEM", 141, 147]]], ["Tot een zwangerschapsduur van ongeveer 13 weken zijn de uterus en de foetus beschermd in het benige bekken.BuiktraumaNa relatief kleine traumata treedt er zelden (1-5%) een intra-uteriene vruchtdood op als gevolg van een solutio placentae.", [["placentae", "ANATOMY", 229, 238], ["uterus", "ORGAN", 56, 62], ["placentae", "TISSUE", 229, 238], ["BuiktraumaNa", "TREATMENT", 107, 119], ["een intra-uteriene vruchtdood", "TREATMENT", 169, 198], ["uterus", "ANATOMY", 56, 62]]], ["Toch lijkt het van belang na elk stomp buiktrauma van enige betekenis de foetale conditie en de wee\u00ebnactiviteit met een cardiotocogram (CTG) te controleren.BuiktraumaBij grotere ongevallen is een multidisciplinaire aanpak noodzakelijk.", [["Toch lijkt het van belang na elk stomp buiktrauma van enige betekenis de foetale conditie en de wee\u00ebnactiviteit met een cardiotocogram (CTG) te controleren", "SPECIES", 0, 155]]], ["Bij een ernstig trauma kunnen schuifkrachten tussen het myometrium en de placenta een placentaloslating veroorzaken.", [["trauma", "DISEASE", 16, 22], ["myometrium", "TISSUE", 56, 66], ["Bij een ernstig trauma", "TREATMENT", 0, 22], ["het myometrium en de placenta een placentaloslating veroorzaken", "TREATMENT", 52, 115]]], ["Bij een groot trauma is de kans hierop 20-50%.", [["trauma", "DISEASE", 14, 20]]], ["Geadviseerd wordt continue foetale bewaking toe te passen gedurende de eerste vier uur na het trauma.", [["na", "CHEMICAL", 87, 89], ["trauma", "DISEASE", 94, 100]]], ["Indien uteruscontracties ook na deze periode blijven bestaan, moet de foetale bewaking worden gecontinueerd.", [["na", "CHEMICAL", 29, 31]]], ["Als de contracties zijn verdwenen, kan intermitterend een CTG worden vervaardigd.BuiktraumaBij een rhesusnegatieve bloedgroep wordt geadviseerd immunoglobuline anti-D toe te dienen.", [["BuiktraumaBij een", "TREATMENT", 81, 98], ["immunoglobuline anti-D toe te dienen", "TREATMENT", 144, 180]]], ["Hiernaast kan de kleihauer-betke-test ook als indicator optreden voor de ernst van het trauma.", [["het trauma", "DISEASE", 83, 93]]], ["Een zwangere kan vanaf die zwangerschapsduur nooit als nuchter beschouwd worden.", [["Een zwangere kan vanaf", "TREATMENT", 0, 22]]], ["Deze bloeddrukschommelingen kunnen worden veroorzaakt door de operatie zelf maar ook door het te veel op de rug neerleggen van de zwangere.", [["Deze bloeddrukschommelingen kunnen worden veroorzaakt door de operatie zelf maar ook door het te veel op de rug neerleggen van de zwangere", "SPECIES", 0, 138]]], ["Met name wanneer de uterus boven de navel uitkomt, kan in rugligging de vena cava inferior worden afgedrukt.", [["vena cava", "MULTI-TISSUE_STRUCTURE", 72, 81], ["uterus", "ANATOMY", 20, 26], ["vena cava", "ANATOMY", 72, 81]]], ["Door de middelen die tijdens narcose worden toegediend, zal de variabiliteit van het CTG wel tijdelijk verminderen.Anesthesie en zwangerschapOmdat veel van deze middelen in vet oplosbaar zijn, duurt het enige tijd voor ze het lichaam hebben verlaten.", [["vet oplosbaar zijn, duurt het enige tijd voor ze het lichaam hebben verlaten", "SPECIES", 173, 249]]], ["Dit geldt vaak ook voor regionale anesthesie omdat hierbij vaak dezelfde middelen worden toegepast.Anesthesie en zwangerschapVoor postoperatieve pijnstilling kunnen opio\u00efden en paracetamol worden gebruikt.", [["paracetamol", "CHEMICAL", 177, 188], ["paracetamol", "CHEMICAL", 177, 188]]], ["Het is niet duidelijk of profylactisch toedienen van peri-en postoperatieve tocolyse deze preterme contracties kan voorkomen.Anesthesie en zwangerschapTromboseprofylaxe is voor deze groep pati\u00ebnten extra belangrijk.", [["Tromboseprofylaxe", "CHEMICAL", 151, 168], ["Tromboseprofylaxe", "SIMPLE_CHEMICAL", 151, 168], ["Tromboseprofylaxe", "TREATMENT", 151, 168]]], ["Dit kan medicamenteus maar ook met mechanische middelen (steunkousen, snelle mobilisatie) bewerkstelligd worden.Laparoscopie tijdens de zwangerschapDe voordelen van een laparoscopische benadering van chirurgische of gynaecologische problemen zijn evident: minder postoperatieve morbiditeit, minder postoperatieve pijnklachten, kleinere incisies, snel herstel van de darmfunctie en kortere opnameduur, waardoor een sneller herstel van normaal functioneren wordt bereikt.", [["Laparoscopie tijdens", "TREATMENT", 112, 132]]], ["In 1991 werd de eerste laparoscopische ingreep tijdens de zwangerschap verricht, een cholecystectomie.", [["een cholecystectomie", "TREATMENT", 81, 101], ["een cholecystectomie", "OBSERVATION", 81, 101]]], ["Dit ondanks het feit dat het profylactisch geven van tocolytica niet wordt geadviseerd.Laparoscopie tijdens de zwangerschapNaarmate de zwangerschap verder is gevorderd, is door de groeiende uterus een laparoscopie technisch steeds moeilijker uit te voeren.", [["uterus", "ANATOMY", 190, 196]]], ["Beschadiging van de uterus hierdoor is enkele malen beschreven.", [["uterus", "ANATOMY", 20, 26]]], ["Vanaf het tweede trimester is het raadzaam om een open laparoscopische techniek te gebruiken.", [["Vanaf het tweede trimester", "TREATMENT", 0, 26]]], ["Het laatste geldt overigens ook voor andere operatieve ingrepen.Obesitas en zwangerschapDe gezondheid van mannen en vrouwen wordt wereldwijd in toenemende mate be\u00efnvloed door obesitas en dit vormt momenteel de grootste bedreiging voor een gezonde zwangerschapsafloop.", [["Obesitas", "PROBLEM", 64, 72]]], ["De prevalentie van obesitas, die meestal gedefinieerd wordt als een body mass index (BMI) van 30 kg/m 2 of meer, neemt vooral in de westerse wereld snel toe, ook onder vrouwen in hun vruchtbare levensfase (tabel 21.15).", [["toe", "ANATOMY", 153, 156]]], ["Later in de zwangerschap is de BMI geen goede maat meer voor de mate van obesitas.Obesitas en zwangerschapEigenlijk alle bekende zwangerschapscomplicaties nemen toe naarmate de BMI van de zwangere vrouw toeneemt (tabel 21.16).", [["Obesitas", "PROBLEM", 82, 90], ["en zwangerschapEigenlijk alle", "TREATMENT", 91, 120]]], ["Dit geldt met name voor het optreden van diabetes gravidarum en preeclampsie, maar ook voor het optreden van miskramen.", [["diabetes gravidarum", "DISEASE", 41, 60], ["gravidarum", "PROBLEM", 50, 60]]], ["Serotiniteit komt tweemaal vaker voor bij vrouwen met obesitas.", [["Serotiniteit", "TEST", 0, 12], ["obesitas", "PROBLEM", 54, 62], ["met obesitas", "OBSERVATION", 50, 62]]], ["In hoeverre actief beperken van de gewichtstoename inderdaad zwangerschapscomplicaties kan beperken, is nog niet geheel duidelijk.Obesitas en zwangerschapOok baringscomplicaties komen vaker voor.", [["Obesitas", "PROBLEM", 130, 138]]], ["Het aantal vaginale kunstverlossingen is niet verhoogd.", [["Het aantal vaginale kunstverlossingen", "ORGANISM", 0, 37], ["aantal vaginale kunstverlossingen", "SPECIES", 4, 37], ["Het aantal vaginale kunstverlossingen", "SPECIES", 0, 37], ["vaginale kunstverlossingen", "OBSERVATION", 11, 37]]], ["Macrosomie en onvoldoende vordering van de baring door enerzijds onvoldoende wee\u00ebnactiviteit en anderzijds door belemmerend vetweefsel in het kleine bekken spelen hierbij waarschijnlijk een rol.", [["Macrosomie", "TREATMENT", 0, 10]]], ["Zowel bij vaginale baringen als ook bij een sectio caesarea treedt meer bloedverlies op.Obesitas en zwangerschapIn het kraambed is de kans op wondinfecties, endomyometritis en trombose toegenomen.", [["Zowel bij vaginale baringen", "TREATMENT", 0, 27], ["Obesitas", "PROBLEM", 88, 96], ["endomyometritis en trombose toegenomen", "PROBLEM", 157, 195]]], ["Vroege mobilisatie, aanpassing van de dosering anticoagulantia en mechanische maatregelen (steunkousen) kunnen de kans op een trombo-embolie verminderen. ,5 18,5-24,9 25,0-29,9 30,0-34,9 35,0-39,9 \u226540 Depressieve klachten treden vaker op bij een hogere BMI en vereisen speciale aandacht.Obesitas en zwangerschapEen apart probleem bij zwangeren met obesitas vormt de anesthesiologische zorg.", [[",5 18,5-24,9 25,0-29,9 30,0-34,9 35,0-39,9 \u226540", "CHEMICAL", 154, 200], ["anticoagulantia en mechanische maatregelen (steunkousen)", "TREATMENT", 47, 103], ["Obesitas", "PROBLEM", 287, 295]]], ["Aangezien bij deze categorie pati\u00ebnten algehele anesthesie duidelijk nog minder de voorkeur verdient dan bij zwangeren met een normale BMI en het toedienen van locoregionale anesthesie vaak meer tijd kost, moet tijdens de baring tijdig de anesthesioloog in consult worden gevraagd.Obesitas en zwangerschapNa bariatrische chirurgie wordt afgeraden om tijdens de fase van snelle gewichtsreductie zwanger te worden en wordt aangeraden adequate anticonceptie te gebruiken.", [["Obesitas", "PROBLEM", 281, 289]]], ["Uiteindelijk resulteert zelfs beperkte gewichtsreductie, ook als dat zonder bariatrische chirurgie wordt bereikt, in betere zwangerschapsuitkomsten.Obesitas en zwangerschapNiet alleen medische problemen maar ook logistieke problemen vragen de aandacht.", [["Obesitas", "PROBLEM", 148, 156]]], ["Gewichtsafname in het kraambed behoort tot de meest effectieve en langdurige methoden van afvallen.LiteratuurInfectieziekten", [["LiteratuurInfectieziekten", "CHEMICAL", 99, 124]]]], "PMC3481691": [["IntroductionDue to worldwide occurrence, substantial morbidity and mortality rates, respiratory viral infection which swiftly and easily spread, pose a serious public health problem (1).", [["respiratory viral infection", "DISEASE", 84, 111], ["substantial morbidity", "PROBLEM", 41, 62], ["mortality rates", "TEST", 67, 82], ["respiratory viral infection", "PROBLEM", 84, 111], ["substantial", "OBSERVATION_MODIFIER", 41, 52], ["morbidity", "OBSERVATION", 53, 62], ["respiratory", "ANATOMY", 84, 95], ["viral infection", "OBSERVATION", 96, 111], ["serious", "OBSERVATION_MODIFIER", 152, 159]]], ["Human metapneumovirus (hMPV) is one of the etiological agents of acute respiratory tract infections (ARTIs) which can infect people in all age groups (2).", [["respiratory tract", "ANATOMY", 71, 88], ["Human metapneumovirus (hMPV)", "DISEASE", 0, 28], ["acute respiratory tract infections", "DISEASE", 65, 99], ["ARTIs", "DISEASE", 101, 106], ["Human metapneumovirus", "ORGANISM", 0, 21], ["hMPV", "ORGANISM", 23, 27], ["acute respiratory tract", "ORGANISM_SUBDIVISION", 65, 88], ["people", "ORGANISM", 125, 131], ["Human", "SPECIES", 0, 5], ["metapneumovirus", "SPECIES", 6, 21], ["hMPV", "SPECIES", 23, 27], ["people", "SPECIES", 125, 131], ["Human metapneumovirus", "SPECIES", 0, 21], ["hMPV", "SPECIES", 23, 27], ["Human metapneumovirus (hMPV", "PROBLEM", 0, 27], ["acute respiratory tract infections (ARTIs)", "PROBLEM", 65, 107], ["metapneumovirus", "OBSERVATION", 6, 21], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory tract", "ANATOMY", 71, 88]]], ["It induces clinical symptoms ranging from upper to lower respiratory tract illnesses such as bronchiolitis, bronchitis and pneumonia (3\u20135).", [["lower respiratory tract", "ANATOMY", 51, 74], ["respiratory tract illnesses", "DISEASE", 57, 84], ["bronchiolitis", "DISEASE", 93, 106], ["bronchitis", "DISEASE", 108, 118], ["pneumonia", "DISEASE", 123, 132], ["upper", "ORGANISM_SUBDIVISION", 42, 47], ["tract", "ORGANISM_SUBDIVISION", 69, 74], ["clinical symptoms", "PROBLEM", 11, 28], ["upper to lower respiratory tract illnesses", "PROBLEM", 42, 84], ["bronchiolitis", "PROBLEM", 93, 106], ["bronchitis", "PROBLEM", 108, 118], ["pneumonia", "PROBLEM", 123, 132], ["upper", "ANATOMY_MODIFIER", 42, 47], ["lower", "ANATOMY_MODIFIER", 51, 56], ["respiratory tract", "ANATOMY", 57, 74], ["bronchiolitis", "OBSERVATION", 93, 106], ["bronchitis", "OBSERVATION", 108, 118], ["pneumonia", "OBSERVATION", 123, 132]]], ["In 2001, HMPV was identified in samples from children with respiratory tract disease for the first time (6).", [["samples", "ANATOMY", 32, 39], ["respiratory tract", "ANATOMY", 59, 76], ["respiratory tract disease", "DISEASE", 59, 84], ["HMPV", "ORGANISM", 9, 13], ["children", "ORGANISM", 45, 53], ["tract", "ORGANISM_SUBDIVISION", 71, 76], ["children", "SPECIES", 45, 53], ["HMPV", "SPECIES", 9, 13], ["HMPV", "PROBLEM", 9, 13], ["respiratory tract disease", "PROBLEM", 59, 84], ["respiratory tract", "ANATOMY", 59, 76]]], ["In addition, it is a new member of the family paramyxoviridae, subfamily pneumovirus, genus metapneumovirus (7).", [["paramyxoviridae", "GENE_OR_GENE_PRODUCT", 46, 61], ["subfamily pneumovirus", "ORGANISM", 63, 84], ["genus metapneumovirus", "ORGANISM", 86, 107], ["metapneumovirus", "SPECIES", 92, 107], ["genus metapneumovirus", "PROBLEM", 86, 107], ["genus metapneumovirus", "OBSERVATION", 86, 107]]], ["RSV is one of the most important respiratory pathogens of childhood, with detection rates reaching 70\u201385% in hospitalized infants during seasonal winter epidemics worldwide (1, 8).", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 122, 129], ["infants", "SPECIES", 122, 129], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["detection rates", "TEST", 74, 89], ["respiratory", "OBSERVATION_MODIFIER", 33, 44], ["pathogens", "OBSERVATION", 45, 54]]], ["RSV causes severe lower respiratory infections like bronchiolitis or pneumonia in infants and young children (9).", [["respiratory", "ANATOMY", 24, 35], ["RSV", "DISEASE", 0, 3], ["lower respiratory infections", "DISEASE", 18, 46], ["bronchiolitis", "DISEASE", 52, 65], ["pneumonia", "DISEASE", 69, 78], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 82, 89], ["children", "ORGANISM", 100, 108], ["RSV", "SPECIES", 0, 3], ["infants", "SPECIES", 82, 89], ["children", "SPECIES", 100, 108], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["severe lower respiratory infections", "PROBLEM", 11, 46], ["bronchiolitis", "PROBLEM", 52, 65], ["pneumonia", "PROBLEM", 69, 78], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["lower", "ANATOMY_MODIFIER", 18, 23], ["respiratory", "ANATOMY", 24, 35], ["infections", "OBSERVATION", 36, 46], ["bronchiolitis", "OBSERVATION", 52, 65], ["pneumonia", "OBSERVATION", 69, 78]]], ["Coinfection of hMPV with RSV in infants has been suggested to be a factor that influences the severity of bronchiolitis (9).", [["hMPV", "DISEASE", 15, 19], ["RSV", "DISEASE", 25, 28], ["bronchiolitis", "DISEASE", 106, 119], ["hMPV", "ORGANISM", 15, 19], ["RSV", "ORGANISM", 25, 28], ["infants", "ORGANISM", 32, 39], ["infants", "SPECIES", 32, 39], ["hMPV", "SPECIES", 15, 19], ["RSV", "SPECIES", 25, 28], ["hMPV", "PROBLEM", 15, 19], ["RSV", "PROBLEM", 25, 28], ["bronchiolitis", "PROBLEM", 106, 119], ["hMPV", "OBSERVATION", 15, 19], ["RSV", "OBSERVATION", 25, 28], ["bronchiolitis", "OBSERVATION", 106, 119]]], ["Phylogenetically, RSV is the closest human virus related to hMPV, and the clinical manifestations of hMPV may share an overlapping spectrum with RSV, so that these two viruses cannot be distinguished by clinical manifestations (4, 7, 9, 10).", [["hMPV", "DISEASE", 60, 64], ["hMPV", "DISEASE", 101, 105], ["RSV", "ORGANISM", 18, 21], ["human", "ORGANISM", 37, 42], ["hMPV", "ORGANISM", 60, 64], ["hMPV", "ORGANISM", 101, 105], ["RSV", "ORGANISM", 145, 148], ["human", "SPECIES", 37, 42], ["RSV", "SPECIES", 18, 21], ["human virus", "SPECIES", 37, 48], ["hMPV", "SPECIES", 60, 64], ["hMPV", "SPECIES", 101, 105], ["RSV", "SPECIES", 145, 148], ["RSV", "PROBLEM", 18, 21], ["the closest human virus", "PROBLEM", 25, 48], ["hMPV", "PROBLEM", 60, 64], ["hMPV", "PROBLEM", 101, 105], ["RSV", "PROBLEM", 145, 148], ["these two viruses", "PROBLEM", 158, 175], ["RSV", "OBSERVATION", 18, 21], ["hMPV", "OBSERVATION", 60, 64], ["RSV", "OBSERVATION", 145, 148]]], ["RSV and hMPV might have similar seasonal patterns, so co-infection is possible (6, 9).IntroductionThis report describes a case who did not have the respiratory sign and symptoms, while was actually infected with RSV and hMPV simultaneously.Case reportA 24 mo old girl, who was originally from Tehran, Capital of Iran, was admitted to a pediatric hospital in Tehran on 29 Jan 2007 with a 2 wk history of fever and erythema of cheeks, lips, throat, and mouth since 4 d ago.", [["respiratory", "ANATOMY", 148, 159], ["cheeks", "ANATOMY", 425, 431], ["lips", "ANATOMY", 433, 437], ["throat", "ANATOMY", 439, 445], ["mouth", "ANATOMY", 451, 456], ["co-infection", "DISEASE", 54, 66], ["fever", "DISEASE", 403, 408], ["erythema of cheeks", "DISEASE", 413, 431], ["RSV", "ORGANISM", 0, 3], ["hMPV", "ORGANISM", 8, 12], ["RSV", "ORGANISM", 212, 215], ["hMPV", "ORGANISM", 220, 224], ["girl", "ORGANISM", 263, 267], ["cheeks", "ORGANISM_SUBDIVISION", 425, 431], ["lips", "ORGANISM_SUBDIVISION", 433, 437], ["throat", "ORGANISM_SUBDIVISION", 439, 445], ["mouth", "ORGANISM_SUBDIVISION", 451, 456], ["girl", "SPECIES", 263, 267], ["RSV", "SPECIES", 0, 3], ["hMPV", "SPECIES", 8, 12], ["RSV", "SPECIES", 212, 215], ["hMPV", "SPECIES", 220, 224], ["RSV", "PROBLEM", 0, 3], ["hMPV", "PROBLEM", 8, 12], ["co-infection", "PROBLEM", 54, 66], ["the respiratory sign", "PROBLEM", 144, 164], ["symptoms", "PROBLEM", 169, 177], ["RSV", "PROBLEM", 212, 215], ["hMPV", "PROBLEM", 220, 224], ["fever", "PROBLEM", 403, 408], ["erythema of cheeks, lips, throat, and mouth", "PROBLEM", 413, 456], ["hMPV", "OBSERVATION", 8, 12], ["co-infection", "OBSERVATION", 54, 66], ["fever", "OBSERVATION", 403, 408], ["erythema", "OBSERVATION", 413, 421], ["cheeks", "ANATOMY", 425, 431], ["lips", "ANATOMY", 433, 437], ["throat", "ANATOMY", 439, 445], ["mouth", "ANATOMY", 451, 456]]], ["In spite of treating with antipyretics, fever still was persistent.", [["fever", "DISEASE", 40, 45], ["antipyretics", "TREATMENT", 26, 38], ["fever", "PROBLEM", 40, 45], ["persistent", "OBSERVATION_MODIFIER", 56, 66]]], ["On physical examination, the vital signs were as follow: respiration, 22 breath/min; pulse, 104 beats/min and temperature, 38\u00b0 C. Cardiac, abdominal, neurological and respiratory findings were normal.", [["Cardiac", "ANATOMY", 130, 137], ["abdominal", "ANATOMY", 139, 148], ["respiratory", "ANATOMY", 167, 178], ["Cardiac, abdominal, neurological and respiratory findings", "DISEASE", 130, 187], ["abdominal", "ORGANISM_SUBDIVISION", 139, 148], ["physical examination", "TEST", 3, 23], ["the vital signs", "TEST", 25, 40], ["respiration", "TEST", 57, 68], ["pulse", "TEST", 85, 90], ["beats/min", "TEST", 96, 105], ["temperature", "TEST", 110, 121], ["Cardiac", "ANATOMY", 130, 137], ["abdominal", "ANATOMY", 139, 148], ["respiratory", "ANATOMY", 167, 178], ["normal", "OBSERVATION", 193, 199]]], ["Laboratory findings were as follows: WBC count, 9.9\u00d7103/\u03bcl; RBC, 3.77\u00d7106/\u03bcl; Hb, 10.6 g/dl; Hct, 34.5%; PLT, 443\u00d7103/\u03bcl; ESR, 90; CRP, +1; Wright/Widal and salmonella Para A/B, Typhi D were negative.", [["WBC", "ANATOMY", 37, 40], ["RBC", "ANATOMY", 60, 63], ["RBC", "CELL", 60, 63], ["Hb", "GENE_OR_GENE_PRODUCT", 78, 80], ["CRP", "GENE_OR_GENE_PRODUCT", 131, 134], ["Typhi D", "GENE_OR_GENE_PRODUCT", 178, 185], ["RBC", "CELL_TYPE", 60, 63], ["Hb", "PROTEIN", 78, 80], ["PLT", "PROTEIN", 105, 108], ["ESR", "PROTEIN", 122, 125], ["CRP", "PROTEIN", 131, 134], ["Laboratory findings", "TEST", 0, 19], ["WBC count", "TEST", 37, 46], ["\u03bcl", "TEST", 56, 58], ["RBC", "TEST", 60, 63], ["\u03bcl", "TEST", 74, 76], ["Hb", "TEST", 78, 80], ["g", "TEST", 87, 88], ["dl", "TEST", 89, 91], ["Hct", "TEST", 93, 96], ["PLT", "TEST", 105, 108], ["\u03bcl", "TEST", 118, 120], ["ESR", "TEST", 122, 125], ["CRP", "TEST", 131, 134], ["Wright", "TEST", 140, 146], ["Widal", "TEST", 147, 152], ["salmonella Para A/B", "TEST", 157, 176], ["Typhi D", "TEST", 178, 185]]], ["Stool exam was normal.", [["Stool", "ORGANISM_SUBSTANCE", 0, 5], ["Stool exam", "TEST", 0, 10], ["normal", "OBSERVATION", 15, 21]]], ["In the abdominal sonography, there was no problem and chest X ray was also normal.", [["abdominal", "ANATOMY", 7, 16], ["abdominal", "ORGAN", 7, 16], ["the abdominal sonography", "TEST", 3, 27], ["problem", "PROBLEM", 42, 49], ["chest X ray", "TEST", 54, 65], ["abdominal", "ANATOMY", 7, 16], ["no", "UNCERTAINTY", 39, 41], ["chest", "ANATOMY", 54, 59], ["normal", "OBSERVATION", 75, 81]]], ["According to the findings, possible diagnosis was Kawasaki syndrome and treatment with IVIG, aspirin and acetaminophen was started.", [["Kawasaki syndrome", "DISEASE", 50, 67], ["aspirin", "CHEMICAL", 93, 100], ["acetaminophen", "CHEMICAL", 105, 118], ["aspirin", "CHEMICAL", 93, 100], ["acetaminophen", "CHEMICAL", 105, 118], ["IVIG", "SIMPLE_CHEMICAL", 87, 91], ["aspirin", "SIMPLE_CHEMICAL", 93, 100], ["acetaminophen", "SIMPLE_CHEMICAL", 105, 118], ["Kawasaki syndrome", "PROBLEM", 50, 67], ["treatment", "TREATMENT", 72, 81], ["IVIG", "TREATMENT", 87, 91], ["aspirin", "TREATMENT", 93, 100], ["acetaminophen", "TREATMENT", 105, 118], ["possible", "UNCERTAINTY", 27, 35], ["Kawasaki syndrome", "OBSERVATION", 50, 67]]], ["After one day, fever was resolved but dry cough started at the day four of the admission.", [["fever", "DISEASE", 15, 20], ["cough", "DISEASE", 42, 47], ["fever", "PROBLEM", 15, 20], ["dry cough", "PROBLEM", 38, 47], ["fever", "OBSERVATION", 15, 20], ["cough", "OBSERVATION", 42, 47]]], ["Because of the history of contact with chickens and possibility of H5N1, throat swab specimen of the patient was collected and sent to the National Influenza Center in Tehran university of Medical Sciences for influenza surveillance.", [["throat swab specimen", "ANATOMY", 73, 93], ["Influenza", "DISEASE", 148, 157], ["influenza", "DISEASE", 210, 219], ["chickens", "ORGANISM", 39, 47], ["H5N1", "ORGANISM", 67, 71], ["throat swab specimen", "MULTI-TISSUE_STRUCTURE", 73, 93], ["patient", "ORGANISM", 101, 108], ["chickens", "SPECIES", 39, 47], ["patient", "SPECIES", 101, 108], ["chickens", "SPECIES", 39, 47], ["H5N1", "SPECIES", 67, 71], ["chickens", "TREATMENT", 39, 47], ["H5N1", "PROBLEM", 67, 71], ["throat swab specimen", "TEST", 73, 93], ["influenza surveillance", "TEST", 210, 232]]], ["The specimen was tested for Influenza virus types and subtypes by real time PCR assay using CDC procedure, CDC Real-Time RT-PCR (r.RT-PCR) protocol for detection and characterization of influenza virus (version.2007), but the result was negative.", [["specimen", "ANATOMY", 4, 12], ["influenza virus", "DISEASE", 186, 201], ["specimen", "CANCER", 4, 12], ["influenza virus", "ORGANISM", 186, 201], ["influenza virus", "SPECIES", 186, 201], ["Influenza virus", "SPECIES", 28, 43], ["influenza virus", "SPECIES", 186, 201], ["The specimen", "TEST", 0, 12], ["Influenza virus types", "PROBLEM", 28, 49], ["CDC procedure", "TEST", 92, 105], ["CDC", "TEST", 107, 110], ["PCR", "TEST", 124, 127], ["detection", "TEST", 152, 161], ["influenza virus", "PROBLEM", 186, 201], ["influenza virus", "OBSERVATION", 186, 201], ["negative", "OBSERVATION", 237, 245]]], ["Subsequently, as a part of a project, the specimen was tested for RSV and hMPV by hemi-nested multiplex PCR and parainfluenza viruses type 1\u20134 by hemi-nested multiplex PCR (11), and adenovirus by hemi-nested PCR (12).", [["specimen", "ANATOMY", 42, 50], ["parainfluenza viruses", "DISEASE", 112, 133], ["specimen", "CANCER", 42, 50], ["RSV", "ORGANISM", 66, 69], ["hMPV", "ORGANISM", 74, 78], ["parainfluenza", "ORGANISM", 112, 125], ["adenovirus", "ORGANISM", 182, 192], ["parainfluenza", "SPECIES", 112, 125], ["RSV", "SPECIES", 66, 69], ["hMPV", "SPECIES", 74, 78], ["parainfluenza viruses type 1\u20134", "SPECIES", 112, 142], ["adenovirus", "SPECIES", 182, 192], ["the specimen", "TEST", 38, 50], ["RSV", "PROBLEM", 66, 69], ["hMPV", "PROBLEM", 74, 78], ["hemi-nested multiplex PCR", "TEST", 82, 107], ["parainfluenza viruses type", "PROBLEM", 112, 138], ["hemi-nested multiplex PCR", "TEST", 146, 171], ["adenovirus", "PROBLEM", 182, 192], ["hemi-nested PCR", "TEST", 196, 211], ["parainfluenza viruses", "OBSERVATION", 112, 133]]], ["In our surprise positive results for RSV and hMPV were observed without any special respiratory sign and symptoms.", [["respiratory", "ANATOMY", 84, 95], ["hMPV", "DISEASE", 45, 49], ["RSV", "ORGANISM", 37, 40], ["hMPV", "ORGANISM", 45, 49], ["RSV", "SPECIES", 37, 40], ["hMPV", "SPECIES", 45, 49], ["RSV", "PROBLEM", 37, 40], ["hMPV", "PROBLEM", 45, 49], ["any special respiratory sign", "PROBLEM", 72, 100], ["symptoms", "PROBLEM", 105, 113]]], ["The test was repeated and the results were confirmed again.", [["The test", "TEST", 0, 8]]], ["The nucleotide sequence of the PCR product of the detected hMPV (the M gene fragment) was submitted to GenBank (Accession no. GQ219792).DiscussionIn the present study, we demonstrated the possibility to detect dual infection which caused by RSV and hMPV.", [["nucleotide", "CHEMICAL", 4, 14], ["GQ219792", "CHEMICAL", 126, 134], ["infection", "DISEASE", 215, 224], ["nucleotide", "CHEMICAL", 4, 14], ["GQ219792", "CHEMICAL", 126, 134], ["hMPV", "ORGANISM", 59, 63], ["GQ219792", "SIMPLE_CHEMICAL", 126, 134], ["RSV", "ORGANISM", 241, 244], ["hMPV", "ORGANISM", 249, 253], ["M gene fragment", "DNA", 69, 84], ["hMPV", "SPECIES", 59, 63], ["RSV", "SPECIES", 241, 244], ["hMPV", "SPECIES", 249, 253], ["The nucleotide sequence", "TEST", 0, 23], ["the PCR product", "TEST", 27, 42], ["the detected hMPV", "PROBLEM", 46, 63], ["the M gene fragment", "TREATMENT", 65, 84], ["the present study", "TEST", 149, 166], ["dual infection", "PROBLEM", 210, 224], ["RSV", "PROBLEM", 241, 244], ["hMPV", "PROBLEM", 249, 253], ["hMPV", "OBSERVATION", 59, 63], ["infection", "OBSERVATION", 215, 224], ["hMPV", "OBSERVATION", 249, 253]]], ["Due to the lack of sensitivity of conventional methods detection of co-infections with different respiratory viruses had been underestimated (13).", [["co-infections", "DISEASE", 68, 81], ["respiratory viruses", "DISEASE", 97, 116], ["co-infections", "PROBLEM", 68, 81], ["different respiratory viruses", "PROBLEM", 87, 116], ["co-infections", "OBSERVATION", 68, 81], ["respiratory viruses", "OBSERVATION", 97, 116]]], ["Severe RSV bronchiolitis in small patient series had been recognized because of co-infection with other viral pathogens (14).", [["bronchiolitis", "DISEASE", 11, 24], ["co-infection", "DISEASE", 80, 92], ["RSV", "ORGANISM", 7, 10], ["patient", "ORGANISM", 34, 41], ["RSV", "SPECIES", 7, 10], ["patient", "SPECIES", 34, 41], ["RSV", "SPECIES", 7, 10], ["Severe RSV bronchiolitis in small patient series", "PROBLEM", 0, 48], ["co-infection", "PROBLEM", 80, 92], ["other viral pathogens", "PROBLEM", 98, 119], ["RSV", "OBSERVATION_MODIFIER", 7, 10], ["bronchiolitis", "OBSERVATION", 11, 24], ["small", "OBSERVATION_MODIFIER", 28, 33], ["co-infection", "OBSERVATION", 80, 92]]], ["Some previous studies have lighted up increased clinical severity in case of dual infection caused by RSV and hMPV (8, 9).", [["infection", "DISEASE", 82, 91], ["hMPV", "DISEASE", 110, 114], ["RSV", "ORGANISM", 102, 105], ["hMPV", "ORGANISM", 110, 114], ["RSV", "SPECIES", 102, 105], ["hMPV", "SPECIES", 110, 114], ["Some previous studies", "TEST", 0, 21], ["increased clinical severity", "PROBLEM", 38, 65], ["dual infection", "PROBLEM", 77, 91], ["RSV", "PROBLEM", 102, 105], ["hMPV", "PROBLEM", 110, 114], ["infection", "OBSERVATION", 82, 91], ["RSV", "OBSERVATION", 102, 105], ["hMPV", "OBSERVATION", 110, 114]]], ["Greensill et al. observed a 70% co-infection rate with HMPV and RSV and a 90% co-infection rate among intubated infants with hMPV and RSV admitted to their PICU (8).", [["hMPV", "DISEASE", 125, 129], ["RSV", "DISEASE", 134, 137], ["HMPV", "ORGANISM", 55, 59], ["RSV", "ORGANISM", 64, 67], ["infants", "ORGANISM", 112, 119], ["hMPV", "ORGANISM", 125, 129], ["RSV", "ORGANISM", 134, 137], ["infants", "SPECIES", 112, 119], ["HMPV", "SPECIES", 55, 59], ["RSV", "SPECIES", 64, 67], ["hMPV", "SPECIES", 125, 129], ["RSV", "SPECIES", 134, 137], ["a 70% co-infection rate", "PROBLEM", 26, 49], ["HMPV", "PROBLEM", 55, 59], ["RSV", "PROBLEM", 64, 67], ["a 90% co-infection rate", "TREATMENT", 72, 95], ["intubated", "TREATMENT", 102, 111], ["hMPV", "PROBLEM", 125, 129]]], ["Although Greensill et al. did not include an appropriate control group in their study, these findings suggest that co-infection with both hMPV and RSV is common and that together the two viruses may contribute to increase the severity of disease (9, 14).", [["co-infection", "DISEASE", 115, 127], ["hMPV", "DISEASE", 138, 142], ["RSV", "DISEASE", 147, 150], ["hMPV", "ORGANISM", 138, 142], ["RSV", "ORGANISM", 147, 150], ["hMPV", "SPECIES", 138, 142], ["RSV", "SPECIES", 147, 150], ["their study", "TEST", 74, 85], ["co-infection", "PROBLEM", 115, 127], ["both hMPV and RSV", "PROBLEM", 133, 150], ["the two viruses", "PROBLEM", 179, 194], ["the severity of disease", "PROBLEM", 222, 245], ["co-infection", "OBSERVATION", 115, 127], ["hMPV", "OBSERVATION", 138, 142], ["RSV", "OBSERVATION", 147, 150], ["severity", "OBSERVATION_MODIFIER", 226, 234], ["disease", "OBSERVATION", 238, 245]]], ["Whereas in other reports hMPV did not contribute to the severity of RSV infection (15, 16).", [["RSV infection", "DISEASE", 68, 81], ["hMPV", "ORGANISM", 25, 29], ["RSV", "ORGANISM", 68, 71], ["hMPV", "SPECIES", 25, 29], ["RSV", "SPECIES", 68, 71], ["hMPV", "PROBLEM", 25, 29], ["RSV infection", "PROBLEM", 68, 81], ["hMPV", "OBSERVATION", 25, 29], ["RSV", "OBSERVATION_MODIFIER", 68, 71], ["infection", "OBSERVATION", 72, 81]]], ["The basis of the pathogenesis of severe RSV disease is multifactorial.", [["RSV disease", "DISEASE", 40, 51], ["RSV", "ORGANISM", 40, 43], ["RSV", "SPECIES", 40, 43], ["severe RSV disease", "PROBLEM", 33, 51], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["RSV disease", "OBSERVATION", 40, 51]]], ["Since severe RSV disease may develop in apparently healthy children, known host risk factors cannot completely account for instances of severe illness.", [["RSV disease", "DISEASE", 13, 24], ["illness", "DISEASE", 143, 150], ["RSV", "ORGANISM", 13, 16], ["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67], ["RSV", "SPECIES", 13, 16], ["severe RSV disease", "PROBLEM", 6, 24], ["severe illness", "PROBLEM", 136, 150], ["severe", "OBSERVATION_MODIFIER", 6, 12], ["RSV", "OBSERVATION", 13, 16], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["illness", "OBSERVATION", 143, 150]]], ["Preexisting or maternally acquired immunity, innate immunity, viral factors and genotypes and environment all likely contribute to disease pathogenesis.", [["viral factors", "PROTEIN", 62, 75], ["viral factors and genotypes", "PROBLEM", 62, 89], ["disease pathogenesis", "PROBLEM", 131, 151], ["disease", "OBSERVATION", 131, 138]]], ["We detected co-infection of hMPV and RSV in Kawasaki patient without special respiratory sign and symptoms, we could not find the patient to follow up her and study more about the immunity status and other possibilities of this scenario.", [["hMPV and RSV", "DISEASE", 28, 40], ["Kawasaki", "DISEASE", 44, 52], ["hMPV", "ORGANISM", 28, 32], ["RSV", "ORGANISM", 37, 40], ["patient", "ORGANISM", 53, 60], ["patient", "ORGANISM", 130, 137], ["hMPV", "SPECIES", 28, 32], ["RSV", "SPECIES", 37, 40], ["patient", "SPECIES", 53, 60], ["patient", "SPECIES", 130, 137], ["hMPV", "SPECIES", 28, 32], ["RSV", "SPECIES", 37, 40], ["co-infection", "PROBLEM", 12, 24], ["hMPV", "PROBLEM", 28, 32], ["RSV", "PROBLEM", 37, 40], ["special respiratory sign", "PROBLEM", 69, 93], ["symptoms", "PROBLEM", 98, 106], ["co-infection", "OBSERVATION", 12, 24], ["hMPV", "OBSERVATION", 28, 32]]], ["More investigation is suggested specially on Kawasaki patients to detect the viral pathogens.Ethical ConsiderationsAll ethical issues including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc have been completely observed by the authors.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["the viral pathogens", "PROBLEM", 73, 92], ["falsification", "PROBLEM", 210, 223], ["double publication", "PROBLEM", 225, 243], ["viral pathogens", "OBSERVATION", 77, 92]]]], "PMC7128536": [["Etiolog\u00edaLos agentes infecciosos (v\u00edricos y/o bacterianos) y los contaminantes a\u00e9reos (NO2, SO2, ozono) se han se\u00f1alado como los principales responsables de desencadenar las agudizaciones de la EPOC (AEPOC) (tabla 1), pero hasta en una cuarta parte de las AEPOC graves no se logra identificar su causa1, 2.", [["NO2", "CHEMICAL", 87, 90], ["NO2", "CHEMICAL", 87, 90], ["SO2", "CHEMICAL", 92, 95], ["NO2", "SIMPLE_CHEMICAL", 87, 90], ["Etiolog\u00edaLos", "TEST", 0, 12], ["infecciosos", "PROBLEM", 21, 32]]], ["La infecci\u00f3n respiratoria se se\u00f1ala como responsable hasta en el 70% de los episodios de AEPOC, aisl\u00e1ndose bacterias hasta en el 30 o 50% de los cultivos de esputo o secreciones bronquiales, respectivamente, de los pacientes agudizados, e incluso superan el 70% en las AEPOC que requieren soporte ventilatorio.", [["soporte ventilatorio", "TREATMENT", 289, 309]]], ["Los microorganismos m\u00e1s frecuentemente aislados son Haemophilus influenzae, Streptococcus pneumoniae y Moraxella catarhallis.", [["Haemophilus influenzae", "DISEASE", 52, 74], ["Haemophilus influenzae", "ORGANISM", 52, 74], ["Streptococcus pneumoniae", "ORGANISM", 76, 100], ["Haemophilus influenzae", "SPECIES", 52, 74], ["Streptococcus pneumoniae", "SPECIES", 76, 100], ["Haemophilus influenzae", "SPECIES", 52, 74], ["Streptococcus pneumoniae", "SPECIES", 76, 100], ["Moraxella catarhallis", "SPECIES", 103, 124], ["Los microorganismos", "TEST", 0, 19], ["m\u00e1s", "TEST", 20, 23], ["frecuentemente", "TEST", 24, 38], ["aislados", "TEST", 39, 47], ["Haemophilus influenzae", "PROBLEM", 52, 74], ["Streptococcus pneumoniae y Moraxella catarhallis", "PROBLEM", 76, 124], ["Moraxella catarhallis", "OBSERVATION", 103, 124]]], ["En la actualidad, los fen\u00f3menos que influyen en que se desencadene una AEPOC de origen bacteriano no son conocidos completamente, y est\u00e1n implicados, adem\u00e1s de factores modificadores extr\u00ednsecos como la carga bacteriana, el recambio din\u00e1mico de cepas de una misma especie y la baja temperatura ambiental, otros que ata\u00f1en a cada individuo, como su funci\u00f3n pulmonar, la hipersecreci\u00f3n mucosa, su h\u00e1bito tab\u00e1quico, su comorbilidad y el mayor o menor desarrollo de respuesta inmunol\u00f3gica espec\u00edfica tras la adquisici\u00f3n de nuevas cepas.", [["mucosa", "MULTI-TISSUE_STRUCTURE", 384, 390], ["la", "ANATOMY_MODIFIER", 366, 368], ["hipersecreci\u00f3n mucosa", "ANATOMY", 369, 390]]], ["A\u00fan queda por aclarar si las AEPOC son debidas a mutaciones de cepas de bacterias colonizadoras, o son por adquisici\u00f3n de nuevas cepas o especies bacterianas.", [["bacterianas", "PROBLEM", 146, 157]]], ["La hip\u00f3tesis explicativa de \u00absubida y bajada de carga bacteriana\u00bb para el desarrollo de las AEPOC bacterianas aboga por la rotaci\u00f3n de antibi\u00f3ticos para reducir las AEPOC4.PatogeniaActualmente se preconiza que las AEPOC est\u00e1n ocasionadas por la interacci\u00f3n compleja entre los agentes etiol\u00f3gicos conocidos y el hu\u00e9sped, conduciendo a un aumento de los fen\u00f3menos inflamatorios 5 (fig. 1y tabla 2).", [["La hip\u00f3tesis", "PROBLEM", 0, 12], ["PatogeniaActualmente", "TEST", 172, 192], ["a un aumento de los fen\u00f3menos inflamatorios", "TREATMENT", 332, 375]]], ["El estudio de los fen\u00f3menos inflamatorios en la AEPOC se ha llevado a cabo tanto a nivel sist\u00e9mico como tisular en las v\u00edas a\u00e9reas.", [["a cabo tanto", "TREATMENT", 68, 80]]], ["Se han descrito m\u00e1s de 30 biomarcadores usados para tratar infructuosamente de correlacionar sus valores s\u00e9ricos con la intensidad inflamatoria, siendo la PCR el menos inespec\u00edfico5, 6.", [["para tratar", "TEST", 47, 58], ["la PCR", "TEST", 152, 158]]], ["Los primeros hacen referencia a la \u00abhip\u00f3tesis del c\u00edrculo vicioso\u00bb, seg\u00fan la cual la presencia de bacterias y sus toxinas estimulan a los macr\u00f3fagos alveolares a la producci\u00f3n de enzimas lesivas para el epitelio y citocinas proinflamatorias que atraen a los neutr\u00f3filos, ocasionando un mayor secuestro de neutr\u00f3filos en la microcirculaci\u00f3n pulmonar previo a la invasi\u00f3n de las v\u00edas a\u00e9reas, mayor destrucci\u00f3n del intersticio pulmonar, menor aclaraci\u00f3n mucociliar y cronificaci\u00f3n de la respuesta inflamatoria.", [["respuesta inflamatoria", "DISEASE", 484, 506], ["Los primeros", "TEST", 0, 12], ["a la \u00abhip\u00f3tesis", "PROBLEM", 30, 45]]], ["Directamente, las bacterias pueden estimular una hipersecreci\u00f3n mucosa, inhibir el movimiento ciliar o da\u00f1ar el epitelio.PatogeniaLos estudios llevados a cabo sobre la etiopatogenia viral en AEPOC muestran mecanismos directos similares a los descritos por las bacterias, as\u00ed como fen\u00f3menos broncoconstrictores en el \u00e1rbol bronquial distal mediados por receptores muscar\u00ednicos.", [["mucosa", "MULTI-TISSUE_STRUCTURE", 64, 70], ["Directamente", "TEST", 0, 12], ["PatogeniaLos", "TEST", 121, 133], ["estudios", "TEST", 134, 142], ["a los descritos por las bacterias", "PROBLEM", 236, 269], ["mucosa", "ANATOMY", 64, 70], ["distal", "ANATOMY_MODIFIER", 332, 338]]], ["Destacan, entre los mecanismos de lesi\u00f3n indirecta, su adhesi\u00f3n epitelial a trav\u00e9s de las mol\u00e9culas de adhesi\u00f3n intracelular (ICAM-1) e incremento de valores de endotelina-1 (que conducen al reclutamiento, activaci\u00f3n y migraci\u00f3n de c\u00e9lulas inflamatorias desde la circulaci\u00f3n al espacio a\u00e9reo), y de p\u00e9ptido broncoconstrictor (favorece la inflamaci\u00f3n y producci\u00f3n de moco); inducci\u00f3n de genes codificadores de enzimas antioxidantes que aumentan el estr\u00e9s oxidativo y favorecen los efectos inflamatorios presentes durante la AEPOC7.", [["Destacan", "CHEMICAL", 0, 8], ["Destacan", "SIMPLE_CHEMICAL", 0, 8], ["que conducen al reclutamiento", "TREATMENT", 175, 204], ["activaci\u00f3n y migraci\u00f3n", "TREATMENT", 206, 228], ["inducci\u00f3n de genes codificadores", "PROBLEM", 373, 405]]], ["Evidencia del papel de la infecci\u00f3n viral en la etiopatogenia de la AEPOC es el efecto beneficioso de la vacunaci\u00f3n antigripal sobre el n\u00famero de infecciones respiratorias y hospitalizaci\u00f3n por neumon\u00eda en pacientes con EPOC.PatogeniaLos mecanismos de inflamaci\u00f3n involucrados en las AEPOC, sean de causa infecciosa o no, implican a c\u00e9lulas y mediadores inflamatorios caracter\u00edsticos, que muestran diferencias con las fases estables de la EPOC y con otras enfermedades respiratorias caracterizadas tambi\u00e9n por fen\u00f3menos inflamatorios, como el asma bronquial.", [["del papel de la infecci\u00f3n", "PROBLEM", 10, 35]]], ["Los neutr\u00f3filos, los linfocitos T CD8+ y las c\u00e9lulas TNF\u03b1+ son las c\u00e9lulas que adquieren un papel preponderante en los mecanismos inflamatorios propios de las AEPOC, si bien tambi\u00e9n se describe un aumento de eosin\u00f3filos en el esputo y el lavado bronquioalveolar.", [["Los neutr\u00f3filos", "TEST", 0, 15], ["los", "TEST", 17, 20], ["linfocitos", "TEST", 21, 31], ["CD8", "TEST", 34, 37], ["TNF", "TEST", 53, 56], ["los", "OBSERVATION_MODIFIER", 17, 20]]], ["Asimismo, se ha comprobado infiltraci\u00f3n eosinof\u00edlica de mucosa y submucosa de la v\u00eda a\u00e9rea en AEPOC leves.", [["Asimismo", "CHEMICAL", 0, 8], ["Asimismo", "TEST", 0, 8]]], ["Los mediadores inflamatorios descritos durante la AEPOC son la IL-8, IL-6, mieloperoxidasas, leucotrieno B4 y otros marcadores de estr\u00e9s oxidativo8.", [["Los mediadores", "TEST", 0, 14], ["mieloperoxidasas", "TREATMENT", 75, 91], ["leucotrieno", "TREATMENT", 93, 104]]], ["Este potente p\u00e9ptido inflamatorio posee un papel quimiot\u00e1ctico y probablemente induce la activaci\u00f3n del factor de necrosis kappa-B (NF-\u03baB), aumenta la permeabilidad vascular, regula la vasodilataci\u00f3n e influye sobre el sistema inmunol\u00f3gico mediante la estimulaci\u00f3n de respuesta Th1.PatogeniaDado que es sabido que las AEPOC se asocian con incremento de infiltraci\u00f3n de c\u00e9lulas inflamatorias, incremento de liberaci\u00f3n de proteinasas e incremento en carga de oxidantes, es posible que el tratamiento antiinflamatorio pueda mejorar no solo la historia natural de la EPOC, sino que puede reducir la gravedad y/o consecuencias de las AEPOC.", [["necrosis", "DISEASE", 114, 122], ["Este", "TEST", 0, 4], ["kappa", "TEST", 123, 128], ["NF", "TEST", 132, 134], ["PatogeniaDado que es sabido que las AEPOC se asocian con incremento", "TREATMENT", 282, 349], ["vascular", "ANATOMY", 165, 173]]], ["Una interesante v\u00eda de tratamiento se est\u00e1 abriendo paso en la actualidad con el estudio de los efectos terap\u00e9uticos antiinflamatorios de los agentes inhibidores selectivos de la fosfodiesterasa 4, como roflumilast.", [["roflumilast", "CHEMICAL", 203, 214], ["roflumilast", "CHEMICAL", 203, 214], ["roflumilast", "SIMPLE_CHEMICAL", 203, 214], ["selectivos de la fosfodiesterasa", "TREATMENT", 162, 194]]], ["La isoenzima PDE4 se expresa en la mayor\u00eda de las c\u00e9lulas inflamatorias, convirti\u00e9ndose en diana terap\u00e9utica para el tratamiento de enfermedades inflamatorias como la EPOC, mediante la elevaci\u00f3n de los niveles de adenosina monofosfato c\u00edclico (AMPc), cuyos efectos antiinflamatorios tienen un papel prometedor en la prevenci\u00f3n de las AEPOC10, 11.Fisiopatolog\u00edaLas AEPOC se asocian con un incremento en la obstrucci\u00f3n a\u00e9rea y, por tanto, de las resistencias de las mismas, atrapamiento a\u00e9reo e incremento en el trabajo respiratorio y del consumo de ox\u00edgeno que, junto con un empeoramiento de la relaci\u00f3n ventilaci\u00f3n-perfusi\u00f3n, dan lugar a un deterioro del intercambio gaseoso.Fisiopatolog\u00edaLa taquipnea, ocasionada por el aumento de la limitaci\u00f3n de la espiraci\u00f3n durante las agudizaciones, favorece que se reduzca el tiempo para el vaciado pulmonar, resultando una hiperinsuflaci\u00f3n din\u00e1mica, con sobrecarga de la musculatura respiratoria y fatiga de la misma, aumentando la sensaci\u00f3n de disnea y ocasionando otros efectos cardiovasculares, como un aumento de las presiones arteriales pulmonares, que pueden precipitar un fracaso ventricular derecho.", [["ventricular", "ANATOMY", 1129, 1140], ["ventricular derecho", "DISEASE", 1129, 1148], ["La isoenzima PDE4", "PROBLEM", 0, 17], ["cuyos efectos antiinflamatorios", "TREATMENT", 251, 282], ["Fisiopatolog\u00edaLas", "TREATMENT", 346, 363]]], ["Como consecuencia de la hiperinsuflaci\u00f3n pulmonar, la respiraci\u00f3n corriente se desplaza a la zona de menor pendiente de la curva de distensibilidad presi\u00f3n/volumen, donde un mayor aumento de presi\u00f3n genera solo un peque\u00f1o cambio de volumen.Fisiopatolog\u00edaLas AEPOC pueden verse agravadas por un mal funcionamiento del centro respiratorio en el sistema nervioso central debido a hipoxia, hipercapnia y acidosis, por lo que cuando los mecanismos compensadores fracasan en corregir la alteraci\u00f3n del intercambio gaseoso pueden conducir a un fracaso respiratorio (fig. 2).Fisiopatolog\u00edaEn las AEPOC se reduce tambi\u00e9n la precarga del ventr\u00edculo izquierdo, consecuencia de la vasoconstricci\u00f3n pulmonar y una reducci\u00f3n del retorno venoso por la hiperinsuflaci\u00f3n pulmonar, conduciendo a un llenado ventricular izquierdo reducido.Fisiopatolog\u00edaExisten datos no concluyentes sobre si las AEPOC pueden contribuir al declinar en la funci\u00f3n pulmonar, siendo importante su consideraci\u00f3n en la fisiopatolog\u00eda de la EPOC12.", [["hipercapnia y acidosis", "DISEASE", 386, 408], ["Fisiopatolog\u00edaLas", "TREATMENT", 240, 257], ["a hipoxia", "PROBLEM", 375, 384], ["hipercapnia y acidosis", "PROBLEM", 386, 408], ["mecanismos", "TEST", 432, 442], ["Fisiopatolog\u00edaEn", "TEST", 567, 583], ["pulmonar", "ANATOMY", 41, 49]]]], "PMC4055721": [["IntroductionHeart failure (HF) continues to have a significant clinical burden with a high mortality and morbidity, and has a worse one-year prognosis than cancer [1].", [["Heart", "ANATOMY", 12, 17], ["cancer", "ANATOMY", 156, 162], ["Heart failure", "DISEASE", 12, 25], ["HF", "DISEASE", 27, 29], ["cancer", "DISEASE", 156, 162], ["Heart", "ORGAN", 12, 17], ["cancer", "CANCER", 156, 162], ["IntroductionHeart failure (HF", "PROBLEM", 0, 29], ["a significant clinical burden", "PROBLEM", 49, 78], ["a high mortality", "PROBLEM", 84, 100], ["Heart", "ANATOMY", 12, 17], ["failure", "OBSERVATION", 18, 25], ["significant", "OBSERVATION_MODIFIER", 51, 62]]], ["There are several classification schemes in HF; however, a common clinical approach involves classifying ambulatory patients with chronic HF into HF with preserved (\u226550%) or reduced left-ventricular ejection fraction (<50%; HFPEF or HFREF, respectively) [1], [2].", [["left-ventricular", "ANATOMY", 182, 198], ["HF", "DISEASE", 44, 46], ["HF", "DISEASE", 138, 140], ["HF", "DISEASE", 146, 148], ["patients", "ORGANISM", 116, 124], ["ventricular", "MULTI-TISSUE_STRUCTURE", 187, 198], ["patients", "SPECIES", 116, 124], ["HF", "PROBLEM", 44, 46], ["chronic HF into HF", "PROBLEM", 130, 148], ["reduced left-ventricular ejection fraction", "PROBLEM", 174, 216], ["HFPEF", "PROBLEM", 224, 229], ["HFREF", "TEST", 233, 238], ["several", "OBSERVATION_MODIFIER", 10, 17], ["classification", "OBSERVATION", 18, 32], ["HF", "OBSERVATION", 44, 46], ["left-ventricular", "ANATOMY", 182, 198], ["ejection fraction", "OBSERVATION", 199, 216]]], ["HFPEF presently accounts for approximately 40% of HF diagnoses, with a rising incidence, and mortality and morbidity comparable to HFREF [3]\u2013[5].", [["HFPEF", "DISEASE", 0, 5], ["HF", "DISEASE", 50, 52], ["HFREF [3]\u2013[5]", "SIMPLE_CHEMICAL", 131, 144], ["HFPEF", "PROBLEM", 0, 5], ["a rising incidence", "PROBLEM", 69, 87], ["morbidity", "PROBLEM", 107, 116], ["HFREF", "TEST", 131, 136]]], ["Despite similarities in outcomes, it appears that HFPEF and HFREF represent distinct groups, with many pathophysiological differences, along the continuum of the HF [6].", [["HF", "DISEASE", 162, 164], ["HFPEF", "PROBLEM", 50, 55], ["HFREF", "PROBLEM", 60, 65], ["many pathophysiological differences", "PROBLEM", 98, 133], ["HFPEF", "OBSERVATION", 50, 55], ["distinct", "OBSERVATION_MODIFIER", 76, 84], ["HF", "OBSERVATION", 162, 164]]], ["Indeed, differential responses to therapeutic interventions between these two groups strongly support this concept.", [["therapeutic interventions", "TREATMENT", 34, 59]]], ["Clinical trials have validated angiotensin-converting enzyme inhibitors (ACEi), angiotensin II-receptor blockers (ARB), beta-adrenergic receptor antagonists (beta-blockers) and mineralocorticoid receptor antagonists (MRA) as therapeutics in HFREF [1].", [["angiotensin", "CHEMICAL", 31, 42], ["ACEi", "CHEMICAL", 73, 77], ["angiotensin II", "CHEMICAL", 80, 94], ["ARB", "CHEMICAL", 114, 117], ["HFREF", "DISEASE", 241, 246], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 31, 60], ["ACEi", "SIMPLE_CHEMICAL", 73, 77], ["angiotensin II-receptor blockers", "SIMPLE_CHEMICAL", 80, 112], ["ARB", "SIMPLE_CHEMICAL", 114, 117], ["beta-adrenergic receptor antagonists", "SIMPLE_CHEMICAL", 120, 156], ["beta-blockers", "SIMPLE_CHEMICAL", 158, 171], ["mineralocorticoid receptor antagonists", "SIMPLE_CHEMICAL", 177, 215], ["angiotensin", "TREATMENT", 31, 42], ["converting enzyme inhibitors", "TREATMENT", 43, 71], ["ACEi", "TREATMENT", 73, 77], ["angiotensin II", "TREATMENT", 80, 94], ["receptor blockers", "TREATMENT", 95, 112], ["ARB", "TREATMENT", 114, 117], ["beta-adrenergic receptor antagonists", "TREATMENT", 120, 156], ["beta-blockers", "TREATMENT", 158, 171], ["mineralocorticoid receptor antagonists", "TREATMENT", 177, 215], ["MRA", "TEST", 217, 220]]], ["Conversely, trials of ACEi, ARB, beta-blockers, MRA and phosphodiesterase-5 inhibitor failed to show any consistent and significant improvement in the clinical outcomes of patients with HFPEF.IntroductionBiomarker studies have differentially implicated various pathways in HF, including fibrosis and extracellular matrix remodeling, oxidative and cardiomyocyte stress, and inflammation [7]\u2013[12].", [["extracellular matrix", "ANATOMY", 300, 320], ["cardiomyocyte", "ANATOMY", 347, 360], ["ACEi", "CHEMICAL", 22, 26], ["ARB", "CHEMICAL", 28, 31], ["phosphodiesterase-5 inhibitor", "CHEMICAL", 56, 85], ["HFPEF", "DISEASE", 186, 191], ["HF", "DISEASE", 273, 275], ["fibrosis", "DISEASE", 287, 295], ["inflammation", "DISEASE", 373, 385], ["ACEi", "CHEMICAL", 22, 26], ["ACEi", "SIMPLE_CHEMICAL", 22, 26], ["ARB", "SIMPLE_CHEMICAL", 28, 31], ["beta-blockers", "SIMPLE_CHEMICAL", 33, 46], ["MRA", "SIMPLE_CHEMICAL", 48, 51], ["phosphodiesterase-5", "GENE_OR_GENE_PRODUCT", 56, 75], ["patients", "ORGANISM", 172, 180], ["extracellular matrix", "CELLULAR_COMPONENT", 300, 320], ["cardiomyocyte", "CELL", 347, 360], ["patients", "SPECIES", 172, 180], ["ACEi", "TREATMENT", 22, 26], ["ARB", "TREATMENT", 28, 31], ["beta-blockers", "TREATMENT", 33, 46], ["MRA", "TREATMENT", 48, 51], ["phosphodiesterase", "TREATMENT", 56, 73], ["HFPEF", "PROBLEM", 186, 191], ["IntroductionBiomarker studies", "TEST", 192, 221], ["HF", "PROBLEM", 273, 275], ["fibrosis", "PROBLEM", 287, 295], ["extracellular matrix remodeling", "PROBLEM", 300, 331], ["oxidative and cardiomyocyte stress", "PROBLEM", 333, 367], ["inflammation", "PROBLEM", 373, 385], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["improvement", "OBSERVATION_MODIFIER", 132, 143], ["HF", "OBSERVATION", 273, 275], ["fibrosis", "OBSERVATION", 287, 295], ["extracellular matrix remodeling", "OBSERVATION", 300, 331], ["cardiomyocyte", "ANATOMY", 347, 360]]], ["A recent report showed that circulating tumor necrosis factor-alpha (TNF\u03b1) receptor 1 (TNFR1) levels are significant predictors of incident HF, in particular for HFPEF versus HFREF [13].", [["tumor", "DISEASE", 40, 45], ["HF", "DISEASE", 140, 142], ["HFPEF", "DISEASE", 162, 167], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 40, 67], ["TNF\u03b1) receptor 1", "GENE_OR_GENE_PRODUCT", 69, 85], ["TNFR1", "GENE_OR_GENE_PRODUCT", 87, 92], ["TNF\u03b1) receptor 1", "PROTEIN", 69, 85], ["TNFR1", "PROTEIN", 87, 92], ["circulating tumor necrosis factor", "PROBLEM", 28, 61], ["alpha (TNF\u03b1", "TEST", 62, 73], ["receptor", "TEST", 75, 83], ["TNFR1) levels", "TEST", 87, 100], ["HF", "PROBLEM", 140, 142], ["HFPEF", "PROBLEM", 162, 167], ["HFREF", "PROBLEM", 175, 180], ["circulating", "OBSERVATION_MODIFIER", 28, 39], ["tumor", "OBSERVATION", 40, 45], ["necrosis", "OBSERVATION_MODIFIER", 46, 54]]], ["Circulating TNF\u03b1 and its two receptors (TNFR1 and TNFR2) are elevated in patients with heart failure relative to controls [6], [14].", [["heart", "ANATOMY", 87, 92], ["heart failure", "DISEASE", 87, 100], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 12, 16], ["TNFR1", "GENE_OR_GENE_PRODUCT", 40, 45], ["TNFR2", "GENE_OR_GENE_PRODUCT", 50, 55], ["patients", "ORGANISM", 73, 81], ["heart", "ORGAN", 87, 92], ["TNF\u03b1", "PROTEIN", 12, 16], ["TNFR1", "PROTEIN", 40, 45], ["TNFR2", "PROTEIN", 50, 55], ["patients", "SPECIES", 73, 81], ["Circulating TNF\u03b1", "TEST", 0, 16], ["TNFR1", "TEST", 40, 45], ["TNFR2", "TEST", 50, 55], ["elevated", "PROBLEM", 61, 69], ["heart failure", "PROBLEM", 87, 100], ["elevated", "OBSERVATION_MODIFIER", 61, 69], ["heart", "ANATOMY", 87, 92], ["failure", "OBSERVATION", 93, 100]]], ["The study presented herein expands on previous work by exploring associations between diastolic dysfunction or heart failure severity, and plasma levels of TNF\u03b1, TNFR1 and TNFR2, as well as a non-TNF\u03b1 family cytokine, interleukin-6 (IL-6), in community-based cohorts of healthy controls, and ambulatory HFPEF and HFREF patients.", [["heart", "ANATOMY", 111, 116], ["plasma", "ANATOMY", 139, 145], ["diastolic dysfunction", "DISEASE", 86, 107], ["heart failure", "DISEASE", 111, 124], ["HFREF", "DISEASE", 313, 318], ["heart", "ORGAN", 111, 116], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 156, 160], ["TNFR1", "GENE_OR_GENE_PRODUCT", 162, 167], ["TNFR2", "GENE_OR_GENE_PRODUCT", 172, 177], ["non-TNF\u03b1", "GENE_OR_GENE_PRODUCT", 192, 200], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 218, 231], ["IL-6", "GENE_OR_GENE_PRODUCT", 233, 237], ["patients", "ORGANISM", 319, 327], ["TNF\u03b1", "PROTEIN", 156, 160], ["TNFR1", "PROTEIN", 162, 167], ["TNFR2", "PROTEIN", 172, 177], ["non-TNF\u03b1 family cytokine", "PROTEIN", 192, 216], ["interleukin-6", "PROTEIN", 218, 231], ["IL", "PROTEIN", 233, 235], ["patients", "SPECIES", 319, 327], ["The study", "TEST", 0, 9], ["diastolic dysfunction", "PROBLEM", 86, 107], ["heart failure severity", "PROBLEM", 111, 133], ["plasma levels", "TEST", 139, 152], ["TNF", "TEST", 156, 159], ["TNFR1", "TEST", 162, 167], ["TNFR2", "TEST", 172, 177], ["interleukin", "TEST", 218, 229], ["ambulatory HFPEF", "TREATMENT", 292, 308], ["HFREF patients", "TREATMENT", 313, 327], ["dysfunction", "OBSERVATION", 96, 107], ["heart", "ANATOMY", 111, 116], ["failure", "OBSERVATION", 117, 124]]], ["Using well-defined HF cohorts, we set out to elucidate some elements of the mechanisms that drive HFPEF and HFREF.", [["HFPEF", "DISEASE", 98, 103], ["HFREF", "DISEASE", 108, 113], ["HFPEF", "GENE_OR_GENE_PRODUCT", 98, 103], ["HFPEF", "PROBLEM", 98, 103], ["HFREF", "PROBLEM", 108, 113]]], ["Our novel findings suggest that elevated plasma levels of TNF\u03b1 receptors, in particular TNFR2, are more closely linked to the pathophysiology of HFPEF than HFREF.Ethics statement ::: MethodsThis study conforms with the conventions outlined in the Declaration of Helsinki, it received internal ethics board approval at the Universities of Alberta and Calgary for use of human subjects, and all subjects gave written informed consent [15].Patient recruitment and baseline analysis ::: MethodsAs part of a prospective clinical study, the Alberta HEART (Heart Failure Etiology and Analysis Research Team) project, community-based, ambulatory patients with clinical diagnoses of HF and healthy age- and gender-matched controls (n = 50) were consecutively recruited for comprehensive clinical, echocardiographic and biomarker analyses during a three-year period beginning in 2010 through the end of 2012.", [["plasma", "ANATOMY", 41, 47], ["HFPEF", "DISEASE", 145, 150], ["HFREF", "DISEASE", 156, 161], ["HF", "DISEASE", 674, 676], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["TNF\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 58, 72], ["TNFR2", "GENE_OR_GENE_PRODUCT", 88, 93], ["HFPEF", "CANCER", 145, 150], ["human", "ORGANISM", 369, 374], ["patients", "ORGANISM", 638, 646], ["controls", "ORGANISM", 713, 721], ["TNF\u03b1 receptors", "PROTEIN", 58, 72], ["TNFR2", "PROTEIN", 88, 93], ["human", "SPECIES", 369, 374], ["Patient", "SPECIES", 437, 444], ["patients", "SPECIES", 638, 646], ["human", "SPECIES", 369, 374], ["elevated plasma levels", "PROBLEM", 32, 54], ["TNF\u03b1 receptors", "TEST", 58, 72], ["HFPEF", "PROBLEM", 145, 150], ["HFREF", "PROBLEM", 156, 161], ["Methods", "TREATMENT", 183, 190], ["This study", "TEST", 190, 200], ["a prospective clinical study", "TEST", 501, 529], ["the Alberta HEART (Heart Failure", "PROBLEM", 531, 563], ["HF", "PROBLEM", 674, 676], ["biomarker analyses", "TEST", 810, 828], ["elevated", "OBSERVATION_MODIFIER", 32, 40], ["plasma levels", "OBSERVATION_MODIFIER", 41, 54], ["HFPEF", "OBSERVATION", 145, 150], ["HEART", "ANATOMY", 543, 548], ["Heart", "ANATOMY", 550, 555], ["Failure", "OBSERVATION", 556, 563]]], ["Blood pressure was recorded sitting or recumbent, and detailed clinical data were compiled at the time of enrollment.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Transthoracic echocardiograms were performed using the Phillips IE33 ultrasound platform.", [["Transthoracic echocardiograms", "TEST", 0, 29], ["the Phillips IE33 ultrasound platform", "TEST", 51, 88]]], ["Echocardiograms were interpreted by cardiologists with specialized echocardiography training who were blinded to both the clinical classification and biomarker analyses.", [["Echocardiograms", "TEST", 0, 15], ["specialized echocardiography training", "TEST", 55, 92], ["biomarker analyses", "TEST", 150, 168]]], ["LVEF was assessed using Simpson's biplane method of disks.", [["LVEF", "TEST", 0, 4], ["Simpson's biplane method of disks", "TREATMENT", 24, 57]]], ["HF patients were adjudicated as HFREF (n = 100) or HFPEF (n = 100) using an LVEF cutoff of 50%, according to clinical practice guidelines [1], [2].", [["HF", "DISEASE", 0, 2], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["HF", "PROBLEM", 0, 2], ["HFREF", "TEST", 32, 37], ["HFPEF", "PROBLEM", 51, 56], ["an LVEF cutoff", "TEST", 73, 87]]], ["Adjudication of New York Heart Association (NYHA) functional class and primary etiology of HF were determined by cardiologists blinded to biomarker analyses.", [["HF", "DISEASE", 91, 93], ["HF", "PROBLEM", 91, 93], ["biomarker analyses", "TEST", 138, 156], ["New", "OBSERVATION_MODIFIER", 16, 19], ["Heart", "ANATOMY", 25, 30]]], ["Grading of diastolic dysfunction was performed by blinded members of the authorship team based on previously published guidelines [16].", [["diastolic dysfunction", "DISEASE", 11, 32], ["diastolic dysfunction", "PROBLEM", 11, 32], ["diastolic dysfunction", "OBSERVATION", 11, 32]]], ["LA volume index, lateral e' and medial e' were used as a binary classifier for diastolic dysfunction, after which E/A ratio, or average E/e' ratio, for patients in AFib, was used to ascertain grade in those determined to have diastolic dysfunction.", [["lateral e'", "ANATOMY", 17, 27], ["LA", "CHEMICAL", 0, 2], ["diastolic dysfunction", "DISEASE", 79, 100], ["diastolic dysfunction", "DISEASE", 226, 247], ["LA", "MULTI-TISSUE_STRUCTURE", 0, 2], ["patients", "ORGANISM", 152, 160], ["AFib", "CANCER", 164, 168], ["patients", "SPECIES", 152, 160], ["LA volume index", "TEST", 0, 15], ["lateral e' and medial e'", "TREATMENT", 17, 41], ["diastolic dysfunction", "PROBLEM", 79, 100], ["E/A ratio", "TEST", 114, 123], ["AFib", "PROBLEM", 164, 168], ["diastolic dysfunction", "PROBLEM", 226, 247], ["volume index", "OBSERVATION", 3, 15], ["dysfunction", "OBSERVATION", 89, 100], ["diastolic", "OBSERVATION_MODIFIER", 226, 235], ["dysfunction", "OBSERVATION", 236, 247]]], ["Diastolic dysfunction analyses could not be performed due to poor echocardiographic visualization in 9 HFPEF patients and 14 HFREF patients, and a further 1 HFPEF patient and 7 HFREF patients were excluded from diastolic function analyses due to the presence of severe mitral regurgitation (MR).Patient recruitment and baseline analysis ::: MethodsBNP levels were assessed as previously described using an Alere Triage reagent pack (Alere Inc., Ottawa, ON, CAN) read in an automated DxI 800 immunoanalyzer (Beckman-Coulter, Fullerton, CA, USA) at provincial heath laboratories in the province of Alberta [17].", [["mitral", "ANATOMY", 269, 275], ["Diastolic dysfunction", "DISEASE", 0, 21], ["HFPEF", "DISEASE", 103, 108], ["HFREF", "DISEASE", 125, 130], ["HFREF", "DISEASE", 177, 182], ["mitral regurgitation", "DISEASE", 269, 289], ["MR", "DISEASE", 291, 293], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 131, 139], ["patient", "ORGANISM", 163, 170], ["patients", "ORGANISM", 183, 191], ["mitral regurgitation", "PATHOLOGICAL_FORMATION", 269, 289], ["MethodsBNP", "SIMPLE_CHEMICAL", 341, 351], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 131, 139], ["patient", "SPECIES", 163, 170], ["patients", "SPECIES", 183, 191], ["Patient", "SPECIES", 295, 302], ["Diastolic dysfunction analyses", "PROBLEM", 0, 30], ["echocardiographic visualization", "TEST", 66, 97], ["diastolic function analyses", "TEST", 211, 238], ["severe mitral regurgitation", "PROBLEM", 262, 289], ["MethodsBNP levels", "TEST", 341, 358], ["dysfunction", "OBSERVATION", 10, 21], ["severe", "OBSERVATION_MODIFIER", 262, 268], ["mitral", "OBSERVATION", 269, 275], ["regurgitation", "OBSERVATION", 276, 289]]], ["Serum levels of creatinine and lipid profiles were available in study subjects' health records as part of their clinical evaluation.", [["Serum", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 16, 26], ["creatinine", "CHEMICAL", 16, 26], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["creatinine", "SIMPLE_CHEMICAL", 16, 26], ["lipid", "SIMPLE_CHEMICAL", 31, 36], ["Serum levels", "TEST", 0, 12], ["creatinine", "TEST", 16, 26], ["lipid profiles", "TEST", 31, 45], ["their clinical evaluation", "TEST", 106, 131]]], ["Inclusion criteria for healthy controls were as follows: no history of cardiovascular or renal disease, hypertension, diabetes, or atrial fibrillation; and no prescriptions for antiarrhythmics; ACEi; ARB; beta-blockers; digoxin; loop or thiazide diuretics; or MRA.", [["cardiovascular", "ANATOMY", 71, 85], ["renal", "ANATOMY", 89, 94], ["atrial", "ANATOMY", 131, 137], ["cardiovascular or renal disease", "DISEASE", 71, 102], ["hypertension", "DISEASE", 104, 116], ["diabetes", "DISEASE", 118, 126], ["atrial fibrillation", "DISEASE", 131, 150], ["ACEi", "CHEMICAL", 194, 198], ["ARB", "CHEMICAL", 200, 203], ["digoxin", "CHEMICAL", 220, 227], ["thiazide", "CHEMICAL", 237, 245], ["digoxin", "CHEMICAL", 220, 227], ["thiazide", "CHEMICAL", 237, 245], ["renal", "ORGAN", 89, 94], ["ACEi", "SIMPLE_CHEMICAL", 194, 198], ["ARB", "SIMPLE_CHEMICAL", 200, 203], ["beta-blockers", "SIMPLE_CHEMICAL", 205, 218], ["digoxin", "SIMPLE_CHEMICAL", 220, 227], ["thiazide diuretics", "SIMPLE_CHEMICAL", 237, 255], ["healthy controls", "PROBLEM", 23, 39], ["cardiovascular or renal disease", "PROBLEM", 71, 102], ["hypertension", "PROBLEM", 104, 116], ["diabetes", "PROBLEM", 118, 126], ["atrial fibrillation", "PROBLEM", 131, 150], ["prescriptions", "TREATMENT", 159, 172], ["antiarrhythmics", "TREATMENT", 177, 192], ["ACEi", "TREATMENT", 194, 198], ["ARB", "TREATMENT", 200, 203], ["beta-blockers", "TREATMENT", 205, 218], ["digoxin", "TREATMENT", 220, 227], ["loop", "TREATMENT", 229, 233], ["thiazide diuretics", "TREATMENT", 237, 255], ["MRA", "TEST", 260, 263], ["renal", "ANATOMY", 89, 94], ["disease", "OBSERVATION", 95, 102], ["hypertension", "OBSERVATION", 104, 116], ["diabetes", "OBSERVATION", 118, 126], ["atrial", "ANATOMY", 131, 137], ["fibrillation", "OBSERVATION", 138, 150]]], ["Exclusion criteria for all study groups were any of the following: age less than 18 years; known malignancy, with expected survival time less than one year; pregnancy within the previous six months; recent cardiac event, including acute MI and decompensated HF; moderate or severe pulmonary hypertension; or severe mitral or aortic valvular stenosis.Plasma biomarker analyses ::: MethodsBlood for plasma analysis was collected during a one-day baseline enrolment which included the acquisition of the echocardiograms and ECGs.", [["cardiac", "ANATOMY", 206, 213], ["pulmonary", "ANATOMY", 281, 290], ["mitral", "ANATOMY", 315, 321], ["aortic", "ANATOMY", 325, 331], ["valvular", "ANATOMY", 332, 340], ["Blood", "ANATOMY", 387, 392], ["plasma", "ANATOMY", 397, 403], ["malignancy", "DISEASE", 97, 107], ["cardiac event", "DISEASE", 206, 219], ["MI", "DISEASE", 237, 239], ["HF", "DISEASE", 258, 260], ["pulmonary hypertension", "DISEASE", 281, 303], ["mitral or aortic valvular stenosis", "DISEASE", 315, 349], ["cardiac", "ORGAN", 206, 213], ["pulmonary", "ORGAN", 281, 290], ["mitral", "MULTI-TISSUE_STRUCTURE", 315, 321], ["aortic valvular", "PATHOLOGICAL_FORMATION", 325, 340], ["Plasma", "ORGANISM_SUBSTANCE", 350, 356], ["Blood", "ORGANISM_SUBSTANCE", 387, 392], ["plasma", "ORGANISM_SUBSTANCE", 397, 403], ["all study groups", "TEST", 23, 39], ["known malignancy", "PROBLEM", 91, 107], ["recent cardiac event", "PROBLEM", 199, 219], ["acute MI", "PROBLEM", 231, 239], ["decompensated HF", "PROBLEM", 244, 260], ["moderate or severe pulmonary hypertension", "PROBLEM", 262, 303], ["severe mitral or aortic valvular stenosis", "PROBLEM", 308, 349], ["Plasma biomarker analyses", "TEST", 350, 375], ["Methods", "TREATMENT", 380, 387], ["plasma analysis", "TEST", 397, 412], ["the echocardiograms", "TEST", 497, 516], ["ECGs", "TEST", 521, 525], ["malignancy", "OBSERVATION", 97, 107], ["cardiac", "ANATOMY", 206, 213], ["acute", "OBSERVATION_MODIFIER", 231, 236], ["MI", "OBSERVATION", 237, 239], ["decompensated", "OBSERVATION_MODIFIER", 244, 257], ["HF", "OBSERVATION", 258, 260], ["moderate", "OBSERVATION_MODIFIER", 262, 270], ["severe", "OBSERVATION_MODIFIER", 274, 280], ["pulmonary", "ANATOMY", 281, 290], ["hypertension", "OBSERVATION", 291, 303], ["severe", "OBSERVATION_MODIFIER", 308, 314], ["mitral", "OBSERVATION", 315, 321], ["aortic valvular", "ANATOMY", 325, 340], ["stenosis", "OBSERVATION", 341, 349]]], ["Patients were rested and sitting while blood was collected into cooled lithium-heparin tubes, which were immediately placed on ice prior to plasma fractionation and deep freezing at \u2264\u221275\u00b0C. Commercially-available enzyme-linked immunosorbent assay (ELISA) kits for TNF-\u03b1, TNFR1, TNFR2 and IL-6 (catalogue no. 's STA00C, SRT100, SRT200 and S6050, respectively, R&D Systems, MN, USA) were used as previously described [18], [19].", [["blood", "ANATOMY", 39, 44], ["plasma", "ANATOMY", 140, 146], ["lithium", "CHEMICAL", 71, 78], ["heparin", "CHEMICAL", 79, 86], ["lithium", "CHEMICAL", 71, 78], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["lithium-heparin tubes", "SIMPLE_CHEMICAL", 71, 92], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 264, 269], ["TNFR1", "GENE_OR_GENE_PRODUCT", 271, 276], ["TNFR2", "GENE_OR_GENE_PRODUCT", 278, 283], ["IL-6", "GENE_OR_GENE_PRODUCT", 288, 292], ["TNF", "PROTEIN", 264, 267], ["TNFR1", "PROTEIN", 271, 276], ["TNFR2", "PROTEIN", 278, 283], ["IL-6", "PROTEIN", 288, 292], ["Patients", "SPECIES", 0, 8], ["cooled lithium", "TREATMENT", 64, 78], ["heparin tubes", "TREATMENT", 79, 92], ["ice", "TREATMENT", 127, 130], ["plasma fractionation", "TREATMENT", 140, 160], ["enzyme", "TEST", 213, 219], ["immunosorbent assay", "TEST", 227, 246], ["ELISA", "TEST", 248, 253], ["kits", "TEST", 255, 259], ["TNF", "TEST", 264, 267], ["TNFR1", "TEST", 271, 276], ["TNFR2", "TEST", 278, 283], ["IL", "TEST", 288, 290], ["heparin tubes", "OBSERVATION", 79, 92], ["deep freezing", "OBSERVATION", 165, 178]]], ["Absorbance was measured at 450 nm with the wavelength correction set to 540 nm for all assays using a SpectraMax M5 Plate Reader (Molecular Devices, CA, USA).", [["the wavelength correction", "TREATMENT", 39, 64], ["a SpectraMax M5 Plate", "TREATMENT", 100, 121]]], ["Detection rates for the ELISAs were 72.4%, 100%, 100% and 81.2%, respectively.", [["Detection rates", "TEST", 0, 15], ["the ELISAs", "TEST", 20, 30]]], ["The inter- and intra-assay coefficients of variation were 13.1% and 9.5% (n = 4); 7.0% and 5.2% (n = 4); 5.3% and 3.5% (n = 4); and 8.0% and 6.3% (n = 4), respectively.Plasma biomarker analyses ::: MethodsPlasma ACE2 activity was measured using a previously established immunofluorescence protocol [20].", [["Plasma", "ORGANISM_SUBSTANCE", 168, 174], ["ACE2", "GENE_OR_GENE_PRODUCT", 212, 216], ["ACE2", "PROTEIN", 212, 216], ["variation", "TEST", 43, 52], ["Plasma biomarker analyses", "TEST", 168, 193]]], ["Lithium heparin anti-coagulated platelet-free plasma samples were diluted to a final ratio of 30\u223670 in plasma assay buffer: 1 M NaCl (Sigma Chem.", [["platelet", "ANATOMY", 32, 40], ["plasma samples", "ANATOMY", 46, 60], ["plasma", "ANATOMY", 103, 109], ["Lithium", "CHEMICAL", 0, 7], ["heparin", "CHEMICAL", 8, 15], ["NaCl", "CHEMICAL", 128, 132], ["Lithium", "CHEMICAL", 0, 7], ["NaCl", "CHEMICAL", 128, 132], ["Lithium heparin", "SIMPLE_CHEMICAL", 0, 15], ["platelet", "CELL", 32, 40], ["plasma samples", "ORGANISM_SUBSTANCE", 46, 60], ["plasma", "ORGANISM_SUBSTANCE", 103, 109], ["Lithium heparin", "TREATMENT", 0, 15], ["platelet", "TEST", 32, 40], ["free plasma samples", "TEST", 41, 60], ["a final ratio", "TEST", 77, 90]]], ["Co., MO, USA), 75 mM Tris-HCl (Invitrogen, CA, USA) and 5 mM ZnCl2 (Sigma Chem.", [["Tris-HCl", "CHEMICAL", 21, 29], ["ZnCl2", "CHEMICAL", 61, 66], ["Tris-HCl", "CHEMICAL", 21, 29], ["ZnCl2", "CHEMICAL", 61, 66], ["Tris-HCl", "SIMPLE_CHEMICAL", 21, 29], ["Invitrogen", "SIMPLE_CHEMICAL", 31, 41], ["ZnCl2", "SIMPLE_CHEMICAL", 61, 66], ["mM Tris", "TEST", 18, 25], ["Invitrogen", "TEST", 31, 41], ["CA", "TEST", 43, 45]]], ["Co., MO, USA) at pH 6.5.", [["pH", "TEST", 17, 19]]], ["Assay buffer was made to contain various protease inhibitors: 10 \u00b5M captopril (ACE inhibitor; Sigma Chem.", [["captopril", "CHEMICAL", 68, 77], ["ACE inhibitor", "CHEMICAL", 79, 92], ["captopril", "CHEMICAL", 68, 77], ["ACE", "CHEMICAL", 79, 82], ["captopril", "SIMPLE_CHEMICAL", 68, 77], ["ACE", "SIMPLE_CHEMICAL", 79, 82], ["Assay buffer", "TREATMENT", 0, 12], ["various protease inhibitors", "TREATMENT", 33, 60], ["captopril (ACE inhibitor", "TREATMENT", 68, 92], ["Sigma Chem", "TEST", 94, 104]]], ["Co., MO, USA); 5 \u00b5M amastatin (aminopeptidase inhibitor; Sigma Chem.", [["amastatin", "CHEMICAL", 20, 29], ["amastatin", "CHEMICAL", 20, 29], ["amastatin", "SIMPLE_CHEMICAL", 20, 29], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 31, 45], ["amastatin (aminopeptidase inhibitor", "TREATMENT", 20, 55], ["Sigma Chem", "TEST", 57, 67]]], ["Co., MO, USA); and Protease Inhibitor Cocktail (Sigma Chem.", [["Protease Inhibitor Cocktail", "GENE_OR_GENE_PRODUCT", 19, 46], ["Protease Inhibitor Cocktail", "TREATMENT", 19, 46]]], ["Co., MO, USA) dissolved to achieve a concentration of 10 \u00b5M bestatin (aminopeptidase inhibitor), 1 \u00b5M E-64 [N-(trans-Epoxysuccinyl)-L-leucine-4-guanidinobutylamide; cysteine protease inhibitor], 770 nM pepstatin A (aspartyl protease inhibitor), 154 \u00b5M AEBSF [4-(20aminoethyl)benzenesulfonyl fluoride hydrochloride; serine protease inhibitor], 75 nM phosphoramidon (neprilysin inhibitor), 15 nM aprotinin (serine protease inhibitor) and 75 nM leupeptin (cysteine, serine and threonine proteases inhibitor).", [["bestatin", "CHEMICAL", 60, 68], ["E-64 [N-(trans-Epoxysuccinyl)-L-leucine-4-guanidinobutylamide", "CHEMICAL", 102, 163], ["pepstatin A", "CHEMICAL", 202, 213], ["AEBSF", "CHEMICAL", 252, 257], ["4-(20aminoethyl)benzenesulfonyl fluoride hydrochloride", "CHEMICAL", 259, 313], ["phosphoramidon", "CHEMICAL", 349, 363], ["leupeptin", "CHEMICAL", 442, 451], ["cysteine", "CHEMICAL", 453, 461], ["threonine", "CHEMICAL", 474, 483], ["bestatin", "CHEMICAL", 60, 68], ["N-(trans-Epoxysuccinyl)-L-leucine-4-guanidinobutylamide", "CHEMICAL", 108, 163], ["cysteine", "CHEMICAL", 165, 173], ["pepstatin A", "CHEMICAL", 202, 213], ["AEBSF", "CHEMICAL", 252, 257], ["4-(20aminoethyl)benzenesulfonyl fluoride hydrochloride", "CHEMICAL", 259, 313], ["serine", "CHEMICAL", 315, 321], ["phosphoramidon", "CHEMICAL", 349, 363], ["aprotinin", "CHEMICAL", 394, 403], ["serine", "CHEMICAL", 405, 411], ["leupeptin", "CHEMICAL", 442, 451], ["cysteine", "CHEMICAL", 453, 461], ["serine", "CHEMICAL", 463, 469], ["threonine", "CHEMICAL", 474, 483], ["bestatin", "SIMPLE_CHEMICAL", 60, 68], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 70, 84], ["E-64", "SIMPLE_CHEMICAL", 102, 106], ["N-(trans-Epoxysuccinyl)-L-leucine-4-guanidinobutylamide", "SIMPLE_CHEMICAL", 108, 163], ["cysteine protease inhibitor", "SIMPLE_CHEMICAL", 165, 192], ["pepstatin A", "SIMPLE_CHEMICAL", 202, 213], ["aspartyl protease", "GENE_OR_GENE_PRODUCT", 215, 232], ["AEBSF", "SIMPLE_CHEMICAL", 252, 257], ["4-(20aminoethyl)benzenesulfonyl fluoride hydrochloride", "SIMPLE_CHEMICAL", 259, 313], ["serine protease inhibitor", "SIMPLE_CHEMICAL", 315, 340], ["phosphoramidon", "SIMPLE_CHEMICAL", 349, 363], ["neprilysin", "GENE_OR_GENE_PRODUCT", 365, 375], ["aprotinin", "SIMPLE_CHEMICAL", 394, 403], ["leupeptin", "SIMPLE_CHEMICAL", 442, 451], ["cysteine", "AMINO_ACID", 453, 461], ["serine", "AMINO_ACID", 463, 469], ["threonine", "AMINO_ACID", 474, 483], ["a concentration of 10 \u00b5M bestatin (aminopeptidase inhibitor)", "TREATMENT", 35, 95], ["trans-Epoxysuccinyl)", "TREATMENT", 111, 131], ["L-leucine", "TREATMENT", 132, 141], ["guanidinobutylamide", "TREATMENT", 144, 163], ["cysteine protease inhibitor", "TREATMENT", 165, 192], ["nM pepstatin A (aspartyl protease inhibitor", "TREATMENT", 199, 242], ["AEBSF", "TEST", 252, 257], ["20aminoethyl)benzenesulfonyl fluoride hydrochloride", "TREATMENT", 262, 313], ["serine protease inhibitor", "TREATMENT", 315, 340], ["nM phosphoramidon (neprilysin inhibitor", "TREATMENT", 346, 385], ["15 nM aprotinin (serine protease inhibitor", "TREATMENT", 388, 430], ["nM leupeptin (cysteine", "TREATMENT", 439, 461], ["serine", "TREATMENT", 463, 469], ["threonine proteases inhibitor", "TREATMENT", 474, 503]]], ["The use of protease inhibitors in the buffer solution was meant to ensure that the fluorogenic substrate and specific ACE2 inhibitor (both described below), which are integral to the assay, were not cleaved by other proteases naturally present in human plasma.", [["plasma", "ANATOMY", 253, 259], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["human", "ORGANISM", 247, 252], ["plasma", "ORGANISM_SUBSTANCE", 253, 259], ["ACE2", "PROTEIN", 118, 122], ["proteases", "PROTEIN", 216, 225], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 247, 252], ["protease inhibitors", "TREATMENT", 11, 30], ["the buffer solution", "TREATMENT", 34, 53], ["the fluorogenic substrate", "PROBLEM", 79, 104], ["specific ACE2 inhibitor", "TREATMENT", 109, 132]]], ["Samples were incubated with Dnp-quenched Mca-containing fluorogenic substrate (catalogue no. ES007, R&D Systems, MN, USA) at a final concentration of 10 \u00b5M at 37\u00b0C. To find the fluorescence increase due to ACE2 activity, plasma samples were assayed both in the presence and absence of the specific linear ACE2 inhibitor, DX600 (catalogue no. 002-26, Phoenix Pharmaceuticals, CA, USA).", [["Samples", "ANATOMY", 0, 7], ["plasma samples", "ANATOMY", 221, 235], ["ES007", "CHEMICAL", 93, 98], ["DX600", "CHEMICAL", 321, 326], ["Dnp", "CHEMICAL", 28, 31], ["DX600", "CHEMICAL", 321, 326], ["Dnp", "SIMPLE_CHEMICAL", 28, 31], ["ES007", "SIMPLE_CHEMICAL", 93, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 206, 210], ["plasma samples", "ORGANISM_SUBSTANCE", 221, 235], ["ACE2", "GENE_OR_GENE_PRODUCT", 305, 309], ["DX600", "SIMPLE_CHEMICAL", 321, 326], ["ACE2", "PROTEIN", 206, 210], ["ACE2", "PROTEIN", 305, 309], ["Samples", "TEST", 0, 7], ["Dnp", "TEST", 28, 31], ["the fluorescence", "TEST", 173, 189], ["ACE2 activity", "PROBLEM", 206, 219], ["plasma samples", "TEST", 221, 235]]], ["Fluorescence was measured with excitation and emission settings at 320 nm and 405 nm, respectively, using SpectraMax M5 plate reader (Molecular Devices, CA, USA).", [["Fluorescence", "TEST", 0, 12], ["SpectraMax M5 plate", "TREATMENT", 106, 125]]], ["The maximal fluorescence increase due to ACE2 activity was determined from the maximum fluorescence difference between inhibited and uninhibited aliquots; this was normalized to a standard curve for Mca-containing fluorescent peptide (catalogue no. M-1975, Bachem, CA, USA) and scaled for time of measurement and plasma volume over 24 hours, with 1 hour as the baseline.", [["plasma", "ANATOMY", 313, 319], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["plasma", "ORGANISM_SUBSTANCE", 313, 319], ["ACE2", "PROTEIN", 41, 45], ["The maximal fluorescence", "TEST", 0, 24], ["ACE2 activity", "PROBLEM", 41, 54], ["the maximum fluorescence difference", "PROBLEM", 75, 110], ["uninhibited aliquots", "PROBLEM", 133, 153], ["a standard curve", "TEST", 178, 194], ["plasma volume", "TEST", 313, 326]]], ["All ACE2 enzymatic activity values herein are expressed in pmol/hr/mL, which describes the amount of substrate turned over per unit time per unit volume of plasma.", [["plasma", "ANATOMY", 156, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["plasma", "ORGANISM_SUBSTANCE", 156, 162], ["ACE2", "PROTEIN", 4, 8], ["plasma", "TREATMENT", 156, 162]]], ["Inter- and intra-assay coefficients of variation were 10.2% and 7.5% (n = 10), respectively.Data analysis ::: MethodsContinuous data in tables are expressed as median with interquartile range (IQR) in parentheses.", [["variation", "TEST", 39, 48], ["Data analysis", "TEST", 92, 105]]], ["Continuous data in figures are expressed as box and whisker plots on a logarithmic scale to account for non-normal distributions, where boxes represent IQR with median as a bisecting line, while whiskers represent the minimum and maximum values.", [["a logarithmic scale", "TREATMENT", 69, 88], ["non-normal distributions", "PROBLEM", 104, 128], ["a bisecting line", "TREATMENT", 171, 187]]], ["Categorical data are expressed as percentages.", [["Categorical data", "TEST", 0, 16]]], ["All categorical data were compared using Pearson Chi-square tests, while continuous variables analyzed by category were compared using Mann-Whitney U Test or Kruskal-Wallis Test with Mann-Whitney U Test for pairwise comparisons, where appropriate.", [["All categorical data", "TEST", 0, 20], ["Pearson Chi-square tests", "TEST", 41, 65], ["pairwise comparisons", "TEST", 207, 227]]], ["Associations between categorical factors or continuous covariates and circulating inflammatory markers were tested using binary logistic or linear regression analyses, respectively, with log-transformed inflammatory marker levels to account for non-normal distributions.", [["categorical factors", "PROBLEM", 21, 40], ["continuous covariates", "PROBLEM", 44, 65], ["circulating inflammatory markers", "TEST", 70, 102], ["linear regression analyses", "TEST", 140, 166], ["log-transformed inflammatory marker levels", "TEST", 187, 229], ["inflammatory", "OBSERVATION_MODIFIER", 82, 94], ["inflammatory", "OBSERVATION", 203, 215]]], ["Associations between increasing grade of diastolic dysfunction or NYHA functional class and plasma biomarkers were tested using ordinal logistic regression analyses with log-transformed inflammatory marker levels.", [["plasma", "ANATOMY", 92, 98], ["diastolic dysfunction", "DISEASE", 41, 62], ["plasma", "ORGANISM_SUBSTANCE", 92, 98], ["diastolic dysfunction", "PROBLEM", 41, 62], ["NYHA functional class", "PROBLEM", 66, 87], ["plasma biomarkers", "TEST", 92, 109], ["ordinal logistic regression analyses", "TEST", 128, 164], ["diastolic dysfunction", "OBSERVATION", 41, 62], ["inflammatory", "OBSERVATION_MODIFIER", 186, 198]]], ["Forest plots are used to graphically display results from logistic regression analyses.", [["Forest plots", "TEST", 0, 12], ["logistic regression analyses", "TEST", 58, 86]]], ["A p-value<0.05 was considered significant for all statistical analyses.", [["A p-value", "TEST", 0, 9]]], ["Statistical analyses were conducted using SPSS Statistics Version 20 (IBM, NY, USA).", [["Statistical analyses", "TEST", 0, 20]]], ["Obesity was defined as BMI\u226530 kg/m2 per WHO criteria [21].", [["Obesity", "DISEASE", 0, 7], ["Obesity", "PROBLEM", 0, 7]]], ["Estimated glomerular filtration rate (eGFR) was calculated by the revised four-variable Modification of Diet in Renal Disease equation [22].", [["glomerular", "ANATOMY", 10, 20], ["Renal", "ANATOMY", 112, 117], ["glomerular", "TISSUE", 10, 20], ["Renal", "ORGAN", 112, 117], ["Estimated glomerular filtration rate", "TEST", 0, 36], ["eGFR", "TEST", 38, 42], ["glomerular", "OBSERVATION_MODIFIER", 10, 20], ["filtration", "OBSERVATION", 21, 31], ["Renal", "ANATOMY", 112, 117], ["Disease", "OBSERVATION", 118, 125]]], ["Left-ventricular hypertrophy (LVH) was defined as left-ventricular mass index (LVMI) \u2265115 g/m2 for males and \u226595 g/m2 for females per previously published criteria [23].Baseline clinical profile and assessments of heart function ::: ResultsDemographic and clinical information for the control, HFPEF and HFREF groups is displayed in Table 1.", [["Left-ventricular", "ANATOMY", 0, 16], ["left-ventricular", "ANATOMY", 50, 66], ["heart", "ANATOMY", 214, 219], ["Left-ventricular hypertrophy", "DISEASE", 0, 28], ["LVH", "DISEASE", 30, 33], ["ventricular", "MULTI-TISSUE_STRUCTURE", 5, 16], ["ventricular", "MULTI-TISSUE_STRUCTURE", 55, 66], ["heart", "ORGAN", 214, 219], ["Left-ventricular hypertrophy", "PROBLEM", 0, 28], ["LVH", "PROBLEM", 30, 33], ["left-ventricular mass index", "TEST", 50, 77], ["LVMI", "TEST", 79, 83], ["Baseline clinical profile", "TEST", 169, 194], ["assessments of heart function", "TEST", 199, 228], ["HFPEF and HFREF groups", "TREATMENT", 294, 316], ["ventricular", "ANATOMY", 5, 16], ["hypertrophy", "OBSERVATION", 17, 28], ["LVH", "OBSERVATION", 30, 33], ["left", "ANATOMY_MODIFIER", 50, 54], ["ventricular", "ANATOMY", 55, 66], ["mass", "OBSERVATION", 67, 71], ["heart", "ANATOMY", 214, 219]]], ["In this study, the HF patient populations recapitulated observations in previous reports [3]\u2013[5], [24].", [["patient", "ORGANISM", 22, 29], ["[3]\u2013[5]", "SIMPLE_CHEMICAL", 89, 96], ["patient", "SPECIES", 22, 29], ["this study", "TEST", 3, 13]]], ["The study subjects were predominantly of white race in all study groups (Table 1).", [["The study", "TEST", 0, 9], ["white race", "PROBLEM", 41, 51], ["predominantly", "OBSERVATION_MODIFIER", 24, 37]]], ["HFPEF patients were older (p = 0.003), and significantly more were obese (p = 0.016) and hypertensive than HFREF patients, while neither HF group had different gender ratios (p = 0.210), histories of diabetes, peripheral vascular disease (p = 0.234) or atrial fibrillation (AFib; Table 1).", [["peripheral vascular", "ANATOMY", 210, 229], ["atrial", "ANATOMY", 253, 259], ["obese", "DISEASE", 67, 72], ["hypertensive", "DISEASE", 89, 101], ["HFREF", "DISEASE", 107, 112], ["HF", "DISEASE", 137, 139], ["diabetes", "DISEASE", 200, 208], ["peripheral vascular disease", "DISEASE", 210, 237], ["atrial fibrillation", "DISEASE", 253, 272], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 113, 121], ["peripheral vascular", "MULTI-TISSUE_STRUCTURE", 210, 229], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 113, 121], ["HFPEF", "PROBLEM", 0, 5], ["obese", "PROBLEM", 67, 72], ["hypertensive", "PROBLEM", 89, 101], ["diabetes", "PROBLEM", 200, 208], ["peripheral vascular disease", "PROBLEM", 210, 237], ["atrial fibrillation", "PROBLEM", 253, 272], ["AFib", "PROBLEM", 274, 278], ["obese", "OBSERVATION", 67, 72], ["diabetes", "OBSERVATION", 200, 208], ["peripheral", "ANATOMY_MODIFIER", 210, 220], ["vascular", "ANATOMY", 221, 229], ["disease", "OBSERVATION", 230, 237], ["atrial", "ANATOMY", 253, 259], ["fibrillation", "OBSERVATION", 260, 272]]], ["Interestingly, total cholesterol (p = 0.774), triglycerides (p = 0.656) and total cholesterol:high-density lipoprotein (HDL) ratio (p = 0.187) were not significantly different between HF phenotypes, despite differences in obesity prevalence (Table 1).", [["cholesterol", "CHEMICAL", 21, 32], ["cholesterol", "CHEMICAL", 82, 93], ["obesity", "DISEASE", 222, 229], ["cholesterol", "CHEMICAL", 21, 32], ["triglycerides", "CHEMICAL", 46, 59], ["cholesterol", "CHEMICAL", 82, 93], ["cholesterol", "SIMPLE_CHEMICAL", 21, 32], ["triglycerides", "SIMPLE_CHEMICAL", 46, 59], ["cholesterol", "SIMPLE_CHEMICAL", 82, 93], ["high-density lipoprotein", "SIMPLE_CHEMICAL", 94, 118], ["HDL", "SIMPLE_CHEMICAL", 120, 123], ["high-density lipoprotein", "PROTEIN", 94, 118], ["HDL", "PROTEIN", 120, 123], ["total cholesterol", "TEST", 15, 32], ["triglycerides", "TEST", 46, 59], ["total cholesterol", "TEST", 76, 93], ["HDL", "TEST", 120, 123], ["ratio", "TEST", 125, 130], ["HF phenotypes", "PROBLEM", 184, 197]]], ["Ischemic etiology was more prevalent in HFREF than HFPEF, but both groups were on evidence-based therapeutic regimens (Table 1).", [["HFREF", "DISEASE", 40, 45], ["HFPEF", "DISEASE", 51, 56], ["Ischemic etiology", "PROBLEM", 0, 17], ["HFREF", "PROBLEM", 40, 45], ["HFPEF", "PROBLEM", 51, 56], ["therapeutic regimens", "TREATMENT", 97, 117]]], ["Importantly, drugs that can affect inflammation were comparably used by the two HF groups: NSAID use was equivalent and statin use was not significantly different (p = 0.438; Table 1).", [["inflammation", "DISEASE", 35, 47], ["statin", "CHEMICAL", 120, 126], ["statin", "CHEMICAL", 120, 126], ["NSAID", "SIMPLE_CHEMICAL", 91, 96], ["drugs", "TREATMENT", 13, 18], ["inflammation", "PROBLEM", 35, 47], ["NSAID use", "TREATMENT", 91, 100], ["statin", "TREATMENT", 120, 126]]], ["NYHA functional class distribution was also not significantly different between the HFPEF and HFREF groups (Table 1).Baseline clinical profile and assessments of heart function ::: ResultsHeart rates did not differ significantly between controls or the two HF groups; however, a significantly greater number of HFPEF patients were in AFib on the day of study than HFREF patients (p = 0.018; Table 2).", [["heart", "ANATOMY", 162, 167], ["Heart", "ANATOMY", 188, 193], ["HFPEF", "DISEASE", 311, 316], ["heart", "ORGAN", 162, 167], ["Heart", "ORGAN", 188, 193], ["patients", "ORGANISM", 317, 325], ["AFib", "CANCER", 334, 338], ["patients", "ORGANISM", 370, 378], ["NYHA", "PROTEIN", 0, 4], ["patients", "SPECIES", 317, 325], ["patients", "SPECIES", 370, 378], ["the HFPEF", "TEST", 80, 89], ["Baseline clinical profile", "TEST", 117, 142], ["assessments of heart function", "TEST", 147, 176], ["Heart rates", "TEST", 188, 199], ["AFib", "PROBLEM", 334, 338], ["HFREF", "TEST", 364, 369], ["not significantly different", "OBSERVATION_MODIFIER", 44, 71], ["HFPEF", "OBSERVATION", 84, 89], ["heart", "ANATOMY", 162, 167], ["Heart", "ANATOMY", 188, 193], ["HFPEF", "OBSERVATION", 311, 316]]], ["The HFREF group had significantly lower LVEF compared to control and HFPEF groups, while both HFPEF and HFREF had greater LV posterior wall thickness (LVPW; p<0.001 for both) and mass index (LVMI; p<0.001 for both); left atrial volume index (LA volume index; p<0.001 for both); and average E/e' ratio (p<0.001 for both) compared to control (Table 2).", [["LV posterior wall", "ANATOMY", 122, 139], ["left atrial", "ANATOMY", 216, 227], ["HFREF", "CANCER", 4, 9], ["LV posterior wall", "TISSUE", 122, 139], ["atrial", "MULTI-TISSUE_STRUCTURE", 221, 227], ["significantly lower LVEF", "PROBLEM", 20, 44], ["HFPEF groups", "TEST", 69, 81], ["HFPEF", "TEST", 94, 99], ["HFREF", "TEST", 104, 109], ["LVPW", "TEST", 151, 155], ["p", "TEST", 157, 158], ["mass index", "TEST", 179, 189], ["LVMI", "TEST", 191, 195], ["p", "TEST", 197, 198], ["left atrial volume index", "TEST", 216, 240], ["LA volume index", "TEST", 242, 257], ["p", "TEST", 259, 260], ["average E/e' ratio", "TEST", 282, 300], ["HFPEF", "OBSERVATION", 94, 99], ["posterior", "ANATOMY_MODIFIER", 125, 134], ["wall", "ANATOMY_MODIFIER", 135, 139], ["thickness", "OBSERVATION_MODIFIER", 140, 149], ["mass", "OBSERVATION", 179, 183], ["left atrial", "ANATOMY", 216, 227], ["volume index", "OBSERVATION", 228, 240]]], ["LVPW (p<0.05), and left ventricular end diastolic and systolic dimensions (LVEDD and LVESD, respectively; p<0.001 for both) were significantly different between the two HF groups (Table 2).", [["left ventricular", "ANATOMY", 19, 35], ["ventricular", "MULTI-TISSUE_STRUCTURE", 24, 35], ["LVPW", "TEST", 0, 4], ["p", "TEST", 6, 7], ["left ventricular end diastolic", "TEST", 19, 49], ["LVEDD", "TEST", 75, 80], ["LVESD", "TEST", 85, 90], ["p", "TEST", 106, 107], ["left ventricular", "ANATOMY", 19, 35], ["end", "ANATOMY_MODIFIER", 36, 39], ["diastolic", "ANATOMY_MODIFIER", 40, 49], ["systolic", "OBSERVATION_MODIFIER", 54, 62], ["dimensions", "OBSERVATION_MODIFIER", 63, 73], ["LVEDD", "OBSERVATION", 75, 80]]], ["The distributions of grades of diastolic dysfunction were also significantly different (p = 0.043), which might be due to the high prevalence of AFib acting as a confounder in this analysis (Table 2).", [["diastolic dysfunction", "DISEASE", 31, 52], ["AFib", "GENE_OR_GENE_PRODUCT", 145, 149], ["AFib", "PROTEIN", 145, 149], ["diastolic dysfunction", "PROBLEM", 31, 52], ["AFib", "PROBLEM", 145, 149], ["this analysis", "TEST", 176, 189], ["grades", "OBSERVATION_MODIFIER", 21, 27], ["diastolic dysfunction", "OBSERVATION", 31, 52], ["significantly", "OBSERVATION_MODIFIER", 63, 76], ["different", "OBSERVATION_MODIFIER", 77, 86]]], ["Significantly more HFREF subjects had left-ventricular hypertrophy (LVH) than HFPEF subjects (p<0.001; Table 2).Circulating inflammatory markers in healthy control, HFPEF and HFREF ::: ResultsCompared to control, plasma levels of TNF\u03b1 were only significantly elevated in HPFEF, while levels of TNFR1 and TNFR2 were significantly elevated in both HFPEF and HFREF (Figure 1A\u2013C).", [["left-ventricular", "ANATOMY", 38, 54], ["plasma", "ANATOMY", 213, 219], ["HPFEF", "ANATOMY", 271, 276], ["left-ventricular hypertrophy", "DISEASE", 38, 66], ["LVH", "DISEASE", 68, 71], ["ventricular", "MULTI-TISSUE_STRUCTURE", 43, 54], ["plasma", "ORGANISM_SUBSTANCE", 213, 219], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 230, 234], ["TNFR1", "GENE_OR_GENE_PRODUCT", 294, 299], ["TNFR2", "GENE_OR_GENE_PRODUCT", 304, 309], ["Circulating inflammatory markers", "PROTEIN", 112, 144], ["TNF\u03b1", "PROTEIN", 230, 234], ["TNFR1", "PROTEIN", 294, 299], ["TNFR2", "PROTEIN", 304, 309], ["left-ventricular hypertrophy", "PROBLEM", 38, 66], ["LVH", "PROBLEM", 68, 71], ["HFPEF subjects", "PROBLEM", 78, 92], ["Circulating inflammatory markers in healthy control", "PROBLEM", 112, 163], ["HFPEF", "PROBLEM", 165, 170], ["plasma levels", "TEST", 213, 226], ["TNF\u03b1", "TEST", 230, 234], ["significantly elevated", "PROBLEM", 245, 267], ["HPFEF", "TEST", 271, 276], ["TNFR1", "TEST", 294, 299], ["TNFR2", "TEST", 304, 309], ["significantly elevated", "PROBLEM", 315, 337], ["HFPEF", "TEST", 346, 351], ["HFREF", "TEST", 356, 361], ["HFREF", "OBSERVATION", 19, 24], ["left", "ANATOMY_MODIFIER", 38, 42], ["ventricular", "ANATOMY", 43, 54], ["hypertrophy", "OBSERVATION", 55, 66], ["LVH", "OBSERVATION", 68, 71], ["inflammatory", "OBSERVATION_MODIFIER", 124, 136], ["healthy control", "OBSERVATION_MODIFIER", 148, 163]]], ["Meanwhile, IL-6 was not significantly different between control and the HF groups (Figure 1D).", [["IL-6", "GENE_OR_GENE_PRODUCT", 11, 15], ["IL-6", "PROTEIN", 11, 15]]], ["Interestingly, TNFR2 was significantly elevated in HFPEF relative to HFREF, while TNF\u03b1 and TNFR1 were non-significantly elevated in HFPEF (Figure 1A\u2013C).", [["HFPEF", "ANATOMY", 51, 56], ["HFREF", "ANATOMY", 69, 74], ["TNFR2", "GENE_OR_GENE_PRODUCT", 15, 20], ["HFPEF", "CANCER", 51, 56], ["HFREF", "CANCER", 69, 74], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 82, 86], ["TNFR1", "GENE_OR_GENE_PRODUCT", 91, 96], ["TNFR2", "PROTEIN", 15, 20], ["TNF\u03b1", "PROTEIN", 82, 86], ["TNFR1", "PROTEIN", 91, 96], ["TNFR2", "TEST", 15, 20], ["significantly elevated", "PROBLEM", 25, 47], ["HFPEF", "PROBLEM", 51, 56], ["HFREF", "TEST", 69, 74], ["TNF", "TEST", 82, 85], ["TNFR1", "TEST", 91, 96], ["non-significantly elevated", "PROBLEM", 102, 128], ["HFPEF", "PROBLEM", 132, 137], ["HFPEF", "OBSERVATION", 51, 56]]], ["We explored the relationship between age, eGFR, sex, obesity, LVH, hypertension, diabetes, smoking status, peripheral vascular disease or history of atrial fibrillation with TNF\u03b1, TNFR1, TNFR2 and IL-6 in the combined HF group (Table 3).", [["peripheral vascular", "ANATOMY", 107, 126], ["atrial", "ANATOMY", 149, 155], ["obesity", "DISEASE", 53, 60], ["LVH", "DISEASE", 62, 65], ["hypertension", "DISEASE", 67, 79], ["diabetes", "DISEASE", 81, 89], ["peripheral vascular disease", "DISEASE", 107, 134], ["atrial fibrillation", "DISEASE", 149, 168], ["HF", "DISEASE", 218, 220], ["peripheral vascular", "MULTI-TISSUE_STRUCTURE", 107, 126], ["atrial", "MULTI-TISSUE_STRUCTURE", 149, 155], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 174, 178], ["TNFR1", "GENE_OR_GENE_PRODUCT", 180, 185], ["TNFR2", "GENE_OR_GENE_PRODUCT", 187, 192], ["IL-6", "GENE_OR_GENE_PRODUCT", 197, 201], ["TNF\u03b1", "PROTEIN", 174, 178], ["TNFR1", "PROTEIN", 180, 185], ["TNFR2", "PROTEIN", 187, 192], ["IL-6", "PROTEIN", 197, 201], ["obesity", "PROBLEM", 53, 60], ["LVH", "PROBLEM", 62, 65], ["hypertension", "PROBLEM", 67, 79], ["diabetes", "PROBLEM", 81, 89], ["peripheral vascular disease", "PROBLEM", 107, 134], ["atrial fibrillation", "PROBLEM", 149, 168], ["TNF\u03b1", "TREATMENT", 174, 178], ["TNFR1", "TREATMENT", 180, 185], ["TNFR2", "TREATMENT", 187, 192], ["IL", "TREATMENT", 197, 199], ["obesity", "OBSERVATION", 53, 60], ["LVH", "OBSERVATION", 62, 65], ["hypertension", "OBSERVATION", 67, 79], ["diabetes", "OBSERVATION", 81, 89], ["peripheral", "ANATOMY_MODIFIER", 107, 117], ["vascular", "ANATOMY", 118, 126], ["disease", "OBSERVATION", 127, 134], ["atrial", "ANATOMY", 149, 155], ["fibrillation", "OBSERVATION", 156, 168]]], ["Advanced age was significantly associated with elevated TNFR1 and TNFR2, and low eGFR was significantly associated with elevated TNF\u03b1 in addition to its two receptors (Table 3).", [["TNFR1", "GENE_OR_GENE_PRODUCT", 56, 61], ["TNFR2", "GENE_OR_GENE_PRODUCT", 66, 71], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 129, 133], ["TNFR1", "PROTEIN", 56, 61], ["TNFR2", "PROTEIN", 66, 71], ["TNF\u03b1", "PROTEIN", 129, 133], ["elevated TNFR1", "PROBLEM", 47, 61], ["TNFR2", "TEST", 66, 71], ["low eGFR", "PROBLEM", 77, 85], ["elevated TNF", "PROBLEM", 120, 132]]], ["TNF\u03b1, TNFR1 and TNFR2 increased differentially in response to smoking status or comorbid conditions, such as hypertension and diabetes, but were always associated with at least two covariates, while IL-6 was not associated with any covariate (Table 3).", [["smoking", "CHEMICAL", 62, 69], ["hypertension", "DISEASE", 109, 121], ["diabetes", "DISEASE", 126, 134], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TNFR1", "GENE_OR_GENE_PRODUCT", 6, 11], ["TNFR2", "GENE_OR_GENE_PRODUCT", 16, 21], ["IL-6", "GENE_OR_GENE_PRODUCT", 199, 203], ["TNF\u03b1", "PROTEIN", 0, 4], ["TNFR1", "PROTEIN", 6, 11], ["TNFR2", "PROTEIN", 16, 21], ["IL-6", "PROTEIN", 199, 203], ["TNF", "TEST", 0, 3], ["TNFR1", "TEST", 6, 11], ["TNFR2", "PROBLEM", 16, 21], ["comorbid conditions", "PROBLEM", 80, 99], ["hypertension", "PROBLEM", 109, 121], ["diabetes", "PROBLEM", 126, 134], ["hypertension", "OBSERVATION", 109, 121], ["diabetes", "OBSERVATION", 126, 134]]], ["Sex, obesity and LVH were not significantly associated with any of the inflammatory markers (Table 3).Modulators of inflammatory markers in HFPEF and HFREF ::: ResultsWe investigated how the inflammatory markers in this study related to two clinically-relevant and commonly-used ordinal quantifications of disease status in HF: grade of diastolic dysfunction and NYHA functional class.", [["obesity", "DISEASE", 5, 12], ["LVH", "DISEASE", 17, 20], ["HF", "DISEASE", 324, 326], ["diastolic dysfunction", "DISEASE", 337, 358], ["inflammatory markers", "PROTEIN", 71, 91], ["inflammatory markers", "PROTEIN", 116, 136], ["inflammatory markers", "PROTEIN", 191, 211], ["obesity", "PROBLEM", 5, 12], ["LVH", "PROBLEM", 17, 20], ["the inflammatory markers", "TEST", 67, 91], ["inflammatory markers", "TEST", 116, 136], ["HFPEF", "PROBLEM", 140, 145], ["the inflammatory markers", "TEST", 187, 211], ["this study", "TEST", 215, 225], ["disease status", "PROBLEM", 306, 320], ["diastolic dysfunction", "PROBLEM", 337, 358], ["NYHA functional class", "PROBLEM", 363, 384], ["obesity", "OBSERVATION", 5, 12], ["LVH", "OBSERVATION", 17, 20], ["inflammatory", "OBSERVATION", 71, 83], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["HFPEF", "OBSERVATION", 140, 145], ["inflammatory", "OBSERVATION_MODIFIER", 191, 203], ["diastolic dysfunction", "OBSERVATION", 337, 358]]], ["We investigated these associations using ordinal logistic regression analyses.", [["ordinal logistic regression analyses", "TEST", 41, 77]]], ["Elevated TNFR2 was significantly associated with increasing grade of diastolic dysfunction in HFPEF, but not in HFREF, while TNFR1 was not associated with diastolic dysfunction in either HF group (Figure 2A).", [["HFPEF", "ANATOMY", 94, 99], ["diastolic dysfunction", "DISEASE", 69, 90], ["diastolic dysfunction", "DISEASE", 155, 176], ["HF", "DISEASE", 187, 189], ["TNFR2", "GENE_OR_GENE_PRODUCT", 9, 14], ["HFREF", "CANCER", 112, 117], ["TNFR1", "GENE_OR_GENE_PRODUCT", 125, 130], ["TNFR2", "PROTEIN", 9, 14], ["TNFR1", "PROTEIN", 125, 130], ["Elevated TNFR2", "PROBLEM", 0, 14], ["diastolic dysfunction", "PROBLEM", 69, 90], ["HFPEF", "PROBLEM", 94, 99], ["HFREF", "PROBLEM", 112, 117], ["diastolic dysfunction", "PROBLEM", 155, 176], ["TNFR2", "OBSERVATION", 9, 14], ["diastolic dysfunction", "OBSERVATION", 69, 90], ["HFPEF", "OBSERVATION", 94, 99], ["dysfunction", "OBSERVATION", 165, 176]]], ["Interestingly, elevated TNFR1 and TNFR2 levels were significantly associated with increasing NYHA functional class in both HPFEF and HFREF (Figure 2A).", [["TNFR1", "GENE_OR_GENE_PRODUCT", 24, 29], ["TNFR2", "GENE_OR_GENE_PRODUCT", 34, 39], ["TNFR1", "PROTEIN", 24, 29], ["TNFR2", "PROTEIN", 34, 39], ["elevated TNFR1", "PROBLEM", 15, 29], ["TNFR2 levels", "TEST", 34, 46], ["increasing NYHA functional class", "PROBLEM", 82, 114], ["HFREF", "PROBLEM", 133, 138], ["elevated", "OBSERVATION_MODIFIER", 15, 23], ["TNFR1", "OBSERVATION", 24, 29]]], ["Neither TNF\u03b1, nor IL-6 were significantly associated with diastolic dysfunction or symptom severity in either HFPEF or HFREF (data not shown).", [["diastolic dysfunction", "DISEASE", 58, 79], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 8, 12], ["IL-6", "GENE_OR_GENE_PRODUCT", 18, 22], ["TNF\u03b1", "PROTEIN", 8, 12], ["IL-6", "PROTEIN", 18, 22], ["TNF", "TEST", 8, 11], ["IL", "TEST", 18, 20], ["diastolic dysfunction", "PROBLEM", 58, 79], ["symptom severity", "PROBLEM", 83, 99], ["HFPEF", "PROBLEM", 110, 115], ["HFREF", "PROBLEM", 119, 124], ["TNF", "OBSERVATION", 8, 11], ["dysfunction", "OBSERVATION", 68, 79]]], ["LA volume index was not associated with plasma TNFR1 or TNFR2 levels in HFPEF (r = 0.110, p = 0.298; and r = 0.170, p = 0.105, respectively) or HFREF (r = 0.083, p = 0.443; and r = 0.056, p = 0.607, respectively).", [["plasma", "ANATOMY", 40, 46], ["LA", "CHEMICAL", 0, 2], ["LA", "SIMPLE_CHEMICAL", 0, 2], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["TNFR1", "GENE_OR_GENE_PRODUCT", 47, 52], ["TNFR2", "GENE_OR_GENE_PRODUCT", 56, 61], ["TNFR1", "PROTEIN", 47, 52], ["TNFR2", "PROTEIN", 56, 61], ["LA volume index", "TEST", 0, 15], ["plasma TNFR1", "TEST", 40, 52], ["TNFR2 levels", "TEST", 56, 68], ["HFPEF", "TEST", 72, 77], ["p", "TEST", 90, 91], ["p", "TEST", 116, 117], ["HFREF", "TEST", 144, 149], ["p", "TEST", 162, 163], ["p", "TEST", 188, 189], ["volume index", "OBSERVATION", 3, 15], ["not associated with", "UNCERTAINTY", 20, 39], ["HFPEF", "OBSERVATION", 72, 77]]], ["Plasma levels of TNFR1 and TNFR2 were weakly, but significantly, associated with average E/e' ratio in HFPEF (Figure 2B & C), but not HFREF (r = 0.215, p = 0.053; and r = 0.112, p = 0.318, respectively).", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["TNFR1", "GENE_OR_GENE_PRODUCT", 17, 22], ["TNFR2", "GENE_OR_GENE_PRODUCT", 27, 32], ["TNFR1", "PROTEIN", 17, 22], ["TNFR2", "PROTEIN", 27, 32], ["Plasma levels", "TEST", 0, 13], ["TNFR1", "TEST", 17, 22], ["TNFR2", "TEST", 27, 32], ["average E/e' ratio", "PROBLEM", 81, 99], ["HFPEF", "TEST", 103, 108], ["HFREF", "TEST", 134, 139], ["p", "TEST", 152, 153], ["p", "TEST", 178, 179], ["HFPEF", "OBSERVATION", 103, 108]]], ["Given that AFib can confound diastolic dysfunction analyses, we investigated associations between TNFR1 or TNFR2 and LA volume index or average E/e' ratio, as alternative measures of diastolic function that can be used for patients in AFib [25].Modulators of inflammatory markers in HFPEF and HFREF ::: ResultsIncreased activity of TNF\u03b1 converting enzyme (TACE), a sheddase involved in proteolytic processing of TNF\u03b1, TNFRs, and angiotensin-converting enzyme 2 (ACE2) might represent a mechanism of increased circulating TNF\u03b1 and TNFRs in HF [26], [27].", [["diastolic dysfunction", "DISEASE", 29, 50], ["angiotensin", "CHEMICAL", 429, 440], ["AFib", "SIMPLE_CHEMICAL", 11, 15], ["TNFR1", "GENE_OR_GENE_PRODUCT", 98, 103], ["TNFR2", "GENE_OR_GENE_PRODUCT", 107, 112], ["LA", "SIMPLE_CHEMICAL", 117, 119], ["patients", "ORGANISM", 223, 231], ["TNF\u03b1 converting enzyme", "GENE_OR_GENE_PRODUCT", 332, 354], ["TACE", "GENE_OR_GENE_PRODUCT", 356, 360], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 412, 416], ["TNFRs", "GENE_OR_GENE_PRODUCT", 418, 423], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 429, 460], ["ACE2", "GENE_OR_GENE_PRODUCT", 462, 466], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 521, 525], ["TNFRs", "GENE_OR_GENE_PRODUCT", 530, 535], ["TNFR1", "PROTEIN", 98, 103], ["TNFR2", "PROTEIN", 107, 112], ["inflammatory markers", "PROTEIN", 259, 279], ["TNF\u03b1 converting enzyme", "PROTEIN", 332, 354], ["TACE", "PROTEIN", 356, 360], ["TNF\u03b1", "PROTEIN", 412, 416], ["TNFRs", "PROTEIN", 418, 423], ["angiotensin-converting enzyme 2", "PROTEIN", 429, 460], ["ACE2", "PROTEIN", 462, 466], ["TNF\u03b1", "PROTEIN", 521, 525], ["TNFRs", "PROTEIN", 530, 535], ["patients", "SPECIES", 223, 231], ["AFib", "PROBLEM", 11, 15], ["diastolic dysfunction analyses", "PROBLEM", 29, 59], ["TNFR1", "TEST", 98, 103], ["TNFR2", "TEST", 107, 112], ["LA volume index", "TEST", 117, 132], ["diastolic function", "TEST", 183, 201], ["AFib", "PROBLEM", 235, 239], ["inflammatory markers", "TEST", 259, 279], ["HFPEF", "PROBLEM", 283, 288], ["TNF", "TREATMENT", 332, 335], ["enzyme (TACE", "TREATMENT", 348, 360], ["TNF", "TEST", 412, 415], ["TNFRs", "TEST", 418, 423], ["angiotensin", "TEST", 429, 440], ["ACE2", "TEST", 462, 466], ["increased circulating TNF", "PROBLEM", 499, 524], ["TNFRs", "TEST", 530, 535], ["HF", "PROBLEM", 539, 541], ["inflammatory", "OBSERVATION_MODIFIER", 259, 271], ["HFPEF", "OBSERVATION", 283, 288], ["increased", "OBSERVATION_MODIFIER", 499, 508], ["circulating TNF", "OBSERVATION", 509, 524]]], ["ACE2 is a counter-regulatory homologue of angiotensin-converting enzyme (ACE) and a major regulator of endothelial function and myocardial fibrosis [28]\u2013[30].", [["endothelial", "ANATOMY", 103, 114], ["myocardial", "ANATOMY", 128, 138], ["angiotensin", "CHEMICAL", 42, 53], ["myocardial fibrosis", "DISEASE", 128, 147], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 42, 71], ["ACE", "GENE_OR_GENE_PRODUCT", 73, 76], ["endothelial", "CELL", 103, 114], ["myocardial", "MULTI-TISSUE_STRUCTURE", 128, 138], ["ACE2", "PROTEIN", 0, 4], ["angiotensin-converting enzyme", "PROTEIN", 42, 71], ["ACE", "PROTEIN", 73, 76], ["angiotensin", "TREATMENT", 42, 53], ["converting enzyme (ACE)", "TREATMENT", 54, 77], ["myocardial fibrosis", "PROBLEM", 128, 147], ["myocardial", "ANATOMY", 128, 138], ["fibrosis", "OBSERVATION", 139, 147]]], ["Since the membrane-bound localization of TACE poses a limitation in assessing its levels or activity in the plasma, we measured plasma ACE2 activity as a surrogate, as it increases with increased TACE activity [31].", [["membrane", "ANATOMY", 10, 18], ["plasma", "ANATOMY", 108, 114], ["plasma", "ANATOMY", 128, 134], ["membrane", "CELLULAR_COMPONENT", 10, 18], ["TACE", "GENE_OR_GENE_PRODUCT", 41, 45], ["plasma", "ORGANISM_SUBSTANCE", 108, 114], ["plasma", "ORGANISM_SUBSTANCE", 128, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["TACE", "PROTEIN", 41, 45], ["ACE2", "PROTEIN", 135, 139], ["TACE", "PROTEIN", 196, 200], ["TACE", "TREATMENT", 41, 45], ["the plasma", "TEST", 104, 114], ["plasma ACE2 activity", "TREATMENT", 128, 148], ["increased TACE activity", "PROBLEM", 186, 209]]], ["Previous reports of plasma ACE2 activity showed an association with clinically diagnosed HFREF, symptom severity and worsening clinical outcomes [20], [32].", [["plasma", "ANATOMY", 20, 26], ["HFREF", "DISEASE", 89, 94], ["plasma", "ORGANISM_SUBSTANCE", 20, 26], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["ACE2", "PROTEIN", 27, 31], ["plasma ACE2 activity", "TEST", 20, 40], ["clinically diagnosed HFREF", "PROBLEM", 68, 94], ["symptom severity", "PROBLEM", 96, 112], ["worsening clinical outcomes", "PROBLEM", 117, 144]]], ["In our HFPEF cohort, plasma ACE2 activity was significantly elevated relative to control (Figure 3A); however, it was not associated with increasing grade of diastolic dysfunction or NYHA class (Figure 3B).DiscussionIn this comparative analysis of healthy controls, and HF patients with preserved or reduced left-ventricular ejection fraction, we found that our cohorts recapitulated previous characterizations, whereby, HFPEF subjects were more likely to be older, hypertensive and obese [3]\u2013[5], [24].", [["plasma", "ANATOMY", 21, 27], ["left-ventricular", "ANATOMY", 308, 324], ["diastolic dysfunction", "DISEASE", 158, 179], ["HF", "DISEASE", 270, 272], ["hypertensive", "DISEASE", 466, 478], ["HFPEF", "CANCER", 7, 12], ["plasma", "ORGANISM_SUBSTANCE", 21, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["patients", "ORGANISM", 273, 281], ["ventricular", "MULTI-TISSUE_STRUCTURE", 313, 324], ["ACE2", "PROTEIN", 28, 32], ["patients", "SPECIES", 273, 281], ["plasma ACE2 activity", "TEST", 21, 41], ["significantly elevated", "PROBLEM", 46, 68], ["diastolic dysfunction", "PROBLEM", 158, 179], ["NYHA class", "PROBLEM", 183, 193], ["HFPEF subjects", "PROBLEM", 421, 435], ["hypertensive and obese", "PROBLEM", 466, 488], ["HFPEF", "OBSERVATION", 7, 12], ["diastolic dysfunction", "OBSERVATION", 158, 179], ["left", "ANATOMY_MODIFIER", 308, 312], ["ventricular ejection", "ANATOMY", 313, 333]]], ["Similarly, AFib was prevalent in both HF groups, which follows the trend observed in the MAGGIC meta-analysis [5].", [["AFib", "CHEMICAL", 11, 15], ["HF", "DISEASE", 38, 40], ["AFib", "GENE_OR_GENE_PRODUCT", 11, 15], ["AFib", "PROTEIN", 11, 15], ["AFib", "PROBLEM", 11, 15], ["AFib", "OBSERVATION", 11, 15]]], ["Furthermore, the primary etiology of HF was much less likely to be ischemic in the HFPEF group.", [["HF", "DISEASE", 37, 39], ["HFPEF", "DISEASE", 83, 88], ["HFPEF", "CANCER", 83, 88], ["HF", "PROBLEM", 37, 39], ["ischemic", "PROBLEM", 67, 75], ["HF", "OBSERVATION", 37, 39], ["ischemic", "OBSERVATION", 67, 75], ["HFPEF", "OBSERVATION", 83, 88]]], ["Despite differences in comorbidities, age and HF etiology the NYHA class distribution was similar between HFREF and HFPEF, which indicates that the two patient populations experienced significant burden of disease.", [["HF", "DISEASE", 46, 48], ["HFPEF", "DISEASE", 116, 121], ["patient", "ORGANISM", 152, 159], ["patient", "SPECIES", 152, 159], ["the NYHA class distribution", "PROBLEM", 58, 85], ["HFREF", "TEST", 106, 111], ["HFPEF", "PROBLEM", 116, 121], ["the two patient populations", "PROBLEM", 144, 171], ["significant burden of disease", "PROBLEM", 184, 213], ["HFPEF", "OBSERVATION", 116, 121], ["significant", "OBSERVATION_MODIFIER", 184, 195], ["burden", "OBSERVATION_MODIFIER", 196, 202], ["disease", "OBSERVATION", 206, 213]]], ["Additionally, both groups had cardiac hypertrophy and exhibited marked diastolic dysfunction.", [["cardiac", "ANATOMY", 30, 37], ["cardiac hypertrophy", "DISEASE", 30, 49], ["diastolic dysfunction", "DISEASE", 71, 92], ["cardiac", "ORGAN", 30, 37], ["cardiac hypertrophy", "PROBLEM", 30, 49], ["marked diastolic dysfunction", "PROBLEM", 64, 92], ["cardiac", "ANATOMY", 30, 37], ["hypertrophy", "OBSERVATION", 38, 49], ["marked", "OBSERVATION_MODIFIER", 64, 70], ["diastolic dysfunction", "OBSERVATION", 71, 92]]], ["In patients without marked systolic dysfunction, a greater prevalence of comorbidities might account for the similarity in symptoms between HFPEF and HFREF.DiscussionImprovement in exercise capacity in a cohort of HFPEF patients after an exercise training regimen was largely mediated by peripheral improvements, which suggests a systemic component to HFPEF, including skeletal muscle dysregulation [33].", [["skeletal muscle", "ANATOMY", 369, 384], ["systolic dysfunction", "DISEASE", 27, 47], ["HFPEF", "DISEASE", 140, 145], ["HFREF", "DISEASE", 150, 155], ["HFPEF", "DISEASE", 214, 219], ["HFPEF", "DISEASE", 352, 357], ["skeletal muscle dysregulation", "DISEASE", 369, 398], ["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 220, 228], ["skeletal muscle", "TISSUE", 369, 384], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 220, 228], ["marked systolic dysfunction", "PROBLEM", 20, 47], ["comorbidities", "PROBLEM", 73, 86], ["symptoms", "PROBLEM", 123, 131], ["HFPEF", "PROBLEM", 140, 145], ["HFREF", "TREATMENT", 150, 155], ["exercise capacity", "PROBLEM", 181, 198], ["an exercise training regimen", "TREATMENT", 235, 263], ["a systemic component", "PROBLEM", 328, 348], ["HFPEF", "PROBLEM", 352, 357], ["skeletal muscle dysregulation", "PROBLEM", 369, 398], ["without", "UNCERTAINTY", 12, 19], ["marked", "OBSERVATION_MODIFIER", 20, 26], ["systolic", "OBSERVATION_MODIFIER", 27, 35], ["dysfunction", "OBSERVATION", 36, 47], ["exercise capacity", "OBSERVATION", 181, 198], ["peripheral", "ANATOMY_MODIFIER", 288, 298], ["improvements", "OBSERVATION", 299, 311], ["systemic", "OBSERVATION_MODIFIER", 330, 338], ["HFPEF", "OBSERVATION", 352, 357], ["skeletal muscle", "ANATOMY", 369, 384]]], ["Indeed, a recent model of HFPEF suggests that comorbidity-mediated systemic inflammation, results in coronary microvascular endothelial dysfunction, myocardial hypertrophy and fibrosis, and skeletal muscle dysregulation to produce the HFPEF phenotype [6].", [["coronary microvascular endothelial", "ANATOMY", 101, 135], ["myocardial", "ANATOMY", 149, 159], ["skeletal muscle", "ANATOMY", 190, 205], ["HFPEF", "DISEASE", 26, 31], ["inflammation", "DISEASE", 76, 88], ["myocardial hypertrophy", "DISEASE", 149, 171], ["fibrosis", "DISEASE", 176, 184], ["skeletal muscle dysregulation", "DISEASE", 190, 219], ["HFPEF", "CANCER", 26, 31], ["coronary microvascular endothelial", "TISSUE", 101, 135], ["myocardial", "MULTI-TISSUE_STRUCTURE", 149, 159], ["skeletal muscle", "TISSUE", 190, 205], ["HFPEF", "PROBLEM", 26, 31], ["comorbidity", "PROBLEM", 46, 57], ["systemic inflammation", "PROBLEM", 67, 88], ["coronary microvascular endothelial dysfunction", "PROBLEM", 101, 147], ["myocardial hypertrophy", "PROBLEM", 149, 171], ["fibrosis", "PROBLEM", 176, 184], ["skeletal muscle dysregulation", "PROBLEM", 190, 219], ["the HFPEF phenotype", "PROBLEM", 231, 250], ["HFPEF", "OBSERVATION", 26, 31], ["comorbidity", "OBSERVATION", 46, 57], ["systemic", "OBSERVATION_MODIFIER", 67, 75], ["inflammation", "OBSERVATION", 76, 88], ["coronary", "ANATOMY", 101, 109], ["microvascular endothelial", "ANATOMY", 110, 135], ["myocardial", "ANATOMY", 149, 159], ["hypertrophy", "OBSERVATION", 160, 171], ["fibrosis", "OBSERVATION", 176, 184], ["skeletal muscle", "ANATOMY", 190, 205]]], ["We investigated TNF\u03b1 and its receptors (TNFR1 and TNFR2) as one component of comorbidity-driven inflammation, and included IL-6 as non-TNF-family cytokine for comparison.", [["inflammation", "DISEASE", 96, 108], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 16, 20], ["TNFR1", "GENE_OR_GENE_PRODUCT", 40, 45], ["TNFR2", "GENE_OR_GENE_PRODUCT", 50, 55], ["IL-6", "GENE_OR_GENE_PRODUCT", 123, 127], ["non-TNF", "GENE_OR_GENE_PRODUCT", 131, 138], ["TNF\u03b1", "PROTEIN", 16, 20], ["TNFR1", "PROTEIN", 40, 45], ["TNFR2", "PROTEIN", 50, 55], ["IL-6", "PROTEIN", 123, 127], ["non-TNF-family cytokine", "PROTEIN", 131, 154], ["TNF", "TEST", 16, 19], ["its receptors (TNFR1 and TNFR2", "TREATMENT", 25, 55], ["comorbidity", "PROBLEM", 77, 88], ["driven inflammation", "PROBLEM", 89, 108], ["IL", "TEST", 123, 125], ["comorbidity", "OBSERVATION", 77, 88], ["inflammation", "OBSERVATION", 96, 108]]], ["We expand on previous work in HF: our data showed that levels of TNF\u03b1 and TNFR1 were significantly increased in HFPEF relative control but not HFREF, while TNFR2 was significantly increased relative to both control and HFREF [14].", [["HFREF", "ANATOMY", 143, 148], ["HF", "DISEASE", 30, 32], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 65, 69], ["TNFR1", "GENE_OR_GENE_PRODUCT", 74, 79], ["HFREF", "CANCER", 143, 148], ["TNFR2", "GENE_OR_GENE_PRODUCT", 156, 161], ["HF", "CELL_TYPE", 30, 32], ["TNF\u03b1", "PROTEIN", 65, 69], ["TNFR1", "PROTEIN", 74, 79], ["TNFR2", "PROTEIN", 156, 161], ["our data", "TEST", 34, 42], ["levels", "TEST", 55, 61], ["TNF", "TEST", 65, 68], ["TNFR1", "TEST", 74, 79], ["HFPEF relative control", "TREATMENT", 112, 134], ["HFREF", "PROBLEM", 143, 148], ["TNFR2", "TEST", 156, 161], ["HFREF", "TEST", 219, 224], ["HFPEF", "OBSERVATION", 112, 117]]], ["Plasma IL-6 levels were very comparable between HFPEF and HFREF, which suggests that TNF\u03b1-mediated inflammation might be a point of pathophysiological difference between HF phenotypes.DiscussionWe found that low eGFR, hypertension, smoking status and history of atrial fibrillation were significantly associated with elevated TNF\u03b1 levels, while elevated TNFR1 levels were associated with aging, low eGFR, hypertension, diabetes and PVD, and elevated TNFR2 levels were associated with aging, low eGFR, diabetes and atrial fibrillation.", [["atrial", "ANATOMY", 262, 268], ["atrial", "ANATOMY", 514, 520], ["inflammation", "DISEASE", 99, 111], ["HF", "DISEASE", 170, 172], ["hypertension", "DISEASE", 218, 230], ["atrial fibrillation", "DISEASE", 262, 281], ["hypertension", "DISEASE", 405, 417], ["diabetes", "DISEASE", 419, 427], ["PVD", "DISEASE", 432, 435], ["diabetes", "DISEASE", 501, 509], ["atrial fibrillation", "DISEASE", 514, 533], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["IL-6", "GENE_OR_GENE_PRODUCT", 7, 11], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 85, 89], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 326, 330], ["TNFR1", "GENE_OR_GENE_PRODUCT", 354, 359], ["TNFR2", "GENE_OR_GENE_PRODUCT", 450, 455], ["IL", "PROTEIN", 7, 9], ["TNF\u03b1", "PROTEIN", 85, 89], ["TNF\u03b1", "PROTEIN", 326, 330], ["TNFR1", "PROTEIN", 354, 359], ["TNFR2", "PROTEIN", 450, 455], ["Plasma IL", "TEST", 0, 9], ["HFPEF", "TEST", 48, 53], ["HFREF", "TEST", 58, 63], ["TNF\u03b1-mediated inflammation", "PROBLEM", 85, 111], ["pathophysiological difference between HF phenotypes", "PROBLEM", 132, 183], ["low eGFR", "PROBLEM", 208, 216], ["hypertension", "PROBLEM", 218, 230], ["atrial fibrillation", "PROBLEM", 262, 281], ["elevated TNF\u03b1 levels", "PROBLEM", 317, 337], ["elevated TNFR1 levels", "PROBLEM", 345, 366], ["low eGFR", "PROBLEM", 395, 403], ["hypertension", "PROBLEM", 405, 417], ["diabetes", "PROBLEM", 419, 427], ["PVD", "PROBLEM", 432, 435], ["elevated TNFR2 levels", "PROBLEM", 441, 462], ["low eGFR", "PROBLEM", 491, 499], ["diabetes", "PROBLEM", 501, 509], ["atrial fibrillation", "PROBLEM", 514, 533], ["HFPEF", "OBSERVATION", 48, 53], ["HFREF", "OBSERVATION", 58, 63], ["inflammation", "OBSERVATION", 99, 111], ["low", "OBSERVATION_MODIFIER", 208, 211], ["eGFR", "OBSERVATION", 212, 216], ["hypertension", "OBSERVATION", 218, 230], ["atrial", "ANATOMY", 262, 268], ["fibrillation", "OBSERVATION", 269, 281], ["low eGFR", "OBSERVATION", 395, 403], ["hypertension", "OBSERVATION", 405, 417], ["diabetes", "OBSERVATION", 419, 427], ["PVD", "OBSERVATION", 432, 435], ["elevated", "OBSERVATION_MODIFIER", 441, 449], ["TNFR2", "OBSERVATION", 450, 455], ["low eGFR", "OBSERVATION", 491, 499], ["diabetes", "OBSERVATION", 501, 509], ["atrial", "ANATOMY", 514, 520], ["fibrillation", "OBSERVATION", 521, 533]]], ["The advanced age and greater prevalence of comorbidities in the HFPEF population could drive the observed elevation in circulating inflammatory markers relative to HFREF.", [["inflammatory markers", "PROTEIN", 131, 151], ["comorbidities", "PROBLEM", 43, 56], ["the HFPEF population", "PROBLEM", 60, 80], ["the observed elevation in circulating inflammatory markers", "PROBLEM", 93, 151], ["HFREF", "TEST", 164, 169], ["greater", "OBSERVATION_MODIFIER", 21, 28], ["comorbidities", "OBSERVATION", 43, 56], ["HFPEF", "OBSERVATION", 64, 69], ["elevation", "OBSERVATION_MODIFIER", 106, 115], ["circulating", "OBSERVATION_MODIFIER", 119, 130], ["inflammatory", "OBSERVATION", 131, 143]]], ["Indeed, non-cardiac comorbidities are more prevalent in HFPEF, with a larger fraction of adverse clinical outcomes attributable to non-cardiac events compared to HFREF [34].", [["non-cardiac", "ANATOMY", 8, 19], ["HFPEF", "ANATOMY", 56, 61], ["non-cardiac", "ANATOMY", 131, 142], ["non-cardiac comorbidities", "DISEASE", 8, 33], ["HFPEF", "DISEASE", 56, 61], ["HFREF", "CHEMICAL", 162, 167], ["HFPEF", "CANCER", 56, 61], ["non-cardiac comorbidities", "PROBLEM", 8, 33], ["HFPEF", "PROBLEM", 56, 61], ["adverse clinical outcomes", "PROBLEM", 89, 114], ["non-cardiac events", "PROBLEM", 131, 149], ["HFREF", "TEST", 162, 167], ["non-cardiac", "ANATOMY", 8, 19], ["comorbidities", "OBSERVATION", 20, 33], ["HFPEF", "OBSERVATION", 56, 61], ["larger", "OBSERVATION_MODIFIER", 70, 76], ["fraction", "OBSERVATION_MODIFIER", 77, 85]]], ["Likewise, increased TNF\u03b1-axis inflammation has been linked to an increased risk of adverse cardiovascular and all-cause outcomes in HF [18], [35], [36].", [["cardiovascular", "ANATOMY", 91, 105], ["inflammation", "DISEASE", 30, 42], ["HF", "DISEASE", 132, 134], ["TNF", "GENE_OR_GENE_PRODUCT", 20, 23], ["cardiovascular", "ANATOMICAL_SYSTEM", 91, 105], ["TNF", "PROTEIN", 20, 23], ["\u03b1", "PROTEIN", 23, 24], ["increased TNF\u03b1-axis inflammation", "PROBLEM", 10, 42], ["adverse cardiovascular", "PROBLEM", 83, 105], ["HF", "PROBLEM", 132, 134], ["increased", "OBSERVATION_MODIFIER", 10, 19], ["TNF", "OBSERVATION_MODIFIER", 20, 23], ["increased", "OBSERVATION_MODIFIER", 65, 74]]], ["Altogether, these data are congruent with the paradigm for HFPEF that includes comorbidities-driven dysregulation of TNF\u03b1-mediated signaling [6], [34].DiscussionOur finding that circulating TNFR2 levels are significantly associated with increasing average E/e' ratio and grade of diastolic dysfunction in HFPEF, but not in HFREF, suggests a greater role for TNF\u03b1-mediated inflammation in this cohort.", [["HFPEF", "ANATOMY", 305, 310], ["HFPEF", "DISEASE", 59, 64], ["diastolic dysfunction", "DISEASE", 280, 301], ["HFPEF", "DISEASE", 305, 310], ["inflammation", "DISEASE", 372, 384], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 117, 121], ["TNFR2", "GENE_OR_GENE_PRODUCT", 190, 195], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 358, 362], ["TNF\u03b1", "PROTEIN", 117, 121], ["TNFR2", "PROTEIN", 190, 195], ["TNF\u03b1", "PROTEIN", 358, 362], ["HFPEF", "PROBLEM", 59, 64], ["comorbidities", "PROBLEM", 79, 92], ["driven dysregulation", "PROBLEM", 93, 113], ["TNF", "TEST", 117, 120], ["circulating TNFR2 levels", "TEST", 178, 202], ["increasing average E/e' ratio", "PROBLEM", 237, 266], ["diastolic dysfunction", "PROBLEM", 280, 301], ["HFPEF", "PROBLEM", 305, 310], ["HFREF", "TEST", 323, 328], ["TNF", "PROBLEM", 358, 361], ["mediated inflammation", "PROBLEM", 363, 384], ["circulating", "OBSERVATION_MODIFIER", 178, 189], ["TNFR2", "OBSERVATION", 190, 195], ["diastolic dysfunction", "OBSERVATION", 280, 301], ["HFPEF", "OBSERVATION", 305, 310], ["greater", "OBSERVATION_MODIFIER", 341, 348], ["inflammation", "OBSERVATION", 372, 384]]], ["However, we found that TNFR1 and TNFR2 levels were significantly associated with increasing NYHA class in both HF phenotypes, which shows that part of the HFREF phenotype can also be attributed to inflammation.", [["inflammation", "DISEASE", 197, 209], ["TNFR1", "GENE_OR_GENE_PRODUCT", 23, 28], ["TNFR2", "GENE_OR_GENE_PRODUCT", 33, 38], ["HFREF", "GENE_OR_GENE_PRODUCT", 155, 160], ["TNFR1", "PROTEIN", 23, 28], ["TNFR2", "PROTEIN", 33, 38], ["TNFR1", "TEST", 23, 28], ["TNFR2 levels", "TEST", 33, 45], ["increasing NYHA class", "PROBLEM", 81, 102], ["both HF phenotypes", "PROBLEM", 106, 124], ["the HFREF phenotype", "PROBLEM", 151, 170], ["inflammation", "PROBLEM", 197, 209], ["HF phenotypes", "OBSERVATION", 111, 124], ["HFREF", "OBSERVATION", 155, 160], ["can also be attributed to", "UNCERTAINTY", 171, 196], ["inflammation", "OBSERVATION", 197, 209]]], ["The association of diastolic dysfunction and symptoms with TNFR2 in HFPEF is consistent with findings in experimental models, as the TNFR1/TNFR2 axis is involved in mediating divergent effects: TNFR1 has been implicated in adverse cardiac remodeling and adipogenesis, while TNFR2 antagonizes the pathological effects of TNFR1, and also stimulates angiogenesis [37]\u2013[40].", [["cardiac", "ANATOMY", 231, 238], ["diastolic dysfunction", "DISEASE", 19, 40], ["HFPEF", "DISEASE", 68, 73], ["TNFR2", "GENE_OR_GENE_PRODUCT", 59, 64], ["TNFR1", "GENE_OR_GENE_PRODUCT", 133, 138], ["TNFR2", "GENE_OR_GENE_PRODUCT", 139, 144], ["TNFR1", "GENE_OR_GENE_PRODUCT", 194, 199], ["cardiac", "ORGAN", 231, 238], ["TNFR2", "GENE_OR_GENE_PRODUCT", 274, 279], ["TNFR1", "GENE_OR_GENE_PRODUCT", 320, 325], ["TNFR2", "PROTEIN", 59, 64], ["TNFR1", "PROTEIN", 133, 138], ["TNFR2", "PROTEIN", 139, 144], ["TNFR1", "PROTEIN", 194, 199], ["TNFR2", "PROTEIN", 274, 279], ["TNFR1", "PROTEIN", 320, 325], ["diastolic dysfunction", "PROBLEM", 19, 40], ["symptoms", "PROBLEM", 45, 53], ["TNFR2 in HFPEF", "PROBLEM", 59, 73], ["the TNFR1/TNFR2 axis", "TEST", 129, 149], ["adverse cardiac remodeling", "PROBLEM", 223, 249], ["adipogenesis", "PROBLEM", 254, 266], ["TNFR1", "TEST", 320, 325], ["diastolic dysfunction", "OBSERVATION", 19, 40], ["HFPEF", "OBSERVATION", 68, 73], ["consistent with", "UNCERTAINTY", 77, 92], ["cardiac", "ANATOMY", 231, 238], ["remodeling", "OBSERVATION", 239, 249]]], ["TNFR1 and TNFR2 also mediate opposite effects on phospholamban and SERCA2, key Ca2+ handling proteins involved in myocardial relaxation [37], [41].", [["myocardial", "ANATOMY", 114, 124], ["Ca2+", "CHEMICAL", 79, 83], ["TNFR1", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNFR2", "GENE_OR_GENE_PRODUCT", 10, 15], ["phospholamban", "GENE_OR_GENE_PRODUCT", 49, 62], ["SERCA2", "GENE_OR_GENE_PRODUCT", 67, 73], ["Ca2+", "SIMPLE_CHEMICAL", 79, 83], ["myocardial", "MULTI-TISSUE_STRUCTURE", 114, 124], ["TNFR1", "PROTEIN", 0, 5], ["TNFR2", "PROTEIN", 10, 15], ["phospholamban", "PROTEIN", 49, 62], ["SERCA2", "PROTEIN", 67, 73], ["Ca2+ handling proteins", "PROTEIN", 79, 101], ["TNFR1", "TEST", 0, 5], ["TNFR2", "TREATMENT", 10, 15], ["phospholamban", "TEST", 49, 62], ["SERCA2", "TEST", 67, 73], ["myocardial relaxation", "TEST", 114, 135], ["SERCA2", "ANATOMY", 67, 73], ["myocardial", "ANATOMY", 114, 124]]], ["An increase in circulating TNFR2 levels might reflect a loss of protective signaling mechanisms due to tissue shedding of TNFR2, thereby leading to the correlation between circulating TNFR2 levels and diastolic dysfunction and symptoms in HFPEF.DiscussionThe differential role of TNFRs might explain why TNF\u03b1 is not associated with function or symptoms: the variable response to TNF\u03b1 is mediated at the receptor level.", [["tissue", "ANATOMY", 103, 109], ["diastolic dysfunction", "DISEASE", 201, 222], ["HFPEF", "DISEASE", 239, 244], ["TNFR2", "GENE_OR_GENE_PRODUCT", 27, 32], ["tissue", "TISSUE", 103, 109], ["TNFR2", "GENE_OR_GENE_PRODUCT", 122, 127], ["TNFR2", "GENE_OR_GENE_PRODUCT", 184, 189], ["TNFRs", "GENE_OR_GENE_PRODUCT", 280, 285], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 304, 308], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 379, 383], ["TNFR2", "PROTEIN", 27, 32], ["TNFR2", "PROTEIN", 122, 127], ["TNFR2", "PROTEIN", 184, 189], ["TNFRs", "PROTEIN", 280, 285], ["TNF\u03b1", "PROTEIN", 304, 308], ["TNF\u03b1", "PROTEIN", 379, 383], ["An increase in circulating TNFR2 levels", "PROBLEM", 0, 39], ["a loss of protective signaling mechanisms", "PROBLEM", 54, 95], ["tissue shedding of TNFR2", "PROBLEM", 103, 127], ["circulating TNFR2 levels", "TEST", 172, 196], ["diastolic dysfunction", "PROBLEM", 201, 222], ["symptoms", "PROBLEM", 227, 235], ["HFPEF", "PROBLEM", 239, 244], ["symptoms", "PROBLEM", 344, 352], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["circulating TNFR2", "OBSERVATION", 15, 32], ["loss", "OBSERVATION_MODIFIER", 56, 60], ["TNFR2", "OBSERVATION", 122, 127], ["diastolic dysfunction", "OBSERVATION", 201, 222]]], ["Congruent with a recent report, we found TNF\u03b1 was not strongly associated with either HF phenotype; however, Marti et al. implicate TNFR1, while our study implicates TNFR2 in HFPEF [13].", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 41, 45], ["TNFR1", "GENE_OR_GENE_PRODUCT", 132, 137], ["TNFR2", "GENE_OR_GENE_PRODUCT", 166, 171], ["TNF\u03b1", "PROTEIN", 41, 45], ["TNFR1", "PROTEIN", 132, 137], ["TNFR2", "PROTEIN", 166, 171], ["TNF", "PROBLEM", 41, 44], ["HF phenotype", "PROBLEM", 86, 98], ["our study", "TEST", 145, 154]]], ["The key difference between the two studies is that Marti et al. explored risk of incident HF, while we examined existing HF populations.", [["HF", "DISEASE", 90, 92], ["the two studies", "TEST", 27, 42], ["HF", "PROBLEM", 90, 92], ["difference", "OBSERVATION_MODIFIER", 8, 18]]], ["Indeed, we found TNFR1 to be associated with the greatest number of HF risk factors, which is congruent with a role for TNFR1 in precipitating incident HFPEF.", [["HF", "DISEASE", 68, 70], ["HFPEF", "DISEASE", 152, 157], ["TNFR1", "GENE_OR_GENE_PRODUCT", 17, 22], ["TNFR1", "GENE_OR_GENE_PRODUCT", 120, 125], ["HFPEF", "PATHOLOGICAL_FORMATION", 152, 157], ["TNFR1", "PROTEIN", 17, 22], ["HF risk factors", "PROTEIN", 68, 83], ["TNFR1", "PROTEIN", 120, 125], ["TNFR1", "PROBLEM", 17, 22], ["HF risk factors", "PROBLEM", 68, 83], ["TNFR1", "TREATMENT", 120, 125], ["HFPEF", "PROBLEM", 152, 157], ["TNFR1", "OBSERVATION", 17, 22], ["greatest", "OBSERVATION_MODIFIER", 49, 57]]], ["Meanwhile, our data show that TNFR2 might then be a better biomarker for gauging severity of established HFPEF.DiscussionCirculating fragments of TNF\u03b1, TNFR1 and TNFR2 are generated from full, transmembrane proteins through the activity of TACE [26], [27].", [["transmembrane", "ANATOMY", 193, 206], ["HFPEF", "DISEASE", 105, 110], ["TNFR2", "GENE_OR_GENE_PRODUCT", 30, 35], ["HFPEF", "CANCER", 105, 110], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 146, 150], ["TNFR1", "GENE_OR_GENE_PRODUCT", 152, 157], ["TNFR2", "GENE_OR_GENE_PRODUCT", 162, 167], ["TNFR2", "PROTEIN", 30, 35], ["TNF\u03b1", "PROTEIN", 146, 150], ["TNFR1", "PROTEIN", 152, 157], ["TNFR2", "PROTEIN", 162, 167], ["transmembrane proteins", "PROTEIN", 193, 215], ["TACE", "PROTEIN", 240, 244], ["our data", "TEST", 11, 19], ["TNFR2", "PROBLEM", 30, 35], ["established HFPEF", "PROBLEM", 93, 110], ["DiscussionCirculating fragments of TNF\u03b1, TNFR1 and TNFR2", "TEST", 111, 167], ["HFPEF", "OBSERVATION", 105, 110]]], ["We hypothesized that increased circulating levels of TNFR1 and TNFR2 might reflect increased activity of TACE.", [["TNFR1", "GENE_OR_GENE_PRODUCT", 53, 58], ["TNFR2", "GENE_OR_GENE_PRODUCT", 63, 68], ["TACE", "GENE_OR_GENE_PRODUCT", 105, 109], ["TNFR1", "PROTEIN", 53, 58], ["TNFR2", "PROTEIN", 63, 68], ["TACE", "PROTEIN", 105, 109], ["increased circulating levels of TNFR1", "PROBLEM", 21, 58], ["TNFR2", "PROBLEM", 63, 68], ["increased activity of TACE", "PROBLEM", 83, 109], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["circulating levels", "OBSERVATION", 31, 49], ["might reflect", "UNCERTAINTY", 69, 82], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["activity", "OBSERVATION_MODIFIER", 93, 101]]], ["ACE2 is also a substrate of TACE, and plasma ACE2 activity increases in conjunction with increased TACE activity [26], [31].", [["plasma", "ANATOMY", 38, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TACE", "GENE_OR_GENE_PRODUCT", 28, 32], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["TACE", "GENE_OR_GENE_PRODUCT", 99, 103], ["ACE2", "PROTEIN", 0, 4], ["TACE", "PROTEIN", 28, 32], ["ACE2", "PROTEIN", 45, 49], ["TACE", "PROTEIN", 99, 103], ["a substrate of TACE", "TREATMENT", 13, 32], ["plasma ACE2 activity", "TREATMENT", 38, 58], ["increased TACE activity", "TREATMENT", 89, 112]]], ["Since TACE is membrane-bound, as a surrogate of TACE-activity we measured plasma ACE2 activity in HFPEF patients relative to healthy controls.", [["membrane", "ANATOMY", 14, 22], ["plasma", "ANATOMY", 74, 80], ["HFPEF", "ANATOMY", 98, 103], ["TACE", "GENE_OR_GENE_PRODUCT", 6, 10], ["membrane", "CELLULAR_COMPONENT", 14, 22], ["TACE", "GENE_OR_GENE_PRODUCT", 48, 52], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["patients", "ORGANISM", 104, 112], ["TACE", "PROTEIN", 6, 10], ["TACE", "PROTEIN", 48, 52], ["ACE2", "PROTEIN", 81, 85], ["patients", "SPECIES", 104, 112], ["TACE", "TREATMENT", 48, 52], ["plasma ACE2 activity", "TREATMENT", 74, 94], ["HFPEF", "PROBLEM", 98, 103]]], ["Previous work showed a significant association between ACE2 and symptom severity and adverse clinical outcomes in patients with HFREF [20], [32].", [["HFREF", "DISEASE", 128, 133], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["patients", "ORGANISM", 114, 122], ["ACE2", "PROTEIN", 55, 59], ["patients", "SPECIES", 114, 122], ["ACE2", "PROBLEM", 55, 59], ["symptom severity", "PROBLEM", 64, 80], ["HFREF", "TEST", 128, 133]]], ["We found significantly elevated plasma ACE2 activity in HFPEF as compared to healthy controls, but no association to diastolic dysfunction or symptoms.", [["plasma", "ANATOMY", 32, 38], ["HFPEF", "ANATOMY", 56, 61], ["diastolic dysfunction", "DISEASE", 117, 138], ["plasma", "ORGANISM_SUBSTANCE", 32, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["HFPEF", "CANCER", 56, 61], ["ACE2", "PROTEIN", 39, 43], ["significantly elevated plasma ACE2 activity in HFPEF", "PROBLEM", 9, 61], ["diastolic dysfunction", "PROBLEM", 117, 138], ["symptoms", "PROBLEM", 142, 150], ["significantly", "OBSERVATION_MODIFIER", 9, 22], ["elevated", "OBSERVATION", 23, 31], ["plasma ACE2 activity", "OBSERVATION", 32, 52], ["HFPEF", "OBSERVATION", 56, 61], ["no association to", "UNCERTAINTY", 99, 116], ["dysfunction", "OBSERVATION", 127, 138]]], ["This is congruent with the idea that elevated ACE2 activity is a consequence of the drivers of HFPEF, rather than an effector as may be the case in HFREF [20], [32].ConclusionTaking our data together with previous reports indicates that the TACE/TNF\u03b1/TNFR1/TNFR2 inflammatory axis is a part of the pathogenesis of HFPEF [7]\u2013[10], [37]\u2013[40].", [["HFPEF [7]\u2013[10], [37]\u2013[40]", "CHEMICAL", 314, 339], ["HFPEF", "CHEMICAL", 314, 319], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["HFPEF", "GENE_OR_GENE_PRODUCT", 95, 100], ["TACE", "GENE_OR_GENE_PRODUCT", 241, 245], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 246, 250], ["TNFR1", "GENE_OR_GENE_PRODUCT", 251, 256], ["TNFR2", "GENE_OR_GENE_PRODUCT", 257, 262], ["HFPEF [7]\u2013[10], [37]\u2013[40]", "SIMPLE_CHEMICAL", 314, 339], ["ACE2", "PROTEIN", 46, 50], ["HFPEF", "PROTEIN", 95, 100], ["TACE", "PROTEIN", 241, 245], ["TNF\u03b1", "PROTEIN", 246, 250], ["TNFR1", "PROTEIN", 251, 256], ["TNFR2", "PROTEIN", 257, 262], ["elevated ACE2 activity", "PROBLEM", 37, 59], ["HFPEF", "PROBLEM", 95, 100], ["our data", "TEST", 182, 190], ["the TACE/TNF", "TEST", 237, 249], ["TNFR1", "TEST", 251, 256], ["TNFR2 inflammatory axis", "PROBLEM", 257, 280], ["HFPEF", "TEST", 314, 319]]], ["In the context of the failure of TNF\u03b1 antagonism as a therapeutic tool in HF, our data suggest that a downstream approach involving TNFR1 inhibition or TNFR2 potentiation may represent a more effective therapeutic approach for patients with HFPEF [42].LimitationsOur study, while larger than most other studies that compared levels of TNF\u03b1 and its receptors in HFPEF versus HFREF, is still relatively small in terms of clinical studies.", [["HF", "DISEASE", 74, 76], ["HFPEF", "DISEASE", 241, 246], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 33, 37], ["TNFR1", "GENE_OR_GENE_PRODUCT", 132, 137], ["TNFR2", "GENE_OR_GENE_PRODUCT", 152, 157], ["patients", "ORGANISM", 227, 235], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 335, 339], ["TNF\u03b1", "PROTEIN", 33, 37], ["TNFR1", "PROTEIN", 132, 137], ["TNFR2", "PROTEIN", 152, 157], ["TNF\u03b1", "PROTEIN", 335, 339], ["patients", "SPECIES", 227, 235], ["the failure of TNF\u03b1 antagonism", "PROBLEM", 18, 48], ["HF", "PROBLEM", 74, 76], ["a downstream approach involving TNFR1 inhibition", "TREATMENT", 100, 148], ["TNFR2 potentiation", "PROBLEM", 152, 170], ["HFPEF", "PROBLEM", 241, 246], ["Our study", "TEST", 263, 272], ["other studies", "TEST", 297, 310], ["TNF", "TEST", 335, 338], ["HFPEF", "PROBLEM", 361, 366], ["HFREF", "TEST", 374, 379], ["clinical studies", "TEST", 419, 435], ["failure", "OBSERVATION", 22, 29], ["may represent", "UNCERTAINTY", 171, 184], ["larger", "OBSERVATION_MODIFIER", 280, 286], ["HFPEF", "OBSERVATION", 361, 366], ["HFREF", "OBSERVATION", 374, 379], ["relatively", "OBSERVATION_MODIFIER", 390, 400], ["small", "OBSERVATION_MODIFIER", 401, 406]]], ["Indeed, TNF\u03b1 might also be informative with respect to differentiating HFPEF from HFREF, but our study cannot resolve whether this is the case.", [["HFPEF", "ANATOMY", 71, 76], ["HFPEF", "DISEASE", 71, 76], ["HFREF", "DISEASE", 82, 87], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 8, 12], ["HFPEF", "CANCER", 71, 76], ["HFREF", "CANCER", 82, 87], ["TNF\u03b1", "PROTEIN", 8, 12], ["HFPEF", "PROBLEM", 71, 76], ["HFREF", "TEST", 82, 87], ["our study", "TEST", 93, 102]]], ["In addition, the results reported herein represent a single cross-section across healthy controls, and HFPEF and HFREF patients, so follow-up measurements are not included, nor are outcomes data.", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["a single cross-section across healthy controls", "TREATMENT", 51, 97], ["HFPEF", "TEST", 103, 108], ["follow-up measurements", "TEST", 132, 154]]], ["Further studies with a longitudinal component will be important for implicating various molecules or pathways in the pathophysiological development of HF, for which work by Marti et al. is a strong contribution [13].", [["HF", "DISEASE", 151, 153], ["Further studies", "TEST", 0, 15], ["a longitudinal component", "TREATMENT", 21, 45], ["various molecules", "PROBLEM", 80, 97], ["HF", "PROBLEM", 151, 153]]], ["Finally, our results only provide correlative evidence of whether these biochemical markers are primary mediators of the HF syndrome, or end-effectors of pathogenic processes.", [["HF syndrome", "DISEASE", 121, 132], ["the HF syndrome", "PROBLEM", 117, 132], ["pathogenic processes", "PROBLEM", 154, 174]]], ["Indeed, while a conglomerate of evidence points towards an interplay between plasma and tissue levels for TNFR1 and TNFR2\u2014shedding increases plasma levels at the expense of tissue levels\u2014direct tissue and plasma comparisons from the same subjects will be necessary to determine the relative effects of proteolytic processing and changes in expression.", [["plasma", "ANATOMY", 77, 83], ["tissue", "ANATOMY", 88, 94], ["plasma", "ANATOMY", 141, 147], ["tissue", "ANATOMY", 173, 179], ["tissue", "ANATOMY", 194, 200], ["plasma", "ANATOMY", 205, 211], ["plasma", "ORGANISM_SUBSTANCE", 77, 83], ["tissue", "TISSUE", 88, 94], ["TNFR1", "GENE_OR_GENE_PRODUCT", 106, 111], ["TNFR2", "GENE_OR_GENE_PRODUCT", 116, 121], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["tissue", "TISSUE", 173, 179], ["tissue", "TISSUE", 194, 200], ["plasma", "ORGANISM_SUBSTANCE", 205, 211], ["TNFR1", "PROTEIN", 106, 111], ["TNFR2", "PROTEIN", 116, 121], ["plasma and tissue levels", "TEST", 77, 101], ["TNFR1", "TEST", 106, 111], ["TNFR2", "TEST", 116, 121], ["plasma levels", "TEST", 141, 154], ["tissue levels", "TEST", 173, 186], ["plasma comparisons", "TEST", 205, 223], ["proteolytic processing", "TREATMENT", 302, 324]]]], "PMC7273038": []}